Province, Autonomous City and Community of hospitalization;Main diagnosis (ICD-9-CM) reduced list;Sex;Total TOTAL NATIONAL;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;4.746.651 TOTAL NATIONAL;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;2.244.928 TOTAL NATIONAL;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;2.501.723 TOTAL NATIONAL;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;108.095 TOTAL NATIONAL;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;59.825 TOTAL NATIONAL;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;48.270 TOTAL NATIONAL;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;16.738 TOTAL NATIONAL;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;8.712 TOTAL NATIONAL;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;8.026 TOTAL NATIONAL;Group 0102 Imprecise intestinal infections 009;Both sexes;8.721 TOTAL NATIONAL;Group 0102 Imprecise intestinal infections 009;Men;4.326 TOTAL NATIONAL;Group 0102 Imprecise intestinal infections 009;Women;4.395 TOTAL NATIONAL;Group 0103 Tuberculosis 010-018, 137;Both sexes;3.725 TOTAL NATIONAL;Group 0103 Tuberculosis 010-018, 137;Men;2.373 TOTAL NATIONAL;Group 0103 Tuberculosis 010-018, 137;Women;1.352 TOTAL NATIONAL;Group 0104 Septicaemia 038;Both sexes;43.749 TOTAL NATIONAL;Group 0104 Septicaemia 038;Men;23.652 TOTAL NATIONAL;Group 0104 Septicaemia 038;Women;20.097 TOTAL NATIONAL;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;2.959 TOTAL NATIONAL;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;2.234 TOTAL NATIONAL;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;725 TOTAL NATIONAL;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;32.203 TOTAL NATIONAL;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;18.528 TOTAL NATIONAL;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;13.675 TOTAL NATIONAL;Group 0200 Neoplasms 140-239;Both sexes;454.891 TOTAL NATIONAL;Group 0200 Neoplasms 140-239;Men;240.207 TOTAL NATIONAL;Group 0200 Neoplasms 140-239;Women;214.684 TOTAL NATIONAL;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;46.736 TOTAL NATIONAL;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;28.270 TOTAL NATIONAL;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;18.466 TOTAL NATIONAL;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;35.029 TOTAL NATIONAL;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;27.360 TOTAL NATIONAL;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;7.669 TOTAL NATIONAL;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;8.323 TOTAL NATIONAL;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;4.813 TOTAL NATIONAL;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;3.510 TOTAL NATIONAL;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;34.220 TOTAL NATIONAL;Group 0204 Malignant neoplasm of breast 174-175;Men;283 TOTAL NATIONAL;Group 0204 Malignant neoplasm of breast 174-175;Women;33.937 TOTAL NATIONAL;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;9.261 TOTAL NATIONAL;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. TOTAL NATIONAL;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;9.261 TOTAL NATIONAL;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;4.972 TOTAL NATIONAL;Group 0206 Malignant neoplasm of ovary 1830;Men;.. TOTAL NATIONAL;Group 0206 Malignant neoplasm of ovary 1830;Women;4.972 TOTAL NATIONAL;Group 0207 Malignant neoplasm of prostate 185;Both sexes;17.121 TOTAL NATIONAL;Group 0207 Malignant neoplasm of prostate 185;Men;17.121 TOTAL NATIONAL;Group 0207 Malignant neoplasm of prostate 185;Women;.. TOTAL NATIONAL;Group 0208 Malignant neoplasm of bladder 188;Both sexes;42.301 TOTAL NATIONAL;Group 0208 Malignant neoplasm of bladder 188;Men;35.384 TOTAL NATIONAL;Group 0208 Malignant neoplasm of bladder 188;Women;6.917 TOTAL NATIONAL;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;161.465 TOTAL NATIONAL;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;94.166 TOTAL NATIONAL;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;67.299 TOTAL NATIONAL;Group 0210 Carcinoma in situ 230-234;Both sexes;7.433 TOTAL NATIONAL;Group 0210 Carcinoma in situ 230-234;Men;2.899 TOTAL NATIONAL;Group 0210 Carcinoma in situ 230-234;Women;4.534 TOTAL NATIONAL;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;5.495 TOTAL NATIONAL;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;3.317 TOTAL NATIONAL;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;2.177 TOTAL NATIONAL;Grupo 0212 Leiomyoma of uterus 218;Both sexes;21.306 TOTAL NATIONAL;Grupo 0212 Leiomyoma of uterus 218;Men;.. TOTAL NATIONAL;Grupo 0212 Leiomyoma of uterus 218;Women;21.306 TOTAL NATIONAL;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;61.229 TOTAL NATIONAL;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;26.593 TOTAL NATIONAL;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;34.636 TOTAL NATIONAL;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;42.492 TOTAL NATIONAL;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;20.760 TOTAL NATIONAL;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;21.732 TOTAL NATIONAL;Group 0301 Anaemias 280-285;Both sexes;25.630 TOTAL NATIONAL;Group 0301 Anaemias 280-285;Men;12.231 TOTAL NATIONAL;Group 0301 Anaemias 280-285;Women;13.400 TOTAL NATIONAL;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;16.862 TOTAL NATIONAL;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;8.530 TOTAL NATIONAL;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;8.332 TOTAL NATIONAL;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;85.273 TOTAL NATIONAL;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;34.570 TOTAL NATIONAL;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;50.703 TOTAL NATIONAL;Group 0401 Diabetes mellitus 249-250;Both sexes;26.481 TOTAL NATIONAL;Group 0401 Diabetes mellitus 249-250;Men;15.482 TOTAL NATIONAL;Group 0401 Diabetes mellitus 249-250;Women;10.998 TOTAL NATIONAL;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;58.792 TOTAL NATIONAL;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;19.088 TOTAL NATIONAL;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;39.704 TOTAL NATIONAL;Group 0500 Mental disorders 290-319;Both sexes;116.445 TOTAL NATIONAL;Group 0500 Mental disorders 290-319;Men;60.643 TOTAL NATIONAL;Group 0500 Mental disorders 290-319;Women;55.802 TOTAL NATIONAL;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;4.434 TOTAL NATIONAL;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;1.979 TOTAL NATIONAL;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2.455 TOTAL NATIONAL;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;8.466 TOTAL NATIONAL;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;6.294 TOTAL NATIONAL;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;2.172 TOTAL NATIONAL;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;7.144 TOTAL NATIONAL;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;5.263 TOTAL NATIONAL;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;1.880 TOTAL NATIONAL;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;33.568 TOTAL NATIONAL;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;20.509 TOTAL NATIONAL;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;13.060 TOTAL NATIONAL;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;26.465 TOTAL NATIONAL;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;10.418 TOTAL NATIONAL;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;16.047 TOTAL NATIONAL;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;36.368 TOTAL NATIONAL;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;16.180 TOTAL NATIONAL;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;20.188 TOTAL NATIONAL;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;104.277 TOTAL NATIONAL;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;52.422 TOTAL NATIONAL;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;51.855 TOTAL NATIONAL;Group 0601 Alzheimer's disease 3310;Both sexes;3.693 TOTAL NATIONAL;Group 0601 Alzheimer's disease 3310;Men;1.316 TOTAL NATIONAL;Group 0601 Alzheimer's disease 3310;Women;2.377 TOTAL NATIONAL;Group 0602 Multiple sclerosis 340;Both sexes;2.303 TOTAL NATIONAL;Group 0602 Multiple sclerosis 340;Men;734 TOTAL NATIONAL;Group 0602 Multiple sclerosis 340;Women;1.568 TOTAL NATIONAL;Group 0603 Epilepsy 345;Both sexes;17.878 TOTAL NATIONAL;Group 0603 Epilepsy 345;Men;9.592 TOTAL NATIONAL;Group 0603 Epilepsy 345;Women;8.286 TOTAL NATIONAL;Group 0604 Transient cerebral ischemia 435;Both sexes;14.940 TOTAL NATIONAL;Group 0604 Transient cerebral ischemia 435;Men;7.632 TOTAL NATIONAL;Group 0604 Transient cerebral ischemia 435;Women;7.309 TOTAL NATIONAL;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;65.462 TOTAL NATIONAL;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;33.147 TOTAL NATIONAL;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;32.315 TOTAL NATIONAL;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;27.624 TOTAL NATIONAL;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;14.255 TOTAL NATIONAL;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;13.369 TOTAL NATIONAL;Grupo 0701 Cataract 366;Both sexes;4.840 TOTAL NATIONAL;Grupo 0701 Cataract 366;Men;2.344 TOTAL NATIONAL;Grupo 0701 Cataract 366;Women;2.496 TOTAL NATIONAL;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;22.784 TOTAL NATIONAL;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;11.911 TOTAL NATIONAL;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;10.874 TOTAL NATIONAL;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;23.194 TOTAL NATIONAL;Group 0800 Diseases of the ear and the mastoid 380-389;Men;11.309 TOTAL NATIONAL;Group 0800 Diseases of the ear and the mastoid 380-389;Women;11.885 TOTAL NATIONAL;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;613.148 TOTAL NATIONAL;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;343.744 TOTAL NATIONAL;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;269.404 TOTAL NATIONAL;Group 0901 Hypertensive disease 401-405;Both sexes;31.589 TOTAL NATIONAL;Group 0901 Hypertensive disease 401-405;Men;13.729 TOTAL NATIONAL;Group 0901 Hypertensive disease 401-405;Women;17.861 TOTAL NATIONAL;Group 0902 Angina pectoris 4111, 413;Both sexes;25.175 TOTAL NATIONAL;Group 0902 Angina pectoris 4111, 413;Men;15.710 TOTAL NATIONAL;Group 0902 Angina pectoris 4111, 413;Women;9.465 TOTAL NATIONAL;Group 0903 Acute myocardial infarction 410;Both sexes;54.090 TOTAL NATIONAL;Group 0903 Acute myocardial infarction 410;Men;38.340 TOTAL NATIONAL;Group 0903 Acute myocardial infarction 410;Women;15.751 TOTAL NATIONAL;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;41.068 TOTAL NATIONAL;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;31.512 TOTAL NATIONAL;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;9.556 TOTAL NATIONAL;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;20.164 TOTAL NATIONAL;Group 0905 Diseases of the lungs circulation 415-417;Men;9.116 TOTAL NATIONAL;Group 0905 Diseases of the lungs circulation 415-417;Women;11.048 TOTAL NATIONAL;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;78.991 TOTAL NATIONAL;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;42.862 TOTAL NATIONAL;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;36.129 TOTAL NATIONAL;Grupo 0907 Heart failure 428;Both sexes;127.382 TOTAL NATIONAL;Grupo 0907 Heart failure 428;Men;59.737 TOTAL NATIONAL;Grupo 0907 Heart failure 428;Women;67.644 TOTAL NATIONAL;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;104.413 TOTAL NATIONAL;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;56.113 TOTAL NATIONAL;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;48.300 TOTAL NATIONAL;Grupo 0909 Atherosclerosis 440;Both sexes;21.102 TOTAL NATIONAL;Grupo 0909 Atherosclerosis 440;Men;15.705 TOTAL NATIONAL;Grupo 0909 Atherosclerosis 440;Women;5.398 TOTAL NATIONAL;Group 0910 Varicose veins of lower extremities 454;Both sexes;14.259 TOTAL NATIONAL;Group 0910 Varicose veins of lower extremities 454;Men;5.135 TOTAL NATIONAL;Group 0910 Varicose veins of lower extremities 454;Women;9.124 TOTAL NATIONAL;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;94.914 TOTAL NATIONAL;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;55.785 TOTAL NATIONAL;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;39.129 TOTAL NATIONAL;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;573.208 TOTAL NATIONAL;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;321.649 TOTAL NATIONAL;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;251.559 TOTAL NATIONAL;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;26.183 TOTAL NATIONAL;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;13.672 TOTAL NATIONAL;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;12.511 TOTAL NATIONAL;Group 1002 Pneumonia 480-486;Both sexes;128.975 TOTAL NATIONAL;Group 1002 Pneumonia 480-486;Men;74.598 TOTAL NATIONAL;Group 1002 Pneumonia 480-486;Women;54.377 TOTAL NATIONAL;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;56.629 TOTAL NATIONAL;Group 1003 Acute bronchitis and bronchiolitis 466;Men;26.963 TOTAL NATIONAL;Group 1003 Acute bronchitis and bronchiolitis 466;Women;29.666 TOTAL NATIONAL;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;25.168 TOTAL NATIONAL;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;13.346 TOTAL NATIONAL;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;11.822 TOTAL NATIONAL;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;41.567 TOTAL NATIONAL;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;25.591 TOTAL NATIONAL;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;15.976 TOTAL NATIONAL;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;90.176 TOTAL NATIONAL;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;67.844 TOTAL NATIONAL;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;22.332 TOTAL NATIONAL;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;23.094 TOTAL NATIONAL;Group 1007 Asthma 4930-4931,4938-4939;Men;6.999 TOTAL NATIONAL;Group 1007 Asthma 4930-4931,4938-4939;Women;16.096 TOTAL NATIONAL;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;181.416 TOTAL NATIONAL;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;92.637 TOTAL NATIONAL;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;88.779 TOTAL NATIONAL;Group 1100 Diseases of the digestive system 520-579;Both sexes;572.587 TOTAL NATIONAL;Group 1100 Diseases of the digestive system 520-579;Men;317.370 TOTAL NATIONAL;Group 1100 Diseases of the digestive system 520-579;Women;255.217 TOTAL NATIONAL;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;9.469 TOTAL NATIONAL;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;4.371 TOTAL NATIONAL;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;5.098 TOTAL NATIONAL;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;8.125 TOTAL NATIONAL;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;4.465 TOTAL NATIONAL;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;3.661 TOTAL NATIONAL;Group 1103 Diseases of the esophagus 530;Both sexes;10.979 TOTAL NATIONAL;Group 1103 Diseases of the esophagus 530;Men;6.606 TOTAL NATIONAL;Group 1103 Diseases of the esophagus 530;Women;4.374 TOTAL NATIONAL;Group 1104 Peptic ulcer 531-534;Both sexes;10.825 TOTAL NATIONAL;Group 1104 Peptic ulcer 531-534;Men;7.349 TOTAL NATIONAL;Group 1104 Peptic ulcer 531-534;Women;3.476 TOTAL NATIONAL;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;14.035 TOTAL NATIONAL;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;6.826 TOTAL NATIONAL;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;7.208 TOTAL NATIONAL;Group 1106 Appendicitis 540-543;Both sexes;48.489 TOTAL NATIONAL;Group 1106 Appendicitis 540-543;Men;27.387 TOTAL NATIONAL;Group 1106 Appendicitis 540-543;Women;21.102 TOTAL NATIONAL;Group 1107 Inguinal hernia 550;Both sexes;56.897 TOTAL NATIONAL;Group 1107 Inguinal hernia 550;Men;50.330 TOTAL NATIONAL;Group 1107 Inguinal hernia 550;Women;6.567 TOTAL NATIONAL;Group 1108 Other abdominal hernia 551-553;Both sexes;47.577 TOTAL NATIONAL;Group 1108 Other abdominal hernia 551-553;Men;22.444 TOTAL NATIONAL;Group 1108 Other abdominal hernia 551-553;Women;25.132 TOTAL NATIONAL;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;11.142 TOTAL NATIONAL;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;5.688 TOTAL NATIONAL;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;5.454 TOTAL NATIONAL;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;33.148 TOTAL NATIONAL;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;15.456 TOTAL NATIONAL;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;17.692 TOTAL NATIONAL;Group 1111 Intestinal obstruction without hernia 560;Both sexes;26.850 TOTAL NATIONAL;Group 1111 Intestinal obstruction without hernia 560;Men;13.711 TOTAL NATIONAL;Group 1111 Intestinal obstruction without hernia 560;Women;13.139 TOTAL NATIONAL;Group 1112 Intestinal diverticulosis 562;Both sexes;24.843 TOTAL NATIONAL;Group 1112 Intestinal diverticulosis 562;Men;12.267 TOTAL NATIONAL;Group 1112 Intestinal diverticulosis 562;Women;12.576 TOTAL NATIONAL;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;32.955 TOTAL NATIONAL;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;21.210 TOTAL NATIONAL;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;11.744 TOTAL NATIONAL;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;19.230 TOTAL NATIONAL;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;8.773 TOTAL NATIONAL;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;10.457 TOTAL NATIONAL;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;10.270 TOTAL NATIONAL;Group 1115 Alcoholic hepatitis 5710-5713;Men;8.613 TOTAL NATIONAL;Group 1115 Alcoholic hepatitis 5710-5713;Women;1.657 TOTAL NATIONAL;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;20.125 TOTAL NATIONAL;Group 1116 Other diseases of the liver 570,5714-573;Men;12.164 TOTAL NATIONAL;Group 1116 Other diseases of the liver 570,5714-573;Women;7.961 TOTAL NATIONAL;Group 1117 Cholelithiasis 574;Both sexes;103.090 TOTAL NATIONAL;Group 1117 Cholelithiasis 574;Men;43.235 TOTAL NATIONAL;Group 1117 Cholelithiasis 574;Women;59.854 TOTAL NATIONAL;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;28.382 TOTAL NATIONAL;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;15.464 TOTAL NATIONAL;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;12.919 TOTAL NATIONAL;Group 1119 Pancreatic diseases 577;Both sexes;31.712 TOTAL NATIONAL;Group 1119 Pancreatic diseases 577;Men;17.677 TOTAL NATIONAL;Group 1119 Pancreatic diseases 577;Women;14.034 TOTAL NATIONAL;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;24.444 TOTAL NATIONAL;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;13.333 TOTAL NATIONAL;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;11.111 TOTAL NATIONAL;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;48.339 TOTAL NATIONAL;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;25.805 TOTAL NATIONAL;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;22.534 TOTAL NATIONAL;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;30.158 TOTAL NATIONAL;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;17.424 TOTAL NATIONAL;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;12.733 TOTAL NATIONAL;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;2.130 TOTAL NATIONAL;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;1.066 TOTAL NATIONAL;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;1.064 TOTAL NATIONAL;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;16.052 TOTAL NATIONAL;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;7.315 TOTAL NATIONAL;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;8.737 TOTAL NATIONAL;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;346.416 TOTAL NATIONAL;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;165.083 TOTAL NATIONAL;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;181.333 TOTAL NATIONAL;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. TOTAL NATIONAL;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. TOTAL NATIONAL;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. TOTAL NATIONAL;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. TOTAL NATIONAL;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. TOTAL NATIONAL;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. TOTAL NATIONAL;Group 1303 Internal derangement of knee 717;Both sexes;45.891 TOTAL NATIONAL;Group 1303 Internal derangement of knee 717;Men;30.921 TOTAL NATIONAL;Group 1303 Internal derangement of knee 717;Women;14.970 TOTAL NATIONAL;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;128.819 TOTAL NATIONAL;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;55.070 TOTAL NATIONAL;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;73.749 TOTAL NATIONAL;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;6.317 TOTAL NATIONAL;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;2.272 TOTAL NATIONAL;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;4.045 TOTAL NATIONAL;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;17.559 TOTAL NATIONAL;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;8.570 TOTAL NATIONAL;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;8.989 TOTAL NATIONAL;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;32.328 TOTAL NATIONAL;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;17.031 TOTAL NATIONAL;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;15.297 TOTAL NATIONAL;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;8.887 TOTAL NATIONAL;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;3.982 TOTAL NATIONAL;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;4.905 TOTAL NATIONAL;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;51.818 TOTAL NATIONAL;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;26.834 TOTAL NATIONAL;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;24.985 TOTAL NATIONAL;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;54.796 TOTAL NATIONAL;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;20.403 TOTAL NATIONAL;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;34.393 TOTAL NATIONAL;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;317.891 TOTAL NATIONAL;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;147.271 TOTAL NATIONAL;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;170.620 TOTAL NATIONAL;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;31.664 TOTAL NATIONAL;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;11.304 TOTAL NATIONAL;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;20.361 TOTAL NATIONAL;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;29.297 TOTAL NATIONAL;Group 1402 Renal failure 5836-5837, 584-586;Men;16.879 TOTAL NATIONAL;Group 1402 Renal failure 5836-5837, 584-586;Women;12.418 TOTAL NATIONAL;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;42.509 TOTAL NATIONAL;Group 1403 Urolithiasis 592, 594, 7880;Men;25.398 TOTAL NATIONAL;Group 1403 Urolithiasis 592, 594, 7880;Women;17.111 TOTAL NATIONAL;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;88.236 TOTAL NATIONAL;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;42.712 TOTAL NATIONAL;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;45.524 TOTAL NATIONAL;Group 1405 Prostatic hyperplasia 600;Both sexes;26.433 TOTAL NATIONAL;Group 1405 Prostatic hyperplasia 600;Men;26.433 TOTAL NATIONAL;Group 1405 Prostatic hyperplasia 600;Women;.. TOTAL NATIONAL;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;22.186 TOTAL NATIONAL;Group 1406 Other diseases of the male genital organs 601-608;Men;22.186 TOTAL NATIONAL;Group 1406 Other diseases of the male genital organs 601-608;Women;.. TOTAL NATIONAL;Group 1407 Disorders of breast 610-612;Both sexes;21.735 TOTAL NATIONAL;Group 1407 Disorders of breast 610-612;Men;1.668 TOTAL NATIONAL;Group 1407 Disorders of breast 610-612;Women;20.067 TOTAL NATIONAL;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;8.149 TOTAL NATIONAL;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. TOTAL NATIONAL;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;8.149 TOTAL NATIONAL;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;3.737 TOTAL NATIONAL;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. TOTAL NATIONAL;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;3.737 TOTAL NATIONAL;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;43.944 TOTAL NATIONAL;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;692 TOTAL NATIONAL;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;43.253 TOTAL NATIONAL;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;480.528 TOTAL NATIONAL;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. TOTAL NATIONAL;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;480.528 TOTAL NATIONAL;Group 1501 Legally induced abortion 635;Both sexes;2.013 TOTAL NATIONAL;Group 1501 Legally induced abortion 635;Men;.. TOTAL NATIONAL;Group 1501 Legally induced abortion 635;Women;2.013 TOTAL NATIONAL;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;24.950 TOTAL NATIONAL;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. TOTAL NATIONAL;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;24.950 TOTAL NATIONAL;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;290.779 TOTAL NATIONAL;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. TOTAL NATIONAL;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;290.779 TOTAL NATIONAL;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;83.396 TOTAL NATIONAL;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. TOTAL NATIONAL;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;83.396 TOTAL NATIONAL;Group 1505 Single spontaneous delivery 650;Both sexes;29.203 TOTAL NATIONAL;Group 1505 Single spontaneous delivery 650;Men;.. TOTAL NATIONAL;Group 1505 Single spontaneous delivery 650;Women;29.203 TOTAL NATIONAL;Group 1506 Other deliveries 6695-6697;Both sexes;13.947 TOTAL NATIONAL;Group 1506 Other deliveries 6695-6697;Men;.. TOTAL NATIONAL;Group 1506 Other deliveries 6695-6697;Women;13.947 TOTAL NATIONAL;Group 1507 Complications related to the puerperium 670-676;Both sexes;3.902 TOTAL NATIONAL;Group 1507 Complications related to the puerperium 670-676;Men;.. TOTAL NATIONAL;Group 1507 Complications related to the puerperium 670-676;Women;3.902 TOTAL NATIONAL;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;32.338 TOTAL NATIONAL;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. TOTAL NATIONAL;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;32.338 TOTAL NATIONAL;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;61.711 TOTAL NATIONAL;Group 1600 Some disorders originating in the perinatal period 760-779;Men;33.962 TOTAL NATIONAL;Group 1600 Some disorders originating in the perinatal period 760-779;Women;27.749 TOTAL NATIONAL;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;16.839 TOTAL NATIONAL;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;8.967 TOTAL NATIONAL;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;7.872 TOTAL NATIONAL;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;44.872 TOTAL NATIONAL;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;24.995 TOTAL NATIONAL;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;19.877 TOTAL NATIONAL;Grupo 1700 Congenital abnormalities 740-759;Both sexes;37.234 TOTAL NATIONAL;Grupo 1700 Congenital abnormalities 740-759;Men;20.786 TOTAL NATIONAL;Grupo 1700 Congenital abnormalities 740-759;Women;16.448 TOTAL NATIONAL;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;212.140 TOTAL NATIONAL;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;113.872 TOTAL NATIONAL;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;98.268 TOTAL NATIONAL;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;24.515 TOTAL NATIONAL;Group 1801 Pain in throat and chest 7841, 7865;Men;13.888 TOTAL NATIONAL;Group 1801 Pain in throat and chest 7841, 7865;Women;10.627 TOTAL NATIONAL;Group 1802 Abdominal pain 7890;Both sexes;23.921 TOTAL NATIONAL;Group 1802 Abdominal pain 7890;Men;9.305 TOTAL NATIONAL;Group 1802 Abdominal pain 7890;Women;14.616 TOTAL NATIONAL;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;16.997 TOTAL NATIONAL;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;8.775 TOTAL NATIONAL;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;8.222 TOTAL NATIONAL;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;146.707 TOTAL NATIONAL;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;81.905 TOTAL NATIONAL;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;64.803 TOTAL NATIONAL;Group 1900 Injuries and poisoning 800-999;Both sexes;424.014 TOTAL NATIONAL;Group 1900 Injuries and poisoning 800-999;Men;214.698 TOTAL NATIONAL;Group 1900 Injuries and poisoning 800-999;Women;209.315 TOTAL NATIONAL;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;23.935 TOTAL NATIONAL;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;13.553 TOTAL NATIONAL;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;10.382 TOTAL NATIONAL;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;11.249 TOTAL NATIONAL;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;7.916 TOTAL NATIONAL;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;3.333 TOTAL NATIONAL;Group 1903 Radius and ulna fracture 813;Both sexes;25.880 TOTAL NATIONAL;Group 1903 Radius and ulna fracture 813;Men;11.980 TOTAL NATIONAL;Group 1903 Radius and ulna fracture 813;Women;13.900 TOTAL NATIONAL;Group 1904 Femur fracture 820-821;Both sexes;71.414 TOTAL NATIONAL;Group 1904 Femur fracture 820-821;Men;20.212 TOTAL NATIONAL;Group 1904 Femur fracture 820-821;Women;51.202 TOTAL NATIONAL;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;30.937 TOTAL NATIONAL;Group 1905 Leg fracture, including the ankle 823-824;Men;15.299 TOTAL NATIONAL;Group 1905 Leg fracture, including the ankle 823-824;Women;15.637 TOTAL NATIONAL;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;121.784 TOTAL NATIONAL;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;72.341 TOTAL NATIONAL;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;49.443 TOTAL NATIONAL;Group 1907 Burns 940-949;Both sexes;3.257 TOTAL NATIONAL;Group 1907 Burns 940-949;Men;2.027 TOTAL NATIONAL;Group 1907 Burns 940-949;Women;1.230 TOTAL NATIONAL;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;11.367 TOTAL NATIONAL;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;5.023 TOTAL NATIONAL;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;6.344 TOTAL NATIONAL;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;110.009 TOTAL NATIONAL;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;58.911 TOTAL NATIONAL;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;51.098 TOTAL NATIONAL;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1.199 TOTAL NATIONAL;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;731 TOTAL NATIONAL;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;469 TOTAL NATIONAL;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;12.983 TOTAL NATIONAL;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;6.706 TOTAL NATIONAL;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;6.277 TOTAL NATIONAL;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;97.144 TOTAL NATIONAL;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;46.695 TOTAL NATIONAL;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;50.449 TOTAL NATIONAL;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;3.832 TOTAL NATIONAL;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;2.171 TOTAL NATIONAL;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;1.661 TOTAL NATIONAL;Group 2102 Contraceptive management V25;Both sexes;1.398 TOTAL NATIONAL;Group 2102 Contraceptive management V25;Men;104 TOTAL NATIONAL;Group 2102 Contraceptive management V25;Women;1.294 TOTAL NATIONAL;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. TOTAL NATIONAL;Group 2103 Living newborns by type of delivery V30-V39;Men;.. TOTAL NATIONAL;Group 2103 Living newborns by type of delivery V30-V39;Women;.. TOTAL NATIONAL;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;32.133 TOTAL NATIONAL;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;19.208 TOTAL NATIONAL;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;12.925 TOTAL NATIONAL;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;59.781 TOTAL NATIONAL;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;25.211 TOTAL NATIONAL;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;34.570 ANDALUC═A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;696.093 ANDALUC═A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;313.556 ANDALUC═A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;382.538 ANDALUC═A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;17.868 ANDALUC═A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;9.922 ANDALUC═A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;7.946 ANDALUC═A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;2.133 ANDALUC═A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;1.184 ANDALUC═A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;949 ANDALUC═A;Group 0102 Imprecise intestinal infections 009;Both sexes;1.918 ANDALUC═A;Group 0102 Imprecise intestinal infections 009;Men;970 ANDALUC═A;Group 0102 Imprecise intestinal infections 009;Women;949 ANDALUC═A;Group 0103 Tuberculosis 010-018, 137;Both sexes;591 ANDALUC═A;Group 0103 Tuberculosis 010-018, 137;Men;377 ANDALUC═A;Group 0103 Tuberculosis 010-018, 137;Women;214 ANDALUC═A;Group 0104 Septicaemia 038;Both sexes;7.541 ANDALUC═A;Group 0104 Septicaemia 038;Men;4.010 ANDALUC═A;Group 0104 Septicaemia 038;Women;3.530 ANDALUC═A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;510 ANDALUC═A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;385 ANDALUC═A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;125 ANDALUC═A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;5.175 ANDALUC═A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2.996 ANDALUC═A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;2.179 ANDALUC═A;Group 0200 Neoplasms 140-239;Both sexes;64.660 ANDALUC═A;Group 0200 Neoplasms 140-239;Men;33.473 ANDALUC═A;Group 0200 Neoplasms 140-239;Women;31.188 ANDALUC═A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;6.606 ANDALUC═A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;3.940 ANDALUC═A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2.666 ANDALUC═A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;4.741 ANDALUC═A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;3.901 ANDALUC═A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;840 ANDALUC═A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;1.486 ANDALUC═A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;873 ANDALUC═A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;612 ANDALUC═A;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;5.335 ANDALUC═A;Group 0204 Malignant neoplasm of breast 174-175;Men;53 ANDALUC═A;Group 0204 Malignant neoplasm of breast 174-175;Women;5.282 ANDALUC═A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1.394 ANDALUC═A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ANDALUC═A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1.394 ANDALUC═A;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;816 ANDALUC═A;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ANDALUC═A;Group 0206 Malignant neoplasm of ovary 1830;Women;816 ANDALUC═A;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.750 ANDALUC═A;Group 0207 Malignant neoplasm of prostate 185;Men;1.750 ANDALUC═A;Group 0207 Malignant neoplasm of prostate 185;Women;.. ANDALUC═A;Group 0208 Malignant neoplasm of bladder 188;Both sexes;6.139 ANDALUC═A;Group 0208 Malignant neoplasm of bladder 188;Men;5.181 ANDALUC═A;Group 0208 Malignant neoplasm of bladder 188;Women;958 ANDALUC═A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;22.407 ANDALUC═A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;13.232 ANDALUC═A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;9.175 ANDALUC═A;Group 0210 Carcinoma in situ 230-234;Both sexes;766 ANDALUC═A;Group 0210 Carcinoma in situ 230-234;Men;259 ANDALUC═A;Group 0210 Carcinoma in situ 230-234;Women;507 ANDALUC═A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;552 ANDALUC═A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;328 ANDALUC═A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;224 ANDALUC═A;Grupo 0212 Leiomyoma of uterus 218;Both sexes;3.588 ANDALUC═A;Grupo 0212 Leiomyoma of uterus 218;Men;.. ANDALUC═A;Grupo 0212 Leiomyoma of uterus 218;Women;3.588 ANDALUC═A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;9.082 ANDALUC═A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;3.955 ANDALUC═A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;5.127 ANDALUC═A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;6.365 ANDALUC═A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;3.077 ANDALUC═A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;3.288 ANDALUC═A;Group 0301 Anaemias 280-285;Both sexes;3.611 ANDALUC═A;Group 0301 Anaemias 280-285;Men;1.790 ANDALUC═A;Group 0301 Anaemias 280-285;Women;1.820 ANDALUC═A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;2.754 ANDALUC═A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1.287 ANDALUC═A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1.468 ANDALUC═A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;12.129 ANDALUC═A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;5.005 ANDALUC═A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;7.124 ANDALUC═A;Group 0401 Diabetes mellitus 249-250;Both sexes;3.758 ANDALUC═A;Group 0401 Diabetes mellitus 249-250;Men;2.280 ANDALUC═A;Group 0401 Diabetes mellitus 249-250;Women;1.478 ANDALUC═A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;8.371 ANDALUC═A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;2.725 ANDALUC═A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;5.646 ANDALUC═A;Group 0500 Mental disorders 290-319;Both sexes;13.068 ANDALUC═A;Group 0500 Mental disorders 290-319;Men;7.248 ANDALUC═A;Group 0500 Mental disorders 290-319;Women;5.819 ANDALUC═A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;260 ANDALUC═A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;115 ANDALUC═A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;146 ANDALUC═A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;527 ANDALUC═A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;425 ANDALUC═A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;102 ANDALUC═A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;798 ANDALUC═A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;626 ANDALUC═A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;173 ANDALUC═A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;4.190 ANDALUC═A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;2.795 ANDALUC═A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;1.395 ANDALUC═A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;3.114 ANDALUC═A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;1.331 ANDALUC═A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;1.783 ANDALUC═A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;4.178 ANDALUC═A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;1.958 ANDALUC═A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;2.220 ANDALUC═A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;13.561 ANDALUC═A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;6.802 ANDALUC═A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;6.759 ANDALUC═A;Group 0601 Alzheimer's disease 3310;Both sexes;250 ANDALUC═A;Group 0601 Alzheimer's disease 3310;Men;102 ANDALUC═A;Group 0601 Alzheimer's disease 3310;Women;147 ANDALUC═A;Group 0602 Multiple sclerosis 340;Both sexes;361 ANDALUC═A;Group 0602 Multiple sclerosis 340;Men;111 ANDALUC═A;Group 0602 Multiple sclerosis 340;Women;250 ANDALUC═A;Group 0603 Epilepsy 345;Both sexes;2.251 ANDALUC═A;Group 0603 Epilepsy 345;Men;1.204 ANDALUC═A;Group 0603 Epilepsy 345;Women;1.047 ANDALUC═A;Group 0604 Transient cerebral ischemia 435;Both sexes;2.383 ANDALUC═A;Group 0604 Transient cerebral ischemia 435;Men;1.269 ANDALUC═A;Group 0604 Transient cerebral ischemia 435;Women;1.114 ANDALUC═A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;8.317 ANDALUC═A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;4.116 ANDALUC═A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;4.200 ANDALUC═A;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;4.837 ANDALUC═A;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;2.657 ANDALUC═A;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;2.180 ANDALUC═A;Grupo 0701 Cataract 366;Both sexes;702 ANDALUC═A;Grupo 0701 Cataract 366;Men;408 ANDALUC═A;Grupo 0701 Cataract 366;Women;294 ANDALUC═A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;4.135 ANDALUC═A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;2.249 ANDALUC═A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1.886 ANDALUC═A;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;3.229 ANDALUC═A;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1.596 ANDALUC═A;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1.633 ANDALUC═A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;92.863 ANDALUC═A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;52.791 ANDALUC═A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;40.073 ANDALUC═A;Group 0901 Hypertensive disease 401-405;Both sexes;6.352 ANDALUC═A;Group 0901 Hypertensive disease 401-405;Men;2.712 ANDALUC═A;Group 0901 Hypertensive disease 401-405;Women;3.640 ANDALUC═A;Group 0902 Angina pectoris 4111, 413;Both sexes;5.344 ANDALUC═A;Group 0902 Angina pectoris 4111, 413;Men;3.271 ANDALUC═A;Group 0902 Angina pectoris 4111, 413;Women;2.073 ANDALUC═A;Group 0903 Acute myocardial infarction 410;Both sexes;10.029 ANDALUC═A;Group 0903 Acute myocardial infarction 410;Men;6.932 ANDALUC═A;Group 0903 Acute myocardial infarction 410;Women;3.097 ANDALUC═A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;7.185 ANDALUC═A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;5.409 ANDALUC═A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1.775 ANDALUC═A;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;2.467 ANDALUC═A;Group 0905 Diseases of the lungs circulation 415-417;Men;1.142 ANDALUC═A;Group 0905 Diseases of the lungs circulation 415-417;Women;1.325 ANDALUC═A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;11.397 ANDALUC═A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;6.116 ANDALUC═A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;5.282 ANDALUC═A;Grupo 0907 Heart failure 428;Both sexes;15.629 ANDALUC═A;Grupo 0907 Heart failure 428;Men;7.464 ANDALUC═A;Grupo 0907 Heart failure 428;Women;8.166 ANDALUC═A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;16.279 ANDALUC═A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;9.007 ANDALUC═A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;7.273 ANDALUC═A;Grupo 0909 Atherosclerosis 440;Both sexes;3.130 ANDALUC═A;Grupo 0909 Atherosclerosis 440;Men;2.382 ANDALUC═A;Grupo 0909 Atherosclerosis 440;Women;748 ANDALUC═A;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.659 ANDALUC═A;Group 0910 Varicose veins of lower extremities 454;Men;611 ANDALUC═A;Group 0910 Varicose veins of lower extremities 454;Women;1.047 ANDALUC═A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;13.391 ANDALUC═A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;7.745 ANDALUC═A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;5.647 ANDALUC═A;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;68.822 ANDALUC═A;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;39.320 ANDALUC═A;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;29.502 ANDALUC═A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;3.394 ANDALUC═A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1.752 ANDALUC═A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1.641 ANDALUC═A;Group 1002 Pneumonia 480-486;Both sexes;15.670 ANDALUC═A;Group 1002 Pneumonia 480-486;Men;9.006 ANDALUC═A;Group 1002 Pneumonia 480-486;Women;6.663 ANDALUC═A;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;7.631 ANDALUC═A;Group 1003 Acute bronchitis and bronchiolitis 466;Men;3.946 ANDALUC═A;Group 1003 Acute bronchitis and bronchiolitis 466;Women;3.685 ANDALUC═A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;2.886 ANDALUC═A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.446 ANDALUC═A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1.440 ANDALUC═A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;5.983 ANDALUC═A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;3.655 ANDALUC═A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2.328 ANDALUC═A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;8.060 ANDALUC═A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;6.310 ANDALUC═A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1.750 ANDALUC═A;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;2.124 ANDALUC═A;Group 1007 Asthma 4930-4931,4938-4939;Men;639 ANDALUC═A;Group 1007 Asthma 4930-4931,4938-4939;Women;1.485 ANDALUC═A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;23.075 ANDALUC═A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;12.565 ANDALUC═A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;10.510 ANDALUC═A;Group 1100 Diseases of the digestive system 520-579;Both sexes;86.834 ANDALUC═A;Group 1100 Diseases of the digestive system 520-579;Men;46.919 ANDALUC═A;Group 1100 Diseases of the digestive system 520-579;Women;39.914 ANDALUC═A;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;1.333 ANDALUC═A;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;656 ANDALUC═A;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;676 ANDALUC═A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1.300 ANDALUC═A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;689 ANDALUC═A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;611 ANDALUC═A;Group 1103 Diseases of the esophagus 530;Both sexes;1.957 ANDALUC═A;Group 1103 Diseases of the esophagus 530;Men;1.143 ANDALUC═A;Group 1103 Diseases of the esophagus 530;Women;814 ANDALUC═A;Group 1104 Peptic ulcer 531-534;Both sexes;1.787 ANDALUC═A;Group 1104 Peptic ulcer 531-534;Men;1.242 ANDALUC═A;Group 1104 Peptic ulcer 531-534;Women;545 ANDALUC═A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;2.362 ANDALUC═A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;1.097 ANDALUC═A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;1.266 ANDALUC═A;Group 1106 Appendicitis 540-543;Both sexes;7.749 ANDALUC═A;Group 1106 Appendicitis 540-543;Men;4.374 ANDALUC═A;Group 1106 Appendicitis 540-543;Women;3.375 ANDALUC═A;Group 1107 Inguinal hernia 550;Both sexes;6.853 ANDALUC═A;Group 1107 Inguinal hernia 550;Men;5.878 ANDALUC═A;Group 1107 Inguinal hernia 550;Women;975 ANDALUC═A;Group 1108 Other abdominal hernia 551-553;Both sexes;6.911 ANDALUC═A;Group 1108 Other abdominal hernia 551-553;Men;2.995 ANDALUC═A;Group 1108 Other abdominal hernia 551-553;Women;3.917 ANDALUC═A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;2.142 ANDALUC═A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;1.121 ANDALUC═A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;1.021 ANDALUC═A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;4.717 ANDALUC═A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;2.141 ANDALUC═A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2.576 ANDALUC═A;Group 1111 Intestinal obstruction without hernia 560;Both sexes;3.579 ANDALUC═A;Group 1111 Intestinal obstruction without hernia 560;Men;1.807 ANDALUC═A;Group 1111 Intestinal obstruction without hernia 560;Women;1.772 ANDALUC═A;Group 1112 Intestinal diverticulosis 562;Both sexes;3.374 ANDALUC═A;Group 1112 Intestinal diverticulosis 562;Men;1.733 ANDALUC═A;Group 1112 Intestinal diverticulosis 562;Women;1.642 ANDALUC═A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;5.328 ANDALUC═A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;3.462 ANDALUC═A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1.865 ANDALUC═A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2.470 ANDALUC═A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1.142 ANDALUC═A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1.329 ANDALUC═A;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1.645 ANDALUC═A;Group 1115 Alcoholic hepatitis 5710-5713;Men;1.423 ANDALUC═A;Group 1115 Alcoholic hepatitis 5710-5713;Women;222 ANDALUC═A;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;3.081 ANDALUC═A;Group 1116 Other diseases of the liver 570,5714-573;Men;1.920 ANDALUC═A;Group 1116 Other diseases of the liver 570,5714-573;Women;1.161 ANDALUC═A;Group 1117 Cholelithiasis 574;Both sexes;16.728 ANDALUC═A;Group 1117 Cholelithiasis 574;Men;6.767 ANDALUC═A;Group 1117 Cholelithiasis 574;Women;9.961 ANDALUC═A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;3.883 ANDALUC═A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;2.095 ANDALUC═A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;1.788 ANDALUC═A;Group 1119 Pancreatic diseases 577;Both sexes;5.982 ANDALUC═A;Group 1119 Pancreatic diseases 577;Men;3.241 ANDALUC═A;Group 1119 Pancreatic diseases 577;Women;2.742 ANDALUC═A;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;3.652 ANDALUC═A;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1.995 ANDALUC═A;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1.656 ANDALUC═A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;6.332 ANDALUC═A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;3.465 ANDALUC═A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;2.867 ANDALUC═A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;3.850 ANDALUC═A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;2.320 ANDALUC═A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1.530 ANDALUC═A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;269 ANDALUC═A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;146 ANDALUC═A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;124 ANDALUC═A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;2.212 ANDALUC═A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;999 ANDALUC═A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1.213 ANDALUC═A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;43.639 ANDALUC═A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;20.053 ANDALUC═A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;23.586 ANDALUC═A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ANDALUC═A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ANDALUC═A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ANDALUC═A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ANDALUC═A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ANDALUC═A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ANDALUC═A;Group 1303 Internal derangement of knee 717;Both sexes;4.505 ANDALUC═A;Group 1303 Internal derangement of knee 717;Men;2.988 ANDALUC═A;Group 1303 Internal derangement of knee 717;Women;1.517 ANDALUC═A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;17.883 ANDALUC═A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;7.287 ANDALUC═A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;10.596 ANDALUC═A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;946 ANDALUC═A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;339 ANDALUC═A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;606 ANDALUC═A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;2.376 ANDALUC═A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1.177 ANDALUC═A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1.200 ANDALUC═A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;4.414 ANDALUC═A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;2.225 ANDALUC═A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;2.189 ANDALUC═A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;1.254 ANDALUC═A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;510 ANDALUC═A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;744 ANDALUC═A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;5.737 ANDALUC═A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;2.888 ANDALUC═A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;2.849 ANDALUC═A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;6.523 ANDALUC═A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;2.639 ANDALUC═A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;3.884 ANDALUC═A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;44.611 ANDALUC═A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;19.019 ANDALUC═A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;25.592 ANDALUC═A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;4.882 ANDALUC═A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1.836 ANDALUC═A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;3.046 ANDALUC═A;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;4.877 ANDALUC═A;Group 1402 Renal failure 5836-5837, 584-586;Men;2.847 ANDALUC═A;Group 1402 Renal failure 5836-5837, 584-586;Women;2.030 ANDALUC═A;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;6.319 ANDALUC═A;Group 1403 Urolithiasis 592, 594, 7880;Men;3.490 ANDALUC═A;Group 1403 Urolithiasis 592, 594, 7880;Women;2.830 ANDALUC═A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;9.296 ANDALUC═A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;4.636 ANDALUC═A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;4.660 ANDALUC═A;Group 1405 Prostatic hyperplasia 600;Both sexes;2.960 ANDALUC═A;Group 1405 Prostatic hyperplasia 600;Men;2.960 ANDALUC═A;Group 1405 Prostatic hyperplasia 600;Women;.. ANDALUC═A;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;2.846 ANDALUC═A;Group 1406 Other diseases of the male genital organs 601-608;Men;2.846 ANDALUC═A;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ANDALUC═A;Group 1407 Disorders of breast 610-612;Both sexes;4.232 ANDALUC═A;Group 1407 Disorders of breast 610-612;Men;318 ANDALUC═A;Group 1407 Disorders of breast 610-612;Women;3.913 ANDALUC═A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;1.340 ANDALUC═A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ANDALUC═A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;1.340 ANDALUC═A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;755 ANDALUC═A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ANDALUC═A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;755 ANDALUC═A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;7.104 ANDALUC═A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;86 ANDALUC═A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;7.018 ANDALUC═A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;95.708 ANDALUC═A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ANDALUC═A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;95.708 ANDALUC═A;Group 1501 Legally induced abortion 635;Both sexes;166 ANDALUC═A;Group 1501 Legally induced abortion 635;Men;.. ANDALUC═A;Group 1501 Legally induced abortion 635;Women;166 ANDALUC═A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;5.268 ANDALUC═A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ANDALUC═A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;5.268 ANDALUC═A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;60.986 ANDALUC═A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ANDALUC═A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;60.986 ANDALUC═A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;13.310 ANDALUC═A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ANDALUC═A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;13.310 ANDALUC═A;Group 1505 Single spontaneous delivery 650;Both sexes;6.077 ANDALUC═A;Group 1505 Single spontaneous delivery 650;Men;.. ANDALUC═A;Group 1505 Single spontaneous delivery 650;Women;6.077 ANDALUC═A;Group 1506 Other deliveries 6695-6697;Both sexes;3.464 ANDALUC═A;Group 1506 Other deliveries 6695-6697;Men;.. ANDALUC═A;Group 1506 Other deliveries 6695-6697;Women;3.464 ANDALUC═A;Group 1507 Complications related to the puerperium 670-676;Both sexes;694 ANDALUC═A;Group 1507 Complications related to the puerperium 670-676;Men;.. ANDALUC═A;Group 1507 Complications related to the puerperium 670-676;Women;694 ANDALUC═A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;5.744 ANDALUC═A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ANDALUC═A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;5.744 ANDALUC═A;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;9.652 ANDALUC═A;Group 1600 Some disorders originating in the perinatal period 760-779;Men;5.284 ANDALUC═A;Group 1600 Some disorders originating in the perinatal period 760-779;Women;4.368 ANDALUC═A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;3.343 ANDALUC═A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1.736 ANDALUC═A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1.608 ANDALUC═A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;6.308 ANDALUC═A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;3.548 ANDALUC═A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;2.760 ANDALUC═A;Grupo 1700 Congenital abnormalities 740-759;Both sexes;6.220 ANDALUC═A;Grupo 1700 Congenital abnormalities 740-759;Men;3.413 ANDALUC═A;Grupo 1700 Congenital abnormalities 740-759;Women;2.807 ANDALUC═A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;32.735 ANDALUC═A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;17.268 ANDALUC═A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;15.467 ANDALUC═A;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;4.663 ANDALUC═A;Group 1801 Pain in throat and chest 7841, 7865;Men;2.581 ANDALUC═A;Group 1801 Pain in throat and chest 7841, 7865;Women;2.082 ANDALUC═A;Group 1802 Abdominal pain 7890;Both sexes;4.485 ANDALUC═A;Group 1802 Abdominal pain 7890;Men;1.735 ANDALUC═A;Group 1802 Abdominal pain 7890;Women;2.750 ANDALUC═A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.905 ANDALUC═A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1.016 ANDALUC═A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;889 ANDALUC═A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;21.682 ANDALUC═A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;11.936 ANDALUC═A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;9.745 ANDALUC═A;Group 1900 Injuries and poisoning 800-999;Both sexes;61.427 ANDALUC═A;Group 1900 Injuries and poisoning 800-999;Men;31.085 ANDALUC═A;Group 1900 Injuries and poisoning 800-999;Women;30.341 ANDALUC═A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;2.937 ANDALUC═A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1.773 ANDALUC═A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;1.164 ANDALUC═A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1.798 ANDALUC═A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;1.302 ANDALUC═A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;496 ANDALUC═A;Group 1903 Radius and ulna fracture 813;Both sexes;4.556 ANDALUC═A;Group 1903 Radius and ulna fracture 813;Men;2.165 ANDALUC═A;Group 1903 Radius and ulna fracture 813;Women;2.391 ANDALUC═A;Group 1904 Femur fracture 820-821;Both sexes;10.518 ANDALUC═A;Group 1904 Femur fracture 820-821;Men;3.134 ANDALUC═A;Group 1904 Femur fracture 820-821;Women;7.384 ANDALUC═A;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;5.263 ANDALUC═A;Group 1905 Leg fracture, including the ankle 823-824;Men;2.717 ANDALUC═A;Group 1905 Leg fracture, including the ankle 823-824;Women;2.546 ANDALUC═A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;16.527 ANDALUC═A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;9.511 ANDALUC═A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;7.017 ANDALUC═A;Group 1907 Burns 940-949;Both sexes;530 ANDALUC═A;Group 1907 Burns 940-949;Men;303 ANDALUC═A;Group 1907 Burns 940-949;Women;227 ANDALUC═A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;1.881 ANDALUC═A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;916 ANDALUC═A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;966 ANDALUC═A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;15.837 ANDALUC═A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;8.385 ANDALUC═A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;7.453 ANDALUC═A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;290 ANDALUC═A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;170 ANDALUC═A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;120 ANDALUC═A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1.289 ANDALUC═A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;710 ANDALUC═A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;578 ANDALUC═A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;11.535 ANDALUC═A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;5.158 ANDALUC═A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;6.377 ANDALUC═A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;558 ANDALUC═A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;323 ANDALUC═A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;235 ANDALUC═A;Group 2102 Contraceptive management V25;Both sexes;142 ANDALUC═A;Group 2102 Contraceptive management V25;Men;22 ANDALUC═A;Group 2102 Contraceptive management V25;Women;120 ANDALUC═A;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ANDALUC═A;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ANDALUC═A;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ANDALUC═A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;4.039 ANDALUC═A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;2.502 ANDALUC═A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1.537 ANDALUC═A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;6.796 ANDALUC═A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;2.311 ANDALUC═A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;4.486 AlmerÝa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;53.840 AlmerÝa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;23.986 AlmerÝa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;29.854 AlmerÝa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.481 AlmerÝa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;866 AlmerÝa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;615 AlmerÝa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;219 AlmerÝa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;119 AlmerÝa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;100 AlmerÝa;Group 0102 Imprecise intestinal infections 009;Both sexes;237 AlmerÝa;Group 0102 Imprecise intestinal infections 009;Men;121 AlmerÝa;Group 0102 Imprecise intestinal infections 009;Women;116 AlmerÝa;Group 0103 Tuberculosis 010-018, 137;Both sexes;91 AlmerÝa;Group 0103 Tuberculosis 010-018, 137;Men;66 AlmerÝa;Group 0103 Tuberculosis 010-018, 137;Women;25 AlmerÝa;Group 0104 Septicaemia 038;Both sexes;468 AlmerÝa;Group 0104 Septicaemia 038;Men;254 AlmerÝa;Group 0104 Septicaemia 038;Women;214 AlmerÝa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;51 AlmerÝa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;38 AlmerÝa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;13 AlmerÝa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;415 AlmerÝa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;268 AlmerÝa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;147 AlmerÝa;Group 0200 Neoplasms 140-239;Both sexes;4.183 AlmerÝa;Group 0200 Neoplasms 140-239;Men;2.175 AlmerÝa;Group 0200 Neoplasms 140-239;Women;2.008 AlmerÝa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;461 AlmerÝa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;272 AlmerÝa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;189 AlmerÝa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;380 AlmerÝa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;329 AlmerÝa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;51 AlmerÝa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;46 AlmerÝa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;33 AlmerÝa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;13 AlmerÝa;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;334 AlmerÝa;Group 0204 Malignant neoplasm of breast 174-175;Men;5 AlmerÝa;Group 0204 Malignant neoplasm of breast 174-175;Women;329 AlmerÝa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;98 AlmerÝa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. AlmerÝa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;98 AlmerÝa;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;60 AlmerÝa;Group 0206 Malignant neoplasm of ovary 1830;Men;.. AlmerÝa;Group 0206 Malignant neoplasm of ovary 1830;Women;60 AlmerÝa;Group 0207 Malignant neoplasm of prostate 185;Both sexes;116 AlmerÝa;Group 0207 Malignant neoplasm of prostate 185;Men;116 AlmerÝa;Group 0207 Malignant neoplasm of prostate 185;Women;.. AlmerÝa;Group 0208 Malignant neoplasm of bladder 188;Both sexes;428 AlmerÝa;Group 0208 Malignant neoplasm of bladder 188;Men;381 AlmerÝa;Group 0208 Malignant neoplasm of bladder 188;Women;47 AlmerÝa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.348 AlmerÝa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;758 AlmerÝa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;590 AlmerÝa;Group 0210 Carcinoma in situ 230-234;Both sexes;30 AlmerÝa;Group 0210 Carcinoma in situ 230-234;Men;5 AlmerÝa;Group 0210 Carcinoma in situ 230-234;Women;25 AlmerÝa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;32 AlmerÝa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;18 AlmerÝa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;14 AlmerÝa;Grupo 0212 Leiomyoma of uterus 218;Both sexes;295 AlmerÝa;Grupo 0212 Leiomyoma of uterus 218;Men;.. AlmerÝa;Grupo 0212 Leiomyoma of uterus 218;Women;295 AlmerÝa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;555 AlmerÝa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;258 AlmerÝa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;297 AlmerÝa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;479 AlmerÝa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;238 AlmerÝa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;241 AlmerÝa;Group 0301 Anaemias 280-285;Both sexes;262 AlmerÝa;Group 0301 Anaemias 280-285;Men;142 AlmerÝa;Group 0301 Anaemias 280-285;Women;120 AlmerÝa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;217 AlmerÝa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;96 AlmerÝa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;121 AlmerÝa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;938 AlmerÝa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;445 AlmerÝa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;493 AlmerÝa;Group 0401 Diabetes mellitus 249-250;Both sexes;338 AlmerÝa;Group 0401 Diabetes mellitus 249-250;Men;218 AlmerÝa;Group 0401 Diabetes mellitus 249-250;Women;120 AlmerÝa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;600 AlmerÝa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;227 AlmerÝa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;373 AlmerÝa;Group 0500 Mental disorders 290-319;Both sexes;949 AlmerÝa;Group 0500 Mental disorders 290-319;Men;555 AlmerÝa;Group 0500 Mental disorders 290-319;Women;394 AlmerÝa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;14 AlmerÝa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;11 AlmerÝa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;3 AlmerÝa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;20 AlmerÝa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;18 AlmerÝa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;2 AlmerÝa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;41 AlmerÝa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;28 AlmerÝa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;13 AlmerÝa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;408 AlmerÝa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;266 AlmerÝa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;142 AlmerÝa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;157 AlmerÝa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;92 AlmerÝa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;65 AlmerÝa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;309 AlmerÝa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;140 AlmerÝa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;169 AlmerÝa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;882 AlmerÝa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;446 AlmerÝa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;436 AlmerÝa;Group 0601 Alzheimer's disease 3310;Both sexes;38 AlmerÝa;Group 0601 Alzheimer's disease 3310;Men;18 AlmerÝa;Group 0601 Alzheimer's disease 3310;Women;20 AlmerÝa;Group 0602 Multiple sclerosis 340;Both sexes;16 AlmerÝa;Group 0602 Multiple sclerosis 340;Men;2 AlmerÝa;Group 0602 Multiple sclerosis 340;Women;14 AlmerÝa;Group 0603 Epilepsy 345;Both sexes;119 AlmerÝa;Group 0603 Epilepsy 345;Men;66 AlmerÝa;Group 0603 Epilepsy 345;Women;53 AlmerÝa;Group 0604 Transient cerebral ischemia 435;Both sexes;215 AlmerÝa;Group 0604 Transient cerebral ischemia 435;Men;111 AlmerÝa;Group 0604 Transient cerebral ischemia 435;Women;104 AlmerÝa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;494 AlmerÝa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;249 AlmerÝa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;245 AlmerÝa;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;343 AlmerÝa;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;200 AlmerÝa;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;143 AlmerÝa;Grupo 0701 Cataract 366;Both sexes;27 AlmerÝa;Grupo 0701 Cataract 366;Men;19 AlmerÝa;Grupo 0701 Cataract 366;Women;8 AlmerÝa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;316 AlmerÝa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;181 AlmerÝa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;135 AlmerÝa;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;266 AlmerÝa;Group 0800 Diseases of the ear and the mastoid 380-389;Men;120 AlmerÝa;Group 0800 Diseases of the ear and the mastoid 380-389;Women;146 AlmerÝa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5.863 AlmerÝa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.489 AlmerÝa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.374 AlmerÝa;Group 0901 Hypertensive disease 401-405;Both sexes;302 AlmerÝa;Group 0901 Hypertensive disease 401-405;Men;116 AlmerÝa;Group 0901 Hypertensive disease 401-405;Women;186 AlmerÝa;Group 0902 Angina pectoris 4111, 413;Both sexes;251 AlmerÝa;Group 0902 Angina pectoris 4111, 413;Men;164 AlmerÝa;Group 0902 Angina pectoris 4111, 413;Women;87 AlmerÝa;Group 0903 Acute myocardial infarction 410;Both sexes;813 AlmerÝa;Group 0903 Acute myocardial infarction 410;Men;601 AlmerÝa;Group 0903 Acute myocardial infarction 410;Women;212 AlmerÝa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;408 AlmerÝa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;310 AlmerÝa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;98 AlmerÝa;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;188 AlmerÝa;Group 0905 Diseases of the lungs circulation 415-417;Men;93 AlmerÝa;Group 0905 Diseases of the lungs circulation 415-417;Women;95 AlmerÝa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;679 AlmerÝa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;381 AlmerÝa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;298 AlmerÝa;Grupo 0907 Heart failure 428;Both sexes;1.115 AlmerÝa;Grupo 0907 Heart failure 428;Men;538 AlmerÝa;Grupo 0907 Heart failure 428;Women;577 AlmerÝa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.216 AlmerÝa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;681 AlmerÝa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;535 AlmerÝa;Grupo 0909 Atherosclerosis 440;Both sexes;243 AlmerÝa;Grupo 0909 Atherosclerosis 440;Men;197 AlmerÝa;Grupo 0909 Atherosclerosis 440;Women;46 AlmerÝa;Group 0910 Varicose veins of lower extremities 454;Both sexes;4 AlmerÝa;Group 0910 Varicose veins of lower extremities 454;Men;1 AlmerÝa;Group 0910 Varicose veins of lower extremities 454;Women;3 AlmerÝa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;644 AlmerÝa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;407 AlmerÝa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;237 AlmerÝa;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6.671 AlmerÝa;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.865 AlmerÝa;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.806 AlmerÝa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;301 AlmerÝa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;170 AlmerÝa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;131 AlmerÝa;Group 1002 Pneumonia 480-486;Both sexes;1.612 AlmerÝa;Group 1002 Pneumonia 480-486;Men;961 AlmerÝa;Group 1002 Pneumonia 480-486;Women;651 AlmerÝa;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.102 AlmerÝa;Group 1003 Acute bronchitis and bronchiolitis 466;Men;516 AlmerÝa;Group 1003 Acute bronchitis and bronchiolitis 466;Women;586 AlmerÝa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;223 AlmerÝa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;118 AlmerÝa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;105 AlmerÝa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;393 AlmerÝa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;271 AlmerÝa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;122 AlmerÝa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;968 AlmerÝa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;825 AlmerÝa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;143 AlmerÝa;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;282 AlmerÝa;Group 1007 Asthma 4930-4931,4938-4939;Men;107 AlmerÝa;Group 1007 Asthma 4930-4931,4938-4939;Women;175 AlmerÝa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.790 AlmerÝa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;897 AlmerÝa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;893 AlmerÝa;Group 1100 Diseases of the digestive system 520-579;Both sexes;6.530 AlmerÝa;Group 1100 Diseases of the digestive system 520-579;Men;3.604 AlmerÝa;Group 1100 Diseases of the digestive system 520-579;Women;2.926 AlmerÝa;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;107 AlmerÝa;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;58 AlmerÝa;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;49 AlmerÝa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;160 AlmerÝa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;95 AlmerÝa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;65 AlmerÝa;Group 1103 Diseases of the esophagus 530;Both sexes;131 AlmerÝa;Group 1103 Diseases of the esophagus 530;Men;75 AlmerÝa;Group 1103 Diseases of the esophagus 530;Women;56 AlmerÝa;Group 1104 Peptic ulcer 531-534;Both sexes;143 AlmerÝa;Group 1104 Peptic ulcer 531-534;Men;116 AlmerÝa;Group 1104 Peptic ulcer 531-534;Women;27 AlmerÝa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;171 AlmerÝa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;72 AlmerÝa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;99 AlmerÝa;Group 1106 Appendicitis 540-543;Both sexes;712 AlmerÝa;Group 1106 Appendicitis 540-543;Men;440 AlmerÝa;Group 1106 Appendicitis 540-543;Women;272 AlmerÝa;Group 1107 Inguinal hernia 550;Both sexes;351 AlmerÝa;Group 1107 Inguinal hernia 550;Men;308 AlmerÝa;Group 1107 Inguinal hernia 550;Women;43 AlmerÝa;Group 1108 Other abdominal hernia 551-553;Both sexes;344 AlmerÝa;Group 1108 Other abdominal hernia 551-553;Men;168 AlmerÝa;Group 1108 Other abdominal hernia 551-553;Women;176 AlmerÝa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;177 AlmerÝa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;90 AlmerÝa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;87 AlmerÝa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;361 AlmerÝa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;155 AlmerÝa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;206 AlmerÝa;Group 1111 Intestinal obstruction without hernia 560;Both sexes;279 AlmerÝa;Group 1111 Intestinal obstruction without hernia 560;Men;150 AlmerÝa;Group 1111 Intestinal obstruction without hernia 560;Women;129 AlmerÝa;Group 1112 Intestinal diverticulosis 562;Both sexes;290 AlmerÝa;Group 1112 Intestinal diverticulosis 562;Men;155 AlmerÝa;Group 1112 Intestinal diverticulosis 562;Women;135 AlmerÝa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;391 AlmerÝa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;262 AlmerÝa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;129 AlmerÝa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;184 AlmerÝa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;77 AlmerÝa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;107 AlmerÝa;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;140 AlmerÝa;Group 1115 Alcoholic hepatitis 5710-5713;Men;119 AlmerÝa;Group 1115 Alcoholic hepatitis 5710-5713;Women;21 AlmerÝa;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;192 AlmerÝa;Group 1116 Other diseases of the liver 570,5714-573;Men;117 AlmerÝa;Group 1116 Other diseases of the liver 570,5714-573;Women;75 AlmerÝa;Group 1117 Cholelithiasis 574;Both sexes;1.301 AlmerÝa;Group 1117 Cholelithiasis 574;Men;541 AlmerÝa;Group 1117 Cholelithiasis 574;Women;760 AlmerÝa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;320 AlmerÝa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;172 AlmerÝa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;148 AlmerÝa;Group 1119 Pancreatic diseases 577;Both sexes;535 AlmerÝa;Group 1119 Pancreatic diseases 577;Men;304 AlmerÝa;Group 1119 Pancreatic diseases 577;Women;231 AlmerÝa;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;241 AlmerÝa;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;130 AlmerÝa;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;111 AlmerÝa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;456 AlmerÝa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;263 AlmerÝa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;193 AlmerÝa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;319 AlmerÝa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;202 AlmerÝa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;117 AlmerÝa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;16 AlmerÝa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;7 AlmerÝa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;9 AlmerÝa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;121 AlmerÝa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;54 AlmerÝa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;67 AlmerÝa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3.349 AlmerÝa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.614 AlmerÝa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.735 AlmerÝa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. AlmerÝa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. AlmerÝa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. AlmerÝa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. AlmerÝa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. AlmerÝa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. AlmerÝa;Group 1303 Internal derangement of knee 717;Both sexes;397 AlmerÝa;Group 1303 Internal derangement of knee 717;Men;262 AlmerÝa;Group 1303 Internal derangement of knee 717;Women;135 AlmerÝa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.288 AlmerÝa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;523 AlmerÝa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;765 AlmerÝa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;86 AlmerÝa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;41 AlmerÝa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;45 AlmerÝa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;153 AlmerÝa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;92 AlmerÝa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;61 AlmerÝa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;277 AlmerÝa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;146 AlmerÝa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;131 AlmerÝa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;68 AlmerÝa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;32 AlmerÝa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;36 AlmerÝa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;549 AlmerÝa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;274 AlmerÝa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;275 AlmerÝa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;531 AlmerÝa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;244 AlmerÝa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;287 AlmerÝa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.438 AlmerÝa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.477 AlmerÝa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.961 AlmerÝa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;435 AlmerÝa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;181 AlmerÝa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;254 AlmerÝa;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;363 AlmerÝa;Group 1402 Renal failure 5836-5837, 584-586;Men;215 AlmerÝa;Group 1402 Renal failure 5836-5837, 584-586;Women;148 AlmerÝa;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;379 AlmerÝa;Group 1403 Urolithiasis 592, 594, 7880;Men;215 AlmerÝa;Group 1403 Urolithiasis 592, 594, 7880;Women;164 AlmerÝa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;968 AlmerÝa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;475 AlmerÝa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;493 AlmerÝa;Group 1405 Prostatic hyperplasia 600;Both sexes;220 AlmerÝa;Group 1405 Prostatic hyperplasia 600;Men;220 AlmerÝa;Group 1405 Prostatic hyperplasia 600;Women;.. AlmerÝa;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;148 AlmerÝa;Group 1406 Other diseases of the male genital organs 601-608;Men;148 AlmerÝa;Group 1406 Other diseases of the male genital organs 601-608;Women;.. AlmerÝa;Group 1407 Disorders of breast 610-612;Both sexes;252 AlmerÝa;Group 1407 Disorders of breast 610-612;Men;21 AlmerÝa;Group 1407 Disorders of breast 610-612;Women;231 AlmerÝa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;112 AlmerÝa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. AlmerÝa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;112 AlmerÝa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;38 AlmerÝa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. AlmerÝa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;38 AlmerÝa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;523 AlmerÝa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 AlmerÝa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;521 AlmerÝa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;9.599 AlmerÝa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. AlmerÝa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;9.599 AlmerÝa;Group 1501 Legally induced abortion 635;Both sexes;23 AlmerÝa;Group 1501 Legally induced abortion 635;Men;.. AlmerÝa;Group 1501 Legally induced abortion 635;Women;23 AlmerÝa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;614 AlmerÝa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. AlmerÝa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;614 AlmerÝa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.441 AlmerÝa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. AlmerÝa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.441 AlmerÝa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.048 AlmerÝa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. AlmerÝa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.048 AlmerÝa;Group 1505 Single spontaneous delivery 650;Both sexes;462 AlmerÝa;Group 1505 Single spontaneous delivery 650;Men;.. AlmerÝa;Group 1505 Single spontaneous delivery 650;Women;462 AlmerÝa;Group 1506 Other deliveries 6695-6697;Both sexes;287 AlmerÝa;Group 1506 Other deliveries 6695-6697;Men;.. AlmerÝa;Group 1506 Other deliveries 6695-6697;Women;287 AlmerÝa;Group 1507 Complications related to the puerperium 670-676;Both sexes;34 AlmerÝa;Group 1507 Complications related to the puerperium 670-676;Men;.. AlmerÝa;Group 1507 Complications related to the puerperium 670-676;Women;34 AlmerÝa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;690 AlmerÝa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. AlmerÝa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;690 AlmerÝa;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;836 AlmerÝa;Group 1600 Some disorders originating in the perinatal period 760-779;Men;480 AlmerÝa;Group 1600 Some disorders originating in the perinatal period 760-779;Women;356 AlmerÝa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;291 AlmerÝa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;151 AlmerÝa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;140 AlmerÝa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;545 AlmerÝa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;329 AlmerÝa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;216 AlmerÝa;Grupo 1700 Congenital abnormalities 740-759;Both sexes;408 AlmerÝa;Grupo 1700 Congenital abnormalities 740-759;Men;241 AlmerÝa;Grupo 1700 Congenital abnormalities 740-759;Women;167 AlmerÝa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.186 AlmerÝa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.179 AlmerÝa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.007 AlmerÝa;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;270 AlmerÝa;Group 1801 Pain in throat and chest 7841, 7865;Men;145 AlmerÝa;Group 1801 Pain in throat and chest 7841, 7865;Women;125 AlmerÝa;Group 1802 Abdominal pain 7890;Both sexes;289 AlmerÝa;Group 1802 Abdominal pain 7890;Men;117 AlmerÝa;Group 1802 Abdominal pain 7890;Women;172 AlmerÝa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;108 AlmerÝa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;57 AlmerÝa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;51 AlmerÝa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.519 AlmerÝa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;860 AlmerÝa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;659 AlmerÝa;Group 1900 Injuries and poisoning 800-999;Both sexes;4.371 AlmerÝa;Group 1900 Injuries and poisoning 800-999;Men;2.381 AlmerÝa;Group 1900 Injuries and poisoning 800-999;Women;1.990 AlmerÝa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;207 AlmerÝa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;135 AlmerÝa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;72 AlmerÝa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;146 AlmerÝa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;113 AlmerÝa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;33 AlmerÝa;Group 1903 Radius and ulna fracture 813;Both sexes;388 AlmerÝa;Group 1903 Radius and ulna fracture 813;Men;217 AlmerÝa;Group 1903 Radius and ulna fracture 813;Women;171 AlmerÝa;Group 1904 Femur fracture 820-821;Both sexes;784 AlmerÝa;Group 1904 Femur fracture 820-821;Men;242 AlmerÝa;Group 1904 Femur fracture 820-821;Women;542 AlmerÝa;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;407 AlmerÝa;Group 1905 Leg fracture, including the ankle 823-824;Men;221 AlmerÝa;Group 1905 Leg fracture, including the ankle 823-824;Women;186 AlmerÝa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.187 AlmerÝa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;802 AlmerÝa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;385 AlmerÝa;Group 1907 Burns 940-949;Both sexes;38 AlmerÝa;Group 1907 Burns 940-949;Men;20 AlmerÝa;Group 1907 Burns 940-949;Women;18 AlmerÝa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;142 AlmerÝa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;75 AlmerÝa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;67 AlmerÝa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;954 AlmerÝa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;496 AlmerÝa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;458 AlmerÝa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;7 AlmerÝa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;5 AlmerÝa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 AlmerÝa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;111 AlmerÝa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;55 AlmerÝa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;56 AlmerÝa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;612 AlmerÝa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;348 AlmerÝa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;264 AlmerÝa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;12 AlmerÝa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;7 AlmerÝa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;5 AlmerÝa;Group 2102 Contraceptive management V25;Both sexes;6 AlmerÝa;Group 2102 Contraceptive management V25;Men;2 AlmerÝa;Group 2102 Contraceptive management V25;Women;4 AlmerÝa;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. AlmerÝa;Group 2103 Living newborns by type of delivery V30-V39;Men;.. AlmerÝa;Group 2103 Living newborns by type of delivery V30-V39;Women;.. AlmerÝa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;347 AlmerÝa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;205 AlmerÝa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;142 AlmerÝa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;247 AlmerÝa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;134 AlmerÝa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;113 Cßdiz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;104.518 Cßdiz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;47.918 Cßdiz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;56.600 Cßdiz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;4.015 Cßdiz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2.220 Cßdiz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.795 Cßdiz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;308 Cßdiz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;164 Cßdiz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;144 Cßdiz;Group 0102 Imprecise intestinal infections 009;Both sexes;613 Cßdiz;Group 0102 Imprecise intestinal infections 009;Men;336 Cßdiz;Group 0102 Imprecise intestinal infections 009;Women;277 Cßdiz;Group 0103 Tuberculosis 010-018, 137;Both sexes;83 Cßdiz;Group 0103 Tuberculosis 010-018, 137;Men;55 Cßdiz;Group 0103 Tuberculosis 010-018, 137;Women;28 Cßdiz;Group 0104 Septicaemia 038;Both sexes;1.999 Cßdiz;Group 0104 Septicaemia 038;Men;1.079 Cßdiz;Group 0104 Septicaemia 038;Women;920 Cßdiz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;87 Cßdiz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;62 Cßdiz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;25 Cßdiz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;925 Cßdiz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;524 Cßdiz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;400 Cßdiz;Group 0200 Neoplasms 140-239;Both sexes;8.824 Cßdiz;Group 0200 Neoplasms 140-239;Men;4.713 Cßdiz;Group 0200 Neoplasms 140-239;Women;4.111 Cßdiz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;886 Cßdiz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;513 Cßdiz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;373 Cßdiz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;728 Cßdiz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;610 Cßdiz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;118 Cßdiz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;174 Cßdiz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;99 Cßdiz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;75 Cßdiz;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;758 Cßdiz;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Cßdiz;Group 0204 Malignant neoplasm of breast 174-175;Women;755 Cßdiz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;180 Cßdiz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Cßdiz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;180 Cßdiz;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;103 Cßdiz;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Cßdiz;Group 0206 Malignant neoplasm of ovary 1830;Women;103 Cßdiz;Group 0207 Malignant neoplasm of prostate 185;Both sexes;216 Cßdiz;Group 0207 Malignant neoplasm of prostate 185;Men;216 Cßdiz;Group 0207 Malignant neoplasm of prostate 185;Women;.. Cßdiz;Group 0208 Malignant neoplasm of bladder 188;Both sexes;880 Cßdiz;Group 0208 Malignant neoplasm of bladder 188;Men;754 Cßdiz;Group 0208 Malignant neoplasm of bladder 188;Women;126 Cßdiz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3.123 Cßdiz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.887 Cßdiz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.237 Cßdiz;Group 0210 Carcinoma in situ 230-234;Both sexes;169 Cßdiz;Group 0210 Carcinoma in situ 230-234;Men;97 Cßdiz;Group 0210 Carcinoma in situ 230-234;Women;72 Cßdiz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;72 Cßdiz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;47 Cßdiz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;25 Cßdiz;Grupo 0212 Leiomyoma of uterus 218;Both sexes;453 Cßdiz;Grupo 0212 Leiomyoma of uterus 218;Men;.. Cßdiz;Grupo 0212 Leiomyoma of uterus 218;Women;453 Cßdiz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.083 Cßdiz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;489 Cßdiz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;594 Cßdiz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.108 Cßdiz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;513 Cßdiz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;594 Cßdiz;Group 0301 Anaemias 280-285;Both sexes;666 Cßdiz;Group 0301 Anaemias 280-285;Men;323 Cßdiz;Group 0301 Anaemias 280-285;Women;342 Cßdiz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;442 Cßdiz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;190 Cßdiz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;252 Cßdiz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.846 Cßdiz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;805 Cßdiz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.041 Cßdiz;Group 0401 Diabetes mellitus 249-250;Both sexes;646 Cßdiz;Group 0401 Diabetes mellitus 249-250;Men;383 Cßdiz;Group 0401 Diabetes mellitus 249-250;Women;263 Cßdiz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.200 Cßdiz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;422 Cßdiz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;778 Cßdiz;Group 0500 Mental disorders 290-319;Both sexes;1.703 Cßdiz;Group 0500 Mental disorders 290-319;Men;973 Cßdiz;Group 0500 Mental disorders 290-319;Women;730 Cßdiz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;62 Cßdiz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;28 Cßdiz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;34 Cßdiz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;93 Cßdiz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;72 Cßdiz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;21 Cßdiz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;133 Cßdiz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;102 Cßdiz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;31 Cßdiz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;492 Cßdiz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;346 Cßdiz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;145 Cßdiz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;360 Cßdiz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;165 Cßdiz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;195 Cßdiz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;563 Cßdiz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;260 Cßdiz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;303 Cßdiz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.239 Cßdiz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.131 Cßdiz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.109 Cßdiz;Group 0601 Alzheimer's disease 3310;Both sexes;39 Cßdiz;Group 0601 Alzheimer's disease 3310;Men;12 Cßdiz;Group 0601 Alzheimer's disease 3310;Women;26 Cßdiz;Group 0602 Multiple sclerosis 340;Both sexes;72 Cßdiz;Group 0602 Multiple sclerosis 340;Men;26 Cßdiz;Group 0602 Multiple sclerosis 340;Women;46 Cßdiz;Group 0603 Epilepsy 345;Both sexes;333 Cßdiz;Group 0603 Epilepsy 345;Men;183 Cßdiz;Group 0603 Epilepsy 345;Women;150 Cßdiz;Group 0604 Transient cerebral ischemia 435;Both sexes;497 Cßdiz;Group 0604 Transient cerebral ischemia 435;Men;264 Cßdiz;Group 0604 Transient cerebral ischemia 435;Women;233 Cßdiz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.299 Cßdiz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;645 Cßdiz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;653 Cßdiz;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;540 Cßdiz;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;256 Cßdiz;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;284 Cßdiz;Grupo 0701 Cataract 366;Both sexes;98 Cßdiz;Grupo 0701 Cataract 366;Men;48 Cßdiz;Grupo 0701 Cataract 366;Women;50 Cßdiz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;443 Cßdiz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;208 Cßdiz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;235 Cßdiz;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;411 Cßdiz;Group 0800 Diseases of the ear and the mastoid 380-389;Men;195 Cßdiz;Group 0800 Diseases of the ear and the mastoid 380-389;Women;216 Cßdiz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;14.310 Cßdiz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;8.006 Cßdiz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;6.304 Cßdiz;Group 0901 Hypertensive disease 401-405;Both sexes;777 Cßdiz;Group 0901 Hypertensive disease 401-405;Men;346 Cßdiz;Group 0901 Hypertensive disease 401-405;Women;431 Cßdiz;Group 0902 Angina pectoris 4111, 413;Both sexes;980 Cßdiz;Group 0902 Angina pectoris 4111, 413;Men;568 Cßdiz;Group 0902 Angina pectoris 4111, 413;Women;412 Cßdiz;Group 0903 Acute myocardial infarction 410;Both sexes;1.422 Cßdiz;Group 0903 Acute myocardial infarction 410;Men;1.005 Cßdiz;Group 0903 Acute myocardial infarction 410;Women;417 Cßdiz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.364 Cßdiz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;977 Cßdiz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;386 Cßdiz;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;274 Cßdiz;Group 0905 Diseases of the lungs circulation 415-417;Men;130 Cßdiz;Group 0905 Diseases of the lungs circulation 415-417;Women;144 Cßdiz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.884 Cßdiz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;991 Cßdiz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;893 Cßdiz;Grupo 0907 Heart failure 428;Both sexes;2.529 Cßdiz;Grupo 0907 Heart failure 428;Men;1.123 Cßdiz;Grupo 0907 Heart failure 428;Women;1.406 Cßdiz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.564 Cßdiz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.383 Cßdiz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.181 Cßdiz;Grupo 0909 Atherosclerosis 440;Both sexes;475 Cßdiz;Grupo 0909 Atherosclerosis 440;Men;358 Cßdiz;Grupo 0909 Atherosclerosis 440;Women;117 Cßdiz;Group 0910 Varicose veins of lower extremities 454;Both sexes;145 Cßdiz;Group 0910 Varicose veins of lower extremities 454;Men;53 Cßdiz;Group 0910 Varicose veins of lower extremities 454;Women;92 Cßdiz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.897 Cßdiz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.073 Cßdiz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;824 Cßdiz;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;10.763 Cßdiz;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;6.045 Cßdiz;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4.717 Cßdiz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;568 Cßdiz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;283 Cßdiz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;284 Cßdiz;Group 1002 Pneumonia 480-486;Both sexes;2.255 Cßdiz;Group 1002 Pneumonia 480-486;Men;1.244 Cßdiz;Group 1002 Pneumonia 480-486;Women;1.012 Cßdiz;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.733 Cßdiz;Group 1003 Acute bronchitis and bronchiolitis 466;Men;886 Cßdiz;Group 1003 Acute bronchitis and bronchiolitis 466;Women;847 Cßdiz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;375 Cßdiz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;181 Cßdiz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;194 Cßdiz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;909 Cßdiz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;588 Cßdiz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;321 Cßdiz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.178 Cßdiz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;899 Cßdiz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;278 Cßdiz;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;304 Cßdiz;Group 1007 Asthma 4930-4931,4938-4939;Men;107 Cßdiz;Group 1007 Asthma 4930-4931,4938-4939;Women;197 Cßdiz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.440 Cßdiz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.857 Cßdiz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.583 Cßdiz;Group 1100 Diseases of the digestive system 520-579;Both sexes;13.013 Cßdiz;Group 1100 Diseases of the digestive system 520-579;Men;7.212 Cßdiz;Group 1100 Diseases of the digestive system 520-579;Women;5.801 Cßdiz;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;140 Cßdiz;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;70 Cßdiz;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;70 Cßdiz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;169 Cßdiz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;94 Cßdiz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;74 Cßdiz;Group 1103 Diseases of the esophagus 530;Both sexes;198 Cßdiz;Group 1103 Diseases of the esophagus 530;Men;130 Cßdiz;Group 1103 Diseases of the esophagus 530;Women;68 Cßdiz;Group 1104 Peptic ulcer 531-534;Both sexes;264 Cßdiz;Group 1104 Peptic ulcer 531-534;Men;177 Cßdiz;Group 1104 Peptic ulcer 531-534;Women;87 Cßdiz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;496 Cßdiz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;228 Cßdiz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;268 Cßdiz;Group 1106 Appendicitis 540-543;Both sexes;1.065 Cßdiz;Group 1106 Appendicitis 540-543;Men;609 Cßdiz;Group 1106 Appendicitis 540-543;Women;456 Cßdiz;Group 1107 Inguinal hernia 550;Both sexes;1.285 Cßdiz;Group 1107 Inguinal hernia 550;Men;1.146 Cßdiz;Group 1107 Inguinal hernia 550;Women;139 Cßdiz;Group 1108 Other abdominal hernia 551-553;Both sexes;973 Cßdiz;Group 1108 Other abdominal hernia 551-553;Men;446 Cßdiz;Group 1108 Other abdominal hernia 551-553;Women;527 Cßdiz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;376 Cßdiz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;187 Cßdiz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;189 Cßdiz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;808 Cßdiz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;340 Cßdiz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;467 Cßdiz;Group 1111 Intestinal obstruction without hernia 560;Both sexes;528 Cßdiz;Group 1111 Intestinal obstruction without hernia 560;Men;285 Cßdiz;Group 1111 Intestinal obstruction without hernia 560;Women;243 Cßdiz;Group 1112 Intestinal diverticulosis 562;Both sexes;484 Cßdiz;Group 1112 Intestinal diverticulosis 562;Men;256 Cßdiz;Group 1112 Intestinal diverticulosis 562;Women;228 Cßdiz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;745 Cßdiz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;457 Cßdiz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;288 Cßdiz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;392 Cßdiz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;179 Cßdiz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;213 Cßdiz;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;306 Cßdiz;Group 1115 Alcoholic hepatitis 5710-5713;Men;261 Cßdiz;Group 1115 Alcoholic hepatitis 5710-5713;Women;45 Cßdiz;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;518 Cßdiz;Group 1116 Other diseases of the liver 570,5714-573;Men;334 Cßdiz;Group 1116 Other diseases of the liver 570,5714-573;Women;184 Cßdiz;Group 1117 Cholelithiasis 574;Both sexes;2.288 Cßdiz;Group 1117 Cholelithiasis 574;Men;901 Cßdiz;Group 1117 Cholelithiasis 574;Women;1.387 Cßdiz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;602 Cßdiz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;327 Cßdiz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;274 Cßdiz;Group 1119 Pancreatic diseases 577;Both sexes;822 Cßdiz;Group 1119 Pancreatic diseases 577;Men;469 Cßdiz;Group 1119 Pancreatic diseases 577;Women;353 Cßdiz;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;555 Cßdiz;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;315 Cßdiz;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;240 Cßdiz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.167 Cßdiz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;641 Cßdiz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;526 Cßdiz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;701 Cßdiz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;426 Cßdiz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;275 Cßdiz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;62 Cßdiz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;35 Cßdiz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;27 Cßdiz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;404 Cßdiz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;181 Cßdiz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;224 Cßdiz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;5.307 Cßdiz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.454 Cßdiz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.853 Cßdiz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Cßdiz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Cßdiz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Cßdiz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Cßdiz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Cßdiz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Cßdiz;Group 1303 Internal derangement of knee 717;Both sexes;613 Cßdiz;Group 1303 Internal derangement of knee 717;Men;417 Cßdiz;Group 1303 Internal derangement of knee 717;Women;196 Cßdiz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.205 Cßdiz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;921 Cßdiz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.284 Cßdiz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;129 Cßdiz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;46 Cßdiz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;83 Cßdiz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;240 Cßdiz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;130 Cßdiz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;110 Cßdiz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;462 Cßdiz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;247 Cßdiz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;215 Cßdiz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;289 Cßdiz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;120 Cßdiz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;169 Cßdiz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;501 Cßdiz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;260 Cßdiz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;241 Cßdiz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;868 Cßdiz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;313 Cßdiz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;555 Cßdiz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;7.898 Cßdiz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.322 Cßdiz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4.576 Cßdiz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;841 Cßdiz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;309 Cßdiz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;532 Cßdiz;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;744 Cßdiz;Group 1402 Renal failure 5836-5837, 584-586;Men;417 Cßdiz;Group 1402 Renal failure 5836-5837, 584-586;Women;327 Cßdiz;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.279 Cßdiz;Group 1403 Urolithiasis 592, 594, 7880;Men;683 Cßdiz;Group 1403 Urolithiasis 592, 594, 7880;Women;596 Cßdiz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.010 Cßdiz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;978 Cßdiz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.031 Cßdiz;Group 1405 Prostatic hyperplasia 600;Both sexes;367 Cßdiz;Group 1405 Prostatic hyperplasia 600;Men;367 Cßdiz;Group 1405 Prostatic hyperplasia 600;Women;.. Cßdiz;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;518 Cßdiz;Group 1406 Other diseases of the male genital organs 601-608;Men;518 Cßdiz;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Cßdiz;Group 1407 Disorders of breast 610-612;Both sexes;586 Cßdiz;Group 1407 Disorders of breast 610-612;Men;46 Cßdiz;Group 1407 Disorders of breast 610-612;Women;540 Cßdiz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;191 Cßdiz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Cßdiz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;191 Cßdiz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;266 Cßdiz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Cßdiz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;266 Cßdiz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.096 Cßdiz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;5 Cßdiz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.091 Cßdiz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;13.212 Cßdiz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Cßdiz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;13.212 Cßdiz;Group 1501 Legally induced abortion 635;Both sexes;39 Cßdiz;Group 1501 Legally induced abortion 635;Men;.. Cßdiz;Group 1501 Legally induced abortion 635;Women;39 Cßdiz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;771 Cßdiz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Cßdiz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;771 Cßdiz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;7.605 Cßdiz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Cßdiz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;7.605 Cßdiz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.616 Cßdiz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Cßdiz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.616 Cßdiz;Group 1505 Single spontaneous delivery 650;Both sexes;1.442 Cßdiz;Group 1505 Single spontaneous delivery 650;Men;.. Cßdiz;Group 1505 Single spontaneous delivery 650;Women;1.442 Cßdiz;Group 1506 Other deliveries 6695-6697;Both sexes;1.106 Cßdiz;Group 1506 Other deliveries 6695-6697;Men;.. Cßdiz;Group 1506 Other deliveries 6695-6697;Women;1.106 Cßdiz;Group 1507 Complications related to the puerperium 670-676;Both sexes;52 Cßdiz;Group 1507 Complications related to the puerperium 670-676;Men;.. Cßdiz;Group 1507 Complications related to the puerperium 670-676;Women;52 Cßdiz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;582 Cßdiz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Cßdiz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;582 Cßdiz;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.697 Cßdiz;Group 1600 Some disorders originating in the perinatal period 760-779;Men;893 Cßdiz;Group 1600 Some disorders originating in the perinatal period 760-779;Women;804 Cßdiz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;488 Cßdiz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;220 Cßdiz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;268 Cßdiz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.209 Cßdiz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;673 Cßdiz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;536 Cßdiz;Grupo 1700 Congenital abnormalities 740-759;Both sexes;792 Cßdiz;Grupo 1700 Congenital abnormalities 740-759;Men;465 Cßdiz;Grupo 1700 Congenital abnormalities 740-759;Women;326 Cßdiz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;6.595 Cßdiz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3.489 Cßdiz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.106 Cßdiz;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;792 Cßdiz;Group 1801 Pain in throat and chest 7841, 7865;Men;453 Cßdiz;Group 1801 Pain in throat and chest 7841, 7865;Women;338 Cßdiz;Group 1802 Abdominal pain 7890;Both sexes;1.203 Cßdiz;Group 1802 Abdominal pain 7890;Men;509 Cßdiz;Group 1802 Abdominal pain 7890;Women;694 Cßdiz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;214 Cßdiz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;135 Cßdiz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;79 Cßdiz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;4.387 Cßdiz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.391 Cßdiz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.995 Cßdiz;Group 1900 Injuries and poisoning 800-999;Both sexes;7.691 Cßdiz;Group 1900 Injuries and poisoning 800-999;Men;3.952 Cßdiz;Group 1900 Injuries and poisoning 800-999;Women;3.739 Cßdiz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;537 Cßdiz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;303 Cßdiz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;235 Cßdiz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;246 Cßdiz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;184 Cßdiz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;62 Cßdiz;Group 1903 Radius and ulna fracture 813;Both sexes;511 Cßdiz;Group 1903 Radius and ulna fracture 813;Men;268 Cßdiz;Group 1903 Radius and ulna fracture 813;Women;243 Cßdiz;Group 1904 Femur fracture 820-821;Both sexes;1.335 Cßdiz;Group 1904 Femur fracture 820-821;Men;428 Cßdiz;Group 1904 Femur fracture 820-821;Women;907 Cßdiz;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;647 Cßdiz;Group 1905 Leg fracture, including the ankle 823-824;Men;329 Cßdiz;Group 1905 Leg fracture, including the ankle 823-824;Women;318 Cßdiz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.956 Cßdiz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.130 Cßdiz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;826 Cßdiz;Group 1907 Burns 940-949;Both sexes;26 Cßdiz;Group 1907 Burns 940-949;Men;17 Cßdiz;Group 1907 Burns 940-949;Women;9 Cßdiz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;258 Cßdiz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;142 Cßdiz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;116 Cßdiz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.904 Cßdiz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;990 Cßdiz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;914 Cßdiz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;70 Cßdiz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;39 Cßdiz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;31 Cßdiz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;200 Cßdiz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;123 Cßdiz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;77 Cßdiz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.385 Cßdiz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;631 Cßdiz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;754 Cßdiz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;43 Cßdiz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;17 Cßdiz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;25 Cßdiz;Group 2102 Contraceptive management V25;Both sexes;31 Cßdiz;Group 2102 Contraceptive management V25;Men;7 Cßdiz;Group 2102 Contraceptive management V25;Women;24 Cßdiz;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Cßdiz;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Cßdiz;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Cßdiz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;513 Cßdiz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;348 Cßdiz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;166 Cßdiz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;798 Cßdiz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;259 Cßdiz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;539 C¾rdoba;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;71.406 C¾rdoba;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;33.449 C¾rdoba;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;37.957 C¾rdoba;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.192 C¾rdoba;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;640 C¾rdoba;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;552 C¾rdoba;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;183 C¾rdoba;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;100 C¾rdoba;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;83 C¾rdoba;Group 0102 Imprecise intestinal infections 009;Both sexes;58 C¾rdoba;Group 0102 Imprecise intestinal infections 009;Men;24 C¾rdoba;Group 0102 Imprecise intestinal infections 009;Women;34 C¾rdoba;Group 0103 Tuberculosis 010-018, 137;Both sexes;52 C¾rdoba;Group 0103 Tuberculosis 010-018, 137;Men;32 C¾rdoba;Group 0103 Tuberculosis 010-018, 137;Women;20 C¾rdoba;Group 0104 Septicaemia 038;Both sexes;388 C¾rdoba;Group 0104 Septicaemia 038;Men;183 C¾rdoba;Group 0104 Septicaemia 038;Women;205 C¾rdoba;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;44 C¾rdoba;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;34 C¾rdoba;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;10 C¾rdoba;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;467 C¾rdoba;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;267 C¾rdoba;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;200 C¾rdoba;Group 0200 Neoplasms 140-239;Both sexes;7.166 C¾rdoba;Group 0200 Neoplasms 140-239;Men;3.751 C¾rdoba;Group 0200 Neoplasms 140-239;Women;3.415 C¾rdoba;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;702 C¾rdoba;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;419 C¾rdoba;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;283 C¾rdoba;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;452 C¾rdoba;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;379 C¾rdoba;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;73 C¾rdoba;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;223 C¾rdoba;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;134 C¾rdoba;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;89 C¾rdoba;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;529 C¾rdoba;Group 0204 Malignant neoplasm of breast 174-175;Men;4 C¾rdoba;Group 0204 Malignant neoplasm of breast 174-175;Women;525 C¾rdoba;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;169 C¾rdoba;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. C¾rdoba;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;169 C¾rdoba;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;85 C¾rdoba;Group 0206 Malignant neoplasm of ovary 1830;Men;.. C¾rdoba;Group 0206 Malignant neoplasm of ovary 1830;Women;85 C¾rdoba;Group 0207 Malignant neoplasm of prostate 185;Both sexes;224 C¾rdoba;Group 0207 Malignant neoplasm of prostate 185;Men;224 C¾rdoba;Group 0207 Malignant neoplasm of prostate 185;Women;.. C¾rdoba;Group 0208 Malignant neoplasm of bladder 188;Both sexes;680 C¾rdoba;Group 0208 Malignant neoplasm of bladder 188;Men;562 C¾rdoba;Group 0208 Malignant neoplasm of bladder 188;Women;118 C¾rdoba;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.405 C¾rdoba;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.377 C¾rdoba;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.028 C¾rdoba;Group 0210 Carcinoma in situ 230-234;Both sexes;67 C¾rdoba;Group 0210 Carcinoma in situ 230-234;Men;10 C¾rdoba;Group 0210 Carcinoma in situ 230-234;Women;57 C¾rdoba;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;71 C¾rdoba;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;38 C¾rdoba;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;33 C¾rdoba;Grupo 0212 Leiomyoma of uterus 218;Both sexes;193 C¾rdoba;Grupo 0212 Leiomyoma of uterus 218;Men;.. C¾rdoba;Grupo 0212 Leiomyoma of uterus 218;Women;193 C¾rdoba;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.366 C¾rdoba;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;604 C¾rdoba;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;762 C¾rdoba;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;701 C¾rdoba;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;330 C¾rdoba;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;371 C¾rdoba;Group 0301 Anaemias 280-285;Both sexes;435 C¾rdoba;Group 0301 Anaemias 280-285;Men;206 C¾rdoba;Group 0301 Anaemias 280-285;Women;229 C¾rdoba;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;266 C¾rdoba;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;124 C¾rdoba;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;142 C¾rdoba;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.221 C¾rdoba;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;491 C¾rdoba;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;730 C¾rdoba;Group 0401 Diabetes mellitus 249-250;Both sexes;293 C¾rdoba;Group 0401 Diabetes mellitus 249-250;Men;146 C¾rdoba;Group 0401 Diabetes mellitus 249-250;Women;147 C¾rdoba;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;928 C¾rdoba;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;345 C¾rdoba;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;583 C¾rdoba;Group 0500 Mental disorders 290-319;Both sexes;1.005 C¾rdoba;Group 0500 Mental disorders 290-319;Men;526 C¾rdoba;Group 0500 Mental disorders 290-319;Women;479 C¾rdoba;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;26 C¾rdoba;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;13 C¾rdoba;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;13 C¾rdoba;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;37 C¾rdoba;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;32 C¾rdoba;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;5 C¾rdoba;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;56 C¾rdoba;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;43 C¾rdoba;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;13 C¾rdoba;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;259 C¾rdoba;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;151 C¾rdoba;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;108 C¾rdoba;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;290 C¾rdoba;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;139 C¾rdoba;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;151 C¾rdoba;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;337 C¾rdoba;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;148 C¾rdoba;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;189 C¾rdoba;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.178 C¾rdoba;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;578 C¾rdoba;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;600 C¾rdoba;Group 0601 Alzheimer's disease 3310;Both sexes;16 C¾rdoba;Group 0601 Alzheimer's disease 3310;Men;6 C¾rdoba;Group 0601 Alzheimer's disease 3310;Women;10 C¾rdoba;Group 0602 Multiple sclerosis 340;Both sexes;24 C¾rdoba;Group 0602 Multiple sclerosis 340;Men;8 C¾rdoba;Group 0602 Multiple sclerosis 340;Women;16 C¾rdoba;Group 0603 Epilepsy 345;Both sexes;156 C¾rdoba;Group 0603 Epilepsy 345;Men;83 C¾rdoba;Group 0603 Epilepsy 345;Women;73 C¾rdoba;Group 0604 Transient cerebral ischemia 435;Both sexes;188 C¾rdoba;Group 0604 Transient cerebral ischemia 435;Men;101 C¾rdoba;Group 0604 Transient cerebral ischemia 435;Women;87 C¾rdoba;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;794 C¾rdoba;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;380 C¾rdoba;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;414 C¾rdoba;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;932 C¾rdoba;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;535 C¾rdoba;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;397 C¾rdoba;Grupo 0701 Cataract 366;Both sexes;140 C¾rdoba;Grupo 0701 Cataract 366;Men;80 C¾rdoba;Grupo 0701 Cataract 366;Women;60 C¾rdoba;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;792 C¾rdoba;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;455 C¾rdoba;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;337 C¾rdoba;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;271 C¾rdoba;Group 0800 Diseases of the ear and the mastoid 380-389;Men;133 C¾rdoba;Group 0800 Diseases of the ear and the mastoid 380-389;Women;138 C¾rdoba;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;10.434 C¾rdoba;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6.037 C¾rdoba;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.397 C¾rdoba;Group 0901 Hypertensive disease 401-405;Both sexes;366 C¾rdoba;Group 0901 Hypertensive disease 401-405;Men;165 C¾rdoba;Group 0901 Hypertensive disease 401-405;Women;201 C¾rdoba;Group 0902 Angina pectoris 4111, 413;Both sexes;577 C¾rdoba;Group 0902 Angina pectoris 4111, 413;Men;364 C¾rdoba;Group 0902 Angina pectoris 4111, 413;Women;213 C¾rdoba;Group 0903 Acute myocardial infarction 410;Both sexes;899 C¾rdoba;Group 0903 Acute myocardial infarction 410;Men;656 C¾rdoba;Group 0903 Acute myocardial infarction 410;Women;243 C¾rdoba;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;672 C¾rdoba;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;530 C¾rdoba;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;142 C¾rdoba;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;310 C¾rdoba;Group 0905 Diseases of the lungs circulation 415-417;Men;139 C¾rdoba;Group 0905 Diseases of the lungs circulation 415-417;Women;171 C¾rdoba;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.309 C¾rdoba;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;721 C¾rdoba;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;588 C¾rdoba;Grupo 0907 Heart failure 428;Both sexes;1.966 C¾rdoba;Grupo 0907 Heart failure 428;Men;924 C¾rdoba;Grupo 0907 Heart failure 428;Women;1.042 C¾rdoba;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.874 C¾rdoba;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.074 C¾rdoba;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;800 C¾rdoba;Grupo 0909 Atherosclerosis 440;Both sexes;279 C¾rdoba;Grupo 0909 Atherosclerosis 440;Men;226 C¾rdoba;Grupo 0909 Atherosclerosis 440;Women;53 C¾rdoba;Group 0910 Varicose veins of lower extremities 454;Both sexes;119 C¾rdoba;Group 0910 Varicose veins of lower extremities 454;Men;56 C¾rdoba;Group 0910 Varicose veins of lower extremities 454;Women;63 C¾rdoba;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.063 C¾rdoba;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.182 C¾rdoba;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;881 C¾rdoba;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7.772 C¾rdoba;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.427 C¾rdoba;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.345 C¾rdoba;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;253 C¾rdoba;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;144 C¾rdoba;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;109 C¾rdoba;Group 1002 Pneumonia 480-486;Both sexes;1.903 C¾rdoba;Group 1002 Pneumonia 480-486;Men;1.108 C¾rdoba;Group 1002 Pneumonia 480-486;Women;795 C¾rdoba;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;390 C¾rdoba;Group 1003 Acute bronchitis and bronchiolitis 466;Men;211 C¾rdoba;Group 1003 Acute bronchitis and bronchiolitis 466;Women;179 C¾rdoba;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;136 C¾rdoba;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;59 C¾rdoba;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;77 C¾rdoba;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;393 C¾rdoba;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;234 C¾rdoba;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;159 C¾rdoba;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.389 C¾rdoba;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.094 C¾rdoba;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;295 C¾rdoba;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;191 C¾rdoba;Group 1007 Asthma 4930-4931,4938-4939;Men;46 C¾rdoba;Group 1007 Asthma 4930-4931,4938-4939;Women;145 C¾rdoba;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.117 C¾rdoba;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.531 C¾rdoba;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.586 C¾rdoba;Group 1100 Diseases of the digestive system 520-579;Both sexes;10.220 C¾rdoba;Group 1100 Diseases of the digestive system 520-579;Men;5.650 C¾rdoba;Group 1100 Diseases of the digestive system 520-579;Women;4.570 C¾rdoba;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;162 C¾rdoba;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;82 C¾rdoba;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;80 C¾rdoba;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;207 C¾rdoba;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;110 C¾rdoba;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;97 C¾rdoba;Group 1103 Diseases of the esophagus 530;Both sexes;235 C¾rdoba;Group 1103 Diseases of the esophagus 530;Men;139 C¾rdoba;Group 1103 Diseases of the esophagus 530;Women;96 C¾rdoba;Group 1104 Peptic ulcer 531-534;Both sexes;196 C¾rdoba;Group 1104 Peptic ulcer 531-534;Men;133 C¾rdoba;Group 1104 Peptic ulcer 531-534;Women;63 C¾rdoba;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;182 C¾rdoba;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;92 C¾rdoba;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;90 C¾rdoba;Group 1106 Appendicitis 540-543;Both sexes;778 C¾rdoba;Group 1106 Appendicitis 540-543;Men;421 C¾rdoba;Group 1106 Appendicitis 540-543;Women;357 C¾rdoba;Group 1107 Inguinal hernia 550;Both sexes;800 C¾rdoba;Group 1107 Inguinal hernia 550;Men;716 C¾rdoba;Group 1107 Inguinal hernia 550;Women;84 C¾rdoba;Group 1108 Other abdominal hernia 551-553;Both sexes;1.009 C¾rdoba;Group 1108 Other abdominal hernia 551-553;Men;441 C¾rdoba;Group 1108 Other abdominal hernia 551-553;Women;568 C¾rdoba;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;207 C¾rdoba;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;108 C¾rdoba;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;99 C¾rdoba;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;547 C¾rdoba;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;276 C¾rdoba;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;271 C¾rdoba;Group 1111 Intestinal obstruction without hernia 560;Both sexes;564 C¾rdoba;Group 1111 Intestinal obstruction without hernia 560;Men;314 C¾rdoba;Group 1111 Intestinal obstruction without hernia 560;Women;250 C¾rdoba;Group 1112 Intestinal diverticulosis 562;Both sexes;371 C¾rdoba;Group 1112 Intestinal diverticulosis 562;Men;175 C¾rdoba;Group 1112 Intestinal diverticulosis 562;Women;196 C¾rdoba;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;598 C¾rdoba;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;389 C¾rdoba;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;209 C¾rdoba;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;317 C¾rdoba;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;155 C¾rdoba;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;162 C¾rdoba;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;245 C¾rdoba;Group 1115 Alcoholic hepatitis 5710-5713;Men;219 C¾rdoba;Group 1115 Alcoholic hepatitis 5710-5713;Women;26 C¾rdoba;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;362 C¾rdoba;Group 1116 Other diseases of the liver 570,5714-573;Men;238 C¾rdoba;Group 1116 Other diseases of the liver 570,5714-573;Women;124 C¾rdoba;Group 1117 Cholelithiasis 574;Both sexes;1.990 C¾rdoba;Group 1117 Cholelithiasis 574;Men;850 C¾rdoba;Group 1117 Cholelithiasis 574;Women;1.140 C¾rdoba;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;315 C¾rdoba;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;171 C¾rdoba;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;144 C¾rdoba;Group 1119 Pancreatic diseases 577;Both sexes;701 C¾rdoba;Group 1119 Pancreatic diseases 577;Men;383 C¾rdoba;Group 1119 Pancreatic diseases 577;Women;318 C¾rdoba;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;434 C¾rdoba;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;238 C¾rdoba;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;196 C¾rdoba;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;690 C¾rdoba;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;379 C¾rdoba;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;311 C¾rdoba;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;386 C¾rdoba;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;240 C¾rdoba;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;146 C¾rdoba;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;18 C¾rdoba;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;7 C¾rdoba;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;11 C¾rdoba;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;286 C¾rdoba;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;132 C¾rdoba;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;154 C¾rdoba;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4.841 C¾rdoba;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.024 C¾rdoba;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.817 C¾rdoba;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. C¾rdoba;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. C¾rdoba;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. C¾rdoba;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. C¾rdoba;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. C¾rdoba;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. C¾rdoba;Group 1303 Internal derangement of knee 717;Both sexes;382 C¾rdoba;Group 1303 Internal derangement of knee 717;Men;261 C¾rdoba;Group 1303 Internal derangement of knee 717;Women;121 C¾rdoba;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.349 C¾rdoba;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;833 C¾rdoba;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.516 C¾rdoba;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;95 C¾rdoba;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;39 C¾rdoba;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;56 C¾rdoba;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;286 C¾rdoba;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;133 C¾rdoba;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;153 C¾rdoba;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;414 C¾rdoba;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;220 C¾rdoba;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;194 C¾rdoba;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;45 C¾rdoba;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;22 C¾rdoba;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;23 C¾rdoba;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;368 C¾rdoba;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;199 C¾rdoba;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;169 C¾rdoba;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;902 C¾rdoba;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;317 C¾rdoba;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;585 C¾rdoba;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;4.243 C¾rdoba;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.936 C¾rdoba;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.307 C¾rdoba;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;438 C¾rdoba;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;176 C¾rdoba;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;262 C¾rdoba;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;629 C¾rdoba;Group 1402 Renal failure 5836-5837, 584-586;Men;358 C¾rdoba;Group 1402 Renal failure 5836-5837, 584-586;Women;271 C¾rdoba;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;581 C¾rdoba;Group 1403 Urolithiasis 592, 594, 7880;Men;314 C¾rdoba;Group 1403 Urolithiasis 592, 594, 7880;Women;267 C¾rdoba;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;747 C¾rdoba;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;418 C¾rdoba;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;329 C¾rdoba;Group 1405 Prostatic hyperplasia 600;Both sexes;298 C¾rdoba;Group 1405 Prostatic hyperplasia 600;Men;298 C¾rdoba;Group 1405 Prostatic hyperplasia 600;Women;.. C¾rdoba;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;324 C¾rdoba;Group 1406 Other diseases of the male genital organs 601-608;Men;324 C¾rdoba;Group 1406 Other diseases of the male genital organs 601-608;Women;.. C¾rdoba;Group 1407 Disorders of breast 610-612;Both sexes;489 C¾rdoba;Group 1407 Disorders of breast 610-612;Men;45 C¾rdoba;Group 1407 Disorders of breast 610-612;Women;444 C¾rdoba;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;120 C¾rdoba;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. C¾rdoba;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;120 C¾rdoba;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;31 C¾rdoba;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. C¾rdoba;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;31 C¾rdoba;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;586 C¾rdoba;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;3 C¾rdoba;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;583 C¾rdoba;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;8.228 C¾rdoba;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. C¾rdoba;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;8.228 C¾rdoba;Group 1501 Legally induced abortion 635;Both sexes;3 C¾rdoba;Group 1501 Legally induced abortion 635;Men;.. C¾rdoba;Group 1501 Legally induced abortion 635;Women;3 C¾rdoba;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;305 C¾rdoba;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. C¾rdoba;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;305 C¾rdoba;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;5.271 C¾rdoba;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. C¾rdoba;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;5.271 C¾rdoba;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.016 C¾rdoba;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. C¾rdoba;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.016 C¾rdoba;Group 1505 Single spontaneous delivery 650;Both sexes;713 C¾rdoba;Group 1505 Single spontaneous delivery 650;Men;.. C¾rdoba;Group 1505 Single spontaneous delivery 650;Women;713 C¾rdoba;Group 1506 Other deliveries 6695-6697;Both sexes;387 C¾rdoba;Group 1506 Other deliveries 6695-6697;Men;.. C¾rdoba;Group 1506 Other deliveries 6695-6697;Women;387 C¾rdoba;Group 1507 Complications related to the puerperium 670-676;Both sexes;43 C¾rdoba;Group 1507 Complications related to the puerperium 670-676;Men;.. C¾rdoba;Group 1507 Complications related to the puerperium 670-676;Women;43 C¾rdoba;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;490 C¾rdoba;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. C¾rdoba;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;490 C¾rdoba;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;921 C¾rdoba;Group 1600 Some disorders originating in the perinatal period 760-779;Men;515 C¾rdoba;Group 1600 Some disorders originating in the perinatal period 760-779;Women;406 C¾rdoba;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;283 C¾rdoba;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;136 C¾rdoba;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;147 C¾rdoba;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;638 C¾rdoba;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;379 C¾rdoba;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;259 C¾rdoba;Grupo 1700 Congenital abnormalities 740-759;Both sexes;986 C¾rdoba;Grupo 1700 Congenital abnormalities 740-759;Men;457 C¾rdoba;Grupo 1700 Congenital abnormalities 740-759;Women;529 C¾rdoba;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.736 C¾rdoba;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.489 C¾rdoba;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.247 C¾rdoba;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;480 C¾rdoba;Group 1801 Pain in throat and chest 7841, 7865;Men;298 C¾rdoba;Group 1801 Pain in throat and chest 7841, 7865;Women;182 C¾rdoba;Group 1802 Abdominal pain 7890;Both sexes;485 C¾rdoba;Group 1802 Abdominal pain 7890;Men;184 C¾rdoba;Group 1802 Abdominal pain 7890;Women;301 C¾rdoba;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;23 C¾rdoba;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;15 C¾rdoba;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;8 C¾rdoba;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.748 C¾rdoba;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;992 C¾rdoba;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;756 C¾rdoba;Group 1900 Injuries and poisoning 800-999;Both sexes;5.823 C¾rdoba;Group 1900 Injuries and poisoning 800-999;Men;3.052 C¾rdoba;Group 1900 Injuries and poisoning 800-999;Women;2.771 C¾rdoba;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;379 C¾rdoba;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;224 C¾rdoba;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;155 C¾rdoba;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;197 C¾rdoba;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;155 C¾rdoba;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;42 C¾rdoba;Group 1903 Radius and ulna fracture 813;Both sexes;307 C¾rdoba;Group 1903 Radius and ulna fracture 813;Men;153 C¾rdoba;Group 1903 Radius and ulna fracture 813;Women;154 C¾rdoba;Group 1904 Femur fracture 820-821;Both sexes;1.076 C¾rdoba;Group 1904 Femur fracture 820-821;Men;344 C¾rdoba;Group 1904 Femur fracture 820-821;Women;732 C¾rdoba;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;401 C¾rdoba;Group 1905 Leg fracture, including the ankle 823-824;Men;227 C¾rdoba;Group 1905 Leg fracture, including the ankle 823-824;Women;174 C¾rdoba;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.155 C¾rdoba;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;742 C¾rdoba;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;413 C¾rdoba;Group 1907 Burns 940-949;Both sexes;68 C¾rdoba;Group 1907 Burns 940-949;Men;35 C¾rdoba;Group 1907 Burns 940-949;Women;33 C¾rdoba;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;190 C¾rdoba;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;87 C¾rdoba;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;103 C¾rdoba;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.919 C¾rdoba;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.018 C¾rdoba;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;901 C¾rdoba;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;4 C¾rdoba;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 C¾rdoba;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 C¾rdoba;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;127 C¾rdoba;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;65 C¾rdoba;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;62 C¾rdoba;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;846 C¾rdoba;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;499 C¾rdoba;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;347 C¾rdoba;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;52 C¾rdoba;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;28 C¾rdoba;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;24 C¾rdoba;Group 2102 Contraceptive management V25;Both sexes;5 C¾rdoba;Group 2102 Contraceptive management V25;Men;1 C¾rdoba;Group 2102 Contraceptive management V25;Women;4 C¾rdoba;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. C¾rdoba;Group 2103 Living newborns by type of delivery V30-V39;Men;.. C¾rdoba;Group 2103 Living newborns by type of delivery V30-V39;Women;.. C¾rdoba;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;496 C¾rdoba;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;317 C¾rdoba;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;179 C¾rdoba;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;293 C¾rdoba;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;153 C¾rdoba;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;140 Granada;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;73.482 Granada;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;33.031 Granada;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;40.451 Granada;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.951 Granada;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.088 Granada;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;863 Granada;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;167 Granada;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;91 Granada;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;76 Granada;Group 0102 Imprecise intestinal infections 009;Both sexes;85 Granada;Group 0102 Imprecise intestinal infections 009;Men;47 Granada;Group 0102 Imprecise intestinal infections 009;Women;38 Granada;Group 0103 Tuberculosis 010-018, 137;Both sexes;63 Granada;Group 0103 Tuberculosis 010-018, 137;Men;41 Granada;Group 0103 Tuberculosis 010-018, 137;Women;22 Granada;Group 0104 Septicaemia 038;Both sexes;1.086 Granada;Group 0104 Septicaemia 038;Men;585 Granada;Group 0104 Septicaemia 038;Women;501 Granada;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;39 Granada;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;31 Granada;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;8 Granada;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;511 Granada;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;293 Granada;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;218 Granada;Group 0200 Neoplasms 140-239;Both sexes;7.279 Granada;Group 0200 Neoplasms 140-239;Men;3.733 Granada;Group 0200 Neoplasms 140-239;Women;3.546 Granada;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;718 Granada;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;416 Granada;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;302 Granada;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;491 Granada;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;405 Granada;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;86 Granada;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;288 Granada;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;173 Granada;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;115 Granada;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;639 Granada;Group 0204 Malignant neoplasm of breast 174-175;Men;4 Granada;Group 0204 Malignant neoplasm of breast 174-175;Women;635 Granada;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;189 Granada;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Granada;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;189 Granada;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;77 Granada;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Granada;Group 0206 Malignant neoplasm of ovary 1830;Women;77 Granada;Group 0207 Malignant neoplasm of prostate 185;Both sexes;178 Granada;Group 0207 Malignant neoplasm of prostate 185;Men;178 Granada;Group 0207 Malignant neoplasm of prostate 185;Women;.. Granada;Group 0208 Malignant neoplasm of bladder 188;Both sexes;674 Granada;Group 0208 Malignant neoplasm of bladder 188;Men;553 Granada;Group 0208 Malignant neoplasm of bladder 188;Women;121 Granada;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.549 Granada;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.497 Granada;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.052 Granada;Group 0210 Carcinoma in situ 230-234;Both sexes;63 Granada;Group 0210 Carcinoma in situ 230-234;Men;16 Granada;Group 0210 Carcinoma in situ 230-234;Women;47 Granada;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;43 Granada;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;23 Granada;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;20 Granada;Grupo 0212 Leiomyoma of uterus 218;Both sexes;409 Granada;Grupo 0212 Leiomyoma of uterus 218;Men;.. Granada;Grupo 0212 Leiomyoma of uterus 218;Women;409 Granada;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;961 Granada;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;468 Granada;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;493 Granada;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;535 Granada;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;252 Granada;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;283 Granada;Group 0301 Anaemias 280-285;Both sexes;207 Granada;Group 0301 Anaemias 280-285;Men;112 Granada;Group 0301 Anaemias 280-285;Women;95 Granada;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;328 Granada;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;140 Granada;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;188 Granada;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.436 Granada;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;547 Granada;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;889 Granada;Group 0401 Diabetes mellitus 249-250;Both sexes;458 Granada;Group 0401 Diabetes mellitus 249-250;Men;269 Granada;Group 0401 Diabetes mellitus 249-250;Women;189 Granada;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;978 Granada;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;278 Granada;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;700 Granada;Group 0500 Mental disorders 290-319;Both sexes;1.295 Granada;Group 0500 Mental disorders 290-319;Men;716 Granada;Group 0500 Mental disorders 290-319;Women;579 Granada;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;17 Granada;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;8 Granada;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;9 Granada;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;70 Granada;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;48 Granada;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;22 Granada;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;86 Granada;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;72 Granada;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;14 Granada;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;501 Granada;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;325 Granada;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;176 Granada;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;312 Granada;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;134 Granada;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;178 Granada;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;309 Granada;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;129 Granada;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;180 Granada;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.559 Granada;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;794 Granada;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;765 Granada;Group 0601 Alzheimer's disease 3310;Both sexes;15 Granada;Group 0601 Alzheimer's disease 3310;Men;2 Granada;Group 0601 Alzheimer's disease 3310;Women;13 Granada;Group 0602 Multiple sclerosis 340;Both sexes;26 Granada;Group 0602 Multiple sclerosis 340;Men;11 Granada;Group 0602 Multiple sclerosis 340;Women;15 Granada;Group 0603 Epilepsy 345;Both sexes;237 Granada;Group 0603 Epilepsy 345;Men;126 Granada;Group 0603 Epilepsy 345;Women;111 Granada;Group 0604 Transient cerebral ischemia 435;Both sexes;226 Granada;Group 0604 Transient cerebral ischemia 435;Men;124 Granada;Group 0604 Transient cerebral ischemia 435;Women;102 Granada;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.055 Granada;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;531 Granada;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;524 Granada;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;562 Granada;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;314 Granada;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;248 Granada;Grupo 0701 Cataract 366;Both sexes;82 Granada;Grupo 0701 Cataract 366;Men;49 Granada;Grupo 0701 Cataract 366;Women;33 Granada;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;480 Granada;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;265 Granada;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;215 Granada;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;352 Granada;Group 0800 Diseases of the ear and the mastoid 380-389;Men;171 Granada;Group 0800 Diseases of the ear and the mastoid 380-389;Women;181 Granada;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;10.007 Granada;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5.584 Granada;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.423 Granada;Group 0901 Hypertensive disease 401-405;Both sexes;665 Granada;Group 0901 Hypertensive disease 401-405;Men;265 Granada;Group 0901 Hypertensive disease 401-405;Women;400 Granada;Group 0902 Angina pectoris 4111, 413;Both sexes;581 Granada;Group 0902 Angina pectoris 4111, 413;Men;349 Granada;Group 0902 Angina pectoris 4111, 413;Women;232 Granada;Group 0903 Acute myocardial infarction 410;Both sexes;1.107 Granada;Group 0903 Acute myocardial infarction 410;Men;755 Granada;Group 0903 Acute myocardial infarction 410;Women;352 Granada;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;543 Granada;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;403 Granada;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;140 Granada;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;449 Granada;Group 0905 Diseases of the lungs circulation 415-417;Men;217 Granada;Group 0905 Diseases of the lungs circulation 415-417;Women;232 Granada;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.189 Granada;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;643 Granada;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;546 Granada;Grupo 0907 Heart failure 428;Both sexes;1.614 Granada;Grupo 0907 Heart failure 428;Men;746 Granada;Grupo 0907 Heart failure 428;Women;868 Granada;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.031 Granada;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.096 Granada;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;935 Granada;Grupo 0909 Atherosclerosis 440;Both sexes;337 Granada;Grupo 0909 Atherosclerosis 440;Men;251 Granada;Grupo 0909 Atherosclerosis 440;Women;86 Granada;Group 0910 Varicose veins of lower extremities 454;Both sexes;73 Granada;Group 0910 Varicose veins of lower extremities 454;Men;29 Granada;Group 0910 Varicose veins of lower extremities 454;Women;44 Granada;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.418 Granada;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;830 Granada;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;588 Granada;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7.238 Granada;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.215 Granada;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.023 Granada;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;404 Granada;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;224 Granada;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;180 Granada;Group 1002 Pneumonia 480-486;Both sexes;1.737 Granada;Group 1002 Pneumonia 480-486;Men;1.085 Granada;Group 1002 Pneumonia 480-486;Women;652 Granada;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;704 Granada;Group 1003 Acute bronchitis and bronchiolitis 466;Men;363 Granada;Group 1003 Acute bronchitis and bronchiolitis 466;Women;341 Granada;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;220 Granada;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;112 Granada;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;108 Granada;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;609 Granada;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;373 Granada;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;236 Granada;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;705 Granada;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;597 Granada;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;108 Granada;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;362 Granada;Group 1007 Asthma 4930-4931,4938-4939;Men;116 Granada;Group 1007 Asthma 4930-4931,4938-4939;Women;246 Granada;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.497 Granada;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.345 Granada;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.152 Granada;Group 1100 Diseases of the digestive system 520-579;Both sexes;9.199 Granada;Group 1100 Diseases of the digestive system 520-579;Men;4.934 Granada;Group 1100 Diseases of the digestive system 520-579;Women;4.265 Granada;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;204 Granada;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;96 Granada;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;108 Granada;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;164 Granada;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;80 Granada;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;84 Granada;Group 1103 Diseases of the esophagus 530;Both sexes;148 Granada;Group 1103 Diseases of the esophagus 530;Men;93 Granada;Group 1103 Diseases of the esophagus 530;Women;55 Granada;Group 1104 Peptic ulcer 531-534;Both sexes;208 Granada;Group 1104 Peptic ulcer 531-534;Men;143 Granada;Group 1104 Peptic ulcer 531-534;Women;65 Granada;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;183 Granada;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;87 Granada;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;96 Granada;Group 1106 Appendicitis 540-543;Both sexes;1.014 Granada;Group 1106 Appendicitis 540-543;Men;566 Granada;Group 1106 Appendicitis 540-543;Women;448 Granada;Group 1107 Inguinal hernia 550;Both sexes;499 Granada;Group 1107 Inguinal hernia 550;Men;435 Granada;Group 1107 Inguinal hernia 550;Women;64 Granada;Group 1108 Other abdominal hernia 551-553;Both sexes;727 Granada;Group 1108 Other abdominal hernia 551-553;Men;304 Granada;Group 1108 Other abdominal hernia 551-553;Women;423 Granada;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;184 Granada;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;99 Granada;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;85 Granada;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;309 Granada;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;153 Granada;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;156 Granada;Group 1111 Intestinal obstruction without hernia 560;Both sexes;421 Granada;Group 1111 Intestinal obstruction without hernia 560;Men;209 Granada;Group 1111 Intestinal obstruction without hernia 560;Women;212 Granada;Group 1112 Intestinal diverticulosis 562;Both sexes;295 Granada;Group 1112 Intestinal diverticulosis 562;Men;142 Granada;Group 1112 Intestinal diverticulosis 562;Women;153 Granada;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;747 Granada;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;491 Granada;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;256 Granada;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;216 Granada;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;108 Granada;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;108 Granada;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;123 Granada;Group 1115 Alcoholic hepatitis 5710-5713;Men;101 Granada;Group 1115 Alcoholic hepatitis 5710-5713;Women;22 Granada;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;363 Granada;Group 1116 Other diseases of the liver 570,5714-573;Men;238 Granada;Group 1116 Other diseases of the liver 570,5714-573;Women;125 Granada;Group 1117 Cholelithiasis 574;Both sexes;1.822 Granada;Group 1117 Cholelithiasis 574;Men;768 Granada;Group 1117 Cholelithiasis 574;Women;1.054 Granada;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;465 Granada;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;251 Granada;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;214 Granada;Group 1119 Pancreatic diseases 577;Both sexes;740 Granada;Group 1119 Pancreatic diseases 577;Men;386 Granada;Group 1119 Pancreatic diseases 577;Women;354 Granada;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;367 Granada;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;184 Granada;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;183 Granada;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;624 Granada;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;362 Granada;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;262 Granada;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;361 Granada;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;236 Granada;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;125 Granada;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;25 Granada;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;13 Granada;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;12 Granada;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;238 Granada;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;113 Granada;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;125 Granada;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4.182 Granada;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.944 Granada;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.238 Granada;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Granada;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Granada;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Granada;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Granada;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Granada;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Granada;Group 1303 Internal derangement of knee 717;Both sexes;198 Granada;Group 1303 Internal derangement of knee 717;Men;139 Granada;Group 1303 Internal derangement of knee 717;Women;59 Granada;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.017 Granada;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;840 Granada;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.177 Granada;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;168 Granada;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;35 Granada;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;133 Granada;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;376 Granada;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;190 Granada;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;186 Granada;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;343 Granada;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;173 Granada;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;170 Granada;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;43 Granada;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;23 Granada;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;20 Granada;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;468 Granada;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;248 Granada;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;220 Granada;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;569 Granada;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;296 Granada;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;273 Granada;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;4.351 Granada;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.915 Granada;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.436 Granada;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;510 Granada;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;191 Granada;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;319 Granada;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;591 Granada;Group 1402 Renal failure 5836-5837, 584-586;Men;375 Granada;Group 1402 Renal failure 5836-5837, 584-586;Women;216 Granada;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;457 Granada;Group 1403 Urolithiasis 592, 594, 7880;Men;265 Granada;Group 1403 Urolithiasis 592, 594, 7880;Women;192 Granada;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;808 Granada;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;487 Granada;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;321 Granada;Group 1405 Prostatic hyperplasia 600;Both sexes;321 Granada;Group 1405 Prostatic hyperplasia 600;Men;321 Granada;Group 1405 Prostatic hyperplasia 600;Women;.. Granada;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;245 Granada;Group 1406 Other diseases of the male genital organs 601-608;Men;245 Granada;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Granada;Group 1407 Disorders of breast 610-612;Both sexes;375 Granada;Group 1407 Disorders of breast 610-612;Men;22 Granada;Group 1407 Disorders of breast 610-612;Women;353 Granada;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;142 Granada;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Granada;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;142 Granada;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;92 Granada;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Granada;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;92 Granada;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;810 Granada;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;9 Granada;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;801 Granada;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;10.554 Granada;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Granada;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;10.554 Granada;Group 1501 Legally induced abortion 635;Both sexes;5 Granada;Group 1501 Legally induced abortion 635;Men;.. Granada;Group 1501 Legally induced abortion 635;Women;5 Granada;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;880 Granada;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Granada;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;880 Granada;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.134 Granada;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Granada;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.134 Granada;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.401 Granada;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Granada;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.401 Granada;Group 1505 Single spontaneous delivery 650;Both sexes;665 Granada;Group 1505 Single spontaneous delivery 650;Men;.. Granada;Group 1505 Single spontaneous delivery 650;Women;665 Granada;Group 1506 Other deliveries 6695-6697;Both sexes;557 Granada;Group 1506 Other deliveries 6695-6697;Men;.. Granada;Group 1506 Other deliveries 6695-6697;Women;557 Granada;Group 1507 Complications related to the puerperium 670-676;Both sexes;78 Granada;Group 1507 Complications related to the puerperium 670-676;Men;.. Granada;Group 1507 Complications related to the puerperium 670-676;Women;78 Granada;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;834 Granada;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Granada;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;834 Granada;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;927 Granada;Group 1600 Some disorders originating in the perinatal period 760-779;Men;532 Granada;Group 1600 Some disorders originating in the perinatal period 760-779;Women;395 Granada;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;328 Granada;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;192 Granada;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;136 Granada;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;599 Granada;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;340 Granada;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;259 Granada;Grupo 1700 Congenital abnormalities 740-759;Both sexes;558 Granada;Grupo 1700 Congenital abnormalities 740-759;Men;293 Granada;Grupo 1700 Congenital abnormalities 740-759;Women;265 Granada;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.941 Granada;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.055 Granada;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;886 Granada;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;238 Granada;Group 1801 Pain in throat and chest 7841, 7865;Men;127 Granada;Group 1801 Pain in throat and chest 7841, 7865;Women;111 Granada;Group 1802 Abdominal pain 7890;Both sexes;190 Granada;Group 1802 Abdominal pain 7890;Men;66 Granada;Group 1802 Abdominal pain 7890;Women;124 Granada;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;73 Granada;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;36 Granada;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;37 Granada;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.440 Granada;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;826 Granada;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;614 Granada;Group 1900 Injuries and poisoning 800-999;Both sexes;7.779 Granada;Group 1900 Injuries and poisoning 800-999;Men;4.039 Granada;Group 1900 Injuries and poisoning 800-999;Women;3.740 Granada;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;248 Granada;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;156 Granada;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;92 Granada;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;239 Granada;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;159 Granada;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;80 Granada;Group 1903 Radius and ulna fracture 813;Both sexes;732 Granada;Group 1903 Radius and ulna fracture 813;Men;307 Granada;Group 1903 Radius and ulna fracture 813;Women;425 Granada;Group 1904 Femur fracture 820-821;Both sexes;1.355 Granada;Group 1904 Femur fracture 820-821;Men;395 Granada;Group 1904 Femur fracture 820-821;Women;960 Granada;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;695 Granada;Group 1905 Leg fracture, including the ankle 823-824;Men;408 Granada;Group 1905 Leg fracture, including the ankle 823-824;Women;287 Granada;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.106 Granada;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.354 Granada;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;752 Granada;Group 1907 Burns 940-949;Both sexes;53 Granada;Group 1907 Burns 940-949;Men;27 Granada;Group 1907 Burns 940-949;Women;26 Granada;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;233 Granada;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;106 Granada;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;127 Granada;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.906 Granada;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.017 Granada;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;889 Granada;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;49 Granada;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;19 Granada;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;30 Granada;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;163 Granada;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;91 Granada;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;72 Granada;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.153 Granada;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;543 Granada;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;610 Granada;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;36 Granada;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;27 Granada;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;9 Granada;Group 2102 Contraceptive management V25;Both sexes;11 Granada;Group 2102 Contraceptive management V25;Men;2 Granada;Group 2102 Contraceptive management V25;Women;9 Granada;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Granada;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Granada;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Granada;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;471 Granada;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;244 Granada;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;227 Granada;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;635 Granada;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;270 Granada;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;365 Huelva;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;40.400 Huelva;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18.356 Huelva;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;22.044 Huelva;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;815 Huelva;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;450 Huelva;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;365 Huelva;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;133 Huelva;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;74 Huelva;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;59 Huelva;Group 0102 Imprecise intestinal infections 009;Both sexes;50 Huelva;Group 0102 Imprecise intestinal infections 009;Men;21 Huelva;Group 0102 Imprecise intestinal infections 009;Women;29 Huelva;Group 0103 Tuberculosis 010-018, 137;Both sexes;74 Huelva;Group 0103 Tuberculosis 010-018, 137;Men;49 Huelva;Group 0103 Tuberculosis 010-018, 137;Women;25 Huelva;Group 0104 Septicaemia 038;Both sexes;225 Huelva;Group 0104 Septicaemia 038;Men;126 Huelva;Group 0104 Septicaemia 038;Women;99 Huelva;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;19 Huelva;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;12 Huelva;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;7 Huelva;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;314 Huelva;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;168 Huelva;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;146 Huelva;Group 0200 Neoplasms 140-239;Both sexes;3.366 Huelva;Group 0200 Neoplasms 140-239;Men;1.808 Huelva;Group 0200 Neoplasms 140-239;Women;1.558 Huelva;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;454 Huelva;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;266 Huelva;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;188 Huelva;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;279 Huelva;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;228 Huelva;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;51 Huelva;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;17 Huelva;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;8 Huelva;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;9 Huelva;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;290 Huelva;Group 0204 Malignant neoplasm of breast 174-175;Men;4 Huelva;Group 0204 Malignant neoplasm of breast 174-175;Women;286 Huelva;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;81 Huelva;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Huelva;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;81 Huelva;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;47 Huelva;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Huelva;Group 0206 Malignant neoplasm of ovary 1830;Women;47 Huelva;Group 0207 Malignant neoplasm of prostate 185;Both sexes;98 Huelva;Group 0207 Malignant neoplasm of prostate 185;Men;98 Huelva;Group 0207 Malignant neoplasm of prostate 185;Women;.. Huelva;Group 0208 Malignant neoplasm of bladder 188;Both sexes;349 Huelva;Group 0208 Malignant neoplasm of bladder 188;Men;300 Huelva;Group 0208 Malignant neoplasm of bladder 188;Women;49 Huelva;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.097 Huelva;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;693 Huelva;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;404 Huelva;Group 0210 Carcinoma in situ 230-234;Both sexes;27 Huelva;Group 0210 Carcinoma in situ 230-234;Men;9 Huelva;Group 0210 Carcinoma in situ 230-234;Women;18 Huelva;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;23 Huelva;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;16 Huelva;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;7 Huelva;Grupo 0212 Leiomyoma of uterus 218;Both sexes;189 Huelva;Grupo 0212 Leiomyoma of uterus 218;Men;.. Huelva;Grupo 0212 Leiomyoma of uterus 218;Women;189 Huelva;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;415 Huelva;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;186 Huelva;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;229 Huelva;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;589 Huelva;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;272 Huelva;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;317 Huelva;Group 0301 Anaemias 280-285;Both sexes;405 Huelva;Group 0301 Anaemias 280-285;Men;188 Huelva;Group 0301 Anaemias 280-285;Women;217 Huelva;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;184 Huelva;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;84 Huelva;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;100 Huelva;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;707 Huelva;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;279 Huelva;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;428 Huelva;Group 0401 Diabetes mellitus 249-250;Both sexes;268 Huelva;Group 0401 Diabetes mellitus 249-250;Men;155 Huelva;Group 0401 Diabetes mellitus 249-250;Women;113 Huelva;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;439 Huelva;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;124 Huelva;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;315 Huelva;Group 0500 Mental disorders 290-319;Both sexes;936 Huelva;Group 0500 Mental disorders 290-319;Men;496 Huelva;Group 0500 Mental disorders 290-319;Women;440 Huelva;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;21 Huelva;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;8 Huelva;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;13 Huelva;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;37 Huelva;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;33 Huelva;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;4 Huelva;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;47 Huelva;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;37 Huelva;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;10 Huelva;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;296 Huelva;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;205 Huelva;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;91 Huelva;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;171 Huelva;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;63 Huelva;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;108 Huelva;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;364 Huelva;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;150 Huelva;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;214 Huelva;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;961 Huelva;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;507 Huelva;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;454 Huelva;Group 0601 Alzheimer's disease 3310;Both sexes;20 Huelva;Group 0601 Alzheimer's disease 3310;Men;7 Huelva;Group 0601 Alzheimer's disease 3310;Women;13 Huelva;Group 0602 Multiple sclerosis 340;Both sexes;22 Huelva;Group 0602 Multiple sclerosis 340;Men;5 Huelva;Group 0602 Multiple sclerosis 340;Women;17 Huelva;Group 0603 Epilepsy 345;Both sexes;194 Huelva;Group 0603 Epilepsy 345;Men;99 Huelva;Group 0603 Epilepsy 345;Women;95 Huelva;Group 0604 Transient cerebral ischemia 435;Both sexes;202 Huelva;Group 0604 Transient cerebral ischemia 435;Men;114 Huelva;Group 0604 Transient cerebral ischemia 435;Women;88 Huelva;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;523 Huelva;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;282 Huelva;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;241 Huelva;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;179 Huelva;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;105 Huelva;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;74 Huelva;Grupo 0701 Cataract 366;Both sexes;6 Huelva;Grupo 0701 Cataract 366;Men;5 Huelva;Grupo 0701 Cataract 366;Women;1 Huelva;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;173 Huelva;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;100 Huelva;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;73 Huelva;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;277 Huelva;Group 0800 Diseases of the ear and the mastoid 380-389;Men;131 Huelva;Group 0800 Diseases of the ear and the mastoid 380-389;Women;146 Huelva;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6.230 Huelva;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.463 Huelva;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.767 Huelva;Group 0901 Hypertensive disease 401-405;Both sexes;647 Huelva;Group 0901 Hypertensive disease 401-405;Men;280 Huelva;Group 0901 Hypertensive disease 401-405;Women;367 Huelva;Group 0902 Angina pectoris 4111, 413;Both sexes;391 Huelva;Group 0902 Angina pectoris 4111, 413;Men;219 Huelva;Group 0902 Angina pectoris 4111, 413;Women;172 Huelva;Group 0903 Acute myocardial infarction 410;Both sexes;499 Huelva;Group 0903 Acute myocardial infarction 410;Men;332 Huelva;Group 0903 Acute myocardial infarction 410;Women;167 Huelva;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;465 Huelva;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;346 Huelva;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;119 Huelva;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;140 Huelva;Group 0905 Diseases of the lungs circulation 415-417;Men;49 Huelva;Group 0905 Diseases of the lungs circulation 415-417;Women;91 Huelva;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;925 Huelva;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;465 Huelva;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;460 Huelva;Grupo 0907 Heart failure 428;Both sexes;1.043 Huelva;Grupo 0907 Heart failure 428;Men;496 Huelva;Grupo 0907 Heart failure 428;Women;547 Huelva;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.086 Huelva;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;640 Huelva;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;446 Huelva;Grupo 0909 Atherosclerosis 440;Both sexes;176 Huelva;Grupo 0909 Atherosclerosis 440;Men;146 Huelva;Grupo 0909 Atherosclerosis 440;Women;30 Huelva;Group 0910 Varicose veins of lower extremities 454;Both sexes;48 Huelva;Group 0910 Varicose veins of lower extremities 454;Men;18 Huelva;Group 0910 Varicose veins of lower extremities 454;Women;30 Huelva;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;810 Huelva;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;472 Huelva;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;338 Huelva;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;3.811 Huelva;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.198 Huelva;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.613 Huelva;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;193 Huelva;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;92 Huelva;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;101 Huelva;Group 1002 Pneumonia 480-486;Both sexes;909 Huelva;Group 1002 Pneumonia 480-486;Men;507 Huelva;Group 1002 Pneumonia 480-486;Women;402 Huelva;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;458 Huelva;Group 1003 Acute bronchitis and bronchiolitis 466;Men;209 Huelva;Group 1003 Acute bronchitis and bronchiolitis 466;Women;249 Huelva;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;206 Huelva;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;110 Huelva;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;96 Huelva;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;385 Huelva;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;264 Huelva;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;121 Huelva;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;492 Huelva;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;408 Huelva;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;84 Huelva;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;130 Huelva;Group 1007 Asthma 4930-4931,4938-4939;Men;31 Huelva;Group 1007 Asthma 4930-4931,4938-4939;Women;99 Huelva;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.038 Huelva;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;577 Huelva;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;461 Huelva;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.880 Huelva;Group 1100 Diseases of the digestive system 520-579;Men;2.621 Huelva;Group 1100 Diseases of the digestive system 520-579;Women;2.259 Huelva;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;14 Huelva;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;4 Huelva;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;10 Huelva;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;46 Huelva;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;25 Huelva;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;21 Huelva;Group 1103 Diseases of the esophagus 530;Both sexes;113 Huelva;Group 1103 Diseases of the esophagus 530;Men;60 Huelva;Group 1103 Diseases of the esophagus 530;Women;53 Huelva;Group 1104 Peptic ulcer 531-534;Both sexes;131 Huelva;Group 1104 Peptic ulcer 531-534;Men;95 Huelva;Group 1104 Peptic ulcer 531-534;Women;36 Huelva;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;172 Huelva;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;91 Huelva;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;81 Huelva;Group 1106 Appendicitis 540-543;Both sexes;371 Huelva;Group 1106 Appendicitis 540-543;Men;221 Huelva;Group 1106 Appendicitis 540-543;Women;150 Huelva;Group 1107 Inguinal hernia 550;Both sexes;318 Huelva;Group 1107 Inguinal hernia 550;Men;275 Huelva;Group 1107 Inguinal hernia 550;Women;43 Huelva;Group 1108 Other abdominal hernia 551-553;Both sexes;344 Huelva;Group 1108 Other abdominal hernia 551-553;Men;151 Huelva;Group 1108 Other abdominal hernia 551-553;Women;193 Huelva;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;129 Huelva;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;75 Huelva;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;54 Huelva;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;323 Huelva;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;156 Huelva;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;167 Huelva;Group 1111 Intestinal obstruction without hernia 560;Both sexes;179 Huelva;Group 1111 Intestinal obstruction without hernia 560;Men;91 Huelva;Group 1111 Intestinal obstruction without hernia 560;Women;88 Huelva;Group 1112 Intestinal diverticulosis 562;Both sexes;142 Huelva;Group 1112 Intestinal diverticulosis 562;Men;81 Huelva;Group 1112 Intestinal diverticulosis 562;Women;61 Huelva;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;404 Huelva;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;244 Huelva;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;160 Huelva;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;153 Huelva;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;57 Huelva;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;96 Huelva;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;120 Huelva;Group 1115 Alcoholic hepatitis 5710-5713;Men;109 Huelva;Group 1115 Alcoholic hepatitis 5710-5713;Women;11 Huelva;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;189 Huelva;Group 1116 Other diseases of the liver 570,5714-573;Men;105 Huelva;Group 1116 Other diseases of the liver 570,5714-573;Women;84 Huelva;Group 1117 Cholelithiasis 574;Both sexes;882 Huelva;Group 1117 Cholelithiasis 574;Men;319 Huelva;Group 1117 Cholelithiasis 574;Women;563 Huelva;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;233 Huelva;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;123 Huelva;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;110 Huelva;Group 1119 Pancreatic diseases 577;Both sexes;355 Huelva;Group 1119 Pancreatic diseases 577;Men;182 Huelva;Group 1119 Pancreatic diseases 577;Women;173 Huelva;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;262 Huelva;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;157 Huelva;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;105 Huelva;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;377 Huelva;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;202 Huelva;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;175 Huelva;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;218 Huelva;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;133 Huelva;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;85 Huelva;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;16 Huelva;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;10 Huelva;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;6 Huelva;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;143 Huelva;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;59 Huelva;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;84 Huelva;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.595 Huelva;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.213 Huelva;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.382 Huelva;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Huelva;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Huelva;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Huelva;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Huelva;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Huelva;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Huelva;Group 1303 Internal derangement of knee 717;Both sexes;148 Huelva;Group 1303 Internal derangement of knee 717;Men;99 Huelva;Group 1303 Internal derangement of knee 717;Women;49 Huelva;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.124 Huelva;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;452 Huelva;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;672 Huelva;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;50 Huelva;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;25 Huelva;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;25 Huelva;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;136 Huelva;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;64 Huelva;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;72 Huelva;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;300 Huelva;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;151 Huelva;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;149 Huelva;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;113 Huelva;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;34 Huelva;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;79 Huelva;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;339 Huelva;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;217 Huelva;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;122 Huelva;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;385 Huelva;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;171 Huelva;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;214 Huelva;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.175 Huelva;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;949 Huelva;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.226 Huelva;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;248 Huelva;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;82 Huelva;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;166 Huelva;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;232 Huelva;Group 1402 Renal failure 5836-5837, 584-586;Men;142 Huelva;Group 1402 Renal failure 5836-5837, 584-586;Women;90 Huelva;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;413 Huelva;Group 1403 Urolithiasis 592, 594, 7880;Men;225 Huelva;Group 1403 Urolithiasis 592, 594, 7880;Women;188 Huelva;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;522 Huelva;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;215 Huelva;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;307 Huelva;Group 1405 Prostatic hyperplasia 600;Both sexes;109 Huelva;Group 1405 Prostatic hyperplasia 600;Men;109 Huelva;Group 1405 Prostatic hyperplasia 600;Women;.. Huelva;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;147 Huelva;Group 1406 Other diseases of the male genital organs 601-608;Men;147 Huelva;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Huelva;Group 1407 Disorders of breast 610-612;Both sexes;79 Huelva;Group 1407 Disorders of breast 610-612;Men;28 Huelva;Group 1407 Disorders of breast 610-612;Women;51 Huelva;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;65 Huelva;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Huelva;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;65 Huelva;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;34 Huelva;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Huelva;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;34 Huelva;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;326 Huelva;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Huelva;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;325 Huelva;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.464 Huelva;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Huelva;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.464 Huelva;Group 1501 Legally induced abortion 635;Both sexes;9 Huelva;Group 1501 Legally induced abortion 635;Men;.. Huelva;Group 1501 Legally induced abortion 635;Women;9 Huelva;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;307 Huelva;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Huelva;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;307 Huelva;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.813 Huelva;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Huelva;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.813 Huelva;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;408 Huelva;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Huelva;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;408 Huelva;Group 1505 Single spontaneous delivery 650;Both sexes;354 Huelva;Group 1505 Single spontaneous delivery 650;Men;.. Huelva;Group 1505 Single spontaneous delivery 650;Women;354 Huelva;Group 1506 Other deliveries 6695-6697;Both sexes;135 Huelva;Group 1506 Other deliveries 6695-6697;Men;.. Huelva;Group 1506 Other deliveries 6695-6697;Women;135 Huelva;Group 1507 Complications related to the puerperium 670-676;Both sexes;49 Huelva;Group 1507 Complications related to the puerperium 670-676;Men;.. Huelva;Group 1507 Complications related to the puerperium 670-676;Women;49 Huelva;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;389 Huelva;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Huelva;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;389 Huelva;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;400 Huelva;Group 1600 Some disorders originating in the perinatal period 760-779;Men;231 Huelva;Group 1600 Some disorders originating in the perinatal period 760-779;Women;169 Huelva;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;163 Huelva;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;97 Huelva;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;66 Huelva;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;237 Huelva;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;134 Huelva;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;103 Huelva;Grupo 1700 Congenital abnormalities 740-759;Both sexes;160 Huelva;Grupo 1700 Congenital abnormalities 740-759;Men;88 Huelva;Grupo 1700 Congenital abnormalities 740-759;Women;72 Huelva;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.705 Huelva;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.454 Huelva;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.251 Huelva;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;577 Huelva;Group 1801 Pain in throat and chest 7841, 7865;Men;341 Huelva;Group 1801 Pain in throat and chest 7841, 7865;Women;236 Huelva;Group 1802 Abdominal pain 7890;Both sexes;367 Huelva;Group 1802 Abdominal pain 7890;Men;149 Huelva;Group 1802 Abdominal pain 7890;Women;218 Huelva;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;31 Huelva;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;17 Huelva;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;14 Huelva;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.730 Huelva;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;947 Huelva;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;783 Huelva;Group 1900 Injuries and poisoning 800-999;Both sexes;3.241 Huelva;Group 1900 Injuries and poisoning 800-999;Men;1.620 Huelva;Group 1900 Injuries and poisoning 800-999;Women;1.621 Huelva;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;122 Huelva;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;73 Huelva;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;49 Huelva;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;59 Huelva;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;47 Huelva;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;12 Huelva;Group 1903 Radius and ulna fracture 813;Both sexes;306 Huelva;Group 1903 Radius and ulna fracture 813;Men;161 Huelva;Group 1903 Radius and ulna fracture 813;Women;145 Huelva;Group 1904 Femur fracture 820-821;Both sexes;508 Huelva;Group 1904 Femur fracture 820-821;Men;119 Huelva;Group 1904 Femur fracture 820-821;Women;389 Huelva;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;280 Huelva;Group 1905 Leg fracture, including the ankle 823-824;Men;149 Huelva;Group 1905 Leg fracture, including the ankle 823-824;Women;131 Huelva;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;979 Huelva;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;554 Huelva;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;425 Huelva;Group 1907 Burns 940-949;Both sexes;8 Huelva;Group 1907 Burns 940-949;Men;2 Huelva;Group 1907 Burns 940-949;Women;6 Huelva;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;122 Huelva;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;65 Huelva;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;57 Huelva;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;779 Huelva;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;404 Huelva;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;375 Huelva;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;8 Huelva;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;4 Huelva;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;4 Huelva;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;70 Huelva;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;42 Huelva;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;28 Huelva;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;532 Huelva;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;269 Huelva;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;263 Huelva;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;21 Huelva;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;11 Huelva;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;10 Huelva;Group 2102 Contraceptive management V25;Both sexes;1 Huelva;Group 2102 Contraceptive management V25;Men;.. Huelva;Group 2102 Contraceptive management V25;Women;1 Huelva;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Huelva;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Huelva;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Huelva;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;185 Huelva;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;117 Huelva;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;68 Huelva;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;325 Huelva;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;141 Huelva;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;184 JaÚn;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;47.363 JaÚn;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;21.777 JaÚn;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;25.586 JaÚn;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;861 JaÚn;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;499 JaÚn;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;362 JaÚn;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;102 JaÚn;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;64 JaÚn;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;38 JaÚn;Group 0102 Imprecise intestinal infections 009;Both sexes;14 JaÚn;Group 0102 Imprecise intestinal infections 009;Men;7 JaÚn;Group 0102 Imprecise intestinal infections 009;Women;7 JaÚn;Group 0103 Tuberculosis 010-018, 137;Both sexes;21 JaÚn;Group 0103 Tuberculosis 010-018, 137;Men;15 JaÚn;Group 0103 Tuberculosis 010-018, 137;Women;6 JaÚn;Group 0104 Septicaemia 038;Both sexes;329 JaÚn;Group 0104 Septicaemia 038;Men;176 JaÚn;Group 0104 Septicaemia 038;Women;153 JaÚn;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;32 JaÚn;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;20 JaÚn;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;12 JaÚn;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;363 JaÚn;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;217 JaÚn;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;146 JaÚn;Group 0200 Neoplasms 140-239;Both sexes;3.931 JaÚn;Group 0200 Neoplasms 140-239;Men;2.100 JaÚn;Group 0200 Neoplasms 140-239;Women;1.831 JaÚn;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;612 JaÚn;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;355 JaÚn;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;257 JaÚn;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;340 JaÚn;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;285 JaÚn;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;55 JaÚn;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;40 JaÚn;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;16 JaÚn;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;24 JaÚn;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;316 JaÚn;Group 0204 Malignant neoplasm of breast 174-175;Men;2 JaÚn;Group 0204 Malignant neoplasm of breast 174-175;Women;314 JaÚn;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;80 JaÚn;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. JaÚn;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;80 JaÚn;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;49 JaÚn;Group 0206 Malignant neoplasm of ovary 1830;Men;.. JaÚn;Group 0206 Malignant neoplasm of ovary 1830;Women;49 JaÚn;Group 0207 Malignant neoplasm of prostate 185;Both sexes;59 JaÚn;Group 0207 Malignant neoplasm of prostate 185;Men;59 JaÚn;Group 0207 Malignant neoplasm of prostate 185;Women;.. JaÚn;Group 0208 Malignant neoplasm of bladder 188;Both sexes;395 JaÚn;Group 0208 Malignant neoplasm of bladder 188;Men;316 JaÚn;Group 0208 Malignant neoplasm of bladder 188;Women;79 JaÚn;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.261 JaÚn;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;780 JaÚn;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;481 JaÚn;Group 0210 Carcinoma in situ 230-234;Both sexes;41 JaÚn;Group 0210 Carcinoma in situ 230-234;Men;19 JaÚn;Group 0210 Carcinoma in situ 230-234;Women;22 JaÚn;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;55 JaÚn;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;44 JaÚn;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;11 JaÚn;Grupo 0212 Leiomyoma of uterus 218;Both sexes;217 JaÚn;Grupo 0212 Leiomyoma of uterus 218;Men;.. JaÚn;Grupo 0212 Leiomyoma of uterus 218;Women;217 JaÚn;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;466 JaÚn;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;224 JaÚn;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;242 JaÚn;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;468 JaÚn;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;236 JaÚn;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;232 JaÚn;Group 0301 Anaemias 280-285;Both sexes;259 JaÚn;Group 0301 Anaemias 280-285;Men;120 JaÚn;Group 0301 Anaemias 280-285;Women;139 JaÚn;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;209 JaÚn;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;116 JaÚn;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;93 JaÚn;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;985 JaÚn;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;506 JaÚn;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;479 JaÚn;Group 0401 Diabetes mellitus 249-250;Both sexes;335 JaÚn;Group 0401 Diabetes mellitus 249-250;Men;235 JaÚn;Group 0401 Diabetes mellitus 249-250;Women;100 JaÚn;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;650 JaÚn;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;271 JaÚn;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;379 JaÚn;Group 0500 Mental disorders 290-319;Both sexes;1.065 JaÚn;Group 0500 Mental disorders 290-319;Men;546 JaÚn;Group 0500 Mental disorders 290-319;Women;519 JaÚn;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;30 JaÚn;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;12 JaÚn;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;18 JaÚn;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;31 JaÚn;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;28 JaÚn;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;3 JaÚn;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;46 JaÚn;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;39 JaÚn;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;7 JaÚn;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;269 JaÚn;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;168 JaÚn;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;101 JaÚn;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;291 JaÚn;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;115 JaÚn;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;176 JaÚn;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;398 JaÚn;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;184 JaÚn;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;214 JaÚn;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.000 JaÚn;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;510 JaÚn;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;490 JaÚn;Group 0601 Alzheimer's disease 3310;Both sexes;24 JaÚn;Group 0601 Alzheimer's disease 3310;Men;12 JaÚn;Group 0601 Alzheimer's disease 3310;Women;12 JaÚn;Group 0602 Multiple sclerosis 340;Both sexes;40 JaÚn;Group 0602 Multiple sclerosis 340;Men;13 JaÚn;Group 0602 Multiple sclerosis 340;Women;27 JaÚn;Group 0603 Epilepsy 345;Both sexes;214 JaÚn;Group 0603 Epilepsy 345;Men;119 JaÚn;Group 0603 Epilepsy 345;Women;95 JaÚn;Group 0604 Transient cerebral ischemia 435;Both sexes;242 JaÚn;Group 0604 Transient cerebral ischemia 435;Men;121 JaÚn;Group 0604 Transient cerebral ischemia 435;Women;121 JaÚn;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;480 JaÚn;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;245 JaÚn;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;235 JaÚn;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;582 JaÚn;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;325 JaÚn;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;257 JaÚn;Grupo 0701 Cataract 366;Both sexes;65 JaÚn;Grupo 0701 Cataract 366;Men;42 JaÚn;Grupo 0701 Cataract 366;Women;23 JaÚn;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;517 JaÚn;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;283 JaÚn;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;234 JaÚn;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;166 JaÚn;Group 0800 Diseases of the ear and the mastoid 380-389;Men;85 JaÚn;Group 0800 Diseases of the ear and the mastoid 380-389;Women;81 JaÚn;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6.123 JaÚn;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.471 JaÚn;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.652 JaÚn;Group 0901 Hypertensive disease 401-405;Both sexes;329 JaÚn;Group 0901 Hypertensive disease 401-405;Men;123 JaÚn;Group 0901 Hypertensive disease 401-405;Women;206 JaÚn;Group 0902 Angina pectoris 4111, 413;Both sexes;388 JaÚn;Group 0902 Angina pectoris 4111, 413;Men;272 JaÚn;Group 0902 Angina pectoris 4111, 413;Women;116 JaÚn;Group 0903 Acute myocardial infarction 410;Both sexes;861 JaÚn;Group 0903 Acute myocardial infarction 410;Men;597 JaÚn;Group 0903 Acute myocardial infarction 410;Women;264 JaÚn;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;210 JaÚn;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;169 JaÚn;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;41 JaÚn;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;229 JaÚn;Group 0905 Diseases of the lungs circulation 415-417;Men;105 JaÚn;Group 0905 Diseases of the lungs circulation 415-417;Women;124 JaÚn;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;741 JaÚn;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;366 JaÚn;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;375 JaÚn;Grupo 0907 Heart failure 428;Both sexes;1.112 JaÚn;Grupo 0907 Heart failure 428;Men;508 JaÚn;Grupo 0907 Heart failure 428;Women;604 JaÚn;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.278 JaÚn;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;705 JaÚn;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;573 JaÚn;Grupo 0909 Atherosclerosis 440;Both sexes;162 JaÚn;Grupo 0909 Atherosclerosis 440;Men;146 JaÚn;Grupo 0909 Atherosclerosis 440;Women;16 JaÚn;Group 0910 Varicose veins of lower extremities 454;Both sexes;45 JaÚn;Group 0910 Varicose veins of lower extremities 454;Men;12 JaÚn;Group 0910 Varicose veins of lower extremities 454;Women;33 JaÚn;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;768 JaÚn;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;468 JaÚn;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;300 JaÚn;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5.818 JaÚn;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.428 JaÚn;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.390 JaÚn;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;231 JaÚn;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;113 JaÚn;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;118 JaÚn;Group 1002 Pneumonia 480-486;Both sexes;1.457 JaÚn;Group 1002 Pneumonia 480-486;Men;831 JaÚn;Group 1002 Pneumonia 480-486;Women;626 JaÚn;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;413 JaÚn;Group 1003 Acute bronchitis and bronchiolitis 466;Men;233 JaÚn;Group 1003 Acute bronchitis and bronchiolitis 466;Women;180 JaÚn;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;83 JaÚn;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;41 JaÚn;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;42 JaÚn;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;334 JaÚn;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;218 JaÚn;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;116 JaÚn;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;634 JaÚn;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;533 JaÚn;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;101 JaÚn;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;122 JaÚn;Group 1007 Asthma 4930-4931,4938-4939;Men;54 JaÚn;Group 1007 Asthma 4930-4931,4938-4939;Women;68 JaÚn;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.544 JaÚn;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.405 JaÚn;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.139 JaÚn;Group 1100 Diseases of the digestive system 520-579;Both sexes;5.854 JaÚn;Group 1100 Diseases of the digestive system 520-579;Men;3.240 JaÚn;Group 1100 Diseases of the digestive system 520-579;Women;2.614 JaÚn;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;82 JaÚn;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;44 JaÚn;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;38 JaÚn;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;88 JaÚn;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;47 JaÚn;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;41 JaÚn;Group 1103 Diseases of the esophagus 530;Both sexes;103 JaÚn;Group 1103 Diseases of the esophagus 530;Men;64 JaÚn;Group 1103 Diseases of the esophagus 530;Women;39 JaÚn;Group 1104 Peptic ulcer 531-534;Both sexes;158 JaÚn;Group 1104 Peptic ulcer 531-534;Men;120 JaÚn;Group 1104 Peptic ulcer 531-534;Women;38 JaÚn;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;141 JaÚn;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;65 JaÚn;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;76 JaÚn;Group 1106 Appendicitis 540-543;Both sexes;484 JaÚn;Group 1106 Appendicitis 540-543;Men;259 JaÚn;Group 1106 Appendicitis 540-543;Women;225 JaÚn;Group 1107 Inguinal hernia 550;Both sexes;329 JaÚn;Group 1107 Inguinal hernia 550;Men;286 JaÚn;Group 1107 Inguinal hernia 550;Women;43 JaÚn;Group 1108 Other abdominal hernia 551-553;Both sexes;426 JaÚn;Group 1108 Other abdominal hernia 551-553;Men;161 JaÚn;Group 1108 Other abdominal hernia 551-553;Women;265 JaÚn;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;152 JaÚn;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;83 JaÚn;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;69 JaÚn;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;262 JaÚn;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;138 JaÚn;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;124 JaÚn;Group 1111 Intestinal obstruction without hernia 560;Both sexes;259 JaÚn;Group 1111 Intestinal obstruction without hernia 560;Men;141 JaÚn;Group 1111 Intestinal obstruction without hernia 560;Women;118 JaÚn;Group 1112 Intestinal diverticulosis 562;Both sexes;216 JaÚn;Group 1112 Intestinal diverticulosis 562;Men;102 JaÚn;Group 1112 Intestinal diverticulosis 562;Women;114 JaÚn;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;414 JaÚn;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;280 JaÚn;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;134 JaÚn;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;173 JaÚn;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;91 JaÚn;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;82 JaÚn;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;130 JaÚn;Group 1115 Alcoholic hepatitis 5710-5713;Men;116 JaÚn;Group 1115 Alcoholic hepatitis 5710-5713;Women;14 JaÚn;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;243 JaÚn;Group 1116 Other diseases of the liver 570,5714-573;Men;179 JaÚn;Group 1116 Other diseases of the liver 570,5714-573;Women;64 JaÚn;Group 1117 Cholelithiasis 574;Both sexes;1.082 JaÚn;Group 1117 Cholelithiasis 574;Men;447 JaÚn;Group 1117 Cholelithiasis 574;Women;635 JaÚn;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;287 JaÚn;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;169 JaÚn;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;118 JaÚn;Group 1119 Pancreatic diseases 577;Both sexes;496 JaÚn;Group 1119 Pancreatic diseases 577;Men;269 JaÚn;Group 1119 Pancreatic diseases 577;Women;227 JaÚn;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;329 JaÚn;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;179 JaÚn;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;150 JaÚn;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;321 JaÚn;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;158 JaÚn;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;163 JaÚn;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;226 JaÚn;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;111 JaÚn;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;115 JaÚn;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;13 JaÚn;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;4 JaÚn;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;9 JaÚn;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;82 JaÚn;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;43 JaÚn;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;39 JaÚn;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.444 JaÚn;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.158 JaÚn;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.286 JaÚn;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. JaÚn;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. JaÚn;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. JaÚn;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. JaÚn;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. JaÚn;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. JaÚn;Group 1303 Internal derangement of knee 717;Both sexes;184 JaÚn;Group 1303 Internal derangement of knee 717;Men;143 JaÚn;Group 1303 Internal derangement of knee 717;Women;41 JaÚn;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.345 JaÚn;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;521 JaÚn;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;824 JaÚn;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;49 JaÚn;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;23 JaÚn;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;26 JaÚn;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;139 JaÚn;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;77 JaÚn;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;62 JaÚn;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;162 JaÚn;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;106 JaÚn;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;56 JaÚn;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;45 JaÚn;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;18 JaÚn;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;27 JaÚn;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;277 JaÚn;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;156 JaÚn;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;121 JaÚn;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;243 JaÚn;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;114 JaÚn;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;129 JaÚn;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.681 JaÚn;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.134 JaÚn;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.547 JaÚn;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;276 JaÚn;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;100 JaÚn;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;176 JaÚn;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;500 JaÚn;Group 1402 Renal failure 5836-5837, 584-586;Men;284 JaÚn;Group 1402 Renal failure 5836-5837, 584-586;Women;216 JaÚn;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;386 JaÚn;Group 1403 Urolithiasis 592, 594, 7880;Men;219 JaÚn;Group 1403 Urolithiasis 592, 594, 7880;Women;167 JaÚn;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;463 JaÚn;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;228 JaÚn;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;235 JaÚn;Group 1405 Prostatic hyperplasia 600;Both sexes;121 JaÚn;Group 1405 Prostatic hyperplasia 600;Men;121 JaÚn;Group 1405 Prostatic hyperplasia 600;Women;.. JaÚn;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;161 JaÚn;Group 1406 Other diseases of the male genital organs 601-608;Men;161 JaÚn;Group 1406 Other diseases of the male genital organs 601-608;Women;.. JaÚn;Group 1407 Disorders of breast 610-612;Both sexes;78 JaÚn;Group 1407 Disorders of breast 610-612;Men;17 JaÚn;Group 1407 Disorders of breast 610-612;Women;61 JaÚn;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;72 JaÚn;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. JaÚn;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;72 JaÚn;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;45 JaÚn;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. JaÚn;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;45 JaÚn;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;579 JaÚn;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;4 JaÚn;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;575 JaÚn;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;6.502 JaÚn;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. JaÚn;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;6.502 JaÚn;Group 1501 Legally induced abortion 635;Both sexes;3 JaÚn;Group 1501 Legally induced abortion 635;Men;.. JaÚn;Group 1501 Legally induced abortion 635;Women;3 JaÚn;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;351 JaÚn;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. JaÚn;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;351 JaÚn;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.134 JaÚn;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. JaÚn;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.134 JaÚn;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.263 JaÚn;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. JaÚn;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.263 JaÚn;Group 1505 Single spontaneous delivery 650;Both sexes;399 JaÚn;Group 1505 Single spontaneous delivery 650;Men;.. JaÚn;Group 1505 Single spontaneous delivery 650;Women;399 JaÚn;Group 1506 Other deliveries 6695-6697;Both sexes;94 JaÚn;Group 1506 Other deliveries 6695-6697;Men;.. JaÚn;Group 1506 Other deliveries 6695-6697;Women;94 JaÚn;Group 1507 Complications related to the puerperium 670-676;Both sexes;34 JaÚn;Group 1507 Complications related to the puerperium 670-676;Men;.. JaÚn;Group 1507 Complications related to the puerperium 670-676;Women;34 JaÚn;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;224 JaÚn;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. JaÚn;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;224 JaÚn;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;681 JaÚn;Group 1600 Some disorders originating in the perinatal period 760-779;Men;373 JaÚn;Group 1600 Some disorders originating in the perinatal period 760-779;Women;308 JaÚn;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;253 JaÚn;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;141 JaÚn;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;112 JaÚn;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;428 JaÚn;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;232 JaÚn;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;196 JaÚn;Grupo 1700 Congenital abnormalities 740-759;Both sexes;125 JaÚn;Grupo 1700 Congenital abnormalities 740-759;Men;66 JaÚn;Grupo 1700 Congenital abnormalities 740-759;Women;59 JaÚn;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.745 JaÚn;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.425 JaÚn;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.320 JaÚn;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;332 JaÚn;Group 1801 Pain in throat and chest 7841, 7865;Men;189 JaÚn;Group 1801 Pain in throat and chest 7841, 7865;Women;143 JaÚn;Group 1802 Abdominal pain 7890;Both sexes;240 JaÚn;Group 1802 Abdominal pain 7890;Men;106 JaÚn;Group 1802 Abdominal pain 7890;Women;134 JaÚn;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;722 JaÚn;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;338 JaÚn;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;384 JaÚn;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.451 JaÚn;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;792 JaÚn;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;659 JaÚn;Group 1900 Injuries and poisoning 800-999;Both sexes;4.243 JaÚn;Group 1900 Injuries and poisoning 800-999;Men;2.112 JaÚn;Group 1900 Injuries and poisoning 800-999;Women;2.131 JaÚn;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;239 JaÚn;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;136 JaÚn;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;103 JaÚn;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;111 JaÚn;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;78 JaÚn;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;33 JaÚn;Group 1903 Radius and ulna fracture 813;Both sexes;312 JaÚn;Group 1903 Radius and ulna fracture 813;Men;154 JaÚn;Group 1903 Radius and ulna fracture 813;Women;158 JaÚn;Group 1904 Femur fracture 820-821;Both sexes;903 JaÚn;Group 1904 Femur fracture 820-821;Men;237 JaÚn;Group 1904 Femur fracture 820-821;Women;666 JaÚn;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;359 JaÚn;Group 1905 Leg fracture, including the ankle 823-824;Men;189 JaÚn;Group 1905 Leg fracture, including the ankle 823-824;Women;170 JaÚn;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.119 JaÚn;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;669 JaÚn;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;450 JaÚn;Group 1907 Burns 940-949;Both sexes;17 JaÚn;Group 1907 Burns 940-949;Men;11 JaÚn;Group 1907 Burns 940-949;Women;6 JaÚn;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;158 JaÚn;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;70 JaÚn;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;88 JaÚn;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;932 JaÚn;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;519 JaÚn;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;413 JaÚn;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;9 JaÚn;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 JaÚn;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;6 JaÚn;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;84 JaÚn;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;46 JaÚn;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;38 JaÚn;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;768 JaÚn;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;405 JaÚn;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;363 JaÚn;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;21 JaÚn;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;11 JaÚn;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;10 JaÚn;Group 2102 Contraceptive management V25;Both sexes;10 JaÚn;Group 2102 Contraceptive management V25;Men;1 JaÚn;Group 2102 Contraceptive management V25;Women;9 JaÚn;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. JaÚn;Group 2103 Living newborns by type of delivery V30-V39;Men;.. JaÚn;Group 2103 Living newborns by type of delivery V30-V39;Women;.. JaÚn;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;363 JaÚn;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;232 JaÚn;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;131 JaÚn;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;374 JaÚn;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;161 JaÚn;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;213 Mßlaga;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;140.302 Mßlaga;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;62.728 Mßlaga;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;77.574 Mßlaga;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3.194 Mßlaga;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.734 Mßlaga;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.460 Mßlaga;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;402 Mßlaga;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;217 Mßlaga;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;185 Mßlaga;Group 0102 Imprecise intestinal infections 009;Both sexes;489 Mßlaga;Group 0102 Imprecise intestinal infections 009;Men;227 Mßlaga;Group 0102 Imprecise intestinal infections 009;Women;262 Mßlaga;Group 0103 Tuberculosis 010-018, 137;Both sexes;81 Mßlaga;Group 0103 Tuberculosis 010-018, 137;Men;48 Mßlaga;Group 0103 Tuberculosis 010-018, 137;Women;32 Mßlaga;Group 0104 Septicaemia 038;Both sexes;1.072 Mßlaga;Group 0104 Septicaemia 038;Men;571 Mßlaga;Group 0104 Septicaemia 038;Women;501 Mßlaga;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;131 Mßlaga;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;100 Mßlaga;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;31 Mßlaga;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.019 Mßlaga;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;570 Mßlaga;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;449 Mßlaga;Group 0200 Neoplasms 140-239;Both sexes;13.718 Mßlaga;Group 0200 Neoplasms 140-239;Men;7.000 Mßlaga;Group 0200 Neoplasms 140-239;Women;6.718 Mßlaga;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.211 Mßlaga;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;733 Mßlaga;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;478 Mßlaga;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;940 Mßlaga;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;738 Mßlaga;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;203 Mßlaga;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;344 Mßlaga;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;209 Mßlaga;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;135 Mßlaga;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.158 Mßlaga;Group 0204 Malignant neoplasm of breast 174-175;Men;12 Mßlaga;Group 0204 Malignant neoplasm of breast 174-175;Women;1.146 Mßlaga;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;268 Mßlaga;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Mßlaga;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;268 Mßlaga;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;167 Mßlaga;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Mßlaga;Group 0206 Malignant neoplasm of ovary 1830;Women;167 Mßlaga;Group 0207 Malignant neoplasm of prostate 185;Both sexes;456 Mßlaga;Group 0207 Malignant neoplasm of prostate 185;Men;456 Mßlaga;Group 0207 Malignant neoplasm of prostate 185;Women;.. Mßlaga;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.182 Mßlaga;Group 0208 Malignant neoplasm of bladder 188;Men;1.004 Mßlaga;Group 0208 Malignant neoplasm of bladder 188;Women;178 Mßlaga;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4.851 Mßlaga;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.918 Mßlaga;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.933 Mßlaga;Group 0210 Carcinoma in situ 230-234;Both sexes;208 Mßlaga;Group 0210 Carcinoma in situ 230-234;Men;60 Mßlaga;Group 0210 Carcinoma in situ 230-234;Women;148 Mßlaga;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;92 Mßlaga;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;50 Mßlaga;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;41 Mßlaga;Grupo 0212 Leiomyoma of uterus 218;Both sexes;907 Mßlaga;Grupo 0212 Leiomyoma of uterus 218;Men;.. Mßlaga;Grupo 0212 Leiomyoma of uterus 218;Women;907 Mßlaga;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.934 Mßlaga;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;821 Mßlaga;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.113 Mßlaga;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.063 Mßlaga;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;542 Mßlaga;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;521 Mßlaga;Group 0301 Anaemias 280-285;Both sexes;474 Mßlaga;Group 0301 Anaemias 280-285;Men;252 Mßlaga;Group 0301 Anaemias 280-285;Women;222 Mßlaga;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;588 Mßlaga;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;290 Mßlaga;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;299 Mßlaga;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.209 Mßlaga;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;844 Mßlaga;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.366 Mßlaga;Group 0401 Diabetes mellitus 249-250;Both sexes;623 Mßlaga;Group 0401 Diabetes mellitus 249-250;Men;394 Mßlaga;Group 0401 Diabetes mellitus 249-250;Women;229 Mßlaga;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.587 Mßlaga;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;450 Mßlaga;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.136 Mßlaga;Group 0500 Mental disorders 290-319;Both sexes;2.540 Mßlaga;Group 0500 Mental disorders 290-319;Men;1.441 Mßlaga;Group 0500 Mental disorders 290-319;Women;1.099 Mßlaga;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;39 Mßlaga;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;15 Mßlaga;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;24 Mßlaga;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;100 Mßlaga;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;84 Mßlaga;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;16 Mßlaga;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;173 Mßlaga;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;139 Mßlaga;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;34 Mßlaga;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;807 Mßlaga;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;550 Mßlaga;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;257 Mßlaga;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;650 Mßlaga;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;270 Mßlaga;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;380 Mßlaga;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;771 Mßlaga;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;384 Mßlaga;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;388 Mßlaga;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.495 Mßlaga;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.194 Mßlaga;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.301 Mßlaga;Group 0601 Alzheimer's disease 3310;Both sexes;34 Mßlaga;Group 0601 Alzheimer's disease 3310;Men;16 Mßlaga;Group 0601 Alzheimer's disease 3310;Women;18 Mßlaga;Group 0602 Multiple sclerosis 340;Both sexes;91 Mßlaga;Group 0602 Multiple sclerosis 340;Men;26 Mßlaga;Group 0602 Multiple sclerosis 340;Women;65 Mßlaga;Group 0603 Epilepsy 345;Both sexes;367 Mßlaga;Group 0603 Epilepsy 345;Men;185 Mßlaga;Group 0603 Epilepsy 345;Women;183 Mßlaga;Group 0604 Transient cerebral ischemia 435;Both sexes;339 Mßlaga;Group 0604 Transient cerebral ischemia 435;Men;183 Mßlaga;Group 0604 Transient cerebral ischemia 435;Women;156 Mßlaga;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.663 Mßlaga;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;784 Mßlaga;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;879 Mßlaga;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;986 Mßlaga;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;526 Mßlaga;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;460 Mßlaga;Grupo 0701 Cataract 366;Both sexes;222 Mßlaga;Grupo 0701 Cataract 366;Men;126 Mßlaga;Grupo 0701 Cataract 366;Women;96 Mßlaga;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;764 Mßlaga;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;400 Mßlaga;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;364 Mßlaga;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;767 Mßlaga;Group 0800 Diseases of the ear and the mastoid 380-389;Men;389 Mßlaga;Group 0800 Diseases of the ear and the mastoid 380-389;Women;378 Mßlaga;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;17.717 Mßlaga;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10.411 Mßlaga;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;7.306 Mßlaga;Group 0901 Hypertensive disease 401-405;Both sexes;1.175 Mßlaga;Group 0901 Hypertensive disease 401-405;Men;517 Mßlaga;Group 0901 Hypertensive disease 401-405;Women;658 Mßlaga;Group 0902 Angina pectoris 4111, 413;Both sexes;1.038 Mßlaga;Group 0902 Angina pectoris 4111, 413;Men;674 Mßlaga;Group 0902 Angina pectoris 4111, 413;Women;363 Mßlaga;Group 0903 Acute myocardial infarction 410;Both sexes;2.009 Mßlaga;Group 0903 Acute myocardial infarction 410;Men;1.436 Mßlaga;Group 0903 Acute myocardial infarction 410;Women;572 Mßlaga;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.842 Mßlaga;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.396 Mßlaga;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;446 Mßlaga;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;408 Mßlaga;Group 0905 Diseases of the lungs circulation 415-417;Men;201 Mßlaga;Group 0905 Diseases of the lungs circulation 415-417;Women;207 Mßlaga;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.684 Mßlaga;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;970 Mßlaga;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;714 Mßlaga;Grupo 0907 Heart failure 428;Both sexes;2.404 Mßlaga;Grupo 0907 Heart failure 428;Men;1.261 Mßlaga;Grupo 0907 Heart failure 428;Women;1.144 Mßlaga;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.851 Mßlaga;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.575 Mßlaga;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.277 Mßlaga;Grupo 0909 Atherosclerosis 440;Both sexes;572 Mßlaga;Grupo 0909 Atherosclerosis 440;Men;412 Mßlaga;Grupo 0909 Atherosclerosis 440;Women;160 Mßlaga;Group 0910 Varicose veins of lower extremities 454;Both sexes;772 Mßlaga;Group 0910 Varicose veins of lower extremities 454;Men;277 Mßlaga;Group 0910 Varicose veins of lower extremities 454;Women;496 Mßlaga;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.962 Mßlaga;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.693 Mßlaga;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.269 Mßlaga;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;12.913 Mßlaga;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;7.230 Mßlaga;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;5.683 Mßlaga;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;654 Mßlaga;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;326 Mßlaga;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;328 Mßlaga;Group 1002 Pneumonia 480-486;Both sexes;2.838 Mßlaga;Group 1002 Pneumonia 480-486;Men;1.611 Mßlaga;Group 1002 Pneumonia 480-486;Women;1.227 Mßlaga;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.018 Mßlaga;Group 1003 Acute bronchitis and bronchiolitis 466;Men;543 Mßlaga;Group 1003 Acute bronchitis and bronchiolitis 466;Women;475 Mßlaga;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;983 Mßlaga;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;476 Mßlaga;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;507 Mßlaga;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.578 Mßlaga;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;902 Mßlaga;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;675 Mßlaga;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.384 Mßlaga;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;939 Mßlaga;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;445 Mßlaga;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;387 Mßlaga;Group 1007 Asthma 4930-4931,4938-4939;Men;80 Mßlaga;Group 1007 Asthma 4930-4931,4938-4939;Women;307 Mßlaga;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4.071 Mßlaga;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.353 Mßlaga;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.718 Mßlaga;Group 1100 Diseases of the digestive system 520-579;Both sexes;17.682 Mßlaga;Group 1100 Diseases of the digestive system 520-579;Men;9.404 Mßlaga;Group 1100 Diseases of the digestive system 520-579;Women;8.278 Mßlaga;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;292 Mßlaga;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;143 Mßlaga;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;148 Mßlaga;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;221 Mßlaga;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;119 Mßlaga;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;102 Mßlaga;Group 1103 Diseases of the esophagus 530;Both sexes;309 Mßlaga;Group 1103 Diseases of the esophagus 530;Men;165 Mßlaga;Group 1103 Diseases of the esophagus 530;Women;144 Mßlaga;Group 1104 Peptic ulcer 531-534;Both sexes;330 Mßlaga;Group 1104 Peptic ulcer 531-534;Men;228 Mßlaga;Group 1104 Peptic ulcer 531-534;Women;102 Mßlaga;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;493 Mßlaga;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;228 Mßlaga;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;264 Mßlaga;Group 1106 Appendicitis 540-543;Both sexes;1.735 Mßlaga;Group 1106 Appendicitis 540-543;Men;981 Mßlaga;Group 1106 Appendicitis 540-543;Women;754 Mßlaga;Group 1107 Inguinal hernia 550;Both sexes;1.634 Mßlaga;Group 1107 Inguinal hernia 550;Men;1.446 Mßlaga;Group 1107 Inguinal hernia 550;Women;188 Mßlaga;Group 1108 Other abdominal hernia 551-553;Both sexes;1.420 Mßlaga;Group 1108 Other abdominal hernia 551-553;Men;620 Mßlaga;Group 1108 Other abdominal hernia 551-553;Women;800 Mßlaga;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;453 Mßlaga;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;219 Mßlaga;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;234 Mßlaga;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.049 Mßlaga;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;443 Mßlaga;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;606 Mßlaga;Group 1111 Intestinal obstruction without hernia 560;Both sexes;619 Mßlaga;Group 1111 Intestinal obstruction without hernia 560;Men;286 Mßlaga;Group 1111 Intestinal obstruction without hernia 560;Women;333 Mßlaga;Group 1112 Intestinal diverticulosis 562;Both sexes;939 Mßlaga;Group 1112 Intestinal diverticulosis 562;Men;485 Mßlaga;Group 1112 Intestinal diverticulosis 562;Women;454 Mßlaga;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;989 Mßlaga;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;664 Mßlaga;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;325 Mßlaga;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;424 Mßlaga;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;191 Mßlaga;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;233 Mßlaga;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;208 Mßlaga;Group 1115 Alcoholic hepatitis 5710-5713;Men;176 Mßlaga;Group 1115 Alcoholic hepatitis 5710-5713;Women;32 Mßlaga;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;527 Mßlaga;Group 1116 Other diseases of the liver 570,5714-573;Men;307 Mßlaga;Group 1116 Other diseases of the liver 570,5714-573;Women;220 Mßlaga;Group 1117 Cholelithiasis 574;Both sexes;3.545 Mßlaga;Group 1117 Cholelithiasis 574;Men;1.380 Mßlaga;Group 1117 Cholelithiasis 574;Women;2.165 Mßlaga;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;788 Mßlaga;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;430 Mßlaga;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;358 Mßlaga;Group 1119 Pancreatic diseases 577;Both sexes;1.082 Mßlaga;Group 1119 Pancreatic diseases 577;Men;555 Mßlaga;Group 1119 Pancreatic diseases 577;Women;527 Mßlaga;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;626 Mßlaga;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;339 Mßlaga;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;287 Mßlaga;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.353 Mßlaga;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;759 Mßlaga;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;594 Mßlaga;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;910 Mßlaga;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;558 Mßlaga;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;352 Mßlaga;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;48 Mßlaga;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;23 Mßlaga;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;25 Mßlaga;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;395 Mßlaga;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;178 Mßlaga;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;217 Mßlaga;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9.069 Mßlaga;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.346 Mßlaga;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4.723 Mßlaga;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Mßlaga;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Mßlaga;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Mßlaga;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Mßlaga;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Mßlaga;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Mßlaga;Group 1303 Internal derangement of knee 717;Both sexes;1.167 Mßlaga;Group 1303 Internal derangement of knee 717;Men;791 Mßlaga;Group 1303 Internal derangement of knee 717;Women;375 Mßlaga;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.174 Mßlaga;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.385 Mßlaga;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.789 Mßlaga;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;178 Mßlaga;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;72 Mßlaga;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;106 Mßlaga;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;351 Mßlaga;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;158 Mßlaga;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;193 Mßlaga;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;962 Mßlaga;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;478 Mßlaga;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;483 Mßlaga;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;314 Mßlaga;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;123 Mßlaga;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;191 Mßlaga;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.543 Mßlaga;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;817 Mßlaga;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;727 Mßlaga;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.381 Mßlaga;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;522 Mßlaga;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;859 Mßlaga;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;10.327 Mßlaga;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.262 Mßlaga;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;6.065 Mßlaga;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.139 Mßlaga;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;407 Mßlaga;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;732 Mßlaga;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;809 Mßlaga;Group 1402 Renal failure 5836-5837, 584-586;Men;489 Mßlaga;Group 1402 Renal failure 5836-5837, 584-586;Women;320 Mßlaga;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.437 Mßlaga;Group 1403 Urolithiasis 592, 594, 7880;Men;844 Mßlaga;Group 1403 Urolithiasis 592, 594, 7880;Women;594 Mßlaga;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.895 Mßlaga;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;966 Mßlaga;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;929 Mßlaga;Group 1405 Prostatic hyperplasia 600;Both sexes;848 Mßlaga;Group 1405 Prostatic hyperplasia 600;Men;848 Mßlaga;Group 1405 Prostatic hyperplasia 600;Women;.. Mßlaga;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;604 Mßlaga;Group 1406 Other diseases of the male genital organs 601-608;Men;604 Mßlaga;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Mßlaga;Group 1407 Disorders of breast 610-612;Both sexes;1.490 Mßlaga;Group 1407 Disorders of breast 610-612;Men;71 Mßlaga;Group 1407 Disorders of breast 610-612;Women;1.419 Mßlaga;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;344 Mßlaga;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Mßlaga;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;344 Mßlaga;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;143 Mßlaga;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Mßlaga;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;143 Mßlaga;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.619 Mßlaga;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;34 Mßlaga;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.585 Mßlaga;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;19.123 Mßlaga;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Mßlaga;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;19.123 Mßlaga;Group 1501 Legally induced abortion 635;Both sexes;53 Mßlaga;Group 1501 Legally induced abortion 635;Men;.. Mßlaga;Group 1501 Legally induced abortion 635;Women;53 Mßlaga;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;981 Mßlaga;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Mßlaga;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;981 Mßlaga;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;12.831 Mßlaga;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Mßlaga;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;12.831 Mßlaga;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.913 Mßlaga;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Mßlaga;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.913 Mßlaga;Group 1505 Single spontaneous delivery 650;Both sexes;569 Mßlaga;Group 1505 Single spontaneous delivery 650;Men;.. Mßlaga;Group 1505 Single spontaneous delivery 650;Women;569 Mßlaga;Group 1506 Other deliveries 6695-6697;Both sexes;378 Mßlaga;Group 1506 Other deliveries 6695-6697;Men;.. Mßlaga;Group 1506 Other deliveries 6695-6697;Women;378 Mßlaga;Group 1507 Complications related to the puerperium 670-676;Both sexes;186 Mßlaga;Group 1507 Complications related to the puerperium 670-676;Men;.. Mßlaga;Group 1507 Complications related to the puerperium 670-676;Women;186 Mßlaga;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.211 Mßlaga;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Mßlaga;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.211 Mßlaga;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.085 Mßlaga;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.144 Mßlaga;Group 1600 Some disorders originating in the perinatal period 760-779;Women;942 Mßlaga;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;674 Mßlaga;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;350 Mßlaga;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;324 Mßlaga;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.411 Mßlaga;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;793 Mßlaga;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;618 Mßlaga;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.311 Mßlaga;Grupo 1700 Congenital abnormalities 740-759;Men;722 Mßlaga;Grupo 1700 Congenital abnormalities 740-759;Women;589 Mßlaga;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;5.525 Mßlaga;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2.967 Mßlaga;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.557 Mßlaga;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;624 Mßlaga;Group 1801 Pain in throat and chest 7841, 7865;Men;330 Mßlaga;Group 1801 Pain in throat and chest 7841, 7865;Women;294 Mßlaga;Group 1802 Abdominal pain 7890;Both sexes;598 Mßlaga;Group 1802 Abdominal pain 7890;Men;206 Mßlaga;Group 1802 Abdominal pain 7890;Women;392 Mßlaga;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;297 Mßlaga;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;164 Mßlaga;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;132 Mßlaga;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;4.006 Mßlaga;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.267 Mßlaga;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.739 Mßlaga;Group 1900 Injuries and poisoning 800-999;Both sexes;13.078 Mßlaga;Group 1900 Injuries and poisoning 800-999;Men;6.693 Mßlaga;Group 1900 Injuries and poisoning 800-999;Women;6.385 Mßlaga;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;565 Mßlaga;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;362 Mßlaga;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;203 Mßlaga;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;411 Mßlaga;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;292 Mßlaga;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;119 Mßlaga;Group 1903 Radius and ulna fracture 813;Both sexes;881 Mßlaga;Group 1903 Radius and ulna fracture 813;Men;419 Mßlaga;Group 1903 Radius and ulna fracture 813;Women;462 Mßlaga;Group 1904 Femur fracture 820-821;Both sexes;2.257 Mßlaga;Group 1904 Femur fracture 820-821;Men;681 Mßlaga;Group 1904 Femur fracture 820-821;Women;1.576 Mßlaga;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.138 Mßlaga;Group 1905 Leg fracture, including the ankle 823-824;Men;578 Mßlaga;Group 1905 Leg fracture, including the ankle 823-824;Women;559 Mßlaga;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.637 Mßlaga;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.169 Mßlaga;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.469 Mßlaga;Group 1907 Burns 940-949;Both sexes;172 Mßlaga;Group 1907 Burns 940-949;Men;92 Mßlaga;Group 1907 Burns 940-949;Women;80 Mßlaga;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;357 Mßlaga;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;162 Mßlaga;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;196 Mßlaga;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.264 Mßlaga;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.704 Mßlaga;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.560 Mßlaga;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;100 Mßlaga;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;73 Mßlaga;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;27 Mßlaga;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;296 Mßlaga;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;161 Mßlaga;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;134 Mßlaga;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;3.144 Mßlaga;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.119 Mßlaga;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2.025 Mßlaga;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;130 Mßlaga;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;74 Mßlaga;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;57 Mßlaga;Group 2102 Contraceptive management V25;Both sexes;38 Mßlaga;Group 2102 Contraceptive management V25;Men;5 Mßlaga;Group 2102 Contraceptive management V25;Women;33 Mßlaga;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Mßlaga;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Mßlaga;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Mßlaga;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;644 Mßlaga;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;412 Mßlaga;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;232 Mßlaga;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2.332 Mßlaga;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;629 Mßlaga;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.703 Sevilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;164.783 Sevilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;72.311 Sevilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;92.472 Sevilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;4.358 Sevilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2.425 Sevilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.933 Sevilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;619 Sevilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;355 Sevilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;264 Sevilla;Group 0102 Imprecise intestinal infections 009;Both sexes;372 Sevilla;Group 0102 Imprecise intestinal infections 009;Men;187 Sevilla;Group 0102 Imprecise intestinal infections 009;Women;185 Sevilla;Group 0103 Tuberculosis 010-018, 137;Both sexes;126 Sevilla;Group 0103 Tuberculosis 010-018, 137;Men;71 Sevilla;Group 0103 Tuberculosis 010-018, 137;Women;55 Sevilla;Group 0104 Septicaemia 038;Both sexes;1.974 Sevilla;Group 0104 Septicaemia 038;Men;1.036 Sevilla;Group 0104 Septicaemia 038;Women;938 Sevilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;106 Sevilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;88 Sevilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;18 Sevilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.161 Sevilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;688 Sevilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;473 Sevilla;Group 0200 Neoplasms 140-239;Both sexes;16.193 Sevilla;Group 0200 Neoplasms 140-239;Men;8.192 Sevilla;Group 0200 Neoplasms 140-239;Women;8.001 Sevilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.562 Sevilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;966 Sevilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;596 Sevilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.131 Sevilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;928 Sevilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;203 Sevilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;354 Sevilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;202 Sevilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;152 Sevilla;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.311 Sevilla;Group 0204 Malignant neoplasm of breast 174-175;Men;19 Sevilla;Group 0204 Malignant neoplasm of breast 174-175;Women;1.292 Sevilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;329 Sevilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Sevilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;329 Sevilla;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;229 Sevilla;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Sevilla;Group 0206 Malignant neoplasm of ovary 1830;Women;229 Sevilla;Group 0207 Malignant neoplasm of prostate 185;Both sexes;402 Sevilla;Group 0207 Malignant neoplasm of prostate 185;Men;402 Sevilla;Group 0207 Malignant neoplasm of prostate 185;Women;.. Sevilla;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.551 Sevilla;Group 0208 Malignant neoplasm of bladder 188;Men;1.311 Sevilla;Group 0208 Malignant neoplasm of bladder 188;Women;240 Sevilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5.773 Sevilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3.322 Sevilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.451 Sevilla;Group 0210 Carcinoma in situ 230-234;Both sexes;161 Sevilla;Group 0210 Carcinoma in situ 230-234;Men;44 Sevilla;Group 0210 Carcinoma in situ 230-234;Women;117 Sevilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;164 Sevilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;92 Sevilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;72 Sevilla;Grupo 0212 Leiomyoma of uterus 218;Both sexes;924 Sevilla;Grupo 0212 Leiomyoma of uterus 218;Men;.. Sevilla;Grupo 0212 Leiomyoma of uterus 218;Women;924 Sevilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.302 Sevilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;906 Sevilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.396 Sevilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.423 Sevilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;694 Sevilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;729 Sevilla;Group 0301 Anaemias 280-285;Both sexes;903 Sevilla;Group 0301 Anaemias 280-285;Men;447 Sevilla;Group 0301 Anaemias 280-285;Women;456 Sevilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;520 Sevilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;247 Sevilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;273 Sevilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.786 Sevilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.088 Sevilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.698 Sevilla;Group 0401 Diabetes mellitus 249-250;Both sexes;797 Sevilla;Group 0401 Diabetes mellitus 249-250;Men;480 Sevilla;Group 0401 Diabetes mellitus 249-250;Women;317 Sevilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.989 Sevilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;608 Sevilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.381 Sevilla;Group 0500 Mental disorders 290-319;Both sexes;3.575 Sevilla;Group 0500 Mental disorders 290-319;Men;1.995 Sevilla;Group 0500 Mental disorders 290-319;Women;1.580 Sevilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;51 Sevilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;19 Sevilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;32 Sevilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;139 Sevilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;110 Sevilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;29 Sevilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;216 Sevilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;166 Sevilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;50 Sevilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.158 Sevilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;783 Sevilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;375 Sevilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;884 Sevilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;354 Sevilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;530 Sevilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.127 Sevilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;563 Sevilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;564 Sevilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3.247 Sevilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.642 Sevilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.605 Sevilla;Group 0601 Alzheimer's disease 3310;Both sexes;64 Sevilla;Group 0601 Alzheimer's disease 3310;Men;29 Sevilla;Group 0601 Alzheimer's disease 3310;Women;35 Sevilla;Group 0602 Multiple sclerosis 340;Both sexes;70 Sevilla;Group 0602 Multiple sclerosis 340;Men;19 Sevilla;Group 0602 Multiple sclerosis 340;Women;51 Sevilla;Group 0603 Epilepsy 345;Both sexes;630 Sevilla;Group 0603 Epilepsy 345;Men;343 Sevilla;Group 0603 Epilepsy 345;Women;287 Sevilla;Group 0604 Transient cerebral ischemia 435;Both sexes;474 Sevilla;Group 0604 Transient cerebral ischemia 435;Men;251 Sevilla;Group 0604 Transient cerebral ischemia 435;Women;223 Sevilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2.009 Sevilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.000 Sevilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.009 Sevilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;712 Sevilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;396 Sevilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;316 Sevilla;Grupo 0701 Cataract 366;Both sexes;62 Sevilla;Grupo 0701 Cataract 366;Men;39 Sevilla;Grupo 0701 Cataract 366;Women;23 Sevilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;650 Sevilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;357 Sevilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;293 Sevilla;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;718 Sevilla;Group 0800 Diseases of the ear and the mastoid 380-389;Men;372 Sevilla;Group 0800 Diseases of the ear and the mastoid 380-389;Women;346 Sevilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;22.179 Sevilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;12.329 Sevilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;9.850 Sevilla;Group 0901 Hypertensive disease 401-405;Both sexes;2.091 Sevilla;Group 0901 Hypertensive disease 401-405;Men;900 Sevilla;Group 0901 Hypertensive disease 401-405;Women;1.191 Sevilla;Group 0902 Angina pectoris 4111, 413;Both sexes;1.138 Sevilla;Group 0902 Angina pectoris 4111, 413;Men;661 Sevilla;Group 0902 Angina pectoris 4111, 413;Women;477 Sevilla;Group 0903 Acute myocardial infarction 410;Both sexes;2.420 Sevilla;Group 0903 Acute myocardial infarction 410;Men;1.550 Sevilla;Group 0903 Acute myocardial infarction 410;Women;870 Sevilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.681 Sevilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.278 Sevilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;403 Sevilla;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;469 Sevilla;Group 0905 Diseases of the lungs circulation 415-417;Men;208 Sevilla;Group 0905 Diseases of the lungs circulation 415-417;Women;261 Sevilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.987 Sevilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.579 Sevilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.408 Sevilla;Grupo 0907 Heart failure 428;Both sexes;3.846 Sevilla;Grupo 0907 Heart failure 428;Men;1.868 Sevilla;Grupo 0907 Heart failure 428;Women;1.978 Sevilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3.379 Sevilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.853 Sevilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.526 Sevilla;Grupo 0909 Atherosclerosis 440;Both sexes;886 Sevilla;Grupo 0909 Atherosclerosis 440;Men;646 Sevilla;Grupo 0909 Atherosclerosis 440;Women;240 Sevilla;Group 0910 Varicose veins of lower extremities 454;Both sexes;452 Sevilla;Group 0910 Varicose veins of lower extremities 454;Men;166 Sevilla;Group 0910 Varicose veins of lower extremities 454;Women;286 Sevilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.830 Sevilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.620 Sevilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.210 Sevilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;13.837 Sevilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;7.912 Sevilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;5.925 Sevilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;790 Sevilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;400 Sevilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;390 Sevilla;Group 1002 Pneumonia 480-486;Both sexes;2.958 Sevilla;Group 1002 Pneumonia 480-486;Men;1.660 Sevilla;Group 1002 Pneumonia 480-486;Women;1.298 Sevilla;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.812 Sevilla;Group 1003 Acute bronchitis and bronchiolitis 466;Men;985 Sevilla;Group 1003 Acute bronchitis and bronchiolitis 466;Women;827 Sevilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;660 Sevilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;349 Sevilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;311 Sevilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.382 Sevilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;804 Sevilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;578 Sevilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.310 Sevilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.015 Sevilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;295 Sevilla;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;347 Sevilla;Group 1007 Asthma 4930-4931,4938-4939;Men;99 Sevilla;Group 1007 Asthma 4930-4931,4938-4939;Women;248 Sevilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4.578 Sevilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.600 Sevilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.978 Sevilla;Group 1100 Diseases of the digestive system 520-579;Both sexes;19.455 Sevilla;Group 1100 Diseases of the digestive system 520-579;Men;10.254 Sevilla;Group 1100 Diseases of the digestive system 520-579;Women;9.201 Sevilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;332 Sevilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;159 Sevilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;173 Sevilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;245 Sevilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;118 Sevilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;127 Sevilla;Group 1103 Diseases of the esophagus 530;Both sexes;720 Sevilla;Group 1103 Diseases of the esophagus 530;Men;417 Sevilla;Group 1103 Diseases of the esophagus 530;Women;303 Sevilla;Group 1104 Peptic ulcer 531-534;Both sexes;357 Sevilla;Group 1104 Peptic ulcer 531-534;Men;230 Sevilla;Group 1104 Peptic ulcer 531-534;Women;127 Sevilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;525 Sevilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;234 Sevilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;291 Sevilla;Group 1106 Appendicitis 540-543;Both sexes;1.590 Sevilla;Group 1106 Appendicitis 540-543;Men;877 Sevilla;Group 1106 Appendicitis 540-543;Women;713 Sevilla;Group 1107 Inguinal hernia 550;Both sexes;1.637 Sevilla;Group 1107 Inguinal hernia 550;Men;1.266 Sevilla;Group 1107 Inguinal hernia 550;Women;371 Sevilla;Group 1108 Other abdominal hernia 551-553;Both sexes;1.668 Sevilla;Group 1108 Other abdominal hernia 551-553;Men;704 Sevilla;Group 1108 Other abdominal hernia 551-553;Women;964 Sevilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;464 Sevilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;260 Sevilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;204 Sevilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.059 Sevilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;480 Sevilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;579 Sevilla;Group 1111 Intestinal obstruction without hernia 560;Both sexes;730 Sevilla;Group 1111 Intestinal obstruction without hernia 560;Men;331 Sevilla;Group 1111 Intestinal obstruction without hernia 560;Women;399 Sevilla;Group 1112 Intestinal diverticulosis 562;Both sexes;638 Sevilla;Group 1112 Intestinal diverticulosis 562;Men;337 Sevilla;Group 1112 Intestinal diverticulosis 562;Women;301 Sevilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.039 Sevilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;675 Sevilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;364 Sevilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;611 Sevilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;284 Sevilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;327 Sevilla;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;373 Sevilla;Group 1115 Alcoholic hepatitis 5710-5713;Men;322 Sevilla;Group 1115 Alcoholic hepatitis 5710-5713;Women;51 Sevilla;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;687 Sevilla;Group 1116 Other diseases of the liver 570,5714-573;Men;402 Sevilla;Group 1116 Other diseases of the liver 570,5714-573;Women;285 Sevilla;Group 1117 Cholelithiasis 574;Both sexes;3.818 Sevilla;Group 1117 Cholelithiasis 574;Men;1.561 Sevilla;Group 1117 Cholelithiasis 574;Women;2.257 Sevilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;873 Sevilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;452 Sevilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;421 Sevilla;Group 1119 Pancreatic diseases 577;Both sexes;1.251 Sevilla;Group 1119 Pancreatic diseases 577;Men;692 Sevilla;Group 1119 Pancreatic diseases 577;Women;559 Sevilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;838 Sevilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;453 Sevilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;385 Sevilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.343 Sevilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;701 Sevilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;642 Sevilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;729 Sevilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;414 Sevilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;315 Sevilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;71 Sevilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;47 Sevilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;24 Sevilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;543 Sevilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;240 Sevilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;303 Sevilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;11.852 Sevilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;5.300 Sevilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;6.552 Sevilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Sevilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Sevilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Sevilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Sevilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Sevilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Sevilla;Group 1303 Internal derangement of knee 717;Both sexes;1.416 Sevilla;Group 1303 Internal derangement of knee 717;Men;875 Sevilla;Group 1303 Internal derangement of knee 717;Women;541 Sevilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;4.382 Sevilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.813 Sevilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.569 Sevilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;191 Sevilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;59 Sevilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;132 Sevilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;695 Sevilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;332 Sevilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;363 Sevilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.494 Sevilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;704 Sevilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;790 Sevilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;338 Sevilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;138 Sevilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;200 Sevilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.692 Sevilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;717 Sevilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;975 Sevilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.644 Sevilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;662 Sevilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;982 Sevilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;9.498 Sevilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.024 Sevilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5.474 Sevilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;995 Sevilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;390 Sevilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;605 Sevilla;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.010 Sevilla;Group 1402 Renal failure 5836-5837, 584-586;Men;568 Sevilla;Group 1402 Renal failure 5836-5837, 584-586;Women;442 Sevilla;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.387 Sevilla;Group 1403 Urolithiasis 592, 594, 7880;Men;725 Sevilla;Group 1403 Urolithiasis 592, 594, 7880;Women;662 Sevilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.884 Sevilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;869 Sevilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.015 Sevilla;Group 1405 Prostatic hyperplasia 600;Both sexes;676 Sevilla;Group 1405 Prostatic hyperplasia 600;Men;676 Sevilla;Group 1405 Prostatic hyperplasia 600;Women;.. Sevilla;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;699 Sevilla;Group 1406 Other diseases of the male genital organs 601-608;Men;699 Sevilla;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Sevilla;Group 1407 Disorders of breast 610-612;Both sexes;883 Sevilla;Group 1407 Disorders of breast 610-612;Men;69 Sevilla;Group 1407 Disorders of breast 610-612;Women;814 Sevilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;294 Sevilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Sevilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;294 Sevilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;105 Sevilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Sevilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;105 Sevilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.565 Sevilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;28 Sevilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.537 Sevilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;23.026 Sevilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Sevilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;23.026 Sevilla;Group 1501 Legally induced abortion 635;Both sexes;31 Sevilla;Group 1501 Legally induced abortion 635;Men;.. Sevilla;Group 1501 Legally induced abortion 635;Women;31 Sevilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.059 Sevilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Sevilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.059 Sevilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;14.757 Sevilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Sevilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;14.757 Sevilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.645 Sevilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Sevilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.645 Sevilla;Group 1505 Single spontaneous delivery 650;Both sexes;1.473 Sevilla;Group 1505 Single spontaneous delivery 650;Men;.. Sevilla;Group 1505 Single spontaneous delivery 650;Women;1.473 Sevilla;Group 1506 Other deliveries 6695-6697;Both sexes;520 Sevilla;Group 1506 Other deliveries 6695-6697;Men;.. Sevilla;Group 1506 Other deliveries 6695-6697;Women;520 Sevilla;Group 1507 Complications related to the puerperium 670-676;Both sexes;218 Sevilla;Group 1507 Complications related to the puerperium 670-676;Men;.. Sevilla;Group 1507 Complications related to the puerperium 670-676;Women;218 Sevilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.323 Sevilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Sevilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.323 Sevilla;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.104 Sevilla;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.116 Sevilla;Group 1600 Some disorders originating in the perinatal period 760-779;Women;988 Sevilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;863 Sevilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;448 Sevilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;415 Sevilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.241 Sevilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;668 Sevilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;573 Sevilla;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.880 Sevilla;Grupo 1700 Congenital abnormalities 740-759;Men;1.081 Sevilla;Grupo 1700 Congenital abnormalities 740-759;Women;799 Sevilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;8.302 Sevilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4.210 Sevilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;4.092 Sevilla;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.351 Sevilla;Group 1801 Pain in throat and chest 7841, 7865;Men;698 Sevilla;Group 1801 Pain in throat and chest 7841, 7865;Women;653 Sevilla;Group 1802 Abdominal pain 7890;Both sexes;1.113 Sevilla;Group 1802 Abdominal pain 7890;Men;398 Sevilla;Group 1802 Abdominal pain 7890;Women;715 Sevilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;437 Sevilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;253 Sevilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;184 Sevilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.401 Sevilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.861 Sevilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.540 Sevilla;Group 1900 Injuries and poisoning 800-999;Both sexes;15.200 Sevilla;Group 1900 Injuries and poisoning 800-999;Men;7.236 Sevilla;Group 1900 Injuries and poisoning 800-999;Women;7.964 Sevilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;639 Sevilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;384 Sevilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;255 Sevilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;389 Sevilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;274 Sevilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;115 Sevilla;Group 1903 Radius and ulna fracture 813;Both sexes;1.119 Sevilla;Group 1903 Radius and ulna fracture 813;Men;486 Sevilla;Group 1903 Radius and ulna fracture 813;Women;633 Sevilla;Group 1904 Femur fracture 820-821;Both sexes;2.300 Sevilla;Group 1904 Femur fracture 820-821;Men;688 Sevilla;Group 1904 Femur fracture 820-821;Women;1.612 Sevilla;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.336 Sevilla;Group 1905 Leg fracture, including the ankle 823-824;Men;615 Sevilla;Group 1905 Leg fracture, including the ankle 823-824;Women;721 Sevilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4.388 Sevilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.091 Sevilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.297 Sevilla;Group 1907 Burns 940-949;Both sexes;148 Sevilla;Group 1907 Burns 940-949;Men;99 Sevilla;Group 1907 Burns 940-949;Women;49 Sevilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;421 Sevilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;209 Sevilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;212 Sevilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;4.179 Sevilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2.237 Sevilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.942 Sevilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;43 Sevilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;26 Sevilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;17 Sevilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;238 Sevilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;127 Sevilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;111 Sevilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;3.095 Sevilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.344 Sevilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.751 Sevilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;243 Sevilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;148 Sevilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;95 Sevilla;Group 2102 Contraceptive management V25;Both sexes;39 Sevilla;Group 2102 Contraceptive management V25;Men;4 Sevilla;Group 2102 Contraceptive management V25;Women;35 Sevilla;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Sevilla;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Sevilla;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Sevilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.020 Sevilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;628 Sevilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;392 Sevilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.793 Sevilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;564 Sevilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.229 ARAGËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;153.369 ARAGËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;75.423 ARAGËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;77.946 ARAGËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3.167 ARAGËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.779 ARAGËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.388 ARAGËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;603 ARAGËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;328 ARAGËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;275 ARAGËN;Group 0102 Imprecise intestinal infections 009;Both sexes;232 ARAGËN;Group 0102 Imprecise intestinal infections 009;Men;112 ARAGËN;Group 0102 Imprecise intestinal infections 009;Women;120 ARAGËN;Group 0103 Tuberculosis 010-018, 137;Both sexes;148 ARAGËN;Group 0103 Tuberculosis 010-018, 137;Men;79 ARAGËN;Group 0103 Tuberculosis 010-018, 137;Women;69 ARAGËN;Group 0104 Septicaemia 038;Both sexes;1.332 ARAGËN;Group 0104 Septicaemia 038;Men;739 ARAGËN;Group 0104 Septicaemia 038;Women;593 ARAGËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;44 ARAGËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;31 ARAGËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;13 ARAGËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;808 ARAGËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;490 ARAGËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;318 ARAGËN;Group 0200 Neoplasms 140-239;Both sexes;15.218 ARAGËN;Group 0200 Neoplasms 140-239;Men;7.972 ARAGËN;Group 0200 Neoplasms 140-239;Women;7.246 ARAGËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.493 ARAGËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;903 ARAGËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;590 ARAGËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.088 ARAGËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;890 ARAGËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;198 ARAGËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;344 ARAGËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;208 ARAGËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;136 ARAGËN;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.052 ARAGËN;Group 0204 Malignant neoplasm of breast 174-175;Men;14 ARAGËN;Group 0204 Malignant neoplasm of breast 174-175;Women;1.038 ARAGËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;264 ARAGËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ARAGËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;264 ARAGËN;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;149 ARAGËN;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ARAGËN;Group 0206 Malignant neoplasm of ovary 1830;Women;149 ARAGËN;Group 0207 Malignant neoplasm of prostate 185;Both sexes;498 ARAGËN;Group 0207 Malignant neoplasm of prostate 185;Men;498 ARAGËN;Group 0207 Malignant neoplasm of prostate 185;Women;.. ARAGËN;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.265 ARAGËN;Group 0208 Malignant neoplasm of bladder 188;Men;1.060 ARAGËN;Group 0208 Malignant neoplasm of bladder 188;Women;205 ARAGËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4.991 ARAGËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.904 ARAGËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.087 ARAGËN;Group 0210 Carcinoma in situ 230-234;Both sexes;663 ARAGËN;Group 0210 Carcinoma in situ 230-234;Men;215 ARAGËN;Group 0210 Carcinoma in situ 230-234;Women;448 ARAGËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;164 ARAGËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;97 ARAGËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;67 ARAGËN;Grupo 0212 Leiomyoma of uterus 218;Both sexes;681 ARAGËN;Grupo 0212 Leiomyoma of uterus 218;Men;.. ARAGËN;Grupo 0212 Leiomyoma of uterus 218;Women;681 ARAGËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.566 ARAGËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.183 ARAGËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.383 ARAGËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.377 ARAGËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;654 ARAGËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;723 ARAGËN;Group 0301 Anaemias 280-285;Both sexes;961 ARAGËN;Group 0301 Anaemias 280-285;Men;446 ARAGËN;Group 0301 Anaemias 280-285;Women;515 ARAGËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;416 ARAGËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;208 ARAGËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;208 ARAGËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3.158 ARAGËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.265 ARAGËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.893 ARAGËN;Group 0401 Diabetes mellitus 249-250;Both sexes;889 ARAGËN;Group 0401 Diabetes mellitus 249-250;Men;526 ARAGËN;Group 0401 Diabetes mellitus 249-250;Women;363 ARAGËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2.269 ARAGËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;739 ARAGËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.530 ARAGËN;Group 0500 Mental disorders 290-319;Both sexes;3.405 ARAGËN;Group 0500 Mental disorders 290-319;Men;1.689 ARAGËN;Group 0500 Mental disorders 290-319;Women;1.716 ARAGËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;176 ARAGËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;87 ARAGËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;89 ARAGËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;179 ARAGËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;128 ARAGËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;51 ARAGËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;106 ARAGËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;78 ARAGËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;28 ARAGËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;871 ARAGËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;518 ARAGËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;353 ARAGËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;821 ARAGËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;316 ARAGËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;505 ARAGËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.252 ARAGËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;562 ARAGËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;689 ARAGËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;4.078 ARAGËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.098 ARAGËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.980 ARAGËN;Group 0601 Alzheimer's disease 3310;Both sexes;93 ARAGËN;Group 0601 Alzheimer's disease 3310;Men;37 ARAGËN;Group 0601 Alzheimer's disease 3310;Women;56 ARAGËN;Group 0602 Multiple sclerosis 340;Both sexes;63 ARAGËN;Group 0602 Multiple sclerosis 340;Men;17 ARAGËN;Group 0602 Multiple sclerosis 340;Women;46 ARAGËN;Group 0603 Epilepsy 345;Both sexes;443 ARAGËN;Group 0603 Epilepsy 345;Men;235 ARAGËN;Group 0603 Epilepsy 345;Women;208 ARAGËN;Group 0604 Transient cerebral ischemia 435;Both sexes;397 ARAGËN;Group 0604 Transient cerebral ischemia 435;Men;219 ARAGËN;Group 0604 Transient cerebral ischemia 435;Women;178 ARAGËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.082 ARAGËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.590 ARAGËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.492 ARAGËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;930 ARAGËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;480 ARAGËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;450 ARAGËN;Grupo 0701 Cataract 366;Both sexes;202 ARAGËN;Grupo 0701 Cataract 366;Men;102 ARAGËN;Grupo 0701 Cataract 366;Women;100 ARAGËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;728 ARAGËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;378 ARAGËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;350 ARAGËN;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;691 ARAGËN;Group 0800 Diseases of the ear and the mastoid 380-389;Men;329 ARAGËN;Group 0800 Diseases of the ear and the mastoid 380-389;Women;362 ARAGËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;19.445 ARAGËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10.882 ARAGËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;8.563 ARAGËN;Group 0901 Hypertensive disease 401-405;Both sexes;536 ARAGËN;Group 0901 Hypertensive disease 401-405;Men;272 ARAGËN;Group 0901 Hypertensive disease 401-405;Women;264 ARAGËN;Group 0902 Angina pectoris 4111, 413;Both sexes;789 ARAGËN;Group 0902 Angina pectoris 4111, 413;Men;488 ARAGËN;Group 0902 Angina pectoris 4111, 413;Women;301 ARAGËN;Group 0903 Acute myocardial infarction 410;Both sexes;1.345 ARAGËN;Group 0903 Acute myocardial infarction 410;Men;970 ARAGËN;Group 0903 Acute myocardial infarction 410;Women;375 ARAGËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.276 ARAGËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;974 ARAGËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;302 ARAGËN;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;615 ARAGËN;Group 0905 Diseases of the lungs circulation 415-417;Men;270 ARAGËN;Group 0905 Diseases of the lungs circulation 415-417;Women;345 ARAGËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.340 ARAGËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.262 ARAGËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.078 ARAGËN;Grupo 0907 Heart failure 428;Both sexes;4.862 ARAGËN;Grupo 0907 Heart failure 428;Men;2.391 ARAGËN;Grupo 0907 Heart failure 428;Women;2.471 ARAGËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3.175 ARAGËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.746 ARAGËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.429 ARAGËN;Grupo 0909 Atherosclerosis 440;Both sexes;507 ARAGËN;Grupo 0909 Atherosclerosis 440;Men;376 ARAGËN;Grupo 0909 Atherosclerosis 440;Women;131 ARAGËN;Group 0910 Varicose veins of lower extremities 454;Both sexes;936 ARAGËN;Group 0910 Varicose veins of lower extremities 454;Men;320 ARAGËN;Group 0910 Varicose veins of lower extremities 454;Women;616 ARAGËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3.064 ARAGËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.813 ARAGËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.251 ARAGËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;17.668 ARAGËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;10.107 ARAGËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;7.561 ARAGËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;747 ARAGËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;380 ARAGËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;367 ARAGËN;Group 1002 Pneumonia 480-486;Both sexes;4.095 ARAGËN;Group 1002 Pneumonia 480-486;Men;2.401 ARAGËN;Group 1002 Pneumonia 480-486;Women;1.694 ARAGËN;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.956 ARAGËN;Group 1003 Acute bronchitis and bronchiolitis 466;Men;918 ARAGËN;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.038 ARAGËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;676 ARAGËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;354 ARAGËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;322 ARAGËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.668 ARAGËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1.102 ARAGËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;566 ARAGËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.852 ARAGËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.156 ARAGËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;696 ARAGËN;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;537 ARAGËN;Group 1007 Asthma 4930-4931,4938-4939;Men;153 ARAGËN;Group 1007 Asthma 4930-4931,4938-4939;Women;384 ARAGËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.137 ARAGËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.643 ARAGËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.494 ARAGËN;Group 1100 Diseases of the digestive system 520-579;Both sexes;18.873 ARAGËN;Group 1100 Diseases of the digestive system 520-579;Men;11.025 ARAGËN;Group 1100 Diseases of the digestive system 520-579;Women;7.848 ARAGËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;225 ARAGËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;109 ARAGËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;116 ARAGËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;262 ARAGËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;146 ARAGËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;116 ARAGËN;Group 1103 Diseases of the esophagus 530;Both sexes;305 ARAGËN;Group 1103 Diseases of the esophagus 530;Men;194 ARAGËN;Group 1103 Diseases of the esophagus 530;Women;111 ARAGËN;Group 1104 Peptic ulcer 531-534;Both sexes;442 ARAGËN;Group 1104 Peptic ulcer 531-534;Men;302 ARAGËN;Group 1104 Peptic ulcer 531-534;Women;140 ARAGËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;505 ARAGËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;236 ARAGËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;269 ARAGËN;Group 1106 Appendicitis 540-543;Both sexes;1.288 ARAGËN;Group 1106 Appendicitis 540-543;Men;735 ARAGËN;Group 1106 Appendicitis 540-543;Women;553 ARAGËN;Group 1107 Inguinal hernia 550;Both sexes;2.687 ARAGËN;Group 1107 Inguinal hernia 550;Men;2.395 ARAGËN;Group 1107 Inguinal hernia 550;Women;292 ARAGËN;Group 1108 Other abdominal hernia 551-553;Both sexes;1.799 ARAGËN;Group 1108 Other abdominal hernia 551-553;Men;947 ARAGËN;Group 1108 Other abdominal hernia 551-553;Women;852 ARAGËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;347 ARAGËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;185 ARAGËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;162 ARAGËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;935 ARAGËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;465 ARAGËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;470 ARAGËN;Group 1111 Intestinal obstruction without hernia 560;Both sexes;930 ARAGËN;Group 1111 Intestinal obstruction without hernia 560;Men;447 ARAGËN;Group 1111 Intestinal obstruction without hernia 560;Women;483 ARAGËN;Group 1112 Intestinal diverticulosis 562;Both sexes;769 ARAGËN;Group 1112 Intestinal diverticulosis 562;Men;361 ARAGËN;Group 1112 Intestinal diverticulosis 562;Women;408 ARAGËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.161 ARAGËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;723 ARAGËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;438 ARAGËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;641 ARAGËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;295 ARAGËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;346 ARAGËN;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;285 ARAGËN;Group 1115 Alcoholic hepatitis 5710-5713;Men;254 ARAGËN;Group 1115 Alcoholic hepatitis 5710-5713;Women;31 ARAGËN;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;611 ARAGËN;Group 1116 Other diseases of the liver 570,5714-573;Men;382 ARAGËN;Group 1116 Other diseases of the liver 570,5714-573;Women;229 ARAGËN;Group 1117 Cholelithiasis 574;Both sexes;3.199 ARAGËN;Group 1117 Cholelithiasis 574;Men;1.438 ARAGËN;Group 1117 Cholelithiasis 574;Women;1.761 ARAGËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;829 ARAGËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;496 ARAGËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;333 ARAGËN;Group 1119 Pancreatic diseases 577;Both sexes;899 ARAGËN;Group 1119 Pancreatic diseases 577;Men;517 ARAGËN;Group 1119 Pancreatic diseases 577;Women;382 ARAGËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;754 ARAGËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;398 ARAGËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;356 ARAGËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.433 ARAGËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;798 ARAGËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;635 ARAGËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;965 ARAGËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;585 ARAGËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;380 ARAGËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;69 ARAGËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;35 ARAGËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;34 ARAGËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;399 ARAGËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;178 ARAGËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;221 ARAGËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;11.225 ARAGËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;5.647 ARAGËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5.578 ARAGËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ARAGËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ARAGËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ARAGËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ARAGËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ARAGËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ARAGËN;Group 1303 Internal derangement of knee 717;Both sexes;1.714 ARAGËN;Group 1303 Internal derangement of knee 717;Men;1.120 ARAGËN;Group 1303 Internal derangement of knee 717;Women;594 ARAGËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.351 ARAGËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.579 ARAGËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.772 ARAGËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;212 ARAGËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;83 ARAGËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;129 ARAGËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;485 ARAGËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;222 ARAGËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;263 ARAGËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.023 ARAGËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;607 ARAGËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;416 ARAGËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;275 ARAGËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;121 ARAGËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;154 ARAGËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;2.153 ARAGËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.222 ARAGËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;931 ARAGËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;2.012 ARAGËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;693 ARAGËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.319 ARAGËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;10.308 ARAGËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.909 ARAGËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5.399 ARAGËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;746 ARAGËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;261 ARAGËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;485 ARAGËN;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;872 ARAGËN;Group 1402 Renal failure 5836-5837, 584-586;Men;490 ARAGËN;Group 1402 Renal failure 5836-5837, 584-586;Women;382 ARAGËN;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.553 ARAGËN;Group 1403 Urolithiasis 592, 594, 7880;Men;940 ARAGËN;Group 1403 Urolithiasis 592, 594, 7880;Women;613 ARAGËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.641 ARAGËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.329 ARAGËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.312 ARAGËN;Group 1405 Prostatic hyperplasia 600;Both sexes;1.038 ARAGËN;Group 1405 Prostatic hyperplasia 600;Men;1.038 ARAGËN;Group 1405 Prostatic hyperplasia 600;Women;.. ARAGËN;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;797 ARAGËN;Group 1406 Other diseases of the male genital organs 601-608;Men;797 ARAGËN;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ARAGËN;Group 1407 Disorders of breast 610-612;Both sexes;645 ARAGËN;Group 1407 Disorders of breast 610-612;Men;41 ARAGËN;Group 1407 Disorders of breast 610-612;Women;604 ARAGËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;252 ARAGËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ARAGËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;252 ARAGËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;149 ARAGËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ARAGËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;149 ARAGËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.615 ARAGËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;13 ARAGËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.602 ARAGËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;12.895 ARAGËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ARAGËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;12.895 ARAGËN;Group 1501 Legally induced abortion 635;Both sexes;1 ARAGËN;Group 1501 Legally induced abortion 635;Men;.. ARAGËN;Group 1501 Legally induced abortion 635;Women;1 ARAGËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;750 ARAGËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ARAGËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;750 ARAGËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.824 ARAGËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ARAGËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.824 ARAGËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.011 ARAGËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ARAGËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.011 ARAGËN;Group 1505 Single spontaneous delivery 650;Both sexes;993 ARAGËN;Group 1505 Single spontaneous delivery 650;Men;.. ARAGËN;Group 1505 Single spontaneous delivery 650;Women;993 ARAGËN;Group 1506 Other deliveries 6695-6697;Both sexes;305 ARAGËN;Group 1506 Other deliveries 6695-6697;Men;.. ARAGËN;Group 1506 Other deliveries 6695-6697;Women;305 ARAGËN;Group 1507 Complications related to the puerperium 670-676;Both sexes;106 ARAGËN;Group 1507 Complications related to the puerperium 670-676;Men;.. ARAGËN;Group 1507 Complications related to the puerperium 670-676;Women;106 ARAGËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;905 ARAGËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ARAGËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;905 ARAGËN;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.071 ARAGËN;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.146 ARAGËN;Group 1600 Some disorders originating in the perinatal period 760-779;Women;925 ARAGËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;376 ARAGËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;215 ARAGËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;161 ARAGËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.695 ARAGËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;931 ARAGËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;764 ARAGËN;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.416 ARAGËN;Grupo 1700 Congenital abnormalities 740-759;Men;737 ARAGËN;Grupo 1700 Congenital abnormalities 740-759;Women;679 ARAGËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;7.942 ARAGËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4.266 ARAGËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.676 ARAGËN;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;953 ARAGËN;Group 1801 Pain in throat and chest 7841, 7865;Men;523 ARAGËN;Group 1801 Pain in throat and chest 7841, 7865;Women;430 ARAGËN;Group 1802 Abdominal pain 7890;Both sexes;860 ARAGËN;Group 1802 Abdominal pain 7890;Men;343 ARAGËN;Group 1802 Abdominal pain 7890;Women;517 ARAGËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;733 ARAGËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;380 ARAGËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;353 ARAGËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.396 ARAGËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;3.020 ARAGËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.376 ARAGËN;Group 1900 Injuries and poisoning 800-999;Both sexes;14.374 ARAGËN;Group 1900 Injuries and poisoning 800-999;Men;7.674 ARAGËN;Group 1900 Injuries and poisoning 800-999;Women;6.700 ARAGËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;745 ARAGËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;445 ARAGËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;300 ARAGËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;428 ARAGËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;310 ARAGËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;118 ARAGËN;Group 1903 Radius and ulna fracture 813;Both sexes;814 ARAGËN;Group 1903 Radius and ulna fracture 813;Men;355 ARAGËN;Group 1903 Radius and ulna fracture 813;Women;459 ARAGËN;Group 1904 Femur fracture 820-821;Both sexes;2.488 ARAGËN;Group 1904 Femur fracture 820-821;Men;669 ARAGËN;Group 1904 Femur fracture 820-821;Women;1.819 ARAGËN;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;843 ARAGËN;Group 1905 Leg fracture, including the ankle 823-824;Men;427 ARAGËN;Group 1905 Leg fracture, including the ankle 823-824;Women;416 ARAGËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;5.167 ARAGËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;3.336 ARAGËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.831 ARAGËN;Group 1907 Burns 940-949;Both sexes;129 ARAGËN;Group 1907 Burns 940-949;Men;88 ARAGËN;Group 1907 Burns 940-949;Women;41 ARAGËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;227 ARAGËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;109 ARAGËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;118 ARAGËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.132 ARAGËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.706 ARAGËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.426 ARAGËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;13 ARAGËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 ARAGËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 ARAGËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;388 ARAGËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;221 ARAGËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;167 ARAGËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;3.695 ARAGËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.966 ARAGËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.729 ARAGËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;192 ARAGËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;115 ARAGËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;77 ARAGËN;Group 2102 Contraceptive management V25;Both sexes;47 ARAGËN;Group 2102 Contraceptive management V25;Men;2 ARAGËN;Group 2102 Contraceptive management V25;Women;45 ARAGËN;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ARAGËN;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ARAGËN;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ARAGËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;916 ARAGËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;549 ARAGËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;367 ARAGËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2.540 ARAGËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.300 ARAGËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.240 Huesca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;21.266 Huesca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;10.290 Huesca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;10.976 Huesca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;700 Huesca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;404 Huesca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;296 Huesca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;108 Huesca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;56 Huesca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;52 Huesca;Group 0102 Imprecise intestinal infections 009;Both sexes;70 Huesca;Group 0102 Imprecise intestinal infections 009;Men;37 Huesca;Group 0102 Imprecise intestinal infections 009;Women;33 Huesca;Group 0103 Tuberculosis 010-018, 137;Both sexes;24 Huesca;Group 0103 Tuberculosis 010-018, 137;Men;13 Huesca;Group 0103 Tuberculosis 010-018, 137;Women;11 Huesca;Group 0104 Septicaemia 038;Both sexes;351 Huesca;Group 0104 Septicaemia 038;Men;211 Huesca;Group 0104 Septicaemia 038;Women;140 Huesca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;6 Huesca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;5 Huesca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Huesca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;141 Huesca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;82 Huesca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;59 Huesca;Group 0200 Neoplasms 140-239;Both sexes;1.747 Huesca;Group 0200 Neoplasms 140-239;Men;923 Huesca;Group 0200 Neoplasms 140-239;Women;824 Huesca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;250 Huesca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;166 Huesca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;84 Huesca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;122 Huesca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;92 Huesca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;30 Huesca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;16 Huesca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;8 Huesca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;8 Huesca;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;151 Huesca;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Huesca;Group 0204 Malignant neoplasm of breast 174-175;Women;151 Huesca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;26 Huesca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Huesca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;26 Huesca;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;21 Huesca;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Huesca;Group 0206 Malignant neoplasm of ovary 1830;Women;21 Huesca;Group 0207 Malignant neoplasm of prostate 185;Both sexes;36 Huesca;Group 0207 Malignant neoplasm of prostate 185;Men;36 Huesca;Group 0207 Malignant neoplasm of prostate 185;Women;.. Huesca;Group 0208 Malignant neoplasm of bladder 188;Both sexes;164 Huesca;Group 0208 Malignant neoplasm of bladder 188;Men;138 Huesca;Group 0208 Malignant neoplasm of bladder 188;Women;26 Huesca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;575 Huesca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;332 Huesca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;243 Huesca;Group 0210 Carcinoma in situ 230-234;Both sexes;51 Huesca;Group 0210 Carcinoma in situ 230-234;Men;23 Huesca;Group 0210 Carcinoma in situ 230-234;Women;28 Huesca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;14 Huesca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;8 Huesca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;6 Huesca;Grupo 0212 Leiomyoma of uterus 218;Both sexes;72 Huesca;Grupo 0212 Leiomyoma of uterus 218;Men;.. Huesca;Grupo 0212 Leiomyoma of uterus 218;Women;72 Huesca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;249 Huesca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;120 Huesca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;129 Huesca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;200 Huesca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;114 Huesca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;86 Huesca;Group 0301 Anaemias 280-285;Both sexes;161 Huesca;Group 0301 Anaemias 280-285;Men;94 Huesca;Group 0301 Anaemias 280-285;Women;67 Huesca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;39 Huesca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;20 Huesca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;19 Huesca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;333 Huesca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;154 Huesca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;179 Huesca;Group 0401 Diabetes mellitus 249-250;Both sexes;143 Huesca;Group 0401 Diabetes mellitus 249-250;Men;90 Huesca;Group 0401 Diabetes mellitus 249-250;Women;53 Huesca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;190 Huesca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;64 Huesca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;126 Huesca;Group 0500 Mental disorders 290-319;Both sexes;767 Huesca;Group 0500 Mental disorders 290-319;Men;378 Huesca;Group 0500 Mental disorders 290-319;Women;389 Huesca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;31 Huesca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;18 Huesca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;13 Huesca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;43 Huesca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;29 Huesca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;14 Huesca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;23 Huesca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;15 Huesca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;8 Huesca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;193 Huesca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;107 Huesca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;86 Huesca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;251 Huesca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;92 Huesca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;159 Huesca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;226 Huesca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;117 Huesca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;109 Huesca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;512 Huesca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;237 Huesca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;275 Huesca;Group 0601 Alzheimer's disease 3310;Both sexes;14 Huesca;Group 0601 Alzheimer's disease 3310;Men;6 Huesca;Group 0601 Alzheimer's disease 3310;Women;8 Huesca;Group 0602 Multiple sclerosis 340;Both sexes;3 Huesca;Group 0602 Multiple sclerosis 340;Men;2 Huesca;Group 0602 Multiple sclerosis 340;Women;1 Huesca;Group 0603 Epilepsy 345;Both sexes;73 Huesca;Group 0603 Epilepsy 345;Men;39 Huesca;Group 0603 Epilepsy 345;Women;34 Huesca;Group 0604 Transient cerebral ischemia 435;Both sexes;76 Huesca;Group 0604 Transient cerebral ischemia 435;Men;38 Huesca;Group 0604 Transient cerebral ischemia 435;Women;38 Huesca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;346 Huesca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;152 Huesca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;194 Huesca;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;129 Huesca;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;76 Huesca;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;53 Huesca;Grupo 0701 Cataract 366;Both sexes;71 Huesca;Grupo 0701 Cataract 366;Men;45 Huesca;Grupo 0701 Cataract 366;Women;26 Huesca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;58 Huesca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;31 Huesca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;27 Huesca;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;71 Huesca;Group 0800 Diseases of the ear and the mastoid 380-389;Men;41 Huesca;Group 0800 Diseases of the ear and the mastoid 380-389;Women;30 Huesca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2.719 Huesca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1.387 Huesca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.332 Huesca;Group 0901 Hypertensive disease 401-405;Both sexes;131 Huesca;Group 0901 Hypertensive disease 401-405;Men;61 Huesca;Group 0901 Hypertensive disease 401-405;Women;70 Huesca;Group 0902 Angina pectoris 4111, 413;Both sexes;126 Huesca;Group 0902 Angina pectoris 4111, 413;Men;72 Huesca;Group 0902 Angina pectoris 4111, 413;Women;54 Huesca;Group 0903 Acute myocardial infarction 410;Both sexes;152 Huesca;Group 0903 Acute myocardial infarction 410;Men;102 Huesca;Group 0903 Acute myocardial infarction 410;Women;50 Huesca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;71 Huesca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;50 Huesca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;21 Huesca;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;76 Huesca;Group 0905 Diseases of the lungs circulation 415-417;Men;34 Huesca;Group 0905 Diseases of the lungs circulation 415-417;Women;42 Huesca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;381 Huesca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;184 Huesca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;197 Huesca;Grupo 0907 Heart failure 428;Both sexes;773 Huesca;Grupo 0907 Heart failure 428;Men;369 Huesca;Grupo 0907 Heart failure 428;Women;404 Huesca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;443 Huesca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;239 Huesca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;204 Huesca;Grupo 0909 Atherosclerosis 440;Both sexes;76 Huesca;Grupo 0909 Atherosclerosis 440;Men;53 Huesca;Grupo 0909 Atherosclerosis 440;Women;23 Huesca;Group 0910 Varicose veins of lower extremities 454;Both sexes;162 Huesca;Group 0910 Varicose veins of lower extremities 454;Men;43 Huesca;Group 0910 Varicose veins of lower extremities 454;Women;119 Huesca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;328 Huesca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;180 Huesca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;148 Huesca;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2.608 Huesca;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.446 Huesca;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.162 Huesca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;120 Huesca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;59 Huesca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;61 Huesca;Group 1002 Pneumonia 480-486;Both sexes;502 Huesca;Group 1002 Pneumonia 480-486;Men;267 Huesca;Group 1002 Pneumonia 480-486;Women;235 Huesca;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;384 Huesca;Group 1003 Acute bronchitis and bronchiolitis 466;Men;149 Huesca;Group 1003 Acute bronchitis and bronchiolitis 466;Women;235 Huesca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;35 Huesca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;14 Huesca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;21 Huesca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;257 Huesca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;176 Huesca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;81 Huesca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;386 Huesca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;319 Huesca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;67 Huesca;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;57 Huesca;Group 1007 Asthma 4930-4931,4938-4939;Men;14 Huesca;Group 1007 Asthma 4930-4931,4938-4939;Women;43 Huesca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;867 Huesca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;448 Huesca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;419 Huesca;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.779 Huesca;Group 1100 Diseases of the digestive system 520-579;Men;1.636 Huesca;Group 1100 Diseases of the digestive system 520-579;Women;1.143 Huesca;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;18 Huesca;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;5 Huesca;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;13 Huesca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;21 Huesca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;15 Huesca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;6 Huesca;Group 1103 Diseases of the esophagus 530;Both sexes;35 Huesca;Group 1103 Diseases of the esophagus 530;Men;20 Huesca;Group 1103 Diseases of the esophagus 530;Women;15 Huesca;Group 1104 Peptic ulcer 531-534;Both sexes;79 Huesca;Group 1104 Peptic ulcer 531-534;Men;55 Huesca;Group 1104 Peptic ulcer 531-534;Women;24 Huesca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;104 Huesca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;53 Huesca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;51 Huesca;Group 1106 Appendicitis 540-543;Both sexes;200 Huesca;Group 1106 Appendicitis 540-543;Men;104 Huesca;Group 1106 Appendicitis 540-543;Women;96 Huesca;Group 1107 Inguinal hernia 550;Both sexes;338 Huesca;Group 1107 Inguinal hernia 550;Men;312 Huesca;Group 1107 Inguinal hernia 550;Women;26 Huesca;Group 1108 Other abdominal hernia 551-553;Both sexes;259 Huesca;Group 1108 Other abdominal hernia 551-553;Men;138 Huesca;Group 1108 Other abdominal hernia 551-553;Women;121 Huesca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;43 Huesca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;22 Huesca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;21 Huesca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;166 Huesca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;88 Huesca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;78 Huesca;Group 1111 Intestinal obstruction without hernia 560;Both sexes;128 Huesca;Group 1111 Intestinal obstruction without hernia 560;Men;65 Huesca;Group 1111 Intestinal obstruction without hernia 560;Women;63 Huesca;Group 1112 Intestinal diverticulosis 562;Both sexes;101 Huesca;Group 1112 Intestinal diverticulosis 562;Men;46 Huesca;Group 1112 Intestinal diverticulosis 562;Women;55 Huesca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;139 Huesca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;86 Huesca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;53 Huesca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;110 Huesca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;51 Huesca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;59 Huesca;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;53 Huesca;Group 1115 Alcoholic hepatitis 5710-5713;Men;51 Huesca;Group 1115 Alcoholic hepatitis 5710-5713;Women;2 Huesca;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;106 Huesca;Group 1116 Other diseases of the liver 570,5714-573;Men;70 Huesca;Group 1116 Other diseases of the liver 570,5714-573;Women;36 Huesca;Group 1117 Cholelithiasis 574;Both sexes;504 Huesca;Group 1117 Cholelithiasis 574;Men;237 Huesca;Group 1117 Cholelithiasis 574;Women;267 Huesca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;131 Huesca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;87 Huesca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;44 Huesca;Group 1119 Pancreatic diseases 577;Both sexes;143 Huesca;Group 1119 Pancreatic diseases 577;Men;83 Huesca;Group 1119 Pancreatic diseases 577;Women;60 Huesca;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;101 Huesca;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;48 Huesca;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;53 Huesca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;279 Huesca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;157 Huesca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;122 Huesca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;174 Huesca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;110 Huesca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;64 Huesca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;5 Huesca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;3 Huesca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;2 Huesca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;100 Huesca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;44 Huesca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;56 Huesca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1.368 Huesca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;678 Huesca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;690 Huesca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Huesca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Huesca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Huesca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Huesca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Huesca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Huesca;Group 1303 Internal derangement of knee 717;Both sexes;262 Huesca;Group 1303 Internal derangement of knee 717;Men;171 Huesca;Group 1303 Internal derangement of knee 717;Women;91 Huesca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;469 Huesca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;241 Huesca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;228 Huesca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;39 Huesca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;13 Huesca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;26 Huesca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;16 Huesca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;6 Huesca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;10 Huesca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;66 Huesca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;31 Huesca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;35 Huesca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;52 Huesca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;16 Huesca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;36 Huesca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;250 Huesca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;134 Huesca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;116 Huesca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;214 Huesca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;66 Huesca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;148 Huesca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1.383 Huesca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;696 Huesca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;687 Huesca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;109 Huesca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;47 Huesca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;62 Huesca;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;177 Huesca;Group 1402 Renal failure 5836-5837, 584-586;Men;106 Huesca;Group 1402 Renal failure 5836-5837, 584-586;Women;71 Huesca;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;191 Huesca;Group 1403 Urolithiasis 592, 594, 7880;Men;107 Huesca;Group 1403 Urolithiasis 592, 594, 7880;Women;84 Huesca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;469 Huesca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;254 Huesca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;215 Huesca;Group 1405 Prostatic hyperplasia 600;Both sexes;106 Huesca;Group 1405 Prostatic hyperplasia 600;Men;106 Huesca;Group 1405 Prostatic hyperplasia 600;Women;.. Huesca;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;72 Huesca;Group 1406 Other diseases of the male genital organs 601-608;Men;72 Huesca;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Huesca;Group 1407 Disorders of breast 610-612;Both sexes;48 Huesca;Group 1407 Disorders of breast 610-612;Men;3 Huesca;Group 1407 Disorders of breast 610-612;Women;45 Huesca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;27 Huesca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Huesca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;27 Huesca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;16 Huesca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Huesca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;16 Huesca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;168 Huesca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Huesca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;167 Huesca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.873 Huesca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Huesca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.873 Huesca;Group 1501 Legally induced abortion 635;Both sexes;.. Huesca;Group 1501 Legally induced abortion 635;Men;.. Huesca;Group 1501 Legally induced abortion 635;Women;.. Huesca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;108 Huesca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Huesca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;108 Huesca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.067 Huesca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Huesca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.067 Huesca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;314 Huesca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Huesca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;314 Huesca;Group 1505 Single spontaneous delivery 650;Both sexes;113 Huesca;Group 1505 Single spontaneous delivery 650;Men;.. Huesca;Group 1505 Single spontaneous delivery 650;Women;113 Huesca;Group 1506 Other deliveries 6695-6697;Both sexes;60 Huesca;Group 1506 Other deliveries 6695-6697;Men;.. Huesca;Group 1506 Other deliveries 6695-6697;Women;60 Huesca;Group 1507 Complications related to the puerperium 670-676;Both sexes;18 Huesca;Group 1507 Complications related to the puerperium 670-676;Men;.. Huesca;Group 1507 Complications related to the puerperium 670-676;Women;18 Huesca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;193 Huesca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Huesca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;193 Huesca;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;236 Huesca;Group 1600 Some disorders originating in the perinatal period 760-779;Men;138 Huesca;Group 1600 Some disorders originating in the perinatal period 760-779;Women;98 Huesca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;65 Huesca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;44 Huesca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;21 Huesca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;171 Huesca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;94 Huesca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;77 Huesca;Grupo 1700 Congenital abnormalities 740-759;Both sexes;50 Huesca;Grupo 1700 Congenital abnormalities 740-759;Men;27 Huesca;Grupo 1700 Congenital abnormalities 740-759;Women;23 Huesca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.167 Huesca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;629 Huesca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;538 Huesca;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;124 Huesca;Group 1801 Pain in throat and chest 7841, 7865;Men;75 Huesca;Group 1801 Pain in throat and chest 7841, 7865;Women;49 Huesca;Group 1802 Abdominal pain 7890;Both sexes;183 Huesca;Group 1802 Abdominal pain 7890;Men;74 Huesca;Group 1802 Abdominal pain 7890;Women;109 Huesca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1 Huesca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1 Huesca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. Huesca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;859 Huesca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;479 Huesca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;380 Huesca;Group 1900 Injuries and poisoning 800-999;Both sexes;1.725 Huesca;Group 1900 Injuries and poisoning 800-999;Men;841 Huesca;Group 1900 Injuries and poisoning 800-999;Women;884 Huesca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;116 Huesca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;73 Huesca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;43 Huesca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;18 Huesca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;11 Huesca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;7 Huesca;Group 1903 Radius and ulna fracture 813;Both sexes;94 Huesca;Group 1903 Radius and ulna fracture 813;Men;40 Huesca;Group 1903 Radius and ulna fracture 813;Women;54 Huesca;Group 1904 Femur fracture 820-821;Both sexes;388 Huesca;Group 1904 Femur fracture 820-821;Men;124 Huesca;Group 1904 Femur fracture 820-821;Women;264 Huesca;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;128 Huesca;Group 1905 Leg fracture, including the ankle 823-824;Men;63 Huesca;Group 1905 Leg fracture, including the ankle 823-824;Women;65 Huesca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;495 Huesca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;275 Huesca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;220 Huesca;Group 1907 Burns 940-949;Both sexes;3 Huesca;Group 1907 Burns 940-949;Men;2 Huesca;Group 1907 Burns 940-949;Women;1 Huesca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;36 Huesca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;16 Huesca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;20 Huesca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;381 Huesca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;203 Huesca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;178 Huesca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1 Huesca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Huesca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Huesca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;65 Huesca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;34 Huesca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;31 Huesca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;620 Huesca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;328 Huesca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;292 Huesca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;8 Huesca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;5 Huesca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;3 Huesca;Group 2102 Contraceptive management V25;Both sexes;9 Huesca;Group 2102 Contraceptive management V25;Men;.. Huesca;Group 2102 Contraceptive management V25;Women;9 Huesca;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Huesca;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Huesca;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Huesca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;86 Huesca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;60 Huesca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;26 Huesca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;517 Huesca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;263 Huesca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;254 Teruel;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;14.034 Teruel;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;7.043 Teruel;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;6.991 Teruel;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;250 Teruel;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;139 Teruel;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;111 Teruel;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;89 Teruel;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;54 Teruel;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;35 Teruel;Group 0102 Imprecise intestinal infections 009;Both sexes;11 Teruel;Group 0102 Imprecise intestinal infections 009;Men;7 Teruel;Group 0102 Imprecise intestinal infections 009;Women;4 Teruel;Group 0103 Tuberculosis 010-018, 137;Both sexes;4 Teruel;Group 0103 Tuberculosis 010-018, 137;Men;2 Teruel;Group 0103 Tuberculosis 010-018, 137;Women;2 Teruel;Group 0104 Septicaemia 038;Both sexes;64 Teruel;Group 0104 Septicaemia 038;Men;29 Teruel;Group 0104 Septicaemia 038;Women;35 Teruel;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;.. Teruel;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;.. Teruel;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;.. Teruel;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;82 Teruel;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;47 Teruel;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;35 Teruel;Group 0200 Neoplasms 140-239;Both sexes;1.143 Teruel;Group 0200 Neoplasms 140-239;Men;633 Teruel;Group 0200 Neoplasms 140-239;Women;510 Teruel;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;168 Teruel;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;103 Teruel;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;65 Teruel;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;100 Teruel;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;87 Teruel;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;13 Teruel;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;7 Teruel;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;4 Teruel;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;3 Teruel;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;90 Teruel;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Teruel;Group 0204 Malignant neoplasm of breast 174-175;Women;90 Teruel;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;18 Teruel;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Teruel;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;18 Teruel;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;9 Teruel;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Teruel;Group 0206 Malignant neoplasm of ovary 1830;Women;9 Teruel;Group 0207 Malignant neoplasm of prostate 185;Both sexes;44 Teruel;Group 0207 Malignant neoplasm of prostate 185;Men;44 Teruel;Group 0207 Malignant neoplasm of prostate 185;Women;.. Teruel;Group 0208 Malignant neoplasm of bladder 188;Both sexes;110 Teruel;Group 0208 Malignant neoplasm of bladder 188;Men;85 Teruel;Group 0208 Malignant neoplasm of bladder 188;Women;25 Teruel;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;394 Teruel;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;245 Teruel;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;149 Teruel;Group 0210 Carcinoma in situ 230-234;Both sexes;27 Teruel;Group 0210 Carcinoma in situ 230-234;Men;8 Teruel;Group 0210 Carcinoma in situ 230-234;Women;19 Teruel;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;13 Teruel;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;7 Teruel;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;6 Teruel;Grupo 0212 Leiomyoma of uterus 218;Both sexes;37 Teruel;Grupo 0212 Leiomyoma of uterus 218;Men;.. Teruel;Grupo 0212 Leiomyoma of uterus 218;Women;37 Teruel;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;126 Teruel;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;50 Teruel;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;76 Teruel;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;127 Teruel;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;62 Teruel;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;65 Teruel;Group 0301 Anaemias 280-285;Both sexes;85 Teruel;Group 0301 Anaemias 280-285;Men;42 Teruel;Group 0301 Anaemias 280-285;Women;43 Teruel;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;42 Teruel;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;20 Teruel;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;22 Teruel;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;207 Teruel;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;107 Teruel;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;100 Teruel;Group 0401 Diabetes mellitus 249-250;Both sexes;71 Teruel;Group 0401 Diabetes mellitus 249-250;Men;46 Teruel;Group 0401 Diabetes mellitus 249-250;Women;25 Teruel;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;136 Teruel;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;61 Teruel;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;75 Teruel;Group 0500 Mental disorders 290-319;Both sexes;307 Teruel;Group 0500 Mental disorders 290-319;Men;184 Teruel;Group 0500 Mental disorders 290-319;Women;123 Teruel;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;21 Teruel;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;11 Teruel;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;10 Teruel;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;29 Teruel;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;22 Teruel;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;7 Teruel;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;5 Teruel;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;4 Teruel;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;1 Teruel;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;89 Teruel;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;58 Teruel;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;31 Teruel;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;61 Teruel;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;32 Teruel;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;29 Teruel;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;102 Teruel;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;57 Teruel;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;45 Teruel;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;234 Teruel;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;129 Teruel;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;105 Teruel;Group 0601 Alzheimer's disease 3310;Both sexes;12 Teruel;Group 0601 Alzheimer's disease 3310;Men;5 Teruel;Group 0601 Alzheimer's disease 3310;Women;7 Teruel;Group 0602 Multiple sclerosis 340;Both sexes;1 Teruel;Group 0602 Multiple sclerosis 340;Men;.. Teruel;Group 0602 Multiple sclerosis 340;Women;1 Teruel;Group 0603 Epilepsy 345;Both sexes;50 Teruel;Group 0603 Epilepsy 345;Men;29 Teruel;Group 0603 Epilepsy 345;Women;21 Teruel;Group 0604 Transient cerebral ischemia 435;Both sexes;55 Teruel;Group 0604 Transient cerebral ischemia 435;Men;31 Teruel;Group 0604 Transient cerebral ischemia 435;Women;24 Teruel;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;116 Teruel;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;64 Teruel;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;52 Teruel;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;49 Teruel;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;27 Teruel;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;22 Teruel;Grupo 0701 Cataract 366;Both sexes;20 Teruel;Grupo 0701 Cataract 366;Men;9 Teruel;Grupo 0701 Cataract 366;Women;11 Teruel;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;29 Teruel;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;18 Teruel;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;11 Teruel;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;40 Teruel;Group 0800 Diseases of the ear and the mastoid 380-389;Men;24 Teruel;Group 0800 Diseases of the ear and the mastoid 380-389;Women;16 Teruel;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1.709 Teruel;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;924 Teruel;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;785 Teruel;Group 0901 Hypertensive disease 401-405;Both sexes;47 Teruel;Group 0901 Hypertensive disease 401-405;Men;24 Teruel;Group 0901 Hypertensive disease 401-405;Women;23 Teruel;Group 0902 Angina pectoris 4111, 413;Both sexes;111 Teruel;Group 0902 Angina pectoris 4111, 413;Men;74 Teruel;Group 0902 Angina pectoris 4111, 413;Women;37 Teruel;Group 0903 Acute myocardial infarction 410;Both sexes;77 Teruel;Group 0903 Acute myocardial infarction 410;Men;50 Teruel;Group 0903 Acute myocardial infarction 410;Women;27 Teruel;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;45 Teruel;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;38 Teruel;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;7 Teruel;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;80 Teruel;Group 0905 Diseases of the lungs circulation 415-417;Men;36 Teruel;Group 0905 Diseases of the lungs circulation 415-417;Women;44 Teruel;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;192 Teruel;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;105 Teruel;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;87 Teruel;Grupo 0907 Heart failure 428;Both sexes;584 Teruel;Grupo 0907 Heart failure 428;Men;303 Teruel;Grupo 0907 Heart failure 428;Women;281 Teruel;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;291 Teruel;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;150 Teruel;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;141 Teruel;Grupo 0909 Atherosclerosis 440;Both sexes;24 Teruel;Grupo 0909 Atherosclerosis 440;Men;15 Teruel;Grupo 0909 Atherosclerosis 440;Women;9 Teruel;Group 0910 Varicose veins of lower extremities 454;Both sexes;39 Teruel;Group 0910 Varicose veins of lower extremities 454;Men;5 Teruel;Group 0910 Varicose veins of lower extremities 454;Women;34 Teruel;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;219 Teruel;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;124 Teruel;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;95 Teruel;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2.209 Teruel;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.296 Teruel;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;913 Teruel;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;138 Teruel;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;69 Teruel;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;69 Teruel;Group 1002 Pneumonia 480-486;Both sexes;582 Teruel;Group 1002 Pneumonia 480-486;Men;366 Teruel;Group 1002 Pneumonia 480-486;Women;216 Teruel;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;293 Teruel;Group 1003 Acute bronchitis and bronchiolitis 466;Men;124 Teruel;Group 1003 Acute bronchitis and bronchiolitis 466;Women;169 Teruel;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;39 Teruel;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;17 Teruel;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;22 Teruel;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;118 Teruel;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;72 Teruel;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;46 Teruel;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;424 Teruel;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;334 Teruel;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;90 Teruel;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;63 Teruel;Group 1007 Asthma 4930-4931,4938-4939;Men;19 Teruel;Group 1007 Asthma 4930-4931,4938-4939;Women;44 Teruel;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;552 Teruel;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;295 Teruel;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;257 Teruel;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.208 Teruel;Group 1100 Diseases of the digestive system 520-579;Men;1.283 Teruel;Group 1100 Diseases of the digestive system 520-579;Women;925 Teruel;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;16 Teruel;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;7 Teruel;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;9 Teruel;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;14 Teruel;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;10 Teruel;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;4 Teruel;Group 1103 Diseases of the esophagus 530;Both sexes;25 Teruel;Group 1103 Diseases of the esophagus 530;Men;13 Teruel;Group 1103 Diseases of the esophagus 530;Women;12 Teruel;Group 1104 Peptic ulcer 531-534;Both sexes;54 Teruel;Group 1104 Peptic ulcer 531-534;Men;36 Teruel;Group 1104 Peptic ulcer 531-534;Women;18 Teruel;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;52 Teruel;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;27 Teruel;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;25 Teruel;Group 1106 Appendicitis 540-543;Both sexes;137 Teruel;Group 1106 Appendicitis 540-543;Men;81 Teruel;Group 1106 Appendicitis 540-543;Women;56 Teruel;Group 1107 Inguinal hernia 550;Both sexes;353 Teruel;Group 1107 Inguinal hernia 550;Men;311 Teruel;Group 1107 Inguinal hernia 550;Women;42 Teruel;Group 1108 Other abdominal hernia 551-553;Both sexes;192 Teruel;Group 1108 Other abdominal hernia 551-553;Men;101 Teruel;Group 1108 Other abdominal hernia 551-553;Women;91 Teruel;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;30 Teruel;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;16 Teruel;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;14 Teruel;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;136 Teruel;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;66 Teruel;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;70 Teruel;Group 1111 Intestinal obstruction without hernia 560;Both sexes;125 Teruel;Group 1111 Intestinal obstruction without hernia 560;Men;63 Teruel;Group 1111 Intestinal obstruction without hernia 560;Women;62 Teruel;Group 1112 Intestinal diverticulosis 562;Both sexes;74 Teruel;Group 1112 Intestinal diverticulosis 562;Men;37 Teruel;Group 1112 Intestinal diverticulosis 562;Women;37 Teruel;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;101 Teruel;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;66 Teruel;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;35 Teruel;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;81 Teruel;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;38 Teruel;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;43 Teruel;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;27 Teruel;Group 1115 Alcoholic hepatitis 5710-5713;Men;19 Teruel;Group 1115 Alcoholic hepatitis 5710-5713;Women;8 Teruel;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;74 Teruel;Group 1116 Other diseases of the liver 570,5714-573;Men;41 Teruel;Group 1116 Other diseases of the liver 570,5714-573;Women;33 Teruel;Group 1117 Cholelithiasis 574;Both sexes;400 Teruel;Group 1117 Cholelithiasis 574;Men;179 Teruel;Group 1117 Cholelithiasis 574;Women;221 Teruel;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;114 Teruel;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;68 Teruel;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;46 Teruel;Group 1119 Pancreatic diseases 577;Both sexes;100 Teruel;Group 1119 Pancreatic diseases 577;Men;53 Teruel;Group 1119 Pancreatic diseases 577;Women;47 Teruel;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;103 Teruel;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;51 Teruel;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;52 Teruel;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;175 Teruel;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;94 Teruel;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;81 Teruel;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;118 Teruel;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;61 Teruel;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;57 Teruel;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;6 Teruel;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;6 Teruel;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;.. Teruel;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;51 Teruel;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;27 Teruel;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;24 Teruel;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;719 Teruel;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;311 Teruel;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;408 Teruel;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Teruel;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Teruel;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Teruel;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Teruel;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Teruel;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Teruel;Group 1303 Internal derangement of knee 717;Both sexes;108 Teruel;Group 1303 Internal derangement of knee 717;Men;65 Teruel;Group 1303 Internal derangement of knee 717;Women;43 Teruel;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;336 Teruel;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;137 Teruel;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;199 Teruel;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;30 Teruel;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;11 Teruel;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;19 Teruel;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;4 Teruel;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1 Teruel;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;3 Teruel;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;26 Teruel;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;14 Teruel;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;12 Teruel;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;26 Teruel;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;12 Teruel;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;14 Teruel;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;79 Teruel;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;42 Teruel;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;37 Teruel;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;110 Teruel;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;29 Teruel;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;81 Teruel;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;790 Teruel;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;428 Teruel;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;362 Teruel;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;52 Teruel;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;25 Teruel;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;27 Teruel;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;88 Teruel;Group 1402 Renal failure 5836-5837, 584-586;Men;49 Teruel;Group 1402 Renal failure 5836-5837, 584-586;Women;39 Teruel;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;106 Teruel;Group 1403 Urolithiasis 592, 594, 7880;Men;67 Teruel;Group 1403 Urolithiasis 592, 594, 7880;Women;39 Teruel;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;230 Teruel;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;97 Teruel;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;133 Teruel;Group 1405 Prostatic hyperplasia 600;Both sexes;118 Teruel;Group 1405 Prostatic hyperplasia 600;Men;118 Teruel;Group 1405 Prostatic hyperplasia 600;Women;.. Teruel;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;67 Teruel;Group 1406 Other diseases of the male genital organs 601-608;Men;67 Teruel;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Teruel;Group 1407 Disorders of breast 610-612;Both sexes;16 Teruel;Group 1407 Disorders of breast 610-612;Men;4 Teruel;Group 1407 Disorders of breast 610-612;Women;12 Teruel;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;22 Teruel;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Teruel;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;22 Teruel;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;9 Teruel;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Teruel;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;9 Teruel;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;82 Teruel;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Teruel;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;81 Teruel;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.134 Teruel;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Teruel;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.134 Teruel;Group 1501 Legally induced abortion 635;Both sexes;1 Teruel;Group 1501 Legally induced abortion 635;Men;.. Teruel;Group 1501 Legally induced abortion 635;Women;1 Teruel;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;93 Teruel;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Teruel;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;93 Teruel;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;515 Teruel;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Teruel;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;515 Teruel;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;264 Teruel;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Teruel;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;264 Teruel;Group 1505 Single spontaneous delivery 650;Both sexes;150 Teruel;Group 1505 Single spontaneous delivery 650;Men;.. Teruel;Group 1505 Single spontaneous delivery 650;Women;150 Teruel;Group 1506 Other deliveries 6695-6697;Both sexes;14 Teruel;Group 1506 Other deliveries 6695-6697;Men;.. Teruel;Group 1506 Other deliveries 6695-6697;Women;14 Teruel;Group 1507 Complications related to the puerperium 670-676;Both sexes;4 Teruel;Group 1507 Complications related to the puerperium 670-676;Men;.. Teruel;Group 1507 Complications related to the puerperium 670-676;Women;4 Teruel;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;93 Teruel;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Teruel;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;93 Teruel;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;509 Teruel;Group 1600 Some disorders originating in the perinatal period 760-779;Men;268 Teruel;Group 1600 Some disorders originating in the perinatal period 760-779;Women;241 Teruel;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;22 Teruel;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;15 Teruel;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;7 Teruel;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;487 Teruel;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;253 Teruel;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;234 Teruel;Grupo 1700 Congenital abnormalities 740-759;Both sexes;40 Teruel;Grupo 1700 Congenital abnormalities 740-759;Men;20 Teruel;Grupo 1700 Congenital abnormalities 740-759;Women;20 Teruel;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;690 Teruel;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;373 Teruel;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;317 Teruel;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;43 Teruel;Group 1801 Pain in throat and chest 7841, 7865;Men;29 Teruel;Group 1801 Pain in throat and chest 7841, 7865;Women;14 Teruel;Group 1802 Abdominal pain 7890;Both sexes;81 Teruel;Group 1802 Abdominal pain 7890;Men;40 Teruel;Group 1802 Abdominal pain 7890;Women;41 Teruel;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;56 Teruel;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;21 Teruel;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;35 Teruel;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;510 Teruel;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;283 Teruel;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;227 Teruel;Group 1900 Injuries and poisoning 800-999;Both sexes;1.107 Teruel;Group 1900 Injuries and poisoning 800-999;Men;544 Teruel;Group 1900 Injuries and poisoning 800-999;Women;563 Teruel;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;82 Teruel;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;45 Teruel;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;37 Teruel;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;11 Teruel;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;10 Teruel;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;1 Teruel;Group 1903 Radius and ulna fracture 813;Both sexes;49 Teruel;Group 1903 Radius and ulna fracture 813;Men;30 Teruel;Group 1903 Radius and ulna fracture 813;Women;19 Teruel;Group 1904 Femur fracture 820-821;Both sexes;320 Teruel;Group 1904 Femur fracture 820-821;Men;99 Teruel;Group 1904 Femur fracture 820-821;Women;221 Teruel;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;72 Teruel;Group 1905 Leg fracture, including the ankle 823-824;Men;41 Teruel;Group 1905 Leg fracture, including the ankle 823-824;Women;31 Teruel;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;267 Teruel;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;166 Teruel;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;101 Teruel;Group 1907 Burns 940-949;Both sexes;.. Teruel;Group 1907 Burns 940-949;Men;.. Teruel;Group 1907 Burns 940-949;Women;.. Teruel;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;15 Teruel;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;7 Teruel;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;8 Teruel;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;223 Teruel;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;112 Teruel;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;111 Teruel;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Teruel;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Teruel;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Teruel;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;66 Teruel;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;32 Teruel;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;34 Teruel;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;387 Teruel;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;197 Teruel;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;190 Teruel;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;31 Teruel;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;24 Teruel;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;7 Teruel;Group 2102 Contraceptive management V25;Both sexes;1 Teruel;Group 2102 Contraceptive management V25;Men;.. Teruel;Group 2102 Contraceptive management V25;Women;1 Teruel;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Teruel;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Teruel;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Teruel;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;48 Teruel;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;30 Teruel;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;18 Teruel;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;307 Teruel;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;143 Teruel;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;164 Zaragoza;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;118.069 Zaragoza;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;58.090 Zaragoza;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;59.979 Zaragoza;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.217 Zaragoza;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.236 Zaragoza;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;981 Zaragoza;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;406 Zaragoza;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;218 Zaragoza;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;188 Zaragoza;Group 0102 Imprecise intestinal infections 009;Both sexes;151 Zaragoza;Group 0102 Imprecise intestinal infections 009;Men;68 Zaragoza;Group 0102 Imprecise intestinal infections 009;Women;83 Zaragoza;Group 0103 Tuberculosis 010-018, 137;Both sexes;120 Zaragoza;Group 0103 Tuberculosis 010-018, 137;Men;64 Zaragoza;Group 0103 Tuberculosis 010-018, 137;Women;56 Zaragoza;Group 0104 Septicaemia 038;Both sexes;917 Zaragoza;Group 0104 Septicaemia 038;Men;499 Zaragoza;Group 0104 Septicaemia 038;Women;418 Zaragoza;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;38 Zaragoza;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;26 Zaragoza;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;12 Zaragoza;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;585 Zaragoza;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;361 Zaragoza;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;224 Zaragoza;Group 0200 Neoplasms 140-239;Both sexes;12.328 Zaragoza;Group 0200 Neoplasms 140-239;Men;6.416 Zaragoza;Group 0200 Neoplasms 140-239;Women;5.912 Zaragoza;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.075 Zaragoza;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;634 Zaragoza;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;441 Zaragoza;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;866 Zaragoza;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;711 Zaragoza;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;155 Zaragoza;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;321 Zaragoza;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;196 Zaragoza;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;125 Zaragoza;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;811 Zaragoza;Group 0204 Malignant neoplasm of breast 174-175;Men;14 Zaragoza;Group 0204 Malignant neoplasm of breast 174-175;Women;797 Zaragoza;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;220 Zaragoza;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Zaragoza;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;220 Zaragoza;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;119 Zaragoza;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Zaragoza;Group 0206 Malignant neoplasm of ovary 1830;Women;119 Zaragoza;Group 0207 Malignant neoplasm of prostate 185;Both sexes;418 Zaragoza;Group 0207 Malignant neoplasm of prostate 185;Men;418 Zaragoza;Group 0207 Malignant neoplasm of prostate 185;Women;.. Zaragoza;Group 0208 Malignant neoplasm of bladder 188;Both sexes;991 Zaragoza;Group 0208 Malignant neoplasm of bladder 188;Men;837 Zaragoza;Group 0208 Malignant neoplasm of bladder 188;Women;154 Zaragoza;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4.022 Zaragoza;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.327 Zaragoza;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.695 Zaragoza;Group 0210 Carcinoma in situ 230-234;Both sexes;585 Zaragoza;Group 0210 Carcinoma in situ 230-234;Men;184 Zaragoza;Group 0210 Carcinoma in situ 230-234;Women;401 Zaragoza;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;137 Zaragoza;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;82 Zaragoza;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;55 Zaragoza;Grupo 0212 Leiomyoma of uterus 218;Both sexes;572 Zaragoza;Grupo 0212 Leiomyoma of uterus 218;Men;.. Zaragoza;Grupo 0212 Leiomyoma of uterus 218;Women;572 Zaragoza;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.191 Zaragoza;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.013 Zaragoza;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.178 Zaragoza;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.050 Zaragoza;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;478 Zaragoza;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;572 Zaragoza;Group 0301 Anaemias 280-285;Both sexes;715 Zaragoza;Group 0301 Anaemias 280-285;Men;310 Zaragoza;Group 0301 Anaemias 280-285;Women;405 Zaragoza;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;335 Zaragoza;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;168 Zaragoza;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;167 Zaragoza;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.618 Zaragoza;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.004 Zaragoza;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.614 Zaragoza;Group 0401 Diabetes mellitus 249-250;Both sexes;675 Zaragoza;Group 0401 Diabetes mellitus 249-250;Men;390 Zaragoza;Group 0401 Diabetes mellitus 249-250;Women;285 Zaragoza;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.943 Zaragoza;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;614 Zaragoza;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.329 Zaragoza;Group 0500 Mental disorders 290-319;Both sexes;2.331 Zaragoza;Group 0500 Mental disorders 290-319;Men;1.127 Zaragoza;Group 0500 Mental disorders 290-319;Women;1.204 Zaragoza;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;124 Zaragoza;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;58 Zaragoza;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;66 Zaragoza;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;107 Zaragoza;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;77 Zaragoza;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;30 Zaragoza;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;78 Zaragoza;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;59 Zaragoza;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;19 Zaragoza;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;589 Zaragoza;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;353 Zaragoza;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;236 Zaragoza;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;509 Zaragoza;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;192 Zaragoza;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;317 Zaragoza;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;924 Zaragoza;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;388 Zaragoza;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;535 Zaragoza;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3.332 Zaragoza;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.732 Zaragoza;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.600 Zaragoza;Group 0601 Alzheimer's disease 3310;Both sexes;67 Zaragoza;Group 0601 Alzheimer's disease 3310;Men;26 Zaragoza;Group 0601 Alzheimer's disease 3310;Women;41 Zaragoza;Group 0602 Multiple sclerosis 340;Both sexes;59 Zaragoza;Group 0602 Multiple sclerosis 340;Men;15 Zaragoza;Group 0602 Multiple sclerosis 340;Women;44 Zaragoza;Group 0603 Epilepsy 345;Both sexes;320 Zaragoza;Group 0603 Epilepsy 345;Men;167 Zaragoza;Group 0603 Epilepsy 345;Women;153 Zaragoza;Group 0604 Transient cerebral ischemia 435;Both sexes;266 Zaragoza;Group 0604 Transient cerebral ischemia 435;Men;150 Zaragoza;Group 0604 Transient cerebral ischemia 435;Women;116 Zaragoza;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2.620 Zaragoza;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.374 Zaragoza;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.246 Zaragoza;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;752 Zaragoza;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;377 Zaragoza;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;375 Zaragoza;Grupo 0701 Cataract 366;Both sexes;111 Zaragoza;Grupo 0701 Cataract 366;Men;48 Zaragoza;Grupo 0701 Cataract 366;Women;63 Zaragoza;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;641 Zaragoza;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;329 Zaragoza;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;312 Zaragoza;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;580 Zaragoza;Group 0800 Diseases of the ear and the mastoid 380-389;Men;264 Zaragoza;Group 0800 Diseases of the ear and the mastoid 380-389;Women;316 Zaragoza;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;15.017 Zaragoza;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;8.571 Zaragoza;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;6.446 Zaragoza;Group 0901 Hypertensive disease 401-405;Both sexes;358 Zaragoza;Group 0901 Hypertensive disease 401-405;Men;187 Zaragoza;Group 0901 Hypertensive disease 401-405;Women;171 Zaragoza;Group 0902 Angina pectoris 4111, 413;Both sexes;552 Zaragoza;Group 0902 Angina pectoris 4111, 413;Men;342 Zaragoza;Group 0902 Angina pectoris 4111, 413;Women;210 Zaragoza;Group 0903 Acute myocardial infarction 410;Both sexes;1.116 Zaragoza;Group 0903 Acute myocardial infarction 410;Men;818 Zaragoza;Group 0903 Acute myocardial infarction 410;Women;298 Zaragoza;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.160 Zaragoza;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;886 Zaragoza;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;274 Zaragoza;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;459 Zaragoza;Group 0905 Diseases of the lungs circulation 415-417;Men;200 Zaragoza;Group 0905 Diseases of the lungs circulation 415-417;Women;259 Zaragoza;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.767 Zaragoza;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;973 Zaragoza;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;794 Zaragoza;Grupo 0907 Heart failure 428;Both sexes;3.505 Zaragoza;Grupo 0907 Heart failure 428;Men;1.719 Zaragoza;Grupo 0907 Heart failure 428;Women;1.786 Zaragoza;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.441 Zaragoza;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.357 Zaragoza;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.084 Zaragoza;Grupo 0909 Atherosclerosis 440;Both sexes;407 Zaragoza;Grupo 0909 Atherosclerosis 440;Men;308 Zaragoza;Grupo 0909 Atherosclerosis 440;Women;99 Zaragoza;Group 0910 Varicose veins of lower extremities 454;Both sexes;735 Zaragoza;Group 0910 Varicose veins of lower extremities 454;Men;272 Zaragoza;Group 0910 Varicose veins of lower extremities 454;Women;463 Zaragoza;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.517 Zaragoza;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.509 Zaragoza;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.008 Zaragoza;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;12.851 Zaragoza;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;7.365 Zaragoza;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;5.486 Zaragoza;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;489 Zaragoza;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;252 Zaragoza;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;237 Zaragoza;Group 1002 Pneumonia 480-486;Both sexes;3.011 Zaragoza;Group 1002 Pneumonia 480-486;Men;1.768 Zaragoza;Group 1002 Pneumonia 480-486;Women;1.243 Zaragoza;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.279 Zaragoza;Group 1003 Acute bronchitis and bronchiolitis 466;Men;645 Zaragoza;Group 1003 Acute bronchitis and bronchiolitis 466;Women;634 Zaragoza;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;602 Zaragoza;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;323 Zaragoza;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;279 Zaragoza;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.293 Zaragoza;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;854 Zaragoza;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;439 Zaragoza;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.042 Zaragoza;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.503 Zaragoza;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;539 Zaragoza;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;417 Zaragoza;Group 1007 Asthma 4930-4931,4938-4939;Men;120 Zaragoza;Group 1007 Asthma 4930-4931,4938-4939;Women;297 Zaragoza;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.718 Zaragoza;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.900 Zaragoza;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.818 Zaragoza;Group 1100 Diseases of the digestive system 520-579;Both sexes;13.886 Zaragoza;Group 1100 Diseases of the digestive system 520-579;Men;8.106 Zaragoza;Group 1100 Diseases of the digestive system 520-579;Women;5.780 Zaragoza;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;191 Zaragoza;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;97 Zaragoza;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;94 Zaragoza;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;227 Zaragoza;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;121 Zaragoza;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;106 Zaragoza;Group 1103 Diseases of the esophagus 530;Both sexes;245 Zaragoza;Group 1103 Diseases of the esophagus 530;Men;161 Zaragoza;Group 1103 Diseases of the esophagus 530;Women;84 Zaragoza;Group 1104 Peptic ulcer 531-534;Both sexes;309 Zaragoza;Group 1104 Peptic ulcer 531-534;Men;211 Zaragoza;Group 1104 Peptic ulcer 531-534;Women;98 Zaragoza;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;349 Zaragoza;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;156 Zaragoza;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;193 Zaragoza;Group 1106 Appendicitis 540-543;Both sexes;951 Zaragoza;Group 1106 Appendicitis 540-543;Men;550 Zaragoza;Group 1106 Appendicitis 540-543;Women;401 Zaragoza;Group 1107 Inguinal hernia 550;Both sexes;1.996 Zaragoza;Group 1107 Inguinal hernia 550;Men;1.772 Zaragoza;Group 1107 Inguinal hernia 550;Women;224 Zaragoza;Group 1108 Other abdominal hernia 551-553;Both sexes;1.348 Zaragoza;Group 1108 Other abdominal hernia 551-553;Men;708 Zaragoza;Group 1108 Other abdominal hernia 551-553;Women;640 Zaragoza;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;274 Zaragoza;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;147 Zaragoza;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;127 Zaragoza;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;633 Zaragoza;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;311 Zaragoza;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;322 Zaragoza;Group 1111 Intestinal obstruction without hernia 560;Both sexes;677 Zaragoza;Group 1111 Intestinal obstruction without hernia 560;Men;319 Zaragoza;Group 1111 Intestinal obstruction without hernia 560;Women;358 Zaragoza;Group 1112 Intestinal diverticulosis 562;Both sexes;594 Zaragoza;Group 1112 Intestinal diverticulosis 562;Men;278 Zaragoza;Group 1112 Intestinal diverticulosis 562;Women;316 Zaragoza;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;921 Zaragoza;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;571 Zaragoza;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;350 Zaragoza;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;450 Zaragoza;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;206 Zaragoza;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;244 Zaragoza;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;205 Zaragoza;Group 1115 Alcoholic hepatitis 5710-5713;Men;184 Zaragoza;Group 1115 Alcoholic hepatitis 5710-5713;Women;21 Zaragoza;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;431 Zaragoza;Group 1116 Other diseases of the liver 570,5714-573;Men;271 Zaragoza;Group 1116 Other diseases of the liver 570,5714-573;Women;160 Zaragoza;Group 1117 Cholelithiasis 574;Both sexes;2.295 Zaragoza;Group 1117 Cholelithiasis 574;Men;1.022 Zaragoza;Group 1117 Cholelithiasis 574;Women;1.273 Zaragoza;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;584 Zaragoza;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;341 Zaragoza;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;243 Zaragoza;Group 1119 Pancreatic diseases 577;Both sexes;656 Zaragoza;Group 1119 Pancreatic diseases 577;Men;381 Zaragoza;Group 1119 Pancreatic diseases 577;Women;275 Zaragoza;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;550 Zaragoza;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;299 Zaragoza;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;251 Zaragoza;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;979 Zaragoza;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;547 Zaragoza;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;432 Zaragoza;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;673 Zaragoza;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;414 Zaragoza;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;259 Zaragoza;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;58 Zaragoza;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;26 Zaragoza;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;32 Zaragoza;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;248 Zaragoza;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;107 Zaragoza;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;141 Zaragoza;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9.138 Zaragoza;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.658 Zaragoza;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4.480 Zaragoza;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Zaragoza;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Zaragoza;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Zaragoza;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Zaragoza;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Zaragoza;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Zaragoza;Group 1303 Internal derangement of knee 717;Both sexes;1.344 Zaragoza;Group 1303 Internal derangement of knee 717;Men;884 Zaragoza;Group 1303 Internal derangement of knee 717;Women;460 Zaragoza;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.546 Zaragoza;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.201 Zaragoza;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.345 Zaragoza;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;143 Zaragoza;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;59 Zaragoza;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;84 Zaragoza;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;465 Zaragoza;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;215 Zaragoza;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;250 Zaragoza;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;931 Zaragoza;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;562 Zaragoza;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;369 Zaragoza;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;197 Zaragoza;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;93 Zaragoza;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;104 Zaragoza;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.824 Zaragoza;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.046 Zaragoza;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;778 Zaragoza;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.688 Zaragoza;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;598 Zaragoza;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.090 Zaragoza;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;8.135 Zaragoza;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.785 Zaragoza;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4.350 Zaragoza;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;585 Zaragoza;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;189 Zaragoza;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;396 Zaragoza;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;607 Zaragoza;Group 1402 Renal failure 5836-5837, 584-586;Men;335 Zaragoza;Group 1402 Renal failure 5836-5837, 584-586;Women;272 Zaragoza;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.256 Zaragoza;Group 1403 Urolithiasis 592, 594, 7880;Men;766 Zaragoza;Group 1403 Urolithiasis 592, 594, 7880;Women;490 Zaragoza;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.942 Zaragoza;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;978 Zaragoza;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;964 Zaragoza;Group 1405 Prostatic hyperplasia 600;Both sexes;814 Zaragoza;Group 1405 Prostatic hyperplasia 600;Men;814 Zaragoza;Group 1405 Prostatic hyperplasia 600;Women;.. Zaragoza;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;658 Zaragoza;Group 1406 Other diseases of the male genital organs 601-608;Men;658 Zaragoza;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Zaragoza;Group 1407 Disorders of breast 610-612;Both sexes;581 Zaragoza;Group 1407 Disorders of breast 610-612;Men;34 Zaragoza;Group 1407 Disorders of breast 610-612;Women;547 Zaragoza;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;203 Zaragoza;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Zaragoza;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;203 Zaragoza;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;124 Zaragoza;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Zaragoza;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;124 Zaragoza;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.365 Zaragoza;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;11 Zaragoza;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.354 Zaragoza;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;9.888 Zaragoza;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Zaragoza;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;9.888 Zaragoza;Group 1501 Legally induced abortion 635;Both sexes;.. Zaragoza;Group 1501 Legally induced abortion 635;Men;.. Zaragoza;Group 1501 Legally induced abortion 635;Women;.. Zaragoza;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;549 Zaragoza;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Zaragoza;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;549 Zaragoza;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;5.242 Zaragoza;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Zaragoza;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;5.242 Zaragoza;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.433 Zaragoza;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Zaragoza;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.433 Zaragoza;Group 1505 Single spontaneous delivery 650;Both sexes;730 Zaragoza;Group 1505 Single spontaneous delivery 650;Men;.. Zaragoza;Group 1505 Single spontaneous delivery 650;Women;730 Zaragoza;Group 1506 Other deliveries 6695-6697;Both sexes;231 Zaragoza;Group 1506 Other deliveries 6695-6697;Men;.. Zaragoza;Group 1506 Other deliveries 6695-6697;Women;231 Zaragoza;Group 1507 Complications related to the puerperium 670-676;Both sexes;84 Zaragoza;Group 1507 Complications related to the puerperium 670-676;Men;.. Zaragoza;Group 1507 Complications related to the puerperium 670-676;Women;84 Zaragoza;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;619 Zaragoza;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Zaragoza;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;619 Zaragoza;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.326 Zaragoza;Group 1600 Some disorders originating in the perinatal period 760-779;Men;740 Zaragoza;Group 1600 Some disorders originating in the perinatal period 760-779;Women;586 Zaragoza;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;289 Zaragoza;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;156 Zaragoza;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;133 Zaragoza;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.037 Zaragoza;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;584 Zaragoza;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;453 Zaragoza;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.326 Zaragoza;Grupo 1700 Congenital abnormalities 740-759;Men;690 Zaragoza;Grupo 1700 Congenital abnormalities 740-759;Women;636 Zaragoza;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;6.085 Zaragoza;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3.264 Zaragoza;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.821 Zaragoza;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;786 Zaragoza;Group 1801 Pain in throat and chest 7841, 7865;Men;419 Zaragoza;Group 1801 Pain in throat and chest 7841, 7865;Women;367 Zaragoza;Group 1802 Abdominal pain 7890;Both sexes;596 Zaragoza;Group 1802 Abdominal pain 7890;Men;229 Zaragoza;Group 1802 Abdominal pain 7890;Women;367 Zaragoza;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;676 Zaragoza;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;358 Zaragoza;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;318 Zaragoza;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;4.027 Zaragoza;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.258 Zaragoza;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.769 Zaragoza;Group 1900 Injuries and poisoning 800-999;Both sexes;11.542 Zaragoza;Group 1900 Injuries and poisoning 800-999;Men;6.289 Zaragoza;Group 1900 Injuries and poisoning 800-999;Women;5.253 Zaragoza;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;547 Zaragoza;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;327 Zaragoza;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;220 Zaragoza;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;399 Zaragoza;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;289 Zaragoza;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;110 Zaragoza;Group 1903 Radius and ulna fracture 813;Both sexes;671 Zaragoza;Group 1903 Radius and ulna fracture 813;Men;285 Zaragoza;Group 1903 Radius and ulna fracture 813;Women;386 Zaragoza;Group 1904 Femur fracture 820-821;Both sexes;1.780 Zaragoza;Group 1904 Femur fracture 820-821;Men;446 Zaragoza;Group 1904 Femur fracture 820-821;Women;1.334 Zaragoza;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;643 Zaragoza;Group 1905 Leg fracture, including the ankle 823-824;Men;323 Zaragoza;Group 1905 Leg fracture, including the ankle 823-824;Women;320 Zaragoza;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4.405 Zaragoza;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.895 Zaragoza;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.510 Zaragoza;Group 1907 Burns 940-949;Both sexes;126 Zaragoza;Group 1907 Burns 940-949;Men;86 Zaragoza;Group 1907 Burns 940-949;Women;40 Zaragoza;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;176 Zaragoza;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;86 Zaragoza;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;90 Zaragoza;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.528 Zaragoza;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.391 Zaragoza;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.137 Zaragoza;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;10 Zaragoza;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;6 Zaragoza;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;4 Zaragoza;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;257 Zaragoza;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;155 Zaragoza;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;102 Zaragoza;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.688 Zaragoza;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.441 Zaragoza;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.247 Zaragoza;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;153 Zaragoza;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;86 Zaragoza;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;67 Zaragoza;Group 2102 Contraceptive management V25;Both sexes;37 Zaragoza;Group 2102 Contraceptive management V25;Men;2 Zaragoza;Group 2102 Contraceptive management V25;Women;35 Zaragoza;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Zaragoza;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Zaragoza;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Zaragoza;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;782 Zaragoza;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;459 Zaragoza;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;323 Zaragoza;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.716 Zaragoza;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;894 Zaragoza;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;822 ASTURIAS, PRINCIPADO DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;117.057 ASTURIAS, PRINCIPADO DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;57.488 ASTURIAS, PRINCIPADO DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;59.569 ASTURIAS, PRINCIPADO DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.108 ASTURIAS, PRINCIPADO DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.124 ASTURIAS, PRINCIPADO DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;984 ASTURIAS, PRINCIPADO DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;332 ASTURIAS, PRINCIPADO DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;167 ASTURIAS, PRINCIPADO DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;165 ASTURIAS, PRINCIPADO DE;Group 0102 Imprecise intestinal infections 009;Both sexes;137 ASTURIAS, PRINCIPADO DE;Group 0102 Imprecise intestinal infections 009;Men;68 ASTURIAS, PRINCIPADO DE;Group 0102 Imprecise intestinal infections 009;Women;69 ASTURIAS, PRINCIPADO DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;97 ASTURIAS, PRINCIPADO DE;Group 0103 Tuberculosis 010-018, 137;Men;57 ASTURIAS, PRINCIPADO DE;Group 0103 Tuberculosis 010-018, 137;Women;40 ASTURIAS, PRINCIPADO DE;Group 0104 Septicaemia 038;Both sexes;835 ASTURIAS, PRINCIPADO DE;Group 0104 Septicaemia 038;Men;428 ASTURIAS, PRINCIPADO DE;Group 0104 Septicaemia 038;Women;407 ASTURIAS, PRINCIPADO DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;50 ASTURIAS, PRINCIPADO DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;34 ASTURIAS, PRINCIPADO DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;16 ASTURIAS, PRINCIPADO DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;657 ASTURIAS, PRINCIPADO DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;370 ASTURIAS, PRINCIPADO DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;287 ASTURIAS, PRINCIPADO DE;Group 0200 Neoplasms 140-239;Both sexes;11.405 ASTURIAS, PRINCIPADO DE;Group 0200 Neoplasms 140-239;Men;6.302 ASTURIAS, PRINCIPADO DE;Group 0200 Neoplasms 140-239;Women;5.103 ASTURIAS, PRINCIPADO DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.325 ASTURIAS, PRINCIPADO DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;851 ASTURIAS, PRINCIPADO DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;474 ASTURIAS, PRINCIPADO DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.140 ASTURIAS, PRINCIPADO DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;857 ASTURIAS, PRINCIPADO DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;283 ASTURIAS, PRINCIPADO DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;158 ASTURIAS, PRINCIPADO DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;76 ASTURIAS, PRINCIPADO DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;82 ASTURIAS, PRINCIPADO DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;699 ASTURIAS, PRINCIPADO DE;Group 0204 Malignant neoplasm of breast 174-175;Men;6 ASTURIAS, PRINCIPADO DE;Group 0204 Malignant neoplasm of breast 174-175;Women;693 ASTURIAS, PRINCIPADO DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;199 ASTURIAS, PRINCIPADO DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ASTURIAS, PRINCIPADO DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;199 ASTURIAS, PRINCIPADO DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;125 ASTURIAS, PRINCIPADO DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ASTURIAS, PRINCIPADO DE;Group 0206 Malignant neoplasm of ovary 1830;Women;125 ASTURIAS, PRINCIPADO DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;504 ASTURIAS, PRINCIPADO DE;Group 0207 Malignant neoplasm of prostate 185;Men;504 ASTURIAS, PRINCIPADO DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. ASTURIAS, PRINCIPADO DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;915 ASTURIAS, PRINCIPADO DE;Group 0208 Malignant neoplasm of bladder 188;Men;759 ASTURIAS, PRINCIPADO DE;Group 0208 Malignant neoplasm of bladder 188;Women;156 ASTURIAS, PRINCIPADO DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4.032 ASTURIAS, PRINCIPADO DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.394 ASTURIAS, PRINCIPADO DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.638 ASTURIAS, PRINCIPADO DE;Group 0210 Carcinoma in situ 230-234;Both sexes;349 ASTURIAS, PRINCIPADO DE;Group 0210 Carcinoma in situ 230-234;Men;242 ASTURIAS, PRINCIPADO DE;Group 0210 Carcinoma in situ 230-234;Women;107 ASTURIAS, PRINCIPADO DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;114 ASTURIAS, PRINCIPADO DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;68 ASTURIAS, PRINCIPADO DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;46 ASTURIAS, PRINCIPADO DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;511 ASTURIAS, PRINCIPADO DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. ASTURIAS, PRINCIPADO DE;Grupo 0212 Leiomyoma of uterus 218;Women;511 ASTURIAS, PRINCIPADO DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.334 ASTURIAS, PRINCIPADO DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;545 ASTURIAS, PRINCIPADO DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;789 ASTURIAS, PRINCIPADO DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.078 ASTURIAS, PRINCIPADO DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;483 ASTURIAS, PRINCIPADO DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;595 ASTURIAS, PRINCIPADO DE;Group 0301 Anaemias 280-285;Both sexes;809 ASTURIAS, PRINCIPADO DE;Group 0301 Anaemias 280-285;Men;332 ASTURIAS, PRINCIPADO DE;Group 0301 Anaemias 280-285;Women;477 ASTURIAS, PRINCIPADO DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;269 ASTURIAS, PRINCIPADO DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;151 ASTURIAS, PRINCIPADO DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;118 ASTURIAS, PRINCIPADO DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.736 ASTURIAS, PRINCIPADO DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;730 ASTURIAS, PRINCIPADO DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.006 ASTURIAS, PRINCIPADO DE;Group 0401 Diabetes mellitus 249-250;Both sexes;753 ASTURIAS, PRINCIPADO DE;Group 0401 Diabetes mellitus 249-250;Men;407 ASTURIAS, PRINCIPADO DE;Group 0401 Diabetes mellitus 249-250;Women;346 ASTURIAS, PRINCIPADO DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;983 ASTURIAS, PRINCIPADO DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;323 ASTURIAS, PRINCIPADO DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;660 ASTURIAS, PRINCIPADO DE;Group 0500 Mental disorders 290-319;Both sexes;2.978 ASTURIAS, PRINCIPADO DE;Group 0500 Mental disorders 290-319;Men;1.501 ASTURIAS, PRINCIPADO DE;Group 0500 Mental disorders 290-319;Women;1.477 ASTURIAS, PRINCIPADO DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;90 ASTURIAS, PRINCIPADO DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;42 ASTURIAS, PRINCIPADO DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;48 ASTURIAS, PRINCIPADO DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;206 ASTURIAS, PRINCIPADO DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;162 ASTURIAS, PRINCIPADO DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;44 ASTURIAS, PRINCIPADO DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;177 ASTURIAS, PRINCIPADO DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;138 ASTURIAS, PRINCIPADO DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;39 ASTURIAS, PRINCIPADO DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;748 ASTURIAS, PRINCIPADO DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;432 ASTURIAS, PRINCIPADO DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;316 ASTURIAS, PRINCIPADO DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;666 ASTURIAS, PRINCIPADO DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;222 ASTURIAS, PRINCIPADO DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;444 ASTURIAS, PRINCIPADO DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.091 ASTURIAS, PRINCIPADO DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;505 ASTURIAS, PRINCIPADO DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;586 ASTURIAS, PRINCIPADO DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.344 ASTURIAS, PRINCIPADO DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.236 ASTURIAS, PRINCIPADO DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.108 ASTURIAS, PRINCIPADO DE;Group 0601 Alzheimer's disease 3310;Both sexes;28 ASTURIAS, PRINCIPADO DE;Group 0601 Alzheimer's disease 3310;Men;8 ASTURIAS, PRINCIPADO DE;Group 0601 Alzheimer's disease 3310;Women;20 ASTURIAS, PRINCIPADO DE;Group 0602 Multiple sclerosis 340;Both sexes;92 ASTURIAS, PRINCIPADO DE;Group 0602 Multiple sclerosis 340;Men;34 ASTURIAS, PRINCIPADO DE;Group 0602 Multiple sclerosis 340;Women;58 ASTURIAS, PRINCIPADO DE;Group 0603 Epilepsy 345;Both sexes;447 ASTURIAS, PRINCIPADO DE;Group 0603 Epilepsy 345;Men;272 ASTURIAS, PRINCIPADO DE;Group 0603 Epilepsy 345;Women;175 ASTURIAS, PRINCIPADO DE;Group 0604 Transient cerebral ischemia 435;Both sexes;452 ASTURIAS, PRINCIPADO DE;Group 0604 Transient cerebral ischemia 435;Men;237 ASTURIAS, PRINCIPADO DE;Group 0604 Transient cerebral ischemia 435;Women;215 ASTURIAS, PRINCIPADO DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.325 ASTURIAS, PRINCIPADO DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;685 ASTURIAS, PRINCIPADO DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;640 ASTURIAS, PRINCIPADO DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;511 ASTURIAS, PRINCIPADO DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;223 ASTURIAS, PRINCIPADO DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;288 ASTURIAS, PRINCIPADO DE;Grupo 0701 Cataract 366;Both sexes;204 ASTURIAS, PRINCIPADO DE;Grupo 0701 Cataract 366;Men;76 ASTURIAS, PRINCIPADO DE;Grupo 0701 Cataract 366;Women;128 ASTURIAS, PRINCIPADO DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;307 ASTURIAS, PRINCIPADO DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;147 ASTURIAS, PRINCIPADO DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;160 ASTURIAS, PRINCIPADO DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;427 ASTURIAS, PRINCIPADO DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;190 ASTURIAS, PRINCIPADO DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;237 ASTURIAS, PRINCIPADO DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;19.743 ASTURIAS, PRINCIPADO DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10.649 ASTURIAS, PRINCIPADO DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;9.094 ASTURIAS, PRINCIPADO DE;Group 0901 Hypertensive disease 401-405;Both sexes;1.420 ASTURIAS, PRINCIPADO DE;Group 0901 Hypertensive disease 401-405;Men;585 ASTURIAS, PRINCIPADO DE;Group 0901 Hypertensive disease 401-405;Women;835 ASTURIAS, PRINCIPADO DE;Group 0902 Angina pectoris 4111, 413;Both sexes;1.010 ASTURIAS, PRINCIPADO DE;Group 0902 Angina pectoris 4111, 413;Men;627 ASTURIAS, PRINCIPADO DE;Group 0902 Angina pectoris 4111, 413;Women;383 ASTURIAS, PRINCIPADO DE;Group 0903 Acute myocardial infarction 410;Both sexes;1.647 ASTURIAS, PRINCIPADO DE;Group 0903 Acute myocardial infarction 410;Men;1.119 ASTURIAS, PRINCIPADO DE;Group 0903 Acute myocardial infarction 410;Women;528 ASTURIAS, PRINCIPADO DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;910 ASTURIAS, PRINCIPADO DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;690 ASTURIAS, PRINCIPADO DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;220 ASTURIAS, PRINCIPADO DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;768 ASTURIAS, PRINCIPADO DE;Group 0905 Diseases of the lungs circulation 415-417;Men;338 ASTURIAS, PRINCIPADO DE;Group 0905 Diseases of the lungs circulation 415-417;Women;430 ASTURIAS, PRINCIPADO DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.895 ASTURIAS, PRINCIPADO DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.034 ASTURIAS, PRINCIPADO DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;861 ASTURIAS, PRINCIPADO DE;Grupo 0907 Heart failure 428;Both sexes;3.694 ASTURIAS, PRINCIPADO DE;Grupo 0907 Heart failure 428;Men;1.830 ASTURIAS, PRINCIPADO DE;Grupo 0907 Heart failure 428;Women;1.864 ASTURIAS, PRINCIPADO DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3.373 ASTURIAS, PRINCIPADO DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.728 ASTURIAS, PRINCIPADO DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.645 ASTURIAS, PRINCIPADO DE;Grupo 0909 Atherosclerosis 440;Both sexes;727 ASTURIAS, PRINCIPADO DE;Grupo 0909 Atherosclerosis 440;Men;525 ASTURIAS, PRINCIPADO DE;Grupo 0909 Atherosclerosis 440;Women;202 ASTURIAS, PRINCIPADO DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.461 ASTURIAS, PRINCIPADO DE;Group 0910 Varicose veins of lower extremities 454;Men;498 ASTURIAS, PRINCIPADO DE;Group 0910 Varicose veins of lower extremities 454;Women;963 ASTURIAS, PRINCIPADO DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.838 ASTURIAS, PRINCIPADO DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.675 ASTURIAS, PRINCIPADO DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.163 ASTURIAS, PRINCIPADO DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;16.934 ASTURIAS, PRINCIPADO DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;9.446 ASTURIAS, PRINCIPADO DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;7.488 ASTURIAS, PRINCIPADO DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;651 ASTURIAS, PRINCIPADO DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;355 ASTURIAS, PRINCIPADO DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;296 ASTURIAS, PRINCIPADO DE;Group 1002 Pneumonia 480-486;Both sexes;3.872 ASTURIAS, PRINCIPADO DE;Group 1002 Pneumonia 480-486;Men;2.225 ASTURIAS, PRINCIPADO DE;Group 1002 Pneumonia 480-486;Women;1.647 ASTURIAS, PRINCIPADO DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;701 ASTURIAS, PRINCIPADO DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;337 ASTURIAS, PRINCIPADO DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;364 ASTURIAS, PRINCIPADO DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;198 ASTURIAS, PRINCIPADO DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;84 ASTURIAS, PRINCIPADO DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;114 ASTURIAS, PRINCIPADO DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;751 ASTURIAS, PRINCIPADO DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;443 ASTURIAS, PRINCIPADO DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;308 ASTURIAS, PRINCIPADO DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;3.192 ASTURIAS, PRINCIPADO DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.534 ASTURIAS, PRINCIPADO DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;658 ASTURIAS, PRINCIPADO DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.681 ASTURIAS, PRINCIPADO DE;Group 1007 Asthma 4930-4931,4938-4939;Men;615 ASTURIAS, PRINCIPADO DE;Group 1007 Asthma 4930-4931,4938-4939;Women;1.066 ASTURIAS, PRINCIPADO DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.888 ASTURIAS, PRINCIPADO DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.853 ASTURIAS, PRINCIPADO DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;3.035 ASTURIAS, PRINCIPADO DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;13.498 ASTURIAS, PRINCIPADO DE;Group 1100 Diseases of the digestive system 520-579;Men;7.728 ASTURIAS, PRINCIPADO DE;Group 1100 Diseases of the digestive system 520-579;Women;5.770 ASTURIAS, PRINCIPADO DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;107 ASTURIAS, PRINCIPADO DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;48 ASTURIAS, PRINCIPADO DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;59 ASTURIAS, PRINCIPADO DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;144 ASTURIAS, PRINCIPADO DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;77 ASTURIAS, PRINCIPADO DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;67 ASTURIAS, PRINCIPADO DE;Group 1103 Diseases of the esophagus 530;Both sexes;223 ASTURIAS, PRINCIPADO DE;Group 1103 Diseases of the esophagus 530;Men;135 ASTURIAS, PRINCIPADO DE;Group 1103 Diseases of the esophagus 530;Women;88 ASTURIAS, PRINCIPADO DE;Group 1104 Peptic ulcer 531-534;Both sexes;183 ASTURIAS, PRINCIPADO DE;Group 1104 Peptic ulcer 531-534;Men;121 ASTURIAS, PRINCIPADO DE;Group 1104 Peptic ulcer 531-534;Women;62 ASTURIAS, PRINCIPADO DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;291 ASTURIAS, PRINCIPADO DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;154 ASTURIAS, PRINCIPADO DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;137 ASTURIAS, PRINCIPADO DE;Group 1106 Appendicitis 540-543;Both sexes;1.070 ASTURIAS, PRINCIPADO DE;Group 1106 Appendicitis 540-543;Men;597 ASTURIAS, PRINCIPADO DE;Group 1106 Appendicitis 540-543;Women;473 ASTURIAS, PRINCIPADO DE;Group 1107 Inguinal hernia 550;Both sexes;1.373 ASTURIAS, PRINCIPADO DE;Group 1107 Inguinal hernia 550;Men;1.273 ASTURIAS, PRINCIPADO DE;Group 1107 Inguinal hernia 550;Women;100 ASTURIAS, PRINCIPADO DE;Group 1108 Other abdominal hernia 551-553;Both sexes;1.019 ASTURIAS, PRINCIPADO DE;Group 1108 Other abdominal hernia 551-553;Men;545 ASTURIAS, PRINCIPADO DE;Group 1108 Other abdominal hernia 551-553;Women;474 ASTURIAS, PRINCIPADO DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;324 ASTURIAS, PRINCIPADO DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;137 ASTURIAS, PRINCIPADO DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;187 ASTURIAS, PRINCIPADO DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;775 ASTURIAS, PRINCIPADO DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;350 ASTURIAS, PRINCIPADO DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;425 ASTURIAS, PRINCIPADO DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;913 ASTURIAS, PRINCIPADO DE;Group 1111 Intestinal obstruction without hernia 560;Men;500 ASTURIAS, PRINCIPADO DE;Group 1111 Intestinal obstruction without hernia 560;Women;413 ASTURIAS, PRINCIPADO DE;Group 1112 Intestinal diverticulosis 562;Both sexes;751 ASTURIAS, PRINCIPADO DE;Group 1112 Intestinal diverticulosis 562;Men;355 ASTURIAS, PRINCIPADO DE;Group 1112 Intestinal diverticulosis 562;Women;396 ASTURIAS, PRINCIPADO DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;686 ASTURIAS, PRINCIPADO DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;391 ASTURIAS, PRINCIPADO DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;295 ASTURIAS, PRINCIPADO DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;489 ASTURIAS, PRINCIPADO DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;245 ASTURIAS, PRINCIPADO DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;244 ASTURIAS, PRINCIPADO DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;338 ASTURIAS, PRINCIPADO DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;296 ASTURIAS, PRINCIPADO DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;42 ASTURIAS, PRINCIPADO DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;463 ASTURIAS, PRINCIPADO DE;Group 1116 Other diseases of the liver 570,5714-573;Men;293 ASTURIAS, PRINCIPADO DE;Group 1116 Other diseases of the liver 570,5714-573;Women;170 ASTURIAS, PRINCIPADO DE;Group 1117 Cholelithiasis 574;Both sexes;2.146 ASTURIAS, PRINCIPADO DE;Group 1117 Cholelithiasis 574;Men;954 ASTURIAS, PRINCIPADO DE;Group 1117 Cholelithiasis 574;Women;1.192 ASTURIAS, PRINCIPADO DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;858 ASTURIAS, PRINCIPADO DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;491 ASTURIAS, PRINCIPADO DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;367 ASTURIAS, PRINCIPADO DE;Group 1119 Pancreatic diseases 577;Both sexes;775 ASTURIAS, PRINCIPADO DE;Group 1119 Pancreatic diseases 577;Men;447 ASTURIAS, PRINCIPADO DE;Group 1119 Pancreatic diseases 577;Women;328 ASTURIAS, PRINCIPADO DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;570 ASTURIAS, PRINCIPADO DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;319 ASTURIAS, PRINCIPADO DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;251 ASTURIAS, PRINCIPADO DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.130 ASTURIAS, PRINCIPADO DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;592 ASTURIAS, PRINCIPADO DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;538 ASTURIAS, PRINCIPADO DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;706 ASTURIAS, PRINCIPADO DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;397 ASTURIAS, PRINCIPADO DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;309 ASTURIAS, PRINCIPADO DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;40 ASTURIAS, PRINCIPADO DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;22 ASTURIAS, PRINCIPADO DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;18 ASTURIAS, PRINCIPADO DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;384 ASTURIAS, PRINCIPADO DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;173 ASTURIAS, PRINCIPADO DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;211 ASTURIAS, PRINCIPADO DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;8.372 ASTURIAS, PRINCIPADO DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.063 ASTURIAS, PRINCIPADO DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4.309 ASTURIAS, PRINCIPADO DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ASTURIAS, PRINCIPADO DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ASTURIAS, PRINCIPADO DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ASTURIAS, PRINCIPADO DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ASTURIAS, PRINCIPADO DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ASTURIAS, PRINCIPADO DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ASTURIAS, PRINCIPADO DE;Group 1303 Internal derangement of knee 717;Both sexes;788 ASTURIAS, PRINCIPADO DE;Group 1303 Internal derangement of knee 717;Men;498 ASTURIAS, PRINCIPADO DE;Group 1303 Internal derangement of knee 717;Women;290 ASTURIAS, PRINCIPADO DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;4.182 ASTURIAS, PRINCIPADO DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.983 ASTURIAS, PRINCIPADO DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.199 ASTURIAS, PRINCIPADO DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;99 ASTURIAS, PRINCIPADO DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;52 ASTURIAS, PRINCIPADO DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;47 ASTURIAS, PRINCIPADO DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;344 ASTURIAS, PRINCIPADO DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;147 ASTURIAS, PRINCIPADO DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;197 ASTURIAS, PRINCIPADO DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;829 ASTURIAS, PRINCIPADO DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;425 ASTURIAS, PRINCIPADO DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;404 ASTURIAS, PRINCIPADO DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;227 ASTURIAS, PRINCIPADO DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;103 ASTURIAS, PRINCIPADO DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;124 ASTURIAS, PRINCIPADO DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;934 ASTURIAS, PRINCIPADO DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;515 ASTURIAS, PRINCIPADO DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;419 ASTURIAS, PRINCIPADO DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;969 ASTURIAS, PRINCIPADO DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;340 ASTURIAS, PRINCIPADO DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;629 ASTURIAS, PRINCIPADO DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;7.084 ASTURIAS, PRINCIPADO DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.314 ASTURIAS, PRINCIPADO DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3.770 ASTURIAS, PRINCIPADO DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;494 ASTURIAS, PRINCIPADO DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;177 ASTURIAS, PRINCIPADO DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;317 ASTURIAS, PRINCIPADO DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;548 ASTURIAS, PRINCIPADO DE;Group 1402 Renal failure 5836-5837, 584-586;Men;321 ASTURIAS, PRINCIPADO DE;Group 1402 Renal failure 5836-5837, 584-586;Women;227 ASTURIAS, PRINCIPADO DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;995 ASTURIAS, PRINCIPADO DE;Group 1403 Urolithiasis 592, 594, 7880;Men;592 ASTURIAS, PRINCIPADO DE;Group 1403 Urolithiasis 592, 594, 7880;Women;403 ASTURIAS, PRINCIPADO DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.673 ASTURIAS, PRINCIPADO DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.159 ASTURIAS, PRINCIPADO DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.514 ASTURIAS, PRINCIPADO DE;Group 1405 Prostatic hyperplasia 600;Both sexes;569 ASTURIAS, PRINCIPADO DE;Group 1405 Prostatic hyperplasia 600;Men;569 ASTURIAS, PRINCIPADO DE;Group 1405 Prostatic hyperplasia 600;Women;.. ASTURIAS, PRINCIPADO DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;442 ASTURIAS, PRINCIPADO DE;Group 1406 Other diseases of the male genital organs 601-608;Men;442 ASTURIAS, PRINCIPADO DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ASTURIAS, PRINCIPADO DE;Group 1407 Disorders of breast 610-612;Both sexes;301 ASTURIAS, PRINCIPADO DE;Group 1407 Disorders of breast 610-612;Men;32 ASTURIAS, PRINCIPADO DE;Group 1407 Disorders of breast 610-612;Women;269 ASTURIAS, PRINCIPADO DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;150 ASTURIAS, PRINCIPADO DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ASTURIAS, PRINCIPADO DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;150 ASTURIAS, PRINCIPADO DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;57 ASTURIAS, PRINCIPADO DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ASTURIAS, PRINCIPADO DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;57 ASTURIAS, PRINCIPADO DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;855 ASTURIAS, PRINCIPADO DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;22 ASTURIAS, PRINCIPADO DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;833 ASTURIAS, PRINCIPADO DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;7.688 ASTURIAS, PRINCIPADO DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ASTURIAS, PRINCIPADO DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;7.688 ASTURIAS, PRINCIPADO DE;Group 1501 Legally induced abortion 635;Both sexes;60 ASTURIAS, PRINCIPADO DE;Group 1501 Legally induced abortion 635;Men;.. ASTURIAS, PRINCIPADO DE;Group 1501 Legally induced abortion 635;Women;60 ASTURIAS, PRINCIPADO DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;287 ASTURIAS, PRINCIPADO DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ASTURIAS, PRINCIPADO DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;287 ASTURIAS, PRINCIPADO DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.896 ASTURIAS, PRINCIPADO DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ASTURIAS, PRINCIPADO DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.896 ASTURIAS, PRINCIPADO DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.024 ASTURIAS, PRINCIPADO DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ASTURIAS, PRINCIPADO DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.024 ASTURIAS, PRINCIPADO DE;Group 1505 Single spontaneous delivery 650;Both sexes;719 ASTURIAS, PRINCIPADO DE;Group 1505 Single spontaneous delivery 650;Men;.. ASTURIAS, PRINCIPADO DE;Group 1505 Single spontaneous delivery 650;Women;719 ASTURIAS, PRINCIPADO DE;Group 1506 Other deliveries 6695-6697;Both sexes;373 ASTURIAS, PRINCIPADO DE;Group 1506 Other deliveries 6695-6697;Men;.. ASTURIAS, PRINCIPADO DE;Group 1506 Other deliveries 6695-6697;Women;373 ASTURIAS, PRINCIPADO DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;90 ASTURIAS, PRINCIPADO DE;Group 1507 Complications related to the puerperium 670-676;Men;.. ASTURIAS, PRINCIPADO DE;Group 1507 Complications related to the puerperium 670-676;Women;90 ASTURIAS, PRINCIPADO DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;239 ASTURIAS, PRINCIPADO DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ASTURIAS, PRINCIPADO DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;239 ASTURIAS, PRINCIPADO DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.046 ASTURIAS, PRINCIPADO DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;590 ASTURIAS, PRINCIPADO DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;456 ASTURIAS, PRINCIPADO DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;228 ASTURIAS, PRINCIPADO DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;121 ASTURIAS, PRINCIPADO DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;107 ASTURIAS, PRINCIPADO DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;818 ASTURIAS, PRINCIPADO DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;469 ASTURIAS, PRINCIPADO DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;349 ASTURIAS, PRINCIPADO DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;555 ASTURIAS, PRINCIPADO DE;Grupo 1700 Congenital abnormalities 740-759;Men;295 ASTURIAS, PRINCIPADO DE;Grupo 1700 Congenital abnormalities 740-759;Women;260 ASTURIAS, PRINCIPADO DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;6.457 ASTURIAS, PRINCIPADO DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3.235 ASTURIAS, PRINCIPADO DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.222 ASTURIAS, PRINCIPADO DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;612 ASTURIAS, PRINCIPADO DE;Group 1801 Pain in throat and chest 7841, 7865;Men;345 ASTURIAS, PRINCIPADO DE;Group 1801 Pain in throat and chest 7841, 7865;Women;267 ASTURIAS, PRINCIPADO DE;Group 1802 Abdominal pain 7890;Both sexes;676 ASTURIAS, PRINCIPADO DE;Group 1802 Abdominal pain 7890;Men;281 ASTURIAS, PRINCIPADO DE;Group 1802 Abdominal pain 7890;Women;395 ASTURIAS, PRINCIPADO DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;405 ASTURIAS, PRINCIPADO DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;216 ASTURIAS, PRINCIPADO DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;189 ASTURIAS, PRINCIPADO DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;4.764 ASTURIAS, PRINCIPADO DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.393 ASTURIAS, PRINCIPADO DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.371 ASTURIAS, PRINCIPADO DE;Group 1900 Injuries and poisoning 800-999;Both sexes;10.436 ASTURIAS, PRINCIPADO DE;Group 1900 Injuries and poisoning 800-999;Men;4.968 ASTURIAS, PRINCIPADO DE;Group 1900 Injuries and poisoning 800-999;Women;5.468 ASTURIAS, PRINCIPADO DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;429 ASTURIAS, PRINCIPADO DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;223 ASTURIAS, PRINCIPADO DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;206 ASTURIAS, PRINCIPADO DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;241 ASTURIAS, PRINCIPADO DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;166 ASTURIAS, PRINCIPADO DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;75 ASTURIAS, PRINCIPADO DE;Group 1903 Radius and ulna fracture 813;Both sexes;413 ASTURIAS, PRINCIPADO DE;Group 1903 Radius and ulna fracture 813;Men;178 ASTURIAS, PRINCIPADO DE;Group 1903 Radius and ulna fracture 813;Women;235 ASTURIAS, PRINCIPADO DE;Group 1904 Femur fracture 820-821;Both sexes;2.165 ASTURIAS, PRINCIPADO DE;Group 1904 Femur fracture 820-821;Men;537 ASTURIAS, PRINCIPADO DE;Group 1904 Femur fracture 820-821;Women;1.628 ASTURIAS, PRINCIPADO DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;748 ASTURIAS, PRINCIPADO DE;Group 1905 Leg fracture, including the ankle 823-824;Men;329 ASTURIAS, PRINCIPADO DE;Group 1905 Leg fracture, including the ankle 823-824;Women;419 ASTURIAS, PRINCIPADO DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.076 ASTURIAS, PRINCIPADO DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.791 ASTURIAS, PRINCIPADO DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.285 ASTURIAS, PRINCIPADO DE;Group 1907 Burns 940-949;Both sexes;66 ASTURIAS, PRINCIPADO DE;Group 1907 Burns 940-949;Men;35 ASTURIAS, PRINCIPADO DE;Group 1907 Burns 940-949;Women;31 ASTURIAS, PRINCIPADO DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;365 ASTURIAS, PRINCIPADO DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;150 ASTURIAS, PRINCIPADO DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;215 ASTURIAS, PRINCIPADO DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.654 ASTURIAS, PRINCIPADO DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.421 ASTURIAS, PRINCIPADO DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.233 ASTURIAS, PRINCIPADO DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;11 ASTURIAS, PRINCIPADO DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 ASTURIAS, PRINCIPADO DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;3 ASTURIAS, PRINCIPADO DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;268 ASTURIAS, PRINCIPADO DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;130 ASTURIAS, PRINCIPADO DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;138 ASTURIAS, PRINCIPADO DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.527 ASTURIAS, PRINCIPADO DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;819 ASTURIAS, PRINCIPADO DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;708 ASTURIAS, PRINCIPADO DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;44 ASTURIAS, PRINCIPADO DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;31 ASTURIAS, PRINCIPADO DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;13 ASTURIAS, PRINCIPADO DE;Group 2102 Contraceptive management V25;Both sexes;17 ASTURIAS, PRINCIPADO DE;Group 2102 Contraceptive management V25;Men;1 ASTURIAS, PRINCIPADO DE;Group 2102 Contraceptive management V25;Women;16 ASTURIAS, PRINCIPADO DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ASTURIAS, PRINCIPADO DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ASTURIAS, PRINCIPADO DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ASTURIAS, PRINCIPADO DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;810 ASTURIAS, PRINCIPADO DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;473 ASTURIAS, PRINCIPADO DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;337 ASTURIAS, PRINCIPADO DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;656 ASTURIAS, PRINCIPADO DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;314 ASTURIAS, PRINCIPADO DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;342 BALEARS, ILLES;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;129.603 BALEARS, ILLES;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;62.445 BALEARS, ILLES;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;67.158 BALEARS, ILLES;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3.432 BALEARS, ILLES;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.834 BALEARS, ILLES;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.598 BALEARS, ILLES;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;594 BALEARS, ILLES;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;310 BALEARS, ILLES;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;284 BALEARS, ILLES;Group 0102 Imprecise intestinal infections 009;Both sexes;738 BALEARS, ILLES;Group 0102 Imprecise intestinal infections 009;Men;334 BALEARS, ILLES;Group 0102 Imprecise intestinal infections 009;Women;404 BALEARS, ILLES;Group 0103 Tuberculosis 010-018, 137;Both sexes;81 BALEARS, ILLES;Group 0103 Tuberculosis 010-018, 137;Men;61 BALEARS, ILLES;Group 0103 Tuberculosis 010-018, 137;Women;19 BALEARS, ILLES;Group 0104 Septicaemia 038;Both sexes;966 BALEARS, ILLES;Group 0104 Septicaemia 038;Men;524 BALEARS, ILLES;Group 0104 Septicaemia 038;Women;442 BALEARS, ILLES;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;70 BALEARS, ILLES;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;50 BALEARS, ILLES;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;19 BALEARS, ILLES;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;983 BALEARS, ILLES;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;554 BALEARS, ILLES;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;429 BALEARS, ILLES;Group 0200 Neoplasms 140-239;Both sexes;8.925 BALEARS, ILLES;Group 0200 Neoplasms 140-239;Men;4.713 BALEARS, ILLES;Group 0200 Neoplasms 140-239;Women;4.212 BALEARS, ILLES;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;875 BALEARS, ILLES;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;540 BALEARS, ILLES;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;335 BALEARS, ILLES;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;734 BALEARS, ILLES;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;547 BALEARS, ILLES;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;187 BALEARS, ILLES;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;168 BALEARS, ILLES;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;89 BALEARS, ILLES;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;80 BALEARS, ILLES;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;867 BALEARS, ILLES;Group 0204 Malignant neoplasm of breast 174-175;Men;10 BALEARS, ILLES;Group 0204 Malignant neoplasm of breast 174-175;Women;857 BALEARS, ILLES;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;184 BALEARS, ILLES;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. BALEARS, ILLES;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;184 BALEARS, ILLES;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;82 BALEARS, ILLES;Group 0206 Malignant neoplasm of ovary 1830;Men;.. BALEARS, ILLES;Group 0206 Malignant neoplasm of ovary 1830;Women;82 BALEARS, ILLES;Group 0207 Malignant neoplasm of prostate 185;Both sexes;303 BALEARS, ILLES;Group 0207 Malignant neoplasm of prostate 185;Men;303 BALEARS, ILLES;Group 0207 Malignant neoplasm of prostate 185;Women;.. BALEARS, ILLES;Group 0208 Malignant neoplasm of bladder 188;Both sexes;736 BALEARS, ILLES;Group 0208 Malignant neoplasm of bladder 188;Men;616 BALEARS, ILLES;Group 0208 Malignant neoplasm of bladder 188;Women;120 BALEARS, ILLES;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.962 BALEARS, ILLES;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.754 BALEARS, ILLES;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.208 BALEARS, ILLES;Group 0210 Carcinoma in situ 230-234;Both sexes;248 BALEARS, ILLES;Group 0210 Carcinoma in situ 230-234;Men;168 BALEARS, ILLES;Group 0210 Carcinoma in situ 230-234;Women;80 BALEARS, ILLES;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;106 BALEARS, ILLES;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;58 BALEARS, ILLES;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;47 BALEARS, ILLES;Grupo 0212 Leiomyoma of uterus 218;Both sexes;353 BALEARS, ILLES;Grupo 0212 Leiomyoma of uterus 218;Men;.. BALEARS, ILLES;Grupo 0212 Leiomyoma of uterus 218;Women;353 BALEARS, ILLES;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.309 BALEARS, ILLES;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;629 BALEARS, ILLES;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;680 BALEARS, ILLES;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;986 BALEARS, ILLES;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;457 BALEARS, ILLES;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;528 BALEARS, ILLES;Group 0301 Anaemias 280-285;Both sexes;665 BALEARS, ILLES;Group 0301 Anaemias 280-285;Men;300 BALEARS, ILLES;Group 0301 Anaemias 280-285;Women;365 BALEARS, ILLES;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;320 BALEARS, ILLES;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;157 BALEARS, ILLES;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;163 BALEARS, ILLES;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.053 BALEARS, ILLES;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;935 BALEARS, ILLES;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.118 BALEARS, ILLES;Group 0401 Diabetes mellitus 249-250;Both sexes;797 BALEARS, ILLES;Group 0401 Diabetes mellitus 249-250;Men;478 BALEARS, ILLES;Group 0401 Diabetes mellitus 249-250;Women;320 BALEARS, ILLES;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.256 BALEARS, ILLES;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;458 BALEARS, ILLES;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;798 BALEARS, ILLES;Group 0500 Mental disorders 290-319;Both sexes;3.352 BALEARS, ILLES;Group 0500 Mental disorders 290-319;Men;1.683 BALEARS, ILLES;Group 0500 Mental disorders 290-319;Women;1.669 BALEARS, ILLES;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;130 BALEARS, ILLES;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;54 BALEARS, ILLES;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;77 BALEARS, ILLES;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;361 BALEARS, ILLES;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;256 BALEARS, ILLES;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;105 BALEARS, ILLES;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;118 BALEARS, ILLES;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;78 BALEARS, ILLES;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;40 BALEARS, ILLES;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;808 BALEARS, ILLES;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;477 BALEARS, ILLES;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;330 BALEARS, ILLES;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;826 BALEARS, ILLES;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;344 BALEARS, ILLES;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;483 BALEARS, ILLES;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.109 BALEARS, ILLES;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;475 BALEARS, ILLES;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;634 BALEARS, ILLES;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3.781 BALEARS, ILLES;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.947 BALEARS, ILLES;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.834 BALEARS, ILLES;Group 0601 Alzheimer's disease 3310;Both sexes;92 BALEARS, ILLES;Group 0601 Alzheimer's disease 3310;Men;32 BALEARS, ILLES;Group 0601 Alzheimer's disease 3310;Women;60 BALEARS, ILLES;Group 0602 Multiple sclerosis 340;Both sexes;46 BALEARS, ILLES;Group 0602 Multiple sclerosis 340;Men;14 BALEARS, ILLES;Group 0602 Multiple sclerosis 340;Women;32 BALEARS, ILLES;Group 0603 Epilepsy 345;Both sexes;634 BALEARS, ILLES;Group 0603 Epilepsy 345;Men;368 BALEARS, ILLES;Group 0603 Epilepsy 345;Women;266 BALEARS, ILLES;Group 0604 Transient cerebral ischemia 435;Both sexes;413 BALEARS, ILLES;Group 0604 Transient cerebral ischemia 435;Men;230 BALEARS, ILLES;Group 0604 Transient cerebral ischemia 435;Women;183 BALEARS, ILLES;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2.595 BALEARS, ILLES;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.303 BALEARS, ILLES;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.292 BALEARS, ILLES;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;711 BALEARS, ILLES;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;392 BALEARS, ILLES;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;319 BALEARS, ILLES;Grupo 0701 Cataract 366;Both sexes;55 BALEARS, ILLES;Grupo 0701 Cataract 366;Men;37 BALEARS, ILLES;Grupo 0701 Cataract 366;Women;18 BALEARS, ILLES;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;656 BALEARS, ILLES;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;355 BALEARS, ILLES;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;301 BALEARS, ILLES;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;905 BALEARS, ILLES;Group 0800 Diseases of the ear and the mastoid 380-389;Men;454 BALEARS, ILLES;Group 0800 Diseases of the ear and the mastoid 380-389;Women;450 BALEARS, ILLES;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;14.402 BALEARS, ILLES;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;8.363 BALEARS, ILLES;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;6.038 BALEARS, ILLES;Group 0901 Hypertensive disease 401-405;Both sexes;757 BALEARS, ILLES;Group 0901 Hypertensive disease 401-405;Men;340 BALEARS, ILLES;Group 0901 Hypertensive disease 401-405;Women;417 BALEARS, ILLES;Group 0902 Angina pectoris 4111, 413;Both sexes;992 BALEARS, ILLES;Group 0902 Angina pectoris 4111, 413;Men;605 BALEARS, ILLES;Group 0902 Angina pectoris 4111, 413;Women;387 BALEARS, ILLES;Group 0903 Acute myocardial infarction 410;Both sexes;1.253 BALEARS, ILLES;Group 0903 Acute myocardial infarction 410;Men;924 BALEARS, ILLES;Group 0903 Acute myocardial infarction 410;Women;329 BALEARS, ILLES;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;790 BALEARS, ILLES;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;610 BALEARS, ILLES;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;180 BALEARS, ILLES;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;314 BALEARS, ILLES;Group 0905 Diseases of the lungs circulation 415-417;Men;145 BALEARS, ILLES;Group 0905 Diseases of the lungs circulation 415-417;Women;169 BALEARS, ILLES;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.083 BALEARS, ILLES;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.189 BALEARS, ILLES;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;894 BALEARS, ILLES;Grupo 0907 Heart failure 428;Both sexes;2.769 BALEARS, ILLES;Grupo 0907 Heart failure 428;Men;1.370 BALEARS, ILLES;Grupo 0907 Heart failure 428;Women;1.399 BALEARS, ILLES;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.190 BALEARS, ILLES;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.259 BALEARS, ILLES;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;930 BALEARS, ILLES;Grupo 0909 Atherosclerosis 440;Both sexes;518 BALEARS, ILLES;Grupo 0909 Atherosclerosis 440;Men;410 BALEARS, ILLES;Grupo 0909 Atherosclerosis 440;Women;108 BALEARS, ILLES;Group 0910 Varicose veins of lower extremities 454;Both sexes;478 BALEARS, ILLES;Group 0910 Varicose veins of lower extremities 454;Men;163 BALEARS, ILLES;Group 0910 Varicose veins of lower extremities 454;Women;314 BALEARS, ILLES;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.257 BALEARS, ILLES;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.348 BALEARS, ILLES;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;909 BALEARS, ILLES;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;16.483 BALEARS, ILLES;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8.902 BALEARS, ILLES;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;7.581 BALEARS, ILLES;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;932 BALEARS, ILLES;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;516 BALEARS, ILLES;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;416 BALEARS, ILLES;Group 1002 Pneumonia 480-486;Both sexes;3.893 BALEARS, ILLES;Group 1002 Pneumonia 480-486;Men;2.187 BALEARS, ILLES;Group 1002 Pneumonia 480-486;Women;1.706 BALEARS, ILLES;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;3.041 BALEARS, ILLES;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.342 BALEARS, ILLES;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.698 BALEARS, ILLES;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;537 BALEARS, ILLES;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;253 BALEARS, ILLES;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;284 BALEARS, ILLES;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.139 BALEARS, ILLES;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;663 BALEARS, ILLES;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;476 BALEARS, ILLES;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.841 BALEARS, ILLES;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.999 BALEARS, ILLES;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;843 BALEARS, ILLES;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;616 BALEARS, ILLES;Group 1007 Asthma 4930-4931,4938-4939;Men;184 BALEARS, ILLES;Group 1007 Asthma 4930-4931,4938-4939;Women;431 BALEARS, ILLES;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.485 BALEARS, ILLES;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.758 BALEARS, ILLES;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.728 BALEARS, ILLES;Group 1100 Diseases of the digestive system 520-579;Both sexes;15.176 BALEARS, ILLES;Group 1100 Diseases of the digestive system 520-579;Men;8.282 BALEARS, ILLES;Group 1100 Diseases of the digestive system 520-579;Women;6.894 BALEARS, ILLES;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;234 BALEARS, ILLES;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;111 BALEARS, ILLES;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;123 BALEARS, ILLES;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;184 BALEARS, ILLES;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;97 BALEARS, ILLES;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;88 BALEARS, ILLES;Group 1103 Diseases of the esophagus 530;Both sexes;225 BALEARS, ILLES;Group 1103 Diseases of the esophagus 530;Men;135 BALEARS, ILLES;Group 1103 Diseases of the esophagus 530;Women;90 BALEARS, ILLES;Group 1104 Peptic ulcer 531-534;Both sexes;213 BALEARS, ILLES;Group 1104 Peptic ulcer 531-534;Men;144 BALEARS, ILLES;Group 1104 Peptic ulcer 531-534;Women;69 BALEARS, ILLES;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;672 BALEARS, ILLES;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;313 BALEARS, ILLES;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;359 BALEARS, ILLES;Group 1106 Appendicitis 540-543;Both sexes;1.370 BALEARS, ILLES;Group 1106 Appendicitis 540-543;Men;788 BALEARS, ILLES;Group 1106 Appendicitis 540-543;Women;582 BALEARS, ILLES;Group 1107 Inguinal hernia 550;Both sexes;1.251 BALEARS, ILLES;Group 1107 Inguinal hernia 550;Men;1.110 BALEARS, ILLES;Group 1107 Inguinal hernia 550;Women;141 BALEARS, ILLES;Group 1108 Other abdominal hernia 551-553;Both sexes;1.096 BALEARS, ILLES;Group 1108 Other abdominal hernia 551-553;Men;539 BALEARS, ILLES;Group 1108 Other abdominal hernia 551-553;Women;557 BALEARS, ILLES;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;237 BALEARS, ILLES;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;108 BALEARS, ILLES;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;129 BALEARS, ILLES;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.962 BALEARS, ILLES;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;879 BALEARS, ILLES;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;1.083 BALEARS, ILLES;Group 1111 Intestinal obstruction without hernia 560;Both sexes;657 BALEARS, ILLES;Group 1111 Intestinal obstruction without hernia 560;Men;315 BALEARS, ILLES;Group 1111 Intestinal obstruction without hernia 560;Women;343 BALEARS, ILLES;Group 1112 Intestinal diverticulosis 562;Both sexes;756 BALEARS, ILLES;Group 1112 Intestinal diverticulosis 562;Men;368 BALEARS, ILLES;Group 1112 Intestinal diverticulosis 562;Women;388 BALEARS, ILLES;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;735 BALEARS, ILLES;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;454 BALEARS, ILLES;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;280 BALEARS, ILLES;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;456 BALEARS, ILLES;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;206 BALEARS, ILLES;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;250 BALEARS, ILLES;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;172 BALEARS, ILLES;Group 1115 Alcoholic hepatitis 5710-5713;Men;130 BALEARS, ILLES;Group 1115 Alcoholic hepatitis 5710-5713;Women;42 BALEARS, ILLES;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;378 BALEARS, ILLES;Group 1116 Other diseases of the liver 570,5714-573;Men;233 BALEARS, ILLES;Group 1116 Other diseases of the liver 570,5714-573;Women;145 BALEARS, ILLES;Group 1117 Cholelithiasis 574;Both sexes;2.367 BALEARS, ILLES;Group 1117 Cholelithiasis 574;Men;1.127 BALEARS, ILLES;Group 1117 Cholelithiasis 574;Women;1.240 BALEARS, ILLES;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;828 BALEARS, ILLES;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;410 BALEARS, ILLES;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;418 BALEARS, ILLES;Group 1119 Pancreatic diseases 577;Both sexes;708 BALEARS, ILLES;Group 1119 Pancreatic diseases 577;Men;440 BALEARS, ILLES;Group 1119 Pancreatic diseases 577;Women;268 BALEARS, ILLES;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;675 BALEARS, ILLES;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;376 BALEARS, ILLES;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;299 BALEARS, ILLES;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.592 BALEARS, ILLES;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;856 BALEARS, ILLES;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;737 BALEARS, ILLES;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.133 BALEARS, ILLES;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;663 BALEARS, ILLES;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;470 BALEARS, ILLES;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;60 BALEARS, ILLES;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;23 BALEARS, ILLES;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;37 BALEARS, ILLES;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;399 BALEARS, ILLES;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;169 BALEARS, ILLES;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;230 BALEARS, ILLES;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9.955 BALEARS, ILLES;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.897 BALEARS, ILLES;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5.058 BALEARS, ILLES;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. BALEARS, ILLES;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. BALEARS, ILLES;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. BALEARS, ILLES;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. BALEARS, ILLES;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. BALEARS, ILLES;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. BALEARS, ILLES;Group 1303 Internal derangement of knee 717;Both sexes;1.039 BALEARS, ILLES;Group 1303 Internal derangement of knee 717;Men;703 BALEARS, ILLES;Group 1303 Internal derangement of knee 717;Women;336 BALEARS, ILLES;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.417 BALEARS, ILLES;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.615 BALEARS, ILLES;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.802 BALEARS, ILLES;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;101 BALEARS, ILLES;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;45 BALEARS, ILLES;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;55 BALEARS, ILLES;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;505 BALEARS, ILLES;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;250 BALEARS, ILLES;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;255 BALEARS, ILLES;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;865 BALEARS, ILLES;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;466 BALEARS, ILLES;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;399 BALEARS, ILLES;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;723 BALEARS, ILLES;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;320 BALEARS, ILLES;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;403 BALEARS, ILLES;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.744 BALEARS, ILLES;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;893 BALEARS, ILLES;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;851 BALEARS, ILLES;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.560 BALEARS, ILLES;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;603 BALEARS, ILLES;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;957 BALEARS, ILLES;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;8.964 BALEARS, ILLES;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.450 BALEARS, ILLES;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4.514 BALEARS, ILLES;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;895 BALEARS, ILLES;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;304 BALEARS, ILLES;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;590 BALEARS, ILLES;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;576 BALEARS, ILLES;Group 1402 Renal failure 5836-5837, 584-586;Men;338 BALEARS, ILLES;Group 1402 Renal failure 5836-5837, 584-586;Women;238 BALEARS, ILLES;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.987 BALEARS, ILLES;Group 1403 Urolithiasis 592, 594, 7880;Men;1.244 BALEARS, ILLES;Group 1403 Urolithiasis 592, 594, 7880;Women;743 BALEARS, ILLES;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.605 BALEARS, ILLES;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.246 BALEARS, ILLES;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.359 BALEARS, ILLES;Group 1405 Prostatic hyperplasia 600;Both sexes;585 BALEARS, ILLES;Group 1405 Prostatic hyperplasia 600;Men;585 BALEARS, ILLES;Group 1405 Prostatic hyperplasia 600;Women;.. BALEARS, ILLES;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;678 BALEARS, ILLES;Group 1406 Other diseases of the male genital organs 601-608;Men;678 BALEARS, ILLES;Group 1406 Other diseases of the male genital organs 601-608;Women;.. BALEARS, ILLES;Group 1407 Disorders of breast 610-612;Both sexes;379 BALEARS, ILLES;Group 1407 Disorders of breast 610-612;Men;36 BALEARS, ILLES;Group 1407 Disorders of breast 610-612;Women;343 BALEARS, ILLES;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;212 BALEARS, ILLES;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. BALEARS, ILLES;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;212 BALEARS, ILLES;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;107 BALEARS, ILLES;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. BALEARS, ILLES;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;107 BALEARS, ILLES;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;941 BALEARS, ILLES;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;18 BALEARS, ILLES;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;923 BALEARS, ILLES;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;11.109 BALEARS, ILLES;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. BALEARS, ILLES;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;11.109 BALEARS, ILLES;Group 1501 Legally induced abortion 635;Both sexes;167 BALEARS, ILLES;Group 1501 Legally induced abortion 635;Men;.. BALEARS, ILLES;Group 1501 Legally induced abortion 635;Women;167 BALEARS, ILLES;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;501 BALEARS, ILLES;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. BALEARS, ILLES;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;501 BALEARS, ILLES;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;5.082 BALEARS, ILLES;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. BALEARS, ILLES;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;5.082 BALEARS, ILLES;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.496 BALEARS, ILLES;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. BALEARS, ILLES;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.496 BALEARS, ILLES;Group 1505 Single spontaneous delivery 650;Both sexes;2.059 BALEARS, ILLES;Group 1505 Single spontaneous delivery 650;Men;.. BALEARS, ILLES;Group 1505 Single spontaneous delivery 650;Women;2.059 BALEARS, ILLES;Group 1506 Other deliveries 6695-6697;Both sexes;273 BALEARS, ILLES;Group 1506 Other deliveries 6695-6697;Men;.. BALEARS, ILLES;Group 1506 Other deliveries 6695-6697;Women;273 BALEARS, ILLES;Group 1507 Complications related to the puerperium 670-676;Both sexes;90 BALEARS, ILLES;Group 1507 Complications related to the puerperium 670-676;Men;.. BALEARS, ILLES;Group 1507 Complications related to the puerperium 670-676;Women;90 BALEARS, ILLES;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;441 BALEARS, ILLES;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. BALEARS, ILLES;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;441 BALEARS, ILLES;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.430 BALEARS, ILLES;Group 1600 Some disorders originating in the perinatal period 760-779;Men;763 BALEARS, ILLES;Group 1600 Some disorders originating in the perinatal period 760-779;Women;667 BALEARS, ILLES;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;310 BALEARS, ILLES;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;155 BALEARS, ILLES;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;155 BALEARS, ILLES;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.119 BALEARS, ILLES;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;608 BALEARS, ILLES;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;512 BALEARS, ILLES;Grupo 1700 Congenital abnormalities 740-759;Both sexes;823 BALEARS, ILLES;Grupo 1700 Congenital abnormalities 740-759;Men;485 BALEARS, ILLES;Grupo 1700 Congenital abnormalities 740-759;Women;339 BALEARS, ILLES;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;10.051 BALEARS, ILLES;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;5.108 BALEARS, ILLES;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;4.943 BALEARS, ILLES;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;941 BALEARS, ILLES;Group 1801 Pain in throat and chest 7841, 7865;Men;550 BALEARS, ILLES;Group 1801 Pain in throat and chest 7841, 7865;Women;391 BALEARS, ILLES;Group 1802 Abdominal pain 7890;Both sexes;1.467 BALEARS, ILLES;Group 1802 Abdominal pain 7890;Men;488 BALEARS, ILLES;Group 1802 Abdominal pain 7890;Women;979 BALEARS, ILLES;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.206 BALEARS, ILLES;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;581 BALEARS, ILLES;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;625 BALEARS, ILLES;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;6.437 BALEARS, ILLES;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;3.488 BALEARS, ILLES;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.948 BALEARS, ILLES;Group 1900 Injuries and poisoning 800-999;Both sexes;13.103 BALEARS, ILLES;Group 1900 Injuries and poisoning 800-999;Men;6.916 BALEARS, ILLES;Group 1900 Injuries and poisoning 800-999;Women;6.187 BALEARS, ILLES;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.013 BALEARS, ILLES;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;586 BALEARS, ILLES;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;426 BALEARS, ILLES;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;451 BALEARS, ILLES;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;330 BALEARS, ILLES;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;121 BALEARS, ILLES;Group 1903 Radius and ulna fracture 813;Both sexes;787 BALEARS, ILLES;Group 1903 Radius and ulna fracture 813;Men;340 BALEARS, ILLES;Group 1903 Radius and ulna fracture 813;Women;446 BALEARS, ILLES;Group 1904 Femur fracture 820-821;Both sexes;1.763 BALEARS, ILLES;Group 1904 Femur fracture 820-821;Men;588 BALEARS, ILLES;Group 1904 Femur fracture 820-821;Women;1.175 BALEARS, ILLES;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;967 BALEARS, ILLES;Group 1905 Leg fracture, including the ankle 823-824;Men;436 BALEARS, ILLES;Group 1905 Leg fracture, including the ankle 823-824;Women;531 BALEARS, ILLES;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;5.019 BALEARS, ILLES;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.990 BALEARS, ILLES;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.029 BALEARS, ILLES;Group 1907 Burns 940-949;Both sexes;112 BALEARS, ILLES;Group 1907 Burns 940-949;Men;63 BALEARS, ILLES;Group 1907 Burns 940-949;Women;48 BALEARS, ILLES;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;341 BALEARS, ILLES;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;150 BALEARS, ILLES;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;190 BALEARS, ILLES;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.124 BALEARS, ILLES;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.134 BALEARS, ILLES;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;989 BALEARS, ILLES;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;11 BALEARS, ILLES;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;9 BALEARS, ILLES;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 BALEARS, ILLES;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;516 BALEARS, ILLES;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;287 BALEARS, ILLES;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;229 BALEARS, ILLES;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.370 BALEARS, ILLES;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.009 BALEARS, ILLES;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.362 BALEARS, ILLES;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;48 BALEARS, ILLES;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;24 BALEARS, ILLES;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;24 BALEARS, ILLES;Group 2102 Contraceptive management V25;Both sexes;41 BALEARS, ILLES;Group 2102 Contraceptive management V25;Men;6 BALEARS, ILLES;Group 2102 Contraceptive management V25;Women;35 BALEARS, ILLES;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. BALEARS, ILLES;Group 2103 Living newborns by type of delivery V30-V39;Men;.. BALEARS, ILLES;Group 2103 Living newborns by type of delivery V30-V39;Women;.. BALEARS, ILLES;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;546 BALEARS, ILLES;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;337 BALEARS, ILLES;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;209 BALEARS, ILLES;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.735 BALEARS, ILLES;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;642 BALEARS, ILLES;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.094 CANARIAS;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;177.579 CANARIAS;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;82.949 CANARIAS;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;94.630 CANARIAS;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3.735 CANARIAS;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.962 CANARIAS;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.772 CANARIAS;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;404 CANARIAS;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;199 CANARIAS;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;205 CANARIAS;Group 0102 Imprecise intestinal infections 009;Both sexes;185 CANARIAS;Group 0102 Imprecise intestinal infections 009;Men;88 CANARIAS;Group 0102 Imprecise intestinal infections 009;Women;97 CANARIAS;Group 0103 Tuberculosis 010-018, 137;Both sexes;95 CANARIAS;Group 0103 Tuberculosis 010-018, 137;Men;63 CANARIAS;Group 0103 Tuberculosis 010-018, 137;Women;32 CANARIAS;Group 0104 Septicaemia 038;Both sexes;1.868 CANARIAS;Group 0104 Septicaemia 038;Men;978 CANARIAS;Group 0104 Septicaemia 038;Women;889 CANARIAS;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;57 CANARIAS;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;48 CANARIAS;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;9 CANARIAS;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.126 CANARIAS;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;586 CANARIAS;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;540 CANARIAS;Group 0200 Neoplasms 140-239;Both sexes;16.048 CANARIAS;Group 0200 Neoplasms 140-239;Men;7.977 CANARIAS;Group 0200 Neoplasms 140-239;Women;8.071 CANARIAS;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.401 CANARIAS;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;870 CANARIAS;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;531 CANARIAS;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.221 CANARIAS;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;886 CANARIAS;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;335 CANARIAS;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;346 CANARIAS;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;208 CANARIAS;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;138 CANARIAS;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.114 CANARIAS;Group 0204 Malignant neoplasm of breast 174-175;Men;12 CANARIAS;Group 0204 Malignant neoplasm of breast 174-175;Women;1.102 CANARIAS;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;449 CANARIAS;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CANARIAS;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;449 CANARIAS;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;176 CANARIAS;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CANARIAS;Group 0206 Malignant neoplasm of ovary 1830;Women;176 CANARIAS;Group 0207 Malignant neoplasm of prostate 185;Both sexes;748 CANARIAS;Group 0207 Malignant neoplasm of prostate 185;Men;748 CANARIAS;Group 0207 Malignant neoplasm of prostate 185;Women;.. CANARIAS;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.058 CANARIAS;Group 0208 Malignant neoplasm of bladder 188;Men;897 CANARIAS;Group 0208 Malignant neoplasm of bladder 188;Women;161 CANARIAS;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5.653 CANARIAS;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3.137 CANARIAS;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.516 CANARIAS;Group 0210 Carcinoma in situ 230-234;Both sexes;390 CANARIAS;Group 0210 Carcinoma in situ 230-234;Men;127 CANARIAS;Group 0210 Carcinoma in situ 230-234;Women;263 CANARIAS;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;193 CANARIAS;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;107 CANARIAS;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;86 CANARIAS;Grupo 0212 Leiomyoma of uterus 218;Both sexes;930 CANARIAS;Grupo 0212 Leiomyoma of uterus 218;Men;.. CANARIAS;Grupo 0212 Leiomyoma of uterus 218;Women;930 CANARIAS;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.369 CANARIAS;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;985 CANARIAS;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.384 CANARIAS;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.248 CANARIAS;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;607 CANARIAS;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;641 CANARIAS;Group 0301 Anaemias 280-285;Both sexes;678 CANARIAS;Group 0301 Anaemias 280-285;Men;319 CANARIAS;Group 0301 Anaemias 280-285;Women;359 CANARIAS;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;570 CANARIAS;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;288 CANARIAS;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;282 CANARIAS;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3.966 CANARIAS;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.678 CANARIAS;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2.288 CANARIAS;Group 0401 Diabetes mellitus 249-250;Both sexes;1.190 CANARIAS;Group 0401 Diabetes mellitus 249-250;Men;724 CANARIAS;Group 0401 Diabetes mellitus 249-250;Women;466 CANARIAS;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2.776 CANARIAS;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;954 CANARIAS;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.822 CANARIAS;Group 0500 Mental disorders 290-319;Both sexes;3.856 CANARIAS;Group 0500 Mental disorders 290-319;Men;2.161 CANARIAS;Group 0500 Mental disorders 290-319;Women;1.695 CANARIAS;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;87 CANARIAS;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;50 CANARIAS;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;37 CANARIAS;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;455 CANARIAS;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;369 CANARIAS;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;86 CANARIAS;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;498 CANARIAS;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;377 CANARIAS;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;121 CANARIAS;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.203 CANARIAS;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;710 CANARIAS;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;493 CANARIAS;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;896 CANARIAS;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;344 CANARIAS;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;552 CANARIAS;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;717 CANARIAS;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;311 CANARIAS;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;406 CANARIAS;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3.910 CANARIAS;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.019 CANARIAS;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.890 CANARIAS;Group 0601 Alzheimer's disease 3310;Both sexes;70 CANARIAS;Group 0601 Alzheimer's disease 3310;Men;20 CANARIAS;Group 0601 Alzheimer's disease 3310;Women;50 CANARIAS;Group 0602 Multiple sclerosis 340;Both sexes;215 CANARIAS;Group 0602 Multiple sclerosis 340;Men;57 CANARIAS;Group 0602 Multiple sclerosis 340;Women;158 CANARIAS;Group 0603 Epilepsy 345;Both sexes;396 CANARIAS;Group 0603 Epilepsy 345;Men;203 CANARIAS;Group 0603 Epilepsy 345;Women;193 CANARIAS;Group 0604 Transient cerebral ischemia 435;Both sexes;383 CANARIAS;Group 0604 Transient cerebral ischemia 435;Men;214 CANARIAS;Group 0604 Transient cerebral ischemia 435;Women;169 CANARIAS;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2.845 CANARIAS;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.525 CANARIAS;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.320 CANARIAS;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.078 CANARIAS;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;570 CANARIAS;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;508 CANARIAS;Grupo 0701 Cataract 366;Both sexes;100 CANARIAS;Grupo 0701 Cataract 366;Men;46 CANARIAS;Grupo 0701 Cataract 366;Women;54 CANARIAS;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;978 CANARIAS;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;524 CANARIAS;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;454 CANARIAS;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;946 CANARIAS;Group 0800 Diseases of the ear and the mastoid 380-389;Men;431 CANARIAS;Group 0800 Diseases of the ear and the mastoid 380-389;Women;515 CANARIAS;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;23.176 CANARIAS;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;13.412 CANARIAS;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;9.764 CANARIAS;Group 0901 Hypertensive disease 401-405;Both sexes;1.380 CANARIAS;Group 0901 Hypertensive disease 401-405;Men;662 CANARIAS;Group 0901 Hypertensive disease 401-405;Women;718 CANARIAS;Group 0902 Angina pectoris 4111, 413;Both sexes;781 CANARIAS;Group 0902 Angina pectoris 4111, 413;Men;461 CANARIAS;Group 0902 Angina pectoris 4111, 413;Women;320 CANARIAS;Group 0903 Acute myocardial infarction 410;Both sexes;2.684 CANARIAS;Group 0903 Acute myocardial infarction 410;Men;1.962 CANARIAS;Group 0903 Acute myocardial infarction 410;Women;722 CANARIAS;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.875 CANARIAS;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.390 CANARIAS;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;485 CANARIAS;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;535 CANARIAS;Group 0905 Diseases of the lungs circulation 415-417;Men;234 CANARIAS;Group 0905 Diseases of the lungs circulation 415-417;Women;301 CANARIAS;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.783 CANARIAS;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.616 CANARIAS;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.166 CANARIAS;Grupo 0907 Heart failure 428;Both sexes;3.714 CANARIAS;Grupo 0907 Heart failure 428;Men;1.778 CANARIAS;Grupo 0907 Heart failure 428;Women;1.935 CANARIAS;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3.830 CANARIAS;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2.153 CANARIAS;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.677 CANARIAS;Grupo 0909 Atherosclerosis 440;Both sexes;749 CANARIAS;Grupo 0909 Atherosclerosis 440;Men;539 CANARIAS;Grupo 0909 Atherosclerosis 440;Women;210 CANARIAS;Group 0910 Varicose veins of lower extremities 454;Both sexes;962 CANARIAS;Group 0910 Varicose veins of lower extremities 454;Men;354 CANARIAS;Group 0910 Varicose veins of lower extremities 454;Women;608 CANARIAS;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3.883 CANARIAS;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;2.262 CANARIAS;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.621 CANARIAS;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;20.046 CANARIAS;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;10.638 CANARIAS;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;9.408 CANARIAS;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;887 CANARIAS;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;483 CANARIAS;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;404 CANARIAS;Group 1002 Pneumonia 480-486;Both sexes;5.186 CANARIAS;Group 1002 Pneumonia 480-486;Men;2.735 CANARIAS;Group 1002 Pneumonia 480-486;Women;2.450 CANARIAS;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.278 CANARIAS;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.135 CANARIAS;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.143 CANARIAS;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1.482 CANARIAS;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;752 CANARIAS;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;730 CANARIAS;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.876 CANARIAS;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1.140 CANARIAS;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;736 CANARIAS;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.339 CANARIAS;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.557 CANARIAS;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;782 CANARIAS;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;971 CANARIAS;Group 1007 Asthma 4930-4931,4938-4939;Men;330 CANARIAS;Group 1007 Asthma 4930-4931,4938-4939;Women;641 CANARIAS;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.027 CANARIAS;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.505 CANARIAS;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.522 CANARIAS;Group 1100 Diseases of the digestive system 520-579;Both sexes;22.310 CANARIAS;Group 1100 Diseases of the digestive system 520-579;Men;12.413 CANARIAS;Group 1100 Diseases of the digestive system 520-579;Women;9.896 CANARIAS;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;501 CANARIAS;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;220 CANARIAS;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;281 CANARIAS;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;344 CANARIAS;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;183 CANARIAS;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;161 CANARIAS;Group 1103 Diseases of the esophagus 530;Both sexes;370 CANARIAS;Group 1103 Diseases of the esophagus 530;Men;236 CANARIAS;Group 1103 Diseases of the esophagus 530;Women;134 CANARIAS;Group 1104 Peptic ulcer 531-534;Both sexes;386 CANARIAS;Group 1104 Peptic ulcer 531-534;Men;262 CANARIAS;Group 1104 Peptic ulcer 531-534;Women;124 CANARIAS;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;510 CANARIAS;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;238 CANARIAS;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;272 CANARIAS;Group 1106 Appendicitis 540-543;Both sexes;1.821 CANARIAS;Group 1106 Appendicitis 540-543;Men;1.086 CANARIAS;Group 1106 Appendicitis 540-543;Women;735 CANARIAS;Group 1107 Inguinal hernia 550;Both sexes;2.722 CANARIAS;Group 1107 Inguinal hernia 550;Men;2.462 CANARIAS;Group 1107 Inguinal hernia 550;Women;260 CANARIAS;Group 1108 Other abdominal hernia 551-553;Both sexes;2.353 CANARIAS;Group 1108 Other abdominal hernia 551-553;Men;1.234 CANARIAS;Group 1108 Other abdominal hernia 551-553;Women;1.119 CANARIAS;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;466 CANARIAS;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;234 CANARIAS;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;232 CANARIAS;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.602 CANARIAS;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;723 CANARIAS;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;879 CANARIAS;Group 1111 Intestinal obstruction without hernia 560;Both sexes;778 CANARIAS;Group 1111 Intestinal obstruction without hernia 560;Men;397 CANARIAS;Group 1111 Intestinal obstruction without hernia 560;Women;381 CANARIAS;Group 1112 Intestinal diverticulosis 562;Both sexes;980 CANARIAS;Group 1112 Intestinal diverticulosis 562;Men;512 CANARIAS;Group 1112 Intestinal diverticulosis 562;Women;468 CANARIAS;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;979 CANARIAS;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;647 CANARIAS;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;332 CANARIAS;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;710 CANARIAS;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;317 CANARIAS;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;393 CANARIAS;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;579 CANARIAS;Group 1115 Alcoholic hepatitis 5710-5713;Men;497 CANARIAS;Group 1115 Alcoholic hepatitis 5710-5713;Women;82 CANARIAS;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;687 CANARIAS;Group 1116 Other diseases of the liver 570,5714-573;Men;402 CANARIAS;Group 1116 Other diseases of the liver 570,5714-573;Women;285 CANARIAS;Group 1117 Cholelithiasis 574;Both sexes;3.984 CANARIAS;Group 1117 Cholelithiasis 574;Men;1.432 CANARIAS;Group 1117 Cholelithiasis 574;Women;2.552 CANARIAS;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;898 CANARIAS;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;453 CANARIAS;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;445 CANARIAS;Group 1119 Pancreatic diseases 577;Both sexes;1.043 CANARIAS;Group 1119 Pancreatic diseases 577;Men;569 CANARIAS;Group 1119 Pancreatic diseases 577;Women;474 CANARIAS;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;596 CANARIAS;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;309 CANARIAS;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;287 CANARIAS;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2.523 CANARIAS;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1.383 CANARIAS;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1.140 CANARIAS;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.691 CANARIAS;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;996 CANARIAS;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;695 CANARIAS;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;100 CANARIAS;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;52 CANARIAS;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;48 CANARIAS;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;732 CANARIAS;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;335 CANARIAS;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;397 CANARIAS;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;12.743 CANARIAS;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;6.248 CANARIAS;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;6.495 CANARIAS;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CANARIAS;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CANARIAS;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CANARIAS;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CANARIAS;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CANARIAS;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CANARIAS;Group 1303 Internal derangement of knee 717;Both sexes;2.019 CANARIAS;Group 1303 Internal derangement of knee 717;Men;1.373 CANARIAS;Group 1303 Internal derangement of knee 717;Women;646 CANARIAS;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;4.679 CANARIAS;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.961 CANARIAS;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.718 CANARIAS;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;243 CANARIAS;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;63 CANARIAS;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;180 CANARIAS;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;608 CANARIAS;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;330 CANARIAS;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;278 CANARIAS;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.593 CANARIAS;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;749 CANARIAS;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;844 CANARIAS;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;350 CANARIAS;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;143 CANARIAS;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;207 CANARIAS;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.680 CANARIAS;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;941 CANARIAS;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;739 CANARIAS;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.571 CANARIAS;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;688 CANARIAS;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;883 CANARIAS;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;10.956 CANARIAS;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.455 CANARIAS;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;6.501 CANARIAS;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.084 CANARIAS;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;404 CANARIAS;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;680 CANARIAS;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;706 CANARIAS;Group 1402 Renal failure 5836-5837, 584-586;Men;408 CANARIAS;Group 1402 Renal failure 5836-5837, 584-586;Women;298 CANARIAS;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.203 CANARIAS;Group 1403 Urolithiasis 592, 594, 7880;Men;709 CANARIAS;Group 1403 Urolithiasis 592, 594, 7880;Women;494 CANARIAS;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;3.048 CANARIAS;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.273 CANARIAS;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.775 CANARIAS;Group 1405 Prostatic hyperplasia 600;Both sexes;792 CANARIAS;Group 1405 Prostatic hyperplasia 600;Men;792 CANARIAS;Group 1405 Prostatic hyperplasia 600;Women;.. CANARIAS;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;728 CANARIAS;Group 1406 Other diseases of the male genital organs 601-608;Men;728 CANARIAS;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CANARIAS;Group 1407 Disorders of breast 610-612;Both sexes;1.077 CANARIAS;Group 1407 Disorders of breast 610-612;Men;128 CANARIAS;Group 1407 Disorders of breast 610-612;Women;949 CANARIAS;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;391 CANARIAS;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CANARIAS;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;391 CANARIAS;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;142 CANARIAS;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CANARIAS;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;142 CANARIAS;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.785 CANARIAS;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;13 CANARIAS;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.772 CANARIAS;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;18.051 CANARIAS;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CANARIAS;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;18.051 CANARIAS;Group 1501 Legally induced abortion 635;Both sexes;166 CANARIAS;Group 1501 Legally induced abortion 635;Men;.. CANARIAS;Group 1501 Legally induced abortion 635;Women;166 CANARIAS;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;915 CANARIAS;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CANARIAS;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;915 CANARIAS;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;12.533 CANARIAS;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CANARIAS;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;12.533 CANARIAS;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.023 CANARIAS;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CANARIAS;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.023 CANARIAS;Group 1505 Single spontaneous delivery 650;Both sexes;294 CANARIAS;Group 1505 Single spontaneous delivery 650;Men;.. CANARIAS;Group 1505 Single spontaneous delivery 650;Women;294 CANARIAS;Group 1506 Other deliveries 6695-6697;Both sexes;42 CANARIAS;Group 1506 Other deliveries 6695-6697;Men;.. CANARIAS;Group 1506 Other deliveries 6695-6697;Women;42 CANARIAS;Group 1507 Complications related to the puerperium 670-676;Both sexes;95 CANARIAS;Group 1507 Complications related to the puerperium 670-676;Men;.. CANARIAS;Group 1507 Complications related to the puerperium 670-676;Women;95 CANARIAS;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;983 CANARIAS;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CANARIAS;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;983 CANARIAS;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.477 CANARIAS;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.382 CANARIAS;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.095 CANARIAS;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;587 CANARIAS;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;324 CANARIAS;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;263 CANARIAS;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.890 CANARIAS;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.058 CANARIAS;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;832 CANARIAS;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.480 CANARIAS;Grupo 1700 Congenital abnormalities 740-759;Men;836 CANARIAS;Grupo 1700 Congenital abnormalities 740-759;Women;644 CANARIAS;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;7.392 CANARIAS;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3.839 CANARIAS;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.552 CANARIAS;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;805 CANARIAS;Group 1801 Pain in throat and chest 7841, 7865;Men;436 CANARIAS;Group 1801 Pain in throat and chest 7841, 7865;Women;369 CANARIAS;Group 1802 Abdominal pain 7890;Both sexes;832 CANARIAS;Group 1802 Abdominal pain 7890;Men;310 CANARIAS;Group 1802 Abdominal pain 7890;Women;522 CANARIAS;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;825 CANARIAS;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;404 CANARIAS;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;421 CANARIAS;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;4.930 CANARIAS;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.689 CANARIAS;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.240 CANARIAS;Group 1900 Injuries and poisoning 800-999;Both sexes;17.399 CANARIAS;Group 1900 Injuries and poisoning 800-999;Men;9.137 CANARIAS;Group 1900 Injuries and poisoning 800-999;Women;8.262 CANARIAS;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.093 CANARIAS;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;642 CANARIAS;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;451 CANARIAS;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;653 CANARIAS;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;442 CANARIAS;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;211 CANARIAS;Group 1903 Radius and ulna fracture 813;Both sexes;1.345 CANARIAS;Group 1903 Radius and ulna fracture 813;Men;571 CANARIAS;Group 1903 Radius and ulna fracture 813;Women;774 CANARIAS;Group 1904 Femur fracture 820-821;Both sexes;2.121 CANARIAS;Group 1904 Femur fracture 820-821;Men;670 CANARIAS;Group 1904 Femur fracture 820-821;Women;1.451 CANARIAS;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.632 CANARIAS;Group 1905 Leg fracture, including the ankle 823-824;Men;743 CANARIAS;Group 1905 Leg fracture, including the ankle 823-824;Women;889 CANARIAS;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4.819 CANARIAS;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.903 CANARIAS;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.916 CANARIAS;Group 1907 Burns 940-949;Both sexes;117 CANARIAS;Group 1907 Burns 940-949;Men;76 CANARIAS;Group 1907 Burns 940-949;Women;41 CANARIAS;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;288 CANARIAS;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;147 CANARIAS;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;141 CANARIAS;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;4.797 CANARIAS;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2.670 CANARIAS;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;2.127 CANARIAS;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;26 CANARIAS;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;18 CANARIAS;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;8 CANARIAS;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;508 CANARIAS;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;255 CANARIAS;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;253 CANARIAS;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;4.238 CANARIAS;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.799 CANARIAS;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2.439 CANARIAS;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;299 CANARIAS;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;153 CANARIAS;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;146 CANARIAS;Group 2102 Contraceptive management V25;Both sexes;177 CANARIAS;Group 2102 Contraceptive management V25;Men;10 CANARIAS;Group 2102 Contraceptive management V25;Women;167 CANARIAS;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CANARIAS;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CANARIAS;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CANARIAS;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.395 CANARIAS;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;808 CANARIAS;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;587 CANARIAS;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2.367 CANARIAS;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;828 CANARIAS;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.539 Palmas, Las;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;83.517 Palmas, Las;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;39.471 Palmas, Las;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;44.046 Palmas, Las;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.527 Palmas, Las;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;833 Palmas, Las;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;694 Palmas, Las;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;231 Palmas, Las;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;111 Palmas, Las;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;120 Palmas, Las;Group 0102 Imprecise intestinal infections 009;Both sexes;86 Palmas, Las;Group 0102 Imprecise intestinal infections 009;Men;42 Palmas, Las;Group 0102 Imprecise intestinal infections 009;Women;44 Palmas, Las;Group 0103 Tuberculosis 010-018, 137;Both sexes;51 Palmas, Las;Group 0103 Tuberculosis 010-018, 137;Men;31 Palmas, Las;Group 0103 Tuberculosis 010-018, 137;Women;20 Palmas, Las;Group 0104 Septicaemia 038;Both sexes;665 Palmas, Las;Group 0104 Septicaemia 038;Men;371 Palmas, Las;Group 0104 Septicaemia 038;Women;294 Palmas, Las;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;5 Palmas, Las;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;3 Palmas, Las;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;2 Palmas, Las;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;489 Palmas, Las;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;275 Palmas, Las;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;214 Palmas, Las;Group 0200 Neoplasms 140-239;Both sexes;7.830 Palmas, Las;Group 0200 Neoplasms 140-239;Men;3.920 Palmas, Las;Group 0200 Neoplasms 140-239;Women;3.910 Palmas, Las;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;633 Palmas, Las;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;403 Palmas, Las;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;230 Palmas, Las;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;669 Palmas, Las;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;495 Palmas, Las;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;174 Palmas, Las;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;121 Palmas, Las;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;70 Palmas, Las;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;51 Palmas, Las;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;500 Palmas, Las;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Palmas, Las;Group 0204 Malignant neoplasm of breast 174-175;Women;497 Palmas, Las;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;258 Palmas, Las;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Palmas, Las;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;258 Palmas, Las;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;88 Palmas, Las;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Palmas, Las;Group 0206 Malignant neoplasm of ovary 1830;Women;88 Palmas, Las;Group 0207 Malignant neoplasm of prostate 185;Both sexes;299 Palmas, Las;Group 0207 Malignant neoplasm of prostate 185;Men;299 Palmas, Las;Group 0207 Malignant neoplasm of prostate 185;Women;.. Palmas, Las;Group 0208 Malignant neoplasm of bladder 188;Both sexes;448 Palmas, Las;Group 0208 Malignant neoplasm of bladder 188;Men;386 Palmas, Las;Group 0208 Malignant neoplasm of bladder 188;Women;62 Palmas, Las;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.800 Palmas, Las;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.581 Palmas, Las;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.219 Palmas, Las;Group 0210 Carcinoma in situ 230-234;Both sexes;198 Palmas, Las;Group 0210 Carcinoma in situ 230-234;Men;91 Palmas, Las;Group 0210 Carcinoma in situ 230-234;Women;107 Palmas, Las;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;85 Palmas, Las;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;50 Palmas, Las;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;35 Palmas, Las;Grupo 0212 Leiomyoma of uterus 218;Both sexes;458 Palmas, Las;Grupo 0212 Leiomyoma of uterus 218;Men;.. Palmas, Las;Grupo 0212 Leiomyoma of uterus 218;Women;458 Palmas, Las;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.273 Palmas, Las;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;542 Palmas, Las;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;731 Palmas, Las;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;524 Palmas, Las;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;246 Palmas, Las;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;278 Palmas, Las;Group 0301 Anaemias 280-285;Both sexes;272 Palmas, Las;Group 0301 Anaemias 280-285;Men;132 Palmas, Las;Group 0301 Anaemias 280-285;Women;140 Palmas, Las;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;252 Palmas, Las;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;114 Palmas, Las;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;138 Palmas, Las;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.037 Palmas, Las;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;898 Palmas, Las;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.139 Palmas, Las;Group 0401 Diabetes mellitus 249-250;Both sexes;675 Palmas, Las;Group 0401 Diabetes mellitus 249-250;Men;422 Palmas, Las;Group 0401 Diabetes mellitus 249-250;Women;253 Palmas, Las;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.362 Palmas, Las;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;476 Palmas, Las;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;886 Palmas, Las;Group 0500 Mental disorders 290-319;Both sexes;2.095 Palmas, Las;Group 0500 Mental disorders 290-319;Men;1.201 Palmas, Las;Group 0500 Mental disorders 290-319;Women;894 Palmas, Las;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;58 Palmas, Las;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;30 Palmas, Las;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;28 Palmas, Las;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;186 Palmas, Las;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;150 Palmas, Las;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;36 Palmas, Las;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;261 Palmas, Las;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;198 Palmas, Las;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;63 Palmas, Las;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;692 Palmas, Las;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;423 Palmas, Las;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;269 Palmas, Las;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;477 Palmas, Las;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;205 Palmas, Las;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;272 Palmas, Las;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;421 Palmas, Las;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;195 Palmas, Las;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;226 Palmas, Las;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.486 Palmas, Las;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;795 Palmas, Las;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;691 Palmas, Las;Group 0601 Alzheimer's disease 3310;Both sexes;26 Palmas, Las;Group 0601 Alzheimer's disease 3310;Men;9 Palmas, Las;Group 0601 Alzheimer's disease 3310;Women;17 Palmas, Las;Group 0602 Multiple sclerosis 340;Both sexes;33 Palmas, Las;Group 0602 Multiple sclerosis 340;Men;6 Palmas, Las;Group 0602 Multiple sclerosis 340;Women;27 Palmas, Las;Group 0603 Epilepsy 345;Both sexes;175 Palmas, Las;Group 0603 Epilepsy 345;Men;91 Palmas, Las;Group 0603 Epilepsy 345;Women;84 Palmas, Las;Group 0604 Transient cerebral ischemia 435;Both sexes;159 Palmas, Las;Group 0604 Transient cerebral ischemia 435;Men;96 Palmas, Las;Group 0604 Transient cerebral ischemia 435;Women;63 Palmas, Las;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.093 Palmas, Las;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;593 Palmas, Las;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;500 Palmas, Las;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;293 Palmas, Las;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;150 Palmas, Las;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;143 Palmas, Las;Grupo 0701 Cataract 366;Both sexes;13 Palmas, Las;Grupo 0701 Cataract 366;Men;6 Palmas, Las;Grupo 0701 Cataract 366;Women;7 Palmas, Las;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;280 Palmas, Las;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;144 Palmas, Las;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;136 Palmas, Las;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;497 Palmas, Las;Group 0800 Diseases of the ear and the mastoid 380-389;Men;228 Palmas, Las;Group 0800 Diseases of the ear and the mastoid 380-389;Women;269 Palmas, Las;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;11.430 Palmas, Las;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6.804 Palmas, Las;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.626 Palmas, Las;Group 0901 Hypertensive disease 401-405;Both sexes;740 Palmas, Las;Group 0901 Hypertensive disease 401-405;Men;355 Palmas, Las;Group 0901 Hypertensive disease 401-405;Women;385 Palmas, Las;Group 0902 Angina pectoris 4111, 413;Both sexes;502 Palmas, Las;Group 0902 Angina pectoris 4111, 413;Men;300 Palmas, Las;Group 0902 Angina pectoris 4111, 413;Women;202 Palmas, Las;Group 0903 Acute myocardial infarction 410;Both sexes;1.537 Palmas, Las;Group 0903 Acute myocardial infarction 410;Men;1.135 Palmas, Las;Group 0903 Acute myocardial infarction 410;Women;402 Palmas, Las;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;913 Palmas, Las;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;669 Palmas, Las;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;244 Palmas, Las;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;251 Palmas, Las;Group 0905 Diseases of the lungs circulation 415-417;Men;115 Palmas, Las;Group 0905 Diseases of the lungs circulation 415-417;Women;136 Palmas, Las;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.302 Palmas, Las;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;772 Palmas, Las;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;530 Palmas, Las;Grupo 0907 Heart failure 428;Both sexes;1.863 Palmas, Las;Grupo 0907 Heart failure 428;Men;893 Palmas, Las;Grupo 0907 Heart failure 428;Women;970 Palmas, Las;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.856 Palmas, Las;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.104 Palmas, Las;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;752 Palmas, Las;Grupo 0909 Atherosclerosis 440;Both sexes;385 Palmas, Las;Grupo 0909 Atherosclerosis 440;Men;293 Palmas, Las;Grupo 0909 Atherosclerosis 440;Women;92 Palmas, Las;Group 0910 Varicose veins of lower extremities 454;Both sexes;439 Palmas, Las;Group 0910 Varicose veins of lower extremities 454;Men;167 Palmas, Las;Group 0910 Varicose veins of lower extremities 454;Women;272 Palmas, Las;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.642 Palmas, Las;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.001 Palmas, Las;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;641 Palmas, Las;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;8.835 Palmas, Las;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.802 Palmas, Las;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4.033 Palmas, Las;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;346 Palmas, Las;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;195 Palmas, Las;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;151 Palmas, Las;Group 1002 Pneumonia 480-486;Both sexes;2.353 Palmas, Las;Group 1002 Pneumonia 480-486;Men;1.310 Palmas, Las;Group 1002 Pneumonia 480-486;Women;1.043 Palmas, Las;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;894 Palmas, Las;Group 1003 Acute bronchitis and bronchiolitis 466;Men;467 Palmas, Las;Group 1003 Acute bronchitis and bronchiolitis 466;Women;427 Palmas, Las;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;649 Palmas, Las;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;328 Palmas, Las;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;321 Palmas, Las;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;891 Palmas, Las;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;530 Palmas, Las;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;361 Palmas, Las;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;987 Palmas, Las;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;654 Palmas, Las;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;333 Palmas, Las;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;527 Palmas, Las;Group 1007 Asthma 4930-4931,4938-4939;Men;195 Palmas, Las;Group 1007 Asthma 4930-4931,4938-4939;Women;332 Palmas, Las;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.188 Palmas, Las;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.123 Palmas, Las;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.065 Palmas, Las;Group 1100 Diseases of the digestive system 520-579;Both sexes;10.078 Palmas, Las;Group 1100 Diseases of the digestive system 520-579;Men;5.627 Palmas, Las;Group 1100 Diseases of the digestive system 520-579;Women;4.451 Palmas, Las;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;199 Palmas, Las;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;102 Palmas, Las;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;97 Palmas, Las;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;114 Palmas, Las;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;64 Palmas, Las;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;50 Palmas, Las;Group 1103 Diseases of the esophagus 530;Both sexes;169 Palmas, Las;Group 1103 Diseases of the esophagus 530;Men;103 Palmas, Las;Group 1103 Diseases of the esophagus 530;Women;66 Palmas, Las;Group 1104 Peptic ulcer 531-534;Both sexes;204 Palmas, Las;Group 1104 Peptic ulcer 531-534;Men;139 Palmas, Las;Group 1104 Peptic ulcer 531-534;Women;65 Palmas, Las;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;191 Palmas, Las;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;98 Palmas, Las;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;93 Palmas, Las;Group 1106 Appendicitis 540-543;Both sexes;922 Palmas, Las;Group 1106 Appendicitis 540-543;Men;564 Palmas, Las;Group 1106 Appendicitis 540-543;Women;358 Palmas, Las;Group 1107 Inguinal hernia 550;Both sexes;1.230 Palmas, Las;Group 1107 Inguinal hernia 550;Men;1.118 Palmas, Las;Group 1107 Inguinal hernia 550;Women;112 Palmas, Las;Group 1108 Other abdominal hernia 551-553;Both sexes;1.194 Palmas, Las;Group 1108 Other abdominal hernia 551-553;Men;598 Palmas, Las;Group 1108 Other abdominal hernia 551-553;Women;596 Palmas, Las;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;255 Palmas, Las;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;132 Palmas, Las;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;123 Palmas, Las;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;612 Palmas, Las;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;290 Palmas, Las;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;322 Palmas, Las;Group 1111 Intestinal obstruction without hernia 560;Both sexes;392 Palmas, Las;Group 1111 Intestinal obstruction without hernia 560;Men;188 Palmas, Las;Group 1111 Intestinal obstruction without hernia 560;Women;204 Palmas, Las;Group 1112 Intestinal diverticulosis 562;Both sexes;440 Palmas, Las;Group 1112 Intestinal diverticulosis 562;Men;225 Palmas, Las;Group 1112 Intestinal diverticulosis 562;Women;215 Palmas, Las;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;345 Palmas, Las;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;231 Palmas, Las;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;114 Palmas, Las;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;298 Palmas, Las;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;146 Palmas, Las;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;152 Palmas, Las;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;193 Palmas, Las;Group 1115 Alcoholic hepatitis 5710-5713;Men;158 Palmas, Las;Group 1115 Alcoholic hepatitis 5710-5713;Women;35 Palmas, Las;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;313 Palmas, Las;Group 1116 Other diseases of the liver 570,5714-573;Men;186 Palmas, Las;Group 1116 Other diseases of the liver 570,5714-573;Women;127 Palmas, Las;Group 1117 Cholelithiasis 574;Both sexes;1.864 Palmas, Las;Group 1117 Cholelithiasis 574;Men;673 Palmas, Las;Group 1117 Cholelithiasis 574;Women;1.191 Palmas, Las;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;381 Palmas, Las;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;198 Palmas, Las;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;183 Palmas, Las;Group 1119 Pancreatic diseases 577;Both sexes;542 Palmas, Las;Group 1119 Pancreatic diseases 577;Men;301 Palmas, Las;Group 1119 Pancreatic diseases 577;Women;241 Palmas, Las;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;220 Palmas, Las;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;113 Palmas, Las;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;107 Palmas, Las;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.023 Palmas, Las;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;556 Palmas, Las;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;467 Palmas, Las;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;591 Palmas, Las;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;354 Palmas, Las;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;237 Palmas, Las;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;26 Palmas, Las;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;12 Palmas, Las;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;14 Palmas, Las;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;406 Palmas, Las;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;190 Palmas, Las;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;216 Palmas, Las;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6.033 Palmas, Las;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.996 Palmas, Las;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.037 Palmas, Las;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Palmas, Las;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Palmas, Las;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Palmas, Las;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Palmas, Las;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Palmas, Las;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Palmas, Las;Group 1303 Internal derangement of knee 717;Both sexes;896 Palmas, Las;Group 1303 Internal derangement of knee 717;Men;653 Palmas, Las;Group 1303 Internal derangement of knee 717;Women;243 Palmas, Las;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.033 Palmas, Las;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;852 Palmas, Las;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.181 Palmas, Las;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;139 Palmas, Las;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;42 Palmas, Las;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;97 Palmas, Las;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;347 Palmas, Las;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;181 Palmas, Las;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;166 Palmas, Las;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.001 Palmas, Las;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;464 Palmas, Las;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;537 Palmas, Las;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;203 Palmas, Las;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;82 Palmas, Las;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;121 Palmas, Las;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;693 Palmas, Las;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;399 Palmas, Las;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;294 Palmas, Las;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;721 Palmas, Las;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;323 Palmas, Las;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;398 Palmas, Las;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5.207 Palmas, Las;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.126 Palmas, Las;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3.081 Palmas, Las;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;552 Palmas, Las;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;196 Palmas, Las;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;356 Palmas, Las;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;388 Palmas, Las;Group 1402 Renal failure 5836-5837, 584-586;Men;223 Palmas, Las;Group 1402 Renal failure 5836-5837, 584-586;Women;165 Palmas, Las;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;519 Palmas, Las;Group 1403 Urolithiasis 592, 594, 7880;Men;324 Palmas, Las;Group 1403 Urolithiasis 592, 594, 7880;Women;195 Palmas, Las;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.194 Palmas, Las;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;523 Palmas, Las;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;671 Palmas, Las;Group 1405 Prostatic hyperplasia 600;Both sexes;427 Palmas, Las;Group 1405 Prostatic hyperplasia 600;Men;427 Palmas, Las;Group 1405 Prostatic hyperplasia 600;Women;.. Palmas, Las;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;346 Palmas, Las;Group 1406 Other diseases of the male genital organs 601-608;Men;346 Palmas, Las;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Palmas, Las;Group 1407 Disorders of breast 610-612;Both sexes;681 Palmas, Las;Group 1407 Disorders of breast 610-612;Men;80 Palmas, Las;Group 1407 Disorders of breast 610-612;Women;601 Palmas, Las;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;158 Palmas, Las;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Palmas, Las;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;158 Palmas, Las;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;73 Palmas, Las;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Palmas, Las;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;73 Palmas, Las;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;869 Palmas, Las;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;7 Palmas, Las;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;862 Palmas, Las;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;8.965 Palmas, Las;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Palmas, Las;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;8.965 Palmas, Las;Group 1501 Legally induced abortion 635;Both sexes;85 Palmas, Las;Group 1501 Legally induced abortion 635;Men;.. Palmas, Las;Group 1501 Legally induced abortion 635;Women;85 Palmas, Las;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;442 Palmas, Las;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Palmas, Las;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;442 Palmas, Las;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.189 Palmas, Las;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Palmas, Las;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.189 Palmas, Las;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.658 Palmas, Las;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Palmas, Las;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.658 Palmas, Las;Group 1505 Single spontaneous delivery 650;Both sexes;116 Palmas, Las;Group 1505 Single spontaneous delivery 650;Men;.. Palmas, Las;Group 1505 Single spontaneous delivery 650;Women;116 Palmas, Las;Group 1506 Other deliveries 6695-6697;Both sexes;22 Palmas, Las;Group 1506 Other deliveries 6695-6697;Men;.. Palmas, Las;Group 1506 Other deliveries 6695-6697;Women;22 Palmas, Las;Group 1507 Complications related to the puerperium 670-676;Both sexes;50 Palmas, Las;Group 1507 Complications related to the puerperium 670-676;Men;.. Palmas, Las;Group 1507 Complications related to the puerperium 670-676;Women;50 Palmas, Las;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;403 Palmas, Las;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Palmas, Las;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;403 Palmas, Las;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.413 Palmas, Las;Group 1600 Some disorders originating in the perinatal period 760-779;Men;789 Palmas, Las;Group 1600 Some disorders originating in the perinatal period 760-779;Women;624 Palmas, Las;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;316 Palmas, Las;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;168 Palmas, Las;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;148 Palmas, Las;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.097 Palmas, Las;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;621 Palmas, Las;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;476 Palmas, Las;Grupo 1700 Congenital abnormalities 740-759;Both sexes;909 Palmas, Las;Grupo 1700 Congenital abnormalities 740-759;Men;526 Palmas, Las;Grupo 1700 Congenital abnormalities 740-759;Women;383 Palmas, Las;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.744 Palmas, Las;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2.009 Palmas, Las;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.735 Palmas, Las;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;327 Palmas, Las;Group 1801 Pain in throat and chest 7841, 7865;Men;169 Palmas, Las;Group 1801 Pain in throat and chest 7841, 7865;Women;158 Palmas, Las;Group 1802 Abdominal pain 7890;Both sexes;282 Palmas, Las;Group 1802 Abdominal pain 7890;Men;106 Palmas, Las;Group 1802 Abdominal pain 7890;Women;176 Palmas, Las;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;589 Palmas, Las;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;289 Palmas, Las;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;300 Palmas, Las;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2.546 Palmas, Las;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.445 Palmas, Las;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.101 Palmas, Las;Group 1900 Injuries and poisoning 800-999;Both sexes;7.657 Palmas, Las;Group 1900 Injuries and poisoning 800-999;Men;4.143 Palmas, Las;Group 1900 Injuries and poisoning 800-999;Women;3.514 Palmas, Las;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;567 Palmas, Las;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;352 Palmas, Las;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;215 Palmas, Las;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;206 Palmas, Las;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;144 Palmas, Las;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;62 Palmas, Las;Group 1903 Radius and ulna fracture 813;Both sexes;479 Palmas, Las;Group 1903 Radius and ulna fracture 813;Men;226 Palmas, Las;Group 1903 Radius and ulna fracture 813;Women;253 Palmas, Las;Group 1904 Femur fracture 820-821;Both sexes;992 Palmas, Las;Group 1904 Femur fracture 820-821;Men;341 Palmas, Las;Group 1904 Femur fracture 820-821;Women;651 Palmas, Las;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;730 Palmas, Las;Group 1905 Leg fracture, including the ankle 823-824;Men;352 Palmas, Las;Group 1905 Leg fracture, including the ankle 823-824;Women;378 Palmas, Las;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.088 Palmas, Las;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.272 Palmas, Las;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;816 Palmas, Las;Group 1907 Burns 940-949;Both sexes;58 Palmas, Las;Group 1907 Burns 940-949;Men;38 Palmas, Las;Group 1907 Burns 940-949;Women;20 Palmas, Las;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;160 Palmas, Las;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;81 Palmas, Las;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;79 Palmas, Las;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.200 Palmas, Las;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.236 Palmas, Las;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;964 Palmas, Las;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;13 Palmas, Las;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 Palmas, Las;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 Palmas, Las;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;164 Palmas, Las;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;93 Palmas, Las;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;71 Palmas, Las;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.934 Palmas, Las;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;822 Palmas, Las;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.112 Palmas, Las;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;186 Palmas, Las;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;98 Palmas, Las;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;88 Palmas, Las;Group 2102 Contraceptive management V25;Both sexes;73 Palmas, Las;Group 2102 Contraceptive management V25;Men;2 Palmas, Las;Group 2102 Contraceptive management V25;Women;71 Palmas, Las;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Palmas, Las;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Palmas, Las;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Palmas, Las;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;476 Palmas, Las;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;255 Palmas, Las;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;221 Palmas, Las;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.199 Palmas, Las;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;467 Palmas, Las;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;732 Santa Cruz de Tenerife;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;94.062 Santa Cruz de Tenerife;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;43.478 Santa Cruz de Tenerife;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;50.584 Santa Cruz de Tenerife;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.208 Santa Cruz de Tenerife;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.129 Santa Cruz de Tenerife;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.078 Santa Cruz de Tenerife;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;173 Santa Cruz de Tenerife;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;88 Santa Cruz de Tenerife;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;85 Santa Cruz de Tenerife;Group 0102 Imprecise intestinal infections 009;Both sexes;99 Santa Cruz de Tenerife;Group 0102 Imprecise intestinal infections 009;Men;46 Santa Cruz de Tenerife;Group 0102 Imprecise intestinal infections 009;Women;53 Santa Cruz de Tenerife;Group 0103 Tuberculosis 010-018, 137;Both sexes;44 Santa Cruz de Tenerife;Group 0103 Tuberculosis 010-018, 137;Men;32 Santa Cruz de Tenerife;Group 0103 Tuberculosis 010-018, 137;Women;12 Santa Cruz de Tenerife;Group 0104 Septicaemia 038;Both sexes;1.203 Santa Cruz de Tenerife;Group 0104 Septicaemia 038;Men;607 Santa Cruz de Tenerife;Group 0104 Septicaemia 038;Women;595 Santa Cruz de Tenerife;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;52 Santa Cruz de Tenerife;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;45 Santa Cruz de Tenerife;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;7 Santa Cruz de Tenerife;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;637 Santa Cruz de Tenerife;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;311 Santa Cruz de Tenerife;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;326 Santa Cruz de Tenerife;Group 0200 Neoplasms 140-239;Both sexes;8.218 Santa Cruz de Tenerife;Group 0200 Neoplasms 140-239;Men;4.057 Santa Cruz de Tenerife;Group 0200 Neoplasms 140-239;Women;4.161 Santa Cruz de Tenerife;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;768 Santa Cruz de Tenerife;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;467 Santa Cruz de Tenerife;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;301 Santa Cruz de Tenerife;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;552 Santa Cruz de Tenerife;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;391 Santa Cruz de Tenerife;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;161 Santa Cruz de Tenerife;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;225 Santa Cruz de Tenerife;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;138 Santa Cruz de Tenerife;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;87 Santa Cruz de Tenerife;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;614 Santa Cruz de Tenerife;Group 0204 Malignant neoplasm of breast 174-175;Men;9 Santa Cruz de Tenerife;Group 0204 Malignant neoplasm of breast 174-175;Women;605 Santa Cruz de Tenerife;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;191 Santa Cruz de Tenerife;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Santa Cruz de Tenerife;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;191 Santa Cruz de Tenerife;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;88 Santa Cruz de Tenerife;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Santa Cruz de Tenerife;Group 0206 Malignant neoplasm of ovary 1830;Women;88 Santa Cruz de Tenerife;Group 0207 Malignant neoplasm of prostate 185;Both sexes;449 Santa Cruz de Tenerife;Group 0207 Malignant neoplasm of prostate 185;Men;449 Santa Cruz de Tenerife;Group 0207 Malignant neoplasm of prostate 185;Women;.. Santa Cruz de Tenerife;Group 0208 Malignant neoplasm of bladder 188;Both sexes;610 Santa Cruz de Tenerife;Group 0208 Malignant neoplasm of bladder 188;Men;511 Santa Cruz de Tenerife;Group 0208 Malignant neoplasm of bladder 188;Women;99 Santa Cruz de Tenerife;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.853 Santa Cruz de Tenerife;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.556 Santa Cruz de Tenerife;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.297 Santa Cruz de Tenerife;Group 0210 Carcinoma in situ 230-234;Both sexes;192 Santa Cruz de Tenerife;Group 0210 Carcinoma in situ 230-234;Men;36 Santa Cruz de Tenerife;Group 0210 Carcinoma in situ 230-234;Women;156 Santa Cruz de Tenerife;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;108 Santa Cruz de Tenerife;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;57 Santa Cruz de Tenerife;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;51 Santa Cruz de Tenerife;Grupo 0212 Leiomyoma of uterus 218;Both sexes;472 Santa Cruz de Tenerife;Grupo 0212 Leiomyoma of uterus 218;Men;.. Santa Cruz de Tenerife;Grupo 0212 Leiomyoma of uterus 218;Women;472 Santa Cruz de Tenerife;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.096 Santa Cruz de Tenerife;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;443 Santa Cruz de Tenerife;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;653 Santa Cruz de Tenerife;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;724 Santa Cruz de Tenerife;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;361 Santa Cruz de Tenerife;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;363 Santa Cruz de Tenerife;Group 0301 Anaemias 280-285;Both sexes;406 Santa Cruz de Tenerife;Group 0301 Anaemias 280-285;Men;187 Santa Cruz de Tenerife;Group 0301 Anaemias 280-285;Women;219 Santa Cruz de Tenerife;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;318 Santa Cruz de Tenerife;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;174 Santa Cruz de Tenerife;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;144 Santa Cruz de Tenerife;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.929 Santa Cruz de Tenerife;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;780 Santa Cruz de Tenerife;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.149 Santa Cruz de Tenerife;Group 0401 Diabetes mellitus 249-250;Both sexes;515 Santa Cruz de Tenerife;Group 0401 Diabetes mellitus 249-250;Men;302 Santa Cruz de Tenerife;Group 0401 Diabetes mellitus 249-250;Women;213 Santa Cruz de Tenerife;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.414 Santa Cruz de Tenerife;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;478 Santa Cruz de Tenerife;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;936 Santa Cruz de Tenerife;Group 0500 Mental disorders 290-319;Both sexes;1.761 Santa Cruz de Tenerife;Group 0500 Mental disorders 290-319;Men;960 Santa Cruz de Tenerife;Group 0500 Mental disorders 290-319;Women;801 Santa Cruz de Tenerife;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;29 Santa Cruz de Tenerife;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;20 Santa Cruz de Tenerife;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;9 Santa Cruz de Tenerife;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;269 Santa Cruz de Tenerife;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;219 Santa Cruz de Tenerife;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;50 Santa Cruz de Tenerife;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;237 Santa Cruz de Tenerife;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;179 Santa Cruz de Tenerife;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;58 Santa Cruz de Tenerife;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;511 Santa Cruz de Tenerife;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;287 Santa Cruz de Tenerife;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;224 Santa Cruz de Tenerife;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;419 Santa Cruz de Tenerife;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;139 Santa Cruz de Tenerife;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;280 Santa Cruz de Tenerife;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;296 Santa Cruz de Tenerife;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;116 Santa Cruz de Tenerife;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;180 Santa Cruz de Tenerife;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.424 Santa Cruz de Tenerife;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.224 Santa Cruz de Tenerife;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.199 Santa Cruz de Tenerife;Group 0601 Alzheimer's disease 3310;Both sexes;44 Santa Cruz de Tenerife;Group 0601 Alzheimer's disease 3310;Men;11 Santa Cruz de Tenerife;Group 0601 Alzheimer's disease 3310;Women;33 Santa Cruz de Tenerife;Group 0602 Multiple sclerosis 340;Both sexes;182 Santa Cruz de Tenerife;Group 0602 Multiple sclerosis 340;Men;51 Santa Cruz de Tenerife;Group 0602 Multiple sclerosis 340;Women;131 Santa Cruz de Tenerife;Group 0603 Epilepsy 345;Both sexes;221 Santa Cruz de Tenerife;Group 0603 Epilepsy 345;Men;112 Santa Cruz de Tenerife;Group 0603 Epilepsy 345;Women;109 Santa Cruz de Tenerife;Group 0604 Transient cerebral ischemia 435;Both sexes;224 Santa Cruz de Tenerife;Group 0604 Transient cerebral ischemia 435;Men;118 Santa Cruz de Tenerife;Group 0604 Transient cerebral ischemia 435;Women;106 Santa Cruz de Tenerife;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.752 Santa Cruz de Tenerife;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;932 Santa Cruz de Tenerife;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;820 Santa Cruz de Tenerife;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;785 Santa Cruz de Tenerife;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;420 Santa Cruz de Tenerife;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;365 Santa Cruz de Tenerife;Grupo 0701 Cataract 366;Both sexes;87 Santa Cruz de Tenerife;Grupo 0701 Cataract 366;Men;40 Santa Cruz de Tenerife;Grupo 0701 Cataract 366;Women;47 Santa Cruz de Tenerife;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;698 Santa Cruz de Tenerife;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;380 Santa Cruz de Tenerife;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;318 Santa Cruz de Tenerife;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;449 Santa Cruz de Tenerife;Group 0800 Diseases of the ear and the mastoid 380-389;Men;203 Santa Cruz de Tenerife;Group 0800 Diseases of the ear and the mastoid 380-389;Women;246 Santa Cruz de Tenerife;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;11.746 Santa Cruz de Tenerife;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6.608 Santa Cruz de Tenerife;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;5.138 Santa Cruz de Tenerife;Group 0901 Hypertensive disease 401-405;Both sexes;640 Santa Cruz de Tenerife;Group 0901 Hypertensive disease 401-405;Men;307 Santa Cruz de Tenerife;Group 0901 Hypertensive disease 401-405;Women;333 Santa Cruz de Tenerife;Group 0902 Angina pectoris 4111, 413;Both sexes;279 Santa Cruz de Tenerife;Group 0902 Angina pectoris 4111, 413;Men;161 Santa Cruz de Tenerife;Group 0902 Angina pectoris 4111, 413;Women;118 Santa Cruz de Tenerife;Group 0903 Acute myocardial infarction 410;Both sexes;1.147 Santa Cruz de Tenerife;Group 0903 Acute myocardial infarction 410;Men;827 Santa Cruz de Tenerife;Group 0903 Acute myocardial infarction 410;Women;320 Santa Cruz de Tenerife;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;962 Santa Cruz de Tenerife;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;721 Santa Cruz de Tenerife;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;241 Santa Cruz de Tenerife;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;284 Santa Cruz de Tenerife;Group 0905 Diseases of the lungs circulation 415-417;Men;119 Santa Cruz de Tenerife;Group 0905 Diseases of the lungs circulation 415-417;Women;165 Santa Cruz de Tenerife;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.481 Santa Cruz de Tenerife;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;844 Santa Cruz de Tenerife;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;636 Santa Cruz de Tenerife;Grupo 0907 Heart failure 428;Both sexes;1.851 Santa Cruz de Tenerife;Grupo 0907 Heart failure 428;Men;885 Santa Cruz de Tenerife;Grupo 0907 Heart failure 428;Women;965 Santa Cruz de Tenerife;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.974 Santa Cruz de Tenerife;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.049 Santa Cruz de Tenerife;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;925 Santa Cruz de Tenerife;Grupo 0909 Atherosclerosis 440;Both sexes;364 Santa Cruz de Tenerife;Grupo 0909 Atherosclerosis 440;Men;246 Santa Cruz de Tenerife;Grupo 0909 Atherosclerosis 440;Women;118 Santa Cruz de Tenerife;Group 0910 Varicose veins of lower extremities 454;Both sexes;523 Santa Cruz de Tenerife;Group 0910 Varicose veins of lower extremities 454;Men;187 Santa Cruz de Tenerife;Group 0910 Varicose veins of lower extremities 454;Women;336 Santa Cruz de Tenerife;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.241 Santa Cruz de Tenerife;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.261 Santa Cruz de Tenerife;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;980 Santa Cruz de Tenerife;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;11.211 Santa Cruz de Tenerife;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5.836 Santa Cruz de Tenerife;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;5.375 Santa Cruz de Tenerife;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;541 Santa Cruz de Tenerife;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;288 Santa Cruz de Tenerife;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;253 Santa Cruz de Tenerife;Group 1002 Pneumonia 480-486;Both sexes;2.833 Santa Cruz de Tenerife;Group 1002 Pneumonia 480-486;Men;1.425 Santa Cruz de Tenerife;Group 1002 Pneumonia 480-486;Women;1.407 Santa Cruz de Tenerife;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.384 Santa Cruz de Tenerife;Group 1003 Acute bronchitis and bronchiolitis 466;Men;668 Santa Cruz de Tenerife;Group 1003 Acute bronchitis and bronchiolitis 466;Women;716 Santa Cruz de Tenerife;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;833 Santa Cruz de Tenerife;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;424 Santa Cruz de Tenerife;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;409 Santa Cruz de Tenerife;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;985 Santa Cruz de Tenerife;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;610 Santa Cruz de Tenerife;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;375 Santa Cruz de Tenerife;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.352 Santa Cruz de Tenerife;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;903 Santa Cruz de Tenerife;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;449 Santa Cruz de Tenerife;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;444 Santa Cruz de Tenerife;Group 1007 Asthma 4930-4931,4938-4939;Men;135 Santa Cruz de Tenerife;Group 1007 Asthma 4930-4931,4938-4939;Women;309 Santa Cruz de Tenerife;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.839 Santa Cruz de Tenerife;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.382 Santa Cruz de Tenerife;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.457 Santa Cruz de Tenerife;Group 1100 Diseases of the digestive system 520-579;Both sexes;12.232 Santa Cruz de Tenerife;Group 1100 Diseases of the digestive system 520-579;Men;6.786 Santa Cruz de Tenerife;Group 1100 Diseases of the digestive system 520-579;Women;5.445 Santa Cruz de Tenerife;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;302 Santa Cruz de Tenerife;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;118 Santa Cruz de Tenerife;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;184 Santa Cruz de Tenerife;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;230 Santa Cruz de Tenerife;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;119 Santa Cruz de Tenerife;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;111 Santa Cruz de Tenerife;Group 1103 Diseases of the esophagus 530;Both sexes;201 Santa Cruz de Tenerife;Group 1103 Diseases of the esophagus 530;Men;133 Santa Cruz de Tenerife;Group 1103 Diseases of the esophagus 530;Women;68 Santa Cruz de Tenerife;Group 1104 Peptic ulcer 531-534;Both sexes;182 Santa Cruz de Tenerife;Group 1104 Peptic ulcer 531-534;Men;123 Santa Cruz de Tenerife;Group 1104 Peptic ulcer 531-534;Women;59 Santa Cruz de Tenerife;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;319 Santa Cruz de Tenerife;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;140 Santa Cruz de Tenerife;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;179 Santa Cruz de Tenerife;Group 1106 Appendicitis 540-543;Both sexes;899 Santa Cruz de Tenerife;Group 1106 Appendicitis 540-543;Men;522 Santa Cruz de Tenerife;Group 1106 Appendicitis 540-543;Women;377 Santa Cruz de Tenerife;Group 1107 Inguinal hernia 550;Both sexes;1.492 Santa Cruz de Tenerife;Group 1107 Inguinal hernia 550;Men;1.344 Santa Cruz de Tenerife;Group 1107 Inguinal hernia 550;Women;148 Santa Cruz de Tenerife;Group 1108 Other abdominal hernia 551-553;Both sexes;1.159 Santa Cruz de Tenerife;Group 1108 Other abdominal hernia 551-553;Men;636 Santa Cruz de Tenerife;Group 1108 Other abdominal hernia 551-553;Women;523 Santa Cruz de Tenerife;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;211 Santa Cruz de Tenerife;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;102 Santa Cruz de Tenerife;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;109 Santa Cruz de Tenerife;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;990 Santa Cruz de Tenerife;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;433 Santa Cruz de Tenerife;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;557 Santa Cruz de Tenerife;Group 1111 Intestinal obstruction without hernia 560;Both sexes;386 Santa Cruz de Tenerife;Group 1111 Intestinal obstruction without hernia 560;Men;209 Santa Cruz de Tenerife;Group 1111 Intestinal obstruction without hernia 560;Women;177 Santa Cruz de Tenerife;Group 1112 Intestinal diverticulosis 562;Both sexes;540 Santa Cruz de Tenerife;Group 1112 Intestinal diverticulosis 562;Men;287 Santa Cruz de Tenerife;Group 1112 Intestinal diverticulosis 562;Women;253 Santa Cruz de Tenerife;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;634 Santa Cruz de Tenerife;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;416 Santa Cruz de Tenerife;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;218 Santa Cruz de Tenerife;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;412 Santa Cruz de Tenerife;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;171 Santa Cruz de Tenerife;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;241 Santa Cruz de Tenerife;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;386 Santa Cruz de Tenerife;Group 1115 Alcoholic hepatitis 5710-5713;Men;339 Santa Cruz de Tenerife;Group 1115 Alcoholic hepatitis 5710-5713;Women;47 Santa Cruz de Tenerife;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;374 Santa Cruz de Tenerife;Group 1116 Other diseases of the liver 570,5714-573;Men;216 Santa Cruz de Tenerife;Group 1116 Other diseases of the liver 570,5714-573;Women;158 Santa Cruz de Tenerife;Group 1117 Cholelithiasis 574;Both sexes;2.120 Santa Cruz de Tenerife;Group 1117 Cholelithiasis 574;Men;759 Santa Cruz de Tenerife;Group 1117 Cholelithiasis 574;Women;1.361 Santa Cruz de Tenerife;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;517 Santa Cruz de Tenerife;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;255 Santa Cruz de Tenerife;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;262 Santa Cruz de Tenerife;Group 1119 Pancreatic diseases 577;Both sexes;501 Santa Cruz de Tenerife;Group 1119 Pancreatic diseases 577;Men;268 Santa Cruz de Tenerife;Group 1119 Pancreatic diseases 577;Women;233 Santa Cruz de Tenerife;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;376 Santa Cruz de Tenerife;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;196 Santa Cruz de Tenerife;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;180 Santa Cruz de Tenerife;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.500 Santa Cruz de Tenerife;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;827 Santa Cruz de Tenerife;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;673 Santa Cruz de Tenerife;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.100 Santa Cruz de Tenerife;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;642 Santa Cruz de Tenerife;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;458 Santa Cruz de Tenerife;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;74 Santa Cruz de Tenerife;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;40 Santa Cruz de Tenerife;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;34 Santa Cruz de Tenerife;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;326 Santa Cruz de Tenerife;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;145 Santa Cruz de Tenerife;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;181 Santa Cruz de Tenerife;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6.710 Santa Cruz de Tenerife;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3.252 Santa Cruz de Tenerife;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.458 Santa Cruz de Tenerife;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Santa Cruz de Tenerife;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Santa Cruz de Tenerife;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Santa Cruz de Tenerife;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Santa Cruz de Tenerife;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Santa Cruz de Tenerife;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Santa Cruz de Tenerife;Group 1303 Internal derangement of knee 717;Both sexes;1.123 Santa Cruz de Tenerife;Group 1303 Internal derangement of knee 717;Men;720 Santa Cruz de Tenerife;Group 1303 Internal derangement of knee 717;Women;403 Santa Cruz de Tenerife;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.646 Santa Cruz de Tenerife;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.109 Santa Cruz de Tenerife;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.537 Santa Cruz de Tenerife;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;104 Santa Cruz de Tenerife;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;21 Santa Cruz de Tenerife;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;83 Santa Cruz de Tenerife;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;261 Santa Cruz de Tenerife;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;149 Santa Cruz de Tenerife;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;112 Santa Cruz de Tenerife;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;592 Santa Cruz de Tenerife;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;285 Santa Cruz de Tenerife;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;307 Santa Cruz de Tenerife;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;147 Santa Cruz de Tenerife;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;61 Santa Cruz de Tenerife;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;86 Santa Cruz de Tenerife;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;987 Santa Cruz de Tenerife;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;542 Santa Cruz de Tenerife;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;445 Santa Cruz de Tenerife;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;850 Santa Cruz de Tenerife;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;365 Santa Cruz de Tenerife;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;485 Santa Cruz de Tenerife;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5.749 Santa Cruz de Tenerife;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.329 Santa Cruz de Tenerife;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3.420 Santa Cruz de Tenerife;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;532 Santa Cruz de Tenerife;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;208 Santa Cruz de Tenerife;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;324 Santa Cruz de Tenerife;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;318 Santa Cruz de Tenerife;Group 1402 Renal failure 5836-5837, 584-586;Men;185 Santa Cruz de Tenerife;Group 1402 Renal failure 5836-5837, 584-586;Women;133 Santa Cruz de Tenerife;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;684 Santa Cruz de Tenerife;Group 1403 Urolithiasis 592, 594, 7880;Men;385 Santa Cruz de Tenerife;Group 1403 Urolithiasis 592, 594, 7880;Women;299 Santa Cruz de Tenerife;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.854 Santa Cruz de Tenerife;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;750 Santa Cruz de Tenerife;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.104 Santa Cruz de Tenerife;Group 1405 Prostatic hyperplasia 600;Both sexes;365 Santa Cruz de Tenerife;Group 1405 Prostatic hyperplasia 600;Men;365 Santa Cruz de Tenerife;Group 1405 Prostatic hyperplasia 600;Women;.. Santa Cruz de Tenerife;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;382 Santa Cruz de Tenerife;Group 1406 Other diseases of the male genital organs 601-608;Men;382 Santa Cruz de Tenerife;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Santa Cruz de Tenerife;Group 1407 Disorders of breast 610-612;Both sexes;396 Santa Cruz de Tenerife;Group 1407 Disorders of breast 610-612;Men;48 Santa Cruz de Tenerife;Group 1407 Disorders of breast 610-612;Women;348 Santa Cruz de Tenerife;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;233 Santa Cruz de Tenerife;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Santa Cruz de Tenerife;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;233 Santa Cruz de Tenerife;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;69 Santa Cruz de Tenerife;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Santa Cruz de Tenerife;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;69 Santa Cruz de Tenerife;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;916 Santa Cruz de Tenerife;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;6 Santa Cruz de Tenerife;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;910 Santa Cruz de Tenerife;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;9.086 Santa Cruz de Tenerife;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Santa Cruz de Tenerife;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;9.086 Santa Cruz de Tenerife;Group 1501 Legally induced abortion 635;Both sexes;81 Santa Cruz de Tenerife;Group 1501 Legally induced abortion 635;Men;.. Santa Cruz de Tenerife;Group 1501 Legally induced abortion 635;Women;81 Santa Cruz de Tenerife;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;473 Santa Cruz de Tenerife;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Santa Cruz de Tenerife;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;473 Santa Cruz de Tenerife;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6.344 Santa Cruz de Tenerife;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Santa Cruz de Tenerife;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6.344 Santa Cruz de Tenerife;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.365 Santa Cruz de Tenerife;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Santa Cruz de Tenerife;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.365 Santa Cruz de Tenerife;Group 1505 Single spontaneous delivery 650;Both sexes;178 Santa Cruz de Tenerife;Group 1505 Single spontaneous delivery 650;Men;.. Santa Cruz de Tenerife;Group 1505 Single spontaneous delivery 650;Women;178 Santa Cruz de Tenerife;Group 1506 Other deliveries 6695-6697;Both sexes;20 Santa Cruz de Tenerife;Group 1506 Other deliveries 6695-6697;Men;.. Santa Cruz de Tenerife;Group 1506 Other deliveries 6695-6697;Women;20 Santa Cruz de Tenerife;Group 1507 Complications related to the puerperium 670-676;Both sexes;45 Santa Cruz de Tenerife;Group 1507 Complications related to the puerperium 670-676;Men;.. Santa Cruz de Tenerife;Group 1507 Complications related to the puerperium 670-676;Women;45 Santa Cruz de Tenerife;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;580 Santa Cruz de Tenerife;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Santa Cruz de Tenerife;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;580 Santa Cruz de Tenerife;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.064 Santa Cruz de Tenerife;Group 1600 Some disorders originating in the perinatal period 760-779;Men;593 Santa Cruz de Tenerife;Group 1600 Some disorders originating in the perinatal period 760-779;Women;471 Santa Cruz de Tenerife;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;271 Santa Cruz de Tenerife;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;156 Santa Cruz de Tenerife;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;115 Santa Cruz de Tenerife;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;793 Santa Cruz de Tenerife;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;437 Santa Cruz de Tenerife;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;356 Santa Cruz de Tenerife;Grupo 1700 Congenital abnormalities 740-759;Both sexes;571 Santa Cruz de Tenerife;Grupo 1700 Congenital abnormalities 740-759;Men;310 Santa Cruz de Tenerife;Grupo 1700 Congenital abnormalities 740-759;Women;261 Santa Cruz de Tenerife;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.648 Santa Cruz de Tenerife;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.830 Santa Cruz de Tenerife;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.817 Santa Cruz de Tenerife;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;478 Santa Cruz de Tenerife;Group 1801 Pain in throat and chest 7841, 7865;Men;267 Santa Cruz de Tenerife;Group 1801 Pain in throat and chest 7841, 7865;Women;211 Santa Cruz de Tenerife;Group 1802 Abdominal pain 7890;Both sexes;550 Santa Cruz de Tenerife;Group 1802 Abdominal pain 7890;Men;204 Santa Cruz de Tenerife;Group 1802 Abdominal pain 7890;Women;346 Santa Cruz de Tenerife;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;236 Santa Cruz de Tenerife;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;115 Santa Cruz de Tenerife;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;121 Santa Cruz de Tenerife;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2.384 Santa Cruz de Tenerife;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.244 Santa Cruz de Tenerife;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.139 Santa Cruz de Tenerife;Group 1900 Injuries and poisoning 800-999;Both sexes;9.742 Santa Cruz de Tenerife;Group 1900 Injuries and poisoning 800-999;Men;4.994 Santa Cruz de Tenerife;Group 1900 Injuries and poisoning 800-999;Women;4.748 Santa Cruz de Tenerife;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;526 Santa Cruz de Tenerife;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;290 Santa Cruz de Tenerife;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;236 Santa Cruz de Tenerife;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;447 Santa Cruz de Tenerife;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;298 Santa Cruz de Tenerife;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;149 Santa Cruz de Tenerife;Group 1903 Radius and ulna fracture 813;Both sexes;866 Santa Cruz de Tenerife;Group 1903 Radius and ulna fracture 813;Men;345 Santa Cruz de Tenerife;Group 1903 Radius and ulna fracture 813;Women;521 Santa Cruz de Tenerife;Group 1904 Femur fracture 820-821;Both sexes;1.129 Santa Cruz de Tenerife;Group 1904 Femur fracture 820-821;Men;329 Santa Cruz de Tenerife;Group 1904 Femur fracture 820-821;Women;800 Santa Cruz de Tenerife;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;902 Santa Cruz de Tenerife;Group 1905 Leg fracture, including the ankle 823-824;Men;391 Santa Cruz de Tenerife;Group 1905 Leg fracture, including the ankle 823-824;Women;511 Santa Cruz de Tenerife;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.731 Santa Cruz de Tenerife;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.631 Santa Cruz de Tenerife;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.100 Santa Cruz de Tenerife;Group 1907 Burns 940-949;Both sexes;59 Santa Cruz de Tenerife;Group 1907 Burns 940-949;Men;38 Santa Cruz de Tenerife;Group 1907 Burns 940-949;Women;21 Santa Cruz de Tenerife;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;128 Santa Cruz de Tenerife;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;66 Santa Cruz de Tenerife;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;62 Santa Cruz de Tenerife;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.597 Santa Cruz de Tenerife;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.434 Santa Cruz de Tenerife;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.163 Santa Cruz de Tenerife;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;13 Santa Cruz de Tenerife;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;10 Santa Cruz de Tenerife;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;3 Santa Cruz de Tenerife;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;344 Santa Cruz de Tenerife;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;162 Santa Cruz de Tenerife;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;182 Santa Cruz de Tenerife;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.304 Santa Cruz de Tenerife;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;977 Santa Cruz de Tenerife;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.327 Santa Cruz de Tenerife;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;113 Santa Cruz de Tenerife;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;55 Santa Cruz de Tenerife;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;58 Santa Cruz de Tenerife;Group 2102 Contraceptive management V25;Both sexes;104 Santa Cruz de Tenerife;Group 2102 Contraceptive management V25;Men;8 Santa Cruz de Tenerife;Group 2102 Contraceptive management V25;Women;96 Santa Cruz de Tenerife;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Santa Cruz de Tenerife;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Santa Cruz de Tenerife;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Santa Cruz de Tenerife;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;919 Santa Cruz de Tenerife;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;553 Santa Cruz de Tenerife;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;366 Santa Cruz de Tenerife;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.168 Santa Cruz de Tenerife;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;361 Santa Cruz de Tenerife;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;807 CANTABRIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;60.659 CANTABRIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;29.542 CANTABRIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;31.117 CANTABRIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.593 CANTABRIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;888 CANTABRIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;705 CANTABRIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;241 CANTABRIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;132 CANTABRIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;109 CANTABRIA;Group 0102 Imprecise intestinal infections 009;Both sexes;26 CANTABRIA;Group 0102 Imprecise intestinal infections 009;Men;12 CANTABRIA;Group 0102 Imprecise intestinal infections 009;Women;14 CANTABRIA;Group 0103 Tuberculosis 010-018, 137;Both sexes;51 CANTABRIA;Group 0103 Tuberculosis 010-018, 137;Men;28 CANTABRIA;Group 0103 Tuberculosis 010-018, 137;Women;23 CANTABRIA;Group 0104 Septicaemia 038;Both sexes;839 CANTABRIA;Group 0104 Septicaemia 038;Men;443 CANTABRIA;Group 0104 Septicaemia 038;Women;396 CANTABRIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;20 CANTABRIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;17 CANTABRIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 CANTABRIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;416 CANTABRIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;256 CANTABRIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;160 CANTABRIA;Group 0200 Neoplasms 140-239;Both sexes;5.604 CANTABRIA;Group 0200 Neoplasms 140-239;Men;2.939 CANTABRIA;Group 0200 Neoplasms 140-239;Women;2.665 CANTABRIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;533 CANTABRIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;311 CANTABRIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;222 CANTABRIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;430 CANTABRIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;328 CANTABRIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;102 CANTABRIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;103 CANTABRIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;54 CANTABRIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;49 CANTABRIA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;380 CANTABRIA;Group 0204 Malignant neoplasm of breast 174-175;Men;1 CANTABRIA;Group 0204 Malignant neoplasm of breast 174-175;Women;379 CANTABRIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;106 CANTABRIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CANTABRIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;106 CANTABRIA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;50 CANTABRIA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CANTABRIA;Group 0206 Malignant neoplasm of ovary 1830;Women;50 CANTABRIA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;179 CANTABRIA;Group 0207 Malignant neoplasm of prostate 185;Men;179 CANTABRIA;Group 0207 Malignant neoplasm of prostate 185;Women;.. CANTABRIA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;476 CANTABRIA;Group 0208 Malignant neoplasm of bladder 188;Men;382 CANTABRIA;Group 0208 Malignant neoplasm of bladder 188;Women;94 CANTABRIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.047 CANTABRIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.191 CANTABRIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;856 CANTABRIA;Group 0210 Carcinoma in situ 230-234;Both sexes;132 CANTABRIA;Group 0210 Carcinoma in situ 230-234;Men;63 CANTABRIA;Group 0210 Carcinoma in situ 230-234;Women;69 CANTABRIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;78 CANTABRIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;49 CANTABRIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;29 CANTABRIA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;217 CANTABRIA;Grupo 0212 Leiomyoma of uterus 218;Men;.. CANTABRIA;Grupo 0212 Leiomyoma of uterus 218;Women;217 CANTABRIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;873 CANTABRIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;381 CANTABRIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;492 CANTABRIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;670 CANTABRIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;344 CANTABRIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;326 CANTABRIA;Group 0301 Anaemias 280-285;Both sexes;445 CANTABRIA;Group 0301 Anaemias 280-285;Men;212 CANTABRIA;Group 0301 Anaemias 280-285;Women;233 CANTABRIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;225 CANTABRIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;132 CANTABRIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;93 CANTABRIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.139 CANTABRIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;443 CANTABRIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;696 CANTABRIA;Group 0401 Diabetes mellitus 249-250;Both sexes;386 CANTABRIA;Group 0401 Diabetes mellitus 249-250;Men;206 CANTABRIA;Group 0401 Diabetes mellitus 249-250;Women;180 CANTABRIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;753 CANTABRIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;237 CANTABRIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;516 CANTABRIA;Group 0500 Mental disorders 290-319;Both sexes;1.088 CANTABRIA;Group 0500 Mental disorders 290-319;Men;531 CANTABRIA;Group 0500 Mental disorders 290-319;Women;557 CANTABRIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;88 CANTABRIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;40 CANTABRIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;48 CANTABRIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;120 CANTABRIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;93 CANTABRIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;27 CANTABRIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;55 CANTABRIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;34 CANTABRIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;21 CANTABRIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;267 CANTABRIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;122 CANTABRIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;145 CANTABRIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;212 CANTABRIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;82 CANTABRIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;130 CANTABRIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;346 CANTABRIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;160 CANTABRIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;186 CANTABRIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.225 CANTABRIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;592 CANTABRIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;633 CANTABRIA;Group 0601 Alzheimer's disease 3310;Both sexes;63 CANTABRIA;Group 0601 Alzheimer's disease 3310;Men;27 CANTABRIA;Group 0601 Alzheimer's disease 3310;Women;36 CANTABRIA;Group 0602 Multiple sclerosis 340;Both sexes;15 CANTABRIA;Group 0602 Multiple sclerosis 340;Men;4 CANTABRIA;Group 0602 Multiple sclerosis 340;Women;11 CANTABRIA;Group 0603 Epilepsy 345;Both sexes;183 CANTABRIA;Group 0603 Epilepsy 345;Men;107 CANTABRIA;Group 0603 Epilepsy 345;Women;76 CANTABRIA;Group 0604 Transient cerebral ischemia 435;Both sexes;180 CANTABRIA;Group 0604 Transient cerebral ischemia 435;Men;78 CANTABRIA;Group 0604 Transient cerebral ischemia 435;Women;102 CANTABRIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;784 CANTABRIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;376 CANTABRIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;408 CANTABRIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;183 CANTABRIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;102 CANTABRIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;81 CANTABRIA;Grupo 0701 Cataract 366;Both sexes;29 CANTABRIA;Grupo 0701 Cataract 366;Men;15 CANTABRIA;Grupo 0701 Cataract 366;Women;14 CANTABRIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;154 CANTABRIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;87 CANTABRIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;67 CANTABRIA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;234 CANTABRIA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;114 CANTABRIA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;120 CANTABRIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;8.378 CANTABRIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;4.927 CANTABRIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3.451 CANTABRIA;Group 0901 Hypertensive disease 401-405;Both sexes;494 CANTABRIA;Group 0901 Hypertensive disease 401-405;Men;234 CANTABRIA;Group 0901 Hypertensive disease 401-405;Women;260 CANTABRIA;Group 0902 Angina pectoris 4111, 413;Both sexes;379 CANTABRIA;Group 0902 Angina pectoris 4111, 413;Men;232 CANTABRIA;Group 0902 Angina pectoris 4111, 413;Women;147 CANTABRIA;Group 0903 Acute myocardial infarction 410;Both sexes;573 CANTABRIA;Group 0903 Acute myocardial infarction 410;Men;404 CANTABRIA;Group 0903 Acute myocardial infarction 410;Women;169 CANTABRIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;650 CANTABRIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;512 CANTABRIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;138 CANTABRIA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;272 CANTABRIA;Group 0905 Diseases of the lungs circulation 415-417;Men;110 CANTABRIA;Group 0905 Diseases of the lungs circulation 415-417;Women;162 CANTABRIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.180 CANTABRIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;677 CANTABRIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;503 CANTABRIA;Grupo 0907 Heart failure 428;Both sexes;1.463 CANTABRIA;Grupo 0907 Heart failure 428;Men;757 CANTABRIA;Grupo 0907 Heart failure 428;Women;706 CANTABRIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.366 CANTABRIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;696 CANTABRIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;670 CANTABRIA;Grupo 0909 Atherosclerosis 440;Both sexes;424 CANTABRIA;Grupo 0909 Atherosclerosis 440;Men;332 CANTABRIA;Grupo 0909 Atherosclerosis 440;Women;92 CANTABRIA;Group 0910 Varicose veins of lower extremities 454;Both sexes;44 CANTABRIA;Group 0910 Varicose veins of lower extremities 454;Men;20 CANTABRIA;Group 0910 Varicose veins of lower extremities 454;Women;24 CANTABRIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.533 CANTABRIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;953 CANTABRIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;580 CANTABRIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7.509 CANTABRIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.158 CANTABRIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.351 CANTABRIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;295 CANTABRIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;139 CANTABRIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;156 CANTABRIA;Group 1002 Pneumonia 480-486;Both sexes;1.474 CANTABRIA;Group 1002 Pneumonia 480-486;Men;864 CANTABRIA;Group 1002 Pneumonia 480-486;Women;610 CANTABRIA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;321 CANTABRIA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;144 CANTABRIA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;177 CANTABRIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;492 CANTABRIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;256 CANTABRIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;236 CANTABRIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;327 CANTABRIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;209 CANTABRIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;118 CANTABRIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.527 CANTABRIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.107 CANTABRIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;420 CANTABRIA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;530 CANTABRIA;Group 1007 Asthma 4930-4931,4938-4939;Men;193 CANTABRIA;Group 1007 Asthma 4930-4931,4938-4939;Women;337 CANTABRIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.543 CANTABRIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.246 CANTABRIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.297 CANTABRIA;Group 1100 Diseases of the digestive system 520-579;Both sexes;6.421 CANTABRIA;Group 1100 Diseases of the digestive system 520-579;Men;3.513 CANTABRIA;Group 1100 Diseases of the digestive system 520-579;Women;2.908 CANTABRIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;60 CANTABRIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;26 CANTABRIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;34 CANTABRIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;86 CANTABRIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;49 CANTABRIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;37 CANTABRIA;Group 1103 Diseases of the esophagus 530;Both sexes;117 CANTABRIA;Group 1103 Diseases of the esophagus 530;Men;64 CANTABRIA;Group 1103 Diseases of the esophagus 530;Women;53 CANTABRIA;Group 1104 Peptic ulcer 531-534;Both sexes;154 CANTABRIA;Group 1104 Peptic ulcer 531-534;Men;95 CANTABRIA;Group 1104 Peptic ulcer 531-534;Women;59 CANTABRIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;140 CANTABRIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;70 CANTABRIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;70 CANTABRIA;Group 1106 Appendicitis 540-543;Both sexes;610 CANTABRIA;Group 1106 Appendicitis 540-543;Men;358 CANTABRIA;Group 1106 Appendicitis 540-543;Women;252 CANTABRIA;Group 1107 Inguinal hernia 550;Both sexes;424 CANTABRIA;Group 1107 Inguinal hernia 550;Men;353 CANTABRIA;Group 1107 Inguinal hernia 550;Women;71 CANTABRIA;Group 1108 Other abdominal hernia 551-553;Both sexes;478 CANTABRIA;Group 1108 Other abdominal hernia 551-553;Men;225 CANTABRIA;Group 1108 Other abdominal hernia 551-553;Women;253 CANTABRIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;170 CANTABRIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;81 CANTABRIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;89 CANTABRIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;379 CANTABRIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;183 CANTABRIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;196 CANTABRIA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;330 CANTABRIA;Group 1111 Intestinal obstruction without hernia 560;Men;171 CANTABRIA;Group 1111 Intestinal obstruction without hernia 560;Women;159 CANTABRIA;Group 1112 Intestinal diverticulosis 562;Both sexes;319 CANTABRIA;Group 1112 Intestinal diverticulosis 562;Men;138 CANTABRIA;Group 1112 Intestinal diverticulosis 562;Women;181 CANTABRIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;261 CANTABRIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;163 CANTABRIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;98 CANTABRIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;238 CANTABRIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;95 CANTABRIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;143 CANTABRIA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;117 CANTABRIA;Group 1115 Alcoholic hepatitis 5710-5713;Men;89 CANTABRIA;Group 1115 Alcoholic hepatitis 5710-5713;Women;28 CANTABRIA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;193 CANTABRIA;Group 1116 Other diseases of the liver 570,5714-573;Men;124 CANTABRIA;Group 1116 Other diseases of the liver 570,5714-573;Women;69 CANTABRIA;Group 1117 Cholelithiasis 574;Both sexes;1.348 CANTABRIA;Group 1117 Cholelithiasis 574;Men;641 CANTABRIA;Group 1117 Cholelithiasis 574;Women;707 CANTABRIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;329 CANTABRIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;188 CANTABRIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;141 CANTABRIA;Group 1119 Pancreatic diseases 577;Both sexes;374 CANTABRIA;Group 1119 Pancreatic diseases 577;Men;223 CANTABRIA;Group 1119 Pancreatic diseases 577;Women;151 CANTABRIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;294 CANTABRIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;177 CANTABRIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;117 CANTABRIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;638 CANTABRIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;310 CANTABRIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;328 CANTABRIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;328 CANTABRIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;176 CANTABRIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;152 CANTABRIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;42 CANTABRIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;21 CANTABRIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;21 CANTABRIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;268 CANTABRIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;113 CANTABRIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;155 CANTABRIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4.649 CANTABRIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.215 CANTABRIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.434 CANTABRIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CANTABRIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CANTABRIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CANTABRIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CANTABRIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CANTABRIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CANTABRIA;Group 1303 Internal derangement of knee 717;Both sexes;419 CANTABRIA;Group 1303 Internal derangement of knee 717;Men;305 CANTABRIA;Group 1303 Internal derangement of knee 717;Women;114 CANTABRIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.198 CANTABRIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.047 CANTABRIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.151 CANTABRIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;105 CANTABRIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;39 CANTABRIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;66 CANTABRIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;98 CANTABRIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;41 CANTABRIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;57 CANTABRIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;204 CANTABRIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;101 CANTABRIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;103 CANTABRIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;23 CANTABRIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;12 CANTABRIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;11 CANTABRIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;588 CANTABRIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;309 CANTABRIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;279 CANTABRIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.014 CANTABRIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;361 CANTABRIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;653 CANTABRIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.386 CANTABRIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.625 CANTABRIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.761 CANTABRIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;251 CANTABRIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;101 CANTABRIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;150 CANTABRIA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;360 CANTABRIA;Group 1402 Renal failure 5836-5837, 584-586;Men;218 CANTABRIA;Group 1402 Renal failure 5836-5837, 584-586;Women;142 CANTABRIA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;390 CANTABRIA;Group 1403 Urolithiasis 592, 594, 7880;Men;245 CANTABRIA;Group 1403 Urolithiasis 592, 594, 7880;Women;145 CANTABRIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;975 CANTABRIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;420 CANTABRIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;555 CANTABRIA;Group 1405 Prostatic hyperplasia 600;Both sexes;268 CANTABRIA;Group 1405 Prostatic hyperplasia 600;Men;268 CANTABRIA;Group 1405 Prostatic hyperplasia 600;Women;.. CANTABRIA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;364 CANTABRIA;Group 1406 Other diseases of the male genital organs 601-608;Men;364 CANTABRIA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CANTABRIA;Group 1407 Disorders of breast 610-612;Both sexes;97 CANTABRIA;Group 1407 Disorders of breast 610-612;Men;9 CANTABRIA;Group 1407 Disorders of breast 610-612;Women;88 CANTABRIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;124 CANTABRIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CANTABRIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;124 CANTABRIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;74 CANTABRIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CANTABRIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;74 CANTABRIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;483 CANTABRIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. CANTABRIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;483 CANTABRIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.054 CANTABRIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CANTABRIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.054 CANTABRIA;Group 1501 Legally induced abortion 635;Both sexes;2 CANTABRIA;Group 1501 Legally induced abortion 635;Men;.. CANTABRIA;Group 1501 Legally induced abortion 635;Women;2 CANTABRIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;495 CANTABRIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CANTABRIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;495 CANTABRIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.444 CANTABRIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CANTABRIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.444 CANTABRIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;545 CANTABRIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CANTABRIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;545 CANTABRIA;Group 1505 Single spontaneous delivery 650;Both sexes;84 CANTABRIA;Group 1505 Single spontaneous delivery 650;Men;.. CANTABRIA;Group 1505 Single spontaneous delivery 650;Women;84 CANTABRIA;Group 1506 Other deliveries 6695-6697;Both sexes;47 CANTABRIA;Group 1506 Other deliveries 6695-6697;Men;.. CANTABRIA;Group 1506 Other deliveries 6695-6697;Women;47 CANTABRIA;Group 1507 Complications related to the puerperium 670-676;Both sexes;86 CANTABRIA;Group 1507 Complications related to the puerperium 670-676;Men;.. CANTABRIA;Group 1507 Complications related to the puerperium 670-676;Women;86 CANTABRIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;351 CANTABRIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CANTABRIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;351 CANTABRIA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;773 CANTABRIA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;402 CANTABRIA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;371 CANTABRIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;138 CANTABRIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;67 CANTABRIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;71 CANTABRIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;635 CANTABRIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;335 CANTABRIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;300 CANTABRIA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;459 CANTABRIA;Grupo 1700 Congenital abnormalities 740-759;Men;299 CANTABRIA;Grupo 1700 Congenital abnormalities 740-759;Women;160 CANTABRIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.607 CANTABRIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.831 CANTABRIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.776 CANTABRIA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;270 CANTABRIA;Group 1801 Pain in throat and chest 7841, 7865;Men;150 CANTABRIA;Group 1801 Pain in throat and chest 7841, 7865;Women;120 CANTABRIA;Group 1802 Abdominal pain 7890;Both sexes;179 CANTABRIA;Group 1802 Abdominal pain 7890;Men;73 CANTABRIA;Group 1802 Abdominal pain 7890;Women;106 CANTABRIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.451 CANTABRIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;673 CANTABRIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;778 CANTABRIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.707 CANTABRIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;935 CANTABRIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;772 CANTABRIA;Group 1900 Injuries and poisoning 800-999;Both sexes;6.931 CANTABRIA;Group 1900 Injuries and poisoning 800-999;Men;3.641 CANTABRIA;Group 1900 Injuries and poisoning 800-999;Women;3.290 CANTABRIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;360 CANTABRIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;205 CANTABRIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;155 CANTABRIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;130 CANTABRIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;93 CANTABRIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;37 CANTABRIA;Group 1903 Radius and ulna fracture 813;Both sexes;458 CANTABRIA;Group 1903 Radius and ulna fracture 813;Men;164 CANTABRIA;Group 1903 Radius and ulna fracture 813;Women;294 CANTABRIA;Group 1904 Femur fracture 820-821;Both sexes;867 CANTABRIA;Group 1904 Femur fracture 820-821;Men;239 CANTABRIA;Group 1904 Femur fracture 820-821;Women;628 CANTABRIA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;503 CANTABRIA;Group 1905 Leg fracture, including the ankle 823-824;Men;259 CANTABRIA;Group 1905 Leg fracture, including the ankle 823-824;Women;244 CANTABRIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.860 CANTABRIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.211 CANTABRIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;649 CANTABRIA;Group 1907 Burns 940-949;Both sexes;29 CANTABRIA;Group 1907 Burns 940-949;Men;13 CANTABRIA;Group 1907 Burns 940-949;Women;16 CANTABRIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;133 CANTABRIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;73 CANTABRIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;60 CANTABRIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.093 CANTABRIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.177 CANTABRIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;916 CANTABRIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;24 CANTABRIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;19 CANTABRIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 CANTABRIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;474 CANTABRIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;188 CANTABRIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;286 CANTABRIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.118 CANTABRIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;668 CANTABRIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;450 CANTABRIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;55 CANTABRIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;32 CANTABRIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;23 CANTABRIA;Group 2102 Contraceptive management V25;Both sexes;12 CANTABRIA;Group 2102 Contraceptive management V25;Men;.. CANTABRIA;Group 2102 Contraceptive management V25;Women;12 CANTABRIA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CANTABRIA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CANTABRIA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CANTABRIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;515 CANTABRIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;355 CANTABRIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;160 CANTABRIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;536 CANTABRIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;281 CANTABRIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;255 CASTILLA Y LEËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;268.958 CASTILLA Y LEËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;135.531 CASTILLA Y LEËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;133.427 CASTILLA Y LEËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;6.617 CASTILLA Y LEËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;3.682 CASTILLA Y LEËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2.935 CASTILLA Y LEËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1.321 CASTILLA Y LEËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;699 CASTILLA Y LEËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;622 CASTILLA Y LEËN;Group 0102 Imprecise intestinal infections 009;Both sexes;411 CASTILLA Y LEËN;Group 0102 Imprecise intestinal infections 009;Men;199 CASTILLA Y LEËN;Group 0102 Imprecise intestinal infections 009;Women;212 CASTILLA Y LEËN;Group 0103 Tuberculosis 010-018, 137;Both sexes;206 CASTILLA Y LEËN;Group 0103 Tuberculosis 010-018, 137;Men;126 CASTILLA Y LEËN;Group 0103 Tuberculosis 010-018, 137;Women;80 CASTILLA Y LEËN;Group 0104 Septicaemia 038;Both sexes;3.085 CASTILLA Y LEËN;Group 0104 Septicaemia 038;Men;1.753 CASTILLA Y LEËN;Group 0104 Septicaemia 038;Women;1.332 CASTILLA Y LEËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;86 CASTILLA Y LEËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;62 CASTILLA Y LEËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;24 CASTILLA Y LEËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.508 CASTILLA Y LEËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;843 CASTILLA Y LEËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;665 CASTILLA Y LEËN;Group 0200 Neoplasms 140-239;Both sexes;27.750 CASTILLA Y LEËN;Group 0200 Neoplasms 140-239;Men;15.289 CASTILLA Y LEËN;Group 0200 Neoplasms 140-239;Women;12.461 CASTILLA Y LEËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;3.460 CASTILLA Y LEËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;2.203 CASTILLA Y LEËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;1.257 CASTILLA Y LEËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.994 CASTILLA Y LEËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1.586 CASTILLA Y LEËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;408 CASTILLA Y LEËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;626 CASTILLA Y LEËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;338 CASTILLA Y LEËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;288 CASTILLA Y LEËN;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.746 CASTILLA Y LEËN;Group 0204 Malignant neoplasm of breast 174-175;Men;14 CASTILLA Y LEËN;Group 0204 Malignant neoplasm of breast 174-175;Women;1.732 CASTILLA Y LEËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;471 CASTILLA Y LEËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CASTILLA Y LEËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;471 CASTILLA Y LEËN;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;298 CASTILLA Y LEËN;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CASTILLA Y LEËN;Group 0206 Malignant neoplasm of ovary 1830;Women;298 CASTILLA Y LEËN;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.068 CASTILLA Y LEËN;Group 0207 Malignant neoplasm of prostate 185;Men;1.068 CASTILLA Y LEËN;Group 0207 Malignant neoplasm of prostate 185;Women;.. CASTILLA Y LEËN;Group 0208 Malignant neoplasm of bladder 188;Both sexes;2.446 CASTILLA Y LEËN;Group 0208 Malignant neoplasm of bladder 188;Men;2.096 CASTILLA Y LEËN;Group 0208 Malignant neoplasm of bladder 188;Women;350 CASTILLA Y LEËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;9.853 CASTILLA Y LEËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;5.783 CASTILLA Y LEËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;4.070 CASTILLA Y LEËN;Group 0210 Carcinoma in situ 230-234;Both sexes;443 CASTILLA Y LEËN;Group 0210 Carcinoma in situ 230-234;Men;162 CASTILLA Y LEËN;Group 0210 Carcinoma in situ 230-234;Women;281 CASTILLA Y LEËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;288 CASTILLA Y LEËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;180 CASTILLA Y LEËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;108 CASTILLA Y LEËN;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1.048 CASTILLA Y LEËN;Grupo 0212 Leiomyoma of uterus 218;Men;.. CASTILLA Y LEËN;Grupo 0212 Leiomyoma of uterus 218;Women;1.048 CASTILLA Y LEËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;4.009 CASTILLA Y LEËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.859 CASTILLA Y LEËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;2.150 CASTILLA Y LEËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2.468 CASTILLA Y LEËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1.255 CASTILLA Y LEËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1.213 CASTILLA Y LEËN;Group 0301 Anaemias 280-285;Both sexes;1.603 CASTILLA Y LEËN;Group 0301 Anaemias 280-285;Men;782 CASTILLA Y LEËN;Group 0301 Anaemias 280-285;Women;821 CASTILLA Y LEËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;865 CASTILLA Y LEËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;473 CASTILLA Y LEËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;392 CASTILLA Y LEËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;5.013 CASTILLA Y LEËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;2.108 CASTILLA Y LEËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2.905 CASTILLA Y LEËN;Group 0401 Diabetes mellitus 249-250;Both sexes;1.741 CASTILLA Y LEËN;Group 0401 Diabetes mellitus 249-250;Men;970 CASTILLA Y LEËN;Group 0401 Diabetes mellitus 249-250;Women;771 CASTILLA Y LEËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;3.272 CASTILLA Y LEËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;1.138 CASTILLA Y LEËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;2.134 CASTILLA Y LEËN;Group 0500 Mental disorders 290-319;Both sexes;6.269 CASTILLA Y LEËN;Group 0500 Mental disorders 290-319;Men;3.177 CASTILLA Y LEËN;Group 0500 Mental disorders 290-319;Women;3.092 CASTILLA Y LEËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;208 CASTILLA Y LEËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;102 CASTILLA Y LEËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;106 CASTILLA Y LEËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;499 CASTILLA Y LEËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;386 CASTILLA Y LEËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;113 CASTILLA Y LEËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;439 CASTILLA Y LEËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;350 CASTILLA Y LEËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;89 CASTILLA Y LEËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.611 CASTILLA Y LEËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;926 CASTILLA Y LEËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;685 CASTILLA Y LEËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1.582 CASTILLA Y LEËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;525 CASTILLA Y LEËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;1.057 CASTILLA Y LEËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.930 CASTILLA Y LEËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;888 CASTILLA Y LEËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1.042 CASTILLA Y LEËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5.062 CASTILLA Y LEËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.401 CASTILLA Y LEËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.661 CASTILLA Y LEËN;Group 0601 Alzheimer's disease 3310;Both sexes;141 CASTILLA Y LEËN;Group 0601 Alzheimer's disease 3310;Men;48 CASTILLA Y LEËN;Group 0601 Alzheimer's disease 3310;Women;93 CASTILLA Y LEËN;Group 0602 Multiple sclerosis 340;Both sexes;155 CASTILLA Y LEËN;Group 0602 Multiple sclerosis 340;Men;64 CASTILLA Y LEËN;Group 0602 Multiple sclerosis 340;Women;91 CASTILLA Y LEËN;Group 0603 Epilepsy 345;Both sexes;802 CASTILLA Y LEËN;Group 0603 Epilepsy 345;Men;455 CASTILLA Y LEËN;Group 0603 Epilepsy 345;Women;347 CASTILLA Y LEËN;Group 0604 Transient cerebral ischemia 435;Both sexes;923 CASTILLA Y LEËN;Group 0604 Transient cerebral ischemia 435;Men;422 CASTILLA Y LEËN;Group 0604 Transient cerebral ischemia 435;Women;501 CASTILLA Y LEËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.041 CASTILLA Y LEËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.412 CASTILLA Y LEËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.629 CASTILLA Y LEËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.939 CASTILLA Y LEËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;976 CASTILLA Y LEËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;963 CASTILLA Y LEËN;Grupo 0701 Cataract 366;Both sexes;380 CASTILLA Y LEËN;Grupo 0701 Cataract 366;Men;178 CASTILLA Y LEËN;Grupo 0701 Cataract 366;Women;202 CASTILLA Y LEËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1.559 CASTILLA Y LEËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;798 CASTILLA Y LEËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;761 CASTILLA Y LEËN;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1.719 CASTILLA Y LEËN;Group 0800 Diseases of the ear and the mastoid 380-389;Men;859 CASTILLA Y LEËN;Group 0800 Diseases of the ear and the mastoid 380-389;Women;860 CASTILLA Y LEËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;37.147 CASTILLA Y LEËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;20.818 CASTILLA Y LEËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;16.329 CASTILLA Y LEËN;Group 0901 Hypertensive disease 401-405;Both sexes;2.036 CASTILLA Y LEËN;Group 0901 Hypertensive disease 401-405;Men;812 CASTILLA Y LEËN;Group 0901 Hypertensive disease 401-405;Women;1.224 CASTILLA Y LEËN;Group 0902 Angina pectoris 4111, 413;Both sexes;1.232 CASTILLA Y LEËN;Group 0902 Angina pectoris 4111, 413;Men;838 CASTILLA Y LEËN;Group 0902 Angina pectoris 4111, 413;Women;394 CASTILLA Y LEËN;Group 0903 Acute myocardial infarction 410;Both sexes;3.447 CASTILLA Y LEËN;Group 0903 Acute myocardial infarction 410;Men;2.472 CASTILLA Y LEËN;Group 0903 Acute myocardial infarction 410;Women;975 CASTILLA Y LEËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.704 CASTILLA Y LEËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.307 CASTILLA Y LEËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;397 CASTILLA Y LEËN;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1.657 CASTILLA Y LEËN;Group 0905 Diseases of the lungs circulation 415-417;Men;781 CASTILLA Y LEËN;Group 0905 Diseases of the lungs circulation 415-417;Women;876 CASTILLA Y LEËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4.826 CASTILLA Y LEËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2.665 CASTILLA Y LEËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;2.161 CASTILLA Y LEËN;Grupo 0907 Heart failure 428;Both sexes;8.294 CASTILLA Y LEËN;Grupo 0907 Heart failure 428;Men;4.002 CASTILLA Y LEËN;Grupo 0907 Heart failure 428;Women;4.292 CASTILLA Y LEËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;5.883 CASTILLA Y LEËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;3.147 CASTILLA Y LEËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2.736 CASTILLA Y LEËN;Grupo 0909 Atherosclerosis 440;Both sexes;1.129 CASTILLA Y LEËN;Grupo 0909 Atherosclerosis 440;Men;852 CASTILLA Y LEËN;Grupo 0909 Atherosclerosis 440;Women;277 CASTILLA Y LEËN;Group 0910 Varicose veins of lower extremities 454;Both sexes;982 CASTILLA Y LEËN;Group 0910 Varicose veins of lower extremities 454;Men;380 CASTILLA Y LEËN;Group 0910 Varicose veins of lower extremities 454;Women;602 CASTILLA Y LEËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;5.957 CASTILLA Y LEËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;3.562 CASTILLA Y LEËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2.395 CASTILLA Y LEËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;36.005 CASTILLA Y LEËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;20.967 CASTILLA Y LEËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;15.038 CASTILLA Y LEËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.585 CASTILLA Y LEËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;825 CASTILLA Y LEËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;760 CASTILLA Y LEËN;Group 1002 Pneumonia 480-486;Both sexes;7.916 CASTILLA Y LEËN;Group 1002 Pneumonia 480-486;Men;4.841 CASTILLA Y LEËN;Group 1002 Pneumonia 480-486;Women;3.075 CASTILLA Y LEËN;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.733 CASTILLA Y LEËN;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.213 CASTILLA Y LEËN;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.520 CASTILLA Y LEËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1.935 CASTILLA Y LEËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.028 CASTILLA Y LEËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;907 CASTILLA Y LEËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;3.380 CASTILLA Y LEËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;2.224 CASTILLA Y LEËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;1.156 CASTILLA Y LEËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;5.671 CASTILLA Y LEËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;4.554 CASTILLA Y LEËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1.117 CASTILLA Y LEËN;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.372 CASTILLA Y LEËN;Group 1007 Asthma 4930-4931,4938-4939;Men;415 CASTILLA Y LEËN;Group 1007 Asthma 4930-4931,4938-4939;Women;957 CASTILLA Y LEËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;11.413 CASTILLA Y LEËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;5.867 CASTILLA Y LEËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;5.546 CASTILLA Y LEËN;Group 1100 Diseases of the digestive system 520-579;Both sexes;35.833 CASTILLA Y LEËN;Group 1100 Diseases of the digestive system 520-579;Men;21.320 CASTILLA Y LEËN;Group 1100 Diseases of the digestive system 520-579;Women;14.513 CASTILLA Y LEËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;412 CASTILLA Y LEËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;206 CASTILLA Y LEËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;206 CASTILLA Y LEËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;455 CASTILLA Y LEËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;266 CASTILLA Y LEËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;189 CASTILLA Y LEËN;Group 1103 Diseases of the esophagus 530;Both sexes;603 CASTILLA Y LEËN;Group 1103 Diseases of the esophagus 530;Men;381 CASTILLA Y LEËN;Group 1103 Diseases of the esophagus 530;Women;222 CASTILLA Y LEËN;Group 1104 Peptic ulcer 531-534;Both sexes;730 CASTILLA Y LEËN;Group 1104 Peptic ulcer 531-534;Men;468 CASTILLA Y LEËN;Group 1104 Peptic ulcer 531-534;Women;262 CASTILLA Y LEËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;863 CASTILLA Y LEËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;456 CASTILLA Y LEËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;407 CASTILLA Y LEËN;Group 1106 Appendicitis 540-543;Both sexes;2.588 CASTILLA Y LEËN;Group 1106 Appendicitis 540-543;Men;1.483 CASTILLA Y LEËN;Group 1106 Appendicitis 540-543;Women;1.105 CASTILLA Y LEËN;Group 1107 Inguinal hernia 550;Both sexes;5.530 CASTILLA Y LEËN;Group 1107 Inguinal hernia 550;Men;4.971 CASTILLA Y LEËN;Group 1107 Inguinal hernia 550;Women;559 CASTILLA Y LEËN;Group 1108 Other abdominal hernia 551-553;Both sexes;2.780 CASTILLA Y LEËN;Group 1108 Other abdominal hernia 551-553;Men;1.508 CASTILLA Y LEËN;Group 1108 Other abdominal hernia 551-553;Women;1.272 CASTILLA Y LEËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;526 CASTILLA Y LEËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;275 CASTILLA Y LEËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;251 CASTILLA Y LEËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;2.210 CASTILLA Y LEËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1.042 CASTILLA Y LEËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;1.168 CASTILLA Y LEËN;Group 1111 Intestinal obstruction without hernia 560;Both sexes;2.019 CASTILLA Y LEËN;Group 1111 Intestinal obstruction without hernia 560;Men;1.069 CASTILLA Y LEËN;Group 1111 Intestinal obstruction without hernia 560;Women;950 CASTILLA Y LEËN;Group 1112 Intestinal diverticulosis 562;Both sexes;1.491 CASTILLA Y LEËN;Group 1112 Intestinal diverticulosis 562;Men;712 CASTILLA Y LEËN;Group 1112 Intestinal diverticulosis 562;Women;779 CASTILLA Y LEËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.882 CASTILLA Y LEËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1.238 CASTILLA Y LEËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;644 CASTILLA Y LEËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;1.403 CASTILLA Y LEËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;661 CASTILLA Y LEËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;742 CASTILLA Y LEËN;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;590 CASTILLA Y LEËN;Group 1115 Alcoholic hepatitis 5710-5713;Men;511 CASTILLA Y LEËN;Group 1115 Alcoholic hepatitis 5710-5713;Women;79 CASTILLA Y LEËN;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1.062 CASTILLA Y LEËN;Group 1116 Other diseases of the liver 570,5714-573;Men;651 CASTILLA Y LEËN;Group 1116 Other diseases of the liver 570,5714-573;Women;411 CASTILLA Y LEËN;Group 1117 Cholelithiasis 574;Both sexes;6.003 CASTILLA Y LEËN;Group 1117 Cholelithiasis 574;Men;2.818 CASTILLA Y LEËN;Group 1117 Cholelithiasis 574;Women;3.185 CASTILLA Y LEËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.575 CASTILLA Y LEËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;907 CASTILLA Y LEËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;668 CASTILLA Y LEËN;Group 1119 Pancreatic diseases 577;Both sexes;1.499 CASTILLA Y LEËN;Group 1119 Pancreatic diseases 577;Men;838 CASTILLA Y LEËN;Group 1119 Pancreatic diseases 577;Women;661 CASTILLA Y LEËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1.612 CASTILLA Y LEËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;859 CASTILLA Y LEËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;753 CASTILLA Y LEËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2.951 CASTILLA Y LEËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1.644 CASTILLA Y LEËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1.307 CASTILLA Y LEËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.682 CASTILLA Y LEËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1.014 CASTILLA Y LEËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;668 CASTILLA Y LEËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;121 CASTILLA Y LEËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;57 CASTILLA Y LEËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;64 CASTILLA Y LEËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;1.148 CASTILLA Y LEËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;573 CASTILLA Y LEËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;575 CASTILLA Y LEËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;16.357 CASTILLA Y LEËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;7.924 CASTILLA Y LEËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;8.433 CASTILLA Y LEËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA Y LEËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CASTILLA Y LEËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CASTILLA Y LEËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA Y LEËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CASTILLA Y LEËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CASTILLA Y LEËN;Group 1303 Internal derangement of knee 717;Both sexes;1.899 CASTILLA Y LEËN;Group 1303 Internal derangement of knee 717;Men;1.280 CASTILLA Y LEËN;Group 1303 Internal derangement of knee 717;Women;619 CASTILLA Y LEËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;6.512 CASTILLA Y LEËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;3.035 CASTILLA Y LEËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;3.477 CASTILLA Y LEËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;426 CASTILLA Y LEËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;139 CASTILLA Y LEËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;287 CASTILLA Y LEËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;770 CASTILLA Y LEËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;403 CASTILLA Y LEËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;367 CASTILLA Y LEËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.306 CASTILLA Y LEËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;673 CASTILLA Y LEËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;633 CASTILLA Y LEËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;567 CASTILLA Y LEËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;268 CASTILLA Y LEËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;299 CASTILLA Y LEËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;2.270 CASTILLA Y LEËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.276 CASTILLA Y LEËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;994 CASTILLA Y LEËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;2.607 CASTILLA Y LEËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;850 CASTILLA Y LEËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.757 CASTILLA Y LEËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;17.260 CASTILLA Y LEËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;8.596 CASTILLA Y LEËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;8.664 CASTILLA Y LEËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.224 CASTILLA Y LEËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;494 CASTILLA Y LEËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;730 CASTILLA Y LEËN;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.590 CASTILLA Y LEËN;Group 1402 Renal failure 5836-5837, 584-586;Men;963 CASTILLA Y LEËN;Group 1402 Renal failure 5836-5837, 584-586;Women;627 CASTILLA Y LEËN;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;2.380 CASTILLA Y LEËN;Group 1403 Urolithiasis 592, 594, 7880;Men;1.386 CASTILLA Y LEËN;Group 1403 Urolithiasis 592, 594, 7880;Women;994 CASTILLA Y LEËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;5.612 CASTILLA Y LEËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2.822 CASTILLA Y LEËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2.790 CASTILLA Y LEËN;Group 1405 Prostatic hyperplasia 600;Both sexes;1.489 CASTILLA Y LEËN;Group 1405 Prostatic hyperplasia 600;Men;1.489 CASTILLA Y LEËN;Group 1405 Prostatic hyperplasia 600;Women;.. CASTILLA Y LEËN;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;1.350 CASTILLA Y LEËN;Group 1406 Other diseases of the male genital organs 601-608;Men;1.350 CASTILLA Y LEËN;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CASTILLA Y LEËN;Group 1407 Disorders of breast 610-612;Both sexes;631 CASTILLA Y LEËN;Group 1407 Disorders of breast 610-612;Men;65 CASTILLA Y LEËN;Group 1407 Disorders of breast 610-612;Women;566 CASTILLA Y LEËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;410 CASTILLA Y LEËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CASTILLA Y LEËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;410 CASTILLA Y LEËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;266 CASTILLA Y LEËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CASTILLA Y LEËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;266 CASTILLA Y LEËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2.308 CASTILLA Y LEËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;27 CASTILLA Y LEËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2.281 CASTILLA Y LEËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;19.867 CASTILLA Y LEËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CASTILLA Y LEËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;19.867 CASTILLA Y LEËN;Group 1501 Legally induced abortion 635;Both sexes;11 CASTILLA Y LEËN;Group 1501 Legally induced abortion 635;Men;.. CASTILLA Y LEËN;Group 1501 Legally induced abortion 635;Women;11 CASTILLA Y LEËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.342 CASTILLA Y LEËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CASTILLA Y LEËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.342 CASTILLA Y LEËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;11.713 CASTILLA Y LEËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CASTILLA Y LEËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;11.713 CASTILLA Y LEËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.390 CASTILLA Y LEËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CASTILLA Y LEËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.390 CASTILLA Y LEËN;Group 1505 Single spontaneous delivery 650;Both sexes;1.312 CASTILLA Y LEËN;Group 1505 Single spontaneous delivery 650;Men;.. CASTILLA Y LEËN;Group 1505 Single spontaneous delivery 650;Women;1.312 CASTILLA Y LEËN;Group 1506 Other deliveries 6695-6697;Both sexes;766 CASTILLA Y LEËN;Group 1506 Other deliveries 6695-6697;Men;.. CASTILLA Y LEËN;Group 1506 Other deliveries 6695-6697;Women;766 CASTILLA Y LEËN;Group 1507 Complications related to the puerperium 670-676;Both sexes;156 CASTILLA Y LEËN;Group 1507 Complications related to the puerperium 670-676;Men;.. CASTILLA Y LEËN;Group 1507 Complications related to the puerperium 670-676;Women;156 CASTILLA Y LEËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.177 CASTILLA Y LEËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CASTILLA Y LEËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.177 CASTILLA Y LEËN;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.837 CASTILLA Y LEËN;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.537 CASTILLA Y LEËN;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.300 CASTILLA Y LEËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;595 CASTILLA Y LEËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;301 CASTILLA Y LEËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;294 CASTILLA Y LEËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2.242 CASTILLA Y LEËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.236 CASTILLA Y LEËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;1.006 CASTILLA Y LEËN;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.485 CASTILLA Y LEËN;Grupo 1700 Congenital abnormalities 740-759;Men;874 CASTILLA Y LEËN;Grupo 1700 Congenital abnormalities 740-759;Women;611 CASTILLA Y LEËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;12.951 CASTILLA Y LEËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;7.148 CASTILLA Y LEËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;5.803 CASTILLA Y LEËN;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.204 CASTILLA Y LEËN;Group 1801 Pain in throat and chest 7841, 7865;Men;748 CASTILLA Y LEËN;Group 1801 Pain in throat and chest 7841, 7865;Women;456 CASTILLA Y LEËN;Group 1802 Abdominal pain 7890;Both sexes;1.414 CASTILLA Y LEËN;Group 1802 Abdominal pain 7890;Men;599 CASTILLA Y LEËN;Group 1802 Abdominal pain 7890;Women;815 CASTILLA Y LEËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;2.172 CASTILLA Y LEËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1.205 CASTILLA Y LEËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;967 CASTILLA Y LEËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;8.161 CASTILLA Y LEËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4.596 CASTILLA Y LEËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3.565 CASTILLA Y LEËN;Group 1900 Injuries and poisoning 800-999;Both sexes;24.129 CASTILLA Y LEËN;Group 1900 Injuries and poisoning 800-999;Men;12.146 CASTILLA Y LEËN;Group 1900 Injuries and poisoning 800-999;Women;11.983 CASTILLA Y LEËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.440 CASTILLA Y LEËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;814 CASTILLA Y LEËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;626 CASTILLA Y LEËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;728 CASTILLA Y LEËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;499 CASTILLA Y LEËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;229 CASTILLA Y LEËN;Group 1903 Radius and ulna fracture 813;Both sexes;1.132 CASTILLA Y LEËN;Group 1903 Radius and ulna fracture 813;Men;512 CASTILLA Y LEËN;Group 1903 Radius and ulna fracture 813;Women;620 CASTILLA Y LEËN;Group 1904 Femur fracture 820-821;Both sexes;4.591 CASTILLA Y LEËN;Group 1904 Femur fracture 820-821;Men;1.180 CASTILLA Y LEËN;Group 1904 Femur fracture 820-821;Women;3.411 CASTILLA Y LEËN;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.455 CASTILLA Y LEËN;Group 1905 Leg fracture, including the ankle 823-824;Men;713 CASTILLA Y LEËN;Group 1905 Leg fracture, including the ankle 823-824;Women;742 CASTILLA Y LEËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;6.656 CASTILLA Y LEËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;3.993 CASTILLA Y LEËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.663 CASTILLA Y LEËN;Group 1907 Burns 940-949;Both sexes;184 CASTILLA Y LEËN;Group 1907 Burns 940-949;Men;113 CASTILLA Y LEËN;Group 1907 Burns 940-949;Women;71 CASTILLA Y LEËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;708 CASTILLA Y LEËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;341 CASTILLA Y LEËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;367 CASTILLA Y LEËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;6.462 CASTILLA Y LEËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;3.590 CASTILLA Y LEËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;2.872 CASTILLA Y LEËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;33 CASTILLA Y LEËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;22 CASTILLA Y LEËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;11 CASTILLA Y LEËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;740 CASTILLA Y LEËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;369 CASTILLA Y LEËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;371 CASTILLA Y LEËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;5.299 CASTILLA Y LEËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;2.810 CASTILLA Y LEËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2.489 CASTILLA Y LEËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;160 CASTILLA Y LEËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;98 CASTILLA Y LEËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;62 CASTILLA Y LEËN;Group 2102 Contraceptive management V25;Both sexes;123 CASTILLA Y LEËN;Group 2102 Contraceptive management V25;Men;5 CASTILLA Y LEËN;Group 2102 Contraceptive management V25;Women;118 CASTILLA Y LEËN;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CASTILLA Y LEËN;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CASTILLA Y LEËN;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CASTILLA Y LEËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;2.346 CASTILLA Y LEËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1.406 CASTILLA Y LEËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;940 CASTILLA Y LEËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2.670 CASTILLA Y LEËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.301 CASTILLA Y LEËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.369 ┴vila;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;14.708 ┴vila;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;7.482 ┴vila;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;7.226 ┴vila;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;411 ┴vila;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;218 ┴vila;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;193 ┴vila;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;126 ┴vila;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;56 ┴vila;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;70 ┴vila;Group 0102 Imprecise intestinal infections 009;Both sexes;13 ┴vila;Group 0102 Imprecise intestinal infections 009;Men;3 ┴vila;Group 0102 Imprecise intestinal infections 009;Women;10 ┴vila;Group 0103 Tuberculosis 010-018, 137;Both sexes;7 ┴vila;Group 0103 Tuberculosis 010-018, 137;Men;3 ┴vila;Group 0103 Tuberculosis 010-018, 137;Women;4 ┴vila;Group 0104 Septicaemia 038;Both sexes;165 ┴vila;Group 0104 Septicaemia 038;Men;96 ┴vila;Group 0104 Septicaemia 038;Women;69 ┴vila;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;8 ┴vila;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;5 ┴vila;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 ┴vila;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;92 ┴vila;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;55 ┴vila;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;37 ┴vila;Group 0200 Neoplasms 140-239;Both sexes;1.338 ┴vila;Group 0200 Neoplasms 140-239;Men;738 ┴vila;Group 0200 Neoplasms 140-239;Women;600 ┴vila;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;188 ┴vila;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;112 ┴vila;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;76 ┴vila;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;94 ┴vila;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;85 ┴vila;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;9 ┴vila;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;45 ┴vila;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;26 ┴vila;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;19 ┴vila;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;113 ┴vila;Group 0204 Malignant neoplasm of breast 174-175;Men;.. ┴vila;Group 0204 Malignant neoplasm of breast 174-175;Women;113 ┴vila;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;38 ┴vila;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ┴vila;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;38 ┴vila;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;16 ┴vila;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ┴vila;Group 0206 Malignant neoplasm of ovary 1830;Women;16 ┴vila;Group 0207 Malignant neoplasm of prostate 185;Both sexes;68 ┴vila;Group 0207 Malignant neoplasm of prostate 185;Men;68 ┴vila;Group 0207 Malignant neoplasm of prostate 185;Women;.. ┴vila;Group 0208 Malignant neoplasm of bladder 188;Both sexes;126 ┴vila;Group 0208 Malignant neoplasm of bladder 188;Men;104 ┴vila;Group 0208 Malignant neoplasm of bladder 188;Women;22 ┴vila;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;432 ┴vila;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;286 ┴vila;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;146 ┴vila;Group 0210 Carcinoma in situ 230-234;Both sexes;16 ┴vila;Group 0210 Carcinoma in situ 230-234;Men;9 ┴vila;Group 0210 Carcinoma in situ 230-234;Women;7 ┴vila;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;16 ┴vila;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;10 ┴vila;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;6 ┴vila;Grupo 0212 Leiomyoma of uterus 218;Both sexes;54 ┴vila;Grupo 0212 Leiomyoma of uterus 218;Men;.. ┴vila;Grupo 0212 Leiomyoma of uterus 218;Women;54 ┴vila;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;132 ┴vila;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;38 ┴vila;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;94 ┴vila;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;115 ┴vila;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;62 ┴vila;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;53 ┴vila;Group 0301 Anaemias 280-285;Both sexes;69 ┴vila;Group 0301 Anaemias 280-285;Men;32 ┴vila;Group 0301 Anaemias 280-285;Women;37 ┴vila;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;46 ┴vila;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;30 ┴vila;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;16 ┴vila;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;315 ┴vila;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;121 ┴vila;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;194 ┴vila;Group 0401 Diabetes mellitus 249-250;Both sexes;97 ┴vila;Group 0401 Diabetes mellitus 249-250;Men;56 ┴vila;Group 0401 Diabetes mellitus 249-250;Women;41 ┴vila;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;218 ┴vila;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;65 ┴vila;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;153 ┴vila;Group 0500 Mental disorders 290-319;Both sexes;345 ┴vila;Group 0500 Mental disorders 290-319;Men;155 ┴vila;Group 0500 Mental disorders 290-319;Women;190 ┴vila;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;7 ┴vila;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;4 ┴vila;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;3 ┴vila;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;18 ┴vila;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;11 ┴vila;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;7 ┴vila;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;12 ┴vila;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;7 ┴vila;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;5 ┴vila;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;79 ┴vila;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;47 ┴vila;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;32 ┴vila;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;90 ┴vila;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;33 ┴vila;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;57 ┴vila;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;139 ┴vila;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;53 ┴vila;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;86 ┴vila;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;264 ┴vila;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;119 ┴vila;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;145 ┴vila;Group 0601 Alzheimer's disease 3310;Both sexes;4 ┴vila;Group 0601 Alzheimer's disease 3310;Men;.. ┴vila;Group 0601 Alzheimer's disease 3310;Women;4 ┴vila;Group 0602 Multiple sclerosis 340;Both sexes;2 ┴vila;Group 0602 Multiple sclerosis 340;Men;.. ┴vila;Group 0602 Multiple sclerosis 340;Women;2 ┴vila;Group 0603 Epilepsy 345;Both sexes;53 ┴vila;Group 0603 Epilepsy 345;Men;28 ┴vila;Group 0603 Epilepsy 345;Women;25 ┴vila;Group 0604 Transient cerebral ischemia 435;Both sexes;54 ┴vila;Group 0604 Transient cerebral ischemia 435;Men;18 ┴vila;Group 0604 Transient cerebral ischemia 435;Women;36 ┴vila;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;151 ┴vila;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;73 ┴vila;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;78 ┴vila;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;77 ┴vila;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;51 ┴vila;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;26 ┴vila;Grupo 0701 Cataract 366;Both sexes;15 ┴vila;Grupo 0701 Cataract 366;Men;9 ┴vila;Grupo 0701 Cataract 366;Women;6 ┴vila;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;62 ┴vila;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;42 ┴vila;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;20 ┴vila;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;68 ┴vila;Group 0800 Diseases of the ear and the mastoid 380-389;Men;29 ┴vila;Group 0800 Diseases of the ear and the mastoid 380-389;Women;39 ┴vila;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1.941 ┴vila;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1.018 ┴vila;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;923 ┴vila;Group 0901 Hypertensive disease 401-405;Both sexes;123 ┴vila;Group 0901 Hypertensive disease 401-405;Men;53 ┴vila;Group 0901 Hypertensive disease 401-405;Women;70 ┴vila;Group 0902 Angina pectoris 4111, 413;Both sexes;105 ┴vila;Group 0902 Angina pectoris 4111, 413;Men;69 ┴vila;Group 0902 Angina pectoris 4111, 413;Women;36 ┴vila;Group 0903 Acute myocardial infarction 410;Both sexes;128 ┴vila;Group 0903 Acute myocardial infarction 410;Men;90 ┴vila;Group 0903 Acute myocardial infarction 410;Women;38 ┴vila;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;12 ┴vila;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;9 ┴vila;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;3 ┴vila;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;109 ┴vila;Group 0905 Diseases of the lungs circulation 415-417;Men;57 ┴vila;Group 0905 Diseases of the lungs circulation 415-417;Women;52 ┴vila;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;314 ┴vila;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;167 ┴vila;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;147 ┴vila;Grupo 0907 Heart failure 428;Both sexes;584 ┴vila;Grupo 0907 Heart failure 428;Men;265 ┴vila;Grupo 0907 Heart failure 428;Women;319 ┴vila;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;328 ┴vila;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;179 ┴vila;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;149 ┴vila;Grupo 0909 Atherosclerosis 440;Both sexes;1 ┴vila;Grupo 0909 Atherosclerosis 440;Men;.. ┴vila;Grupo 0909 Atherosclerosis 440;Women;1 ┴vila;Group 0910 Varicose veins of lower extremities 454;Both sexes;42 ┴vila;Group 0910 Varicose veins of lower extremities 454;Men;19 ┴vila;Group 0910 Varicose veins of lower extremities 454;Women;23 ┴vila;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;195 ┴vila;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;110 ┴vila;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;85 ┴vila;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2.253 ┴vila;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.350 ┴vila;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;903 ┴vila;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;59 ┴vila;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;35 ┴vila;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;24 ┴vila;Group 1002 Pneumonia 480-486;Both sexes;444 ┴vila;Group 1002 Pneumonia 480-486;Men;267 ┴vila;Group 1002 Pneumonia 480-486;Women;177 ┴vila;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;83 ┴vila;Group 1003 Acute bronchitis and bronchiolitis 466;Men;40 ┴vila;Group 1003 Acute bronchitis and bronchiolitis 466;Women;43 ┴vila;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;91 ┴vila;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;52 ┴vila;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;39 ┴vila;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;221 ┴vila;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;156 ┴vila;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;65 ┴vila;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;326 ┴vila;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;284 ┴vila;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;42 ┴vila;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;62 ┴vila;Group 1007 Asthma 4930-4931,4938-4939;Men;11 ┴vila;Group 1007 Asthma 4930-4931,4938-4939;Women;51 ┴vila;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;967 ┴vila;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;505 ┴vila;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;462 ┴vila;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.212 ┴vila;Group 1100 Diseases of the digestive system 520-579;Men;1.351 ┴vila;Group 1100 Diseases of the digestive system 520-579;Women;861 ┴vila;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;27 ┴vila;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;15 ┴vila;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;12 ┴vila;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;23 ┴vila;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;13 ┴vila;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;10 ┴vila;Group 1103 Diseases of the esophagus 530;Both sexes;42 ┴vila;Group 1103 Diseases of the esophagus 530;Men;28 ┴vila;Group 1103 Diseases of the esophagus 530;Women;14 ┴vila;Group 1104 Peptic ulcer 531-534;Both sexes;39 ┴vila;Group 1104 Peptic ulcer 531-534;Men;30 ┴vila;Group 1104 Peptic ulcer 531-534;Women;9 ┴vila;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;39 ┴vila;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;25 ┴vila;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;14 ┴vila;Group 1106 Appendicitis 540-543;Both sexes;163 ┴vila;Group 1106 Appendicitis 540-543;Men;95 ┴vila;Group 1106 Appendicitis 540-543;Women;68 ┴vila;Group 1107 Inguinal hernia 550;Both sexes;423 ┴vila;Group 1107 Inguinal hernia 550;Men;379 ┴vila;Group 1107 Inguinal hernia 550;Women;44 ┴vila;Group 1108 Other abdominal hernia 551-553;Both sexes;142 ┴vila;Group 1108 Other abdominal hernia 551-553;Men;81 ┴vila;Group 1108 Other abdominal hernia 551-553;Women;61 ┴vila;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;21 ┴vila;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;10 ┴vila;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;11 ┴vila;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;139 ┴vila;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;65 ┴vila;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;74 ┴vila;Group 1111 Intestinal obstruction without hernia 560;Both sexes;109 ┴vila;Group 1111 Intestinal obstruction without hernia 560;Men;68 ┴vila;Group 1111 Intestinal obstruction without hernia 560;Women;41 ┴vila;Group 1112 Intestinal diverticulosis 562;Both sexes;67 ┴vila;Group 1112 Intestinal diverticulosis 562;Men;27 ┴vila;Group 1112 Intestinal diverticulosis 562;Women;40 ┴vila;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;132 ┴vila;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;80 ┴vila;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;52 ┴vila;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;75 ┴vila;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;34 ┴vila;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;41 ┴vila;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;28 ┴vila;Group 1115 Alcoholic hepatitis 5710-5713;Men;22 ┴vila;Group 1115 Alcoholic hepatitis 5710-5713;Women;6 ┴vila;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;53 ┴vila;Group 1116 Other diseases of the liver 570,5714-573;Men;26 ┴vila;Group 1116 Other diseases of the liver 570,5714-573;Women;27 ┴vila;Group 1117 Cholelithiasis 574;Both sexes;355 ┴vila;Group 1117 Cholelithiasis 574;Men;163 ┴vila;Group 1117 Cholelithiasis 574;Women;192 ┴vila;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;109 ┴vila;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;58 ┴vila;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;51 ┴vila;Group 1119 Pancreatic diseases 577;Both sexes;94 ┴vila;Group 1119 Pancreatic diseases 577;Men;60 ┴vila;Group 1119 Pancreatic diseases 577;Women;34 ┴vila;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;132 ┴vila;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;72 ┴vila;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;60 ┴vila;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;193 ┴vila;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;107 ┴vila;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;86 ┴vila;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;125 ┴vila;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;73 ┴vila;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;52 ┴vila;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;5 ┴vila;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;4 ┴vila;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;1 ┴vila;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;63 ┴vila;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;30 ┴vila;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;33 ┴vila;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;490 ┴vila;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;223 ┴vila;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;267 ┴vila;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ┴vila;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ┴vila;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ┴vila;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ┴vila;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ┴vila;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ┴vila;Group 1303 Internal derangement of knee 717;Both sexes;68 ┴vila;Group 1303 Internal derangement of knee 717;Men;43 ┴vila;Group 1303 Internal derangement of knee 717;Women;25 ┴vila;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;212 ┴vila;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;94 ┴vila;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;118 ┴vila;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;12 ┴vila;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;3 ┴vila;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;9 ┴vila;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;5 ┴vila;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;3 ┴vila;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;2 ┴vila;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;31 ┴vila;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;20 ┴vila;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;11 ┴vila;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;5 ┴vila;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;1 ┴vila;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;4 ┴vila;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;75 ┴vila;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;45 ┴vila;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;30 ┴vila;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;82 ┴vila;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;14 ┴vila;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;68 ┴vila;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1.010 ┴vila;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;576 ┴vila;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;434 ┴vila;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;52 ┴vila;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;27 ┴vila;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;25 ┴vila;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;85 ┴vila;Group 1402 Renal failure 5836-5837, 584-586;Men;53 ┴vila;Group 1402 Renal failure 5836-5837, 584-586;Women;32 ┴vila;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;131 ┴vila;Group 1403 Urolithiasis 592, 594, 7880;Men;76 ┴vila;Group 1403 Urolithiasis 592, 594, 7880;Women;55 ┴vila;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;395 ┴vila;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;206 ┴vila;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;189 ┴vila;Group 1405 Prostatic hyperplasia 600;Both sexes;107 ┴vila;Group 1405 Prostatic hyperplasia 600;Men;107 ┴vila;Group 1405 Prostatic hyperplasia 600;Women;.. ┴vila;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;105 ┴vila;Group 1406 Other diseases of the male genital organs 601-608;Men;105 ┴vila;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ┴vila;Group 1407 Disorders of breast 610-612;Both sexes;16 ┴vila;Group 1407 Disorders of breast 610-612;Men;2 ┴vila;Group 1407 Disorders of breast 610-612;Women;14 ┴vila;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;27 ┴vila;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ┴vila;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;27 ┴vila;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;5 ┴vila;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ┴vila;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;5 ┴vila;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;87 ┴vila;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. ┴vila;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;87 ┴vila;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.113 ┴vila;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ┴vila;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.113 ┴vila;Group 1501 Legally induced abortion 635;Both sexes;.. ┴vila;Group 1501 Legally induced abortion 635;Men;.. ┴vila;Group 1501 Legally induced abortion 635;Women;.. ┴vila;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;79 ┴vila;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ┴vila;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;79 ┴vila;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;589 ┴vila;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ┴vila;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;589 ┴vila;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;292 ┴vila;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ┴vila;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;292 ┴vila;Group 1505 Single spontaneous delivery 650;Both sexes;38 ┴vila;Group 1505 Single spontaneous delivery 650;Men;.. ┴vila;Group 1505 Single spontaneous delivery 650;Women;38 ┴vila;Group 1506 Other deliveries 6695-6697;Both sexes;43 ┴vila;Group 1506 Other deliveries 6695-6697;Men;.. ┴vila;Group 1506 Other deliveries 6695-6697;Women;43 ┴vila;Group 1507 Complications related to the puerperium 670-676;Both sexes;14 ┴vila;Group 1507 Complications related to the puerperium 670-676;Men;.. ┴vila;Group 1507 Complications related to the puerperium 670-676;Women;14 ┴vila;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;58 ┴vila;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ┴vila;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;58 ┴vila;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;245 ┴vila;Group 1600 Some disorders originating in the perinatal period 760-779;Men;138 ┴vila;Group 1600 Some disorders originating in the perinatal period 760-779;Women;107 ┴vila;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;30 ┴vila;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;14 ┴vila;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;16 ┴vila;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;215 ┴vila;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;124 ┴vila;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;91 ┴vila;Grupo 1700 Congenital abnormalities 740-759;Both sexes;52 ┴vila;Grupo 1700 Congenital abnormalities 740-759;Men;37 ┴vila;Grupo 1700 Congenital abnormalities 740-759;Women;15 ┴vila;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.035 ┴vila;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;598 ┴vila;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;437 ┴vila;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;135 ┴vila;Group 1801 Pain in throat and chest 7841, 7865;Men;92 ┴vila;Group 1801 Pain in throat and chest 7841, 7865;Women;43 ┴vila;Group 1802 Abdominal pain 7890;Both sexes;140 ┴vila;Group 1802 Abdominal pain 7890;Men;64 ┴vila;Group 1802 Abdominal pain 7890;Women;76 ┴vila;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;.. ┴vila;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. ┴vila;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. ┴vila;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;760 ┴vila;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;442 ┴vila;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;318 ┴vila;Group 1900 Injuries and poisoning 800-999;Both sexes;1.145 ┴vila;Group 1900 Injuries and poisoning 800-999;Men;550 ┴vila;Group 1900 Injuries and poisoning 800-999;Women;595 ┴vila;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;92 ┴vila;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;50 ┴vila;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;42 ┴vila;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;25 ┴vila;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;19 ┴vila;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;6 ┴vila;Group 1903 Radius and ulna fracture 813;Both sexes;40 ┴vila;Group 1903 Radius and ulna fracture 813;Men;17 ┴vila;Group 1903 Radius and ulna fracture 813;Women;23 ┴vila;Group 1904 Femur fracture 820-821;Both sexes;292 ┴vila;Group 1904 Femur fracture 820-821;Men;80 ┴vila;Group 1904 Femur fracture 820-821;Women;212 ┴vila;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;82 ┴vila;Group 1905 Leg fracture, including the ankle 823-824;Men;39 ┴vila;Group 1905 Leg fracture, including the ankle 823-824;Women;43 ┴vila;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;237 ┴vila;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;143 ┴vila;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;94 ┴vila;Group 1907 Burns 940-949;Both sexes;5 ┴vila;Group 1907 Burns 940-949;Men;3 ┴vila;Group 1907 Burns 940-949;Women;2 ┴vila;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;26 ┴vila;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;15 ┴vila;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;11 ┴vila;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;292 ┴vila;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;157 ┴vila;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;135 ┴vila;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. ┴vila;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. ┴vila;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. ┴vila;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;54 ┴vila;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;27 ┴vila;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;27 ┴vila;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;86 ┴vila;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;41 ┴vila;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;45 ┴vila;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;3 ┴vila;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;1 ┴vila;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2 ┴vila;Group 2102 Contraceptive management V25;Both sexes;6 ┴vila;Group 2102 Contraceptive management V25;Men;.. ┴vila;Group 2102 Contraceptive management V25;Women;6 ┴vila;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ┴vila;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ┴vila;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ┴vila;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;47 ┴vila;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;25 ┴vila;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;22 ┴vila;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;30 ┴vila;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;15 ┴vila;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;15 Burgos;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;42.881 Burgos;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;21.983 Burgos;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;20.898 Burgos;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.104 Burgos;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;663 Burgos;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;441 Burgos;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;190 Burgos;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;103 Burgos;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;87 Burgos;Group 0102 Imprecise intestinal infections 009;Both sexes;49 Burgos;Group 0102 Imprecise intestinal infections 009;Men;25 Burgos;Group 0102 Imprecise intestinal infections 009;Women;24 Burgos;Group 0103 Tuberculosis 010-018, 137;Both sexes;54 Burgos;Group 0103 Tuberculosis 010-018, 137;Men;34 Burgos;Group 0103 Tuberculosis 010-018, 137;Women;20 Burgos;Group 0104 Septicaemia 038;Both sexes;536 Burgos;Group 0104 Septicaemia 038;Men;325 Burgos;Group 0104 Septicaemia 038;Women;211 Burgos;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;37 Burgos;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;28 Burgos;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;9 Burgos;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;238 Burgos;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;148 Burgos;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;90 Burgos;Group 0200 Neoplasms 140-239;Both sexes;4.436 Burgos;Group 0200 Neoplasms 140-239;Men;2.435 Burgos;Group 0200 Neoplasms 140-239;Women;2.001 Burgos;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;551 Burgos;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;374 Burgos;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;177 Burgos;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;340 Burgos;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;244 Burgos;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;96 Burgos;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;104 Burgos;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;59 Burgos;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;45 Burgos;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;291 Burgos;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Burgos;Group 0204 Malignant neoplasm of breast 174-175;Women;290 Burgos;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;58 Burgos;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Burgos;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;58 Burgos;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;52 Burgos;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Burgos;Group 0206 Malignant neoplasm of ovary 1830;Women;52 Burgos;Group 0207 Malignant neoplasm of prostate 185;Both sexes;137 Burgos;Group 0207 Malignant neoplasm of prostate 185;Men;137 Burgos;Group 0207 Malignant neoplasm of prostate 185;Women;.. Burgos;Group 0208 Malignant neoplasm of bladder 188;Both sexes;382 Burgos;Group 0208 Malignant neoplasm of bladder 188;Men;344 Burgos;Group 0208 Malignant neoplasm of bladder 188;Women;38 Burgos;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.622 Burgos;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;958 Burgos;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;664 Burgos;Group 0210 Carcinoma in situ 230-234;Both sexes;88 Burgos;Group 0210 Carcinoma in situ 230-234;Men;27 Burgos;Group 0210 Carcinoma in situ 230-234;Women;61 Burgos;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;88 Burgos;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;54 Burgos;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;34 Burgos;Grupo 0212 Leiomyoma of uterus 218;Both sexes;109 Burgos;Grupo 0212 Leiomyoma of uterus 218;Men;.. Burgos;Grupo 0212 Leiomyoma of uterus 218;Women;109 Burgos;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;614 Burgos;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;237 Burgos;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;377 Burgos;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;446 Burgos;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;211 Burgos;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;235 Burgos;Group 0301 Anaemias 280-285;Both sexes;318 Burgos;Group 0301 Anaemias 280-285;Men;152 Burgos;Group 0301 Anaemias 280-285;Women;166 Burgos;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;128 Burgos;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;59 Burgos;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;69 Burgos;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;760 Burgos;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;329 Burgos;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;431 Burgos;Group 0401 Diabetes mellitus 249-250;Both sexes;220 Burgos;Group 0401 Diabetes mellitus 249-250;Men;103 Burgos;Group 0401 Diabetes mellitus 249-250;Women;117 Burgos;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;540 Burgos;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;226 Burgos;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;314 Burgos;Group 0500 Mental disorders 290-319;Both sexes;1.112 Burgos;Group 0500 Mental disorders 290-319;Men;462 Burgos;Group 0500 Mental disorders 290-319;Women;650 Burgos;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;13 Burgos;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;5 Burgos;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;8 Burgos;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;85 Burgos;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;68 Burgos;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;17 Burgos;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;29 Burgos;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;24 Burgos;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;5 Burgos;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;260 Burgos;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;136 Burgos;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;124 Burgos;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;485 Burgos;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;123 Burgos;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;362 Burgos;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;240 Burgos;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;106 Burgos;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;134 Burgos;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;728 Burgos;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;385 Burgos;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;343 Burgos;Group 0601 Alzheimer's disease 3310;Both sexes;13 Burgos;Group 0601 Alzheimer's disease 3310;Men;4 Burgos;Group 0601 Alzheimer's disease 3310;Women;9 Burgos;Group 0602 Multiple sclerosis 340;Both sexes;12 Burgos;Group 0602 Multiple sclerosis 340;Men;7 Burgos;Group 0602 Multiple sclerosis 340;Women;5 Burgos;Group 0603 Epilepsy 345;Both sexes;140 Burgos;Group 0603 Epilepsy 345;Men;77 Burgos;Group 0603 Epilepsy 345;Women;63 Burgos;Group 0604 Transient cerebral ischemia 435;Both sexes;111 Burgos;Group 0604 Transient cerebral ischemia 435;Men;63 Burgos;Group 0604 Transient cerebral ischemia 435;Women;48 Burgos;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;452 Burgos;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;234 Burgos;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;218 Burgos;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;441 Burgos;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;220 Burgos;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;221 Burgos;Grupo 0701 Cataract 366;Both sexes;121 Burgos;Grupo 0701 Cataract 366;Men;62 Burgos;Grupo 0701 Cataract 366;Women;59 Burgos;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;320 Burgos;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;158 Burgos;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;162 Burgos;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;242 Burgos;Group 0800 Diseases of the ear and the mastoid 380-389;Men;126 Burgos;Group 0800 Diseases of the ear and the mastoid 380-389;Women;116 Burgos;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4.957 Burgos;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.830 Burgos;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.127 Burgos;Group 0901 Hypertensive disease 401-405;Both sexes;196 Burgos;Group 0901 Hypertensive disease 401-405;Men;86 Burgos;Group 0901 Hypertensive disease 401-405;Women;110 Burgos;Group 0902 Angina pectoris 4111, 413;Both sexes;179 Burgos;Group 0902 Angina pectoris 4111, 413;Men;134 Burgos;Group 0902 Angina pectoris 4111, 413;Women;45 Burgos;Group 0903 Acute myocardial infarction 410;Both sexes;328 Burgos;Group 0903 Acute myocardial infarction 410;Men;252 Burgos;Group 0903 Acute myocardial infarction 410;Women;76 Burgos;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;205 Burgos;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;160 Burgos;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;45 Burgos;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;175 Burgos;Group 0905 Diseases of the lungs circulation 415-417;Men;80 Burgos;Group 0905 Diseases of the lungs circulation 415-417;Women;95 Burgos;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;697 Burgos;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;385 Burgos;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;312 Burgos;Grupo 0907 Heart failure 428;Both sexes;1.354 Burgos;Grupo 0907 Heart failure 428;Men;662 Burgos;Grupo 0907 Heart failure 428;Women;692 Burgos;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;919 Burgos;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;503 Burgos;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;416 Burgos;Grupo 0909 Atherosclerosis 440;Both sexes;193 Burgos;Grupo 0909 Atherosclerosis 440;Men;142 Burgos;Grupo 0909 Atherosclerosis 440;Women;51 Burgos;Group 0910 Varicose veins of lower extremities 454;Both sexes;35 Burgos;Group 0910 Varicose veins of lower extremities 454;Men;13 Burgos;Group 0910 Varicose veins of lower extremities 454;Women;22 Burgos;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;676 Burgos;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;413 Burgos;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;263 Burgos;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6.023 Burgos;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.543 Burgos;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.480 Burgos;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;404 Burgos;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;207 Burgos;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;197 Burgos;Group 1002 Pneumonia 480-486;Both sexes;1.523 Burgos;Group 1002 Pneumonia 480-486;Men;944 Burgos;Group 1002 Pneumonia 480-486;Women;579 Burgos;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;332 Burgos;Group 1003 Acute bronchitis and bronchiolitis 466;Men;158 Burgos;Group 1003 Acute bronchitis and bronchiolitis 466;Women;174 Burgos;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;342 Burgos;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;185 Burgos;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;157 Burgos;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;501 Burgos;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;342 Burgos;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;159 Burgos;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.042 Burgos;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;793 Burgos;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;249 Burgos;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;314 Burgos;Group 1007 Asthma 4930-4931,4938-4939;Men;120 Burgos;Group 1007 Asthma 4930-4931,4938-4939;Women;194 Burgos;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.565 Burgos;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;794 Burgos;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;771 Burgos;Group 1100 Diseases of the digestive system 520-579;Both sexes;5.893 Burgos;Group 1100 Diseases of the digestive system 520-579;Men;3.593 Burgos;Group 1100 Diseases of the digestive system 520-579;Women;2.300 Burgos;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;58 Burgos;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;30 Burgos;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;28 Burgos;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;77 Burgos;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;48 Burgos;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;29 Burgos;Group 1103 Diseases of the esophagus 530;Both sexes;90 Burgos;Group 1103 Diseases of the esophagus 530;Men;60 Burgos;Group 1103 Diseases of the esophagus 530;Women;30 Burgos;Group 1104 Peptic ulcer 531-534;Both sexes;109 Burgos;Group 1104 Peptic ulcer 531-534;Men;74 Burgos;Group 1104 Peptic ulcer 531-534;Women;35 Burgos;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;110 Burgos;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;59 Burgos;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;51 Burgos;Group 1106 Appendicitis 540-543;Both sexes;453 Burgos;Group 1106 Appendicitis 540-543;Men;256 Burgos;Group 1106 Appendicitis 540-543;Women;197 Burgos;Group 1107 Inguinal hernia 550;Both sexes;1.101 Burgos;Group 1107 Inguinal hernia 550;Men;958 Burgos;Group 1107 Inguinal hernia 550;Women;143 Burgos;Group 1108 Other abdominal hernia 551-553;Both sexes;533 Burgos;Group 1108 Other abdominal hernia 551-553;Men;291 Burgos;Group 1108 Other abdominal hernia 551-553;Women;242 Burgos;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;69 Burgos;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;35 Burgos;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;34 Burgos;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;376 Burgos;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;181 Burgos;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;195 Burgos;Group 1111 Intestinal obstruction without hernia 560;Both sexes;364 Burgos;Group 1111 Intestinal obstruction without hernia 560;Men;203 Burgos;Group 1111 Intestinal obstruction without hernia 560;Women;161 Burgos;Group 1112 Intestinal diverticulosis 562;Both sexes;163 Burgos;Group 1112 Intestinal diverticulosis 562;Men;73 Burgos;Group 1112 Intestinal diverticulosis 562;Women;90 Burgos;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;267 Burgos;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;171 Burgos;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;96 Burgos;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;197 Burgos;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;88 Burgos;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;109 Burgos;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;97 Burgos;Group 1115 Alcoholic hepatitis 5710-5713;Men;80 Burgos;Group 1115 Alcoholic hepatitis 5710-5713;Women;17 Burgos;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;196 Burgos;Group 1116 Other diseases of the liver 570,5714-573;Men;110 Burgos;Group 1116 Other diseases of the liver 570,5714-573;Women;86 Burgos;Group 1117 Cholelithiasis 574;Both sexes;812 Burgos;Group 1117 Cholelithiasis 574;Men;381 Burgos;Group 1117 Cholelithiasis 574;Women;431 Burgos;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;304 Burgos;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;171 Burgos;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;133 Burgos;Group 1119 Pancreatic diseases 577;Both sexes;275 Burgos;Group 1119 Pancreatic diseases 577;Men;169 Burgos;Group 1119 Pancreatic diseases 577;Women;106 Burgos;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;242 Burgos;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;155 Burgos;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;87 Burgos;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;675 Burgos;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;388 Burgos;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;287 Burgos;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;335 Burgos;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;211 Burgos;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;124 Burgos;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;30 Burgos;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;16 Burgos;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;14 Burgos;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;310 Burgos;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;161 Burgos;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;149 Burgos;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.810 Burgos;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.492 Burgos;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.318 Burgos;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Burgos;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Burgos;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Burgos;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Burgos;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Burgos;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Burgos;Group 1303 Internal derangement of knee 717;Both sexes;552 Burgos;Group 1303 Internal derangement of knee 717;Men;360 Burgos;Group 1303 Internal derangement of knee 717;Women;192 Burgos;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;976 Burgos;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;522 Burgos;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;454 Burgos;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;47 Burgos;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;15 Burgos;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;32 Burgos;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;110 Burgos;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;62 Burgos;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;48 Burgos;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;161 Burgos;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;98 Burgos;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;63 Burgos;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;98 Burgos;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;46 Burgos;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;52 Burgos;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;418 Burgos;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;251 Burgos;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;167 Burgos;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;448 Burgos;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;138 Burgos;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;310 Burgos;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.781 Burgos;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.367 Burgos;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.414 Burgos;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;244 Burgos;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;96 Burgos;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;148 Burgos;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;201 Burgos;Group 1402 Renal failure 5836-5837, 584-586;Men;117 Burgos;Group 1402 Renal failure 5836-5837, 584-586;Women;84 Burgos;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;457 Burgos;Group 1403 Urolithiasis 592, 594, 7880;Men;262 Burgos;Group 1403 Urolithiasis 592, 594, 7880;Women;195 Burgos;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.000 Burgos;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;518 Burgos;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;482 Burgos;Group 1405 Prostatic hyperplasia 600;Both sexes;209 Burgos;Group 1405 Prostatic hyperplasia 600;Men;209 Burgos;Group 1405 Prostatic hyperplasia 600;Women;.. Burgos;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;147 Burgos;Group 1406 Other diseases of the male genital organs 601-608;Men;147 Burgos;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Burgos;Group 1407 Disorders of breast 610-612;Both sexes;147 Burgos;Group 1407 Disorders of breast 610-612;Men;9 Burgos;Group 1407 Disorders of breast 610-612;Women;138 Burgos;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;69 Burgos;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Burgos;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;69 Burgos;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;18 Burgos;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Burgos;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;18 Burgos;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;289 Burgos;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;9 Burgos;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;280 Burgos;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3.104 Burgos;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Burgos;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3.104 Burgos;Group 1501 Legally induced abortion 635;Both sexes;4 Burgos;Group 1501 Legally induced abortion 635;Men;.. Burgos;Group 1501 Legally induced abortion 635;Women;4 Burgos;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;183 Burgos;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Burgos;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;183 Burgos;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.887 Burgos;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Burgos;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.887 Burgos;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;622 Burgos;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Burgos;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;622 Burgos;Group 1505 Single spontaneous delivery 650;Both sexes;145 Burgos;Group 1505 Single spontaneous delivery 650;Men;.. Burgos;Group 1505 Single spontaneous delivery 650;Women;145 Burgos;Group 1506 Other deliveries 6695-6697;Both sexes;51 Burgos;Group 1506 Other deliveries 6695-6697;Men;.. Burgos;Group 1506 Other deliveries 6695-6697;Women;51 Burgos;Group 1507 Complications related to the puerperium 670-676;Both sexes;20 Burgos;Group 1507 Complications related to the puerperium 670-676;Men;.. Burgos;Group 1507 Complications related to the puerperium 670-676;Women;20 Burgos;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;192 Burgos;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Burgos;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;192 Burgos;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;553 Burgos;Group 1600 Some disorders originating in the perinatal period 760-779;Men;299 Burgos;Group 1600 Some disorders originating in the perinatal period 760-779;Women;254 Burgos;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;114 Burgos;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;60 Burgos;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;54 Burgos;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;439 Burgos;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;239 Burgos;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;200 Burgos;Grupo 1700 Congenital abnormalities 740-759;Both sexes;325 Burgos;Grupo 1700 Congenital abnormalities 740-759;Men;179 Burgos;Grupo 1700 Congenital abnormalities 740-759;Women;146 Burgos;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.643 Burgos;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;882 Burgos;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;761 Burgos;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;126 Burgos;Group 1801 Pain in throat and chest 7841, 7865;Men;76 Burgos;Group 1801 Pain in throat and chest 7841, 7865;Women;50 Burgos;Group 1802 Abdominal pain 7890;Both sexes;241 Burgos;Group 1802 Abdominal pain 7890;Men;109 Burgos;Group 1802 Abdominal pain 7890;Women;132 Burgos;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;2 Burgos;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. Burgos;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;2 Burgos;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.274 Burgos;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;697 Burgos;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;577 Burgos;Group 1900 Injuries and poisoning 800-999;Both sexes;4.122 Burgos;Group 1900 Injuries and poisoning 800-999;Men;2.207 Burgos;Group 1900 Injuries and poisoning 800-999;Women;1.915 Burgos;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;268 Burgos;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;159 Burgos;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;109 Burgos;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;178 Burgos;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;126 Burgos;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;52 Burgos;Group 1903 Radius and ulna fracture 813;Both sexes;241 Burgos;Group 1903 Radius and ulna fracture 813;Men;103 Burgos;Group 1903 Radius and ulna fracture 813;Women;138 Burgos;Group 1904 Femur fracture 820-821;Both sexes;611 Burgos;Group 1904 Femur fracture 820-821;Men;171 Burgos;Group 1904 Femur fracture 820-821;Women;440 Burgos;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;222 Burgos;Group 1905 Leg fracture, including the ankle 823-824;Men;116 Burgos;Group 1905 Leg fracture, including the ankle 823-824;Women;106 Burgos;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.381 Burgos;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;853 Burgos;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;528 Burgos;Group 1907 Burns 940-949;Both sexes;56 Burgos;Group 1907 Burns 940-949;Men;33 Burgos;Group 1907 Burns 940-949;Women;23 Burgos;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;92 Burgos;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;47 Burgos;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;45 Burgos;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;939 Burgos;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;531 Burgos;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;408 Burgos;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;8 Burgos;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;6 Burgos;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 Burgos;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;126 Burgos;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;62 Burgos;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;64 Burgos;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;726 Burgos;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;372 Burgos;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;354 Burgos;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;33 Burgos;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;23 Burgos;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;10 Burgos;Group 2102 Contraceptive management V25;Both sexes;13 Burgos;Group 2102 Contraceptive management V25;Men;.. Burgos;Group 2102 Contraceptive management V25;Women;13 Burgos;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Burgos;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Burgos;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Burgos;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;127 Burgos;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;66 Burgos;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;61 Burgos;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;553 Burgos;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;283 Burgos;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;270 Le¾n;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;59.446 Le¾n;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;29.232 Le¾n;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;30.214 Le¾n;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.100 Le¾n;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;603 Le¾n;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;497 Le¾n;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;187 Le¾n;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;105 Le¾n;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;82 Le¾n;Group 0102 Imprecise intestinal infections 009;Both sexes;187 Le¾n;Group 0102 Imprecise intestinal infections 009;Men;96 Le¾n;Group 0102 Imprecise intestinal infections 009;Women;91 Le¾n;Group 0103 Tuberculosis 010-018, 137;Both sexes;59 Le¾n;Group 0103 Tuberculosis 010-018, 137;Men;39 Le¾n;Group 0103 Tuberculosis 010-018, 137;Women;20 Le¾n;Group 0104 Septicaemia 038;Both sexes;396 Le¾n;Group 0104 Septicaemia 038;Men;213 Le¾n;Group 0104 Septicaemia 038;Women;183 Le¾n;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;.. Le¾n;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;.. Le¾n;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;.. Le¾n;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;271 Le¾n;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;150 Le¾n;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;121 Le¾n;Group 0200 Neoplasms 140-239;Both sexes;6.055 Le¾n;Group 0200 Neoplasms 140-239;Men;3.238 Le¾n;Group 0200 Neoplasms 140-239;Women;2.817 Le¾n;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;856 Le¾n;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;510 Le¾n;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;346 Le¾n;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;404 Le¾n;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;331 Le¾n;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;73 Le¾n;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;259 Le¾n;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;134 Le¾n;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;125 Le¾n;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;377 Le¾n;Group 0204 Malignant neoplasm of breast 174-175;Men;7 Le¾n;Group 0204 Malignant neoplasm of breast 174-175;Women;370 Le¾n;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;110 Le¾n;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Le¾n;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;110 Le¾n;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;68 Le¾n;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Le¾n;Group 0206 Malignant neoplasm of ovary 1830;Women;68 Le¾n;Group 0207 Malignant neoplasm of prostate 185;Both sexes;213 Le¾n;Group 0207 Malignant neoplasm of prostate 185;Men;213 Le¾n;Group 0207 Malignant neoplasm of prostate 185;Women;.. Le¾n;Group 0208 Malignant neoplasm of bladder 188;Both sexes;593 Le¾n;Group 0208 Malignant neoplasm of bladder 188;Men;489 Le¾n;Group 0208 Malignant neoplasm of bladder 188;Women;104 Le¾n;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.079 Le¾n;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.167 Le¾n;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;912 Le¾n;Group 0210 Carcinoma in situ 230-234;Both sexes;124 Le¾n;Group 0210 Carcinoma in situ 230-234;Men;38 Le¾n;Group 0210 Carcinoma in situ 230-234;Women;86 Le¾n;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;62 Le¾n;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;43 Le¾n;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;19 Le¾n;Grupo 0212 Leiomyoma of uterus 218;Both sexes;206 Le¾n;Grupo 0212 Leiomyoma of uterus 218;Men;.. Le¾n;Grupo 0212 Leiomyoma of uterus 218;Women;206 Le¾n;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;704 Le¾n;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;306 Le¾n;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;398 Le¾n;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;460 Le¾n;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;226 Le¾n;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;234 Le¾n;Group 0301 Anaemias 280-285;Both sexes;293 Le¾n;Group 0301 Anaemias 280-285;Men;127 Le¾n;Group 0301 Anaemias 280-285;Women;166 Le¾n;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;167 Le¾n;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;99 Le¾n;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;68 Le¾n;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;970 Le¾n;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;414 Le¾n;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;556 Le¾n;Group 0401 Diabetes mellitus 249-250;Both sexes;336 Le¾n;Group 0401 Diabetes mellitus 249-250;Men;183 Le¾n;Group 0401 Diabetes mellitus 249-250;Women;153 Le¾n;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;634 Le¾n;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;231 Le¾n;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;403 Le¾n;Group 0500 Mental disorders 290-319;Both sexes;1.084 Le¾n;Group 0500 Mental disorders 290-319;Men;559 Le¾n;Group 0500 Mental disorders 290-319;Women;525 Le¾n;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;60 Le¾n;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;29 Le¾n;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;31 Le¾n;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;47 Le¾n;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;38 Le¾n;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;9 Le¾n;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;20 Le¾n;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;14 Le¾n;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;6 Le¾n;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;350 Le¾n;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;203 Le¾n;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;147 Le¾n;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;202 Le¾n;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;77 Le¾n;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;125 Le¾n;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;405 Le¾n;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;198 Le¾n;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;207 Le¾n;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.161 Le¾n;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;549 Le¾n;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;612 Le¾n;Group 0601 Alzheimer's disease 3310;Both sexes;32 Le¾n;Group 0601 Alzheimer's disease 3310;Men;11 Le¾n;Group 0601 Alzheimer's disease 3310;Women;21 Le¾n;Group 0602 Multiple sclerosis 340;Both sexes;48 Le¾n;Group 0602 Multiple sclerosis 340;Men;17 Le¾n;Group 0602 Multiple sclerosis 340;Women;31 Le¾n;Group 0603 Epilepsy 345;Both sexes;138 Le¾n;Group 0603 Epilepsy 345;Men;76 Le¾n;Group 0603 Epilepsy 345;Women;62 Le¾n;Group 0604 Transient cerebral ischemia 435;Both sexes;299 Le¾n;Group 0604 Transient cerebral ischemia 435;Men;136 Le¾n;Group 0604 Transient cerebral ischemia 435;Women;163 Le¾n;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;644 Le¾n;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;309 Le¾n;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;335 Le¾n;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;660 Le¾n;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;336 Le¾n;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;324 Le¾n;Grupo 0701 Cataract 366;Both sexes;143 Le¾n;Grupo 0701 Cataract 366;Men;61 Le¾n;Grupo 0701 Cataract 366;Women;82 Le¾n;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;517 Le¾n;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;275 Le¾n;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;242 Le¾n;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;220 Le¾n;Group 0800 Diseases of the ear and the mastoid 380-389;Men;104 Le¾n;Group 0800 Diseases of the ear and the mastoid 380-389;Women;116 Le¾n;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;9.265 Le¾n;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5.051 Le¾n;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.214 Le¾n;Group 0901 Hypertensive disease 401-405;Both sexes;640 Le¾n;Group 0901 Hypertensive disease 401-405;Men;249 Le¾n;Group 0901 Hypertensive disease 401-405;Women;391 Le¾n;Group 0902 Angina pectoris 4111, 413;Both sexes;167 Le¾n;Group 0902 Angina pectoris 4111, 413;Men;113 Le¾n;Group 0902 Angina pectoris 4111, 413;Women;54 Le¾n;Group 0903 Acute myocardial infarction 410;Both sexes;809 Le¾n;Group 0903 Acute myocardial infarction 410;Men;584 Le¾n;Group 0903 Acute myocardial infarction 410;Women;225 Le¾n;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;457 Le¾n;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;354 Le¾n;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;103 Le¾n;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;377 Le¾n;Group 0905 Diseases of the lungs circulation 415-417;Men;196 Le¾n;Group 0905 Diseases of the lungs circulation 415-417;Women;181 Le¾n;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.156 Le¾n;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;565 Le¾n;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;591 Le¾n;Grupo 0907 Heart failure 428;Both sexes;2.013 Le¾n;Grupo 0907 Heart failure 428;Men;990 Le¾n;Grupo 0907 Heart failure 428;Women;1.023 Le¾n;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.345 Le¾n;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;698 Le¾n;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;647 Le¾n;Grupo 0909 Atherosclerosis 440;Both sexes;249 Le¾n;Grupo 0909 Atherosclerosis 440;Men;184 Le¾n;Grupo 0909 Atherosclerosis 440;Women;65 Le¾n;Group 0910 Varicose veins of lower extremities 454;Both sexes;387 Le¾n;Group 0910 Varicose veins of lower extremities 454;Men;142 Le¾n;Group 0910 Varicose veins of lower extremities 454;Women;245 Le¾n;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.665 Le¾n;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;976 Le¾n;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;689 Le¾n;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7.728 Le¾n;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.354 Le¾n;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.374 Le¾n;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;225 Le¾n;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;117 Le¾n;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;108 Le¾n;Group 1002 Pneumonia 480-486;Both sexes;1.667 Le¾n;Group 1002 Pneumonia 480-486;Men;993 Le¾n;Group 1002 Pneumonia 480-486;Women;674 Le¾n;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;534 Le¾n;Group 1003 Acute bronchitis and bronchiolitis 466;Men;251 Le¾n;Group 1003 Acute bronchitis and bronchiolitis 466;Women;283 Le¾n;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;285 Le¾n;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;151 Le¾n;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;134 Le¾n;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;588 Le¾n;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;366 Le¾n;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;222 Le¾n;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.245 Le¾n;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;935 Le¾n;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;310 Le¾n;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;277 Le¾n;Group 1007 Asthma 4930-4931,4938-4939;Men;78 Le¾n;Group 1007 Asthma 4930-4931,4938-4939;Women;199 Le¾n;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.907 Le¾n;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.463 Le¾n;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.444 Le¾n;Group 1100 Diseases of the digestive system 520-579;Both sexes;7.500 Le¾n;Group 1100 Diseases of the digestive system 520-579;Men;4.458 Le¾n;Group 1100 Diseases of the digestive system 520-579;Women;3.042 Le¾n;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;97 Le¾n;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;40 Le¾n;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;57 Le¾n;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;95 Le¾n;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;56 Le¾n;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;39 Le¾n;Group 1103 Diseases of the esophagus 530;Both sexes;90 Le¾n;Group 1103 Diseases of the esophagus 530;Men;63 Le¾n;Group 1103 Diseases of the esophagus 530;Women;27 Le¾n;Group 1104 Peptic ulcer 531-534;Both sexes;116 Le¾n;Group 1104 Peptic ulcer 531-534;Men;72 Le¾n;Group 1104 Peptic ulcer 531-534;Women;44 Le¾n;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;227 Le¾n;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;112 Le¾n;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;115 Le¾n;Group 1106 Appendicitis 540-543;Both sexes;508 Le¾n;Group 1106 Appendicitis 540-543;Men;295 Le¾n;Group 1106 Appendicitis 540-543;Women;213 Le¾n;Group 1107 Inguinal hernia 550;Both sexes;1.215 Le¾n;Group 1107 Inguinal hernia 550;Men;1.095 Le¾n;Group 1107 Inguinal hernia 550;Women;120 Le¾n;Group 1108 Other abdominal hernia 551-553;Both sexes;571 Le¾n;Group 1108 Other abdominal hernia 551-553;Men;340 Le¾n;Group 1108 Other abdominal hernia 551-553;Women;231 Le¾n;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;97 Le¾n;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;54 Le¾n;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;43 Le¾n;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;524 Le¾n;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;236 Le¾n;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;288 Le¾n;Group 1111 Intestinal obstruction without hernia 560;Both sexes;378 Le¾n;Group 1111 Intestinal obstruction without hernia 560;Men;195 Le¾n;Group 1111 Intestinal obstruction without hernia 560;Women;183 Le¾n;Group 1112 Intestinal diverticulosis 562;Both sexes;367 Le¾n;Group 1112 Intestinal diverticulosis 562;Men;178 Le¾n;Group 1112 Intestinal diverticulosis 562;Women;189 Le¾n;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;424 Le¾n;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;286 Le¾n;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;138 Le¾n;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;369 Le¾n;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;163 Le¾n;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;206 Le¾n;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;112 Le¾n;Group 1115 Alcoholic hepatitis 5710-5713;Men;91 Le¾n;Group 1115 Alcoholic hepatitis 5710-5713;Women;21 Le¾n;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;196 Le¾n;Group 1116 Other diseases of the liver 570,5714-573;Men;108 Le¾n;Group 1116 Other diseases of the liver 570,5714-573;Women;88 Le¾n;Group 1117 Cholelithiasis 574;Both sexes;1.251 Le¾n;Group 1117 Cholelithiasis 574;Men;590 Le¾n;Group 1117 Cholelithiasis 574;Women;661 Le¾n;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;301 Le¾n;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;174 Le¾n;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;127 Le¾n;Group 1119 Pancreatic diseases 577;Both sexes;312 Le¾n;Group 1119 Pancreatic diseases 577;Men;163 Le¾n;Group 1119 Pancreatic diseases 577;Women;149 Le¾n;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;250 Le¾n;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;147 Le¾n;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;103 Le¾n;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;728 Le¾n;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;399 Le¾n;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;329 Le¾n;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;376 Le¾n;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;232 Le¾n;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;144 Le¾n;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;35 Le¾n;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;13 Le¾n;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;22 Le¾n;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;317 Le¾n;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;154 Le¾n;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;163 Le¾n;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4.624 Le¾n;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.139 Le¾n;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.485 Le¾n;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Le¾n;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Le¾n;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Le¾n;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Le¾n;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Le¾n;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Le¾n;Group 1303 Internal derangement of knee 717;Both sexes;464 Le¾n;Group 1303 Internal derangement of knee 717;Men;295 Le¾n;Group 1303 Internal derangement of knee 717;Women;169 Le¾n;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.761 Le¾n;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;779 Le¾n;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;982 Le¾n;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;88 Le¾n;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;37 Le¾n;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;51 Le¾n;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;298 Le¾n;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;154 Le¾n;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;144 Le¾n;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;375 Le¾n;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;184 Le¾n;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;191 Le¾n;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;287 Le¾n;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;131 Le¾n;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;156 Le¾n;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;682 Le¾n;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;336 Le¾n;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;346 Le¾n;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;669 Le¾n;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;223 Le¾n;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;446 Le¾n;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.556 Le¾n;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.423 Le¾n;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.133 Le¾n;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;189 Le¾n;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;79 Le¾n;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;110 Le¾n;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;309 Le¾n;Group 1402 Renal failure 5836-5837, 584-586;Men;187 Le¾n;Group 1402 Renal failure 5836-5837, 584-586;Women;122 Le¾n;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;381 Le¾n;Group 1403 Urolithiasis 592, 594, 7880;Men;205 Le¾n;Group 1403 Urolithiasis 592, 594, 7880;Women;176 Le¾n;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.223 Le¾n;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;495 Le¾n;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;728 Le¾n;Group 1405 Prostatic hyperplasia 600;Both sexes;202 Le¾n;Group 1405 Prostatic hyperplasia 600;Men;202 Le¾n;Group 1405 Prostatic hyperplasia 600;Women;.. Le¾n;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;239 Le¾n;Group 1406 Other diseases of the male genital organs 601-608;Men;239 Le¾n;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Le¾n;Group 1407 Disorders of breast 610-612;Both sexes;131 Le¾n;Group 1407 Disorders of breast 610-612;Men;15 Le¾n;Group 1407 Disorders of breast 610-612;Women;116 Le¾n;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;73 Le¾n;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Le¾n;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;73 Le¾n;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;147 Le¾n;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Le¾n;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;147 Le¾n;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;662 Le¾n;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Le¾n;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;661 Le¾n;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3.671 Le¾n;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Le¾n;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3.671 Le¾n;Group 1501 Legally induced abortion 635;Both sexes;4 Le¾n;Group 1501 Legally induced abortion 635;Men;.. Le¾n;Group 1501 Legally induced abortion 635;Women;4 Le¾n;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;245 Le¾n;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Le¾n;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;245 Le¾n;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;2.046 Le¾n;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Le¾n;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;2.046 Le¾n;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;575 Le¾n;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Le¾n;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;575 Le¾n;Group 1505 Single spontaneous delivery 650;Both sexes;413 Le¾n;Group 1505 Single spontaneous delivery 650;Men;.. Le¾n;Group 1505 Single spontaneous delivery 650;Women;413 Le¾n;Group 1506 Other deliveries 6695-6697;Both sexes;154 Le¾n;Group 1506 Other deliveries 6695-6697;Men;.. Le¾n;Group 1506 Other deliveries 6695-6697;Women;154 Le¾n;Group 1507 Complications related to the puerperium 670-676;Both sexes;36 Le¾n;Group 1507 Complications related to the puerperium 670-676;Men;.. Le¾n;Group 1507 Complications related to the puerperium 670-676;Women;36 Le¾n;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;198 Le¾n;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Le¾n;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;198 Le¾n;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;530 Le¾n;Group 1600 Some disorders originating in the perinatal period 760-779;Men;286 Le¾n;Group 1600 Some disorders originating in the perinatal period 760-779;Women;244 Le¾n;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;147 Le¾n;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;75 Le¾n;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;72 Le¾n;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;383 Le¾n;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;211 Le¾n;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;172 Le¾n;Grupo 1700 Congenital abnormalities 740-759;Both sexes;274 Le¾n;Grupo 1700 Congenital abnormalities 740-759;Men;158 Le¾n;Grupo 1700 Congenital abnormalities 740-759;Women;116 Le¾n;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.666 Le¾n;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.394 Le¾n;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.272 Le¾n;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;232 Le¾n;Group 1801 Pain in throat and chest 7841, 7865;Men;137 Le¾n;Group 1801 Pain in throat and chest 7841, 7865;Women;95 Le¾n;Group 1802 Abdominal pain 7890;Both sexes;278 Le¾n;Group 1802 Abdominal pain 7890;Men;101 Le¾n;Group 1802 Abdominal pain 7890;Women;177 Le¾n;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;390 Le¾n;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;182 Le¾n;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;208 Le¾n;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.766 Le¾n;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;974 Le¾n;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;792 Le¾n;Group 1900 Injuries and poisoning 800-999;Both sexes;5.381 Le¾n;Group 1900 Injuries and poisoning 800-999;Men;2.604 Le¾n;Group 1900 Injuries and poisoning 800-999;Women;2.777 Le¾n;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;363 Le¾n;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;200 Le¾n;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;163 Le¾n;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;168 Le¾n;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;111 Le¾n;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;57 Le¾n;Group 1903 Radius and ulna fracture 813;Both sexes;211 Le¾n;Group 1903 Radius and ulna fracture 813;Men;97 Le¾n;Group 1903 Radius and ulna fracture 813;Women;114 Le¾n;Group 1904 Femur fracture 820-821;Both sexes;1.104 Le¾n;Group 1904 Femur fracture 820-821;Men;296 Le¾n;Group 1904 Femur fracture 820-821;Women;808 Le¾n;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;321 Le¾n;Group 1905 Leg fracture, including the ankle 823-824;Men;141 Le¾n;Group 1905 Leg fracture, including the ankle 823-824;Women;180 Le¾n;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.608 Le¾n;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;918 Le¾n;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;690 Le¾n;Group 1907 Burns 940-949;Both sexes;34 Le¾n;Group 1907 Burns 940-949;Men;23 Le¾n;Group 1907 Burns 940-949;Women;11 Le¾n;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;114 Le¾n;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;49 Le¾n;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;65 Le¾n;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.281 Le¾n;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;689 Le¾n;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;592 Le¾n;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;12 Le¾n;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;9 Le¾n;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;3 Le¾n;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;165 Le¾n;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;71 Le¾n;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;94 Le¾n;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.813 Le¾n;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;937 Le¾n;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;876 Le¾n;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;38 Le¾n;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;25 Le¾n;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;13 Le¾n;Group 2102 Contraceptive management V25;Both sexes;18 Le¾n;Group 2102 Contraceptive management V25;Men;.. Le¾n;Group 2102 Contraceptive management V25;Women;18 Le¾n;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Le¾n;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Le¾n;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Le¾n;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;436 Le¾n;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;275 Le¾n;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;161 Le¾n;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.321 Le¾n;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;637 Le¾n;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;684 Palencia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;18.188 Palencia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;9.367 Palencia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;8.821 Palencia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;435 Palencia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;245 Palencia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;190 Palencia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;147 Palencia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;83 Palencia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;64 Palencia;Group 0102 Imprecise intestinal infections 009;Both sexes;20 Palencia;Group 0102 Imprecise intestinal infections 009;Men;10 Palencia;Group 0102 Imprecise intestinal infections 009;Women;10 Palencia;Group 0103 Tuberculosis 010-018, 137;Both sexes;19 Palencia;Group 0103 Tuberculosis 010-018, 137;Men;10 Palencia;Group 0103 Tuberculosis 010-018, 137;Women;9 Palencia;Group 0104 Septicaemia 038;Both sexes;108 Palencia;Group 0104 Septicaemia 038;Men;60 Palencia;Group 0104 Septicaemia 038;Women;48 Palencia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;9 Palencia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;6 Palencia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 Palencia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;132 Palencia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;76 Palencia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;56 Palencia;Group 0200 Neoplasms 140-239;Both sexes;1.665 Palencia;Group 0200 Neoplasms 140-239;Men;957 Palencia;Group 0200 Neoplasms 140-239;Women;708 Palencia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;208 Palencia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;146 Palencia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;62 Palencia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;109 Palencia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;91 Palencia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;18 Palencia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;8 Palencia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;1 Palencia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;7 Palencia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;108 Palencia;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Palencia;Group 0204 Malignant neoplasm of breast 174-175;Women;107 Palencia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;35 Palencia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Palencia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;35 Palencia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;12 Palencia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Palencia;Group 0206 Malignant neoplasm of ovary 1830;Women;12 Palencia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;60 Palencia;Group 0207 Malignant neoplasm of prostate 185;Men;60 Palencia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Palencia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;173 Palencia;Group 0208 Malignant neoplasm of bladder 188;Men;145 Palencia;Group 0208 Malignant neoplasm of bladder 188;Women;28 Palencia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;612 Palencia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;389 Palencia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;223 Palencia;Group 0210 Carcinoma in situ 230-234;Both sexes;28 Palencia;Group 0210 Carcinoma in situ 230-234;Men;10 Palencia;Group 0210 Carcinoma in situ 230-234;Women;18 Palencia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;14 Palencia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;10 Palencia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;4 Palencia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;73 Palencia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Palencia;Grupo 0212 Leiomyoma of uterus 218;Women;73 Palencia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;225 Palencia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;104 Palencia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;121 Palencia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;160 Palencia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;96 Palencia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;64 Palencia;Group 0301 Anaemias 280-285;Both sexes;115 Palencia;Group 0301 Anaemias 280-285;Men;73 Palencia;Group 0301 Anaemias 280-285;Women;42 Palencia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;45 Palencia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;23 Palencia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;22 Palencia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;285 Palencia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;126 Palencia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;159 Palencia;Group 0401 Diabetes mellitus 249-250;Both sexes;109 Palencia;Group 0401 Diabetes mellitus 249-250;Men;51 Palencia;Group 0401 Diabetes mellitus 249-250;Women;58 Palencia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;176 Palencia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;75 Palencia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;101 Palencia;Group 0500 Mental disorders 290-319;Both sexes;715 Palencia;Group 0500 Mental disorders 290-319;Men;405 Palencia;Group 0500 Mental disorders 290-319;Women;310 Palencia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;38 Palencia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;18 Palencia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;20 Palencia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;57 Palencia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;43 Palencia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;14 Palencia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;117 Palencia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;102 Palencia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;15 Palencia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;164 Palencia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;101 Palencia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;63 Palencia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;155 Palencia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;41 Palencia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;114 Palencia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;184 Palencia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;100 Palencia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;84 Palencia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;343 Palencia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;167 Palencia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;176 Palencia;Group 0601 Alzheimer's disease 3310;Both sexes;30 Palencia;Group 0601 Alzheimer's disease 3310;Men;9 Palencia;Group 0601 Alzheimer's disease 3310;Women;21 Palencia;Group 0602 Multiple sclerosis 340;Both sexes;31 Palencia;Group 0602 Multiple sclerosis 340;Men;15 Palencia;Group 0602 Multiple sclerosis 340;Women;16 Palencia;Group 0603 Epilepsy 345;Both sexes;64 Palencia;Group 0603 Epilepsy 345;Men;39 Palencia;Group 0603 Epilepsy 345;Women;25 Palencia;Group 0604 Transient cerebral ischemia 435;Both sexes;58 Palencia;Group 0604 Transient cerebral ischemia 435;Men;25 Palencia;Group 0604 Transient cerebral ischemia 435;Women;33 Palencia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;160 Palencia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;79 Palencia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;81 Palencia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;94 Palencia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;44 Palencia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;50 Palencia;Grupo 0701 Cataract 366;Both sexes;38 Palencia;Grupo 0701 Cataract 366;Men;17 Palencia;Grupo 0701 Cataract 366;Women;21 Palencia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;56 Palencia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;27 Palencia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;29 Palencia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;97 Palencia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;53 Palencia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;44 Palencia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2.329 Palencia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1.204 Palencia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.125 Palencia;Group 0901 Hypertensive disease 401-405;Both sexes;204 Palencia;Group 0901 Hypertensive disease 401-405;Men;77 Palencia;Group 0901 Hypertensive disease 401-405;Women;127 Palencia;Group 0902 Angina pectoris 4111, 413;Both sexes;92 Palencia;Group 0902 Angina pectoris 4111, 413;Men;60 Palencia;Group 0902 Angina pectoris 4111, 413;Women;32 Palencia;Group 0903 Acute myocardial infarction 410;Both sexes;221 Palencia;Group 0903 Acute myocardial infarction 410;Men;145 Palencia;Group 0903 Acute myocardial infarction 410;Women;76 Palencia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;97 Palencia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;71 Palencia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;26 Palencia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;98 Palencia;Group 0905 Diseases of the lungs circulation 415-417;Men;48 Palencia;Group 0905 Diseases of the lungs circulation 415-417;Women;50 Palencia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;468 Palencia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;245 Palencia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;223 Palencia;Grupo 0907 Heart failure 428;Both sexes;499 Palencia;Grupo 0907 Heart failure 428;Men;223 Palencia;Grupo 0907 Heart failure 428;Women;276 Palencia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;347 Palencia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;166 Palencia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;181 Palencia;Grupo 0909 Atherosclerosis 440;Both sexes;23 Palencia;Grupo 0909 Atherosclerosis 440;Men;10 Palencia;Grupo 0909 Atherosclerosis 440;Women;13 Palencia;Group 0910 Varicose veins of lower extremities 454;Both sexes;4 Palencia;Group 0910 Varicose veins of lower extremities 454;Men;1 Palencia;Group 0910 Varicose veins of lower extremities 454;Women;3 Palencia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;276 Palencia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;158 Palencia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;118 Palencia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2.910 Palencia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.658 Palencia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.252 Palencia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;176 Palencia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;91 Palencia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;85 Palencia;Group 1002 Pneumonia 480-486;Both sexes;492 Palencia;Group 1002 Pneumonia 480-486;Men;314 Palencia;Group 1002 Pneumonia 480-486;Women;178 Palencia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;197 Palencia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;88 Palencia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;109 Palencia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;197 Palencia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;108 Palencia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;89 Palencia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;314 Palencia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;206 Palencia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;108 Palencia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;580 Palencia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;459 Palencia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;121 Palencia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;102 Palencia;Group 1007 Asthma 4930-4931,4938-4939;Men;24 Palencia;Group 1007 Asthma 4930-4931,4938-4939;Women;78 Palencia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;852 Palencia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;368 Palencia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;484 Palencia;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.530 Palencia;Group 1100 Diseases of the digestive system 520-579;Men;1.523 Palencia;Group 1100 Diseases of the digestive system 520-579;Women;1.007 Palencia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;12 Palencia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;6 Palencia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;6 Palencia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;17 Palencia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;11 Palencia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;6 Palencia;Group 1103 Diseases of the esophagus 530;Both sexes;49 Palencia;Group 1103 Diseases of the esophagus 530;Men;32 Palencia;Group 1103 Diseases of the esophagus 530;Women;17 Palencia;Group 1104 Peptic ulcer 531-534;Both sexes;59 Palencia;Group 1104 Peptic ulcer 531-534;Men;41 Palencia;Group 1104 Peptic ulcer 531-534;Women;18 Palencia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;58 Palencia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;26 Palencia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;32 Palencia;Group 1106 Appendicitis 540-543;Both sexes;148 Palencia;Group 1106 Appendicitis 540-543;Men;82 Palencia;Group 1106 Appendicitis 540-543;Women;66 Palencia;Group 1107 Inguinal hernia 550;Both sexes;426 Palencia;Group 1107 Inguinal hernia 550;Men;393 Palencia;Group 1107 Inguinal hernia 550;Women;33 Palencia;Group 1108 Other abdominal hernia 551-553;Both sexes;172 Palencia;Group 1108 Other abdominal hernia 551-553;Men;89 Palencia;Group 1108 Other abdominal hernia 551-553;Women;83 Palencia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;38 Palencia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;14 Palencia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;24 Palencia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;213 Palencia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;101 Palencia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;112 Palencia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;108 Palencia;Group 1111 Intestinal obstruction without hernia 560;Men;49 Palencia;Group 1111 Intestinal obstruction without hernia 560;Women;59 Palencia;Group 1112 Intestinal diverticulosis 562;Both sexes;88 Palencia;Group 1112 Intestinal diverticulosis 562;Men;38 Palencia;Group 1112 Intestinal diverticulosis 562;Women;50 Palencia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;162 Palencia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;105 Palencia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;57 Palencia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;103 Palencia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;60 Palencia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;43 Palencia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;60 Palencia;Group 1115 Alcoholic hepatitis 5710-5713;Men;57 Palencia;Group 1115 Alcoholic hepatitis 5710-5713;Women;3 Palencia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;79 Palencia;Group 1116 Other diseases of the liver 570,5714-573;Men;53 Palencia;Group 1116 Other diseases of the liver 570,5714-573;Women;26 Palencia;Group 1117 Cholelithiasis 574;Both sexes;448 Palencia;Group 1117 Cholelithiasis 574;Men;210 Palencia;Group 1117 Cholelithiasis 574;Women;238 Palencia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;128 Palencia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;70 Palencia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;58 Palencia;Group 1119 Pancreatic diseases 577;Both sexes;77 Palencia;Group 1119 Pancreatic diseases 577;Men;44 Palencia;Group 1119 Pancreatic diseases 577;Women;33 Palencia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;85 Palencia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;42 Palencia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;43 Palencia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;195 Palencia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;119 Palencia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;76 Palencia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;137 Palencia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;90 Palencia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;47 Palencia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;8 Palencia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;6 Palencia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;2 Palencia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;50 Palencia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;23 Palencia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;27 Palencia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;931 Palencia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;499 Palencia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;432 Palencia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Palencia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Palencia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Palencia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Palencia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Palencia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Palencia;Group 1303 Internal derangement of knee 717;Both sexes;118 Palencia;Group 1303 Internal derangement of knee 717;Men;95 Palencia;Group 1303 Internal derangement of knee 717;Women;23 Palencia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;397 Palencia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;195 Palencia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;202 Palencia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;19 Palencia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;5 Palencia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;14 Palencia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;11 Palencia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;2 Palencia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;9 Palencia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;32 Palencia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;14 Palencia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;18 Palencia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;46 Palencia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;27 Palencia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;19 Palencia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;164 Palencia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;109 Palencia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;55 Palencia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;144 Palencia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;52 Palencia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;92 Palencia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1.416 Palencia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;786 Palencia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;630 Palencia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;75 Palencia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;20 Palencia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;55 Palencia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;123 Palencia;Group 1402 Renal failure 5836-5837, 584-586;Men;75 Palencia;Group 1402 Renal failure 5836-5837, 584-586;Women;48 Palencia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;205 Palencia;Group 1403 Urolithiasis 592, 594, 7880;Men;120 Palencia;Group 1403 Urolithiasis 592, 594, 7880;Women;85 Palencia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;512 Palencia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;281 Palencia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;231 Palencia;Group 1405 Prostatic hyperplasia 600;Both sexes;168 Palencia;Group 1405 Prostatic hyperplasia 600;Men;168 Palencia;Group 1405 Prostatic hyperplasia 600;Women;.. Palencia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;117 Palencia;Group 1406 Other diseases of the male genital organs 601-608;Men;117 Palencia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Palencia;Group 1407 Disorders of breast 610-612;Both sexes;17 Palencia;Group 1407 Disorders of breast 610-612;Men;4 Palencia;Group 1407 Disorders of breast 610-612;Women;13 Palencia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;21 Palencia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Palencia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;21 Palencia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;16 Palencia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Palencia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;16 Palencia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;162 Palencia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Palencia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;161 Palencia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.268 Palencia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Palencia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.268 Palencia;Group 1501 Legally induced abortion 635;Both sexes;1 Palencia;Group 1501 Legally induced abortion 635;Men;.. Palencia;Group 1501 Legally induced abortion 635;Women;1 Palencia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;149 Palencia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Palencia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;149 Palencia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;710 Palencia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Palencia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;710 Palencia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;233 Palencia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Palencia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;233 Palencia;Group 1505 Single spontaneous delivery 650;Both sexes;35 Palencia;Group 1505 Single spontaneous delivery 650;Men;.. Palencia;Group 1505 Single spontaneous delivery 650;Women;35 Palencia;Group 1506 Other deliveries 6695-6697;Both sexes;73 Palencia;Group 1506 Other deliveries 6695-6697;Men;.. Palencia;Group 1506 Other deliveries 6695-6697;Women;73 Palencia;Group 1507 Complications related to the puerperium 670-676;Both sexes;14 Palencia;Group 1507 Complications related to the puerperium 670-676;Men;.. Palencia;Group 1507 Complications related to the puerperium 670-676;Women;14 Palencia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;53 Palencia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Palencia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;53 Palencia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;192 Palencia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;111 Palencia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;81 Palencia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;42 Palencia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;26 Palencia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;16 Palencia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;150 Palencia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;85 Palencia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;65 Palencia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;62 Palencia;Grupo 1700 Congenital abnormalities 740-759;Men;35 Palencia;Grupo 1700 Congenital abnormalities 740-759;Women;27 Palencia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;820 Palencia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;455 Palencia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;365 Palencia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;142 Palencia;Group 1801 Pain in throat and chest 7841, 7865;Men;97 Palencia;Group 1801 Pain in throat and chest 7841, 7865;Women;45 Palencia;Group 1802 Abdominal pain 7890;Both sexes;91 Palencia;Group 1802 Abdominal pain 7890;Men;40 Palencia;Group 1802 Abdominal pain 7890;Women;51 Palencia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;9 Palencia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;8 Palencia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1 Palencia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;578 Palencia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;310 Palencia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;268 Palencia;Group 1900 Injuries and poisoning 800-999;Both sexes;1.501 Palencia;Group 1900 Injuries and poisoning 800-999;Men;723 Palencia;Group 1900 Injuries and poisoning 800-999;Women;778 Palencia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;113 Palencia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;53 Palencia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;60 Palencia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;21 Palencia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;10 Palencia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;11 Palencia;Group 1903 Radius and ulna fracture 813;Both sexes;82 Palencia;Group 1903 Radius and ulna fracture 813;Men;45 Palencia;Group 1903 Radius and ulna fracture 813;Women;37 Palencia;Group 1904 Femur fracture 820-821;Both sexes;326 Palencia;Group 1904 Femur fracture 820-821;Men;77 Palencia;Group 1904 Femur fracture 820-821;Women;249 Palencia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;90 Palencia;Group 1905 Leg fracture, including the ankle 823-824;Men;44 Palencia;Group 1905 Leg fracture, including the ankle 823-824;Women;46 Palencia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;362 Palencia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;222 Palencia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;140 Palencia;Group 1907 Burns 940-949;Both sexes;2 Palencia;Group 1907 Burns 940-949;Men;.. Palencia;Group 1907 Burns 940-949;Women;2 Palencia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;61 Palencia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;27 Palencia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;34 Palencia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;389 Palencia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;218 Palencia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;171 Palencia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Palencia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Palencia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Palencia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;55 Palencia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;27 Palencia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;28 Palencia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;240 Palencia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;161 Palencia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;79 Palencia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;.. Palencia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;.. Palencia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;.. Palencia;Group 2102 Contraceptive management V25;Both sexes;1 Palencia;Group 2102 Contraceptive management V25;Men;.. Palencia;Group 2102 Contraceptive management V25;Women;1 Palencia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Palencia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Palencia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Palencia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;172 Palencia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;130 Palencia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;42 Palencia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;67 Palencia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;31 Palencia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;36 Salamanca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;34.241 Salamanca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;17.256 Salamanca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;16.985 Salamanca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.074 Salamanca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;605 Salamanca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;469 Salamanca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;114 Salamanca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;59 Salamanca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;55 Salamanca;Group 0102 Imprecise intestinal infections 009;Both sexes;33 Salamanca;Group 0102 Imprecise intestinal infections 009;Men;16 Salamanca;Group 0102 Imprecise intestinal infections 009;Women;17 Salamanca;Group 0103 Tuberculosis 010-018, 137;Both sexes;21 Salamanca;Group 0103 Tuberculosis 010-018, 137;Men;12 Salamanca;Group 0103 Tuberculosis 010-018, 137;Women;9 Salamanca;Group 0104 Septicaemia 038;Both sexes;744 Salamanca;Group 0104 Septicaemia 038;Men;428 Salamanca;Group 0104 Septicaemia 038;Women;316 Salamanca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;15 Salamanca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;12 Salamanca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 Salamanca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;147 Salamanca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;78 Salamanca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;69 Salamanca;Group 0200 Neoplasms 140-239;Both sexes;3.802 Salamanca;Group 0200 Neoplasms 140-239;Men;2.072 Salamanca;Group 0200 Neoplasms 140-239;Women;1.730 Salamanca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;452 Salamanca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;282 Salamanca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;170 Salamanca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;307 Salamanca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;227 Salamanca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;80 Salamanca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;98 Salamanca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;52 Salamanca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;46 Salamanca;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;180 Salamanca;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Salamanca;Group 0204 Malignant neoplasm of breast 174-175;Women;180 Salamanca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;58 Salamanca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Salamanca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;58 Salamanca;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;31 Salamanca;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Salamanca;Group 0206 Malignant neoplasm of ovary 1830;Women;31 Salamanca;Group 0207 Malignant neoplasm of prostate 185;Both sexes;122 Salamanca;Group 0207 Malignant neoplasm of prostate 185;Men;122 Salamanca;Group 0207 Malignant neoplasm of prostate 185;Women;.. Salamanca;Group 0208 Malignant neoplasm of bladder 188;Both sexes;287 Salamanca;Group 0208 Malignant neoplasm of bladder 188;Men;241 Salamanca;Group 0208 Malignant neoplasm of bladder 188;Women;46 Salamanca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.414 Salamanca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;761 Salamanca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;653 Salamanca;Group 0210 Carcinoma in situ 230-234;Both sexes;24 Salamanca;Group 0210 Carcinoma in situ 230-234;Men;4 Salamanca;Group 0210 Carcinoma in situ 230-234;Women;20 Salamanca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;17 Salamanca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;12 Salamanca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;5 Salamanca;Grupo 0212 Leiomyoma of uterus 218;Both sexes;147 Salamanca;Grupo 0212 Leiomyoma of uterus 218;Men;.. Salamanca;Grupo 0212 Leiomyoma of uterus 218;Women;147 Salamanca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;665 Salamanca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;371 Salamanca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;294 Salamanca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;333 Salamanca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;171 Salamanca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;162 Salamanca;Group 0301 Anaemias 280-285;Both sexes;225 Salamanca;Group 0301 Anaemias 280-285;Men;113 Salamanca;Group 0301 Anaemias 280-285;Women;112 Salamanca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;108 Salamanca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;58 Salamanca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;50 Salamanca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;805 Salamanca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;377 Salamanca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;428 Salamanca;Group 0401 Diabetes mellitus 249-250;Both sexes;357 Salamanca;Group 0401 Diabetes mellitus 249-250;Men;218 Salamanca;Group 0401 Diabetes mellitus 249-250;Women;139 Salamanca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;448 Salamanca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;159 Salamanca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;289 Salamanca;Group 0500 Mental disorders 290-319;Both sexes;699 Salamanca;Group 0500 Mental disorders 290-319;Men;401 Salamanca;Group 0500 Mental disorders 290-319;Women;298 Salamanca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;10 Salamanca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;7 Salamanca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;3 Salamanca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;68 Salamanca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;51 Salamanca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;17 Salamanca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;158 Salamanca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;124 Salamanca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;34 Salamanca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;147 Salamanca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;87 Salamanca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;60 Salamanca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;148 Salamanca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;53 Salamanca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;95 Salamanca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;168 Salamanca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;79 Salamanca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;89 Salamanca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;862 Salamanca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;375 Salamanca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;487 Salamanca;Group 0601 Alzheimer's disease 3310;Both sexes;6 Salamanca;Group 0601 Alzheimer's disease 3310;Men;3 Salamanca;Group 0601 Alzheimer's disease 3310;Women;3 Salamanca;Group 0602 Multiple sclerosis 340;Both sexes;5 Salamanca;Group 0602 Multiple sclerosis 340;Men;2 Salamanca;Group 0602 Multiple sclerosis 340;Women;3 Salamanca;Group 0603 Epilepsy 345;Both sexes;64 Salamanca;Group 0603 Epilepsy 345;Men;40 Salamanca;Group 0603 Epilepsy 345;Women;24 Salamanca;Group 0604 Transient cerebral ischemia 435;Both sexes;66 Salamanca;Group 0604 Transient cerebral ischemia 435;Men;37 Salamanca;Group 0604 Transient cerebral ischemia 435;Women;29 Salamanca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;721 Salamanca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;293 Salamanca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;428 Salamanca;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;131 Salamanca;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;72 Salamanca;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;59 Salamanca;Grupo 0701 Cataract 366;Both sexes;6 Salamanca;Grupo 0701 Cataract 366;Men;3 Salamanca;Grupo 0701 Cataract 366;Women;3 Salamanca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;125 Salamanca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;69 Salamanca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;56 Salamanca;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;264 Salamanca;Group 0800 Diseases of the ear and the mastoid 380-389;Men;136 Salamanca;Group 0800 Diseases of the ear and the mastoid 380-389;Women;128 Salamanca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4.595 Salamanca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.636 Salamanca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.959 Salamanca;Group 0901 Hypertensive disease 401-405;Both sexes;244 Salamanca;Group 0901 Hypertensive disease 401-405;Men;91 Salamanca;Group 0901 Hypertensive disease 401-405;Women;153 Salamanca;Group 0902 Angina pectoris 4111, 413;Both sexes;117 Salamanca;Group 0902 Angina pectoris 4111, 413;Men;87 Salamanca;Group 0902 Angina pectoris 4111, 413;Women;30 Salamanca;Group 0903 Acute myocardial infarction 410;Both sexes;594 Salamanca;Group 0903 Acute myocardial infarction 410;Men;433 Salamanca;Group 0903 Acute myocardial infarction 410;Women;161 Salamanca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;139 Salamanca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;111 Salamanca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;28 Salamanca;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;241 Salamanca;Group 0905 Diseases of the lungs circulation 415-417;Men;114 Salamanca;Group 0905 Diseases of the lungs circulation 415-417;Women;127 Salamanca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;381 Salamanca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;225 Salamanca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;156 Salamanca;Grupo 0907 Heart failure 428;Both sexes;916 Salamanca;Grupo 0907 Heart failure 428;Men;475 Salamanca;Grupo 0907 Heart failure 428;Women;441 Salamanca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;799 Salamanca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;436 Salamanca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;363 Salamanca;Grupo 0909 Atherosclerosis 440;Both sexes;176 Salamanca;Grupo 0909 Atherosclerosis 440;Men;137 Salamanca;Grupo 0909 Atherosclerosis 440;Women;39 Salamanca;Group 0910 Varicose veins of lower extremities 454;Both sexes;168 Salamanca;Group 0910 Varicose veins of lower extremities 454;Men;48 Salamanca;Group 0910 Varicose veins of lower extremities 454;Women;120 Salamanca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;820 Salamanca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;479 Salamanca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;341 Salamanca;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4.196 Salamanca;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.515 Salamanca;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.681 Salamanca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;117 Salamanca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;60 Salamanca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;57 Salamanca;Group 1002 Pneumonia 480-486;Both sexes;892 Salamanca;Group 1002 Pneumonia 480-486;Men;552 Salamanca;Group 1002 Pneumonia 480-486;Women;340 Salamanca;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;536 Salamanca;Group 1003 Acute bronchitis and bronchiolitis 466;Men;245 Salamanca;Group 1003 Acute bronchitis and bronchiolitis 466;Women;291 Salamanca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;122 Salamanca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;56 Salamanca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;66 Salamanca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;470 Salamanca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;304 Salamanca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;166 Salamanca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;554 Salamanca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;476 Salamanca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;78 Salamanca;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;177 Salamanca;Group 1007 Asthma 4930-4931,4938-4939;Men;59 Salamanca;Group 1007 Asthma 4930-4931,4938-4939;Women;118 Salamanca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.328 Salamanca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;763 Salamanca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;565 Salamanca;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.192 Salamanca;Group 1100 Diseases of the digestive system 520-579;Men;2.417 Salamanca;Group 1100 Diseases of the digestive system 520-579;Women;1.775 Salamanca;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;52 Salamanca;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;29 Salamanca;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;23 Salamanca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;80 Salamanca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;47 Salamanca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;33 Salamanca;Group 1103 Diseases of the esophagus 530;Both sexes;90 Salamanca;Group 1103 Diseases of the esophagus 530;Men;52 Salamanca;Group 1103 Diseases of the esophagus 530;Women;38 Salamanca;Group 1104 Peptic ulcer 531-534;Both sexes;110 Salamanca;Group 1104 Peptic ulcer 531-534;Men;63 Salamanca;Group 1104 Peptic ulcer 531-534;Women;47 Salamanca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;106 Salamanca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;55 Salamanca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;51 Salamanca;Group 1106 Appendicitis 540-543;Both sexes;289 Salamanca;Group 1106 Appendicitis 540-543;Men;166 Salamanca;Group 1106 Appendicitis 540-543;Women;123 Salamanca;Group 1107 Inguinal hernia 550;Both sexes;435 Salamanca;Group 1107 Inguinal hernia 550;Men;389 Salamanca;Group 1107 Inguinal hernia 550;Women;46 Salamanca;Group 1108 Other abdominal hernia 551-553;Both sexes;300 Salamanca;Group 1108 Other abdominal hernia 551-553;Men;149 Salamanca;Group 1108 Other abdominal hernia 551-553;Women;151 Salamanca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;69 Salamanca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;40 Salamanca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;29 Salamanca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;177 Salamanca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;96 Salamanca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;81 Salamanca;Group 1111 Intestinal obstruction without hernia 560;Both sexes;316 Salamanca;Group 1111 Intestinal obstruction without hernia 560;Men;166 Salamanca;Group 1111 Intestinal obstruction without hernia 560;Women;150 Salamanca;Group 1112 Intestinal diverticulosis 562;Both sexes;188 Salamanca;Group 1112 Intestinal diverticulosis 562;Men;97 Salamanca;Group 1112 Intestinal diverticulosis 562;Women;91 Salamanca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;233 Salamanca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;151 Salamanca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;82 Salamanca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;159 Salamanca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;80 Salamanca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;79 Salamanca;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;53 Salamanca;Group 1115 Alcoholic hepatitis 5710-5713;Men;45 Salamanca;Group 1115 Alcoholic hepatitis 5710-5713;Women;8 Salamanca;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;124 Salamanca;Group 1116 Other diseases of the liver 570,5714-573;Men;83 Salamanca;Group 1116 Other diseases of the liver 570,5714-573;Women;41 Salamanca;Group 1117 Cholelithiasis 574;Both sexes;764 Salamanca;Group 1117 Cholelithiasis 574;Men;357 Salamanca;Group 1117 Cholelithiasis 574;Women;407 Salamanca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;214 Salamanca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;131 Salamanca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;83 Salamanca;Group 1119 Pancreatic diseases 577;Both sexes;186 Salamanca;Group 1119 Pancreatic diseases 577;Men;105 Salamanca;Group 1119 Pancreatic diseases 577;Women;81 Salamanca;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;247 Salamanca;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;116 Salamanca;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;131 Salamanca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;238 Salamanca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;122 Salamanca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;116 Salamanca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;121 Salamanca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;68 Salamanca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;53 Salamanca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;10 Salamanca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;4 Salamanca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;6 Salamanca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;107 Salamanca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;50 Salamanca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;57 Salamanca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1.571 Salamanca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;729 Salamanca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;842 Salamanca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Salamanca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Salamanca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Salamanca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Salamanca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Salamanca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Salamanca;Group 1303 Internal derangement of knee 717;Both sexes;62 Salamanca;Group 1303 Internal derangement of knee 717;Men;45 Salamanca;Group 1303 Internal derangement of knee 717;Women;17 Salamanca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;645 Salamanca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;274 Salamanca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;371 Salamanca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;47 Salamanca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;15 Salamanca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;32 Salamanca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;116 Salamanca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;62 Salamanca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;54 Salamanca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;281 Salamanca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;146 Salamanca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;135 Salamanca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;23 Salamanca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;9 Salamanca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;14 Salamanca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;155 Salamanca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;79 Salamanca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;76 Salamanca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;242 Salamanca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;99 Salamanca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;143 Salamanca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1.959 Salamanca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;924 Salamanca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.035 Salamanca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;173 Salamanca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;81 Salamanca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;92 Salamanca;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;204 Salamanca;Group 1402 Renal failure 5836-5837, 584-586;Men;114 Salamanca;Group 1402 Renal failure 5836-5837, 584-586;Women;90 Salamanca;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;270 Salamanca;Group 1403 Urolithiasis 592, 594, 7880;Men;153 Salamanca;Group 1403 Urolithiasis 592, 594, 7880;Women;117 Salamanca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;534 Salamanca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;274 Salamanca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;260 Salamanca;Group 1405 Prostatic hyperplasia 600;Both sexes;140 Salamanca;Group 1405 Prostatic hyperplasia 600;Men;140 Salamanca;Group 1405 Prostatic hyperplasia 600;Women;.. Salamanca;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;147 Salamanca;Group 1406 Other diseases of the male genital organs 601-608;Men;147 Salamanca;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Salamanca;Group 1407 Disorders of breast 610-612;Both sexes;99 Salamanca;Group 1407 Disorders of breast 610-612;Men;4 Salamanca;Group 1407 Disorders of breast 610-612;Women;95 Salamanca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;61 Salamanca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Salamanca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;61 Salamanca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;32 Salamanca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Salamanca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;32 Salamanca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;299 Salamanca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;11 Salamanca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;288 Salamanca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2.797 Salamanca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Salamanca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2.797 Salamanca;Group 1501 Legally induced abortion 635;Both sexes;.. Salamanca;Group 1501 Legally induced abortion 635;Men;.. Salamanca;Group 1501 Legally induced abortion 635;Women;.. Salamanca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;187 Salamanca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Salamanca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;187 Salamanca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.533 Salamanca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Salamanca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.533 Salamanca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;684 Salamanca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Salamanca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;684 Salamanca;Group 1505 Single spontaneous delivery 650;Both sexes;133 Salamanca;Group 1505 Single spontaneous delivery 650;Men;.. Salamanca;Group 1505 Single spontaneous delivery 650;Women;133 Salamanca;Group 1506 Other deliveries 6695-6697;Both sexes;81 Salamanca;Group 1506 Other deliveries 6695-6697;Men;.. Salamanca;Group 1506 Other deliveries 6695-6697;Women;81 Salamanca;Group 1507 Complications related to the puerperium 670-676;Both sexes;13 Salamanca;Group 1507 Complications related to the puerperium 670-676;Men;.. Salamanca;Group 1507 Complications related to the puerperium 670-676;Women;13 Salamanca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;166 Salamanca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Salamanca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;166 Salamanca;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;391 Salamanca;Group 1600 Some disorders originating in the perinatal period 760-779;Men;212 Salamanca;Group 1600 Some disorders originating in the perinatal period 760-779;Women;179 Salamanca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;127 Salamanca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;64 Salamanca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;63 Salamanca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;264 Salamanca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;148 Salamanca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;116 Salamanca;Grupo 1700 Congenital abnormalities 740-759;Both sexes;240 Salamanca;Grupo 1700 Congenital abnormalities 740-759;Men;170 Salamanca;Grupo 1700 Congenital abnormalities 740-759;Women;70 Salamanca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.840 Salamanca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.049 Salamanca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;791 Salamanca;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;90 Salamanca;Group 1801 Pain in throat and chest 7841, 7865;Men;61 Salamanca;Group 1801 Pain in throat and chest 7841, 7865;Women;29 Salamanca;Group 1802 Abdominal pain 7890;Both sexes;173 Salamanca;Group 1802 Abdominal pain 7890;Men;77 Salamanca;Group 1802 Abdominal pain 7890;Women;96 Salamanca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;698 Salamanca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;379 Salamanca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;319 Salamanca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;879 Salamanca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;532 Salamanca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;347 Salamanca;Group 1900 Injuries and poisoning 800-999;Both sexes;3.326 Salamanca;Group 1900 Injuries and poisoning 800-999;Men;1.712 Salamanca;Group 1900 Injuries and poisoning 800-999;Women;1.614 Salamanca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;195 Salamanca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;120 Salamanca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;75 Salamanca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;76 Salamanca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;56 Salamanca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;20 Salamanca;Group 1903 Radius and ulna fracture 813;Both sexes;181 Salamanca;Group 1903 Radius and ulna fracture 813;Men;83 Salamanca;Group 1903 Radius and ulna fracture 813;Women;98 Salamanca;Group 1904 Femur fracture 820-821;Both sexes;611 Salamanca;Group 1904 Femur fracture 820-821;Men;143 Salamanca;Group 1904 Femur fracture 820-821;Women;468 Salamanca;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;195 Salamanca;Group 1905 Leg fracture, including the ankle 823-824;Men;100 Salamanca;Group 1905 Leg fracture, including the ankle 823-824;Women;95 Salamanca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;906 Salamanca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;587 Salamanca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;319 Salamanca;Group 1907 Burns 940-949;Both sexes;28 Salamanca;Group 1907 Burns 940-949;Men;17 Salamanca;Group 1907 Burns 940-949;Women;11 Salamanca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;98 Salamanca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;53 Salamanca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;45 Salamanca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;942 Salamanca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;510 Salamanca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;432 Salamanca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Salamanca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Salamanca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Salamanca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;94 Salamanca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;43 Salamanca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;51 Salamanca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;926 Salamanca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;561 Salamanca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;365 Salamanca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;17 Salamanca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;7 Salamanca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;10 Salamanca;Group 2102 Contraceptive management V25;Both sexes;22 Salamanca;Group 2102 Contraceptive management V25;Men;1 Salamanca;Group 2102 Contraceptive management V25;Women;21 Salamanca;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Salamanca;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Salamanca;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Salamanca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;745 Salamanca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;490 Salamanca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;255 Salamanca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;142 Salamanca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;63 Salamanca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;79 Segovia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;12.612 Segovia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;6.389 Segovia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;6.223 Segovia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;278 Segovia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;159 Segovia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;119 Segovia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;73 Segovia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;40 Segovia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;33 Segovia;Group 0102 Imprecise intestinal infections 009;Both sexes;11 Segovia;Group 0102 Imprecise intestinal infections 009;Men;4 Segovia;Group 0102 Imprecise intestinal infections 009;Women;7 Segovia;Group 0103 Tuberculosis 010-018, 137;Both sexes;.. Segovia;Group 0103 Tuberculosis 010-018, 137;Men;.. Segovia;Group 0103 Tuberculosis 010-018, 137;Women;.. Segovia;Group 0104 Septicaemia 038;Both sexes;116 Segovia;Group 0104 Septicaemia 038;Men;71 Segovia;Group 0104 Septicaemia 038;Women;45 Segovia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;1 Segovia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;1 Segovia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;.. Segovia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;77 Segovia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;43 Segovia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;34 Segovia;Group 0200 Neoplasms 140-239;Both sexes;1.082 Segovia;Group 0200 Neoplasms 140-239;Men;612 Segovia;Group 0200 Neoplasms 140-239;Women;470 Segovia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;175 Segovia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;116 Segovia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;59 Segovia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;69 Segovia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;60 Segovia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;9 Segovia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;6 Segovia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;4 Segovia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;2 Segovia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;80 Segovia;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Segovia;Group 0204 Malignant neoplasm of breast 174-175;Women;80 Segovia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;27 Segovia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Segovia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;27 Segovia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;7 Segovia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Segovia;Group 0206 Malignant neoplasm of ovary 1830;Women;7 Segovia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;56 Segovia;Group 0207 Malignant neoplasm of prostate 185;Men;56 Segovia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Segovia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;83 Segovia;Group 0208 Malignant neoplasm of bladder 188;Men;70 Segovia;Group 0208 Malignant neoplasm of bladder 188;Women;13 Segovia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;423 Segovia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;240 Segovia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;183 Segovia;Group 0210 Carcinoma in situ 230-234;Both sexes;35 Segovia;Group 0210 Carcinoma in situ 230-234;Men;19 Segovia;Group 0210 Carcinoma in situ 230-234;Women;16 Segovia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;5 Segovia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;3 Segovia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;2 Segovia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;29 Segovia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Segovia;Grupo 0212 Leiomyoma of uterus 218;Women;29 Segovia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;87 Segovia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;44 Segovia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;43 Segovia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;110 Segovia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;52 Segovia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;58 Segovia;Group 0301 Anaemias 280-285;Both sexes;67 Segovia;Group 0301 Anaemias 280-285;Men;31 Segovia;Group 0301 Anaemias 280-285;Women;36 Segovia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;43 Segovia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;21 Segovia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;22 Segovia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;182 Segovia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;79 Segovia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;103 Segovia;Group 0401 Diabetes mellitus 249-250;Both sexes;51 Segovia;Group 0401 Diabetes mellitus 249-250;Men;23 Segovia;Group 0401 Diabetes mellitus 249-250;Women;28 Segovia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;131 Segovia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;56 Segovia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;75 Segovia;Group 0500 Mental disorders 290-319;Both sexes;395 Segovia;Group 0500 Mental disorders 290-319;Men;213 Segovia;Group 0500 Mental disorders 290-319;Women;182 Segovia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;16 Segovia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;4 Segovia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;12 Segovia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;55 Segovia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;43 Segovia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;12 Segovia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;16 Segovia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;13 Segovia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;3 Segovia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;93 Segovia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;49 Segovia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;44 Segovia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;93 Segovia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;42 Segovia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;51 Segovia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;122 Segovia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;62 Segovia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;60 Segovia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;246 Segovia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;112 Segovia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;134 Segovia;Group 0601 Alzheimer's disease 3310;Both sexes;8 Segovia;Group 0601 Alzheimer's disease 3310;Men;5 Segovia;Group 0601 Alzheimer's disease 3310;Women;3 Segovia;Group 0602 Multiple sclerosis 340;Both sexes;8 Segovia;Group 0602 Multiple sclerosis 340;Men;3 Segovia;Group 0602 Multiple sclerosis 340;Women;5 Segovia;Group 0603 Epilepsy 345;Both sexes;46 Segovia;Group 0603 Epilepsy 345;Men;20 Segovia;Group 0603 Epilepsy 345;Women;26 Segovia;Group 0604 Transient cerebral ischemia 435;Both sexes;55 Segovia;Group 0604 Transient cerebral ischemia 435;Men;27 Segovia;Group 0604 Transient cerebral ischemia 435;Women;28 Segovia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;129 Segovia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;57 Segovia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;72 Segovia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;163 Segovia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;84 Segovia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;79 Segovia;Grupo 0701 Cataract 366;Both sexes;17 Segovia;Grupo 0701 Cataract 366;Men;7 Segovia;Grupo 0701 Cataract 366;Women;10 Segovia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;146 Segovia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;77 Segovia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;69 Segovia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;103 Segovia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;47 Segovia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;56 Segovia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1.593 Segovia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;868 Segovia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;725 Segovia;Group 0901 Hypertensive disease 401-405;Both sexes;68 Segovia;Group 0901 Hypertensive disease 401-405;Men;31 Segovia;Group 0901 Hypertensive disease 401-405;Women;37 Segovia;Group 0902 Angina pectoris 4111, 413;Both sexes;58 Segovia;Group 0902 Angina pectoris 4111, 413;Men;29 Segovia;Group 0902 Angina pectoris 4111, 413;Women;29 Segovia;Group 0903 Acute myocardial infarction 410;Both sexes;151 Segovia;Group 0903 Acute myocardial infarction 410;Men;106 Segovia;Group 0903 Acute myocardial infarction 410;Women;45 Segovia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;63 Segovia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;52 Segovia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;11 Segovia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;78 Segovia;Group 0905 Diseases of the lungs circulation 415-417;Men;34 Segovia;Group 0905 Diseases of the lungs circulation 415-417;Women;44 Segovia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;218 Segovia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;131 Segovia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;87 Segovia;Grupo 0907 Heart failure 428;Both sexes;455 Segovia;Grupo 0907 Heart failure 428;Men;197 Segovia;Grupo 0907 Heart failure 428;Women;258 Segovia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;268 Segovia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;144 Segovia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;124 Segovia;Grupo 0909 Atherosclerosis 440;Both sexes;25 Segovia;Grupo 0909 Atherosclerosis 440;Men;14 Segovia;Grupo 0909 Atherosclerosis 440;Women;11 Segovia;Group 0910 Varicose veins of lower extremities 454;Both sexes;13 Segovia;Group 0910 Varicose veins of lower extremities 454;Men;8 Segovia;Group 0910 Varicose veins of lower extremities 454;Women;5 Segovia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;196 Segovia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;122 Segovia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;74 Segovia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1.634 Segovia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;982 Segovia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;652 Segovia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;109 Segovia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;58 Segovia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;51 Segovia;Group 1002 Pneumonia 480-486;Both sexes;397 Segovia;Group 1002 Pneumonia 480-486;Men;241 Segovia;Group 1002 Pneumonia 480-486;Women;156 Segovia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;97 Segovia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;54 Segovia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;43 Segovia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;107 Segovia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;57 Segovia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;50 Segovia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;172 Segovia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;124 Segovia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;48 Segovia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;254 Segovia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;215 Segovia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;39 Segovia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;52 Segovia;Group 1007 Asthma 4930-4931,4938-4939;Men;21 Segovia;Group 1007 Asthma 4930-4931,4938-4939;Women;31 Segovia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;446 Segovia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;212 Segovia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;234 Segovia;Group 1100 Diseases of the digestive system 520-579;Both sexes;1.640 Segovia;Group 1100 Diseases of the digestive system 520-579;Men;987 Segovia;Group 1100 Diseases of the digestive system 520-579;Women;653 Segovia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;5 Segovia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;3 Segovia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;2 Segovia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;15 Segovia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;9 Segovia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;6 Segovia;Group 1103 Diseases of the esophagus 530;Both sexes;27 Segovia;Group 1103 Diseases of the esophagus 530;Men;18 Segovia;Group 1103 Diseases of the esophagus 530;Women;9 Segovia;Group 1104 Peptic ulcer 531-534;Both sexes;37 Segovia;Group 1104 Peptic ulcer 531-534;Men;27 Segovia;Group 1104 Peptic ulcer 531-534;Women;10 Segovia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;29 Segovia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;15 Segovia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;14 Segovia;Group 1106 Appendicitis 540-543;Both sexes;152 Segovia;Group 1106 Appendicitis 540-543;Men;87 Segovia;Group 1106 Appendicitis 540-543;Women;65 Segovia;Group 1107 Inguinal hernia 550;Both sexes;209 Segovia;Group 1107 Inguinal hernia 550;Men;195 Segovia;Group 1107 Inguinal hernia 550;Women;14 Segovia;Group 1108 Other abdominal hernia 551-553;Both sexes;104 Segovia;Group 1108 Other abdominal hernia 551-553;Men;47 Segovia;Group 1108 Other abdominal hernia 551-553;Women;57 Segovia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;15 Segovia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;7 Segovia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;8 Segovia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;98 Segovia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;50 Segovia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;48 Segovia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;116 Segovia;Group 1111 Intestinal obstruction without hernia 560;Men;58 Segovia;Group 1111 Intestinal obstruction without hernia 560;Women;58 Segovia;Group 1112 Intestinal diverticulosis 562;Both sexes;81 Segovia;Group 1112 Intestinal diverticulosis 562;Men;36 Segovia;Group 1112 Intestinal diverticulosis 562;Women;45 Segovia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;95 Segovia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;65 Segovia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;30 Segovia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;50 Segovia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;31 Segovia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;19 Segovia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;16 Segovia;Group 1115 Alcoholic hepatitis 5710-5713;Men;14 Segovia;Group 1115 Alcoholic hepatitis 5710-5713;Women;2 Segovia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;56 Segovia;Group 1116 Other diseases of the liver 570,5714-573;Men;42 Segovia;Group 1116 Other diseases of the liver 570,5714-573;Women;14 Segovia;Group 1117 Cholelithiasis 574;Both sexes;297 Segovia;Group 1117 Cholelithiasis 574;Men;144 Segovia;Group 1117 Cholelithiasis 574;Women;153 Segovia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;91 Segovia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;60 Segovia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;31 Segovia;Group 1119 Pancreatic diseases 577;Both sexes;80 Segovia;Group 1119 Pancreatic diseases 577;Men;42 Segovia;Group 1119 Pancreatic diseases 577;Women;38 Segovia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;67 Segovia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;37 Segovia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;30 Segovia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;172 Segovia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;94 Segovia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;78 Segovia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;101 Segovia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;60 Segovia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;41 Segovia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;3 Segovia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;.. Segovia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;3 Segovia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;68 Segovia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;34 Segovia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;34 Segovia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;847 Segovia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;432 Segovia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;415 Segovia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Segovia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Segovia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Segovia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Segovia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Segovia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Segovia;Group 1303 Internal derangement of knee 717;Both sexes;104 Segovia;Group 1303 Internal derangement of knee 717;Men;70 Segovia;Group 1303 Internal derangement of knee 717;Women;34 Segovia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;462 Segovia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;227 Segovia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;235 Segovia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;13 Segovia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;2 Segovia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;11 Segovia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;6 Segovia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1 Segovia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;5 Segovia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;11 Segovia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;4 Segovia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;7 Segovia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;16 Segovia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;11 Segovia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;5 Segovia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;125 Segovia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;78 Segovia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;47 Segovia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;110 Segovia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;39 Segovia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;71 Segovia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;884 Segovia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;525 Segovia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;359 Segovia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;62 Segovia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;22 Segovia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;40 Segovia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;65 Segovia;Group 1402 Renal failure 5836-5837, 584-586;Men;45 Segovia;Group 1402 Renal failure 5836-5837, 584-586;Women;20 Segovia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;152 Segovia;Group 1403 Urolithiasis 592, 594, 7880;Men;91 Segovia;Group 1403 Urolithiasis 592, 594, 7880;Women;61 Segovia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;247 Segovia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;148 Segovia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;99 Segovia;Group 1405 Prostatic hyperplasia 600;Both sexes;124 Segovia;Group 1405 Prostatic hyperplasia 600;Men;124 Segovia;Group 1405 Prostatic hyperplasia 600;Women;.. Segovia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;92 Segovia;Group 1406 Other diseases of the male genital organs 601-608;Men;92 Segovia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Segovia;Group 1407 Disorders of breast 610-612;Both sexes;9 Segovia;Group 1407 Disorders of breast 610-612;Men;1 Segovia;Group 1407 Disorders of breast 610-612;Women;8 Segovia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;20 Segovia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Segovia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;20 Segovia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;6 Segovia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Segovia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;6 Segovia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;107 Segovia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 Segovia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;105 Segovia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.081 Segovia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Segovia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.081 Segovia;Group 1501 Legally induced abortion 635;Both sexes;.. Segovia;Group 1501 Legally induced abortion 635;Men;.. Segovia;Group 1501 Legally induced abortion 635;Women;.. Segovia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;45 Segovia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Segovia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;45 Segovia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;626 Segovia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Segovia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;626 Segovia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;240 Segovia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Segovia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;240 Segovia;Group 1505 Single spontaneous delivery 650;Both sexes;53 Segovia;Group 1505 Single spontaneous delivery 650;Men;.. Segovia;Group 1505 Single spontaneous delivery 650;Women;53 Segovia;Group 1506 Other deliveries 6695-6697;Both sexes;6 Segovia;Group 1506 Other deliveries 6695-6697;Men;.. Segovia;Group 1506 Other deliveries 6695-6697;Women;6 Segovia;Group 1507 Complications related to the puerperium 670-676;Both sexes;10 Segovia;Group 1507 Complications related to the puerperium 670-676;Men;.. Segovia;Group 1507 Complications related to the puerperium 670-676;Women;10 Segovia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;101 Segovia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Segovia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;101 Segovia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;136 Segovia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;64 Segovia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;72 Segovia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;46 Segovia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;19 Segovia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;27 Segovia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;90 Segovia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;45 Segovia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;45 Segovia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;60 Segovia;Grupo 1700 Congenital abnormalities 740-759;Men;35 Segovia;Grupo 1700 Congenital abnormalities 740-759;Women;25 Segovia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;544 Segovia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;279 Segovia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;265 Segovia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;37 Segovia;Group 1801 Pain in throat and chest 7841, 7865;Men;22 Segovia;Group 1801 Pain in throat and chest 7841, 7865;Women;15 Segovia;Group 1802 Abdominal pain 7890;Both sexes;113 Segovia;Group 1802 Abdominal pain 7890;Men;49 Segovia;Group 1802 Abdominal pain 7890;Women;64 Segovia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1 Segovia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1 Segovia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. Segovia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;393 Segovia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;207 Segovia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;186 Segovia;Group 1900 Injuries and poisoning 800-999;Both sexes;1.250 Segovia;Group 1900 Injuries and poisoning 800-999;Men;639 Segovia;Group 1900 Injuries and poisoning 800-999;Women;611 Segovia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;57 Segovia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;35 Segovia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;22 Segovia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;14 Segovia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;11 Segovia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;3 Segovia;Group 1903 Radius and ulna fracture 813;Both sexes;81 Segovia;Group 1903 Radius and ulna fracture 813;Men;33 Segovia;Group 1903 Radius and ulna fracture 813;Women;48 Segovia;Group 1904 Femur fracture 820-821;Both sexes;248 Segovia;Group 1904 Femur fracture 820-821;Men;73 Segovia;Group 1904 Femur fracture 820-821;Women;175 Segovia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;80 Segovia;Group 1905 Leg fracture, including the ankle 823-824;Men;47 Segovia;Group 1905 Leg fracture, including the ankle 823-824;Women;33 Segovia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;344 Segovia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;204 Segovia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;140 Segovia;Group 1907 Burns 940-949;Both sexes;4 Segovia;Group 1907 Burns 940-949;Men;2 Segovia;Group 1907 Burns 940-949;Women;2 Segovia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;44 Segovia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;22 Segovia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;22 Segovia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;325 Segovia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;189 Segovia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;136 Segovia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Segovia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Segovia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Segovia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;53 Segovia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;23 Segovia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;30 Segovia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;212 Segovia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;126 Segovia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;86 Segovia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;6 Segovia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;1 Segovia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;5 Segovia;Group 2102 Contraceptive management V25;Both sexes;10 Segovia;Group 2102 Contraceptive management V25;Men;1 Segovia;Group 2102 Contraceptive management V25;Women;9 Segovia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Segovia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Segovia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Segovia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;118 Segovia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;73 Segovia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;45 Segovia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;78 Segovia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;51 Segovia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;27 Soria;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;8.218 Soria;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;4.318 Soria;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;3.900 Soria;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;245 Soria;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;146 Soria;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;99 Soria;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;46 Soria;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;24 Soria;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;22 Soria;Group 0102 Imprecise intestinal infections 009;Both sexes;1 Soria;Group 0102 Imprecise intestinal infections 009;Men;.. Soria;Group 0102 Imprecise intestinal infections 009;Women;1 Soria;Group 0103 Tuberculosis 010-018, 137;Both sexes;2 Soria;Group 0103 Tuberculosis 010-018, 137;Men;2 Soria;Group 0103 Tuberculosis 010-018, 137;Women;.. Soria;Group 0104 Septicaemia 038;Both sexes;153 Soria;Group 0104 Septicaemia 038;Men;99 Soria;Group 0104 Septicaemia 038;Women;54 Soria;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;1 Soria;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;.. Soria;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Soria;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;42 Soria;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;21 Soria;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;21 Soria;Group 0200 Neoplasms 140-239;Both sexes;797 Soria;Group 0200 Neoplasms 140-239;Men;455 Soria;Group 0200 Neoplasms 140-239;Women;342 Soria;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;107 Soria;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;61 Soria;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;46 Soria;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;38 Soria;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;31 Soria;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;7 Soria;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;3 Soria;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;2 Soria;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;1 Soria;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;75 Soria;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Soria;Group 0204 Malignant neoplasm of breast 174-175;Women;74 Soria;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;15 Soria;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Soria;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;15 Soria;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;6 Soria;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Soria;Group 0206 Malignant neoplasm of ovary 1830;Women;6 Soria;Group 0207 Malignant neoplasm of prostate 185;Both sexes;77 Soria;Group 0207 Malignant neoplasm of prostate 185;Men;77 Soria;Group 0207 Malignant neoplasm of prostate 185;Women;.. Soria;Group 0208 Malignant neoplasm of bladder 188;Both sexes;89 Soria;Group 0208 Malignant neoplasm of bladder 188;Men;74 Soria;Group 0208 Malignant neoplasm of bladder 188;Women;15 Soria;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;260 Soria;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;166 Soria;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;94 Soria;Group 0210 Carcinoma in situ 230-234;Both sexes;10 Soria;Group 0210 Carcinoma in situ 230-234;Men;3 Soria;Group 0210 Carcinoma in situ 230-234;Women;7 Soria;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;4 Soria;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;3 Soria;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;1 Soria;Grupo 0212 Leiomyoma of uterus 218;Both sexes;34 Soria;Grupo 0212 Leiomyoma of uterus 218;Men;.. Soria;Grupo 0212 Leiomyoma of uterus 218;Women;34 Soria;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;79 Soria;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;37 Soria;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;42 Soria;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;82 Soria;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;48 Soria;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;34 Soria;Group 0301 Anaemias 280-285;Both sexes;59 Soria;Group 0301 Anaemias 280-285;Men;33 Soria;Group 0301 Anaemias 280-285;Women;26 Soria;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;23 Soria;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;15 Soria;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;8 Soria;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;111 Soria;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;47 Soria;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;64 Soria;Group 0401 Diabetes mellitus 249-250;Both sexes;45 Soria;Group 0401 Diabetes mellitus 249-250;Men;28 Soria;Group 0401 Diabetes mellitus 249-250;Women;17 Soria;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;66 Soria;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;19 Soria;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;47 Soria;Group 0500 Mental disorders 290-319;Both sexes;260 Soria;Group 0500 Mental disorders 290-319;Men;145 Soria;Group 0500 Mental disorders 290-319;Women;115 Soria;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;4 Soria;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;3 Soria;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;1 Soria;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;22 Soria;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;19 Soria;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;3 Soria;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;15 Soria;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;10 Soria;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;5 Soria;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;72 Soria;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;41 Soria;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;31 Soria;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;45 Soria;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;21 Soria;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;24 Soria;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;102 Soria;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;51 Soria;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;51 Soria;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;179 Soria;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;97 Soria;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;82 Soria;Group 0601 Alzheimer's disease 3310;Both sexes;13 Soria;Group 0601 Alzheimer's disease 3310;Men;3 Soria;Group 0601 Alzheimer's disease 3310;Women;10 Soria;Group 0602 Multiple sclerosis 340;Both sexes;4 Soria;Group 0602 Multiple sclerosis 340;Men;2 Soria;Group 0602 Multiple sclerosis 340;Women;2 Soria;Group 0603 Epilepsy 345;Both sexes;49 Soria;Group 0603 Epilepsy 345;Men;30 Soria;Group 0603 Epilepsy 345;Women;19 Soria;Group 0604 Transient cerebral ischemia 435;Both sexes;51 Soria;Group 0604 Transient cerebral ischemia 435;Men;25 Soria;Group 0604 Transient cerebral ischemia 435;Women;26 Soria;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;62 Soria;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;37 Soria;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;25 Soria;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;14 Soria;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;10 Soria;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;4 Soria;Grupo 0701 Cataract 366;Both sexes;1 Soria;Grupo 0701 Cataract 366;Men;1 Soria;Grupo 0701 Cataract 366;Women;.. Soria;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;13 Soria;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;9 Soria;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;4 Soria;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;21 Soria;Group 0800 Diseases of the ear and the mastoid 380-389;Men;11 Soria;Group 0800 Diseases of the ear and the mastoid 380-389;Women;10 Soria;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1.256 Soria;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;707 Soria;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;549 Soria;Group 0901 Hypertensive disease 401-405;Both sexes;48 Soria;Group 0901 Hypertensive disease 401-405;Men;19 Soria;Group 0901 Hypertensive disease 401-405;Women;29 Soria;Group 0902 Angina pectoris 4111, 413;Both sexes;66 Soria;Group 0902 Angina pectoris 4111, 413;Men;46 Soria;Group 0902 Angina pectoris 4111, 413;Women;20 Soria;Group 0903 Acute myocardial infarction 410;Both sexes;126 Soria;Group 0903 Acute myocardial infarction 410;Men;90 Soria;Group 0903 Acute myocardial infarction 410;Women;36 Soria;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;37 Soria;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;26 Soria;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;11 Soria;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;63 Soria;Group 0905 Diseases of the lungs circulation 415-417;Men;36 Soria;Group 0905 Diseases of the lungs circulation 415-417;Women;27 Soria;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;168 Soria;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;91 Soria;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;77 Soria;Grupo 0907 Heart failure 428;Both sexes;356 Soria;Grupo 0907 Heart failure 428;Men;188 Soria;Grupo 0907 Heart failure 428;Women;168 Soria;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;212 Soria;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;117 Soria;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;95 Soria;Grupo 0909 Atherosclerosis 440;Both sexes;18 Soria;Grupo 0909 Atherosclerosis 440;Men;11 Soria;Grupo 0909 Atherosclerosis 440;Women;7 Soria;Group 0910 Varicose veins of lower extremities 454;Both sexes;70 Soria;Group 0910 Varicose veins of lower extremities 454;Men;29 Soria;Group 0910 Varicose veins of lower extremities 454;Women;41 Soria;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;92 Soria;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;54 Soria;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;38 Soria;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1.203 Soria;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;716 Soria;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;487 Soria;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;18 Soria;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;9 Soria;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;9 Soria;Group 1002 Pneumonia 480-486;Both sexes;321 Soria;Group 1002 Pneumonia 480-486;Men;190 Soria;Group 1002 Pneumonia 480-486;Women;131 Soria;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;24 Soria;Group 1003 Acute bronchitis and bronchiolitis 466;Men;15 Soria;Group 1003 Acute bronchitis and bronchiolitis 466;Women;9 Soria;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;80 Soria;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;52 Soria;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;28 Soria;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;111 Soria;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;76 Soria;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;35 Soria;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;127 Soria;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;93 Soria;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;34 Soria;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;23 Soria;Group 1007 Asthma 4930-4931,4938-4939;Men;10 Soria;Group 1007 Asthma 4930-4931,4938-4939;Women;13 Soria;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;499 Soria;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;271 Soria;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;228 Soria;Group 1100 Diseases of the digestive system 520-579;Both sexes;1.195 Soria;Group 1100 Diseases of the digestive system 520-579;Men;731 Soria;Group 1100 Diseases of the digestive system 520-579;Women;464 Soria;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;3 Soria;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;2 Soria;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;1 Soria;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;12 Soria;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;7 Soria;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;5 Soria;Group 1103 Diseases of the esophagus 530;Both sexes;21 Soria;Group 1103 Diseases of the esophagus 530;Men;13 Soria;Group 1103 Diseases of the esophagus 530;Women;8 Soria;Group 1104 Peptic ulcer 531-534;Both sexes;31 Soria;Group 1104 Peptic ulcer 531-534;Men;14 Soria;Group 1104 Peptic ulcer 531-534;Women;17 Soria;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;24 Soria;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;14 Soria;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;10 Soria;Group 1106 Appendicitis 540-543;Both sexes;96 Soria;Group 1106 Appendicitis 540-543;Men;57 Soria;Group 1106 Appendicitis 540-543;Women;39 Soria;Group 1107 Inguinal hernia 550;Both sexes;159 Soria;Group 1107 Inguinal hernia 550;Men;138 Soria;Group 1107 Inguinal hernia 550;Women;21 Soria;Group 1108 Other abdominal hernia 551-553;Both sexes;101 Soria;Group 1108 Other abdominal hernia 551-553;Men;54 Soria;Group 1108 Other abdominal hernia 551-553;Women;47 Soria;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;11 Soria;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;8 Soria;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;3 Soria;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;59 Soria;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;32 Soria;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;27 Soria;Group 1111 Intestinal obstruction without hernia 560;Both sexes;71 Soria;Group 1111 Intestinal obstruction without hernia 560;Men;40 Soria;Group 1111 Intestinal obstruction without hernia 560;Women;31 Soria;Group 1112 Intestinal diverticulosis 562;Both sexes;47 Soria;Group 1112 Intestinal diverticulosis 562;Men;30 Soria;Group 1112 Intestinal diverticulosis 562;Women;17 Soria;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;46 Soria;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;35 Soria;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;11 Soria;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;31 Soria;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;12 Soria;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;19 Soria;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;12 Soria;Group 1115 Alcoholic hepatitis 5710-5713;Men;12 Soria;Group 1115 Alcoholic hepatitis 5710-5713;Women;.. Soria;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;35 Soria;Group 1116 Other diseases of the liver 570,5714-573;Men;27 Soria;Group 1116 Other diseases of the liver 570,5714-573;Women;8 Soria;Group 1117 Cholelithiasis 574;Both sexes;201 Soria;Group 1117 Cholelithiasis 574;Men;90 Soria;Group 1117 Cholelithiasis 574;Women;111 Soria;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;66 Soria;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;42 Soria;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;24 Soria;Group 1119 Pancreatic diseases 577;Both sexes;62 Soria;Group 1119 Pancreatic diseases 577;Men;40 Soria;Group 1119 Pancreatic diseases 577;Women;22 Soria;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;107 Soria;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;64 Soria;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;43 Soria;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;76 Soria;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;42 Soria;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;34 Soria;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;57 Soria;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;32 Soria;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;25 Soria;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;3 Soria;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;2 Soria;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;1 Soria;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;16 Soria;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;8 Soria;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;8 Soria;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;480 Soria;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;259 Soria;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;221 Soria;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Soria;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Soria;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Soria;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Soria;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Soria;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Soria;Group 1303 Internal derangement of knee 717;Both sexes;109 Soria;Group 1303 Internal derangement of knee 717;Men;78 Soria;Group 1303 Internal derangement of knee 717;Women;31 Soria;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;194 Soria;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;101 Soria;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;93 Soria;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;9 Soria;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;4 Soria;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;5 Soria;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;8 Soria;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;5 Soria;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;3 Soria;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;13 Soria;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;6 Soria;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;7 Soria;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;15 Soria;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;4 Soria;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;11 Soria;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;74 Soria;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;44 Soria;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;30 Soria;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;58 Soria;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;17 Soria;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;41 Soria;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;416 Soria;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;224 Soria;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;192 Soria;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;46 Soria;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;14 Soria;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;32 Soria;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;46 Soria;Group 1402 Renal failure 5836-5837, 584-586;Men;22 Soria;Group 1402 Renal failure 5836-5837, 584-586;Women;24 Soria;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;48 Soria;Group 1403 Urolithiasis 592, 594, 7880;Men;30 Soria;Group 1403 Urolithiasis 592, 594, 7880;Women;18 Soria;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;163 Soria;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;81 Soria;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;82 Soria;Group 1405 Prostatic hyperplasia 600;Both sexes;38 Soria;Group 1405 Prostatic hyperplasia 600;Men;38 Soria;Group 1405 Prostatic hyperplasia 600;Women;.. Soria;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;38 Soria;Group 1406 Other diseases of the male genital organs 601-608;Men;38 Soria;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Soria;Group 1407 Disorders of breast 610-612;Both sexes;20 Soria;Group 1407 Disorders of breast 610-612;Men;1 Soria;Group 1407 Disorders of breast 610-612;Women;19 Soria;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;1 Soria;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Soria;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;1 Soria;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;3 Soria;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Soria;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;3 Soria;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;13 Soria;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Soria;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;13 Soria;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;638 Soria;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Soria;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;638 Soria;Group 1501 Legally induced abortion 635;Both sexes;.. Soria;Group 1501 Legally induced abortion 635;Men;.. Soria;Group 1501 Legally induced abortion 635;Women;.. Soria;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;22 Soria;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Soria;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;22 Soria;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;463 Soria;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Soria;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;463 Soria;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;111 Soria;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Soria;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;111 Soria;Group 1505 Single spontaneous delivery 650;Both sexes;8 Soria;Group 1505 Single spontaneous delivery 650;Men;.. Soria;Group 1505 Single spontaneous delivery 650;Women;8 Soria;Group 1506 Other deliveries 6695-6697;Both sexes;14 Soria;Group 1506 Other deliveries 6695-6697;Men;.. Soria;Group 1506 Other deliveries 6695-6697;Women;14 Soria;Group 1507 Complications related to the puerperium 670-676;Both sexes;3 Soria;Group 1507 Complications related to the puerperium 670-676;Men;.. Soria;Group 1507 Complications related to the puerperium 670-676;Women;3 Soria;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;17 Soria;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Soria;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;17 Soria;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;87 Soria;Group 1600 Some disorders originating in the perinatal period 760-779;Men;40 Soria;Group 1600 Some disorders originating in the perinatal period 760-779;Women;47 Soria;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;17 Soria;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;6 Soria;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;11 Soria;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;70 Soria;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;34 Soria;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;36 Soria;Grupo 1700 Congenital abnormalities 740-759;Both sexes;28 Soria;Grupo 1700 Congenital abnormalities 740-759;Men;23 Soria;Grupo 1700 Congenital abnormalities 740-759;Women;5 Soria;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;329 Soria;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;207 Soria;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;122 Soria;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;54 Soria;Group 1801 Pain in throat and chest 7841, 7865;Men;31 Soria;Group 1801 Pain in throat and chest 7841, 7865;Women;23 Soria;Group 1802 Abdominal pain 7890;Both sexes;56 Soria;Group 1802 Abdominal pain 7890;Men;27 Soria;Group 1802 Abdominal pain 7890;Women;29 Soria;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1 Soria;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1 Soria;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. Soria;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;218 Soria;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;148 Soria;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;70 Soria;Group 1900 Injuries and poisoning 800-999;Both sexes;715 Soria;Group 1900 Injuries and poisoning 800-999;Men;361 Soria;Group 1900 Injuries and poisoning 800-999;Women;354 Soria;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;45 Soria;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;24 Soria;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;21 Soria;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;8 Soria;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;6 Soria;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;2 Soria;Group 1903 Radius and ulna fracture 813;Both sexes;33 Soria;Group 1903 Radius and ulna fracture 813;Men;19 Soria;Group 1903 Radius and ulna fracture 813;Women;14 Soria;Group 1904 Femur fracture 820-821;Both sexes;190 Soria;Group 1904 Femur fracture 820-821;Men;61 Soria;Group 1904 Femur fracture 820-821;Women;129 Soria;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;50 Soria;Group 1905 Leg fracture, including the ankle 823-824;Men;23 Soria;Group 1905 Leg fracture, including the ankle 823-824;Women;27 Soria;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;183 Soria;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;105 Soria;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;78 Soria;Group 1907 Burns 940-949;Both sexes;1 Soria;Group 1907 Burns 940-949;Men;1 Soria;Group 1907 Burns 940-949;Women;.. Soria;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;24 Soria;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;14 Soria;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;10 Soria;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;162 Soria;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;93 Soria;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;69 Soria;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Soria;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Soria;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Soria;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;19 Soria;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;15 Soria;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;4 Soria;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;86 Soria;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;49 Soria;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;37 Soria;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;3 Soria;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;2 Soria;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;1 Soria;Group 2102 Contraceptive management V25;Both sexes;2 Soria;Group 2102 Contraceptive management V25;Men;2 Soria;Group 2102 Contraceptive management V25;Women;.. Soria;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Soria;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Soria;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Soria;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;56 Soria;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;29 Soria;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;27 Soria;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;25 Soria;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;16 Soria;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;9 Valladolid;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;60.053 Valladolid;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;30.180 Valladolid;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;29.873 Valladolid;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.232 Valladolid;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;670 Valladolid;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;562 Valladolid;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;274 Valladolid;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;146 Valladolid;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;128 Valladolid;Group 0102 Imprecise intestinal infections 009;Both sexes;43 Valladolid;Group 0102 Imprecise intestinal infections 009;Men;27 Valladolid;Group 0102 Imprecise intestinal infections 009;Women;16 Valladolid;Group 0103 Tuberculosis 010-018, 137;Both sexes;29 Valladolid;Group 0103 Tuberculosis 010-018, 137;Men;18 Valladolid;Group 0103 Tuberculosis 010-018, 137;Women;11 Valladolid;Group 0104 Septicaemia 038;Both sexes;591 Valladolid;Group 0104 Septicaemia 038;Men;312 Valladolid;Group 0104 Septicaemia 038;Women;279 Valladolid;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;.. Valladolid;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;.. Valladolid;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;.. Valladolid;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;295 Valladolid;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;167 Valladolid;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;128 Valladolid;Group 0200 Neoplasms 140-239;Both sexes;6.528 Valladolid;Group 0200 Neoplasms 140-239;Men;3.616 Valladolid;Group 0200 Neoplasms 140-239;Women;2.912 Valladolid;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;621 Valladolid;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;399 Valladolid;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;222 Valladolid;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;511 Valladolid;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;417 Valladolid;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;94 Valladolid;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;87 Valladolid;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;52 Valladolid;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;35 Valladolid;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;396 Valladolid;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Valladolid;Group 0204 Malignant neoplasm of breast 174-175;Women;393 Valladolid;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;88 Valladolid;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Valladolid;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;88 Valladolid;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;69 Valladolid;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Valladolid;Group 0206 Malignant neoplasm of ovary 1830;Women;69 Valladolid;Group 0207 Malignant neoplasm of prostate 185;Both sexes;257 Valladolid;Group 0207 Malignant neoplasm of prostate 185;Men;257 Valladolid;Group 0207 Malignant neoplasm of prostate 185;Women;.. Valladolid;Group 0208 Malignant neoplasm of bladder 188;Both sexes;490 Valladolid;Group 0208 Malignant neoplasm of bladder 188;Men;437 Valladolid;Group 0208 Malignant neoplasm of bladder 188;Women;53 Valladolid;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.226 Valladolid;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.332 Valladolid;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;894 Valladolid;Group 0210 Carcinoma in situ 230-234;Both sexes;97 Valladolid;Group 0210 Carcinoma in situ 230-234;Men;42 Valladolid;Group 0210 Carcinoma in situ 230-234;Women;55 Valladolid;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;62 Valladolid;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;33 Valladolid;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;29 Valladolid;Grupo 0212 Leiomyoma of uterus 218;Both sexes;331 Valladolid;Grupo 0212 Leiomyoma of uterus 218;Men;.. Valladolid;Grupo 0212 Leiomyoma of uterus 218;Women;331 Valladolid;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.293 Valladolid;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;644 Valladolid;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;649 Valladolid;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;574 Valladolid;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;284 Valladolid;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;290 Valladolid;Group 0301 Anaemias 280-285;Both sexes;354 Valladolid;Group 0301 Anaemias 280-285;Men;168 Valladolid;Group 0301 Anaemias 280-285;Women;186 Valladolid;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;220 Valladolid;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;116 Valladolid;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;104 Valladolid;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.208 Valladolid;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;455 Valladolid;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;753 Valladolid;Group 0401 Diabetes mellitus 249-250;Both sexes;372 Valladolid;Group 0401 Diabetes mellitus 249-250;Men;227 Valladolid;Group 0401 Diabetes mellitus 249-250;Women;145 Valladolid;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;836 Valladolid;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;228 Valladolid;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;608 Valladolid;Group 0500 Mental disorders 290-319;Both sexes;1.273 Valladolid;Group 0500 Mental disorders 290-319;Men;635 Valladolid;Group 0500 Mental disorders 290-319;Women;638 Valladolid;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;55 Valladolid;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;29 Valladolid;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;26 Valladolid;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;127 Valladolid;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;97 Valladolid;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;30 Valladolid;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;59 Valladolid;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;43 Valladolid;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;16 Valladolid;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;289 Valladolid;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;166 Valladolid;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;123 Valladolid;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;279 Valladolid;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;102 Valladolid;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;177 Valladolid;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;464 Valladolid;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;198 Valladolid;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;266 Valladolid;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.039 Valladolid;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;485 Valladolid;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;554 Valladolid;Group 0601 Alzheimer's disease 3310;Both sexes;29 Valladolid;Group 0601 Alzheimer's disease 3310;Men;9 Valladolid;Group 0601 Alzheimer's disease 3310;Women;20 Valladolid;Group 0602 Multiple sclerosis 340;Both sexes;39 Valladolid;Group 0602 Multiple sclerosis 340;Men;13 Valladolid;Group 0602 Multiple sclerosis 340;Women;26 Valladolid;Group 0603 Epilepsy 345;Both sexes;199 Valladolid;Group 0603 Epilepsy 345;Men;119 Valladolid;Group 0603 Epilepsy 345;Women;80 Valladolid;Group 0604 Transient cerebral ischemia 435;Both sexes;163 Valladolid;Group 0604 Transient cerebral ischemia 435;Men;64 Valladolid;Group 0604 Transient cerebral ischemia 435;Women;99 Valladolid;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;609 Valladolid;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;280 Valladolid;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;329 Valladolid;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;313 Valladolid;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;137 Valladolid;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;176 Valladolid;Grupo 0701 Cataract 366;Both sexes;36 Valladolid;Grupo 0701 Cataract 366;Men;16 Valladolid;Grupo 0701 Cataract 366;Women;20 Valladolid;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;277 Valladolid;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;121 Valladolid;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;156 Valladolid;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;548 Valladolid;Group 0800 Diseases of the ear and the mastoid 380-389;Men;279 Valladolid;Group 0800 Diseases of the ear and the mastoid 380-389;Women;269 Valladolid;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;8.802 Valladolid;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5.239 Valladolid;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3.563 Valladolid;Group 0901 Hypertensive disease 401-405;Both sexes;409 Valladolid;Group 0901 Hypertensive disease 401-405;Men;169 Valladolid;Group 0901 Hypertensive disease 401-405;Women;240 Valladolid;Group 0902 Angina pectoris 4111, 413;Both sexes;396 Valladolid;Group 0902 Angina pectoris 4111, 413;Men;259 Valladolid;Group 0902 Angina pectoris 4111, 413;Women;137 Valladolid;Group 0903 Acute myocardial infarction 410;Both sexes;866 Valladolid;Group 0903 Acute myocardial infarction 410;Men;617 Valladolid;Group 0903 Acute myocardial infarction 410;Women;249 Valladolid;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;641 Valladolid;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;483 Valladolid;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;158 Valladolid;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;390 Valladolid;Group 0905 Diseases of the lungs circulation 415-417;Men;159 Valladolid;Group 0905 Diseases of the lungs circulation 415-417;Women;231 Valladolid;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.109 Valladolid;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;664 Valladolid;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;445 Valladolid;Grupo 0907 Heart failure 428;Both sexes;1.461 Valladolid;Grupo 0907 Heart failure 428;Men;703 Valladolid;Grupo 0907 Heart failure 428;Women;758 Valladolid;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.222 Valladolid;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;691 Valladolid;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;531 Valladolid;Grupo 0909 Atherosclerosis 440;Both sexes;418 Valladolid;Grupo 0909 Atherosclerosis 440;Men;336 Valladolid;Grupo 0909 Atherosclerosis 440;Women;82 Valladolid;Group 0910 Varicose veins of lower extremities 454;Both sexes;188 Valladolid;Group 0910 Varicose veins of lower extremities 454;Men;87 Valladolid;Group 0910 Varicose veins of lower extremities 454;Women;101 Valladolid;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.702 Valladolid;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.071 Valladolid;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;631 Valladolid;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7.129 Valladolid;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.145 Valladolid;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.984 Valladolid;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;288 Valladolid;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;153 Valladolid;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;135 Valladolid;Group 1002 Pneumonia 480-486;Both sexes;1.546 Valladolid;Group 1002 Pneumonia 480-486;Men;935 Valladolid;Group 1002 Pneumonia 480-486;Women;611 Valladolid;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;624 Valladolid;Group 1003 Acute bronchitis and bronchiolitis 466;Men;247 Valladolid;Group 1003 Acute bronchitis and bronchiolitis 466;Women;377 Valladolid;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;539 Valladolid;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;280 Valladolid;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;259 Valladolid;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;752 Valladolid;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;508 Valladolid;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;244 Valladolid;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.043 Valladolid;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;850 Valladolid;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;193 Valladolid;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;218 Valladolid;Group 1007 Asthma 4930-4931,4938-4939;Men;56 Valladolid;Group 1007 Asthma 4930-4931,4938-4939;Women;162 Valladolid;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.119 Valladolid;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.116 Valladolid;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.003 Valladolid;Group 1100 Diseases of the digestive system 520-579;Both sexes;7.908 Valladolid;Group 1100 Diseases of the digestive system 520-579;Men;4.664 Valladolid;Group 1100 Diseases of the digestive system 520-579;Women;3.244 Valladolid;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;146 Valladolid;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;76 Valladolid;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;70 Valladolid;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;97 Valladolid;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;53 Valladolid;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;44 Valladolid;Group 1103 Diseases of the esophagus 530;Both sexes;135 Valladolid;Group 1103 Diseases of the esophagus 530;Men;84 Valladolid;Group 1103 Diseases of the esophagus 530;Women;51 Valladolid;Group 1104 Peptic ulcer 531-534;Both sexes;154 Valladolid;Group 1104 Peptic ulcer 531-534;Men;95 Valladolid;Group 1104 Peptic ulcer 531-534;Women;59 Valladolid;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;175 Valladolid;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;93 Valladolid;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;82 Valladolid;Group 1106 Appendicitis 540-543;Both sexes;588 Valladolid;Group 1106 Appendicitis 540-543;Men;334 Valladolid;Group 1106 Appendicitis 540-543;Women;254 Valladolid;Group 1107 Inguinal hernia 550;Both sexes;1.183 Valladolid;Group 1107 Inguinal hernia 550;Men;1.076 Valladolid;Group 1107 Inguinal hernia 550;Women;107 Valladolid;Group 1108 Other abdominal hernia 551-553;Both sexes;706 Valladolid;Group 1108 Other abdominal hernia 551-553;Men;374 Valladolid;Group 1108 Other abdominal hernia 551-553;Women;332 Valladolid;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;143 Valladolid;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;82 Valladolid;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;61 Valladolid;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;440 Valladolid;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;194 Valladolid;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;246 Valladolid;Group 1111 Intestinal obstruction without hernia 560;Both sexes;378 Valladolid;Group 1111 Intestinal obstruction without hernia 560;Men;190 Valladolid;Group 1111 Intestinal obstruction without hernia 560;Women;188 Valladolid;Group 1112 Intestinal diverticulosis 562;Both sexes;358 Valladolid;Group 1112 Intestinal diverticulosis 562;Men;178 Valladolid;Group 1112 Intestinal diverticulosis 562;Women;180 Valladolid;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;426 Valladolid;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;279 Valladolid;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;147 Valladolid;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;288 Valladolid;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;129 Valladolid;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;159 Valladolid;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;179 Valladolid;Group 1115 Alcoholic hepatitis 5710-5713;Men;161 Valladolid;Group 1115 Alcoholic hepatitis 5710-5713;Women;18 Valladolid;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;232 Valladolid;Group 1116 Other diseases of the liver 570,5714-573;Men;151 Valladolid;Group 1116 Other diseases of the liver 570,5714-573;Women;81 Valladolid;Group 1117 Cholelithiasis 574;Both sexes;1.359 Valladolid;Group 1117 Cholelithiasis 574;Men;645 Valladolid;Group 1117 Cholelithiasis 574;Women;714 Valladolid;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;294 Valladolid;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;163 Valladolid;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;131 Valladolid;Group 1119 Pancreatic diseases 577;Both sexes;277 Valladolid;Group 1119 Pancreatic diseases 577;Men;151 Valladolid;Group 1119 Pancreatic diseases 577;Women;126 Valladolid;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;350 Valladolid;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;156 Valladolid;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;194 Valladolid;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;533 Valladolid;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;293 Valladolid;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;240 Valladolid;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;333 Valladolid;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;191 Valladolid;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;142 Valladolid;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;20 Valladolid;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;10 Valladolid;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;10 Valladolid;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;180 Valladolid;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;92 Valladolid;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;88 Valladolid;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3.748 Valladolid;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.778 Valladolid;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.970 Valladolid;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Valladolid;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Valladolid;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Valladolid;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Valladolid;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Valladolid;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Valladolid;Group 1303 Internal derangement of knee 717;Both sexes;346 Valladolid;Group 1303 Internal derangement of knee 717;Men;244 Valladolid;Group 1303 Internal derangement of knee 717;Women;102 Valladolid;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.408 Valladolid;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;649 Valladolid;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;759 Valladolid;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;178 Valladolid;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;51 Valladolid;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;127 Valladolid;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;206 Valladolid;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;106 Valladolid;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;100 Valladolid;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;359 Valladolid;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;180 Valladolid;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;179 Valladolid;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;68 Valladolid;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;38 Valladolid;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;30 Valladolid;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;473 Valladolid;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;279 Valladolid;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;194 Valladolid;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;710 Valladolid;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;231 Valladolid;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;479 Valladolid;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.970 Valladolid;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.081 Valladolid;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.889 Valladolid;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;273 Valladolid;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;119 Valladolid;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;154 Valladolid;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;428 Valladolid;Group 1402 Renal failure 5836-5837, 584-586;Men;277 Valladolid;Group 1402 Renal failure 5836-5837, 584-586;Women;151 Valladolid;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;632 Valladolid;Group 1403 Urolithiasis 592, 594, 7880;Men;382 Valladolid;Group 1403 Urolithiasis 592, 594, 7880;Women;250 Valladolid;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.098 Valladolid;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;573 Valladolid;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;525 Valladolid;Group 1405 Prostatic hyperplasia 600;Both sexes;315 Valladolid;Group 1405 Prostatic hyperplasia 600;Men;315 Valladolid;Group 1405 Prostatic hyperplasia 600;Women;.. Valladolid;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;388 Valladolid;Group 1406 Other diseases of the male genital organs 601-608;Men;388 Valladolid;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Valladolid;Group 1407 Disorders of breast 610-612;Both sexes;172 Valladolid;Group 1407 Disorders of breast 610-612;Men;25 Valladolid;Group 1407 Disorders of breast 610-612;Women;147 Valladolid;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;104 Valladolid;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Valladolid;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;104 Valladolid;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;25 Valladolid;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Valladolid;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;25 Valladolid;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;535 Valladolid;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 Valladolid;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;533 Valladolid;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;4.993 Valladolid;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Valladolid;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;4.993 Valladolid;Group 1501 Legally induced abortion 635;Both sexes;2 Valladolid;Group 1501 Legally induced abortion 635;Men;.. Valladolid;Group 1501 Legally induced abortion 635;Women;2 Valladolid;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;328 Valladolid;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Valladolid;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;328 Valladolid;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.028 Valladolid;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Valladolid;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.028 Valladolid;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;499 Valladolid;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Valladolid;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;499 Valladolid;Group 1505 Single spontaneous delivery 650;Both sexes;452 Valladolid;Group 1505 Single spontaneous delivery 650;Men;.. Valladolid;Group 1505 Single spontaneous delivery 650;Women;452 Valladolid;Group 1506 Other deliveries 6695-6697;Both sexes;337 Valladolid;Group 1506 Other deliveries 6695-6697;Men;.. Valladolid;Group 1506 Other deliveries 6695-6697;Women;337 Valladolid;Group 1507 Complications related to the puerperium 670-676;Both sexes;32 Valladolid;Group 1507 Complications related to the puerperium 670-676;Men;.. Valladolid;Group 1507 Complications related to the puerperium 670-676;Women;32 Valladolid;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;315 Valladolid;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Valladolid;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;315 Valladolid;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;596 Valladolid;Group 1600 Some disorders originating in the perinatal period 760-779;Men;321 Valladolid;Group 1600 Some disorders originating in the perinatal period 760-779;Women;275 Valladolid;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;47 Valladolid;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;21 Valladolid;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;26 Valladolid;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;549 Valladolid;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;300 Valladolid;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;249 Valladolid;Grupo 1700 Congenital abnormalities 740-759;Both sexes;399 Valladolid;Grupo 1700 Congenital abnormalities 740-759;Men;217 Valladolid;Grupo 1700 Congenital abnormalities 740-759;Women;182 Valladolid;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.357 Valladolid;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.894 Valladolid;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.463 Valladolid;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;308 Valladolid;Group 1801 Pain in throat and chest 7841, 7865;Men;184 Valladolid;Group 1801 Pain in throat and chest 7841, 7865;Women;124 Valladolid;Group 1802 Abdominal pain 7890;Both sexes;234 Valladolid;Group 1802 Abdominal pain 7890;Men;97 Valladolid;Group 1802 Abdominal pain 7890;Women;137 Valladolid;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.028 Valladolid;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;605 Valladolid;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;423 Valladolid;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.787 Valladolid;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.008 Valladolid;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;779 Valladolid;Group 1900 Injuries and poisoning 800-999;Both sexes;5.103 Valladolid;Group 1900 Injuries and poisoning 800-999;Men;2.591 Valladolid;Group 1900 Injuries and poisoning 800-999;Women;2.512 Valladolid;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;202 Valladolid;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;119 Valladolid;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;83 Valladolid;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;187 Valladolid;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;124 Valladolid;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;63 Valladolid;Group 1903 Radius and ulna fracture 813;Both sexes;188 Valladolid;Group 1903 Radius and ulna fracture 813;Men;87 Valladolid;Group 1903 Radius and ulna fracture 813;Women;101 Valladolid;Group 1904 Femur fracture 820-821;Both sexes;857 Valladolid;Group 1904 Femur fracture 820-821;Men;198 Valladolid;Group 1904 Femur fracture 820-821;Women;659 Valladolid;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;305 Valladolid;Group 1905 Leg fracture, including the ankle 823-824;Men;142 Valladolid;Group 1905 Leg fracture, including the ankle 823-824;Women;163 Valladolid;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.340 Valladolid;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;786 Valladolid;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;554 Valladolid;Group 1907 Burns 940-949;Both sexes;53 Valladolid;Group 1907 Burns 940-949;Men;33 Valladolid;Group 1907 Burns 940-949;Women;20 Valladolid;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;198 Valladolid;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;91 Valladolid;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;107 Valladolid;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.661 Valladolid;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;945 Valladolid;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;716 Valladolid;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;13 Valladolid;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;7 Valladolid;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;6 Valladolid;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;99 Valladolid;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;59 Valladolid;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;40 Valladolid;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;800 Valladolid;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;396 Valladolid;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;404 Valladolid;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;49 Valladolid;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;32 Valladolid;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;17 Valladolid;Group 2102 Contraceptive management V25;Both sexes;38 Valladolid;Group 2102 Contraceptive management V25;Men;1 Valladolid;Group 2102 Contraceptive management V25;Women;37 Valladolid;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Valladolid;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Valladolid;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Valladolid;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;390 Valladolid;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;237 Valladolid;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;153 Valladolid;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;323 Valladolid;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;126 Valladolid;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;197 Zamora;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;18.611 Zamora;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;9.324 Zamora;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;9.287 Zamora;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;738 Zamora;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;373 Zamora;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;365 Zamora;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;164 Zamora;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;83 Zamora;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;81 Zamora;Group 0102 Imprecise intestinal infections 009;Both sexes;54 Zamora;Group 0102 Imprecise intestinal infections 009;Men;18 Zamora;Group 0102 Imprecise intestinal infections 009;Women;36 Zamora;Group 0103 Tuberculosis 010-018, 137;Both sexes;15 Zamora;Group 0103 Tuberculosis 010-018, 137;Men;8 Zamora;Group 0103 Tuberculosis 010-018, 137;Women;7 Zamora;Group 0104 Septicaemia 038;Both sexes;276 Zamora;Group 0104 Septicaemia 038;Men;149 Zamora;Group 0104 Septicaemia 038;Women;127 Zamora;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;15 Zamora;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;10 Zamora;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;5 Zamora;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;214 Zamora;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;105 Zamora;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;109 Zamora;Group 0200 Neoplasms 140-239;Both sexes;2.047 Zamora;Group 0200 Neoplasms 140-239;Men;1.166 Zamora;Group 0200 Neoplasms 140-239;Women;881 Zamora;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;302 Zamora;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;203 Zamora;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;99 Zamora;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;122 Zamora;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;100 Zamora;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;22 Zamora;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;16 Zamora;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;8 Zamora;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;8 Zamora;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;126 Zamora;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Zamora;Group 0204 Malignant neoplasm of breast 174-175;Women;125 Zamora;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;42 Zamora;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Zamora;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;42 Zamora;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;37 Zamora;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Zamora;Group 0206 Malignant neoplasm of ovary 1830;Women;37 Zamora;Group 0207 Malignant neoplasm of prostate 185;Both sexes;78 Zamora;Group 0207 Malignant neoplasm of prostate 185;Men;78 Zamora;Group 0207 Malignant neoplasm of prostate 185;Women;.. Zamora;Group 0208 Malignant neoplasm of bladder 188;Both sexes;223 Zamora;Group 0208 Malignant neoplasm of bladder 188;Men;192 Zamora;Group 0208 Malignant neoplasm of bladder 188;Women;31 Zamora;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;785 Zamora;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;484 Zamora;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;301 Zamora;Group 0210 Carcinoma in situ 230-234;Both sexes;21 Zamora;Group 0210 Carcinoma in situ 230-234;Men;10 Zamora;Group 0210 Carcinoma in situ 230-234;Women;11 Zamora;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;20 Zamora;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;12 Zamora;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;8 Zamora;Grupo 0212 Leiomyoma of uterus 218;Both sexes;65 Zamora;Grupo 0212 Leiomyoma of uterus 218;Men;.. Zamora;Grupo 0212 Leiomyoma of uterus 218;Women;65 Zamora;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;210 Zamora;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;78 Zamora;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;132 Zamora;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;188 Zamora;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;105 Zamora;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;83 Zamora;Group 0301 Anaemias 280-285;Both sexes;103 Zamora;Group 0301 Anaemias 280-285;Men;53 Zamora;Group 0301 Anaemias 280-285;Women;50 Zamora;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;85 Zamora;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;52 Zamora;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;33 Zamora;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;377 Zamora;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;160 Zamora;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;217 Zamora;Group 0401 Diabetes mellitus 249-250;Both sexes;154 Zamora;Group 0401 Diabetes mellitus 249-250;Men;81 Zamora;Group 0401 Diabetes mellitus 249-250;Women;73 Zamora;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;223 Zamora;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;79 Zamora;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;144 Zamora;Group 0500 Mental disorders 290-319;Both sexes;386 Zamora;Group 0500 Mental disorders 290-319;Men;202 Zamora;Group 0500 Mental disorders 290-319;Women;184 Zamora;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;5 Zamora;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;3 Zamora;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2 Zamora;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;20 Zamora;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;16 Zamora;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;4 Zamora;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;13 Zamora;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;13 Zamora;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;.. Zamora;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;157 Zamora;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;96 Zamora;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;61 Zamora;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;85 Zamora;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;33 Zamora;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;52 Zamora;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;106 Zamora;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;41 Zamora;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;65 Zamora;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;240 Zamora;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;112 Zamora;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;128 Zamora;Group 0601 Alzheimer's disease 3310;Both sexes;6 Zamora;Group 0601 Alzheimer's disease 3310;Men;4 Zamora;Group 0601 Alzheimer's disease 3310;Women;2 Zamora;Group 0602 Multiple sclerosis 340;Both sexes;6 Zamora;Group 0602 Multiple sclerosis 340;Men;5 Zamora;Group 0602 Multiple sclerosis 340;Women;1 Zamora;Group 0603 Epilepsy 345;Both sexes;49 Zamora;Group 0603 Epilepsy 345;Men;26 Zamora;Group 0603 Epilepsy 345;Women;23 Zamora;Group 0604 Transient cerebral ischemia 435;Both sexes;66 Zamora;Group 0604 Transient cerebral ischemia 435;Men;27 Zamora;Group 0604 Transient cerebral ischemia 435;Women;39 Zamora;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;113 Zamora;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;50 Zamora;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;63 Zamora;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;46 Zamora;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;22 Zamora;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;24 Zamora;Grupo 0701 Cataract 366;Both sexes;3 Zamora;Grupo 0701 Cataract 366;Men;2 Zamora;Grupo 0701 Cataract 366;Women;1 Zamora;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;43 Zamora;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;20 Zamora;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;23 Zamora;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;156 Zamora;Group 0800 Diseases of the ear and the mastoid 380-389;Men;74 Zamora;Group 0800 Diseases of the ear and the mastoid 380-389;Women;82 Zamora;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2.409 Zamora;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1.265 Zamora;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.144 Zamora;Group 0901 Hypertensive disease 401-405;Both sexes;104 Zamora;Group 0901 Hypertensive disease 401-405;Men;37 Zamora;Group 0901 Hypertensive disease 401-405;Women;67 Zamora;Group 0902 Angina pectoris 4111, 413;Both sexes;52 Zamora;Group 0902 Angina pectoris 4111, 413;Men;41 Zamora;Group 0902 Angina pectoris 4111, 413;Women;11 Zamora;Group 0903 Acute myocardial infarction 410;Both sexes;224 Zamora;Group 0903 Acute myocardial infarction 410;Men;155 Zamora;Group 0903 Acute myocardial infarction 410;Women;69 Zamora;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;53 Zamora;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;41 Zamora;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;12 Zamora;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;126 Zamora;Group 0905 Diseases of the lungs circulation 415-417;Men;57 Zamora;Group 0905 Diseases of the lungs circulation 415-417;Women;69 Zamora;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;315 Zamora;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;192 Zamora;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;123 Zamora;Grupo 0907 Heart failure 428;Both sexes;656 Zamora;Grupo 0907 Heart failure 428;Men;299 Zamora;Grupo 0907 Heart failure 428;Women;357 Zamora;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;443 Zamora;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;213 Zamora;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;230 Zamora;Grupo 0909 Atherosclerosis 440;Both sexes;26 Zamora;Grupo 0909 Atherosclerosis 440;Men;18 Zamora;Grupo 0909 Atherosclerosis 440;Women;8 Zamora;Group 0910 Varicose veins of lower extremities 454;Both sexes;75 Zamora;Group 0910 Varicose veins of lower extremities 454;Men;33 Zamora;Group 0910 Varicose veins of lower extremities 454;Women;42 Zamora;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;335 Zamora;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;179 Zamora;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;156 Zamora;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2.929 Zamora;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.704 Zamora;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.225 Zamora;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;189 Zamora;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;95 Zamora;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;94 Zamora;Group 1002 Pneumonia 480-486;Both sexes;634 Zamora;Group 1002 Pneumonia 480-486;Men;405 Zamora;Group 1002 Pneumonia 480-486;Women;229 Zamora;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;306 Zamora;Group 1003 Acute bronchitis and bronchiolitis 466;Men;115 Zamora;Group 1003 Acute bronchitis and bronchiolitis 466;Women;191 Zamora;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;172 Zamora;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;87 Zamora;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;85 Zamora;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;251 Zamora;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;142 Zamora;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;109 Zamora;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;500 Zamora;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;449 Zamora;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;51 Zamora;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;147 Zamora;Group 1007 Asthma 4930-4931,4938-4939;Men;36 Zamora;Group 1007 Asthma 4930-4931,4938-4939;Women;111 Zamora;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;730 Zamora;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;375 Zamora;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;355 Zamora;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.763 Zamora;Group 1100 Diseases of the digestive system 520-579;Men;1.596 Zamora;Group 1100 Diseases of the digestive system 520-579;Women;1.167 Zamora;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;12 Zamora;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;5 Zamora;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;7 Zamora;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;39 Zamora;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;22 Zamora;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;17 Zamora;Group 1103 Diseases of the esophagus 530;Both sexes;59 Zamora;Group 1103 Diseases of the esophagus 530;Men;31 Zamora;Group 1103 Diseases of the esophagus 530;Women;28 Zamora;Group 1104 Peptic ulcer 531-534;Both sexes;75 Zamora;Group 1104 Peptic ulcer 531-534;Men;52 Zamora;Group 1104 Peptic ulcer 531-534;Women;23 Zamora;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;95 Zamora;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;57 Zamora;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;38 Zamora;Group 1106 Appendicitis 540-543;Both sexes;191 Zamora;Group 1106 Appendicitis 540-543;Men;111 Zamora;Group 1106 Appendicitis 540-543;Women;80 Zamora;Group 1107 Inguinal hernia 550;Both sexes;379 Zamora;Group 1107 Inguinal hernia 550;Men;348 Zamora;Group 1107 Inguinal hernia 550;Women;31 Zamora;Group 1108 Other abdominal hernia 551-553;Both sexes;151 Zamora;Group 1108 Other abdominal hernia 551-553;Men;83 Zamora;Group 1108 Other abdominal hernia 551-553;Women;68 Zamora;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;63 Zamora;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;25 Zamora;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;38 Zamora;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;184 Zamora;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;87 Zamora;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;97 Zamora;Group 1111 Intestinal obstruction without hernia 560;Both sexes;179 Zamora;Group 1111 Intestinal obstruction without hernia 560;Men;100 Zamora;Group 1111 Intestinal obstruction without hernia 560;Women;79 Zamora;Group 1112 Intestinal diverticulosis 562;Both sexes;132 Zamora;Group 1112 Intestinal diverticulosis 562;Men;55 Zamora;Group 1112 Intestinal diverticulosis 562;Women;77 Zamora;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;97 Zamora;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;66 Zamora;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;31 Zamora;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;131 Zamora;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;64 Zamora;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;67 Zamora;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;33 Zamora;Group 1115 Alcoholic hepatitis 5710-5713;Men;29 Zamora;Group 1115 Alcoholic hepatitis 5710-5713;Women;4 Zamora;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;91 Zamora;Group 1116 Other diseases of the liver 570,5714-573;Men;51 Zamora;Group 1116 Other diseases of the liver 570,5714-573;Women;40 Zamora;Group 1117 Cholelithiasis 574;Both sexes;516 Zamora;Group 1117 Cholelithiasis 574;Men;238 Zamora;Group 1117 Cholelithiasis 574;Women;278 Zamora;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;68 Zamora;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;38 Zamora;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;30 Zamora;Group 1119 Pancreatic diseases 577;Both sexes;136 Zamora;Group 1119 Pancreatic diseases 577;Men;64 Zamora;Group 1119 Pancreatic diseases 577;Women;72 Zamora;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;132 Zamora;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;70 Zamora;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;62 Zamora;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;141 Zamora;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;80 Zamora;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;61 Zamora;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;97 Zamora;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;57 Zamora;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;40 Zamora;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;7 Zamora;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;2 Zamora;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;5 Zamora;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;37 Zamora;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;21 Zamora;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;16 Zamora;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;856 Zamora;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;373 Zamora;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;483 Zamora;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Zamora;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Zamora;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Zamora;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Zamora;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Zamora;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Zamora;Group 1303 Internal derangement of knee 717;Both sexes;76 Zamora;Group 1303 Internal derangement of knee 717;Men;50 Zamora;Group 1303 Internal derangement of knee 717;Women;26 Zamora;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;457 Zamora;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;194 Zamora;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;263 Zamora;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;13 Zamora;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;7 Zamora;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;6 Zamora;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;10 Zamora;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;8 Zamora;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;2 Zamora;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;43 Zamora;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;21 Zamora;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;22 Zamora;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;9 Zamora;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;1 Zamora;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;8 Zamora;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;104 Zamora;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;55 Zamora;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;49 Zamora;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;144 Zamora;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;37 Zamora;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;107 Zamora;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1.268 Zamora;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;690 Zamora;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;578 Zamora;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;110 Zamora;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;36 Zamora;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;74 Zamora;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;129 Zamora;Group 1402 Renal failure 5836-5837, 584-586;Men;73 Zamora;Group 1402 Renal failure 5836-5837, 584-586;Women;56 Zamora;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;104 Zamora;Group 1403 Urolithiasis 592, 594, 7880;Men;67 Zamora;Group 1403 Urolithiasis 592, 594, 7880;Women;37 Zamora;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;440 Zamora;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;246 Zamora;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;194 Zamora;Group 1405 Prostatic hyperplasia 600;Both sexes;186 Zamora;Group 1405 Prostatic hyperplasia 600;Men;186 Zamora;Group 1405 Prostatic hyperplasia 600;Women;.. Zamora;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;77 Zamora;Group 1406 Other diseases of the male genital organs 601-608;Men;77 Zamora;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Zamora;Group 1407 Disorders of breast 610-612;Both sexes;20 Zamora;Group 1407 Disorders of breast 610-612;Men;4 Zamora;Group 1407 Disorders of breast 610-612;Women;16 Zamora;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;34 Zamora;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Zamora;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;34 Zamora;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;14 Zamora;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Zamora;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;14 Zamora;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;154 Zamora;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Zamora;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;153 Zamora;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.202 Zamora;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Zamora;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.202 Zamora;Group 1501 Legally induced abortion 635;Both sexes;.. Zamora;Group 1501 Legally induced abortion 635;Men;.. Zamora;Group 1501 Legally induced abortion 635;Women;.. Zamora;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;104 Zamora;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Zamora;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;104 Zamora;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;831 Zamora;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Zamora;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;831 Zamora;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;134 Zamora;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Zamora;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;134 Zamora;Group 1505 Single spontaneous delivery 650;Both sexes;35 Zamora;Group 1505 Single spontaneous delivery 650;Men;.. Zamora;Group 1505 Single spontaneous delivery 650;Women;35 Zamora;Group 1506 Other deliveries 6695-6697;Both sexes;7 Zamora;Group 1506 Other deliveries 6695-6697;Men;.. Zamora;Group 1506 Other deliveries 6695-6697;Women;7 Zamora;Group 1507 Complications related to the puerperium 670-676;Both sexes;14 Zamora;Group 1507 Complications related to the puerperium 670-676;Men;.. Zamora;Group 1507 Complications related to the puerperium 670-676;Women;14 Zamora;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;77 Zamora;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Zamora;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;77 Zamora;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;107 Zamora;Group 1600 Some disorders originating in the perinatal period 760-779;Men;66 Zamora;Group 1600 Some disorders originating in the perinatal period 760-779;Women;41 Zamora;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;25 Zamora;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;16 Zamora;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;9 Zamora;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;82 Zamora;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;50 Zamora;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;32 Zamora;Grupo 1700 Congenital abnormalities 740-759;Both sexes;45 Zamora;Grupo 1700 Congenital abnormalities 740-759;Men;20 Zamora;Grupo 1700 Congenital abnormalities 740-759;Women;25 Zamora;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;717 Zamora;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;390 Zamora;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;327 Zamora;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;80 Zamora;Group 1801 Pain in throat and chest 7841, 7865;Men;48 Zamora;Group 1801 Pain in throat and chest 7841, 7865;Women;32 Zamora;Group 1802 Abdominal pain 7890;Both sexes;88 Zamora;Group 1802 Abdominal pain 7890;Men;35 Zamora;Group 1802 Abdominal pain 7890;Women;53 Zamora;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;43 Zamora;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;29 Zamora;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;14 Zamora;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;506 Zamora;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;278 Zamora;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;228 Zamora;Group 1900 Injuries and poisoning 800-999;Both sexes;1.586 Zamora;Group 1900 Injuries and poisoning 800-999;Men;759 Zamora;Group 1900 Injuries and poisoning 800-999;Women;827 Zamora;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;105 Zamora;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;54 Zamora;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;51 Zamora;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;51 Zamora;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;36 Zamora;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;15 Zamora;Group 1903 Radius and ulna fracture 813;Both sexes;75 Zamora;Group 1903 Radius and ulna fracture 813;Men;28 Zamora;Group 1903 Radius and ulna fracture 813;Women;47 Zamora;Group 1904 Femur fracture 820-821;Both sexes;352 Zamora;Group 1904 Femur fracture 820-821;Men;81 Zamora;Group 1904 Femur fracture 820-821;Women;271 Zamora;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;110 Zamora;Group 1905 Leg fracture, including the ankle 823-824;Men;61 Zamora;Group 1905 Leg fracture, including the ankle 823-824;Women;49 Zamora;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;295 Zamora;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;175 Zamora;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;120 Zamora;Group 1907 Burns 940-949;Both sexes;1 Zamora;Group 1907 Burns 940-949;Men;1 Zamora;Group 1907 Burns 940-949;Women;.. Zamora;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;51 Zamora;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;23 Zamora;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;28 Zamora;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;471 Zamora;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;258 Zamora;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;213 Zamora;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Zamora;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Zamora;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Zamora;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;75 Zamora;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;42 Zamora;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;33 Zamora;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;410 Zamora;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;167 Zamora;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;243 Zamora;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;11 Zamora;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;7 Zamora;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;4 Zamora;Group 2102 Contraceptive management V25;Both sexes;13 Zamora;Group 2102 Contraceptive management V25;Men;.. Zamora;Group 2102 Contraceptive management V25;Women;13 Zamora;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Zamora;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Zamora;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Zamora;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;255 Zamora;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;81 Zamora;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;174 Zamora;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;131 Zamora;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;79 Zamora;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;52 CASTILLA - LA MANCHA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;176.141 CASTILLA - LA MANCHA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;84.275 CASTILLA - LA MANCHA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;91.866 CASTILLA - LA MANCHA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;4.641 CASTILLA - LA MANCHA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2.610 CASTILLA - LA MANCHA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2.031 CASTILLA - LA MANCHA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;782 CASTILLA - LA MANCHA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;439 CASTILLA - LA MANCHA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;343 CASTILLA - LA MANCHA;Group 0102 Imprecise intestinal infections 009;Both sexes;212 CASTILLA - LA MANCHA;Group 0102 Imprecise intestinal infections 009;Men;108 CASTILLA - LA MANCHA;Group 0102 Imprecise intestinal infections 009;Women;104 CASTILLA - LA MANCHA;Group 0103 Tuberculosis 010-018, 137;Both sexes;97 CASTILLA - LA MANCHA;Group 0103 Tuberculosis 010-018, 137;Men;66 CASTILLA - LA MANCHA;Group 0103 Tuberculosis 010-018, 137;Women;31 CASTILLA - LA MANCHA;Group 0104 Septicaemia 038;Both sexes;2.310 CASTILLA - LA MANCHA;Group 0104 Septicaemia 038;Men;1.251 CASTILLA - LA MANCHA;Group 0104 Septicaemia 038;Women;1.059 CASTILLA - LA MANCHA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;72 CASTILLA - LA MANCHA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;51 CASTILLA - LA MANCHA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;21 CASTILLA - LA MANCHA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.168 CASTILLA - LA MANCHA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;695 CASTILLA - LA MANCHA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;473 CASTILLA - LA MANCHA;Group 0200 Neoplasms 140-239;Both sexes;15.702 CASTILLA - LA MANCHA;Group 0200 Neoplasms 140-239;Men;8.790 CASTILLA - LA MANCHA;Group 0200 Neoplasms 140-239;Women;6.912 CASTILLA - LA MANCHA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.809 CASTILLA - LA MANCHA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1.123 CASTILLA - LA MANCHA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;686 CASTILLA - LA MANCHA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.272 CASTILLA - LA MANCHA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1.070 CASTILLA - LA MANCHA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;202 CASTILLA - LA MANCHA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;366 CASTILLA - LA MANCHA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;218 CASTILLA - LA MANCHA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;148 CASTILLA - LA MANCHA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.083 CASTILLA - LA MANCHA;Group 0204 Malignant neoplasm of breast 174-175;Men;9 CASTILLA - LA MANCHA;Group 0204 Malignant neoplasm of breast 174-175;Women;1.074 CASTILLA - LA MANCHA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;300 CASTILLA - LA MANCHA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CASTILLA - LA MANCHA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;300 CASTILLA - LA MANCHA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;166 CASTILLA - LA MANCHA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CASTILLA - LA MANCHA;Group 0206 Malignant neoplasm of ovary 1830;Women;166 CASTILLA - LA MANCHA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;513 CASTILLA - LA MANCHA;Group 0207 Malignant neoplasm of prostate 185;Men;513 CASTILLA - LA MANCHA;Group 0207 Malignant neoplasm of prostate 185;Women;.. CASTILLA - LA MANCHA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.177 CASTILLA - LA MANCHA;Group 0208 Malignant neoplasm of bladder 188;Men;1.015 CASTILLA - LA MANCHA;Group 0208 Malignant neoplasm of bladder 188;Women;162 CASTILLA - LA MANCHA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5.425 CASTILLA - LA MANCHA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3.311 CASTILLA - LA MANCHA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.114 CASTILLA - LA MANCHA;Group 0210 Carcinoma in situ 230-234;Both sexes;226 CASTILLA - LA MANCHA;Group 0210 Carcinoma in situ 230-234;Men;101 CASTILLA - LA MANCHA;Group 0210 Carcinoma in situ 230-234;Women;125 CASTILLA - LA MANCHA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;196 CASTILLA - LA MANCHA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;121 CASTILLA - LA MANCHA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;75 CASTILLA - LA MANCHA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;609 CASTILLA - LA MANCHA;Grupo 0212 Leiomyoma of uterus 218;Men;.. CASTILLA - LA MANCHA;Grupo 0212 Leiomyoma of uterus 218;Women;609 CASTILLA - LA MANCHA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.560 CASTILLA - LA MANCHA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.309 CASTILLA - LA MANCHA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.251 CASTILLA - LA MANCHA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.632 CASTILLA - LA MANCHA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;824 CASTILLA - LA MANCHA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;808 CASTILLA - LA MANCHA;Group 0301 Anaemias 280-285;Both sexes;953 CASTILLA - LA MANCHA;Group 0301 Anaemias 280-285;Men;452 CASTILLA - LA MANCHA;Group 0301 Anaemias 280-285;Women;501 CASTILLA - LA MANCHA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;679 CASTILLA - LA MANCHA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;372 CASTILLA - LA MANCHA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;307 CASTILLA - LA MANCHA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.899 CASTILLA - LA MANCHA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.197 CASTILLA - LA MANCHA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.702 CASTILLA - LA MANCHA;Group 0401 Diabetes mellitus 249-250;Both sexes;990 CASTILLA - LA MANCHA;Group 0401 Diabetes mellitus 249-250;Men;571 CASTILLA - LA MANCHA;Group 0401 Diabetes mellitus 249-250;Women;419 CASTILLA - LA MANCHA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.909 CASTILLA - LA MANCHA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;626 CASTILLA - LA MANCHA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.283 CASTILLA - LA MANCHA;Group 0500 Mental disorders 290-319;Both sexes;4.122 CASTILLA - LA MANCHA;Group 0500 Mental disorders 290-319;Men;2.049 CASTILLA - LA MANCHA;Group 0500 Mental disorders 290-319;Women;2.073 CASTILLA - LA MANCHA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;108 CASTILLA - LA MANCHA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;52 CASTILLA - LA MANCHA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;56 CASTILLA - LA MANCHA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;249 CASTILLA - LA MANCHA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;181 CASTILLA - LA MANCHA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;68 CASTILLA - LA MANCHA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;159 CASTILLA - LA MANCHA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;109 CASTILLA - LA MANCHA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;50 CASTILLA - LA MANCHA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.250 CASTILLA - LA MANCHA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;808 CASTILLA - LA MANCHA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;442 CASTILLA - LA MANCHA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;927 CASTILLA - LA MANCHA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;318 CASTILLA - LA MANCHA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;609 CASTILLA - LA MANCHA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.429 CASTILLA - LA MANCHA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;581 CASTILLA - LA MANCHA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;848 CASTILLA - LA MANCHA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;4.482 CASTILLA - LA MANCHA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.293 CASTILLA - LA MANCHA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.189 CASTILLA - LA MANCHA;Group 0601 Alzheimer's disease 3310;Both sexes;63 CASTILLA - LA MANCHA;Group 0601 Alzheimer's disease 3310;Men;23 CASTILLA - LA MANCHA;Group 0601 Alzheimer's disease 3310;Women;40 CASTILLA - LA MANCHA;Group 0602 Multiple sclerosis 340;Both sexes;119 CASTILLA - LA MANCHA;Group 0602 Multiple sclerosis 340;Men;23 CASTILLA - LA MANCHA;Group 0602 Multiple sclerosis 340;Women;96 CASTILLA - LA MANCHA;Group 0603 Epilepsy 345;Both sexes;539 CASTILLA - LA MANCHA;Group 0603 Epilepsy 345;Men;286 CASTILLA - LA MANCHA;Group 0603 Epilepsy 345;Women;253 CASTILLA - LA MANCHA;Group 0604 Transient cerebral ischemia 435;Both sexes;660 CASTILLA - LA MANCHA;Group 0604 Transient cerebral ischemia 435;Men;312 CASTILLA - LA MANCHA;Group 0604 Transient cerebral ischemia 435;Women;348 CASTILLA - LA MANCHA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.101 CASTILLA - LA MANCHA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.649 CASTILLA - LA MANCHA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.452 CASTILLA - LA MANCHA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;969 CASTILLA - LA MANCHA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;529 CASTILLA - LA MANCHA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;440 CASTILLA - LA MANCHA;Grupo 0701 Cataract 366;Both sexes;138 CASTILLA - LA MANCHA;Grupo 0701 Cataract 366;Men;75 CASTILLA - LA MANCHA;Grupo 0701 Cataract 366;Women;63 CASTILLA - LA MANCHA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;831 CASTILLA - LA MANCHA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;454 CASTILLA - LA MANCHA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;377 CASTILLA - LA MANCHA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;753 CASTILLA - LA MANCHA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;331 CASTILLA - LA MANCHA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;422 CASTILLA - LA MANCHA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;23.471 CASTILLA - LA MANCHA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;13.063 CASTILLA - LA MANCHA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;10.408 CASTILLA - LA MANCHA;Group 0901 Hypertensive disease 401-405;Both sexes;1.262 CASTILLA - LA MANCHA;Group 0901 Hypertensive disease 401-405;Men;545 CASTILLA - LA MANCHA;Group 0901 Hypertensive disease 401-405;Women;717 CASTILLA - LA MANCHA;Group 0902 Angina pectoris 4111, 413;Both sexes;1.000 CASTILLA - LA MANCHA;Group 0902 Angina pectoris 4111, 413;Men;634 CASTILLA - LA MANCHA;Group 0902 Angina pectoris 4111, 413;Women;366 CASTILLA - LA MANCHA;Group 0903 Acute myocardial infarction 410;Both sexes;2.209 CASTILLA - LA MANCHA;Group 0903 Acute myocardial infarction 410;Men;1.615 CASTILLA - LA MANCHA;Group 0903 Acute myocardial infarction 410;Women;594 CASTILLA - LA MANCHA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.227 CASTILLA - LA MANCHA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;916 CASTILLA - LA MANCHA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;311 CASTILLA - LA MANCHA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;886 CASTILLA - LA MANCHA;Group 0905 Diseases of the lungs circulation 415-417;Men;414 CASTILLA - LA MANCHA;Group 0905 Diseases of the lungs circulation 415-417;Women;472 CASTILLA - LA MANCHA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;3.264 CASTILLA - LA MANCHA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.758 CASTILLA - LA MANCHA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.506 CASTILLA - LA MANCHA;Grupo 0907 Heart failure 428;Both sexes;5.415 CASTILLA - LA MANCHA;Grupo 0907 Heart failure 428;Men;2.373 CASTILLA - LA MANCHA;Grupo 0907 Heart failure 428;Women;3.042 CASTILLA - LA MANCHA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;4.059 CASTILLA - LA MANCHA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2.238 CASTILLA - LA MANCHA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.821 CASTILLA - LA MANCHA;Grupo 0909 Atherosclerosis 440;Both sexes;781 CASTILLA - LA MANCHA;Grupo 0909 Atherosclerosis 440;Men;611 CASTILLA - LA MANCHA;Grupo 0909 Atherosclerosis 440;Women;170 CASTILLA - LA MANCHA;Group 0910 Varicose veins of lower extremities 454;Both sexes;206 CASTILLA - LA MANCHA;Group 0910 Varicose veins of lower extremities 454;Men;80 CASTILLA - LA MANCHA;Group 0910 Varicose veins of lower extremities 454;Women;126 CASTILLA - LA MANCHA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3.162 CASTILLA - LA MANCHA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.879 CASTILLA - LA MANCHA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.283 CASTILLA - LA MANCHA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;24.281 CASTILLA - LA MANCHA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;14.113 CASTILLA - LA MANCHA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;10.168 CASTILLA - LA MANCHA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.115 CASTILLA - LA MANCHA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;628 CASTILLA - LA MANCHA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;487 CASTILLA - LA MANCHA;Group 1002 Pneumonia 480-486;Both sexes;6.308 CASTILLA - LA MANCHA;Group 1002 Pneumonia 480-486;Men;3.872 CASTILLA - LA MANCHA;Group 1002 Pneumonia 480-486;Women;2.436 CASTILLA - LA MANCHA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.001 CASTILLA - LA MANCHA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;907 CASTILLA - LA MANCHA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.094 CASTILLA - LA MANCHA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;814 CASTILLA - LA MANCHA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;441 CASTILLA - LA MANCHA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;373 CASTILLA - LA MANCHA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.315 CASTILLA - LA MANCHA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;869 CASTILLA - LA MANCHA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;446 CASTILLA - LA MANCHA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;3.590 CASTILLA - LA MANCHA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.973 CASTILLA - LA MANCHA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;617 CASTILLA - LA MANCHA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;733 CASTILLA - LA MANCHA;Group 1007 Asthma 4930-4931,4938-4939;Men;239 CASTILLA - LA MANCHA;Group 1007 Asthma 4930-4931,4938-4939;Women;494 CASTILLA - LA MANCHA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;8.405 CASTILLA - LA MANCHA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;4.184 CASTILLA - LA MANCHA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;4.221 CASTILLA - LA MANCHA;Group 1100 Diseases of the digestive system 520-579;Both sexes;22.423 CASTILLA - LA MANCHA;Group 1100 Diseases of the digestive system 520-579;Men;12.393 CASTILLA - LA MANCHA;Group 1100 Diseases of the digestive system 520-579;Women;10.030 CASTILLA - LA MANCHA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;313 CASTILLA - LA MANCHA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;148 CASTILLA - LA MANCHA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;165 CASTILLA - LA MANCHA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;283 CASTILLA - LA MANCHA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;154 CASTILLA - LA MANCHA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;129 CASTILLA - LA MANCHA;Group 1103 Diseases of the esophagus 530;Both sexes;427 CASTILLA - LA MANCHA;Group 1103 Diseases of the esophagus 530;Men;267 CASTILLA - LA MANCHA;Group 1103 Diseases of the esophagus 530;Women;160 CASTILLA - LA MANCHA;Group 1104 Peptic ulcer 531-534;Both sexes;527 CASTILLA - LA MANCHA;Group 1104 Peptic ulcer 531-534;Men;362 CASTILLA - LA MANCHA;Group 1104 Peptic ulcer 531-534;Women;165 CASTILLA - LA MANCHA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;527 CASTILLA - LA MANCHA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;262 CASTILLA - LA MANCHA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;265 CASTILLA - LA MANCHA;Group 1106 Appendicitis 540-543;Both sexes;1.925 CASTILLA - LA MANCHA;Group 1106 Appendicitis 540-543;Men;1.143 CASTILLA - LA MANCHA;Group 1106 Appendicitis 540-543;Women;782 CASTILLA - LA MANCHA;Group 1107 Inguinal hernia 550;Both sexes;1.623 CASTILLA - LA MANCHA;Group 1107 Inguinal hernia 550;Men;1.444 CASTILLA - LA MANCHA;Group 1107 Inguinal hernia 550;Women;179 CASTILLA - LA MANCHA;Group 1108 Other abdominal hernia 551-553;Both sexes;1.775 CASTILLA - LA MANCHA;Group 1108 Other abdominal hernia 551-553;Men;762 CASTILLA - LA MANCHA;Group 1108 Other abdominal hernia 551-553;Women;1.013 CASTILLA - LA MANCHA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;420 CASTILLA - LA MANCHA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;225 CASTILLA - LA MANCHA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;195 CASTILLA - LA MANCHA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.395 CASTILLA - LA MANCHA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;686 CASTILLA - LA MANCHA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;709 CASTILLA - LA MANCHA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1.279 CASTILLA - LA MANCHA;Group 1111 Intestinal obstruction without hernia 560;Men;620 CASTILLA - LA MANCHA;Group 1111 Intestinal obstruction without hernia 560;Women;659 CASTILLA - LA MANCHA;Group 1112 Intestinal diverticulosis 562;Both sexes;786 CASTILLA - LA MANCHA;Group 1112 Intestinal diverticulosis 562;Men;412 CASTILLA - LA MANCHA;Group 1112 Intestinal diverticulosis 562;Women;374 CASTILLA - LA MANCHA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.260 CASTILLA - LA MANCHA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;859 CASTILLA - LA MANCHA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;401 CASTILLA - LA MANCHA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;889 CASTILLA - LA MANCHA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;404 CASTILLA - LA MANCHA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;485 CASTILLA - LA MANCHA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;289 CASTILLA - LA MANCHA;Group 1115 Alcoholic hepatitis 5710-5713;Men;247 CASTILLA - LA MANCHA;Group 1115 Alcoholic hepatitis 5710-5713;Women;42 CASTILLA - LA MANCHA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;627 CASTILLA - LA MANCHA;Group 1116 Other diseases of the liver 570,5714-573;Men;406 CASTILLA - LA MANCHA;Group 1116 Other diseases of the liver 570,5714-573;Women;221 CASTILLA - LA MANCHA;Group 1117 Cholelithiasis 574;Both sexes;4.184 CASTILLA - LA MANCHA;Group 1117 Cholelithiasis 574;Men;1.830 CASTILLA - LA MANCHA;Group 1117 Cholelithiasis 574;Women;2.354 CASTILLA - LA MANCHA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.365 CASTILLA - LA MANCHA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;748 CASTILLA - LA MANCHA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;617 CASTILLA - LA MANCHA;Group 1119 Pancreatic diseases 577;Both sexes;1.540 CASTILLA - LA MANCHA;Group 1119 Pancreatic diseases 577;Men;868 CASTILLA - LA MANCHA;Group 1119 Pancreatic diseases 577;Women;672 CASTILLA - LA MANCHA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;989 CASTILLA - LA MANCHA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;546 CASTILLA - LA MANCHA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;443 CASTILLA - LA MANCHA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.468 CASTILLA - LA MANCHA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;782 CASTILLA - LA MANCHA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;686 CASTILLA - LA MANCHA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;901 CASTILLA - LA MANCHA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;511 CASTILLA - LA MANCHA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;390 CASTILLA - LA MANCHA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;66 CASTILLA - LA MANCHA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;38 CASTILLA - LA MANCHA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;28 CASTILLA - LA MANCHA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;501 CASTILLA - LA MANCHA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;233 CASTILLA - LA MANCHA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;268 CASTILLA - LA MANCHA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9.738 CASTILLA - LA MANCHA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.694 CASTILLA - LA MANCHA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5.044 CASTILLA - LA MANCHA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA - LA MANCHA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CASTILLA - LA MANCHA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CASTILLA - LA MANCHA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA - LA MANCHA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CASTILLA - LA MANCHA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CASTILLA - LA MANCHA;Group 1303 Internal derangement of knee 717;Both sexes;897 CASTILLA - LA MANCHA;Group 1303 Internal derangement of knee 717;Men;634 CASTILLA - LA MANCHA;Group 1303 Internal derangement of knee 717;Women;263 CASTILLA - LA MANCHA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.873 CASTILLA - LA MANCHA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.612 CASTILLA - LA MANCHA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.261 CASTILLA - LA MANCHA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;178 CASTILLA - LA MANCHA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;80 CASTILLA - LA MANCHA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;98 CASTILLA - LA MANCHA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;705 CASTILLA - LA MANCHA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;376 CASTILLA - LA MANCHA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;329 CASTILLA - LA MANCHA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;917 CASTILLA - LA MANCHA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;463 CASTILLA - LA MANCHA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;454 CASTILLA - LA MANCHA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;202 CASTILLA - LA MANCHA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;117 CASTILLA - LA MANCHA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;85 CASTILLA - LA MANCHA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.428 CASTILLA - LA MANCHA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;801 CASTILLA - LA MANCHA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;627 CASTILLA - LA MANCHA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.538 CASTILLA - LA MANCHA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;611 CASTILLA - LA MANCHA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;927 CASTILLA - LA MANCHA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;11.752 CASTILLA - LA MANCHA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;5.354 CASTILLA - LA MANCHA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;6.398 CASTILLA - LA MANCHA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.061 CASTILLA - LA MANCHA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;416 CASTILLA - LA MANCHA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;645 CASTILLA - LA MANCHA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.268 CASTILLA - LA MANCHA;Group 1402 Renal failure 5836-5837, 584-586;Men;691 CASTILLA - LA MANCHA;Group 1402 Renal failure 5836-5837, 584-586;Women;577 CASTILLA - LA MANCHA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.609 CASTILLA - LA MANCHA;Group 1403 Urolithiasis 592, 594, 7880;Men;932 CASTILLA - LA MANCHA;Group 1403 Urolithiasis 592, 594, 7880;Women;677 CASTILLA - LA MANCHA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;3.556 CASTILLA - LA MANCHA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.763 CASTILLA - LA MANCHA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.793 CASTILLA - LA MANCHA;Group 1405 Prostatic hyperplasia 600;Both sexes;649 CASTILLA - LA MANCHA;Group 1405 Prostatic hyperplasia 600;Men;649 CASTILLA - LA MANCHA;Group 1405 Prostatic hyperplasia 600;Women;.. CASTILLA - LA MANCHA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;844 CASTILLA - LA MANCHA;Group 1406 Other diseases of the male genital organs 601-608;Men;844 CASTILLA - LA MANCHA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CASTILLA - LA MANCHA;Group 1407 Disorders of breast 610-612;Both sexes;555 CASTILLA - LA MANCHA;Group 1407 Disorders of breast 610-612;Men;47 CASTILLA - LA MANCHA;Group 1407 Disorders of breast 610-612;Women;508 CASTILLA - LA MANCHA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;324 CASTILLA - LA MANCHA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CASTILLA - LA MANCHA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;324 CASTILLA - LA MANCHA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;164 CASTILLA - LA MANCHA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CASTILLA - LA MANCHA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;164 CASTILLA - LA MANCHA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.722 CASTILLA - LA MANCHA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;12 CASTILLA - LA MANCHA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.710 CASTILLA - LA MANCHA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;18.710 CASTILLA - LA MANCHA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CASTILLA - LA MANCHA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;18.710 CASTILLA - LA MANCHA;Group 1501 Legally induced abortion 635;Both sexes;20 CASTILLA - LA MANCHA;Group 1501 Legally induced abortion 635;Men;.. CASTILLA - LA MANCHA;Group 1501 Legally induced abortion 635;Women;20 CASTILLA - LA MANCHA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.531 CASTILLA - LA MANCHA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CASTILLA - LA MANCHA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.531 CASTILLA - LA MANCHA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;11.709 CASTILLA - LA MANCHA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CASTILLA - LA MANCHA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;11.709 CASTILLA - LA MANCHA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.328 CASTILLA - LA MANCHA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CASTILLA - LA MANCHA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.328 CASTILLA - LA MANCHA;Group 1505 Single spontaneous delivery 650;Both sexes;1.048 CASTILLA - LA MANCHA;Group 1505 Single spontaneous delivery 650;Men;.. CASTILLA - LA MANCHA;Group 1505 Single spontaneous delivery 650;Women;1.048 CASTILLA - LA MANCHA;Group 1506 Other deliveries 6695-6697;Both sexes;769 CASTILLA - LA MANCHA;Group 1506 Other deliveries 6695-6697;Men;.. CASTILLA - LA MANCHA;Group 1506 Other deliveries 6695-6697;Women;769 CASTILLA - LA MANCHA;Group 1507 Complications related to the puerperium 670-676;Both sexes;153 CASTILLA - LA MANCHA;Group 1507 Complications related to the puerperium 670-676;Men;.. CASTILLA - LA MANCHA;Group 1507 Complications related to the puerperium 670-676;Women;153 CASTILLA - LA MANCHA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.152 CASTILLA - LA MANCHA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CASTILLA - LA MANCHA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.152 CASTILLA - LA MANCHA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.934 CASTILLA - LA MANCHA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.585 CASTILLA - LA MANCHA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.349 CASTILLA - LA MANCHA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;767 CASTILLA - LA MANCHA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;410 CASTILLA - LA MANCHA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;357 CASTILLA - LA MANCHA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2.167 CASTILLA - LA MANCHA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.175 CASTILLA - LA MANCHA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;992 CASTILLA - LA MANCHA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.029 CASTILLA - LA MANCHA;Grupo 1700 Congenital abnormalities 740-759;Men;637 CASTILLA - LA MANCHA;Grupo 1700 Congenital abnormalities 740-759;Women;392 CASTILLA - LA MANCHA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;7.657 CASTILLA - LA MANCHA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4.127 CASTILLA - LA MANCHA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.530 CASTILLA - LA MANCHA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;790 CASTILLA - LA MANCHA;Group 1801 Pain in throat and chest 7841, 7865;Men;446 CASTILLA - LA MANCHA;Group 1801 Pain in throat and chest 7841, 7865;Women;344 CASTILLA - LA MANCHA;Group 1802 Abdominal pain 7890;Both sexes;945 CASTILLA - LA MANCHA;Group 1802 Abdominal pain 7890;Men;416 CASTILLA - LA MANCHA;Group 1802 Abdominal pain 7890;Women;529 CASTILLA - LA MANCHA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;643 CASTILLA - LA MANCHA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;318 CASTILLA - LA MANCHA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;325 CASTILLA - LA MANCHA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.279 CASTILLA - LA MANCHA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.947 CASTILLA - LA MANCHA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.332 CASTILLA - LA MANCHA;Group 1900 Injuries and poisoning 800-999;Both sexes;14.868 CASTILLA - LA MANCHA;Group 1900 Injuries and poisoning 800-999;Men;7.458 CASTILLA - LA MANCHA;Group 1900 Injuries and poisoning 800-999;Women;7.410 CASTILLA - LA MANCHA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;782 CASTILLA - LA MANCHA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;447 CASTILLA - LA MANCHA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;335 CASTILLA - LA MANCHA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;332 CASTILLA - LA MANCHA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;249 CASTILLA - LA MANCHA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;83 CASTILLA - LA MANCHA;Group 1903 Radius and ulna fracture 813;Both sexes;857 CASTILLA - LA MANCHA;Group 1903 Radius and ulna fracture 813;Men;401 CASTILLA - LA MANCHA;Group 1903 Radius and ulna fracture 813;Women;456 CASTILLA - LA MANCHA;Group 1904 Femur fracture 820-821;Both sexes;3.101 CASTILLA - LA MANCHA;Group 1904 Femur fracture 820-821;Men;921 CASTILLA - LA MANCHA;Group 1904 Femur fracture 820-821;Women;2.180 CASTILLA - LA MANCHA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.052 CASTILLA - LA MANCHA;Group 1905 Leg fracture, including the ankle 823-824;Men;526 CASTILLA - LA MANCHA;Group 1905 Leg fracture, including the ankle 823-824;Women;526 CASTILLA - LA MANCHA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.935 CASTILLA - LA MANCHA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.431 CASTILLA - LA MANCHA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.504 CASTILLA - LA MANCHA;Group 1907 Burns 940-949;Both sexes;40 CASTILLA - LA MANCHA;Group 1907 Burns 940-949;Men;29 CASTILLA - LA MANCHA;Group 1907 Burns 940-949;Women;11 CASTILLA - LA MANCHA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;481 CASTILLA - LA MANCHA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;223 CASTILLA - LA MANCHA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;258 CASTILLA - LA MANCHA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.699 CASTILLA - LA MANCHA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.957 CASTILLA - LA MANCHA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.742 CASTILLA - LA MANCHA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;47 CASTILLA - LA MANCHA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;24 CASTILLA - LA MANCHA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;23 CASTILLA - LA MANCHA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;542 CASTILLA - LA MANCHA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;250 CASTILLA - LA MANCHA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;292 CASTILLA - LA MANCHA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.610 CASTILLA - LA MANCHA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.446 CASTILLA - LA MANCHA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.164 CASTILLA - LA MANCHA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;185 CASTILLA - LA MANCHA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;114 CASTILLA - LA MANCHA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;71 CASTILLA - LA MANCHA;Group 2102 Contraceptive management V25;Both sexes;44 CASTILLA - LA MANCHA;Group 2102 Contraceptive management V25;Men;5 CASTILLA - LA MANCHA;Group 2102 Contraceptive management V25;Women;39 CASTILLA - LA MANCHA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CASTILLA - LA MANCHA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CASTILLA - LA MANCHA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CASTILLA - LA MANCHA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.284 CASTILLA - LA MANCHA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;762 CASTILLA - LA MANCHA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;522 CASTILLA - LA MANCHA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.097 CASTILLA - LA MANCHA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;565 CASTILLA - LA MANCHA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;532 Albacete;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;41.350 Albacete;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;19.477 Albacete;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;21.873 Albacete;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.097 Albacete;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;629 Albacete;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;468 Albacete;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;182 Albacete;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;100 Albacete;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;82 Albacete;Group 0102 Imprecise intestinal infections 009;Both sexes;66 Albacete;Group 0102 Imprecise intestinal infections 009;Men;34 Albacete;Group 0102 Imprecise intestinal infections 009;Women;32 Albacete;Group 0103 Tuberculosis 010-018, 137;Both sexes;23 Albacete;Group 0103 Tuberculosis 010-018, 137;Men;17 Albacete;Group 0103 Tuberculosis 010-018, 137;Women;6 Albacete;Group 0104 Septicaemia 038;Both sexes;516 Albacete;Group 0104 Septicaemia 038;Men;297 Albacete;Group 0104 Septicaemia 038;Women;219 Albacete;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;18 Albacete;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;11 Albacete;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;7 Albacete;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;292 Albacete;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;170 Albacete;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;122 Albacete;Group 0200 Neoplasms 140-239;Both sexes;3.617 Albacete;Group 0200 Neoplasms 140-239;Men;1.992 Albacete;Group 0200 Neoplasms 140-239;Women;1.625 Albacete;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;384 Albacete;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;245 Albacete;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;139 Albacete;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;304 Albacete;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;257 Albacete;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;47 Albacete;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;108 Albacete;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;63 Albacete;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;45 Albacete;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;256 Albacete;Group 0204 Malignant neoplasm of breast 174-175;Men;2 Albacete;Group 0204 Malignant neoplasm of breast 174-175;Women;254 Albacete;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;59 Albacete;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Albacete;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;59 Albacete;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;41 Albacete;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Albacete;Group 0206 Malignant neoplasm of ovary 1830;Women;41 Albacete;Group 0207 Malignant neoplasm of prostate 185;Both sexes;94 Albacete;Group 0207 Malignant neoplasm of prostate 185;Men;94 Albacete;Group 0207 Malignant neoplasm of prostate 185;Women;.. Albacete;Group 0208 Malignant neoplasm of bladder 188;Both sexes;297 Albacete;Group 0208 Malignant neoplasm of bladder 188;Men;259 Albacete;Group 0208 Malignant neoplasm of bladder 188;Women;38 Albacete;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.305 Albacete;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;827 Albacete;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;478 Albacete;Group 0210 Carcinoma in situ 230-234;Both sexes;64 Albacete;Group 0210 Carcinoma in situ 230-234;Men;16 Albacete;Group 0210 Carcinoma in situ 230-234;Women;48 Albacete;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;29 Albacete;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;13 Albacete;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;16 Albacete;Grupo 0212 Leiomyoma of uterus 218;Both sexes;146 Albacete;Grupo 0212 Leiomyoma of uterus 218;Men;.. Albacete;Grupo 0212 Leiomyoma of uterus 218;Women;146 Albacete;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;530 Albacete;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;216 Albacete;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;314 Albacete;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;345 Albacete;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;177 Albacete;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;168 Albacete;Group 0301 Anaemias 280-285;Both sexes;192 Albacete;Group 0301 Anaemias 280-285;Men;89 Albacete;Group 0301 Anaemias 280-285;Women;103 Albacete;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;153 Albacete;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;88 Albacete;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;65 Albacete;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;686 Albacete;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;266 Albacete;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;420 Albacete;Group 0401 Diabetes mellitus 249-250;Both sexes;226 Albacete;Group 0401 Diabetes mellitus 249-250;Men;134 Albacete;Group 0401 Diabetes mellitus 249-250;Women;92 Albacete;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;460 Albacete;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;132 Albacete;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;328 Albacete;Group 0500 Mental disorders 290-319;Both sexes;923 Albacete;Group 0500 Mental disorders 290-319;Men;370 Albacete;Group 0500 Mental disorders 290-319;Women;553 Albacete;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;9 Albacete;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;5 Albacete;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;4 Albacete;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;39 Albacete;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;25 Albacete;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;14 Albacete;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;36 Albacete;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;18 Albacete;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;18 Albacete;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;246 Albacete;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;158 Albacete;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;88 Albacete;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;239 Albacete;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;84 Albacete;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;155 Albacete;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;354 Albacete;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;80 Albacete;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;274 Albacete;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;621 Albacete;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;306 Albacete;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;315 Albacete;Group 0601 Alzheimer's disease 3310;Both sexes;6 Albacete;Group 0601 Alzheimer's disease 3310;Men;2 Albacete;Group 0601 Alzheimer's disease 3310;Women;4 Albacete;Group 0602 Multiple sclerosis 340;Both sexes;10 Albacete;Group 0602 Multiple sclerosis 340;Men;.. Albacete;Group 0602 Multiple sclerosis 340;Women;10 Albacete;Group 0603 Epilepsy 345;Both sexes;123 Albacete;Group 0603 Epilepsy 345;Men;57 Albacete;Group 0603 Epilepsy 345;Women;66 Albacete;Group 0604 Transient cerebral ischemia 435;Both sexes;125 Albacete;Group 0604 Transient cerebral ischemia 435;Men;57 Albacete;Group 0604 Transient cerebral ischemia 435;Women;68 Albacete;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;357 Albacete;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;190 Albacete;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;167 Albacete;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;182 Albacete;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;91 Albacete;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;91 Albacete;Grupo 0701 Cataract 366;Both sexes;71 Albacete;Grupo 0701 Cataract 366;Men;38 Albacete;Grupo 0701 Cataract 366;Women;33 Albacete;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;111 Albacete;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;53 Albacete;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;58 Albacete;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;138 Albacete;Group 0800 Diseases of the ear and the mastoid 380-389;Men;65 Albacete;Group 0800 Diseases of the ear and the mastoid 380-389;Women;73 Albacete;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5.208 Albacete;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.979 Albacete;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.229 Albacete;Group 0901 Hypertensive disease 401-405;Both sexes;309 Albacete;Group 0901 Hypertensive disease 401-405;Men;162 Albacete;Group 0901 Hypertensive disease 401-405;Women;147 Albacete;Group 0902 Angina pectoris 4111, 413;Both sexes;233 Albacete;Group 0902 Angina pectoris 4111, 413;Men;146 Albacete;Group 0902 Angina pectoris 4111, 413;Women;87 Albacete;Group 0903 Acute myocardial infarction 410;Both sexes;522 Albacete;Group 0903 Acute myocardial infarction 410;Men;399 Albacete;Group 0903 Acute myocardial infarction 410;Women;123 Albacete;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;291 Albacete;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;216 Albacete;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;75 Albacete;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;210 Albacete;Group 0905 Diseases of the lungs circulation 415-417;Men;93 Albacete;Group 0905 Diseases of the lungs circulation 415-417;Women;117 Albacete;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;564 Albacete;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;299 Albacete;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;265 Albacete;Grupo 0907 Heart failure 428;Both sexes;1.184 Albacete;Grupo 0907 Heart failure 428;Men;559 Albacete;Grupo 0907 Heart failure 428;Women;625 Albacete;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;959 Albacete;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;519 Albacete;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;440 Albacete;Grupo 0909 Atherosclerosis 440;Both sexes;157 Albacete;Grupo 0909 Atherosclerosis 440;Men;123 Albacete;Grupo 0909 Atherosclerosis 440;Women;34 Albacete;Group 0910 Varicose veins of lower extremities 454;Both sexes;36 Albacete;Group 0910 Varicose veins of lower extremities 454;Men;18 Albacete;Group 0910 Varicose veins of lower extremities 454;Women;18 Albacete;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;743 Albacete;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;445 Albacete;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;298 Albacete;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5.041 Albacete;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.821 Albacete;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.220 Albacete;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;245 Albacete;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;133 Albacete;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;112 Albacete;Group 1002 Pneumonia 480-486;Both sexes;1.202 Albacete;Group 1002 Pneumonia 480-486;Men;695 Albacete;Group 1002 Pneumonia 480-486;Women;507 Albacete;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;593 Albacete;Group 1003 Acute bronchitis and bronchiolitis 466;Men;272 Albacete;Group 1003 Acute bronchitis and bronchiolitis 466;Women;321 Albacete;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;203 Albacete;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;107 Albacete;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;96 Albacete;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;217 Albacete;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;118 Albacete;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;99 Albacete;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;551 Albacete;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;460 Albacete;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;91 Albacete;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;137 Albacete;Group 1007 Asthma 4930-4931,4938-4939;Men;35 Albacete;Group 1007 Asthma 4930-4931,4938-4939;Women;102 Albacete;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.893 Albacete;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.001 Albacete;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;892 Albacete;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.937 Albacete;Group 1100 Diseases of the digestive system 520-579;Men;2.826 Albacete;Group 1100 Diseases of the digestive system 520-579;Women;2.111 Albacete;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;64 Albacete;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;37 Albacete;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;27 Albacete;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;58 Albacete;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;36 Albacete;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;22 Albacete;Group 1103 Diseases of the esophagus 530;Both sexes;104 Albacete;Group 1103 Diseases of the esophagus 530;Men;58 Albacete;Group 1103 Diseases of the esophagus 530;Women;46 Albacete;Group 1104 Peptic ulcer 531-534;Both sexes;165 Albacete;Group 1104 Peptic ulcer 531-534;Men;114 Albacete;Group 1104 Peptic ulcer 531-534;Women;51 Albacete;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;140 Albacete;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;80 Albacete;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;60 Albacete;Group 1106 Appendicitis 540-543;Both sexes;442 Albacete;Group 1106 Appendicitis 540-543;Men;280 Albacete;Group 1106 Appendicitis 540-543;Women;162 Albacete;Group 1107 Inguinal hernia 550;Both sexes;324 Albacete;Group 1107 Inguinal hernia 550;Men;281 Albacete;Group 1107 Inguinal hernia 550;Women;43 Albacete;Group 1108 Other abdominal hernia 551-553;Both sexes;367 Albacete;Group 1108 Other abdominal hernia 551-553;Men;145 Albacete;Group 1108 Other abdominal hernia 551-553;Women;222 Albacete;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;91 Albacete;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;55 Albacete;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;36 Albacete;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;264 Albacete;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;135 Albacete;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;129 Albacete;Group 1111 Intestinal obstruction without hernia 560;Both sexes;271 Albacete;Group 1111 Intestinal obstruction without hernia 560;Men;136 Albacete;Group 1111 Intestinal obstruction without hernia 560;Women;135 Albacete;Group 1112 Intestinal diverticulosis 562;Both sexes;179 Albacete;Group 1112 Intestinal diverticulosis 562;Men;109 Albacete;Group 1112 Intestinal diverticulosis 562;Women;70 Albacete;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;368 Albacete;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;279 Albacete;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;89 Albacete;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;164 Albacete;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;74 Albacete;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;90 Albacete;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;66 Albacete;Group 1115 Alcoholic hepatitis 5710-5713;Men;51 Albacete;Group 1115 Alcoholic hepatitis 5710-5713;Women;15 Albacete;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;145 Albacete;Group 1116 Other diseases of the liver 570,5714-573;Men;84 Albacete;Group 1116 Other diseases of the liver 570,5714-573;Women;61 Albacete;Group 1117 Cholelithiasis 574;Both sexes;812 Albacete;Group 1117 Cholelithiasis 574;Men;360 Albacete;Group 1117 Cholelithiasis 574;Women;452 Albacete;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;349 Albacete;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;186 Albacete;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;163 Albacete;Group 1119 Pancreatic diseases 577;Both sexes;321 Albacete;Group 1119 Pancreatic diseases 577;Men;195 Albacete;Group 1119 Pancreatic diseases 577;Women;126 Albacete;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;243 Albacete;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;131 Albacete;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;112 Albacete;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;350 Albacete;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;169 Albacete;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;181 Albacete;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;204 Albacete;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;103 Albacete;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;101 Albacete;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;15 Albacete;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;7 Albacete;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;8 Albacete;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;131 Albacete;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;59 Albacete;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;72 Albacete;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.214 Albacete;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.126 Albacete;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.088 Albacete;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Albacete;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Albacete;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Albacete;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Albacete;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Albacete;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Albacete;Group 1303 Internal derangement of knee 717;Both sexes;98 Albacete;Group 1303 Internal derangement of knee 717;Men;70 Albacete;Group 1303 Internal derangement of knee 717;Women;28 Albacete;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;958 Albacete;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;436 Albacete;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;522 Albacete;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;31 Albacete;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;12 Albacete;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;19 Albacete;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;188 Albacete;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;107 Albacete;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;81 Albacete;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;328 Albacete;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;172 Albacete;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;156 Albacete;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;33 Albacete;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;19 Albacete;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;14 Albacete;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;317 Albacete;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;191 Albacete;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;126 Albacete;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;261 Albacete;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;119 Albacete;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;142 Albacete;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.153 Albacete;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.355 Albacete;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.798 Albacete;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;180 Albacete;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;88 Albacete;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;92 Albacete;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;275 Albacete;Group 1402 Renal failure 5836-5837, 584-586;Men;147 Albacete;Group 1402 Renal failure 5836-5837, 584-586;Women;128 Albacete;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;618 Albacete;Group 1403 Urolithiasis 592, 594, 7880;Men;351 Albacete;Group 1403 Urolithiasis 592, 594, 7880;Women;267 Albacete;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;816 Albacete;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;413 Albacete;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;403 Albacete;Group 1405 Prostatic hyperplasia 600;Both sexes;120 Albacete;Group 1405 Prostatic hyperplasia 600;Men;120 Albacete;Group 1405 Prostatic hyperplasia 600;Women;.. Albacete;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;220 Albacete;Group 1406 Other diseases of the male genital organs 601-608;Men;220 Albacete;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Albacete;Group 1407 Disorders of breast 610-612;Both sexes;275 Albacete;Group 1407 Disorders of breast 610-612;Men;9 Albacete;Group 1407 Disorders of breast 610-612;Women;266 Albacete;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;78 Albacete;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Albacete;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;78 Albacete;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;31 Albacete;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Albacete;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;31 Albacete;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;540 Albacete;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;7 Albacete;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;533 Albacete;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;4.892 Albacete;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Albacete;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;4.892 Albacete;Group 1501 Legally induced abortion 635;Both sexes;15 Albacete;Group 1501 Legally induced abortion 635;Men;.. Albacete;Group 1501 Legally induced abortion 635;Women;15 Albacete;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;350 Albacete;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Albacete;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;350 Albacete;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;2.821 Albacete;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Albacete;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;2.821 Albacete;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;718 Albacete;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Albacete;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;718 Albacete;Group 1505 Single spontaneous delivery 650;Both sexes;496 Albacete;Group 1505 Single spontaneous delivery 650;Men;.. Albacete;Group 1505 Single spontaneous delivery 650;Women;496 Albacete;Group 1506 Other deliveries 6695-6697;Both sexes;228 Albacete;Group 1506 Other deliveries 6695-6697;Men;.. Albacete;Group 1506 Other deliveries 6695-6697;Women;228 Albacete;Group 1507 Complications related to the puerperium 670-676;Both sexes;47 Albacete;Group 1507 Complications related to the puerperium 670-676;Men;.. Albacete;Group 1507 Complications related to the puerperium 670-676;Women;47 Albacete;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;217 Albacete;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Albacete;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;217 Albacete;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;677 Albacete;Group 1600 Some disorders originating in the perinatal period 760-779;Men;378 Albacete;Group 1600 Some disorders originating in the perinatal period 760-779;Women;299 Albacete;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;180 Albacete;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;104 Albacete;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;76 Albacete;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;497 Albacete;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;274 Albacete;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;223 Albacete;Grupo 1700 Congenital abnormalities 740-759;Both sexes;322 Albacete;Grupo 1700 Congenital abnormalities 740-759;Men;203 Albacete;Grupo 1700 Congenital abnormalities 740-759;Women;119 Albacete;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.357 Albacete;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.319 Albacete;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.038 Albacete;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;184 Albacete;Group 1801 Pain in throat and chest 7841, 7865;Men;109 Albacete;Group 1801 Pain in throat and chest 7841, 7865;Women;75 Albacete;Group 1802 Abdominal pain 7890;Both sexes;297 Albacete;Group 1802 Abdominal pain 7890;Men;171 Albacete;Group 1802 Abdominal pain 7890;Women;126 Albacete;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;621 Albacete;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;308 Albacete;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;313 Albacete;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.255 Albacete;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;731 Albacete;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;524 Albacete;Group 1900 Injuries and poisoning 800-999;Both sexes;3.748 Albacete;Group 1900 Injuries and poisoning 800-999;Men;1.961 Albacete;Group 1900 Injuries and poisoning 800-999;Women;1.787 Albacete;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;193 Albacete;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;107 Albacete;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;86 Albacete;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;81 Albacete;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;60 Albacete;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;21 Albacete;Group 1903 Radius and ulna fracture 813;Both sexes;247 Albacete;Group 1903 Radius and ulna fracture 813;Men;114 Albacete;Group 1903 Radius and ulna fracture 813;Women;133 Albacete;Group 1904 Femur fracture 820-821;Both sexes;699 Albacete;Group 1904 Femur fracture 820-821;Men;204 Albacete;Group 1904 Femur fracture 820-821;Women;495 Albacete;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;240 Albacete;Group 1905 Leg fracture, including the ankle 823-824;Men;114 Albacete;Group 1905 Leg fracture, including the ankle 823-824;Women;126 Albacete;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.054 Albacete;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;704 Albacete;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;350 Albacete;Group 1907 Burns 940-949;Both sexes;22 Albacete;Group 1907 Burns 940-949;Men;15 Albacete;Group 1907 Burns 940-949;Women;7 Albacete;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;88 Albacete;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;38 Albacete;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;50 Albacete;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;987 Albacete;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;533 Albacete;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;454 Albacete;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;19 Albacete;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;11 Albacete;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;8 Albacete;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;118 Albacete;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;61 Albacete;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;57 Albacete;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;842 Albacete;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;444 Albacete;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;398 Albacete;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;95 Albacete;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;57 Albacete;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;38 Albacete;Group 2102 Contraceptive management V25;Both sexes;8 Albacete;Group 2102 Contraceptive management V25;Men;2 Albacete;Group 2102 Contraceptive management V25;Women;6 Albacete;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Albacete;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Albacete;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Albacete;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;448 Albacete;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;273 Albacete;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;175 Albacete;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;291 Albacete;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;112 Albacete;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;179 Ciudad Real;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;54.062 Ciudad Real;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;25.237 Ciudad Real;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;28.825 Ciudad Real;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.101 Ciudad Real;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;608 Ciudad Real;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;493 Ciudad Real;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;210 Ciudad Real;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;115 Ciudad Real;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;95 Ciudad Real;Group 0102 Imprecise intestinal infections 009;Both sexes;26 Ciudad Real;Group 0102 Imprecise intestinal infections 009;Men;13 Ciudad Real;Group 0102 Imprecise intestinal infections 009;Women;13 Ciudad Real;Group 0103 Tuberculosis 010-018, 137;Both sexes;29 Ciudad Real;Group 0103 Tuberculosis 010-018, 137;Men;20 Ciudad Real;Group 0103 Tuberculosis 010-018, 137;Women;9 Ciudad Real;Group 0104 Septicaemia 038;Both sexes;478 Ciudad Real;Group 0104 Septicaemia 038;Men;253 Ciudad Real;Group 0104 Septicaemia 038;Women;225 Ciudad Real;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;25 Ciudad Real;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;18 Ciudad Real;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;7 Ciudad Real;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;333 Ciudad Real;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;189 Ciudad Real;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;144 Ciudad Real;Group 0200 Neoplasms 140-239;Both sexes;5.103 Ciudad Real;Group 0200 Neoplasms 140-239;Men;2.809 Ciudad Real;Group 0200 Neoplasms 140-239;Women;2.294 Ciudad Real;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;607 Ciudad Real;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;381 Ciudad Real;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;226 Ciudad Real;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;437 Ciudad Real;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;362 Ciudad Real;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;75 Ciudad Real;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;61 Ciudad Real;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;37 Ciudad Real;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;24 Ciudad Real;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;359 Ciudad Real;Group 0204 Malignant neoplasm of breast 174-175;Men;4 Ciudad Real;Group 0204 Malignant neoplasm of breast 174-175;Women;355 Ciudad Real;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;111 Ciudad Real;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Ciudad Real;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;111 Ciudad Real;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;69 Ciudad Real;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Ciudad Real;Group 0206 Malignant neoplasm of ovary 1830;Women;69 Ciudad Real;Group 0207 Malignant neoplasm of prostate 185;Both sexes;154 Ciudad Real;Group 0207 Malignant neoplasm of prostate 185;Men;154 Ciudad Real;Group 0207 Malignant neoplasm of prostate 185;Women;.. Ciudad Real;Group 0208 Malignant neoplasm of bladder 188;Both sexes;438 Ciudad Real;Group 0208 Malignant neoplasm of bladder 188;Men;367 Ciudad Real;Group 0208 Malignant neoplasm of bladder 188;Women;71 Ciudad Real;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.926 Ciudad Real;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.138 Ciudad Real;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;788 Ciudad Real;Group 0210 Carcinoma in situ 230-234;Both sexes;43 Ciudad Real;Group 0210 Carcinoma in situ 230-234;Men;23 Ciudad Real;Group 0210 Carcinoma in situ 230-234;Women;20 Ciudad Real;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;77 Ciudad Real;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;49 Ciudad Real;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;28 Ciudad Real;Grupo 0212 Leiomyoma of uterus 218;Both sexes;195 Ciudad Real;Grupo 0212 Leiomyoma of uterus 218;Men;.. Ciudad Real;Grupo 0212 Leiomyoma of uterus 218;Women;195 Ciudad Real;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;626 Ciudad Real;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;294 Ciudad Real;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;332 Ciudad Real;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;483 Ciudad Real;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;241 Ciudad Real;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;242 Ciudad Real;Group 0301 Anaemias 280-285;Both sexes;295 Ciudad Real;Group 0301 Anaemias 280-285;Men;148 Ciudad Real;Group 0301 Anaemias 280-285;Women;147 Ciudad Real;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;188 Ciudad Real;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;93 Ciudad Real;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;95 Ciudad Real;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;832 Ciudad Real;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;334 Ciudad Real;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;498 Ciudad Real;Group 0401 Diabetes mellitus 249-250;Both sexes;286 Ciudad Real;Group 0401 Diabetes mellitus 249-250;Men;165 Ciudad Real;Group 0401 Diabetes mellitus 249-250;Women;121 Ciudad Real;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;546 Ciudad Real;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;169 Ciudad Real;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;377 Ciudad Real;Group 0500 Mental disorders 290-319;Both sexes;1.099 Ciudad Real;Group 0500 Mental disorders 290-319;Men;523 Ciudad Real;Group 0500 Mental disorders 290-319;Women;576 Ciudad Real;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;47 Ciudad Real;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;21 Ciudad Real;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;26 Ciudad Real;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;47 Ciudad Real;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;35 Ciudad Real;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;12 Ciudad Real;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;29 Ciudad Real;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;22 Ciudad Real;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;7 Ciudad Real;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;259 Ciudad Real;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;148 Ciudad Real;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;111 Ciudad Real;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;226 Ciudad Real;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;86 Ciudad Real;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;140 Ciudad Real;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;491 Ciudad Real;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;211 Ciudad Real;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;280 Ciudad Real;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.328 Ciudad Real;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;617 Ciudad Real;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;711 Ciudad Real;Group 0601 Alzheimer's disease 3310;Both sexes;34 Ciudad Real;Group 0601 Alzheimer's disease 3310;Men;9 Ciudad Real;Group 0601 Alzheimer's disease 3310;Women;25 Ciudad Real;Group 0602 Multiple sclerosis 340;Both sexes;39 Ciudad Real;Group 0602 Multiple sclerosis 340;Men;8 Ciudad Real;Group 0602 Multiple sclerosis 340;Women;31 Ciudad Real;Group 0603 Epilepsy 345;Both sexes;149 Ciudad Real;Group 0603 Epilepsy 345;Men;89 Ciudad Real;Group 0603 Epilepsy 345;Women;60 Ciudad Real;Group 0604 Transient cerebral ischemia 435;Both sexes;162 Ciudad Real;Group 0604 Transient cerebral ischemia 435;Men;80 Ciudad Real;Group 0604 Transient cerebral ischemia 435;Women;82 Ciudad Real;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;944 Ciudad Real;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;431 Ciudad Real;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;513 Ciudad Real;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;369 Ciudad Real;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;212 Ciudad Real;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;157 Ciudad Real;Grupo 0701 Cataract 366;Both sexes;17 Ciudad Real;Grupo 0701 Cataract 366;Men;9 Ciudad Real;Grupo 0701 Cataract 366;Women;8 Ciudad Real;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;352 Ciudad Real;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;203 Ciudad Real;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;149 Ciudad Real;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;290 Ciudad Real;Group 0800 Diseases of the ear and the mastoid 380-389;Men;126 Ciudad Real;Group 0800 Diseases of the ear and the mastoid 380-389;Women;164 Ciudad Real;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;7.194 Ciudad Real;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.829 Ciudad Real;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3.365 Ciudad Real;Group 0901 Hypertensive disease 401-405;Both sexes;344 Ciudad Real;Group 0901 Hypertensive disease 401-405;Men;117 Ciudad Real;Group 0901 Hypertensive disease 401-405;Women;227 Ciudad Real;Group 0902 Angina pectoris 4111, 413;Both sexes;365 Ciudad Real;Group 0902 Angina pectoris 4111, 413;Men;213 Ciudad Real;Group 0902 Angina pectoris 4111, 413;Women;152 Ciudad Real;Group 0903 Acute myocardial infarction 410;Both sexes;681 Ciudad Real;Group 0903 Acute myocardial infarction 410;Men;478 Ciudad Real;Group 0903 Acute myocardial infarction 410;Women;203 Ciudad Real;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;317 Ciudad Real;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;243 Ciudad Real;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;74 Ciudad Real;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;278 Ciudad Real;Group 0905 Diseases of the lungs circulation 415-417;Men;136 Ciudad Real;Group 0905 Diseases of the lungs circulation 415-417;Women;142 Ciudad Real;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;993 Ciudad Real;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;509 Ciudad Real;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;484 Ciudad Real;Grupo 0907 Heart failure 428;Both sexes;1.726 Ciudad Real;Grupo 0907 Heart failure 428;Men;684 Ciudad Real;Grupo 0907 Heart failure 428;Women;1.042 Ciudad Real;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.214 Ciudad Real;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;652 Ciudad Real;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;562 Ciudad Real;Grupo 0909 Atherosclerosis 440;Both sexes;303 Ciudad Real;Grupo 0909 Atherosclerosis 440;Men;230 Ciudad Real;Grupo 0909 Atherosclerosis 440;Women;73 Ciudad Real;Group 0910 Varicose veins of lower extremities 454;Both sexes;74 Ciudad Real;Group 0910 Varicose veins of lower extremities 454;Men;38 Ciudad Real;Group 0910 Varicose veins of lower extremities 454;Women;36 Ciudad Real;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;899 Ciudad Real;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;529 Ciudad Real;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;370 Ciudad Real;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;8.665 Ciudad Real;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5.071 Ciudad Real;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.594 Ciudad Real;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;337 Ciudad Real;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;195 Ciudad Real;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;142 Ciudad Real;Group 1002 Pneumonia 480-486;Both sexes;2.118 Ciudad Real;Group 1002 Pneumonia 480-486;Men;1.319 Ciudad Real;Group 1002 Pneumonia 480-486;Women;799 Ciudad Real;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;837 Ciudad Real;Group 1003 Acute bronchitis and bronchiolitis 466;Men;356 Ciudad Real;Group 1003 Acute bronchitis and bronchiolitis 466;Women;481 Ciudad Real;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;363 Ciudad Real;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;200 Ciudad Real;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;163 Ciudad Real;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;543 Ciudad Real;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;361 Ciudad Real;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;182 Ciudad Real;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.522 Ciudad Real;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.275 Ciudad Real;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;247 Ciudad Real;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;234 Ciudad Real;Group 1007 Asthma 4930-4931,4938-4939;Men;74 Ciudad Real;Group 1007 Asthma 4930-4931,4938-4939;Women;160 Ciudad Real;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.711 Ciudad Real;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.291 Ciudad Real;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.420 Ciudad Real;Group 1100 Diseases of the digestive system 520-579;Both sexes;7.248 Ciudad Real;Group 1100 Diseases of the digestive system 520-579;Men;3.857 Ciudad Real;Group 1100 Diseases of the digestive system 520-579;Women;3.391 Ciudad Real;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;96 Ciudad Real;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;43 Ciudad Real;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;53 Ciudad Real;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;97 Ciudad Real;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;50 Ciudad Real;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;47 Ciudad Real;Group 1103 Diseases of the esophagus 530;Both sexes;147 Ciudad Real;Group 1103 Diseases of the esophagus 530;Men;94 Ciudad Real;Group 1103 Diseases of the esophagus 530;Women;53 Ciudad Real;Group 1104 Peptic ulcer 531-534;Both sexes;140 Ciudad Real;Group 1104 Peptic ulcer 531-534;Men;92 Ciudad Real;Group 1104 Peptic ulcer 531-534;Women;48 Ciudad Real;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;165 Ciudad Real;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;79 Ciudad Real;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;86 Ciudad Real;Group 1106 Appendicitis 540-543;Both sexes;550 Ciudad Real;Group 1106 Appendicitis 540-543;Men;321 Ciudad Real;Group 1106 Appendicitis 540-543;Women;229 Ciudad Real;Group 1107 Inguinal hernia 550;Both sexes;475 Ciudad Real;Group 1107 Inguinal hernia 550;Men;419 Ciudad Real;Group 1107 Inguinal hernia 550;Women;56 Ciudad Real;Group 1108 Other abdominal hernia 551-553;Both sexes;597 Ciudad Real;Group 1108 Other abdominal hernia 551-553;Men;247 Ciudad Real;Group 1108 Other abdominal hernia 551-553;Women;350 Ciudad Real;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;127 Ciudad Real;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;58 Ciudad Real;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;69 Ciudad Real;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;390 Ciudad Real;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;190 Ciudad Real;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;200 Ciudad Real;Group 1111 Intestinal obstruction without hernia 560;Both sexes;438 Ciudad Real;Group 1111 Intestinal obstruction without hernia 560;Men;208 Ciudad Real;Group 1111 Intestinal obstruction without hernia 560;Women;230 Ciudad Real;Group 1112 Intestinal diverticulosis 562;Both sexes;221 Ciudad Real;Group 1112 Intestinal diverticulosis 562;Men;107 Ciudad Real;Group 1112 Intestinal diverticulosis 562;Women;114 Ciudad Real;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;299 Ciudad Real;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;197 Ciudad Real;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;102 Ciudad Real;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;296 Ciudad Real;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;131 Ciudad Real;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;165 Ciudad Real;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;101 Ciudad Real;Group 1115 Alcoholic hepatitis 5710-5713;Men;90 Ciudad Real;Group 1115 Alcoholic hepatitis 5710-5713;Women;11 Ciudad Real;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;181 Ciudad Real;Group 1116 Other diseases of the liver 570,5714-573;Men;116 Ciudad Real;Group 1116 Other diseases of the liver 570,5714-573;Women;65 Ciudad Real;Group 1117 Cholelithiasis 574;Both sexes;1.667 Ciudad Real;Group 1117 Cholelithiasis 574;Men;720 Ciudad Real;Group 1117 Cholelithiasis 574;Women;947 Ciudad Real;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;394 Ciudad Real;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;201 Ciudad Real;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;193 Ciudad Real;Group 1119 Pancreatic diseases 577;Both sexes;571 Ciudad Real;Group 1119 Pancreatic diseases 577;Men;332 Ciudad Real;Group 1119 Pancreatic diseases 577;Women;239 Ciudad Real;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;296 Ciudad Real;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;162 Ciudad Real;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;134 Ciudad Real;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;364 Ciudad Real;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;195 Ciudad Real;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;169 Ciudad Real;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;220 Ciudad Real;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;128 Ciudad Real;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;92 Ciudad Real;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;11 Ciudad Real;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;6 Ciudad Real;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;5 Ciudad Real;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;133 Ciudad Real;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;61 Ciudad Real;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;72 Ciudad Real;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3.038 Ciudad Real;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.388 Ciudad Real;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.650 Ciudad Real;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Ciudad Real;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Ciudad Real;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Ciudad Real;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Ciudad Real;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Ciudad Real;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Ciudad Real;Group 1303 Internal derangement of knee 717;Both sexes;294 Ciudad Real;Group 1303 Internal derangement of knee 717;Men;193 Ciudad Real;Group 1303 Internal derangement of knee 717;Women;101 Ciudad Real;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.228 Ciudad Real;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;490 Ciudad Real;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;738 Ciudad Real;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;67 Ciudad Real;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;33 Ciudad Real;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;34 Ciudad Real;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;233 Ciudad Real;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;119 Ciudad Real;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;114 Ciudad Real;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;189 Ciudad Real;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;94 Ciudad Real;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;95 Ciudad Real;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;48 Ciudad Real;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;24 Ciudad Real;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;24 Ciudad Real;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;446 Ciudad Real;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;230 Ciudad Real;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;216 Ciudad Real;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;533 Ciudad Real;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;205 Ciudad Real;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;328 Ciudad Real;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.552 Ciudad Real;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.569 Ciudad Real;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.983 Ciudad Real;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;289 Ciudad Real;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;108 Ciudad Real;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;181 Ciudad Real;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;402 Ciudad Real;Group 1402 Renal failure 5836-5837, 584-586;Men;200 Ciudad Real;Group 1402 Renal failure 5836-5837, 584-586;Women;202 Ciudad Real;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;302 Ciudad Real;Group 1403 Urolithiasis 592, 594, 7880;Men;194 Ciudad Real;Group 1403 Urolithiasis 592, 594, 7880;Women;108 Ciudad Real;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.312 Ciudad Real;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;620 Ciudad Real;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;692 Ciudad Real;Group 1405 Prostatic hyperplasia 600;Both sexes;211 Ciudad Real;Group 1405 Prostatic hyperplasia 600;Men;211 Ciudad Real;Group 1405 Prostatic hyperplasia 600;Women;.. Ciudad Real;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;220 Ciudad Real;Group 1406 Other diseases of the male genital organs 601-608;Men;220 Ciudad Real;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Ciudad Real;Group 1407 Disorders of breast 610-612;Both sexes;121 Ciudad Real;Group 1407 Disorders of breast 610-612;Men;15 Ciudad Real;Group 1407 Disorders of breast 610-612;Women;106 Ciudad Real;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;106 Ciudad Real;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Ciudad Real;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;106 Ciudad Real;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;78 Ciudad Real;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Ciudad Real;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;78 Ciudad Real;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;511 Ciudad Real;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Ciudad Real;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;510 Ciudad Real;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.740 Ciudad Real;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Ciudad Real;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.740 Ciudad Real;Group 1501 Legally induced abortion 635;Both sexes;1 Ciudad Real;Group 1501 Legally induced abortion 635;Men;.. Ciudad Real;Group 1501 Legally induced abortion 635;Women;1 Ciudad Real;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;512 Ciudad Real;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Ciudad Real;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;512 Ciudad Real;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.960 Ciudad Real;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Ciudad Real;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.960 Ciudad Real;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;674 Ciudad Real;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Ciudad Real;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;674 Ciudad Real;Group 1505 Single spontaneous delivery 650;Both sexes;219 Ciudad Real;Group 1505 Single spontaneous delivery 650;Men;.. Ciudad Real;Group 1505 Single spontaneous delivery 650;Women;219 Ciudad Real;Group 1506 Other deliveries 6695-6697;Both sexes;20 Ciudad Real;Group 1506 Other deliveries 6695-6697;Men;.. Ciudad Real;Group 1506 Other deliveries 6695-6697;Women;20 Ciudad Real;Group 1507 Complications related to the puerperium 670-676;Both sexes;33 Ciudad Real;Group 1507 Complications related to the puerperium 670-676;Men;.. Ciudad Real;Group 1507 Complications related to the puerperium 670-676;Women;33 Ciudad Real;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;321 Ciudad Real;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Ciudad Real;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;321 Ciudad Real;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.168 Ciudad Real;Group 1600 Some disorders originating in the perinatal period 760-779;Men;615 Ciudad Real;Group 1600 Some disorders originating in the perinatal period 760-779;Women;553 Ciudad Real;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;246 Ciudad Real;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;121 Ciudad Real;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;125 Ciudad Real;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;922 Ciudad Real;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;494 Ciudad Real;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;428 Ciudad Real;Grupo 1700 Congenital abnormalities 740-759;Both sexes;232 Ciudad Real;Grupo 1700 Congenital abnormalities 740-759;Men;151 Ciudad Real;Grupo 1700 Congenital abnormalities 740-759;Women;81 Ciudad Real;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.901 Ciudad Real;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.009 Ciudad Real;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;892 Ciudad Real;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;212 Ciudad Real;Group 1801 Pain in throat and chest 7841, 7865;Men;115 Ciudad Real;Group 1801 Pain in throat and chest 7841, 7865;Women;97 Ciudad Real;Group 1802 Abdominal pain 7890;Both sexes;142 Ciudad Real;Group 1802 Abdominal pain 7890;Men;48 Ciudad Real;Group 1802 Abdominal pain 7890;Women;94 Ciudad Real;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1 Ciudad Real;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. Ciudad Real;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1 Ciudad Real;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.546 Ciudad Real;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;846 Ciudad Real;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;700 Ciudad Real;Group 1900 Injuries and poisoning 800-999;Both sexes;3.775 Ciudad Real;Group 1900 Injuries and poisoning 800-999;Men;1.800 Ciudad Real;Group 1900 Injuries and poisoning 800-999;Women;1.975 Ciudad Real;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;168 Ciudad Real;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;103 Ciudad Real;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;65 Ciudad Real;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;113 Ciudad Real;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;81 Ciudad Real;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;32 Ciudad Real;Group 1903 Radius and ulna fracture 813;Both sexes;241 Ciudad Real;Group 1903 Radius and ulna fracture 813;Men;103 Ciudad Real;Group 1903 Radius and ulna fracture 813;Women;138 Ciudad Real;Group 1904 Femur fracture 820-821;Both sexes;934 Ciudad Real;Group 1904 Femur fracture 820-821;Men;296 Ciudad Real;Group 1904 Femur fracture 820-821;Women;638 Ciudad Real;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;286 Ciudad Real;Group 1905 Leg fracture, including the ankle 823-824;Men;137 Ciudad Real;Group 1905 Leg fracture, including the ankle 823-824;Women;149 Ciudad Real;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;751 Ciudad Real;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;412 Ciudad Real;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;339 Ciudad Real;Group 1907 Burns 940-949;Both sexes;11 Ciudad Real;Group 1907 Burns 940-949;Men;9 Ciudad Real;Group 1907 Burns 940-949;Women;2 Ciudad Real;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;127 Ciudad Real;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;66 Ciudad Real;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;61 Ciudad Real;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.003 Ciudad Real;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;528 Ciudad Real;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;475 Ciudad Real;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;15 Ciudad Real;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 Ciudad Real;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;7 Ciudad Real;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;126 Ciudad Real;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;57 Ciudad Real;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;69 Ciudad Real;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;580 Ciudad Real;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;283 Ciudad Real;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;297 Ciudad Real;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;49 Ciudad Real;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;31 Ciudad Real;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;18 Ciudad Real;Group 2102 Contraceptive management V25;Both sexes;27 Ciudad Real;Group 2102 Contraceptive management V25;Men;.. Ciudad Real;Group 2102 Contraceptive management V25;Women;27 Ciudad Real;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Ciudad Real;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Ciudad Real;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Ciudad Real;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;284 Ciudad Real;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;130 Ciudad Real;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;154 Ciudad Real;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;220 Ciudad Real;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;122 Ciudad Real;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;98 Cuenca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;14.160 Cuenca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;6.973 Cuenca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;7.187 Cuenca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;422 Cuenca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;229 Cuenca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;193 Cuenca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;60 Cuenca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;33 Cuenca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;27 Cuenca;Group 0102 Imprecise intestinal infections 009;Both sexes;24 Cuenca;Group 0102 Imprecise intestinal infections 009;Men;16 Cuenca;Group 0102 Imprecise intestinal infections 009;Women;8 Cuenca;Group 0103 Tuberculosis 010-018, 137;Both sexes;3 Cuenca;Group 0103 Tuberculosis 010-018, 137;Men;1 Cuenca;Group 0103 Tuberculosis 010-018, 137;Women;2 Cuenca;Group 0104 Septicaemia 038;Both sexes;258 Cuenca;Group 0104 Septicaemia 038;Men;132 Cuenca;Group 0104 Septicaemia 038;Women;126 Cuenca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;1 Cuenca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;.. Cuenca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Cuenca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;76 Cuenca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;47 Cuenca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;29 Cuenca;Group 0200 Neoplasms 140-239;Both sexes;989 Cuenca;Group 0200 Neoplasms 140-239;Men;561 Cuenca;Group 0200 Neoplasms 140-239;Women;428 Cuenca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;161 Cuenca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;104 Cuenca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;57 Cuenca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;64 Cuenca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;53 Cuenca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;11 Cuenca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;13 Cuenca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;10 Cuenca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;3 Cuenca;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;63 Cuenca;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Cuenca;Group 0204 Malignant neoplasm of breast 174-175;Women;62 Cuenca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;12 Cuenca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Cuenca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;12 Cuenca;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;2 Cuenca;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Cuenca;Group 0206 Malignant neoplasm of ovary 1830;Women;2 Cuenca;Group 0207 Malignant neoplasm of prostate 185;Both sexes;29 Cuenca;Group 0207 Malignant neoplasm of prostate 185;Men;29 Cuenca;Group 0207 Malignant neoplasm of prostate 185;Women;.. Cuenca;Group 0208 Malignant neoplasm of bladder 188;Both sexes;38 Cuenca;Group 0208 Malignant neoplasm of bladder 188;Men;31 Cuenca;Group 0208 Malignant neoplasm of bladder 188;Women;7 Cuenca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;269 Cuenca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;166 Cuenca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;103 Cuenca;Group 0210 Carcinoma in situ 230-234;Both sexes;15 Cuenca;Group 0210 Carcinoma in situ 230-234;Men;8 Cuenca;Group 0210 Carcinoma in situ 230-234;Women;7 Cuenca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;32 Cuenca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;21 Cuenca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;11 Cuenca;Grupo 0212 Leiomyoma of uterus 218;Both sexes;51 Cuenca;Grupo 0212 Leiomyoma of uterus 218;Men;.. Cuenca;Grupo 0212 Leiomyoma of uterus 218;Women;51 Cuenca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;240 Cuenca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;138 Cuenca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;102 Cuenca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;155 Cuenca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;64 Cuenca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;91 Cuenca;Group 0301 Anaemias 280-285;Both sexes;131 Cuenca;Group 0301 Anaemias 280-285;Men;49 Cuenca;Group 0301 Anaemias 280-285;Women;82 Cuenca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;24 Cuenca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;15 Cuenca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;9 Cuenca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;230 Cuenca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;94 Cuenca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;136 Cuenca;Group 0401 Diabetes mellitus 249-250;Both sexes;92 Cuenca;Group 0401 Diabetes mellitus 249-250;Men;48 Cuenca;Group 0401 Diabetes mellitus 249-250;Women;44 Cuenca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;138 Cuenca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;46 Cuenca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;92 Cuenca;Group 0500 Mental disorders 290-319;Both sexes;436 Cuenca;Group 0500 Mental disorders 290-319;Men;226 Cuenca;Group 0500 Mental disorders 290-319;Women;210 Cuenca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;12 Cuenca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;5 Cuenca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;7 Cuenca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;26 Cuenca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;22 Cuenca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;4 Cuenca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;15 Cuenca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;14 Cuenca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;1 Cuenca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;167 Cuenca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;107 Cuenca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;60 Cuenca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;96 Cuenca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;24 Cuenca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;72 Cuenca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;120 Cuenca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;54 Cuenca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;66 Cuenca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;429 Cuenca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;205 Cuenca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;224 Cuenca;Group 0601 Alzheimer's disease 3310;Both sexes;7 Cuenca;Group 0601 Alzheimer's disease 3310;Men;5 Cuenca;Group 0601 Alzheimer's disease 3310;Women;2 Cuenca;Group 0602 Multiple sclerosis 340;Both sexes;33 Cuenca;Group 0602 Multiple sclerosis 340;Men;7 Cuenca;Group 0602 Multiple sclerosis 340;Women;26 Cuenca;Group 0603 Epilepsy 345;Both sexes;75 Cuenca;Group 0603 Epilepsy 345;Men;45 Cuenca;Group 0603 Epilepsy 345;Women;30 Cuenca;Group 0604 Transient cerebral ischemia 435;Both sexes;120 Cuenca;Group 0604 Transient cerebral ischemia 435;Men;51 Cuenca;Group 0604 Transient cerebral ischemia 435;Women;69 Cuenca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;194 Cuenca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;97 Cuenca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;97 Cuenca;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;143 Cuenca;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;76 Cuenca;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;67 Cuenca;Grupo 0701 Cataract 366;Both sexes;6 Cuenca;Grupo 0701 Cataract 366;Men;3 Cuenca;Grupo 0701 Cataract 366;Women;3 Cuenca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;137 Cuenca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;73 Cuenca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;64 Cuenca;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;58 Cuenca;Group 0800 Diseases of the ear and the mastoid 380-389;Men;22 Cuenca;Group 0800 Diseases of the ear and the mastoid 380-389;Women;36 Cuenca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1.909 Cuenca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1.047 Cuenca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;862 Cuenca;Group 0901 Hypertensive disease 401-405;Both sexes;97 Cuenca;Group 0901 Hypertensive disease 401-405;Men;46 Cuenca;Group 0901 Hypertensive disease 401-405;Women;51 Cuenca;Group 0902 Angina pectoris 4111, 413;Both sexes;129 Cuenca;Group 0902 Angina pectoris 4111, 413;Men;90 Cuenca;Group 0902 Angina pectoris 4111, 413;Women;39 Cuenca;Group 0903 Acute myocardial infarction 410;Both sexes;81 Cuenca;Group 0903 Acute myocardial infarction 410;Men;53 Cuenca;Group 0903 Acute myocardial infarction 410;Women;28 Cuenca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;27 Cuenca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;23 Cuenca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;4 Cuenca;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;62 Cuenca;Group 0905 Diseases of the lungs circulation 415-417;Men;28 Cuenca;Group 0905 Diseases of the lungs circulation 415-417;Women;34 Cuenca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;321 Cuenca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;179 Cuenca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;142 Cuenca;Grupo 0907 Heart failure 428;Both sexes;469 Cuenca;Grupo 0907 Heart failure 428;Men;215 Cuenca;Grupo 0907 Heart failure 428;Women;254 Cuenca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;388 Cuenca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;222 Cuenca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;166 Cuenca;Grupo 0909 Atherosclerosis 440;Both sexes;68 Cuenca;Grupo 0909 Atherosclerosis 440;Men;57 Cuenca;Grupo 0909 Atherosclerosis 440;Women;11 Cuenca;Group 0910 Varicose veins of lower extremities 454;Both sexes;36 Cuenca;Group 0910 Varicose veins of lower extremities 454;Men;10 Cuenca;Group 0910 Varicose veins of lower extremities 454;Women;26 Cuenca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;231 Cuenca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;124 Cuenca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;107 Cuenca;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2.227 Cuenca;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.300 Cuenca;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;927 Cuenca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;117 Cuenca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;62 Cuenca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;55 Cuenca;Group 1002 Pneumonia 480-486;Both sexes;439 Cuenca;Group 1002 Pneumonia 480-486;Men;273 Cuenca;Group 1002 Pneumonia 480-486;Women;166 Cuenca;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;88 Cuenca;Group 1003 Acute bronchitis and bronchiolitis 466;Men;38 Cuenca;Group 1003 Acute bronchitis and bronchiolitis 466;Women;50 Cuenca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;41 Cuenca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;18 Cuenca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;23 Cuenca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;65 Cuenca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;48 Cuenca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;17 Cuenca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;309 Cuenca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;252 Cuenca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;57 Cuenca;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;54 Cuenca;Group 1007 Asthma 4930-4931,4938-4939;Men;19 Cuenca;Group 1007 Asthma 4930-4931,4938-4939;Women;35 Cuenca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.114 Cuenca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;590 Cuenca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;524 Cuenca;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.072 Cuenca;Group 1100 Diseases of the digestive system 520-579;Men;1.165 Cuenca;Group 1100 Diseases of the digestive system 520-579;Women;907 Cuenca;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;56 Cuenca;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;20 Cuenca;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;36 Cuenca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;35 Cuenca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;24 Cuenca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;11 Cuenca;Group 1103 Diseases of the esophagus 530;Both sexes;26 Cuenca;Group 1103 Diseases of the esophagus 530;Men;18 Cuenca;Group 1103 Diseases of the esophagus 530;Women;8 Cuenca;Group 1104 Peptic ulcer 531-534;Both sexes;47 Cuenca;Group 1104 Peptic ulcer 531-534;Men;31 Cuenca;Group 1104 Peptic ulcer 531-534;Women;16 Cuenca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;69 Cuenca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;29 Cuenca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;40 Cuenca;Group 1106 Appendicitis 540-543;Both sexes;156 Cuenca;Group 1106 Appendicitis 540-543;Men;94 Cuenca;Group 1106 Appendicitis 540-543;Women;62 Cuenca;Group 1107 Inguinal hernia 550;Both sexes;168 Cuenca;Group 1107 Inguinal hernia 550;Men;159 Cuenca;Group 1107 Inguinal hernia 550;Women;9 Cuenca;Group 1108 Other abdominal hernia 551-553;Both sexes;133 Cuenca;Group 1108 Other abdominal hernia 551-553;Men;56 Cuenca;Group 1108 Other abdominal hernia 551-553;Women;77 Cuenca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;42 Cuenca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;19 Cuenca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;23 Cuenca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;197 Cuenca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;88 Cuenca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;109 Cuenca;Group 1111 Intestinal obstruction without hernia 560;Both sexes;112 Cuenca;Group 1111 Intestinal obstruction without hernia 560;Men;61 Cuenca;Group 1111 Intestinal obstruction without hernia 560;Women;51 Cuenca;Group 1112 Intestinal diverticulosis 562;Both sexes;72 Cuenca;Group 1112 Intestinal diverticulosis 562;Men;35 Cuenca;Group 1112 Intestinal diverticulosis 562;Women;37 Cuenca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;139 Cuenca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;91 Cuenca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;48 Cuenca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;96 Cuenca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;39 Cuenca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;57 Cuenca;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;30 Cuenca;Group 1115 Alcoholic hepatitis 5710-5713;Men;26 Cuenca;Group 1115 Alcoholic hepatitis 5710-5713;Women;4 Cuenca;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;53 Cuenca;Group 1116 Other diseases of the liver 570,5714-573;Men;41 Cuenca;Group 1116 Other diseases of the liver 570,5714-573;Women;12 Cuenca;Group 1117 Cholelithiasis 574;Both sexes;311 Cuenca;Group 1117 Cholelithiasis 574;Men;152 Cuenca;Group 1117 Cholelithiasis 574;Women;159 Cuenca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;110 Cuenca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;63 Cuenca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;47 Cuenca;Group 1119 Pancreatic diseases 577;Both sexes;105 Cuenca;Group 1119 Pancreatic diseases 577;Men;52 Cuenca;Group 1119 Pancreatic diseases 577;Women;53 Cuenca;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;115 Cuenca;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;67 Cuenca;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;48 Cuenca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;141 Cuenca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;85 Cuenca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;56 Cuenca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;97 Cuenca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;61 Cuenca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;36 Cuenca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;8 Cuenca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;4 Cuenca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;4 Cuenca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;36 Cuenca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;20 Cuenca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;16 Cuenca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;618 Cuenca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;294 Cuenca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;324 Cuenca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Cuenca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Cuenca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Cuenca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Cuenca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Cuenca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Cuenca;Group 1303 Internal derangement of knee 717;Both sexes;109 Cuenca;Group 1303 Internal derangement of knee 717;Men;79 Cuenca;Group 1303 Internal derangement of knee 717;Women;30 Cuenca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;229 Cuenca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;90 Cuenca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;139 Cuenca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;13 Cuenca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;6 Cuenca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;7 Cuenca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;16 Cuenca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;11 Cuenca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;5 Cuenca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;30 Cuenca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;12 Cuenca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;18 Cuenca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;34 Cuenca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;25 Cuenca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;9 Cuenca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;80 Cuenca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;41 Cuenca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;39 Cuenca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;107 Cuenca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;30 Cuenca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;77 Cuenca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;865 Cuenca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;411 Cuenca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;454 Cuenca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;96 Cuenca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;29 Cuenca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;67 Cuenca;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;127 Cuenca;Group 1402 Renal failure 5836-5837, 584-586;Men;80 Cuenca;Group 1402 Renal failure 5836-5837, 584-586;Women;47 Cuenca;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;127 Cuenca;Group 1403 Urolithiasis 592, 594, 7880;Men;68 Cuenca;Group 1403 Urolithiasis 592, 594, 7880;Women;59 Cuenca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;263 Cuenca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;130 Cuenca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;133 Cuenca;Group 1405 Prostatic hyperplasia 600;Both sexes;50 Cuenca;Group 1405 Prostatic hyperplasia 600;Men;50 Cuenca;Group 1405 Prostatic hyperplasia 600;Women;.. Cuenca;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;50 Cuenca;Group 1406 Other diseases of the male genital organs 601-608;Men;50 Cuenca;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Cuenca;Group 1407 Disorders of breast 610-612;Both sexes;11 Cuenca;Group 1407 Disorders of breast 610-612;Men;2 Cuenca;Group 1407 Disorders of breast 610-612;Women;9 Cuenca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;17 Cuenca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Cuenca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;17 Cuenca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;15 Cuenca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Cuenca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;15 Cuenca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;109 Cuenca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 Cuenca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;107 Cuenca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.070 Cuenca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Cuenca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.070 Cuenca;Group 1501 Legally induced abortion 635;Both sexes;.. Cuenca;Group 1501 Legally induced abortion 635;Men;.. Cuenca;Group 1501 Legally induced abortion 635;Women;.. Cuenca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;129 Cuenca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Cuenca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;129 Cuenca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;531 Cuenca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Cuenca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;531 Cuenca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;188 Cuenca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Cuenca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;188 Cuenca;Group 1505 Single spontaneous delivery 650;Both sexes;37 Cuenca;Group 1505 Single spontaneous delivery 650;Men;.. Cuenca;Group 1505 Single spontaneous delivery 650;Women;37 Cuenca;Group 1506 Other deliveries 6695-6697;Both sexes;123 Cuenca;Group 1506 Other deliveries 6695-6697;Men;.. Cuenca;Group 1506 Other deliveries 6695-6697;Women;123 Cuenca;Group 1507 Complications related to the puerperium 670-676;Both sexes;2 Cuenca;Group 1507 Complications related to the puerperium 670-676;Men;.. Cuenca;Group 1507 Complications related to the puerperium 670-676;Women;2 Cuenca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;60 Cuenca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Cuenca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;60 Cuenca;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;105 Cuenca;Group 1600 Some disorders originating in the perinatal period 760-779;Men;58 Cuenca;Group 1600 Some disorders originating in the perinatal period 760-779;Women;47 Cuenca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;33 Cuenca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;16 Cuenca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;17 Cuenca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;72 Cuenca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;42 Cuenca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;30 Cuenca;Grupo 1700 Congenital abnormalities 740-759;Both sexes;50 Cuenca;Grupo 1700 Congenital abnormalities 740-759;Men;23 Cuenca;Grupo 1700 Congenital abnormalities 740-759;Women;27 Cuenca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;821 Cuenca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;420 Cuenca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;401 Cuenca;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;108 Cuenca;Group 1801 Pain in throat and chest 7841, 7865;Men;65 Cuenca;Group 1801 Pain in throat and chest 7841, 7865;Women;43 Cuenca;Group 1802 Abdominal pain 7890;Both sexes;100 Cuenca;Group 1802 Abdominal pain 7890;Men;34 Cuenca;Group 1802 Abdominal pain 7890;Women;66 Cuenca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;10 Cuenca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;6 Cuenca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;4 Cuenca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;603 Cuenca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;315 Cuenca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;288 Cuenca;Group 1900 Injuries and poisoning 800-999;Both sexes;1.212 Cuenca;Group 1900 Injuries and poisoning 800-999;Men;584 Cuenca;Group 1900 Injuries and poisoning 800-999;Women;628 Cuenca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;100 Cuenca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;53 Cuenca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;47 Cuenca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;27 Cuenca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;20 Cuenca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;7 Cuenca;Group 1903 Radius and ulna fracture 813;Both sexes;49 Cuenca;Group 1903 Radius and ulna fracture 813;Men;29 Cuenca;Group 1903 Radius and ulna fracture 813;Women;20 Cuenca;Group 1904 Femur fracture 820-821;Both sexes;295 Cuenca;Group 1904 Femur fracture 820-821;Men;94 Cuenca;Group 1904 Femur fracture 820-821;Women;201 Cuenca;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;91 Cuenca;Group 1905 Leg fracture, including the ankle 823-824;Men;42 Cuenca;Group 1905 Leg fracture, including the ankle 823-824;Women;49 Cuenca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;396 Cuenca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;221 Cuenca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;175 Cuenca;Group 1907 Burns 940-949;Both sexes;.. Cuenca;Group 1907 Burns 940-949;Men;.. Cuenca;Group 1907 Burns 940-949;Women;.. Cuenca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;48 Cuenca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;20 Cuenca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;28 Cuenca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;183 Cuenca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;96 Cuenca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;87 Cuenca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Cuenca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 Cuenca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Cuenca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;21 Cuenca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;8 Cuenca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;13 Cuenca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;208 Cuenca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;109 Cuenca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;99 Cuenca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;3 Cuenca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;1 Cuenca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2 Cuenca;Group 2102 Contraceptive management V25;Both sexes;1 Cuenca;Group 2102 Contraceptive management V25;Men;.. Cuenca;Group 2102 Contraceptive management V25;Women;1 Cuenca;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Cuenca;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Cuenca;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Cuenca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;105 Cuenca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;60 Cuenca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;45 Cuenca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;99 Cuenca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;48 Cuenca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;51 Guadalajara;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;18.673 Guadalajara;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;9.268 Guadalajara;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;9.405 Guadalajara;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;623 Guadalajara;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;361 Guadalajara;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;262 Guadalajara;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;146 Guadalajara;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;91 Guadalajara;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;55 Guadalajara;Group 0102 Imprecise intestinal infections 009;Both sexes;15 Guadalajara;Group 0102 Imprecise intestinal infections 009;Men;10 Guadalajara;Group 0102 Imprecise intestinal infections 009;Women;5 Guadalajara;Group 0103 Tuberculosis 010-018, 137;Both sexes;15 Guadalajara;Group 0103 Tuberculosis 010-018, 137;Men;7 Guadalajara;Group 0103 Tuberculosis 010-018, 137;Women;8 Guadalajara;Group 0104 Septicaemia 038;Both sexes;290 Guadalajara;Group 0104 Septicaemia 038;Men;151 Guadalajara;Group 0104 Septicaemia 038;Women;139 Guadalajara;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;7 Guadalajara;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;6 Guadalajara;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Guadalajara;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;150 Guadalajara;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;96 Guadalajara;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;54 Guadalajara;Group 0200 Neoplasms 140-239;Both sexes;1.438 Guadalajara;Group 0200 Neoplasms 140-239;Men;848 Guadalajara;Group 0200 Neoplasms 140-239;Women;590 Guadalajara;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;204 Guadalajara;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;132 Guadalajara;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;72 Guadalajara;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;80 Guadalajara;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;66 Guadalajara;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;14 Guadalajara;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;59 Guadalajara;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;36 Guadalajara;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;23 Guadalajara;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;88 Guadalajara;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Guadalajara;Group 0204 Malignant neoplasm of breast 174-175;Women;88 Guadalajara;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;25 Guadalajara;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Guadalajara;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;25 Guadalajara;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;23 Guadalajara;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Guadalajara;Group 0206 Malignant neoplasm of ovary 1830;Women;23 Guadalajara;Group 0207 Malignant neoplasm of prostate 185;Both sexes;72 Guadalajara;Group 0207 Malignant neoplasm of prostate 185;Men;72 Guadalajara;Group 0207 Malignant neoplasm of prostate 185;Women;.. Guadalajara;Group 0208 Malignant neoplasm of bladder 188;Both sexes;156 Guadalajara;Group 0208 Malignant neoplasm of bladder 188;Men;138 Guadalajara;Group 0208 Malignant neoplasm of bladder 188;Women;18 Guadalajara;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;503 Guadalajara;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;300 Guadalajara;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;203 Guadalajara;Group 0210 Carcinoma in situ 230-234;Both sexes;31 Guadalajara;Group 0210 Carcinoma in situ 230-234;Men;21 Guadalajara;Group 0210 Carcinoma in situ 230-234;Women;10 Guadalajara;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;15 Guadalajara;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;11 Guadalajara;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;4 Guadalajara;Grupo 0212 Leiomyoma of uterus 218;Both sexes;47 Guadalajara;Grupo 0212 Leiomyoma of uterus 218;Men;.. Guadalajara;Grupo 0212 Leiomyoma of uterus 218;Women;47 Guadalajara;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;135 Guadalajara;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;72 Guadalajara;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;63 Guadalajara;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;231 Guadalajara;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;119 Guadalajara;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;112 Guadalajara;Group 0301 Anaemias 280-285;Both sexes;135 Guadalajara;Group 0301 Anaemias 280-285;Men;65 Guadalajara;Group 0301 Anaemias 280-285;Women;70 Guadalajara;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;96 Guadalajara;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;54 Guadalajara;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;42 Guadalajara;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;305 Guadalajara;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;139 Guadalajara;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;166 Guadalajara;Group 0401 Diabetes mellitus 249-250;Both sexes;132 Guadalajara;Group 0401 Diabetes mellitus 249-250;Men;74 Guadalajara;Group 0401 Diabetes mellitus 249-250;Women;58 Guadalajara;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;173 Guadalajara;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;65 Guadalajara;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;108 Guadalajara;Group 0500 Mental disorders 290-319;Both sexes;387 Guadalajara;Group 0500 Mental disorders 290-319;Men;208 Guadalajara;Group 0500 Mental disorders 290-319;Women;179 Guadalajara;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;19 Guadalajara;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;10 Guadalajara;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;9 Guadalajara;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;43 Guadalajara;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;31 Guadalajara;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;12 Guadalajara;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;24 Guadalajara;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;11 Guadalajara;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;13 Guadalajara;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;144 Guadalajara;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;91 Guadalajara;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;53 Guadalajara;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;79 Guadalajara;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;33 Guadalajara;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;46 Guadalajara;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;78 Guadalajara;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;32 Guadalajara;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;46 Guadalajara;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;326 Guadalajara;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;143 Guadalajara;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;183 Guadalajara;Group 0601 Alzheimer's disease 3310;Both sexes;1 Guadalajara;Group 0601 Alzheimer's disease 3310;Men;.. Guadalajara;Group 0601 Alzheimer's disease 3310;Women;1 Guadalajara;Group 0602 Multiple sclerosis 340;Both sexes;10 Guadalajara;Group 0602 Multiple sclerosis 340;Men;2 Guadalajara;Group 0602 Multiple sclerosis 340;Women;8 Guadalajara;Group 0603 Epilepsy 345;Both sexes;63 Guadalajara;Group 0603 Epilepsy 345;Men;28 Guadalajara;Group 0603 Epilepsy 345;Women;35 Guadalajara;Group 0604 Transient cerebral ischemia 435;Both sexes;64 Guadalajara;Group 0604 Transient cerebral ischemia 435;Men;34 Guadalajara;Group 0604 Transient cerebral ischemia 435;Women;30 Guadalajara;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;188 Guadalajara;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;79 Guadalajara;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;109 Guadalajara;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;58 Guadalajara;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;32 Guadalajara;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;26 Guadalajara;Grupo 0701 Cataract 366;Both sexes;30 Guadalajara;Grupo 0701 Cataract 366;Men;18 Guadalajara;Grupo 0701 Cataract 366;Women;12 Guadalajara;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;28 Guadalajara;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;14 Guadalajara;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;14 Guadalajara;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;77 Guadalajara;Group 0800 Diseases of the ear and the mastoid 380-389;Men;34 Guadalajara;Group 0800 Diseases of the ear and the mastoid 380-389;Women;43 Guadalajara;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2.852 Guadalajara;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1.566 Guadalajara;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.286 Guadalajara;Group 0901 Hypertensive disease 401-405;Both sexes;286 Guadalajara;Group 0901 Hypertensive disease 401-405;Men;125 Guadalajara;Group 0901 Hypertensive disease 401-405;Women;161 Guadalajara;Group 0902 Angina pectoris 4111, 413;Both sexes;55 Guadalajara;Group 0902 Angina pectoris 4111, 413;Men;33 Guadalajara;Group 0902 Angina pectoris 4111, 413;Women;22 Guadalajara;Group 0903 Acute myocardial infarction 410;Both sexes;215 Guadalajara;Group 0903 Acute myocardial infarction 410;Men;163 Guadalajara;Group 0903 Acute myocardial infarction 410;Women;52 Guadalajara;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;188 Guadalajara;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;141 Guadalajara;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;47 Guadalajara;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;90 Guadalajara;Group 0905 Diseases of the lungs circulation 415-417;Men;34 Guadalajara;Group 0905 Diseases of the lungs circulation 415-417;Women;56 Guadalajara;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;501 Guadalajara;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;294 Guadalajara;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;207 Guadalajara;Grupo 0907 Heart failure 428;Both sexes;703 Guadalajara;Grupo 0907 Heart failure 428;Men;310 Guadalajara;Grupo 0907 Heart failure 428;Women;393 Guadalajara;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;371 Guadalajara;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;191 Guadalajara;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;180 Guadalajara;Grupo 0909 Atherosclerosis 440;Both sexes;91 Guadalajara;Grupo 0909 Atherosclerosis 440;Men;72 Guadalajara;Grupo 0909 Atherosclerosis 440;Women;19 Guadalajara;Group 0910 Varicose veins of lower extremities 454;Both sexes;18 Guadalajara;Group 0910 Varicose veins of lower extremities 454;Men;6 Guadalajara;Group 0910 Varicose veins of lower extremities 454;Women;12 Guadalajara;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;334 Guadalajara;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;197 Guadalajara;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;137 Guadalajara;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2.526 Guadalajara;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1.524 Guadalajara;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.002 Guadalajara;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;108 Guadalajara;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;57 Guadalajara;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;51 Guadalajara;Group 1002 Pneumonia 480-486;Both sexes;931 Guadalajara;Group 1002 Pneumonia 480-486;Men;603 Guadalajara;Group 1002 Pneumonia 480-486;Women;328 Guadalajara;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;193 Guadalajara;Group 1003 Acute bronchitis and bronchiolitis 466;Men;97 Guadalajara;Group 1003 Acute bronchitis and bronchiolitis 466;Women;96 Guadalajara;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;90 Guadalajara;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;49 Guadalajara;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;41 Guadalajara;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;123 Guadalajara;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;89 Guadalajara;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;34 Guadalajara;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;312 Guadalajara;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;242 Guadalajara;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;70 Guadalajara;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;84 Guadalajara;Group 1007 Asthma 4930-4931,4938-4939;Men;28 Guadalajara;Group 1007 Asthma 4930-4931,4938-4939;Women;56 Guadalajara;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;685 Guadalajara;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;359 Guadalajara;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;326 Guadalajara;Group 1100 Diseases of the digestive system 520-579;Both sexes;2.532 Guadalajara;Group 1100 Diseases of the digestive system 520-579;Men;1.426 Guadalajara;Group 1100 Diseases of the digestive system 520-579;Women;1.106 Guadalajara;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;25 Guadalajara;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;10 Guadalajara;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;15 Guadalajara;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;23 Guadalajara;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;11 Guadalajara;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;12 Guadalajara;Group 1103 Diseases of the esophagus 530;Both sexes;57 Guadalajara;Group 1103 Diseases of the esophagus 530;Men;43 Guadalajara;Group 1103 Diseases of the esophagus 530;Women;14 Guadalajara;Group 1104 Peptic ulcer 531-534;Both sexes;55 Guadalajara;Group 1104 Peptic ulcer 531-534;Men;43 Guadalajara;Group 1104 Peptic ulcer 531-534;Women;12 Guadalajara;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;48 Guadalajara;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;23 Guadalajara;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;25 Guadalajara;Group 1106 Appendicitis 540-543;Both sexes;210 Guadalajara;Group 1106 Appendicitis 540-543;Men;120 Guadalajara;Group 1106 Appendicitis 540-543;Women;90 Guadalajara;Group 1107 Inguinal hernia 550;Both sexes;237 Guadalajara;Group 1107 Inguinal hernia 550;Men;222 Guadalajara;Group 1107 Inguinal hernia 550;Women;15 Guadalajara;Group 1108 Other abdominal hernia 551-553;Both sexes;188 Guadalajara;Group 1108 Other abdominal hernia 551-553;Men;84 Guadalajara;Group 1108 Other abdominal hernia 551-553;Women;104 Guadalajara;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;43 Guadalajara;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;24 Guadalajara;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;19 Guadalajara;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;199 Guadalajara;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;93 Guadalajara;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;106 Guadalajara;Group 1111 Intestinal obstruction without hernia 560;Both sexes;123 Guadalajara;Group 1111 Intestinal obstruction without hernia 560;Men;55 Guadalajara;Group 1111 Intestinal obstruction without hernia 560;Women;68 Guadalajara;Group 1112 Intestinal diverticulosis 562;Both sexes;96 Guadalajara;Group 1112 Intestinal diverticulosis 562;Men;45 Guadalajara;Group 1112 Intestinal diverticulosis 562;Women;51 Guadalajara;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;106 Guadalajara;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;73 Guadalajara;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;33 Guadalajara;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;88 Guadalajara;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;42 Guadalajara;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;46 Guadalajara;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;35 Guadalajara;Group 1115 Alcoholic hepatitis 5710-5713;Men;32 Guadalajara;Group 1115 Alcoholic hepatitis 5710-5713;Women;3 Guadalajara;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;64 Guadalajara;Group 1116 Other diseases of the liver 570,5714-573;Men;45 Guadalajara;Group 1116 Other diseases of the liver 570,5714-573;Women;19 Guadalajara;Group 1117 Cholelithiasis 574;Both sexes;463 Guadalajara;Group 1117 Cholelithiasis 574;Men;194 Guadalajara;Group 1117 Cholelithiasis 574;Women;269 Guadalajara;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;196 Guadalajara;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;111 Guadalajara;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;85 Guadalajara;Group 1119 Pancreatic diseases 577;Both sexes;135 Guadalajara;Group 1119 Pancreatic diseases 577;Men;76 Guadalajara;Group 1119 Pancreatic diseases 577;Women;59 Guadalajara;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;141 Guadalajara;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;80 Guadalajara;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;61 Guadalajara;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;177 Guadalajara;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;90 Guadalajara;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;87 Guadalajara;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;102 Guadalajara;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;58 Guadalajara;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;44 Guadalajara;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;17 Guadalajara;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;12 Guadalajara;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;5 Guadalajara;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;58 Guadalajara;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;20 Guadalajara;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;38 Guadalajara;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1.059 Guadalajara;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;502 Guadalajara;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;557 Guadalajara;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Guadalajara;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Guadalajara;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Guadalajara;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Guadalajara;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Guadalajara;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Guadalajara;Group 1303 Internal derangement of knee 717;Both sexes;87 Guadalajara;Group 1303 Internal derangement of knee 717;Men;61 Guadalajara;Group 1303 Internal derangement of knee 717;Women;26 Guadalajara;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;378 Guadalajara;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;143 Guadalajara;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;235 Guadalajara;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;22 Guadalajara;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;11 Guadalajara;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;11 Guadalajara;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;54 Guadalajara;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;36 Guadalajara;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;18 Guadalajara;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;86 Guadalajara;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;41 Guadalajara;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;45 Guadalajara;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;27 Guadalajara;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;13 Guadalajara;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;14 Guadalajara;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;153 Guadalajara;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;85 Guadalajara;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;68 Guadalajara;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;252 Guadalajara;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;112 Guadalajara;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;140 Guadalajara;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1.211 Guadalajara;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;629 Guadalajara;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;582 Guadalajara;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;180 Guadalajara;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;56 Guadalajara;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;124 Guadalajara;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;128 Guadalajara;Group 1402 Renal failure 5836-5837, 584-586;Men;73 Guadalajara;Group 1402 Renal failure 5836-5837, 584-586;Women;55 Guadalajara;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;122 Guadalajara;Group 1403 Urolithiasis 592, 594, 7880;Men;68 Guadalajara;Group 1403 Urolithiasis 592, 594, 7880;Women;54 Guadalajara;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;419 Guadalajara;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;229 Guadalajara;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;190 Guadalajara;Group 1405 Prostatic hyperplasia 600;Both sexes;88 Guadalajara;Group 1405 Prostatic hyperplasia 600;Men;88 Guadalajara;Group 1405 Prostatic hyperplasia 600;Women;.. Guadalajara;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;109 Guadalajara;Group 1406 Other diseases of the male genital organs 601-608;Men;109 Guadalajara;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Guadalajara;Group 1407 Disorders of breast 610-612;Both sexes;32 Guadalajara;Group 1407 Disorders of breast 610-612;Men;4 Guadalajara;Group 1407 Disorders of breast 610-612;Women;28 Guadalajara;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;28 Guadalajara;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Guadalajara;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;28 Guadalajara;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;4 Guadalajara;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Guadalajara;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;4 Guadalajara;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;101 Guadalajara;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 Guadalajara;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;99 Guadalajara;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.818 Guadalajara;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Guadalajara;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.818 Guadalajara;Group 1501 Legally induced abortion 635;Both sexes;1 Guadalajara;Group 1501 Legally induced abortion 635;Men;.. Guadalajara;Group 1501 Legally induced abortion 635;Women;1 Guadalajara;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;95 Guadalajara;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Guadalajara;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;95 Guadalajara;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.218 Guadalajara;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Guadalajara;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.218 Guadalajara;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;254 Guadalajara;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Guadalajara;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;254 Guadalajara;Group 1505 Single spontaneous delivery 650;Both sexes;15 Guadalajara;Group 1505 Single spontaneous delivery 650;Men;.. Guadalajara;Group 1505 Single spontaneous delivery 650;Women;15 Guadalajara;Group 1506 Other deliveries 6695-6697;Both sexes;44 Guadalajara;Group 1506 Other deliveries 6695-6697;Men;.. Guadalajara;Group 1506 Other deliveries 6695-6697;Women;44 Guadalajara;Group 1507 Complications related to the puerperium 670-676;Both sexes;24 Guadalajara;Group 1507 Complications related to the puerperium 670-676;Men;.. Guadalajara;Group 1507 Complications related to the puerperium 670-676;Women;24 Guadalajara;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;167 Guadalajara;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Guadalajara;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;167 Guadalajara;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;177 Guadalajara;Group 1600 Some disorders originating in the perinatal period 760-779;Men;102 Guadalajara;Group 1600 Some disorders originating in the perinatal period 760-779;Women;75 Guadalajara;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;59 Guadalajara;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;37 Guadalajara;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;22 Guadalajara;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;118 Guadalajara;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;65 Guadalajara;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;53 Guadalajara;Grupo 1700 Congenital abnormalities 740-759;Both sexes;89 Guadalajara;Grupo 1700 Congenital abnormalities 740-759;Men;58 Guadalajara;Grupo 1700 Congenital abnormalities 740-759;Women;31 Guadalajara;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;929 Guadalajara;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;500 Guadalajara;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;429 Guadalajara;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;142 Guadalajara;Group 1801 Pain in throat and chest 7841, 7865;Men;76 Guadalajara;Group 1801 Pain in throat and chest 7841, 7865;Women;66 Guadalajara;Group 1802 Abdominal pain 7890;Both sexes;135 Guadalajara;Group 1802 Abdominal pain 7890;Men;47 Guadalajara;Group 1802 Abdominal pain 7890;Women;88 Guadalajara;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;.. Guadalajara;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. Guadalajara;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. Guadalajara;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;652 Guadalajara;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;377 Guadalajara;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;275 Guadalajara;Group 1900 Injuries and poisoning 800-999;Both sexes;1.521 Guadalajara;Group 1900 Injuries and poisoning 800-999;Men;769 Guadalajara;Group 1900 Injuries and poisoning 800-999;Women;752 Guadalajara;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;78 Guadalajara;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;44 Guadalajara;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;34 Guadalajara;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;27 Guadalajara;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;20 Guadalajara;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;7 Guadalajara;Group 1903 Radius and ulna fracture 813;Both sexes;58 Guadalajara;Group 1903 Radius and ulna fracture 813;Men;31 Guadalajara;Group 1903 Radius and ulna fracture 813;Women;27 Guadalajara;Group 1904 Femur fracture 820-821;Both sexes;310 Guadalajara;Group 1904 Femur fracture 820-821;Men;80 Guadalajara;Group 1904 Femur fracture 820-821;Women;230 Guadalajara;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;81 Guadalajara;Group 1905 Leg fracture, including the ankle 823-824;Men;44 Guadalajara;Group 1905 Leg fracture, including the ankle 823-824;Women;37 Guadalajara;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;286 Guadalajara;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;196 Guadalajara;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;90 Guadalajara;Group 1907 Burns 940-949;Both sexes;1 Guadalajara;Group 1907 Burns 940-949;Men;1 Guadalajara;Group 1907 Burns 940-949;Women;.. Guadalajara;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;48 Guadalajara;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;24 Guadalajara;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;24 Guadalajara;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;498 Guadalajara;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;271 Guadalajara;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;227 Guadalajara;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Guadalajara;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Guadalajara;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Guadalajara;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;134 Guadalajara;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;58 Guadalajara;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;76 Guadalajara;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;337 Guadalajara;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;218 Guadalajara;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;119 Guadalajara;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;18 Guadalajara;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;13 Guadalajara;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;5 Guadalajara;Group 2102 Contraceptive management V25;Both sexes;3 Guadalajara;Group 2102 Contraceptive management V25;Men;1 Guadalajara;Group 2102 Contraceptive management V25;Women;2 Guadalajara;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Guadalajara;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Guadalajara;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Guadalajara;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;140 Guadalajara;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;93 Guadalajara;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;47 Guadalajara;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;176 Guadalajara;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;111 Guadalajara;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;65 Toledo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;47.896 Toledo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;23.320 Toledo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;24.576 Toledo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.398 Toledo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;783 Toledo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;615 Toledo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;184 Toledo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;100 Toledo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;84 Toledo;Group 0102 Imprecise intestinal infections 009;Both sexes;81 Toledo;Group 0102 Imprecise intestinal infections 009;Men;35 Toledo;Group 0102 Imprecise intestinal infections 009;Women;46 Toledo;Group 0103 Tuberculosis 010-018, 137;Both sexes;27 Toledo;Group 0103 Tuberculosis 010-018, 137;Men;21 Toledo;Group 0103 Tuberculosis 010-018, 137;Women;6 Toledo;Group 0104 Septicaemia 038;Both sexes;768 Toledo;Group 0104 Septicaemia 038;Men;418 Toledo;Group 0104 Septicaemia 038;Women;350 Toledo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;21 Toledo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;16 Toledo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;5 Toledo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;317 Toledo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;193 Toledo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;124 Toledo;Group 0200 Neoplasms 140-239;Both sexes;4.555 Toledo;Group 0200 Neoplasms 140-239;Men;2.580 Toledo;Group 0200 Neoplasms 140-239;Women;1.975 Toledo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;453 Toledo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;261 Toledo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;192 Toledo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;387 Toledo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;332 Toledo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;55 Toledo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;125 Toledo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;72 Toledo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;53 Toledo;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;317 Toledo;Group 0204 Malignant neoplasm of breast 174-175;Men;2 Toledo;Group 0204 Malignant neoplasm of breast 174-175;Women;315 Toledo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;93 Toledo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Toledo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;93 Toledo;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;31 Toledo;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Toledo;Group 0206 Malignant neoplasm of ovary 1830;Women;31 Toledo;Group 0207 Malignant neoplasm of prostate 185;Both sexes;164 Toledo;Group 0207 Malignant neoplasm of prostate 185;Men;164 Toledo;Group 0207 Malignant neoplasm of prostate 185;Women;.. Toledo;Group 0208 Malignant neoplasm of bladder 188;Both sexes;248 Toledo;Group 0208 Malignant neoplasm of bladder 188;Men;220 Toledo;Group 0208 Malignant neoplasm of bladder 188;Women;28 Toledo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.422 Toledo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;880 Toledo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;542 Toledo;Group 0210 Carcinoma in situ 230-234;Both sexes;73 Toledo;Group 0210 Carcinoma in situ 230-234;Men;33 Toledo;Group 0210 Carcinoma in situ 230-234;Women;40 Toledo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;43 Toledo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;27 Toledo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;16 Toledo;Grupo 0212 Leiomyoma of uterus 218;Both sexes;170 Toledo;Grupo 0212 Leiomyoma of uterus 218;Men;.. Toledo;Grupo 0212 Leiomyoma of uterus 218;Women;170 Toledo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.029 Toledo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;589 Toledo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;440 Toledo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;418 Toledo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;223 Toledo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;195 Toledo;Group 0301 Anaemias 280-285;Both sexes;200 Toledo;Group 0301 Anaemias 280-285;Men;101 Toledo;Group 0301 Anaemias 280-285;Women;99 Toledo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;218 Toledo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;122 Toledo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;96 Toledo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;846 Toledo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;364 Toledo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;482 Toledo;Group 0401 Diabetes mellitus 249-250;Both sexes;254 Toledo;Group 0401 Diabetes mellitus 249-250;Men;150 Toledo;Group 0401 Diabetes mellitus 249-250;Women;104 Toledo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;592 Toledo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;214 Toledo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;378 Toledo;Group 0500 Mental disorders 290-319;Both sexes;1.277 Toledo;Group 0500 Mental disorders 290-319;Men;722 Toledo;Group 0500 Mental disorders 290-319;Women;555 Toledo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;21 Toledo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;11 Toledo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;10 Toledo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;94 Toledo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;68 Toledo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;26 Toledo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;55 Toledo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;44 Toledo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;11 Toledo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;434 Toledo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;304 Toledo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;130 Toledo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;287 Toledo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;91 Toledo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;196 Toledo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;386 Toledo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;204 Toledo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;182 Toledo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.778 Toledo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.022 Toledo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;756 Toledo;Group 0601 Alzheimer's disease 3310;Both sexes;15 Toledo;Group 0601 Alzheimer's disease 3310;Men;7 Toledo;Group 0601 Alzheimer's disease 3310;Women;8 Toledo;Group 0602 Multiple sclerosis 340;Both sexes;27 Toledo;Group 0602 Multiple sclerosis 340;Men;6 Toledo;Group 0602 Multiple sclerosis 340;Women;21 Toledo;Group 0603 Epilepsy 345;Both sexes;129 Toledo;Group 0603 Epilepsy 345;Men;67 Toledo;Group 0603 Epilepsy 345;Women;62 Toledo;Group 0604 Transient cerebral ischemia 435;Both sexes;189 Toledo;Group 0604 Transient cerebral ischemia 435;Men;90 Toledo;Group 0604 Transient cerebral ischemia 435;Women;99 Toledo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.418 Toledo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;852 Toledo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;566 Toledo;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;217 Toledo;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;118 Toledo;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;99 Toledo;Grupo 0701 Cataract 366;Both sexes;14 Toledo;Grupo 0701 Cataract 366;Men;7 Toledo;Grupo 0701 Cataract 366;Women;7 Toledo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;203 Toledo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;111 Toledo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;92 Toledo;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;190 Toledo;Group 0800 Diseases of the ear and the mastoid 380-389;Men;84 Toledo;Group 0800 Diseases of the ear and the mastoid 380-389;Women;106 Toledo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6.308 Toledo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.642 Toledo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.666 Toledo;Group 0901 Hypertensive disease 401-405;Both sexes;226 Toledo;Group 0901 Hypertensive disease 401-405;Men;95 Toledo;Group 0901 Hypertensive disease 401-405;Women;131 Toledo;Group 0902 Angina pectoris 4111, 413;Both sexes;218 Toledo;Group 0902 Angina pectoris 4111, 413;Men;152 Toledo;Group 0902 Angina pectoris 4111, 413;Women;66 Toledo;Group 0903 Acute myocardial infarction 410;Both sexes;710 Toledo;Group 0903 Acute myocardial infarction 410;Men;522 Toledo;Group 0903 Acute myocardial infarction 410;Women;188 Toledo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;404 Toledo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;293 Toledo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;111 Toledo;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;246 Toledo;Group 0905 Diseases of the lungs circulation 415-417;Men;123 Toledo;Group 0905 Diseases of the lungs circulation 415-417;Women;123 Toledo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;885 Toledo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;477 Toledo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;408 Toledo;Grupo 0907 Heart failure 428;Both sexes;1.333 Toledo;Grupo 0907 Heart failure 428;Men;605 Toledo;Grupo 0907 Heart failure 428;Women;728 Toledo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.127 Toledo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;654 Toledo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;473 Toledo;Grupo 0909 Atherosclerosis 440;Both sexes;162 Toledo;Grupo 0909 Atherosclerosis 440;Men;129 Toledo;Grupo 0909 Atherosclerosis 440;Women;33 Toledo;Group 0910 Varicose veins of lower extremities 454;Both sexes;42 Toledo;Group 0910 Varicose veins of lower extremities 454;Men;8 Toledo;Group 0910 Varicose veins of lower extremities 454;Women;34 Toledo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;955 Toledo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;584 Toledo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;371 Toledo;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5.822 Toledo;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.397 Toledo;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.425 Toledo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;308 Toledo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;181 Toledo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;127 Toledo;Group 1002 Pneumonia 480-486;Both sexes;1.618 Toledo;Group 1002 Pneumonia 480-486;Men;982 Toledo;Group 1002 Pneumonia 480-486;Women;636 Toledo;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;290 Toledo;Group 1003 Acute bronchitis and bronchiolitis 466;Men;144 Toledo;Group 1003 Acute bronchitis and bronchiolitis 466;Women;146 Toledo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;117 Toledo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;67 Toledo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;50 Toledo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;367 Toledo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;253 Toledo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;114 Toledo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;896 Toledo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;744 Toledo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;152 Toledo;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;224 Toledo;Group 1007 Asthma 4930-4931,4938-4939;Men;83 Toledo;Group 1007 Asthma 4930-4931,4938-4939;Women;141 Toledo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.002 Toledo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;943 Toledo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.059 Toledo;Group 1100 Diseases of the digestive system 520-579;Both sexes;5.634 Toledo;Group 1100 Diseases of the digestive system 520-579;Men;3.119 Toledo;Group 1100 Diseases of the digestive system 520-579;Women;2.515 Toledo;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;72 Toledo;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;38 Toledo;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;34 Toledo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;70 Toledo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;33 Toledo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;37 Toledo;Group 1103 Diseases of the esophagus 530;Both sexes;93 Toledo;Group 1103 Diseases of the esophagus 530;Men;54 Toledo;Group 1103 Diseases of the esophagus 530;Women;39 Toledo;Group 1104 Peptic ulcer 531-534;Both sexes;120 Toledo;Group 1104 Peptic ulcer 531-534;Men;82 Toledo;Group 1104 Peptic ulcer 531-534;Women;38 Toledo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;105 Toledo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;51 Toledo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;54 Toledo;Group 1106 Appendicitis 540-543;Both sexes;567 Toledo;Group 1106 Appendicitis 540-543;Men;328 Toledo;Group 1106 Appendicitis 540-543;Women;239 Toledo;Group 1107 Inguinal hernia 550;Both sexes;419 Toledo;Group 1107 Inguinal hernia 550;Men;363 Toledo;Group 1107 Inguinal hernia 550;Women;56 Toledo;Group 1108 Other abdominal hernia 551-553;Both sexes;490 Toledo;Group 1108 Other abdominal hernia 551-553;Men;230 Toledo;Group 1108 Other abdominal hernia 551-553;Women;260 Toledo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;117 Toledo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;69 Toledo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;48 Toledo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;345 Toledo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;180 Toledo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;165 Toledo;Group 1111 Intestinal obstruction without hernia 560;Both sexes;335 Toledo;Group 1111 Intestinal obstruction without hernia 560;Men;160 Toledo;Group 1111 Intestinal obstruction without hernia 560;Women;175 Toledo;Group 1112 Intestinal diverticulosis 562;Both sexes;218 Toledo;Group 1112 Intestinal diverticulosis 562;Men;116 Toledo;Group 1112 Intestinal diverticulosis 562;Women;102 Toledo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;348 Toledo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;219 Toledo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;129 Toledo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;245 Toledo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;118 Toledo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;127 Toledo;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;57 Toledo;Group 1115 Alcoholic hepatitis 5710-5713;Men;48 Toledo;Group 1115 Alcoholic hepatitis 5710-5713;Women;9 Toledo;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;184 Toledo;Group 1116 Other diseases of the liver 570,5714-573;Men;120 Toledo;Group 1116 Other diseases of the liver 570,5714-573;Women;64 Toledo;Group 1117 Cholelithiasis 574;Both sexes;931 Toledo;Group 1117 Cholelithiasis 574;Men;404 Toledo;Group 1117 Cholelithiasis 574;Women;527 Toledo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;316 Toledo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;187 Toledo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;129 Toledo;Group 1119 Pancreatic diseases 577;Both sexes;408 Toledo;Group 1119 Pancreatic diseases 577;Men;213 Toledo;Group 1119 Pancreatic diseases 577;Women;195 Toledo;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;194 Toledo;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;106 Toledo;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;88 Toledo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;436 Toledo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;243 Toledo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;193 Toledo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;278 Toledo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;161 Toledo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;117 Toledo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;15 Toledo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;9 Toledo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;6 Toledo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;143 Toledo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;73 Toledo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;70 Toledo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.809 Toledo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.384 Toledo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.425 Toledo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Toledo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Toledo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Toledo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Toledo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Toledo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Toledo;Group 1303 Internal derangement of knee 717;Both sexes;309 Toledo;Group 1303 Internal derangement of knee 717;Men;231 Toledo;Group 1303 Internal derangement of knee 717;Women;78 Toledo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.080 Toledo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;453 Toledo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;627 Toledo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;45 Toledo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;18 Toledo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;27 Toledo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;214 Toledo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;103 Toledo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;111 Toledo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;284 Toledo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;144 Toledo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;140 Toledo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;60 Toledo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;36 Toledo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;24 Toledo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;432 Toledo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;254 Toledo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;178 Toledo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;385 Toledo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;145 Toledo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;240 Toledo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.971 Toledo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.390 Toledo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.581 Toledo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;316 Toledo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;135 Toledo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;181 Toledo;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;336 Toledo;Group 1402 Renal failure 5836-5837, 584-586;Men;191 Toledo;Group 1402 Renal failure 5836-5837, 584-586;Women;145 Toledo;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;440 Toledo;Group 1403 Urolithiasis 592, 594, 7880;Men;251 Toledo;Group 1403 Urolithiasis 592, 594, 7880;Women;189 Toledo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;746 Toledo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;371 Toledo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;375 Toledo;Group 1405 Prostatic hyperplasia 600;Both sexes;180 Toledo;Group 1405 Prostatic hyperplasia 600;Men;180 Toledo;Group 1405 Prostatic hyperplasia 600;Women;.. Toledo;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;245 Toledo;Group 1406 Other diseases of the male genital organs 601-608;Men;245 Toledo;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Toledo;Group 1407 Disorders of breast 610-612;Both sexes;116 Toledo;Group 1407 Disorders of breast 610-612;Men;17 Toledo;Group 1407 Disorders of breast 610-612;Women;99 Toledo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;95 Toledo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Toledo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;95 Toledo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;36 Toledo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Toledo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;36 Toledo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;461 Toledo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Toledo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;461 Toledo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.190 Toledo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Toledo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.190 Toledo;Group 1501 Legally induced abortion 635;Both sexes;3 Toledo;Group 1501 Legally induced abortion 635;Men;.. Toledo;Group 1501 Legally induced abortion 635;Women;3 Toledo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;445 Toledo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Toledo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;445 Toledo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.179 Toledo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Toledo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.179 Toledo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;494 Toledo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Toledo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;494 Toledo;Group 1505 Single spontaneous delivery 650;Both sexes;281 Toledo;Group 1505 Single spontaneous delivery 650;Men;.. Toledo;Group 1505 Single spontaneous delivery 650;Women;281 Toledo;Group 1506 Other deliveries 6695-6697;Both sexes;354 Toledo;Group 1506 Other deliveries 6695-6697;Men;.. Toledo;Group 1506 Other deliveries 6695-6697;Women;354 Toledo;Group 1507 Complications related to the puerperium 670-676;Both sexes;47 Toledo;Group 1507 Complications related to the puerperium 670-676;Men;.. Toledo;Group 1507 Complications related to the puerperium 670-676;Women;47 Toledo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;387 Toledo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Toledo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;387 Toledo;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;807 Toledo;Group 1600 Some disorders originating in the perinatal period 760-779;Men;432 Toledo;Group 1600 Some disorders originating in the perinatal period 760-779;Women;375 Toledo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;249 Toledo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;132 Toledo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;117 Toledo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;558 Toledo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;300 Toledo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;258 Toledo;Grupo 1700 Congenital abnormalities 740-759;Both sexes;336 Toledo;Grupo 1700 Congenital abnormalities 740-759;Men;202 Toledo;Grupo 1700 Congenital abnormalities 740-759;Women;134 Toledo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.649 Toledo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;879 Toledo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;770 Toledo;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;144 Toledo;Group 1801 Pain in throat and chest 7841, 7865;Men;81 Toledo;Group 1801 Pain in throat and chest 7841, 7865;Women;63 Toledo;Group 1802 Abdominal pain 7890;Both sexes;271 Toledo;Group 1802 Abdominal pain 7890;Men;116 Toledo;Group 1802 Abdominal pain 7890;Women;155 Toledo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;11 Toledo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;4 Toledo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;7 Toledo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.223 Toledo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;678 Toledo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;545 Toledo;Group 1900 Injuries and poisoning 800-999;Both sexes;4.612 Toledo;Group 1900 Injuries and poisoning 800-999;Men;2.344 Toledo;Group 1900 Injuries and poisoning 800-999;Women;2.268 Toledo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;243 Toledo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;140 Toledo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;103 Toledo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;84 Toledo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;68 Toledo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;16 Toledo;Group 1903 Radius and ulna fracture 813;Both sexes;262 Toledo;Group 1903 Radius and ulna fracture 813;Men;124 Toledo;Group 1903 Radius and ulna fracture 813;Women;138 Toledo;Group 1904 Femur fracture 820-821;Both sexes;863 Toledo;Group 1904 Femur fracture 820-821;Men;247 Toledo;Group 1904 Femur fracture 820-821;Women;616 Toledo;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;354 Toledo;Group 1905 Leg fracture, including the ankle 823-824;Men;189 Toledo;Group 1905 Leg fracture, including the ankle 823-824;Women;165 Toledo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.448 Toledo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;898 Toledo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;550 Toledo;Group 1907 Burns 940-949;Both sexes;6 Toledo;Group 1907 Burns 940-949;Men;4 Toledo;Group 1907 Burns 940-949;Women;2 Toledo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;170 Toledo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;75 Toledo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;95 Toledo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.028 Toledo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;529 Toledo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;499 Toledo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;11 Toledo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;4 Toledo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;7 Toledo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;143 Toledo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;66 Toledo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;77 Toledo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;643 Toledo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;392 Toledo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;251 Toledo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;20 Toledo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;12 Toledo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;8 Toledo;Group 2102 Contraceptive management V25;Both sexes;5 Toledo;Group 2102 Contraceptive management V25;Men;2 Toledo;Group 2102 Contraceptive management V25;Women;3 Toledo;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Toledo;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Toledo;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Toledo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;307 Toledo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;206 Toledo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;101 Toledo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;311 Toledo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;172 Toledo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;139 CATALUÐA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;832.753 CATALUÐA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;393.515 CATALUÐA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;439.238 CATALUÐA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;15.859 CATALUÐA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;8.844 CATALUÐA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;7.015 CATALUÐA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;2.369 CATALUÐA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;1.191 CATALUÐA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;1.178 CATALUÐA;Group 0102 Imprecise intestinal infections 009;Both sexes;1.953 CATALUÐA;Group 0102 Imprecise intestinal infections 009;Men;978 CATALUÐA;Group 0102 Imprecise intestinal infections 009;Women;975 CATALUÐA;Group 0103 Tuberculosis 010-018, 137;Both sexes;605 CATALUÐA;Group 0103 Tuberculosis 010-018, 137;Men;403 CATALUÐA;Group 0103 Tuberculosis 010-018, 137;Women;202 CATALUÐA;Group 0104 Septicaemia 038;Both sexes;5.098 CATALUÐA;Group 0104 Septicaemia 038;Men;2.822 CATALUÐA;Group 0104 Septicaemia 038;Women;2.277 CATALUÐA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;619 CATALUÐA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;471 CATALUÐA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;148 CATALUÐA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;5.215 CATALUÐA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2.979 CATALUÐA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;2.236 CATALUÐA;Group 0200 Neoplasms 140-239;Both sexes;78.941 CATALUÐA;Group 0200 Neoplasms 140-239;Men;42.979 CATALUÐA;Group 0200 Neoplasms 140-239;Women;35.962 CATALUÐA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;8.689 CATALUÐA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;5.266 CATALUÐA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;3.423 CATALUÐA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;6.765 CATALUÐA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;5.262 CATALUÐA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;1.503 CATALUÐA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;1.088 CATALUÐA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;636 CATALUÐA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;452 CATALUÐA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;5.600 CATALUÐA;Group 0204 Malignant neoplasm of breast 174-175;Men;48 CATALUÐA;Group 0204 Malignant neoplasm of breast 174-175;Women;5.552 CATALUÐA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1.735 CATALUÐA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CATALUÐA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1.735 CATALUÐA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;912 CATALUÐA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CATALUÐA;Group 0206 Malignant neoplasm of ovary 1830;Women;912 CATALUÐA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;2.877 CATALUÐA;Group 0207 Malignant neoplasm of prostate 185;Men;2.877 CATALUÐA;Group 0207 Malignant neoplasm of prostate 185;Women;.. CATALUÐA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;8.657 CATALUÐA;Group 0208 Malignant neoplasm of bladder 188;Men;7.249 CATALUÐA;Group 0208 Malignant neoplasm of bladder 188;Women;1.408 CATALUÐA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;28.996 CATALUÐA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;17.198 CATALUÐA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;11.798 CATALUÐA;Group 0210 Carcinoma in situ 230-234;Both sexes;809 CATALUÐA;Group 0210 Carcinoma in situ 230-234;Men;323 CATALUÐA;Group 0210 Carcinoma in situ 230-234;Women;486 CATALUÐA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;892 CATALUÐA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;572 CATALUÐA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;320 CATALUÐA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;3.379 CATALUÐA;Grupo 0212 Leiomyoma of uterus 218;Men;.. CATALUÐA;Grupo 0212 Leiomyoma of uterus 218;Women;3.379 CATALUÐA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;8.543 CATALUÐA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;3.548 CATALUÐA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;4.995 CATALUÐA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;6.933 CATALUÐA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;3.405 CATALUÐA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;3.528 CATALUÐA;Group 0301 Anaemias 280-285;Both sexes;3.939 CATALUÐA;Group 0301 Anaemias 280-285;Men;1.832 CATALUÐA;Group 0301 Anaemias 280-285;Women;2.107 CATALUÐA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;2.994 CATALUÐA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1.573 CATALUÐA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1.420 CATALUÐA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;14.318 CATALUÐA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;5.661 CATALUÐA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;8.657 CATALUÐA;Group 0401 Diabetes mellitus 249-250;Both sexes;4.466 CATALUÐA;Group 0401 Diabetes mellitus 249-250;Men;2.583 CATALUÐA;Group 0401 Diabetes mellitus 249-250;Women;1.884 CATALUÐA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;9.851 CATALUÐA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;3.079 CATALUÐA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;6.773 CATALUÐA;Group 0500 Mental disorders 290-319;Both sexes;28.108 CATALUÐA;Group 0500 Mental disorders 290-319;Men;14.646 CATALUÐA;Group 0500 Mental disorders 290-319;Women;13.461 CATALUÐA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;1.978 CATALUÐA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;848 CATALUÐA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;1.130 CATALUÐA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;1.844 CATALUÐA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;1.340 CATALUÐA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;504 CATALUÐA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;1.657 CATALUÐA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;1.219 CATALUÐA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;438 CATALUÐA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;8.470 CATALUÐA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;5.245 CATALUÐA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;3.226 CATALUÐA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;6.130 CATALUÐA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;2.429 CATALUÐA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;3.701 CATALUÐA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;8.029 CATALUÐA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;3.566 CATALUÐA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;4.463 CATALUÐA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;16.754 CATALUÐA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;8.001 CATALUÐA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;8.753 CATALUÐA;Group 0601 Alzheimer's disease 3310;Both sexes;1.779 CATALUÐA;Group 0601 Alzheimer's disease 3310;Men;594 CATALUÐA;Group 0601 Alzheimer's disease 3310;Women;1.185 CATALUÐA;Group 0602 Multiple sclerosis 340;Both sexes;191 CATALUÐA;Group 0602 Multiple sclerosis 340;Men;66 CATALUÐA;Group 0602 Multiple sclerosis 340;Women;124 CATALUÐA;Group 0603 Epilepsy 345;Both sexes;2.825 CATALUÐA;Group 0603 Epilepsy 345;Men;1.535 CATALUÐA;Group 0603 Epilepsy 345;Women;1.291 CATALUÐA;Group 0604 Transient cerebral ischemia 435;Both sexes;2.085 CATALUÐA;Group 0604 Transient cerebral ischemia 435;Men;1.060 CATALUÐA;Group 0604 Transient cerebral ischemia 435;Women;1.025 CATALUÐA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;9.874 CATALUÐA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;4.746 CATALUÐA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;5.128 CATALUÐA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;5.005 CATALUÐA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;2.473 CATALUÐA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;2.532 CATALUÐA;Grupo 0701 Cataract 366;Both sexes;1.488 CATALUÐA;Grupo 0701 Cataract 366;Men;657 CATALUÐA;Grupo 0701 Cataract 366;Women;831 CATALUÐA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;3.517 CATALUÐA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;1.816 CATALUÐA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1.700 CATALUÐA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;4.059 CATALUÐA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1.973 CATALUÐA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;2.086 CATALUÐA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;107.831 CATALUÐA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;59.675 CATALUÐA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;48.156 CATALUÐA;Group 0901 Hypertensive disease 401-405;Both sexes;4.348 CATALUÐA;Group 0901 Hypertensive disease 401-405;Men;1.805 CATALUÐA;Group 0901 Hypertensive disease 401-405;Women;2.543 CATALUÐA;Group 0902 Angina pectoris 4111, 413;Both sexes;3.442 CATALUÐA;Group 0902 Angina pectoris 4111, 413;Men;2.240 CATALUÐA;Group 0902 Angina pectoris 4111, 413;Women;1.202 CATALUÐA;Group 0903 Acute myocardial infarction 410;Both sexes;9.726 CATALUÐA;Group 0903 Acute myocardial infarction 410;Men;6.830 CATALUÐA;Group 0903 Acute myocardial infarction 410;Women;2.896 CATALUÐA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;7.121 CATALUÐA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;5.473 CATALUÐA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1.648 CATALUÐA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;3.119 CATALUÐA;Group 0905 Diseases of the lungs circulation 415-417;Men;1.446 CATALUÐA;Group 0905 Diseases of the lungs circulation 415-417;Women;1.673 CATALUÐA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;13.487 CATALUÐA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;7.127 CATALUÐA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;6.360 CATALUÐA;Grupo 0907 Heart failure 428;Both sexes;26.107 CATALUÐA;Grupo 0907 Heart failure 428;Men;11.771 CATALUÐA;Grupo 0907 Heart failure 428;Women;14.336 CATALUÐA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;19.479 CATALUÐA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;10.395 CATALUÐA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;9.084 CATALUÐA;Grupo 0909 Atherosclerosis 440;Both sexes;4.724 CATALUÐA;Grupo 0909 Atherosclerosis 440;Men;3.351 CATALUÐA;Grupo 0909 Atherosclerosis 440;Women;1.373 CATALUÐA;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.515 CATALUÐA;Group 0910 Varicose veins of lower extremities 454;Men;538 CATALUÐA;Group 0910 Varicose veins of lower extremities 454;Women;976 CATALUÐA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;14.763 CATALUÐA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;8.699 CATALUÐA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;6.064 CATALUÐA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;101.924 CATALUÐA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;57.105 CATALUÐA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;44.820 CATALUÐA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;4.672 CATALUÐA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;2.432 CATALUÐA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;2.240 CATALUÐA;Group 1002 Pneumonia 480-486;Both sexes;20.265 CATALUÐA;Group 1002 Pneumonia 480-486;Men;11.841 CATALUÐA;Group 1002 Pneumonia 480-486;Women;8.424 CATALUÐA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;14.696 CATALUÐA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;6.689 CATALUÐA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;8.007 CATALUÐA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;3.105 CATALUÐA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.697 CATALUÐA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1.408 CATALUÐA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;6.660 CATALUÐA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;4.056 CATALUÐA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2.604 CATALUÐA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;18.943 CATALUÐA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;13.939 CATALUÐA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;5.004 CATALUÐA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;3.678 CATALUÐA;Group 1007 Asthma 4930-4931,4938-4939;Men;883 CATALUÐA;Group 1007 Asthma 4930-4931,4938-4939;Women;2.795 CATALUÐA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;29.906 CATALUÐA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;15.568 CATALUÐA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;14.338 CATALUÐA;Group 1100 Diseases of the digestive system 520-579;Both sexes;94.889 CATALUÐA;Group 1100 Diseases of the digestive system 520-579;Men;51.712 CATALUÐA;Group 1100 Diseases of the digestive system 520-579;Women;43.177 CATALUÐA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;1.284 CATALUÐA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;602 CATALUÐA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;681 CATALUÐA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1.142 CATALUÐA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;593 CATALUÐA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;549 CATALUÐA;Group 1103 Diseases of the esophagus 530;Both sexes;1.582 CATALUÐA;Group 1103 Diseases of the esophagus 530;Men;931 CATALUÐA;Group 1103 Diseases of the esophagus 530;Women;651 CATALUÐA;Group 1104 Peptic ulcer 531-534;Both sexes;1.829 CATALUÐA;Group 1104 Peptic ulcer 531-534;Men;1.219 CATALUÐA;Group 1104 Peptic ulcer 531-534;Women;610 CATALUÐA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;2.111 CATALUÐA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;1.041 CATALUÐA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;1.070 CATALUÐA;Group 1106 Appendicitis 540-543;Both sexes;7.837 CATALUÐA;Group 1106 Appendicitis 540-543;Men;4.381 CATALUÐA;Group 1106 Appendicitis 540-543;Women;3.456 CATALUÐA;Group 1107 Inguinal hernia 550;Both sexes;9.124 CATALUÐA;Group 1107 Inguinal hernia 550;Men;8.030 CATALUÐA;Group 1107 Inguinal hernia 550;Women;1.093 CATALUÐA;Group 1108 Other abdominal hernia 551-553;Both sexes;8.630 CATALUÐA;Group 1108 Other abdominal hernia 551-553;Men;3.835 CATALUÐA;Group 1108 Other abdominal hernia 551-553;Women;4.795 CATALUÐA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1.594 CATALUÐA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;814 CATALUÐA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;780 CATALUÐA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;4.860 CATALUÐA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;2.249 CATALUÐA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2.611 CATALUÐA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;4.478 CATALUÐA;Group 1111 Intestinal obstruction without hernia 560;Men;2.352 CATALUÐA;Group 1111 Intestinal obstruction without hernia 560;Women;2.126 CATALUÐA;Group 1112 Intestinal diverticulosis 562;Both sexes;4.313 CATALUÐA;Group 1112 Intestinal diverticulosis 562;Men;2.122 CATALUÐA;Group 1112 Intestinal diverticulosis 562;Women;2.192 CATALUÐA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;4.961 CATALUÐA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;3.074 CATALUÐA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1.887 CATALUÐA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;3.282 CATALUÐA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1.448 CATALUÐA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1.834 CATALUÐA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1.883 CATALUÐA;Group 1115 Alcoholic hepatitis 5710-5713;Men;1.534 CATALUÐA;Group 1115 Alcoholic hepatitis 5710-5713;Women;349 CATALUÐA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;3.781 CATALUÐA;Group 1116 Other diseases of the liver 570,5714-573;Men;2.200 CATALUÐA;Group 1116 Other diseases of the liver 570,5714-573;Women;1.581 CATALUÐA;Group 1117 Cholelithiasis 574;Both sexes;18.092 CATALUÐA;Group 1117 Cholelithiasis 574;Men;7.542 CATALUÐA;Group 1117 Cholelithiasis 574;Women;10.550 CATALUÐA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;5.134 CATALUÐA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;2.769 CATALUÐA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;2.365 CATALUÐA;Group 1119 Pancreatic diseases 577;Both sexes;5.164 CATALUÐA;Group 1119 Pancreatic diseases 577;Men;2.905 CATALUÐA;Group 1119 Pancreatic diseases 577;Women;2.258 CATALUÐA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;3.808 CATALUÐA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;2.070 CATALUÐA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1.738 CATALUÐA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;9.068 CATALUÐA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;4.678 CATALUÐA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;4.390 CATALUÐA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;5.709 CATALUÐA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;3.210 CATALUÐA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;2.499 CATALUÐA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;316 CATALUÐA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;158 CATALUÐA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;158 CATALUÐA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;3.043 CATALUÐA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;1.311 CATALUÐA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1.732 CATALUÐA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;66.814 CATALUÐA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;31.001 CATALUÐA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;35.813 CATALUÐA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CATALUÐA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CATALUÐA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CATALUÐA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CATALUÐA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CATALUÐA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CATALUÐA;Group 1303 Internal derangement of knee 717;Both sexes;8.559 CATALUÐA;Group 1303 Internal derangement of knee 717;Men;5.542 CATALUÐA;Group 1303 Internal derangement of knee 717;Women;3.017 CATALUÐA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;25.906 CATALUÐA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;10.537 CATALUÐA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;15.369 CATALUÐA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;1.016 CATALUÐA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;387 CATALUÐA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;629 CATALUÐA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;2.931 CATALUÐA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1.389 CATALUÐA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1.542 CATALUÐA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;5.670 CATALUÐA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;3.025 CATALUÐA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;2.645 CATALUÐA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;1.852 CATALUÐA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;832 CATALUÐA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;1.020 CATALUÐA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;10.771 CATALUÐA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;5.226 CATALUÐA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;5.545 CATALUÐA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;10.109 CATALUÐA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;4.063 CATALUÐA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;6.046 CATALUÐA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;61.637 CATALUÐA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;28.931 CATALUÐA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;32.706 CATALUÐA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;7.143 CATALUÐA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;2.211 CATALUÐA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;4.932 CATALUÐA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;5.649 CATALUÐA;Group 1402 Renal failure 5836-5837, 584-586;Men;3.242 CATALUÐA;Group 1402 Renal failure 5836-5837, 584-586;Women;2.407 CATALUÐA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;7.870 CATALUÐA;Group 1403 Urolithiasis 592, 594, 7880;Men;4.750 CATALUÐA;Group 1403 Urolithiasis 592, 594, 7880;Women;3.120 CATALUÐA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;16.160 CATALUÐA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;7.662 CATALUÐA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;8.498 CATALUÐA;Group 1405 Prostatic hyperplasia 600;Both sexes;5.343 CATALUÐA;Group 1405 Prostatic hyperplasia 600;Men;5.343 CATALUÐA;Group 1405 Prostatic hyperplasia 600;Women;.. CATALUÐA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;5.267 CATALUÐA;Group 1406 Other diseases of the male genital organs 601-608;Men;5.267 CATALUÐA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CATALUÐA;Group 1407 Disorders of breast 610-612;Both sexes;4.913 CATALUÐA;Group 1407 Disorders of breast 610-612;Men;281 CATALUÐA;Group 1407 Disorders of breast 610-612;Women;4.632 CATALUÐA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;1.223 CATALUÐA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CATALUÐA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;1.223 CATALUÐA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;430 CATALUÐA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CATALUÐA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;430 CATALUÐA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;7.639 CATALUÐA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;176 CATALUÐA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;7.464 CATALUÐA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;76.061 CATALUÐA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CATALUÐA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;76.061 CATALUÐA;Group 1501 Legally induced abortion 635;Both sexes;656 CATALUÐA;Group 1501 Legally induced abortion 635;Men;.. CATALUÐA;Group 1501 Legally induced abortion 635;Women;656 CATALUÐA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;2.250 CATALUÐA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CATALUÐA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;2.250 CATALUÐA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;39.513 CATALUÐA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CATALUÐA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;39.513 CATALUÐA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;19.082 CATALUÐA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CATALUÐA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;19.082 CATALUÐA;Group 1505 Single spontaneous delivery 650;Both sexes;5.470 CATALUÐA;Group 1505 Single spontaneous delivery 650;Men;.. CATALUÐA;Group 1505 Single spontaneous delivery 650;Women;5.470 CATALUÐA;Group 1506 Other deliveries 6695-6697;Both sexes;1.789 CATALUÐA;Group 1506 Other deliveries 6695-6697;Men;.. CATALUÐA;Group 1506 Other deliveries 6695-6697;Women;1.789 CATALUÐA;Group 1507 Complications related to the puerperium 670-676;Both sexes;826 CATALUÐA;Group 1507 Complications related to the puerperium 670-676;Men;.. CATALUÐA;Group 1507 Complications related to the puerperium 670-676;Women;826 CATALUÐA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;6.475 CATALUÐA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CATALUÐA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;6.475 CATALUÐA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;10.633 CATALUÐA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;5.783 CATALUÐA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;4.850 CATALUÐA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;3.389 CATALUÐA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1.852 CATALUÐA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1.537 CATALUÐA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;7.244 CATALUÐA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;3.931 CATALUÐA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;3.313 CATALUÐA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;6.893 CATALUÐA;Grupo 1700 Congenital abnormalities 740-759;Men;3.880 CATALUÐA;Grupo 1700 Congenital abnormalities 740-759;Women;3.013 CATALUÐA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;29.723 CATALUÐA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;16.108 CATALUÐA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;13.615 CATALUÐA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;2.874 CATALUÐA;Group 1801 Pain in throat and chest 7841, 7865;Men;1.629 CATALUÐA;Group 1801 Pain in throat and chest 7841, 7865;Women;1.245 CATALUÐA;Group 1802 Abdominal pain 7890;Both sexes;3.449 CATALUÐA;Group 1802 Abdominal pain 7890;Men;1.326 CATALUÐA;Group 1802 Abdominal pain 7890;Women;2.123 CATALUÐA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.486 CATALUÐA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;676 CATALUÐA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;810 CATALUÐA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;21.914 CATALUÐA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;12.477 CATALUÐA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;9.437 CATALUÐA;Group 1900 Injuries and poisoning 800-999;Both sexes;80.726 CATALUÐA;Group 1900 Injuries and poisoning 800-999;Men;38.389 CATALUÐA;Group 1900 Injuries and poisoning 800-999;Women;42.337 CATALUÐA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;4.987 CATALUÐA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;2.664 CATALUÐA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;2.322 CATALUÐA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1.645 CATALUÐA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;1.128 CATALUÐA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;517 CATALUÐA;Group 1903 Radius and ulna fracture 813;Both sexes;4.192 CATALUÐA;Group 1903 Radius and ulna fracture 813;Men;1.920 CATALUÐA;Group 1903 Radius and ulna fracture 813;Women;2.272 CATALUÐA;Group 1904 Femur fracture 820-821;Both sexes;16.937 CATALUÐA;Group 1904 Femur fracture 820-821;Men;4.751 CATALUÐA;Group 1904 Femur fracture 820-821;Women;12.186 CATALUÐA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;5.510 CATALUÐA;Group 1905 Leg fracture, including the ankle 823-824;Men;2.686 CATALUÐA;Group 1905 Leg fracture, including the ankle 823-824;Women;2.824 CATALUÐA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;22.588 CATALUÐA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;12.524 CATALUÐA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;10.065 CATALUÐA;Group 1907 Burns 940-949;Both sexes;623 CATALUÐA;Group 1907 Burns 940-949;Men;407 CATALUÐA;Group 1907 Burns 940-949;Women;217 CATALUÐA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;2.106 CATALUÐA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;827 CATALUÐA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;1.279 CATALUÐA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;19.846 CATALUÐA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;10.223 CATALUÐA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;9.624 CATALUÐA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;252 CATALUÐA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;159 CATALUÐA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;93 CATALUÐA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;2.039 CATALUÐA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;1.099 CATALUÐA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;940 CATALUÐA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;16.578 CATALUÐA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;8.270 CATALUÐA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;8.308 CATALUÐA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;363 CATALUÐA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;237 CATALUÐA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;126 CATALUÐA;Group 2102 Contraceptive management V25;Both sexes;207 CATALUÐA;Group 2102 Contraceptive management V25;Men;12 CATALUÐA;Group 2102 Contraceptive management V25;Women;195 CATALUÐA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CATALUÐA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CATALUÐA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CATALUÐA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;4.146 CATALUÐA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;2.517 CATALUÐA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1.629 CATALUÐA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;11.862 CATALUÐA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;5.503 CATALUÐA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;6.358 Barcelona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;647.244 Barcelona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;305.763 Barcelona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;341.480 Barcelona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;12.640 Barcelona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;7.021 Barcelona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;5.620 Barcelona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1.975 Barcelona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;976 Barcelona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;999 Barcelona;Group 0102 Imprecise intestinal infections 009;Both sexes;1.438 Barcelona;Group 0102 Imprecise intestinal infections 009;Men;719 Barcelona;Group 0102 Imprecise intestinal infections 009;Women;719 Barcelona;Group 0103 Tuberculosis 010-018, 137;Both sexes;449 Barcelona;Group 0103 Tuberculosis 010-018, 137;Men;301 Barcelona;Group 0103 Tuberculosis 010-018, 137;Women;148 Barcelona;Group 0104 Septicaemia 038;Both sexes;4.240 Barcelona;Group 0104 Septicaemia 038;Men;2.346 Barcelona;Group 0104 Septicaemia 038;Women;1.894 Barcelona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;461 Barcelona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;349 Barcelona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;112 Barcelona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;4.077 Barcelona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2.330 Barcelona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;1.747 Barcelona;Group 0200 Neoplasms 140-239;Both sexes;62.021 Barcelona;Group 0200 Neoplasms 140-239;Men;33.321 Barcelona;Group 0200 Neoplasms 140-239;Women;28.700 Barcelona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;6.501 Barcelona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;3.896 Barcelona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2.605 Barcelona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;5.116 Barcelona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;3.947 Barcelona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;1.169 Barcelona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;808 Barcelona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;468 Barcelona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;340 Barcelona;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;4.354 Barcelona;Group 0204 Malignant neoplasm of breast 174-175;Men;36 Barcelona;Group 0204 Malignant neoplasm of breast 174-175;Women;4.319 Barcelona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1.399 Barcelona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Barcelona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1.399 Barcelona;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;714 Barcelona;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Barcelona;Group 0206 Malignant neoplasm of ovary 1830;Women;714 Barcelona;Group 0207 Malignant neoplasm of prostate 185;Both sexes;2.329 Barcelona;Group 0207 Malignant neoplasm of prostate 185;Men;2.329 Barcelona;Group 0207 Malignant neoplasm of prostate 185;Women;.. Barcelona;Group 0208 Malignant neoplasm of bladder 188;Both sexes;6.523 Barcelona;Group 0208 Malignant neoplasm of bladder 188;Men;5.460 Barcelona;Group 0208 Malignant neoplasm of bladder 188;Women;1.063 Barcelona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;23.327 Barcelona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;13.686 Barcelona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;9.641 Barcelona;Group 0210 Carcinoma in situ 230-234;Both sexes;679 Barcelona;Group 0210 Carcinoma in situ 230-234;Men;275 Barcelona;Group 0210 Carcinoma in situ 230-234;Women;403 Barcelona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;661 Barcelona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;420 Barcelona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;241 Barcelona;Grupo 0212 Leiomyoma of uterus 218;Both sexes;2.717 Barcelona;Grupo 0212 Leiomyoma of uterus 218;Men;.. Barcelona;Grupo 0212 Leiomyoma of uterus 218;Women;2.717 Barcelona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;6.892 Barcelona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;2.804 Barcelona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;4.088 Barcelona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;5.475 Barcelona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;2.682 Barcelona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;2.793 Barcelona;Group 0301 Anaemias 280-285;Both sexes;3.013 Barcelona;Group 0301 Anaemias 280-285;Men;1.393 Barcelona;Group 0301 Anaemias 280-285;Women;1.620 Barcelona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;2.462 Barcelona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1.288 Barcelona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1.173 Barcelona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;11.568 Barcelona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;4.564 Barcelona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;7.004 Barcelona;Group 0401 Diabetes mellitus 249-250;Both sexes;3.533 Barcelona;Group 0401 Diabetes mellitus 249-250;Men;2.062 Barcelona;Group 0401 Diabetes mellitus 249-250;Women;1.471 Barcelona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;8.035 Barcelona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;2.502 Barcelona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;5.533 Barcelona;Group 0500 Mental disorders 290-319;Both sexes;21.590 Barcelona;Group 0500 Mental disorders 290-319;Men;11.201 Barcelona;Group 0500 Mental disorders 290-319;Women;10.390 Barcelona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;1.588 Barcelona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;680 Barcelona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;908 Barcelona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;1.454 Barcelona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;1.071 Barcelona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;383 Barcelona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;1.276 Barcelona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;924 Barcelona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;352 Barcelona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;6.486 Barcelona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;4.009 Barcelona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;2.478 Barcelona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;4.690 Barcelona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;1.866 Barcelona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;2.824 Barcelona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;6.097 Barcelona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;2.652 Barcelona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;3.445 Barcelona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;13.764 Barcelona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;6.547 Barcelona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;7.217 Barcelona;Group 0601 Alzheimer's disease 3310;Both sexes;1.493 Barcelona;Group 0601 Alzheimer's disease 3310;Men;479 Barcelona;Group 0601 Alzheimer's disease 3310;Women;1.014 Barcelona;Group 0602 Multiple sclerosis 340;Both sexes;138 Barcelona;Group 0602 Multiple sclerosis 340;Men;46 Barcelona;Group 0602 Multiple sclerosis 340;Women;93 Barcelona;Group 0603 Epilepsy 345;Both sexes;2.380 Barcelona;Group 0603 Epilepsy 345;Men;1.308 Barcelona;Group 0603 Epilepsy 345;Women;1.071 Barcelona;Group 0604 Transient cerebral ischemia 435;Both sexes;1.672 Barcelona;Group 0604 Transient cerebral ischemia 435;Men;832 Barcelona;Group 0604 Transient cerebral ischemia 435;Women;839 Barcelona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;8.081 Barcelona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;3.881 Barcelona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;4.200 Barcelona;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;3.932 Barcelona;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;1.943 Barcelona;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;1.990 Barcelona;Grupo 0701 Cataract 366;Both sexes;926 Barcelona;Grupo 0701 Cataract 366;Men;411 Barcelona;Grupo 0701 Cataract 366;Women;515 Barcelona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;3.006 Barcelona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;1.532 Barcelona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1.474 Barcelona;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;3.253 Barcelona;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1.585 Barcelona;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1.668 Barcelona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;84.756 Barcelona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;46.886 Barcelona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;37.870 Barcelona;Group 0901 Hypertensive disease 401-405;Both sexes;3.832 Barcelona;Group 0901 Hypertensive disease 401-405;Men;1.583 Barcelona;Group 0901 Hypertensive disease 401-405;Women;2.249 Barcelona;Group 0902 Angina pectoris 4111, 413;Both sexes;2.523 Barcelona;Group 0902 Angina pectoris 4111, 413;Men;1.597 Barcelona;Group 0902 Angina pectoris 4111, 413;Women;926 Barcelona;Group 0903 Acute myocardial infarction 410;Both sexes;7.263 Barcelona;Group 0903 Acute myocardial infarction 410;Men;5.139 Barcelona;Group 0903 Acute myocardial infarction 410;Women;2.124 Barcelona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;6.108 Barcelona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;4.725 Barcelona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1.382 Barcelona;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;2.350 Barcelona;Group 0905 Diseases of the lungs circulation 415-417;Men;1.090 Barcelona;Group 0905 Diseases of the lungs circulation 415-417;Women;1.260 Barcelona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;10.699 Barcelona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;5.608 Barcelona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;5.091 Barcelona;Grupo 0907 Heart failure 428;Both sexes;20.231 Barcelona;Grupo 0907 Heart failure 428;Men;9.034 Barcelona;Grupo 0907 Heart failure 428;Women;11.196 Barcelona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;14.849 Barcelona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;7.909 Barcelona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;6.940 Barcelona;Grupo 0909 Atherosclerosis 440;Both sexes;3.897 Barcelona;Grupo 0909 Atherosclerosis 440;Men;2.763 Barcelona;Grupo 0909 Atherosclerosis 440;Women;1.134 Barcelona;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.050 Barcelona;Group 0910 Varicose veins of lower extremities 454;Men;370 Barcelona;Group 0910 Varicose veins of lower extremities 454;Women;680 Barcelona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;11.953 Barcelona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;7.066 Barcelona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;4.886 Barcelona;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;77.879 Barcelona;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;43.511 Barcelona;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;34.368 Barcelona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;3.902 Barcelona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;2.026 Barcelona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1.876 Barcelona;Group 1002 Pneumonia 480-486;Both sexes;15.181 Barcelona;Group 1002 Pneumonia 480-486;Men;8.841 Barcelona;Group 1002 Pneumonia 480-486;Women;6.340 Barcelona;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;9.758 Barcelona;Group 1003 Acute bronchitis and bronchiolitis 466;Men;4.392 Barcelona;Group 1003 Acute bronchitis and bronchiolitis 466;Women;5.366 Barcelona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;2.131 Barcelona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.149 Barcelona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;983 Barcelona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;5.051 Barcelona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;3.033 Barcelona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2.018 Barcelona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;14.354 Barcelona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;10.637 Barcelona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;3.717 Barcelona;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;2.855 Barcelona;Group 1007 Asthma 4930-4931,4938-4939;Men;656 Barcelona;Group 1007 Asthma 4930-4931,4938-4939;Women;2.198 Barcelona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;24.647 Barcelona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;12.778 Barcelona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;11.869 Barcelona;Group 1100 Diseases of the digestive system 520-579;Both sexes;72.325 Barcelona;Group 1100 Diseases of the digestive system 520-579;Men;39.016 Barcelona;Group 1100 Diseases of the digestive system 520-579;Women;33.309 Barcelona;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;955 Barcelona;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;447 Barcelona;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;507 Barcelona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;942 Barcelona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;473 Barcelona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;469 Barcelona;Group 1103 Diseases of the esophagus 530;Both sexes;1.261 Barcelona;Group 1103 Diseases of the esophagus 530;Men;718 Barcelona;Group 1103 Diseases of the esophagus 530;Women;543 Barcelona;Group 1104 Peptic ulcer 531-534;Both sexes;1.384 Barcelona;Group 1104 Peptic ulcer 531-534;Men;912 Barcelona;Group 1104 Peptic ulcer 531-534;Women;472 Barcelona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;1.665 Barcelona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;801 Barcelona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;864 Barcelona;Group 1106 Appendicitis 540-543;Both sexes;5.992 Barcelona;Group 1106 Appendicitis 540-543;Men;3.359 Barcelona;Group 1106 Appendicitis 540-543;Women;2.632 Barcelona;Group 1107 Inguinal hernia 550;Both sexes;6.788 Barcelona;Group 1107 Inguinal hernia 550;Men;5.972 Barcelona;Group 1107 Inguinal hernia 550;Women;816 Barcelona;Group 1108 Other abdominal hernia 551-553;Both sexes;6.446 Barcelona;Group 1108 Other abdominal hernia 551-553;Men;2.856 Barcelona;Group 1108 Other abdominal hernia 551-553;Women;3.591 Barcelona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1.225 Barcelona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;624 Barcelona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;601 Barcelona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;3.772 Barcelona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1.712 Barcelona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2.061 Barcelona;Group 1111 Intestinal obstruction without hernia 560;Both sexes;3.425 Barcelona;Group 1111 Intestinal obstruction without hernia 560;Men;1.756 Barcelona;Group 1111 Intestinal obstruction without hernia 560;Women;1.669 Barcelona;Group 1112 Intestinal diverticulosis 562;Both sexes;3.434 Barcelona;Group 1112 Intestinal diverticulosis 562;Men;1.658 Barcelona;Group 1112 Intestinal diverticulosis 562;Women;1.775 Barcelona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;3.605 Barcelona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;2.215 Barcelona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1.389 Barcelona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2.607 Barcelona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1.135 Barcelona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1.471 Barcelona;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1.461 Barcelona;Group 1115 Alcoholic hepatitis 5710-5713;Men;1.187 Barcelona;Group 1115 Alcoholic hepatitis 5710-5713;Women;274 Barcelona;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;3.060 Barcelona;Group 1116 Other diseases of the liver 570,5714-573;Men;1.768 Barcelona;Group 1116 Other diseases of the liver 570,5714-573;Women;1.292 Barcelona;Group 1117 Cholelithiasis 574;Both sexes;13.689 Barcelona;Group 1117 Cholelithiasis 574;Men;5.665 Barcelona;Group 1117 Cholelithiasis 574;Women;8.024 Barcelona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;3.740 Barcelona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;2.009 Barcelona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;1.731 Barcelona;Group 1119 Pancreatic diseases 577;Both sexes;3.916 Barcelona;Group 1119 Pancreatic diseases 577;Men;2.173 Barcelona;Group 1119 Pancreatic diseases 577;Women;1.743 Barcelona;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;2.959 Barcelona;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1.574 Barcelona;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1.384 Barcelona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;7.018 Barcelona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;3.551 Barcelona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;3.467 Barcelona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;4.367 Barcelona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;2.422 Barcelona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1.945 Barcelona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;251 Barcelona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;125 Barcelona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;126 Barcelona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;2.399 Barcelona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;1.004 Barcelona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1.396 Barcelona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;53.447 Barcelona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;24.902 Barcelona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;28.544 Barcelona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Barcelona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Barcelona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Barcelona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Barcelona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Barcelona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Barcelona;Group 1303 Internal derangement of knee 717;Both sexes;7.326 Barcelona;Group 1303 Internal derangement of knee 717;Men;4.775 Barcelona;Group 1303 Internal derangement of knee 717;Women;2.551 Barcelona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;19.883 Barcelona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;8.034 Barcelona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;11.849 Barcelona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;833 Barcelona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;299 Barcelona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;535 Barcelona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;2.431 Barcelona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1.152 Barcelona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1.279 Barcelona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;4.812 Barcelona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;2.580 Barcelona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;2.232 Barcelona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;1.334 Barcelona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;598 Barcelona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;736 Barcelona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;8.622 Barcelona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;4.154 Barcelona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;4.468 Barcelona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;8.204 Barcelona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;3.310 Barcelona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;4.893 Barcelona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;48.430 Barcelona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;22.598 Barcelona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;25.832 Barcelona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;5.385 Barcelona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1.688 Barcelona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;3.697 Barcelona;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;4.472 Barcelona;Group 1402 Renal failure 5836-5837, 584-586;Men;2.534 Barcelona;Group 1402 Renal failure 5836-5837, 584-586;Women;1.939 Barcelona;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;6.097 Barcelona;Group 1403 Urolithiasis 592, 594, 7880;Men;3.685 Barcelona;Group 1403 Urolithiasis 592, 594, 7880;Women;2.411 Barcelona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;12.525 Barcelona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;5.787 Barcelona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;6.738 Barcelona;Group 1405 Prostatic hyperplasia 600;Both sexes;4.270 Barcelona;Group 1405 Prostatic hyperplasia 600;Men;4.270 Barcelona;Group 1405 Prostatic hyperplasia 600;Women;.. Barcelona;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;4.243 Barcelona;Group 1406 Other diseases of the male genital organs 601-608;Men;4.243 Barcelona;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Barcelona;Group 1407 Disorders of breast 610-612;Both sexes;4.397 Barcelona;Group 1407 Disorders of breast 610-612;Men;254 Barcelona;Group 1407 Disorders of breast 610-612;Women;4.143 Barcelona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;924 Barcelona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Barcelona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;924 Barcelona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;265 Barcelona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Barcelona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;265 Barcelona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;5.853 Barcelona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;137 Barcelona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;5.715 Barcelona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;56.579 Barcelona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Barcelona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;56.579 Barcelona;Group 1501 Legally induced abortion 635;Both sexes;545 Barcelona;Group 1501 Legally induced abortion 635;Men;.. Barcelona;Group 1501 Legally induced abortion 635;Women;545 Barcelona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.385 Barcelona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Barcelona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.385 Barcelona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;29.597 Barcelona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Barcelona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;29.597 Barcelona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;15.015 Barcelona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Barcelona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;15.015 Barcelona;Group 1505 Single spontaneous delivery 650;Both sexes;3.215 Barcelona;Group 1505 Single spontaneous delivery 650;Men;.. Barcelona;Group 1505 Single spontaneous delivery 650;Women;3.215 Barcelona;Group 1506 Other deliveries 6695-6697;Both sexes;1.461 Barcelona;Group 1506 Other deliveries 6695-6697;Men;.. Barcelona;Group 1506 Other deliveries 6695-6697;Women;1.461 Barcelona;Group 1507 Complications related to the puerperium 670-676;Both sexes;570 Barcelona;Group 1507 Complications related to the puerperium 670-676;Men;.. Barcelona;Group 1507 Complications related to the puerperium 670-676;Women;570 Barcelona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;4.791 Barcelona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Barcelona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;4.791 Barcelona;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;8.234 Barcelona;Group 1600 Some disorders originating in the perinatal period 760-779;Men;4.450 Barcelona;Group 1600 Some disorders originating in the perinatal period 760-779;Women;3.783 Barcelona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;2.697 Barcelona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1.465 Barcelona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1.232 Barcelona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;5.537 Barcelona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;2.985 Barcelona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;2.551 Barcelona;Grupo 1700 Congenital abnormalities 740-759;Both sexes;6.119 Barcelona;Grupo 1700 Congenital abnormalities 740-759;Men;3.423 Barcelona;Grupo 1700 Congenital abnormalities 740-759;Women;2.695 Barcelona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;22.186 Barcelona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;11.979 Barcelona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;10.207 Barcelona;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;2.095 Barcelona;Group 1801 Pain in throat and chest 7841, 7865;Men;1.197 Barcelona;Group 1801 Pain in throat and chest 7841, 7865;Women;898 Barcelona;Group 1802 Abdominal pain 7890;Both sexes;2.333 Barcelona;Group 1802 Abdominal pain 7890;Men;879 Barcelona;Group 1802 Abdominal pain 7890;Women;1.454 Barcelona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.397 Barcelona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;636 Barcelona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;761 Barcelona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;16.361 Barcelona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;9.267 Barcelona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;7.094 Barcelona;Group 1900 Injuries and poisoning 800-999;Both sexes;62.064 Barcelona;Group 1900 Injuries and poisoning 800-999;Men;29.705 Barcelona;Group 1900 Injuries and poisoning 800-999;Women;32.359 Barcelona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;3.744 Barcelona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1.947 Barcelona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;1.797 Barcelona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1.263 Barcelona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;858 Barcelona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;404 Barcelona;Group 1903 Radius and ulna fracture 813;Both sexes;3.112 Barcelona;Group 1903 Radius and ulna fracture 813;Men;1.425 Barcelona;Group 1903 Radius and ulna fracture 813;Women;1.688 Barcelona;Group 1904 Femur fracture 820-821;Both sexes;12.364 Barcelona;Group 1904 Femur fracture 820-821;Men;3.477 Barcelona;Group 1904 Femur fracture 820-821;Women;8.886 Barcelona;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;4.153 Barcelona;Group 1905 Leg fracture, including the ankle 823-824;Men;1.994 Barcelona;Group 1905 Leg fracture, including the ankle 823-824;Women;2.159 Barcelona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;16.992 Barcelona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;9.485 Barcelona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;7.506 Barcelona;Group 1907 Burns 940-949;Both sexes;564 Barcelona;Group 1907 Burns 940-949;Men;371 Barcelona;Group 1907 Burns 940-949;Women;193 Barcelona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;1.642 Barcelona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;648 Barcelona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;994 Barcelona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;16.487 Barcelona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;8.551 Barcelona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;7.937 Barcelona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;205 Barcelona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;132 Barcelona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;72 Barcelona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1.538 Barcelona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;815 Barcelona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;723 Barcelona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;13.963 Barcelona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;6.878 Barcelona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;7.085 Barcelona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;336 Barcelona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;221 Barcelona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;115 Barcelona;Group 2102 Contraceptive management V25;Both sexes;135 Barcelona;Group 2102 Contraceptive management V25;Men;9 Barcelona;Group 2102 Contraceptive management V25;Women;126 Barcelona;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Barcelona;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Barcelona;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Barcelona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;3.518 Barcelona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;2.101 Barcelona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1.418 Barcelona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;9.974 Barcelona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;4.548 Barcelona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;5.426 Girona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;68.954 Girona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;32.215 Girona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;36.739 Girona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.273 Girona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;738 Girona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;536 Girona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;137 Girona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;79 Girona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;59 Girona;Group 0102 Imprecise intestinal infections 009;Both sexes;221 Girona;Group 0102 Imprecise intestinal infections 009;Men;120 Girona;Group 0102 Imprecise intestinal infections 009;Women;102 Girona;Group 0103 Tuberculosis 010-018, 137;Both sexes;60 Girona;Group 0103 Tuberculosis 010-018, 137;Men;39 Girona;Group 0103 Tuberculosis 010-018, 137;Women;21 Girona;Group 0104 Septicaemia 038;Both sexes;365 Girona;Group 0104 Septicaemia 038;Men;206 Girona;Group 0104 Septicaemia 038;Women;160 Girona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;40 Girona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;29 Girona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;10 Girona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;450 Girona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;266 Girona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;184 Girona;Group 0200 Neoplasms 140-239;Both sexes;6.139 Girona;Group 0200 Neoplasms 140-239;Men;3.357 Girona;Group 0200 Neoplasms 140-239;Women;2.783 Girona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;737 Girona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;457 Girona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;280 Girona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;573 Girona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;444 Girona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;129 Girona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;124 Girona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;62 Girona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;63 Girona;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;517 Girona;Group 0204 Malignant neoplasm of breast 174-175;Men;6 Girona;Group 0204 Malignant neoplasm of breast 174-175;Women;511 Girona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;105 Girona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Girona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;105 Girona;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;55 Girona;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Girona;Group 0206 Malignant neoplasm of ovary 1830;Women;55 Girona;Group 0207 Malignant neoplasm of prostate 185;Both sexes;180 Girona;Group 0207 Malignant neoplasm of prostate 185;Men;180 Girona;Group 0207 Malignant neoplasm of prostate 185;Women;.. Girona;Group 0208 Malignant neoplasm of bladder 188;Both sexes;654 Girona;Group 0208 Malignant neoplasm of bladder 188;Men;550 Girona;Group 0208 Malignant neoplasm of bladder 188;Women;104 Girona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.194 Girona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.359 Girona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;835 Girona;Group 0210 Carcinoma in situ 230-234;Both sexes;40 Girona;Group 0210 Carcinoma in situ 230-234;Men;9 Girona;Group 0210 Carcinoma in situ 230-234;Women;30 Girona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;31 Girona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;22 Girona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;9 Girona;Grupo 0212 Leiomyoma of uterus 218;Both sexes;277 Girona;Grupo 0212 Leiomyoma of uterus 218;Men;.. Girona;Grupo 0212 Leiomyoma of uterus 218;Women;277 Girona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;652 Girona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;268 Girona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;384 Girona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;526 Girona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;251 Girona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;275 Girona;Group 0301 Anaemias 280-285;Both sexes;319 Girona;Group 0301 Anaemias 280-285;Men;156 Girona;Group 0301 Anaemias 280-285;Women;162 Girona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;208 Girona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;95 Girona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;113 Girona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.004 Girona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;381 Girona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;623 Girona;Group 0401 Diabetes mellitus 249-250;Both sexes;322 Girona;Group 0401 Diabetes mellitus 249-250;Men;168 Girona;Group 0401 Diabetes mellitus 249-250;Women;154 Girona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;681 Girona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;213 Girona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;469 Girona;Group 0500 Mental disorders 290-319;Both sexes;1.736 Girona;Group 0500 Mental disorders 290-319;Men;915 Girona;Group 0500 Mental disorders 290-319;Women;821 Girona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;107 Girona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;34 Girona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;73 Girona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;110 Girona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;88 Girona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;22 Girona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;93 Girona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;73 Girona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;19 Girona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;671 Girona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;404 Girona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;267 Girona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;369 Girona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;144 Girona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;225 Girona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;386 Girona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;171 Girona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;215 Girona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.147 Girona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;565 Girona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;582 Girona;Group 0601 Alzheimer's disease 3310;Both sexes;82 Girona;Group 0601 Alzheimer's disease 3310;Men;28 Girona;Group 0601 Alzheimer's disease 3310;Women;53 Girona;Group 0602 Multiple sclerosis 340;Both sexes;19 Girona;Group 0602 Multiple sclerosis 340;Men;7 Girona;Group 0602 Multiple sclerosis 340;Women;11 Girona;Group 0603 Epilepsy 345;Both sexes;175 Girona;Group 0603 Epilepsy 345;Men;89 Girona;Group 0603 Epilepsy 345;Women;86 Girona;Group 0604 Transient cerebral ischemia 435;Both sexes;105 Girona;Group 0604 Transient cerebral ischemia 435;Men;61 Girona;Group 0604 Transient cerebral ischemia 435;Women;44 Girona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;767 Girona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;380 Girona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;387 Girona;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;639 Girona;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;298 Girona;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;341 Girona;Grupo 0701 Cataract 366;Both sexes;381 Girona;Grupo 0701 Cataract 366;Men;168 Girona;Grupo 0701 Cataract 366;Women;213 Girona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;258 Girona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;130 Girona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;128 Girona;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;233 Girona;Group 0800 Diseases of the ear and the mastoid 380-389;Men;121 Girona;Group 0800 Diseases of the ear and the mastoid 380-389;Women;112 Girona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;8.684 Girona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;4.765 Girona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3.919 Girona;Group 0901 Hypertensive disease 401-405;Both sexes;146 Girona;Group 0901 Hypertensive disease 401-405;Men;63 Girona;Group 0901 Hypertensive disease 401-405;Women;83 Girona;Group 0902 Angina pectoris 4111, 413;Both sexes;405 Girona;Group 0902 Angina pectoris 4111, 413;Men;287 Girona;Group 0902 Angina pectoris 4111, 413;Women;117 Girona;Group 0903 Acute myocardial infarction 410;Both sexes;906 Girona;Group 0903 Acute myocardial infarction 410;Men;575 Girona;Group 0903 Acute myocardial infarction 410;Women;331 Girona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;360 Girona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;243 Girona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;117 Girona;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;272 Girona;Group 0905 Diseases of the lungs circulation 415-417;Men;128 Girona;Group 0905 Diseases of the lungs circulation 415-417;Women;144 Girona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.041 Girona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;578 Girona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;464 Girona;Grupo 0907 Heart failure 428;Both sexes;2.110 Girona;Grupo 0907 Heart failure 428;Men;971 Girona;Grupo 0907 Heart failure 428;Women;1.139 Girona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.676 Girona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;874 Girona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;802 Girona;Grupo 0909 Atherosclerosis 440;Both sexes;290 Girona;Grupo 0909 Atherosclerosis 440;Men;213 Girona;Grupo 0909 Atherosclerosis 440;Women;77 Girona;Group 0910 Varicose veins of lower extremities 454;Both sexes;233 Girona;Group 0910 Varicose veins of lower extremities 454;Men;98 Girona;Group 0910 Varicose veins of lower extremities 454;Women;135 Girona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.245 Girona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;735 Girona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;510 Girona;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;8.367 Girona;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.703 Girona;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.664 Girona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;229 Girona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;117 Girona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;111 Girona;Group 1002 Pneumonia 480-486;Both sexes;1.795 Girona;Group 1002 Pneumonia 480-486;Men;1.068 Girona;Group 1002 Pneumonia 480-486;Women;727 Girona;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.558 Girona;Group 1003 Acute bronchitis and bronchiolitis 466;Men;714 Girona;Group 1003 Acute bronchitis and bronchiolitis 466;Women;845 Girona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;460 Girona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;252 Girona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;208 Girona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;703 Girona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;435 Girona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;269 Girona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.386 Girona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.005 Girona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;381 Girona;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;325 Girona;Group 1007 Asthma 4930-4931,4938-4939;Men;110 Girona;Group 1007 Asthma 4930-4931,4938-4939;Women;215 Girona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.911 Girona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.002 Girona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;909 Girona;Group 1100 Diseases of the digestive system 520-579;Both sexes;8.041 Girona;Group 1100 Diseases of the digestive system 520-579;Men;4.562 Girona;Group 1100 Diseases of the digestive system 520-579;Women;3.479 Girona;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;40 Girona;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;23 Girona;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;17 Girona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;62 Girona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;43 Girona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;19 Girona;Group 1103 Diseases of the esophagus 530;Both sexes;108 Girona;Group 1103 Diseases of the esophagus 530;Men;66 Girona;Group 1103 Diseases of the esophagus 530;Women;42 Girona;Group 1104 Peptic ulcer 531-534;Both sexes;177 Girona;Group 1104 Peptic ulcer 531-534;Men;116 Girona;Group 1104 Peptic ulcer 531-534;Women;61 Girona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;135 Girona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;71 Girona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;64 Girona;Group 1106 Appendicitis 540-543;Both sexes;710 Girona;Group 1106 Appendicitis 540-543;Men;403 Girona;Group 1106 Appendicitis 540-543;Women;306 Girona;Group 1107 Inguinal hernia 550;Both sexes;913 Girona;Group 1107 Inguinal hernia 550;Men;796 Girona;Group 1107 Inguinal hernia 550;Women;118 Girona;Group 1108 Other abdominal hernia 551-553;Both sexes;835 Girona;Group 1108 Other abdominal hernia 551-553;Men;390 Girona;Group 1108 Other abdominal hernia 551-553;Women;445 Girona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;133 Girona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;72 Girona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;61 Girona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;329 Girona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;158 Girona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;171 Girona;Group 1111 Intestinal obstruction without hernia 560;Both sexes;363 Girona;Group 1111 Intestinal obstruction without hernia 560;Men;211 Girona;Group 1111 Intestinal obstruction without hernia 560;Women;152 Girona;Group 1112 Intestinal diverticulosis 562;Both sexes;300 Girona;Group 1112 Intestinal diverticulosis 562;Men;153 Girona;Group 1112 Intestinal diverticulosis 562;Women;147 Girona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;536 Girona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;344 Girona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;192 Girona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;220 Girona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;103 Girona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;117 Girona;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;131 Girona;Group 1115 Alcoholic hepatitis 5710-5713;Men;95 Girona;Group 1115 Alcoholic hepatitis 5710-5713;Women;36 Girona;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;260 Girona;Group 1116 Other diseases of the liver 570,5714-573;Men;165 Girona;Group 1116 Other diseases of the liver 570,5714-573;Women;95 Girona;Group 1117 Cholelithiasis 574;Both sexes;1.550 Girona;Group 1117 Cholelithiasis 574;Men;638 Girona;Group 1117 Cholelithiasis 574;Women;912 Girona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;500 Girona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;270 Girona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;231 Girona;Group 1119 Pancreatic diseases 577;Both sexes;403 Girona;Group 1119 Pancreatic diseases 577;Men;252 Girona;Group 1119 Pancreatic diseases 577;Women;151 Girona;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;337 Girona;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;193 Girona;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;143 Girona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;875 Girona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;500 Girona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;375 Girona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;588 Girona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;365 Girona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;223 Girona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;22 Girona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;8 Girona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;13 Girona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;265 Girona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;127 Girona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;138 Girona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;5.781 Girona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.655 Girona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.125 Girona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Girona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Girona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Girona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Girona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Girona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Girona;Group 1303 Internal derangement of knee 717;Both sexes;532 Girona;Group 1303 Internal derangement of knee 717;Men;322 Girona;Group 1303 Internal derangement of knee 717;Women;210 Girona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.434 Girona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.040 Girona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.393 Girona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;63 Girona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;26 Girona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;37 Girona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;202 Girona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;98 Girona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;103 Girona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;347 Girona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;188 Girona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;159 Girona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;246 Girona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;119 Girona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;127 Girona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.102 Girona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;539 Girona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;563 Girona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;856 Girona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;323 Girona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;533 Girona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;4.714 Girona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.230 Girona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.484 Girona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;658 Girona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;216 Girona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;442 Girona;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;483 Girona;Group 1402 Renal failure 5836-5837, 584-586;Men;295 Girona;Group 1402 Renal failure 5836-5837, 584-586;Women;188 Girona;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;550 Girona;Group 1403 Urolithiasis 592, 594, 7880;Men;334 Girona;Group 1403 Urolithiasis 592, 594, 7880;Women;216 Girona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.145 Girona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;610 Girona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;535 Girona;Group 1405 Prostatic hyperplasia 600;Both sexes;405 Girona;Group 1405 Prostatic hyperplasia 600;Men;405 Girona;Group 1405 Prostatic hyperplasia 600;Women;.. Girona;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;332 Girona;Group 1406 Other diseases of the male genital organs 601-608;Men;332 Girona;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Girona;Group 1407 Disorders of breast 610-612;Both sexes;254 Girona;Group 1407 Disorders of breast 610-612;Men;14 Girona;Group 1407 Disorders of breast 610-612;Women;240 Girona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;116 Girona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Girona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;116 Girona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;59 Girona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Girona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;59 Girona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;712 Girona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;24 Girona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;687 Girona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;7.469 Girona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Girona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;7.469 Girona;Group 1501 Legally induced abortion 635;Both sexes;47 Girona;Group 1501 Legally induced abortion 635;Men;.. Girona;Group 1501 Legally induced abortion 635;Women;47 Girona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;274 Girona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Girona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;274 Girona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.853 Girona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Girona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.853 Girona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.508 Girona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Girona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.508 Girona;Group 1505 Single spontaneous delivery 650;Both sexes;906 Girona;Group 1505 Single spontaneous delivery 650;Men;.. Girona;Group 1505 Single spontaneous delivery 650;Women;906 Girona;Group 1506 Other deliveries 6695-6697;Both sexes;214 Girona;Group 1506 Other deliveries 6695-6697;Men;.. Girona;Group 1506 Other deliveries 6695-6697;Women;214 Girona;Group 1507 Complications related to the puerperium 670-676;Both sexes;69 Girona;Group 1507 Complications related to the puerperium 670-676;Men;.. Girona;Group 1507 Complications related to the puerperium 670-676;Women;69 Girona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;597 Girona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Girona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;597 Girona;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;883 Girona;Group 1600 Some disorders originating in the perinatal period 760-779;Men;499 Girona;Group 1600 Some disorders originating in the perinatal period 760-779;Women;384 Girona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;309 Girona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;165 Girona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;144 Girona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;574 Girona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;334 Girona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;240 Girona;Grupo 1700 Congenital abnormalities 740-759;Both sexes;272 Girona;Grupo 1700 Congenital abnormalities 740-759;Men;177 Girona;Grupo 1700 Congenital abnormalities 740-759;Women;94 Girona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.691 Girona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.454 Girona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.237 Girona;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;280 Girona;Group 1801 Pain in throat and chest 7841, 7865;Men;162 Girona;Group 1801 Pain in throat and chest 7841, 7865;Women;119 Girona;Group 1802 Abdominal pain 7890;Both sexes;427 Girona;Group 1802 Abdominal pain 7890;Men;171 Girona;Group 1802 Abdominal pain 7890;Women;256 Girona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;33 Girona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;15 Girona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;19 Girona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.951 Girona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.107 Girona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;844 Girona;Group 1900 Injuries and poisoning 800-999;Both sexes;7.533 Girona;Group 1900 Injuries and poisoning 800-999;Men;3.526 Girona;Group 1900 Injuries and poisoning 800-999;Women;4.008 Girona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;395 Girona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;237 Girona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;158 Girona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;93 Girona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;68 Girona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;25 Girona;Group 1903 Radius and ulna fracture 813;Both sexes;509 Girona;Group 1903 Radius and ulna fracture 813;Men;231 Girona;Group 1903 Radius and ulna fracture 813;Women;278 Girona;Group 1904 Femur fracture 820-821;Both sexes;1.844 Girona;Group 1904 Femur fracture 820-821;Men;510 Girona;Group 1904 Femur fracture 820-821;Women;1.333 Girona;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;601 Girona;Group 1905 Leg fracture, including the ankle 823-824;Men;304 Girona;Group 1905 Leg fracture, including the ankle 823-824;Women;298 Girona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.236 Girona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.261 Girona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;975 Girona;Group 1907 Burns 940-949;Both sexes;32 Girona;Group 1907 Burns 940-949;Men;17 Girona;Group 1907 Burns 940-949;Women;16 Girona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;207 Girona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;77 Girona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;130 Girona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.420 Girona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;708 Girona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;711 Girona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;25 Girona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;17 Girona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;8 Girona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;170 Girona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;95 Girona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;75 Girona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;948 Girona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;520 Girona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;428 Girona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;4 Girona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;3 Girona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;1 Girona;Group 2102 Contraceptive management V25;Both sexes;16 Girona;Group 2102 Contraceptive management V25;Men;3 Girona;Group 2102 Contraceptive management V25;Women;13 Girona;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Girona;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Girona;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Girona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;218 Girona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;147 Girona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;71 Girona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;710 Girona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;366 Girona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;343 Lleida;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;39.241 Lleida;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18.795 Lleida;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;20.446 Lleida;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;649 Lleida;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;391 Lleida;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;258 Lleida;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;80 Lleida;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;36 Lleida;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;44 Lleida;Group 0102 Imprecise intestinal infections 009;Both sexes;121 Lleida;Group 0102 Imprecise intestinal infections 009;Men;61 Lleida;Group 0102 Imprecise intestinal infections 009;Women;60 Lleida;Group 0103 Tuberculosis 010-018, 137;Both sexes;39 Lleida;Group 0103 Tuberculosis 010-018, 137;Men;31 Lleida;Group 0103 Tuberculosis 010-018, 137;Women;8 Lleida;Group 0104 Septicaemia 038;Both sexes;162 Lleida;Group 0104 Septicaemia 038;Men;99 Lleida;Group 0104 Septicaemia 038;Women;63 Lleida;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;26 Lleida;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;23 Lleida;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 Lleida;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;221 Lleida;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;141 Lleida;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;80 Lleida;Group 0200 Neoplasms 140-239;Both sexes;3.764 Lleida;Group 0200 Neoplasms 140-239;Men;2.223 Lleida;Group 0200 Neoplasms 140-239;Women;1.541 Lleida;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;517 Lleida;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;334 Lleida;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;183 Lleida;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;277 Lleida;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;212 Lleida;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;65 Lleida;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;41 Lleida;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;32 Lleida;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;9 Lleida;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;256 Lleida;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Lleida;Group 0204 Malignant neoplasm of breast 174-175;Women;255 Lleida;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;62 Lleida;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Lleida;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;62 Lleida;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;41 Lleida;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Lleida;Group 0206 Malignant neoplasm of ovary 1830;Women;41 Lleida;Group 0207 Malignant neoplasm of prostate 185;Both sexes;157 Lleida;Group 0207 Malignant neoplasm of prostate 185;Men;157 Lleida;Group 0207 Malignant neoplasm of prostate 185;Women;.. Lleida;Group 0208 Malignant neoplasm of bladder 188;Both sexes;473 Lleida;Group 0208 Malignant neoplasm of bladder 188;Men;391 Lleida;Group 0208 Malignant neoplasm of bladder 188;Women;82 Lleida;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.295 Lleida;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;805 Lleida;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;490 Lleida;Group 0210 Carcinoma in situ 230-234;Both sexes;22 Lleida;Group 0210 Carcinoma in situ 230-234;Men;12 Lleida;Group 0210 Carcinoma in situ 230-234;Women;10 Lleida;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;99 Lleida;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;69 Lleida;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;30 Lleida;Grupo 0212 Leiomyoma of uterus 218;Both sexes;110 Lleida;Grupo 0212 Leiomyoma of uterus 218;Men;.. Lleida;Grupo 0212 Leiomyoma of uterus 218;Women;110 Lleida;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;414 Lleida;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;210 Lleida;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;204 Lleida;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;297 Lleida;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;176 Lleida;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;121 Lleida;Group 0301 Anaemias 280-285;Both sexes;175 Lleida;Group 0301 Anaemias 280-285;Men;89 Lleida;Group 0301 Anaemias 280-285;Women;86 Lleida;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;122 Lleida;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;87 Lleida;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;35 Lleida;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;542 Lleida;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;237 Lleida;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;305 Lleida;Group 0401 Diabetes mellitus 249-250;Both sexes;184 Lleida;Group 0401 Diabetes mellitus 249-250;Men;112 Lleida;Group 0401 Diabetes mellitus 249-250;Women;72 Lleida;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;358 Lleida;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;125 Lleida;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;233 Lleida;Group 0500 Mental disorders 290-319;Both sexes;2.133 Lleida;Group 0500 Mental disorders 290-319;Men;1.050 Lleida;Group 0500 Mental disorders 290-319;Women;1.083 Lleida;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;94 Lleida;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;46 Lleida;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;48 Lleida;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;105 Lleida;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;64 Lleida;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;41 Lleida;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;133 Lleida;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;89 Lleida;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;44 Lleida;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;643 Lleida;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;389 Lleida;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;254 Lleida;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;567 Lleida;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;207 Lleida;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;360 Lleida;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;591 Lleida;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;255 Lleida;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;336 Lleida;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;653 Lleida;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;334 Lleida;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;319 Lleida;Group 0601 Alzheimer's disease 3310;Both sexes;86 Lleida;Group 0601 Alzheimer's disease 3310;Men;45 Lleida;Group 0601 Alzheimer's disease 3310;Women;41 Lleida;Group 0602 Multiple sclerosis 340;Both sexes;5 Lleida;Group 0602 Multiple sclerosis 340;Men;4 Lleida;Group 0602 Multiple sclerosis 340;Women;1 Lleida;Group 0603 Epilepsy 345;Both sexes;92 Lleida;Group 0603 Epilepsy 345;Men;45 Lleida;Group 0603 Epilepsy 345;Women;47 Lleida;Group 0604 Transient cerebral ischemia 435;Both sexes;106 Lleida;Group 0604 Transient cerebral ischemia 435;Men;60 Lleida;Group 0604 Transient cerebral ischemia 435;Women;46 Lleida;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;364 Lleida;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;180 Lleida;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;184 Lleida;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;136 Lleida;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;87 Lleida;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;49 Lleida;Grupo 0701 Cataract 366;Both sexes;31 Lleida;Grupo 0701 Cataract 366;Men;17 Lleida;Grupo 0701 Cataract 366;Women;14 Lleida;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;105 Lleida;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;70 Lleida;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;35 Lleida;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;131 Lleida;Group 0800 Diseases of the ear and the mastoid 380-389;Men;56 Lleida;Group 0800 Diseases of the ear and the mastoid 380-389;Women;75 Lleida;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4.777 Lleida;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.641 Lleida;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.136 Lleida;Group 0901 Hypertensive disease 401-405;Both sexes;97 Lleida;Group 0901 Hypertensive disease 401-405;Men;52 Lleida;Group 0901 Hypertensive disease 401-405;Women;45 Lleida;Group 0902 Angina pectoris 4111, 413;Both sexes;77 Lleida;Group 0902 Angina pectoris 4111, 413;Men;52 Lleida;Group 0902 Angina pectoris 4111, 413;Women;25 Lleida;Group 0903 Acute myocardial infarction 410;Both sexes;367 Lleida;Group 0903 Acute myocardial infarction 410;Men;256 Lleida;Group 0903 Acute myocardial infarction 410;Women;111 Lleida;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;301 Lleida;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;243 Lleida;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;58 Lleida;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;178 Lleida;Group 0905 Diseases of the lungs circulation 415-417;Men;84 Lleida;Group 0905 Diseases of the lungs circulation 415-417;Women;94 Lleida;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;637 Lleida;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;321 Lleida;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;316 Lleida;Grupo 0907 Heart failure 428;Both sexes;1.378 Lleida;Grupo 0907 Heart failure 428;Men;637 Lleida;Grupo 0907 Heart failure 428;Women;741 Lleida;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.016 Lleida;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;567 Lleida;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;449 Lleida;Grupo 0909 Atherosclerosis 440;Both sexes;197 Lleida;Grupo 0909 Atherosclerosis 440;Men;124 Lleida;Grupo 0909 Atherosclerosis 440;Women;73 Lleida;Group 0910 Varicose veins of lower extremities 454;Both sexes;55 Lleida;Group 0910 Varicose veins of lower extremities 454;Men;17 Lleida;Group 0910 Varicose veins of lower extremities 454;Women;38 Lleida;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;474 Lleida;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;288 Lleida;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;186 Lleida;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5.331 Lleida;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.089 Lleida;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.242 Lleida;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;130 Lleida;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;72 Lleida;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;58 Lleida;Group 1002 Pneumonia 480-486;Both sexes;980 Lleida;Group 1002 Pneumonia 480-486;Men;581 Lleida;Group 1002 Pneumonia 480-486;Women;399 Lleida;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.088 Lleida;Group 1003 Acute bronchitis and bronchiolitis 466;Men;503 Lleida;Group 1003 Acute bronchitis and bronchiolitis 466;Women;585 Lleida;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;124 Lleida;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;71 Lleida;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;53 Lleida;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;206 Lleida;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;130 Lleida;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;76 Lleida;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.241 Lleida;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;881 Lleida;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;360 Lleida;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;123 Lleida;Group 1007 Asthma 4930-4931,4938-4939;Men;23 Lleida;Group 1007 Asthma 4930-4931,4938-4939;Women;100 Lleida;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.439 Lleida;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;828 Lleida;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;611 Lleida;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.866 Lleida;Group 1100 Diseases of the digestive system 520-579;Men;2.682 Lleida;Group 1100 Diseases of the digestive system 520-579;Women;2.184 Lleida;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;38 Lleida;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;21 Lleida;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;17 Lleida;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;33 Lleida;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;16 Lleida;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;17 Lleida;Group 1103 Diseases of the esophagus 530;Both sexes;85 Lleida;Group 1103 Diseases of the esophagus 530;Men;50 Lleida;Group 1103 Diseases of the esophagus 530;Women;35 Lleida;Group 1104 Peptic ulcer 531-534;Both sexes;103 Lleida;Group 1104 Peptic ulcer 531-534;Men;75 Lleida;Group 1104 Peptic ulcer 531-534;Women;28 Lleida;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;102 Lleida;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;57 Lleida;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;45 Lleida;Group 1106 Appendicitis 540-543;Both sexes;402 Lleida;Group 1106 Appendicitis 540-543;Men;217 Lleida;Group 1106 Appendicitis 540-543;Women;185 Lleida;Group 1107 Inguinal hernia 550;Both sexes;368 Lleida;Group 1107 Inguinal hernia 550;Men;322 Lleida;Group 1107 Inguinal hernia 550;Women;46 Lleida;Group 1108 Other abdominal hernia 551-553;Both sexes;356 Lleida;Group 1108 Other abdominal hernia 551-553;Men;160 Lleida;Group 1108 Other abdominal hernia 551-553;Women;196 Lleida;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;77 Lleida;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;36 Lleida;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;41 Lleida;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;230 Lleida;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;116 Lleida;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;114 Lleida;Group 1111 Intestinal obstruction without hernia 560;Both sexes;260 Lleida;Group 1111 Intestinal obstruction without hernia 560;Men;148 Lleida;Group 1111 Intestinal obstruction without hernia 560;Women;112 Lleida;Group 1112 Intestinal diverticulosis 562;Both sexes;195 Lleida;Group 1112 Intestinal diverticulosis 562;Men;90 Lleida;Group 1112 Intestinal diverticulosis 562;Women;105 Lleida;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;210 Lleida;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;140 Lleida;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;70 Lleida;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;180 Lleida;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;83 Lleida;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;97 Lleida;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;116 Lleida;Group 1115 Alcoholic hepatitis 5710-5713;Men;99 Lleida;Group 1115 Alcoholic hepatitis 5710-5713;Women;17 Lleida;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;165 Lleida;Group 1116 Other diseases of the liver 570,5714-573;Men;95 Lleida;Group 1116 Other diseases of the liver 570,5714-573;Women;70 Lleida;Group 1117 Cholelithiasis 574;Both sexes;1.089 Lleida;Group 1117 Cholelithiasis 574;Men;472 Lleida;Group 1117 Cholelithiasis 574;Women;617 Lleida;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;398 Lleida;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;206 Lleida;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;192 Lleida;Group 1119 Pancreatic diseases 577;Both sexes;253 Lleida;Group 1119 Pancreatic diseases 577;Men;155 Lleida;Group 1119 Pancreatic diseases 577;Women;98 Lleida;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;206 Lleida;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;124 Lleida;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;82 Lleida;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;361 Lleida;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;194 Lleida;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;167 Lleida;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;227 Lleida;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;136 Lleida;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;91 Lleida;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;8 Lleida;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;3 Lleida;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;5 Lleida;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;126 Lleida;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;55 Lleida;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;71 Lleida;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.271 Lleida;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.022 Lleida;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.249 Lleida;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Lleida;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Lleida;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Lleida;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Lleida;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Lleida;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Lleida;Group 1303 Internal derangement of knee 717;Both sexes;118 Lleida;Group 1303 Internal derangement of knee 717;Men;75 Lleida;Group 1303 Internal derangement of knee 717;Women;43 Lleida;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.141 Lleida;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;477 Lleida;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;664 Lleida;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;61 Lleida;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;34 Lleida;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;27 Lleida;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;110 Lleida;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;54 Lleida;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;56 Lleida;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;181 Lleida;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;103 Lleida;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;78 Lleida;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;103 Lleida;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;38 Lleida;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;65 Lleida;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;271 Lleida;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;125 Lleida;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;146 Lleida;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;286 Lleida;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;116 Lleida;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;170 Lleida;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.903 Lleida;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.467 Lleida;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.436 Lleida;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;409 Lleida;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;100 Lleida;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;309 Lleida;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;238 Lleida;Group 1402 Renal failure 5836-5837, 584-586;Men;143 Lleida;Group 1402 Renal failure 5836-5837, 584-586;Women;95 Lleida;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;466 Lleida;Group 1403 Urolithiasis 592, 594, 7880;Men;289 Lleida;Group 1403 Urolithiasis 592, 594, 7880;Women;177 Lleida;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;824 Lleida;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;453 Lleida;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;371 Lleida;Group 1405 Prostatic hyperplasia 600;Both sexes;263 Lleida;Group 1405 Prostatic hyperplasia 600;Men;263 Lleida;Group 1405 Prostatic hyperplasia 600;Women;.. Lleida;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;205 Lleida;Group 1406 Other diseases of the male genital organs 601-608;Men;205 Lleida;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Lleida;Group 1407 Disorders of breast 610-612;Both sexes;111 Lleida;Group 1407 Disorders of breast 610-612;Men;3 Lleida;Group 1407 Disorders of breast 610-612;Women;108 Lleida;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;57 Lleida;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Lleida;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;57 Lleida;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;28 Lleida;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Lleida;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;28 Lleida;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;302 Lleida;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;11 Lleida;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;291 Lleida;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;4.065 Lleida;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Lleida;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;4.065 Lleida;Group 1501 Legally induced abortion 635;Both sexes;26 Lleida;Group 1501 Legally induced abortion 635;Men;.. Lleida;Group 1501 Legally induced abortion 635;Women;26 Lleida;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;186 Lleida;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Lleida;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;186 Lleida;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;2.162 Lleida;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Lleida;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;2.162 Lleida;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;751 Lleida;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Lleida;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;751 Lleida;Group 1505 Single spontaneous delivery 650;Both sexes;372 Lleida;Group 1505 Single spontaneous delivery 650;Men;.. Lleida;Group 1505 Single spontaneous delivery 650;Women;372 Lleida;Group 1506 Other deliveries 6695-6697;Both sexes;57 Lleida;Group 1506 Other deliveries 6695-6697;Men;.. Lleida;Group 1506 Other deliveries 6695-6697;Women;57 Lleida;Group 1507 Complications related to the puerperium 670-676;Both sexes;51 Lleida;Group 1507 Complications related to the puerperium 670-676;Men;.. Lleida;Group 1507 Complications related to the puerperium 670-676;Women;51 Lleida;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;460 Lleida;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Lleida;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;460 Lleida;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;367 Lleida;Group 1600 Some disorders originating in the perinatal period 760-779;Men;209 Lleida;Group 1600 Some disorders originating in the perinatal period 760-779;Women;158 Lleida;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;80 Lleida;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;53 Lleida;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;27 Lleida;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;287 Lleida;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;156 Lleida;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;131 Lleida;Grupo 1700 Congenital abnormalities 740-759;Both sexes;79 Lleida;Grupo 1700 Congenital abnormalities 740-759;Men;45 Lleida;Grupo 1700 Congenital abnormalities 740-759;Women;34 Lleida;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.749 Lleida;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;935 Lleida;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;814 Lleida;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;144 Lleida;Group 1801 Pain in throat and chest 7841, 7865;Men;83 Lleida;Group 1801 Pain in throat and chest 7841, 7865;Women;61 Lleida;Group 1802 Abdominal pain 7890;Both sexes;306 Lleida;Group 1802 Abdominal pain 7890;Men;125 Lleida;Group 1802 Abdominal pain 7890;Women;181 Lleida;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;34 Lleida;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;17 Lleida;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;17 Lleida;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.265 Lleida;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;710 Lleida;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;555 Lleida;Group 1900 Injuries and poisoning 800-999;Both sexes;3.835 Lleida;Group 1900 Injuries and poisoning 800-999;Men;1.774 Lleida;Group 1900 Injuries and poisoning 800-999;Women;2.061 Lleida;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;355 Lleida;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;197 Lleida;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;158 Lleida;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;75 Lleida;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;54 Lleida;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;21 Lleida;Group 1903 Radius and ulna fracture 813;Both sexes;175 Lleida;Group 1903 Radius and ulna fracture 813;Men;70 Lleida;Group 1903 Radius and ulna fracture 813;Women;105 Lleida;Group 1904 Femur fracture 820-821;Both sexes;961 Lleida;Group 1904 Femur fracture 820-821;Men;268 Lleida;Group 1904 Femur fracture 820-821;Women;693 Lleida;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;276 Lleida;Group 1905 Leg fracture, including the ankle 823-824;Men;138 Lleida;Group 1905 Leg fracture, including the ankle 823-824;Women;138 Lleida;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.185 Lleida;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;645 Lleida;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;540 Lleida;Group 1907 Burns 940-949;Both sexes;9 Lleida;Group 1907 Burns 940-949;Men;8 Lleida;Group 1907 Burns 940-949;Women;1 Lleida;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;112 Lleida;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;49 Lleida;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;63 Lleida;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;570 Lleida;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;276 Lleida;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;294 Lleida;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;9 Lleida;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 Lleida;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;6 Lleida;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;108 Lleida;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;66 Lleida;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;42 Lleida;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;332 Lleida;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;183 Lleida;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;149 Lleida;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;18 Lleida;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;9 Lleida;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;9 Lleida;Group 2102 Contraceptive management V25;Both sexes;7 Lleida;Group 2102 Contraceptive management V25;Men;.. Lleida;Group 2102 Contraceptive management V25;Women;7 Lleida;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Lleida;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Lleida;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Lleida;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;144 Lleida;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;92 Lleida;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;52 Lleida;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;163 Lleida;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;82 Lleida;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;81 Tarragona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;77.314 Tarragona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;36.741 Tarragona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;40.573 Tarragona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.296 Tarragona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;694 Tarragona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;602 Tarragona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;177 Tarragona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;100 Tarragona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;76 Tarragona;Group 0102 Imprecise intestinal infections 009;Both sexes;173 Tarragona;Group 0102 Imprecise intestinal infections 009;Men;79 Tarragona;Group 0102 Imprecise intestinal infections 009;Women;94 Tarragona;Group 0103 Tuberculosis 010-018, 137;Both sexes;57 Tarragona;Group 0103 Tuberculosis 010-018, 137;Men;32 Tarragona;Group 0103 Tuberculosis 010-018, 137;Women;24 Tarragona;Group 0104 Septicaemia 038;Both sexes;331 Tarragona;Group 0104 Septicaemia 038;Men;171 Tarragona;Group 0104 Septicaemia 038;Women;160 Tarragona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;92 Tarragona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;69 Tarragona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;22 Tarragona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;468 Tarragona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;243 Tarragona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;225 Tarragona;Group 0200 Neoplasms 140-239;Both sexes;7.017 Tarragona;Group 0200 Neoplasms 140-239;Men;4.078 Tarragona;Group 0200 Neoplasms 140-239;Women;2.939 Tarragona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;934 Tarragona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;578 Tarragona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;355 Tarragona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;799 Tarragona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;659 Tarragona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;140 Tarragona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;114 Tarragona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;74 Tarragona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;40 Tarragona;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;473 Tarragona;Group 0204 Malignant neoplasm of breast 174-175;Men;5 Tarragona;Group 0204 Malignant neoplasm of breast 174-175;Women;468 Tarragona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;169 Tarragona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Tarragona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;169 Tarragona;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;102 Tarragona;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Tarragona;Group 0206 Malignant neoplasm of ovary 1830;Women;102 Tarragona;Group 0207 Malignant neoplasm of prostate 185;Both sexes;211 Tarragona;Group 0207 Malignant neoplasm of prostate 185;Men;211 Tarragona;Group 0207 Malignant neoplasm of prostate 185;Women;.. Tarragona;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.007 Tarragona;Group 0208 Malignant neoplasm of bladder 188;Men;848 Tarragona;Group 0208 Malignant neoplasm of bladder 188;Women;159 Tarragona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.180 Tarragona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.349 Tarragona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;832 Tarragona;Group 0210 Carcinoma in situ 230-234;Both sexes;69 Tarragona;Group 0210 Carcinoma in situ 230-234;Men;27 Tarragona;Group 0210 Carcinoma in situ 230-234;Women;42 Tarragona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;101 Tarragona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;61 Tarragona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;40 Tarragona;Grupo 0212 Leiomyoma of uterus 218;Both sexes;275 Tarragona;Grupo 0212 Leiomyoma of uterus 218;Men;.. Tarragona;Grupo 0212 Leiomyoma of uterus 218;Women;275 Tarragona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;584 Tarragona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;266 Tarragona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;318 Tarragona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;635 Tarragona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;296 Tarragona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;339 Tarragona;Group 0301 Anaemias 280-285;Both sexes;432 Tarragona;Group 0301 Anaemias 280-285;Men;193 Tarragona;Group 0301 Anaemias 280-285;Women;239 Tarragona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;202 Tarragona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;103 Tarragona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;100 Tarragona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.204 Tarragona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;479 Tarragona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;724 Tarragona;Group 0401 Diabetes mellitus 249-250;Both sexes;427 Tarragona;Group 0401 Diabetes mellitus 249-250;Men;241 Tarragona;Group 0401 Diabetes mellitus 249-250;Women;186 Tarragona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;777 Tarragona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;239 Tarragona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;538 Tarragona;Group 0500 Mental disorders 290-319;Both sexes;2.649 Tarragona;Group 0500 Mental disorders 290-319;Men;1.481 Tarragona;Group 0500 Mental disorders 290-319;Women;1.168 Tarragona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;190 Tarragona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;89 Tarragona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;101 Tarragona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;174 Tarragona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;117 Tarragona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;57 Tarragona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;155 Tarragona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;132 Tarragona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;23 Tarragona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;671 Tarragona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;443 Tarragona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;227 Tarragona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;504 Tarragona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;212 Tarragona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;292 Tarragona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;954 Tarragona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;488 Tarragona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;467 Tarragona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.190 Tarragona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;555 Tarragona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;635 Tarragona;Group 0601 Alzheimer's disease 3310;Both sexes;118 Tarragona;Group 0601 Alzheimer's disease 3310;Men;42 Tarragona;Group 0601 Alzheimer's disease 3310;Women;76 Tarragona;Group 0602 Multiple sclerosis 340;Both sexes;29 Tarragona;Group 0602 Multiple sclerosis 340;Men;9 Tarragona;Group 0602 Multiple sclerosis 340;Women;19 Tarragona;Group 0603 Epilepsy 345;Both sexes;179 Tarragona;Group 0603 Epilepsy 345;Men;93 Tarragona;Group 0603 Epilepsy 345;Women;86 Tarragona;Group 0604 Transient cerebral ischemia 435;Both sexes;202 Tarragona;Group 0604 Transient cerebral ischemia 435;Men;107 Tarragona;Group 0604 Transient cerebral ischemia 435;Women;96 Tarragona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;662 Tarragona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;305 Tarragona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;357 Tarragona;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;298 Tarragona;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;145 Tarragona;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;152 Tarragona;Grupo 0701 Cataract 366;Both sexes;150 Tarragona;Grupo 0701 Cataract 366;Men;61 Tarragona;Grupo 0701 Cataract 366;Women;89 Tarragona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;147 Tarragona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;84 Tarragona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;63 Tarragona;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;442 Tarragona;Group 0800 Diseases of the ear and the mastoid 380-389;Men;211 Tarragona;Group 0800 Diseases of the ear and the mastoid 380-389;Women;230 Tarragona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;9.614 Tarragona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5.384 Tarragona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.230 Tarragona;Group 0901 Hypertensive disease 401-405;Both sexes;272 Tarragona;Group 0901 Hypertensive disease 401-405;Men;107 Tarragona;Group 0901 Hypertensive disease 401-405;Women;165 Tarragona;Group 0902 Angina pectoris 4111, 413;Both sexes;437 Tarragona;Group 0902 Angina pectoris 4111, 413;Men;304 Tarragona;Group 0902 Angina pectoris 4111, 413;Women;133 Tarragona;Group 0903 Acute myocardial infarction 410;Both sexes;1.191 Tarragona;Group 0903 Acute myocardial infarction 410;Men;861 Tarragona;Group 0903 Acute myocardial infarction 410;Women;330 Tarragona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;352 Tarragona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;261 Tarragona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;91 Tarragona;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;319 Tarragona;Group 0905 Diseases of the lungs circulation 415-417;Men;143 Tarragona;Group 0905 Diseases of the lungs circulation 415-417;Women;175 Tarragona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.110 Tarragona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;620 Tarragona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;489 Tarragona;Grupo 0907 Heart failure 428;Both sexes;2.388 Tarragona;Grupo 0907 Heart failure 428;Men;1.129 Tarragona;Grupo 0907 Heart failure 428;Women;1.260 Tarragona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.938 Tarragona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.045 Tarragona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;893 Tarragona;Grupo 0909 Atherosclerosis 440;Both sexes;340 Tarragona;Grupo 0909 Atherosclerosis 440;Men;251 Tarragona;Grupo 0909 Atherosclerosis 440;Women;89 Tarragona;Group 0910 Varicose veins of lower extremities 454;Both sexes;176 Tarragona;Group 0910 Varicose veins of lower extremities 454;Men;53 Tarragona;Group 0910 Varicose veins of lower extremities 454;Women;123 Tarragona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.091 Tarragona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;609 Tarragona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;482 Tarragona;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;10.347 Tarragona;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5.801 Tarragona;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4.546 Tarragona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;411 Tarragona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;217 Tarragona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;195 Tarragona;Group 1002 Pneumonia 480-486;Both sexes;2.308 Tarragona;Group 1002 Pneumonia 480-486;Men;1.351 Tarragona;Group 1002 Pneumonia 480-486;Women;958 Tarragona;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.291 Tarragona;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.080 Tarragona;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.211 Tarragona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;390 Tarragona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;225 Tarragona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;164 Tarragona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;699 Tarragona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;458 Tarragona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;241 Tarragona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.963 Tarragona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.416 Tarragona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;547 Tarragona;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;375 Tarragona;Group 1007 Asthma 4930-4931,4938-4939;Men;93 Tarragona;Group 1007 Asthma 4930-4931,4938-4939;Women;282 Tarragona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.909 Tarragona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;960 Tarragona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;948 Tarragona;Group 1100 Diseases of the digestive system 520-579;Both sexes;9.657 Tarragona;Group 1100 Diseases of the digestive system 520-579;Men;5.452 Tarragona;Group 1100 Diseases of the digestive system 520-579;Women;4.205 Tarragona;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;251 Tarragona;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;111 Tarragona;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;140 Tarragona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;106 Tarragona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;61 Tarragona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;45 Tarragona;Group 1103 Diseases of the esophagus 530;Both sexes;128 Tarragona;Group 1103 Diseases of the esophagus 530;Men;96 Tarragona;Group 1103 Diseases of the esophagus 530;Women;31 Tarragona;Group 1104 Peptic ulcer 531-534;Both sexes;165 Tarragona;Group 1104 Peptic ulcer 531-534;Men;116 Tarragona;Group 1104 Peptic ulcer 531-534;Women;50 Tarragona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;209 Tarragona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;112 Tarragona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;98 Tarragona;Group 1106 Appendicitis 540-543;Both sexes;734 Tarragona;Group 1106 Appendicitis 540-543;Men;402 Tarragona;Group 1106 Appendicitis 540-543;Women;332 Tarragona;Group 1107 Inguinal hernia 550;Both sexes;1.055 Tarragona;Group 1107 Inguinal hernia 550;Men;941 Tarragona;Group 1107 Inguinal hernia 550;Women;114 Tarragona;Group 1108 Other abdominal hernia 551-553;Both sexes;992 Tarragona;Group 1108 Other abdominal hernia 551-553;Men;429 Tarragona;Group 1108 Other abdominal hernia 551-553;Women;564 Tarragona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;159 Tarragona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;82 Tarragona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;76 Tarragona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;528 Tarragona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;263 Tarragona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;265 Tarragona;Group 1111 Intestinal obstruction without hernia 560;Both sexes;430 Tarragona;Group 1111 Intestinal obstruction without hernia 560;Men;237 Tarragona;Group 1111 Intestinal obstruction without hernia 560;Women;193 Tarragona;Group 1112 Intestinal diverticulosis 562;Both sexes;385 Tarragona;Group 1112 Intestinal diverticulosis 562;Men;220 Tarragona;Group 1112 Intestinal diverticulosis 562;Women;165 Tarragona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;611 Tarragona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;375 Tarragona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;236 Tarragona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;276 Tarragona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;127 Tarragona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;149 Tarragona;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;175 Tarragona;Group 1115 Alcoholic hepatitis 5710-5713;Men;153 Tarragona;Group 1115 Alcoholic hepatitis 5710-5713;Women;22 Tarragona;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;296 Tarragona;Group 1116 Other diseases of the liver 570,5714-573;Men;172 Tarragona;Group 1116 Other diseases of the liver 570,5714-573;Women;124 Tarragona;Group 1117 Cholelithiasis 574;Both sexes;1.765 Tarragona;Group 1117 Cholelithiasis 574;Men;768 Tarragona;Group 1117 Cholelithiasis 574;Women;997 Tarragona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;496 Tarragona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;284 Tarragona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;211 Tarragona;Group 1119 Pancreatic diseases 577;Both sexes;592 Tarragona;Group 1119 Pancreatic diseases 577;Men;326 Tarragona;Group 1119 Pancreatic diseases 577;Women;266 Tarragona;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;306 Tarragona;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;178 Tarragona;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;128 Tarragona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;815 Tarragona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;433 Tarragona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;382 Tarragona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;527 Tarragona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;287 Tarragona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;240 Tarragona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;36 Tarragona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;21 Tarragona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;14 Tarragona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;252 Tarragona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;125 Tarragona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;127 Tarragona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;5.316 Tarragona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.421 Tarragona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.894 Tarragona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Tarragona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Tarragona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Tarragona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Tarragona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Tarragona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Tarragona;Group 1303 Internal derangement of knee 717;Both sexes;583 Tarragona;Group 1303 Internal derangement of knee 717;Men;370 Tarragona;Group 1303 Internal derangement of knee 717;Women;213 Tarragona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.448 Tarragona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;986 Tarragona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.462 Tarragona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;59 Tarragona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;28 Tarragona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;30 Tarragona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;188 Tarragona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;84 Tarragona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;104 Tarragona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;329 Tarragona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;154 Tarragona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;175 Tarragona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;168 Tarragona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;76 Tarragona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;92 Tarragona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;776 Tarragona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;408 Tarragona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;368 Tarragona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;764 Tarragona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;314 Tarragona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;450 Tarragona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5.590 Tarragona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.636 Tarragona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.953 Tarragona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;691 Tarragona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;207 Tarragona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;484 Tarragona;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;455 Tarragona;Group 1402 Renal failure 5836-5837, 584-586;Men;269 Tarragona;Group 1402 Renal failure 5836-5837, 584-586;Women;186 Tarragona;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;758 Tarragona;Group 1403 Urolithiasis 592, 594, 7880;Men;442 Tarragona;Group 1403 Urolithiasis 592, 594, 7880;Women;316 Tarragona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.666 Tarragona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;813 Tarragona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;854 Tarragona;Group 1405 Prostatic hyperplasia 600;Both sexes;405 Tarragona;Group 1405 Prostatic hyperplasia 600;Men;405 Tarragona;Group 1405 Prostatic hyperplasia 600;Women;.. Tarragona;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;487 Tarragona;Group 1406 Other diseases of the male genital organs 601-608;Men;487 Tarragona;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Tarragona;Group 1407 Disorders of breast 610-612;Both sexes;151 Tarragona;Group 1407 Disorders of breast 610-612;Men;10 Tarragona;Group 1407 Disorders of breast 610-612;Women;141 Tarragona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;126 Tarragona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Tarragona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;126 Tarragona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;78 Tarragona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Tarragona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;78 Tarragona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;773 Tarragona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;3 Tarragona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;770 Tarragona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;7.948 Tarragona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Tarragona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;7.948 Tarragona;Group 1501 Legally induced abortion 635;Both sexes;38 Tarragona;Group 1501 Legally induced abortion 635;Men;.. Tarragona;Group 1501 Legally induced abortion 635;Women;38 Tarragona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;405 Tarragona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Tarragona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;405 Tarragona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.900 Tarragona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Tarragona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.900 Tarragona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.808 Tarragona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Tarragona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.808 Tarragona;Group 1505 Single spontaneous delivery 650;Both sexes;977 Tarragona;Group 1505 Single spontaneous delivery 650;Men;.. Tarragona;Group 1505 Single spontaneous delivery 650;Women;977 Tarragona;Group 1506 Other deliveries 6695-6697;Both sexes;57 Tarragona;Group 1506 Other deliveries 6695-6697;Men;.. Tarragona;Group 1506 Other deliveries 6695-6697;Women;57 Tarragona;Group 1507 Complications related to the puerperium 670-676;Both sexes;136 Tarragona;Group 1507 Complications related to the puerperium 670-676;Men;.. Tarragona;Group 1507 Complications related to the puerperium 670-676;Women;136 Tarragona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;627 Tarragona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Tarragona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;627 Tarragona;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.150 Tarragona;Group 1600 Some disorders originating in the perinatal period 760-779;Men;625 Tarragona;Group 1600 Some disorders originating in the perinatal period 760-779;Women;525 Tarragona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;303 Tarragona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;169 Tarragona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;134 Tarragona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;846 Tarragona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;456 Tarragona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;391 Tarragona;Grupo 1700 Congenital abnormalities 740-759;Both sexes;424 Tarragona;Grupo 1700 Congenital abnormalities 740-759;Men;235 Tarragona;Grupo 1700 Congenital abnormalities 740-759;Women;189 Tarragona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.096 Tarragona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.740 Tarragona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.357 Tarragona;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;354 Tarragona;Group 1801 Pain in throat and chest 7841, 7865;Men;187 Tarragona;Group 1801 Pain in throat and chest 7841, 7865;Women;168 Tarragona;Group 1802 Abdominal pain 7890;Both sexes;383 Tarragona;Group 1802 Abdominal pain 7890;Men;152 Tarragona;Group 1802 Abdominal pain 7890;Women;232 Tarragona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;21 Tarragona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;8 Tarragona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;13 Tarragona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2.337 Tarragona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.393 Tarragona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;944 Tarragona;Group 1900 Injuries and poisoning 800-999;Both sexes;7.294 Tarragona;Group 1900 Injuries and poisoning 800-999;Men;3.385 Tarragona;Group 1900 Injuries and poisoning 800-999;Women;3.909 Tarragona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;492 Tarragona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;283 Tarragona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;210 Tarragona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;214 Tarragona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;148 Tarragona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;66 Tarragona;Group 1903 Radius and ulna fracture 813;Both sexes;396 Tarragona;Group 1903 Radius and ulna fracture 813;Men;195 Tarragona;Group 1903 Radius and ulna fracture 813;Women;201 Tarragona;Group 1904 Femur fracture 820-821;Both sexes;1.769 Tarragona;Group 1904 Femur fracture 820-821;Men;495 Tarragona;Group 1904 Femur fracture 820-821;Women;1.274 Tarragona;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;479 Tarragona;Group 1905 Leg fracture, including the ankle 823-824;Men;250 Tarragona;Group 1905 Leg fracture, including the ankle 823-824;Women;229 Tarragona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.176 Tarragona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.132 Tarragona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.043 Tarragona;Group 1907 Burns 940-949;Both sexes;18 Tarragona;Group 1907 Burns 940-949;Men;11 Tarragona;Group 1907 Burns 940-949;Women;7 Tarragona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;145 Tarragona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;53 Tarragona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;92 Tarragona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.369 Tarragona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;688 Tarragona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;681 Tarragona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;13 Tarragona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;7 Tarragona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;6 Tarragona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;222 Tarragona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;122 Tarragona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;100 Tarragona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.335 Tarragona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;689 Tarragona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;647 Tarragona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;5 Tarragona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;4 Tarragona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;1 Tarragona;Group 2102 Contraceptive management V25;Both sexes;50 Tarragona;Group 2102 Contraceptive management V25;Men;.. Tarragona;Group 2102 Contraceptive management V25;Women;50 Tarragona;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Tarragona;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Tarragona;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Tarragona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;266 Tarragona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;178 Tarragona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;88 Tarragona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.015 Tarragona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;507 Tarragona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;508 COMUNITAT VALENCIANA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;510.074 COMUNITAT VALENCIANA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;243.994 COMUNITAT VALENCIANA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;266.080 COMUNITAT VALENCIANA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;11.392 COMUNITAT VALENCIANA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;6.341 COMUNITAT VALENCIANA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;5.051 COMUNITAT VALENCIANA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1.783 COMUNITAT VALENCIANA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;913 COMUNITAT VALENCIANA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;870 COMUNITAT VALENCIANA;Group 0102 Imprecise intestinal infections 009;Both sexes;1.047 COMUNITAT VALENCIANA;Group 0102 Imprecise intestinal infections 009;Men;516 COMUNITAT VALENCIANA;Group 0102 Imprecise intestinal infections 009;Women;531 COMUNITAT VALENCIANA;Group 0103 Tuberculosis 010-018, 137;Both sexes;400 COMUNITAT VALENCIANA;Group 0103 Tuberculosis 010-018, 137;Men;273 COMUNITAT VALENCIANA;Group 0103 Tuberculosis 010-018, 137;Women;127 COMUNITAT VALENCIANA;Group 0104 Septicaemia 038;Both sexes;4.077 COMUNITAT VALENCIANA;Group 0104 Septicaemia 038;Men;2.269 COMUNITAT VALENCIANA;Group 0104 Septicaemia 038;Women;1.808 COMUNITAT VALENCIANA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;488 COMUNITAT VALENCIANA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;343 COMUNITAT VALENCIANA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;145 COMUNITAT VALENCIANA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;3.597 COMUNITAT VALENCIANA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2.027 COMUNITAT VALENCIANA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;1.570 COMUNITAT VALENCIANA;Group 0200 Neoplasms 140-239;Both sexes;52.929 COMUNITAT VALENCIANA;Group 0200 Neoplasms 140-239;Men;27.920 COMUNITAT VALENCIANA;Group 0200 Neoplasms 140-239;Women;25.009 COMUNITAT VALENCIANA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;5.566 COMUNITAT VALENCIANA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;3.313 COMUNITAT VALENCIANA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2.253 COMUNITAT VALENCIANA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;4.620 COMUNITAT VALENCIANA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;3.623 COMUNITAT VALENCIANA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;997 COMUNITAT VALENCIANA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;766 COMUNITAT VALENCIANA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;479 COMUNITAT VALENCIANA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;287 COMUNITAT VALENCIANA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;4.622 COMUNITAT VALENCIANA;Group 0204 Malignant neoplasm of breast 174-175;Men;24 COMUNITAT VALENCIANA;Group 0204 Malignant neoplasm of breast 174-175;Women;4.598 COMUNITAT VALENCIANA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1.073 COMUNITAT VALENCIANA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. COMUNITAT VALENCIANA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1.073 COMUNITAT VALENCIANA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;620 COMUNITAT VALENCIANA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. COMUNITAT VALENCIANA;Group 0206 Malignant neoplasm of ovary 1830;Women;620 COMUNITAT VALENCIANA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.973 COMUNITAT VALENCIANA;Group 0207 Malignant neoplasm of prostate 185;Men;1.973 COMUNITAT VALENCIANA;Group 0207 Malignant neoplasm of prostate 185;Women;.. COMUNITAT VALENCIANA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;5.742 COMUNITAT VALENCIANA;Group 0208 Malignant neoplasm of bladder 188;Men;4.825 COMUNITAT VALENCIANA;Group 0208 Malignant neoplasm of bladder 188;Women;917 COMUNITAT VALENCIANA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;17.096 COMUNITAT VALENCIANA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;10.046 COMUNITAT VALENCIANA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;7.050 COMUNITAT VALENCIANA;Group 0210 Carcinoma in situ 230-234;Both sexes;680 COMUNITAT VALENCIANA;Group 0210 Carcinoma in situ 230-234;Men;215 COMUNITAT VALENCIANA;Group 0210 Carcinoma in situ 230-234;Women;465 COMUNITAT VALENCIANA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;641 COMUNITAT VALENCIANA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;396 COMUNITAT VALENCIANA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;245 COMUNITAT VALENCIANA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;2.670 COMUNITAT VALENCIANA;Grupo 0212 Leiomyoma of uterus 218;Men;.. COMUNITAT VALENCIANA;Grupo 0212 Leiomyoma of uterus 218;Women;2.670 COMUNITAT VALENCIANA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;6.860 COMUNITAT VALENCIANA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;3.026 COMUNITAT VALENCIANA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;3.834 COMUNITAT VALENCIANA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;4.305 COMUNITAT VALENCIANA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;2.127 COMUNITAT VALENCIANA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;2.178 COMUNITAT VALENCIANA;Group 0301 Anaemias 280-285;Both sexes;2.494 COMUNITAT VALENCIANA;Group 0301 Anaemias 280-285;Men;1.222 COMUNITAT VALENCIANA;Group 0301 Anaemias 280-285;Women;1.272 COMUNITAT VALENCIANA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;1.811 COMUNITAT VALENCIANA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;905 COMUNITAT VALENCIANA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;906 COMUNITAT VALENCIANA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;10.031 COMUNITAT VALENCIANA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;4.192 COMUNITAT VALENCIANA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;5.839 COMUNITAT VALENCIANA;Group 0401 Diabetes mellitus 249-250;Both sexes;3.332 COMUNITAT VALENCIANA;Group 0401 Diabetes mellitus 249-250;Men;1.983 COMUNITAT VALENCIANA;Group 0401 Diabetes mellitus 249-250;Women;1.349 COMUNITAT VALENCIANA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;6.699 COMUNITAT VALENCIANA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;2.209 COMUNITAT VALENCIANA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;4.490 COMUNITAT VALENCIANA;Group 0500 Mental disorders 290-319;Both sexes;10.143 COMUNITAT VALENCIANA;Group 0500 Mental disorders 290-319;Men;5.360 COMUNITAT VALENCIANA;Group 0500 Mental disorders 290-319;Women;4.783 COMUNITAT VALENCIANA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;339 COMUNITAT VALENCIANA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;167 COMUNITAT VALENCIANA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;172 COMUNITAT VALENCIANA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;719 COMUNITAT VALENCIANA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;520 COMUNITAT VALENCIANA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;199 COMUNITAT VALENCIANA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;591 COMUNITAT VALENCIANA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;407 COMUNITAT VALENCIANA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;183 COMUNITAT VALENCIANA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;3.021 COMUNITAT VALENCIANA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;1.846 COMUNITAT VALENCIANA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;1.175 COMUNITAT VALENCIANA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;2.212 COMUNITAT VALENCIANA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;946 COMUNITAT VALENCIANA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;1.265 COMUNITAT VALENCIANA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;3.261 COMUNITAT VALENCIANA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;1.474 COMUNITAT VALENCIANA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1.787 COMUNITAT VALENCIANA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;11.745 COMUNITAT VALENCIANA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;5.877 COMUNITAT VALENCIANA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;5.868 COMUNITAT VALENCIANA;Group 0601 Alzheimer's disease 3310;Both sexes;212 COMUNITAT VALENCIANA;Group 0601 Alzheimer's disease 3310;Men;71 COMUNITAT VALENCIANA;Group 0601 Alzheimer's disease 3310;Women;141 COMUNITAT VALENCIANA;Group 0602 Multiple sclerosis 340;Both sexes;264 COMUNITAT VALENCIANA;Group 0602 Multiple sclerosis 340;Men;69 COMUNITAT VALENCIANA;Group 0602 Multiple sclerosis 340;Women;195 COMUNITAT VALENCIANA;Group 0603 Epilepsy 345;Both sexes;2.546 COMUNITAT VALENCIANA;Group 0603 Epilepsy 345;Men;1.377 COMUNITAT VALENCIANA;Group 0603 Epilepsy 345;Women;1.169 COMUNITAT VALENCIANA;Group 0604 Transient cerebral ischemia 435;Both sexes;1.865 COMUNITAT VALENCIANA;Group 0604 Transient cerebral ischemia 435;Men;983 COMUNITAT VALENCIANA;Group 0604 Transient cerebral ischemia 435;Women;882 COMUNITAT VALENCIANA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;6.858 COMUNITAT VALENCIANA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;3.377 COMUNITAT VALENCIANA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;3.481 COMUNITAT VALENCIANA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;2.306 COMUNITAT VALENCIANA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;1.232 COMUNITAT VALENCIANA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;1.074 COMUNITAT VALENCIANA;Grupo 0701 Cataract 366;Both sexes;298 COMUNITAT VALENCIANA;Grupo 0701 Cataract 366;Men;158 COMUNITAT VALENCIANA;Grupo 0701 Cataract 366;Women;140 COMUNITAT VALENCIANA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;2.008 COMUNITAT VALENCIANA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;1.074 COMUNITAT VALENCIANA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;934 COMUNITAT VALENCIANA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;2.407 COMUNITAT VALENCIANA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1.177 COMUNITAT VALENCIANA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1.230 COMUNITAT VALENCIANA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;66.297 COMUNITAT VALENCIANA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;38.037 COMUNITAT VALENCIANA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;28.260 COMUNITAT VALENCIANA;Group 0901 Hypertensive disease 401-405;Both sexes;2.038 COMUNITAT VALENCIANA;Group 0901 Hypertensive disease 401-405;Men;1.053 COMUNITAT VALENCIANA;Group 0901 Hypertensive disease 401-405;Women;985 COMUNITAT VALENCIANA;Group 0902 Angina pectoris 4111, 413;Both sexes;3.678 COMUNITAT VALENCIANA;Group 0902 Angina pectoris 4111, 413;Men;2.341 COMUNITAT VALENCIANA;Group 0902 Angina pectoris 4111, 413;Women;1.337 COMUNITAT VALENCIANA;Group 0903 Acute myocardial infarction 410;Both sexes;5.989 COMUNITAT VALENCIANA;Group 0903 Acute myocardial infarction 410;Men;4.273 COMUNITAT VALENCIANA;Group 0903 Acute myocardial infarction 410;Women;1.716 COMUNITAT VALENCIANA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;4.216 COMUNITAT VALENCIANA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;3.248 COMUNITAT VALENCIANA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;968 COMUNITAT VALENCIANA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;2.020 COMUNITAT VALENCIANA;Group 0905 Diseases of the lungs circulation 415-417;Men;901 COMUNITAT VALENCIANA;Group 0905 Diseases of the lungs circulation 415-417;Women;1.119 COMUNITAT VALENCIANA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;9.167 COMUNITAT VALENCIANA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;4.946 COMUNITAT VALENCIANA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;4.221 COMUNITAT VALENCIANA;Grupo 0907 Heart failure 428;Both sexes;13.391 COMUNITAT VALENCIANA;Grupo 0907 Heart failure 428;Men;6.347 COMUNITAT VALENCIANA;Grupo 0907 Heart failure 428;Women;7.044 COMUNITAT VALENCIANA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;12.151 COMUNITAT VALENCIANA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;6.736 COMUNITAT VALENCIANA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;5.415 COMUNITAT VALENCIANA;Grupo 0909 Atherosclerosis 440;Both sexes;1.806 COMUNITAT VALENCIANA;Grupo 0909 Atherosclerosis 440;Men;1.360 COMUNITAT VALENCIANA;Grupo 0909 Atherosclerosis 440;Women;446 COMUNITAT VALENCIANA;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.131 COMUNITAT VALENCIANA;Group 0910 Varicose veins of lower extremities 454;Men;401 COMUNITAT VALENCIANA;Group 0910 Varicose veins of lower extremities 454;Women;730 COMUNITAT VALENCIANA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;10.710 COMUNITAT VALENCIANA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;6.431 COMUNITAT VALENCIANA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;4.279 COMUNITAT VALENCIANA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;58.738 COMUNITAT VALENCIANA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;33.442 COMUNITAT VALENCIANA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;25.296 COMUNITAT VALENCIANA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;3.303 COMUNITAT VALENCIANA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1.702 COMUNITAT VALENCIANA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1.601 COMUNITAT VALENCIANA;Group 1002 Pneumonia 480-486;Both sexes;14.518 COMUNITAT VALENCIANA;Group 1002 Pneumonia 480-486;Men;8.479 COMUNITAT VALENCIANA;Group 1002 Pneumonia 480-486;Women;6.039 COMUNITAT VALENCIANA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;5.844 COMUNITAT VALENCIANA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;2.823 COMUNITAT VALENCIANA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;3.021 COMUNITAT VALENCIANA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;3.489 COMUNITAT VALENCIANA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.887 COMUNITAT VALENCIANA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1.602 COMUNITAT VALENCIANA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;3.527 COMUNITAT VALENCIANA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;2.129 COMUNITAT VALENCIANA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;1.398 COMUNITAT VALENCIANA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;9.193 COMUNITAT VALENCIANA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;6.929 COMUNITAT VALENCIANA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;2.264 COMUNITAT VALENCIANA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.767 COMUNITAT VALENCIANA;Group 1007 Asthma 4930-4931,4938-4939;Men;490 COMUNITAT VALENCIANA;Group 1007 Asthma 4930-4931,4938-4939;Women;1.277 COMUNITAT VALENCIANA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;17.097 COMUNITAT VALENCIANA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;9.003 COMUNITAT VALENCIANA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;8.094 COMUNITAT VALENCIANA;Group 1100 Diseases of the digestive system 520-579;Both sexes;63.473 COMUNITAT VALENCIANA;Group 1100 Diseases of the digestive system 520-579;Men;34.993 COMUNITAT VALENCIANA;Group 1100 Diseases of the digestive system 520-579;Women;28.480 COMUNITAT VALENCIANA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;1.083 COMUNITAT VALENCIANA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;488 COMUNITAT VALENCIANA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;595 COMUNITAT VALENCIANA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;876 COMUNITAT VALENCIANA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;483 COMUNITAT VALENCIANA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;393 COMUNITAT VALENCIANA;Group 1103 Diseases of the esophagus 530;Both sexes;1.296 COMUNITAT VALENCIANA;Group 1103 Diseases of the esophagus 530;Men;791 COMUNITAT VALENCIANA;Group 1103 Diseases of the esophagus 530;Women;505 COMUNITAT VALENCIANA;Group 1104 Peptic ulcer 531-534;Both sexes;1.415 COMUNITAT VALENCIANA;Group 1104 Peptic ulcer 531-534;Men;978 COMUNITAT VALENCIANA;Group 1104 Peptic ulcer 531-534;Women;437 COMUNITAT VALENCIANA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;1.894 COMUNITAT VALENCIANA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;901 COMUNITAT VALENCIANA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;993 COMUNITAT VALENCIANA;Group 1106 Appendicitis 540-543;Both sexes;5.624 COMUNITAT VALENCIANA;Group 1106 Appendicitis 540-543;Men;3.131 COMUNITAT VALENCIANA;Group 1106 Appendicitis 540-543;Women;2.493 COMUNITAT VALENCIANA;Group 1107 Inguinal hernia 550;Both sexes;5.685 COMUNITAT VALENCIANA;Group 1107 Inguinal hernia 550;Men;5.063 COMUNITAT VALENCIANA;Group 1107 Inguinal hernia 550;Women;622 COMUNITAT VALENCIANA;Group 1108 Other abdominal hernia 551-553;Both sexes;5.087 COMUNITAT VALENCIANA;Group 1108 Other abdominal hernia 551-553;Men;2.336 COMUNITAT VALENCIANA;Group 1108 Other abdominal hernia 551-553;Women;2.751 COMUNITAT VALENCIANA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1.439 COMUNITAT VALENCIANA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;722 COMUNITAT VALENCIANA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;717 COMUNITAT VALENCIANA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;3.802 COMUNITAT VALENCIANA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1.784 COMUNITAT VALENCIANA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2.018 COMUNITAT VALENCIANA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;2.795 COMUNITAT VALENCIANA;Group 1111 Intestinal obstruction without hernia 560;Men;1.432 COMUNITAT VALENCIANA;Group 1111 Intestinal obstruction without hernia 560;Women;1.363 COMUNITAT VALENCIANA;Group 1112 Intestinal diverticulosis 562;Both sexes;2.668 COMUNITAT VALENCIANA;Group 1112 Intestinal diverticulosis 562;Men;1.373 COMUNITAT VALENCIANA;Group 1112 Intestinal diverticulosis 562;Women;1.295 COMUNITAT VALENCIANA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;3.852 COMUNITAT VALENCIANA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;2.454 COMUNITAT VALENCIANA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1.398 COMUNITAT VALENCIANA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2.046 COMUNITAT VALENCIANA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;976 COMUNITAT VALENCIANA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1.070 COMUNITAT VALENCIANA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1.072 COMUNITAT VALENCIANA;Group 1115 Alcoholic hepatitis 5710-5713;Men;889 COMUNITAT VALENCIANA;Group 1115 Alcoholic hepatitis 5710-5713;Women;183 COMUNITAT VALENCIANA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;2.405 COMUNITAT VALENCIANA;Group 1116 Other diseases of the liver 570,5714-573;Men;1.403 COMUNITAT VALENCIANA;Group 1116 Other diseases of the liver 570,5714-573;Women;1.002 COMUNITAT VALENCIANA;Group 1117 Cholelithiasis 574;Both sexes;10.244 COMUNITAT VALENCIANA;Group 1117 Cholelithiasis 574;Men;4.197 COMUNITAT VALENCIANA;Group 1117 Cholelithiasis 574;Women;6.047 COMUNITAT VALENCIANA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;3.297 COMUNITAT VALENCIANA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;1.813 COMUNITAT VALENCIANA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;1.484 COMUNITAT VALENCIANA;Group 1119 Pancreatic diseases 577;Both sexes;3.435 COMUNITAT VALENCIANA;Group 1119 Pancreatic diseases 577;Men;1.888 COMUNITAT VALENCIANA;Group 1119 Pancreatic diseases 577;Women;1.547 COMUNITAT VALENCIANA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;3.458 COMUNITAT VALENCIANA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1.891 COMUNITAT VALENCIANA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1.567 COMUNITAT VALENCIANA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;4.865 COMUNITAT VALENCIANA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;2.698 COMUNITAT VALENCIANA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;2.167 COMUNITAT VALENCIANA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;3.199 COMUNITAT VALENCIANA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1.881 COMUNITAT VALENCIANA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1.318 COMUNITAT VALENCIANA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;201 COMUNITAT VALENCIANA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;106 COMUNITAT VALENCIANA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;95 COMUNITAT VALENCIANA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;1.465 COMUNITAT VALENCIANA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;711 COMUNITAT VALENCIANA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;754 COMUNITAT VALENCIANA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;35.244 COMUNITAT VALENCIANA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;17.381 COMUNITAT VALENCIANA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;17.863 COMUNITAT VALENCIANA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. COMUNITAT VALENCIANA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. COMUNITAT VALENCIANA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. COMUNITAT VALENCIANA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. COMUNITAT VALENCIANA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. COMUNITAT VALENCIANA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. COMUNITAT VALENCIANA;Group 1303 Internal derangement of knee 717;Both sexes;5.325 COMUNITAT VALENCIANA;Group 1303 Internal derangement of knee 717;Men;3.756 COMUNITAT VALENCIANA;Group 1303 Internal derangement of knee 717;Women;1.569 COMUNITAT VALENCIANA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;12.229 COMUNITAT VALENCIANA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;5.218 COMUNITAT VALENCIANA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;7.011 COMUNITAT VALENCIANA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;682 COMUNITAT VALENCIANA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;232 COMUNITAT VALENCIANA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;450 COMUNITAT VALENCIANA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;2.020 COMUNITAT VALENCIANA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1.049 COMUNITAT VALENCIANA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;971 COMUNITAT VALENCIANA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;3.051 COMUNITAT VALENCIANA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;1.621 COMUNITAT VALENCIANA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;1.430 COMUNITAT VALENCIANA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;898 COMUNITAT VALENCIANA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;428 COMUNITAT VALENCIANA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;470 COMUNITAT VALENCIANA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;5.438 COMUNITAT VALENCIANA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;2.933 COMUNITAT VALENCIANA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;2.505 COMUNITAT VALENCIANA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;5.601 COMUNITAT VALENCIANA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;2.144 COMUNITAT VALENCIANA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;3.457 COMUNITAT VALENCIANA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;36.050 COMUNITAT VALENCIANA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;16.272 COMUNITAT VALENCIANA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;19.778 COMUNITAT VALENCIANA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;3.735 COMUNITAT VALENCIANA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1.374 COMUNITAT VALENCIANA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;2.361 COMUNITAT VALENCIANA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;3.232 COMUNITAT VALENCIANA;Group 1402 Renal failure 5836-5837, 584-586;Men;1.887 COMUNITAT VALENCIANA;Group 1402 Renal failure 5836-5837, 584-586;Women;1.345 COMUNITAT VALENCIANA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;4.746 COMUNITAT VALENCIANA;Group 1403 Urolithiasis 592, 594, 7880;Men;2.920 COMUNITAT VALENCIANA;Group 1403 Urolithiasis 592, 594, 7880;Women;1.826 COMUNITAT VALENCIANA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;10.223 COMUNITAT VALENCIANA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;5.037 COMUNITAT VALENCIANA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;5.186 COMUNITAT VALENCIANA;Group 1405 Prostatic hyperplasia 600;Both sexes;2.821 COMUNITAT VALENCIANA;Group 1405 Prostatic hyperplasia 600;Men;2.821 COMUNITAT VALENCIANA;Group 1405 Prostatic hyperplasia 600;Women;.. COMUNITAT VALENCIANA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;1.994 COMUNITAT VALENCIANA;Group 1406 Other diseases of the male genital organs 601-608;Men;1.994 COMUNITAT VALENCIANA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. COMUNITAT VALENCIANA;Group 1407 Disorders of breast 610-612;Both sexes;2.794 COMUNITAT VALENCIANA;Group 1407 Disorders of breast 610-612;Men;185 COMUNITAT VALENCIANA;Group 1407 Disorders of breast 610-612;Women;2.609 COMUNITAT VALENCIANA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;995 COMUNITAT VALENCIANA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. COMUNITAT VALENCIANA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;995 COMUNITAT VALENCIANA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;398 COMUNITAT VALENCIANA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. COMUNITAT VALENCIANA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;398 COMUNITAT VALENCIANA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;5.112 COMUNITAT VALENCIANA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;54 COMUNITAT VALENCIANA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;5.058 COMUNITAT VALENCIANA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;50.289 COMUNITAT VALENCIANA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. COMUNITAT VALENCIANA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;50.289 COMUNITAT VALENCIANA;Group 1501 Legally induced abortion 635;Both sexes;182 COMUNITAT VALENCIANA;Group 1501 Legally induced abortion 635;Men;.. COMUNITAT VALENCIANA;Group 1501 Legally induced abortion 635;Women;182 COMUNITAT VALENCIANA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;2.994 COMUNITAT VALENCIANA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. COMUNITAT VALENCIANA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;2.994 COMUNITAT VALENCIANA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;30.522 COMUNITAT VALENCIANA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. COMUNITAT VALENCIANA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;30.522 COMUNITAT VALENCIANA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;7.786 COMUNITAT VALENCIANA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. COMUNITAT VALENCIANA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;7.786 COMUNITAT VALENCIANA;Group 1505 Single spontaneous delivery 650;Both sexes;3.343 COMUNITAT VALENCIANA;Group 1505 Single spontaneous delivery 650;Men;.. COMUNITAT VALENCIANA;Group 1505 Single spontaneous delivery 650;Women;3.343 COMUNITAT VALENCIANA;Group 1506 Other deliveries 6695-6697;Both sexes;1.759 COMUNITAT VALENCIANA;Group 1506 Other deliveries 6695-6697;Men;.. COMUNITAT VALENCIANA;Group 1506 Other deliveries 6695-6697;Women;1.759 COMUNITAT VALENCIANA;Group 1507 Complications related to the puerperium 670-676;Both sexes;384 COMUNITAT VALENCIANA;Group 1507 Complications related to the puerperium 670-676;Men;.. COMUNITAT VALENCIANA;Group 1507 Complications related to the puerperium 670-676;Women;384 COMUNITAT VALENCIANA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;3.319 COMUNITAT VALENCIANA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. COMUNITAT VALENCIANA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;3.319 COMUNITAT VALENCIANA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;7.103 COMUNITAT VALENCIANA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;3.919 COMUNITAT VALENCIANA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;3.184 COMUNITAT VALENCIANA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;1.923 COMUNITAT VALENCIANA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;999 COMUNITAT VALENCIANA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;924 COMUNITAT VALENCIANA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;5.180 COMUNITAT VALENCIANA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;2.920 COMUNITAT VALENCIANA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;2.260 COMUNITAT VALENCIANA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;3.773 COMUNITAT VALENCIANA;Grupo 1700 Congenital abnormalities 740-759;Men;2.099 COMUNITAT VALENCIANA;Grupo 1700 Congenital abnormalities 740-759;Women;1.674 COMUNITAT VALENCIANA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;24.265 COMUNITAT VALENCIANA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;13.401 COMUNITAT VALENCIANA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;10.864 COMUNITAT VALENCIANA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;3.316 COMUNITAT VALENCIANA;Group 1801 Pain in throat and chest 7841, 7865;Men;1.896 COMUNITAT VALENCIANA;Group 1801 Pain in throat and chest 7841, 7865;Women;1.420 COMUNITAT VALENCIANA;Group 1802 Abdominal pain 7890;Both sexes;2.429 COMUNITAT VALENCIANA;Group 1802 Abdominal pain 7890;Men;908 COMUNITAT VALENCIANA;Group 1802 Abdominal pain 7890;Women;1.521 COMUNITAT VALENCIANA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;560 COMUNITAT VALENCIANA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;308 COMUNITAT VALENCIANA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;252 COMUNITAT VALENCIANA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;17.960 COMUNITAT VALENCIANA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;10.289 COMUNITAT VALENCIANA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;7.671 COMUNITAT VALENCIANA;Group 1900 Injuries and poisoning 800-999;Both sexes;45.036 COMUNITAT VALENCIANA;Group 1900 Injuries and poisoning 800-999;Men;22.807 COMUNITAT VALENCIANA;Group 1900 Injuries and poisoning 800-999;Women;22.229 COMUNITAT VALENCIANA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;2.492 COMUNITAT VALENCIANA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1.438 COMUNITAT VALENCIANA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;1.054 COMUNITAT VALENCIANA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1.060 COMUNITAT VALENCIANA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;733 COMUNITAT VALENCIANA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;327 COMUNITAT VALENCIANA;Group 1903 Radius and ulna fracture 813;Both sexes;3.306 COMUNITAT VALENCIANA;Group 1903 Radius and ulna fracture 813;Men;1.529 COMUNITAT VALENCIANA;Group 1903 Radius and ulna fracture 813;Women;1.777 COMUNITAT VALENCIANA;Group 1904 Femur fracture 820-821;Both sexes;7.237 COMUNITAT VALENCIANA;Group 1904 Femur fracture 820-821;Men;2.157 COMUNITAT VALENCIANA;Group 1904 Femur fracture 820-821;Women;5.080 COMUNITAT VALENCIANA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;3.527 COMUNITAT VALENCIANA;Group 1905 Leg fracture, including the ankle 823-824;Men;1.779 COMUNITAT VALENCIANA;Group 1905 Leg fracture, including the ankle 823-824;Women;1.748 COMUNITAT VALENCIANA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;13.723 COMUNITAT VALENCIANA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;8.163 COMUNITAT VALENCIANA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;5.560 COMUNITAT VALENCIANA;Group 1907 Burns 940-949;Both sexes;289 COMUNITAT VALENCIANA;Group 1907 Burns 940-949;Men;204 COMUNITAT VALENCIANA;Group 1907 Burns 940-949;Women;85 COMUNITAT VALENCIANA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;1.317 COMUNITAT VALENCIANA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;524 COMUNITAT VALENCIANA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;793 COMUNITAT VALENCIANA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;10.105 COMUNITAT VALENCIANA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;5.244 COMUNITAT VALENCIANA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;4.861 COMUNITAT VALENCIANA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;211 COMUNITAT VALENCIANA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;129 COMUNITAT VALENCIANA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;82 COMUNITAT VALENCIANA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1.769 COMUNITAT VALENCIANA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;907 COMUNITAT VALENCIANA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;862 COMUNITAT VALENCIANA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;9.683 COMUNITAT VALENCIANA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;4.719 COMUNITAT VALENCIANA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;4.964 COMUNITAT VALENCIANA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;592 COMUNITAT VALENCIANA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;330 COMUNITAT VALENCIANA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;262 COMUNITAT VALENCIANA;Group 2102 Contraceptive management V25;Both sexes;126 COMUNITAT VALENCIANA;Group 2102 Contraceptive management V25;Men;5 COMUNITAT VALENCIANA;Group 2102 Contraceptive management V25;Women;121 COMUNITAT VALENCIANA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. COMUNITAT VALENCIANA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. COMUNITAT VALENCIANA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. COMUNITAT VALENCIANA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;3.060 COMUNITAT VALENCIANA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1.841 COMUNITAT VALENCIANA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1.219 COMUNITAT VALENCIANA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;5.905 COMUNITAT VALENCIANA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;2.543 COMUNITAT VALENCIANA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;3.362 Alicante/Alacant;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;198.794 Alicante/Alacant;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;95.121 Alicante/Alacant;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;103.673 Alicante/Alacant;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;4.715 Alicante/Alacant;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2.615 Alicante/Alacant;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2.100 Alicante/Alacant;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;705 Alicante/Alacant;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;347 Alicante/Alacant;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;358 Alicante/Alacant;Group 0102 Imprecise intestinal infections 009;Both sexes;551 Alicante/Alacant;Group 0102 Imprecise intestinal infections 009;Men;267 Alicante/Alacant;Group 0102 Imprecise intestinal infections 009;Women;284 Alicante/Alacant;Group 0103 Tuberculosis 010-018, 137;Both sexes;130 Alicante/Alacant;Group 0103 Tuberculosis 010-018, 137;Men;89 Alicante/Alacant;Group 0103 Tuberculosis 010-018, 137;Women;41 Alicante/Alacant;Group 0104 Septicaemia 038;Both sexes;2.028 Alicante/Alacant;Group 0104 Septicaemia 038;Men;1.123 Alicante/Alacant;Group 0104 Septicaemia 038;Women;905 Alicante/Alacant;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;124 Alicante/Alacant;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;97 Alicante/Alacant;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;27 Alicante/Alacant;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.177 Alicante/Alacant;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;692 Alicante/Alacant;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;485 Alicante/Alacant;Group 0200 Neoplasms 140-239;Both sexes;17.529 Alicante/Alacant;Group 0200 Neoplasms 140-239;Men;9.167 Alicante/Alacant;Group 0200 Neoplasms 140-239;Women;8.362 Alicante/Alacant;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.955 Alicante/Alacant;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1.176 Alicante/Alacant;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;779 Alicante/Alacant;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.602 Alicante/Alacant;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1.227 Alicante/Alacant;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;375 Alicante/Alacant;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;211 Alicante/Alacant;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;135 Alicante/Alacant;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;76 Alicante/Alacant;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.326 Alicante/Alacant;Group 0204 Malignant neoplasm of breast 174-175;Men;11 Alicante/Alacant;Group 0204 Malignant neoplasm of breast 174-175;Women;1.315 Alicante/Alacant;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;298 Alicante/Alacant;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Alicante/Alacant;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;298 Alicante/Alacant;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;188 Alicante/Alacant;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Alicante/Alacant;Group 0206 Malignant neoplasm of ovary 1830;Women;188 Alicante/Alacant;Group 0207 Malignant neoplasm of prostate 185;Both sexes;421 Alicante/Alacant;Group 0207 Malignant neoplasm of prostate 185;Men;421 Alicante/Alacant;Group 0207 Malignant neoplasm of prostate 185;Women;.. Alicante/Alacant;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.708 Alicante/Alacant;Group 0208 Malignant neoplasm of bladder 188;Men;1.426 Alicante/Alacant;Group 0208 Malignant neoplasm of bladder 188;Women;282 Alicante/Alacant;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5.737 Alicante/Alacant;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3.400 Alicante/Alacant;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.337 Alicante/Alacant;Group 0210 Carcinoma in situ 230-234;Both sexes;203 Alicante/Alacant;Group 0210 Carcinoma in situ 230-234;Men;49 Alicante/Alacant;Group 0210 Carcinoma in situ 230-234;Women;154 Alicante/Alacant;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;334 Alicante/Alacant;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;200 Alicante/Alacant;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;134 Alicante/Alacant;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1.082 Alicante/Alacant;Grupo 0212 Leiomyoma of uterus 218;Men;.. Alicante/Alacant;Grupo 0212 Leiomyoma of uterus 218;Women;1.082 Alicante/Alacant;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.464 Alicante/Alacant;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.122 Alicante/Alacant;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.342 Alicante/Alacant;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.876 Alicante/Alacant;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;906 Alicante/Alacant;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;970 Alicante/Alacant;Group 0301 Anaemias 280-285;Both sexes;1.129 Alicante/Alacant;Group 0301 Anaemias 280-285;Men;555 Alicante/Alacant;Group 0301 Anaemias 280-285;Women;574 Alicante/Alacant;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;747 Alicante/Alacant;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;351 Alicante/Alacant;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;396 Alicante/Alacant;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3.713 Alicante/Alacant;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.651 Alicante/Alacant;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2.062 Alicante/Alacant;Group 0401 Diabetes mellitus 249-250;Both sexes;1.310 Alicante/Alacant;Group 0401 Diabetes mellitus 249-250;Men;814 Alicante/Alacant;Group 0401 Diabetes mellitus 249-250;Women;496 Alicante/Alacant;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2.403 Alicante/Alacant;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;837 Alicante/Alacant;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.566 Alicante/Alacant;Group 0500 Mental disorders 290-319;Both sexes;4.106 Alicante/Alacant;Group 0500 Mental disorders 290-319;Men;2.137 Alicante/Alacant;Group 0500 Mental disorders 290-319;Women;1.969 Alicante/Alacant;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;165 Alicante/Alacant;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;86 Alicante/Alacant;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;79 Alicante/Alacant;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;300 Alicante/Alacant;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;209 Alicante/Alacant;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;91 Alicante/Alacant;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;216 Alicante/Alacant;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;143 Alicante/Alacant;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;72 Alicante/Alacant;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.174 Alicante/Alacant;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;709 Alicante/Alacant;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;465 Alicante/Alacant;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;839 Alicante/Alacant;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;348 Alicante/Alacant;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;490 Alicante/Alacant;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.412 Alicante/Alacant;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;642 Alicante/Alacant;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;770 Alicante/Alacant;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5.299 Alicante/Alacant;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.618 Alicante/Alacant;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.681 Alicante/Alacant;Group 0601 Alzheimer's disease 3310;Both sexes;115 Alicante/Alacant;Group 0601 Alzheimer's disease 3310;Men;36 Alicante/Alacant;Group 0601 Alzheimer's disease 3310;Women;79 Alicante/Alacant;Group 0602 Multiple sclerosis 340;Both sexes;108 Alicante/Alacant;Group 0602 Multiple sclerosis 340;Men;24 Alicante/Alacant;Group 0602 Multiple sclerosis 340;Women;84 Alicante/Alacant;Group 0603 Epilepsy 345;Both sexes;1.171 Alicante/Alacant;Group 0603 Epilepsy 345;Men;626 Alicante/Alacant;Group 0603 Epilepsy 345;Women;545 Alicante/Alacant;Group 0604 Transient cerebral ischemia 435;Both sexes;889 Alicante/Alacant;Group 0604 Transient cerebral ischemia 435;Men;452 Alicante/Alacant;Group 0604 Transient cerebral ischemia 435;Women;437 Alicante/Alacant;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.016 Alicante/Alacant;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.480 Alicante/Alacant;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.536 Alicante/Alacant;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;929 Alicante/Alacant;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;497 Alicante/Alacant;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;432 Alicante/Alacant;Grupo 0701 Cataract 366;Both sexes;134 Alicante/Alacant;Grupo 0701 Cataract 366;Men;72 Alicante/Alacant;Grupo 0701 Cataract 366;Women;62 Alicante/Alacant;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;795 Alicante/Alacant;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;425 Alicante/Alacant;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;370 Alicante/Alacant;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;791 Alicante/Alacant;Group 0800 Diseases of the ear and the mastoid 380-389;Men;371 Alicante/Alacant;Group 0800 Diseases of the ear and the mastoid 380-389;Women;420 Alicante/Alacant;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;28.335 Alicante/Alacant;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;16.357 Alicante/Alacant;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;11.978 Alicante/Alacant;Group 0901 Hypertensive disease 401-405;Both sexes;1.178 Alicante/Alacant;Group 0901 Hypertensive disease 401-405;Men;626 Alicante/Alacant;Group 0901 Hypertensive disease 401-405;Women;552 Alicante/Alacant;Group 0902 Angina pectoris 4111, 413;Both sexes;1.510 Alicante/Alacant;Group 0902 Angina pectoris 4111, 413;Men;937 Alicante/Alacant;Group 0902 Angina pectoris 4111, 413;Women;573 Alicante/Alacant;Group 0903 Acute myocardial infarction 410;Both sexes;2.592 Alicante/Alacant;Group 0903 Acute myocardial infarction 410;Men;1.877 Alicante/Alacant;Group 0903 Acute myocardial infarction 410;Women;715 Alicante/Alacant;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.856 Alicante/Alacant;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.422 Alicante/Alacant;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;434 Alicante/Alacant;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;839 Alicante/Alacant;Group 0905 Diseases of the lungs circulation 415-417;Men;378 Alicante/Alacant;Group 0905 Diseases of the lungs circulation 415-417;Women;461 Alicante/Alacant;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4.552 Alicante/Alacant;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2.510 Alicante/Alacant;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;2.042 Alicante/Alacant;Grupo 0907 Heart failure 428;Both sexes;5.556 Alicante/Alacant;Grupo 0907 Heart failure 428;Men;2.691 Alicante/Alacant;Grupo 0907 Heart failure 428;Women;2.865 Alicante/Alacant;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;4.945 Alicante/Alacant;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2.766 Alicante/Alacant;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2.179 Alicante/Alacant;Grupo 0909 Atherosclerosis 440;Both sexes;676 Alicante/Alacant;Grupo 0909 Atherosclerosis 440;Men;501 Alicante/Alacant;Grupo 0909 Atherosclerosis 440;Women;175 Alicante/Alacant;Group 0910 Varicose veins of lower extremities 454;Both sexes;446 Alicante/Alacant;Group 0910 Varicose veins of lower extremities 454;Men;174 Alicante/Alacant;Group 0910 Varicose veins of lower extremities 454;Women;272 Alicante/Alacant;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;4.185 Alicante/Alacant;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;2.475 Alicante/Alacant;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.710 Alicante/Alacant;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;22.769 Alicante/Alacant;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;12.847 Alicante/Alacant;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;9.922 Alicante/Alacant;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.335 Alicante/Alacant;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;664 Alicante/Alacant;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;671 Alicante/Alacant;Group 1002 Pneumonia 480-486;Both sexes;5.268 Alicante/Alacant;Group 1002 Pneumonia 480-486;Men;3.058 Alicante/Alacant;Group 1002 Pneumonia 480-486;Women;2.210 Alicante/Alacant;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.543 Alicante/Alacant;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.187 Alicante/Alacant;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.356 Alicante/Alacant;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1.089 Alicante/Alacant;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;588 Alicante/Alacant;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;501 Alicante/Alacant;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.197 Alicante/Alacant;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;741 Alicante/Alacant;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;456 Alicante/Alacant;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;3.888 Alicante/Alacant;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.876 Alicante/Alacant;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1.012 Alicante/Alacant;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;710 Alicante/Alacant;Group 1007 Asthma 4930-4931,4938-4939;Men;189 Alicante/Alacant;Group 1007 Asthma 4930-4931,4938-4939;Women;521 Alicante/Alacant;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;6.739 Alicante/Alacant;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3.544 Alicante/Alacant;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;3.195 Alicante/Alacant;Group 1100 Diseases of the digestive system 520-579;Both sexes;25.802 Alicante/Alacant;Group 1100 Diseases of the digestive system 520-579;Men;14.260 Alicante/Alacant;Group 1100 Diseases of the digestive system 520-579;Women;11.542 Alicante/Alacant;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;339 Alicante/Alacant;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;138 Alicante/Alacant;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;201 Alicante/Alacant;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;283 Alicante/Alacant;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;151 Alicante/Alacant;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;132 Alicante/Alacant;Group 1103 Diseases of the esophagus 530;Both sexes;551 Alicante/Alacant;Group 1103 Diseases of the esophagus 530;Men;338 Alicante/Alacant;Group 1103 Diseases of the esophagus 530;Women;213 Alicante/Alacant;Group 1104 Peptic ulcer 531-534;Both sexes;682 Alicante/Alacant;Group 1104 Peptic ulcer 531-534;Men;454 Alicante/Alacant;Group 1104 Peptic ulcer 531-534;Women;228 Alicante/Alacant;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;926 Alicante/Alacant;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;415 Alicante/Alacant;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;511 Alicante/Alacant;Group 1106 Appendicitis 540-543;Both sexes;2.168 Alicante/Alacant;Group 1106 Appendicitis 540-543;Men;1.171 Alicante/Alacant;Group 1106 Appendicitis 540-543;Women;997 Alicante/Alacant;Group 1107 Inguinal hernia 550;Both sexes;2.355 Alicante/Alacant;Group 1107 Inguinal hernia 550;Men;2.109 Alicante/Alacant;Group 1107 Inguinal hernia 550;Women;246 Alicante/Alacant;Group 1108 Other abdominal hernia 551-553;Both sexes;1.987 Alicante/Alacant;Group 1108 Other abdominal hernia 551-553;Men;974 Alicante/Alacant;Group 1108 Other abdominal hernia 551-553;Women;1.013 Alicante/Alacant;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;634 Alicante/Alacant;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;313 Alicante/Alacant;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;321 Alicante/Alacant;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.852 Alicante/Alacant;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;876 Alicante/Alacant;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;976 Alicante/Alacant;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1.044 Alicante/Alacant;Group 1111 Intestinal obstruction without hernia 560;Men;518 Alicante/Alacant;Group 1111 Intestinal obstruction without hernia 560;Women;526 Alicante/Alacant;Group 1112 Intestinal diverticulosis 562;Both sexes;1.329 Alicante/Alacant;Group 1112 Intestinal diverticulosis 562;Men;662 Alicante/Alacant;Group 1112 Intestinal diverticulosis 562;Women;667 Alicante/Alacant;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.374 Alicante/Alacant;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;873 Alicante/Alacant;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;501 Alicante/Alacant;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;927 Alicante/Alacant;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;466 Alicante/Alacant;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;461 Alicante/Alacant;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;533 Alicante/Alacant;Group 1115 Alcoholic hepatitis 5710-5713;Men;433 Alicante/Alacant;Group 1115 Alcoholic hepatitis 5710-5713;Women;100 Alicante/Alacant;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;895 Alicante/Alacant;Group 1116 Other diseases of the liver 570,5714-573;Men;529 Alicante/Alacant;Group 1116 Other diseases of the liver 570,5714-573;Women;366 Alicante/Alacant;Group 1117 Cholelithiasis 574;Both sexes;3.981 Alicante/Alacant;Group 1117 Cholelithiasis 574;Men;1.645 Alicante/Alacant;Group 1117 Cholelithiasis 574;Women;2.336 Alicante/Alacant;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.252 Alicante/Alacant;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;715 Alicante/Alacant;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;537 Alicante/Alacant;Group 1119 Pancreatic diseases 577;Both sexes;1.470 Alicante/Alacant;Group 1119 Pancreatic diseases 577;Men;807 Alicante/Alacant;Group 1119 Pancreatic diseases 577;Women;663 Alicante/Alacant;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1.220 Alicante/Alacant;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;673 Alicante/Alacant;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;547 Alicante/Alacant;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2.086 Alicante/Alacant;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1.175 Alicante/Alacant;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;911 Alicante/Alacant;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.397 Alicante/Alacant;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;823 Alicante/Alacant;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;574 Alicante/Alacant;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;100 Alicante/Alacant;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;53 Alicante/Alacant;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;47 Alicante/Alacant;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;589 Alicante/Alacant;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;299 Alicante/Alacant;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;290 Alicante/Alacant;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;12.549 Alicante/Alacant;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;5.968 Alicante/Alacant;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;6.581 Alicante/Alacant;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Alicante/Alacant;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Alicante/Alacant;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Alicante/Alacant;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Alicante/Alacant;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Alicante/Alacant;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Alicante/Alacant;Group 1303 Internal derangement of knee 717;Both sexes;1.618 Alicante/Alacant;Group 1303 Internal derangement of knee 717;Men;1.105 Alicante/Alacant;Group 1303 Internal derangement of knee 717;Women;513 Alicante/Alacant;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;4.454 Alicante/Alacant;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.858 Alicante/Alacant;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.596 Alicante/Alacant;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;261 Alicante/Alacant;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;98 Alicante/Alacant;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;163 Alicante/Alacant;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;937 Alicante/Alacant;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;489 Alicante/Alacant;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;448 Alicante/Alacant;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.018 Alicante/Alacant;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;520 Alicante/Alacant;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;498 Alicante/Alacant;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;347 Alicante/Alacant;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;148 Alicante/Alacant;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;199 Alicante/Alacant;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.917 Alicante/Alacant;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.026 Alicante/Alacant;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;891 Alicante/Alacant;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.997 Alicante/Alacant;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;724 Alicante/Alacant;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.273 Alicante/Alacant;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;13.898 Alicante/Alacant;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;6.039 Alicante/Alacant;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;7.859 Alicante/Alacant;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.568 Alicante/Alacant;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;537 Alicante/Alacant;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;1.031 Alicante/Alacant;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.257 Alicante/Alacant;Group 1402 Renal failure 5836-5837, 584-586;Men;725 Alicante/Alacant;Group 1402 Renal failure 5836-5837, 584-586;Women;532 Alicante/Alacant;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.883 Alicante/Alacant;Group 1403 Urolithiasis 592, 594, 7880;Men;1.159 Alicante/Alacant;Group 1403 Urolithiasis 592, 594, 7880;Women;724 Alicante/Alacant;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;3.653 Alicante/Alacant;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.774 Alicante/Alacant;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.879 Alicante/Alacant;Group 1405 Prostatic hyperplasia 600;Both sexes;1.005 Alicante/Alacant;Group 1405 Prostatic hyperplasia 600;Men;1.005 Alicante/Alacant;Group 1405 Prostatic hyperplasia 600;Women;.. Alicante/Alacant;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;744 Alicante/Alacant;Group 1406 Other diseases of the male genital organs 601-608;Men;744 Alicante/Alacant;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Alicante/Alacant;Group 1407 Disorders of breast 610-612;Both sexes;1.498 Alicante/Alacant;Group 1407 Disorders of breast 610-612;Men;75 Alicante/Alacant;Group 1407 Disorders of breast 610-612;Women;1.423 Alicante/Alacant;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;397 Alicante/Alacant;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Alicante/Alacant;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;397 Alicante/Alacant;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;130 Alicante/Alacant;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Alicante/Alacant;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;130 Alicante/Alacant;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.763 Alicante/Alacant;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;20 Alicante/Alacant;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.743 Alicante/Alacant;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;19.073 Alicante/Alacant;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Alicante/Alacant;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;19.073 Alicante/Alacant;Group 1501 Legally induced abortion 635;Both sexes;39 Alicante/Alacant;Group 1501 Legally induced abortion 635;Men;.. Alicante/Alacant;Group 1501 Legally induced abortion 635;Women;39 Alicante/Alacant;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.867 Alicante/Alacant;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Alicante/Alacant;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.867 Alicante/Alacant;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;11.180 Alicante/Alacant;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Alicante/Alacant;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;11.180 Alicante/Alacant;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.835 Alicante/Alacant;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Alicante/Alacant;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.835 Alicante/Alacant;Group 1505 Single spontaneous delivery 650;Both sexes;1.124 Alicante/Alacant;Group 1505 Single spontaneous delivery 650;Men;.. Alicante/Alacant;Group 1505 Single spontaneous delivery 650;Women;1.124 Alicante/Alacant;Group 1506 Other deliveries 6695-6697;Both sexes;792 Alicante/Alacant;Group 1506 Other deliveries 6695-6697;Men;.. Alicante/Alacant;Group 1506 Other deliveries 6695-6697;Women;792 Alicante/Alacant;Group 1507 Complications related to the puerperium 670-676;Both sexes;171 Alicante/Alacant;Group 1507 Complications related to the puerperium 670-676;Men;.. Alicante/Alacant;Group 1507 Complications related to the puerperium 670-676;Women;171 Alicante/Alacant;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.065 Alicante/Alacant;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Alicante/Alacant;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.065 Alicante/Alacant;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.553 Alicante/Alacant;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.433 Alicante/Alacant;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.120 Alicante/Alacant;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;669 Alicante/Alacant;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;353 Alicante/Alacant;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;316 Alicante/Alacant;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.884 Alicante/Alacant;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.080 Alicante/Alacant;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;804 Alicante/Alacant;Grupo 1700 Congenital abnormalities 740-759;Both sexes;963 Alicante/Alacant;Grupo 1700 Congenital abnormalities 740-759;Men;584 Alicante/Alacant;Grupo 1700 Congenital abnormalities 740-759;Women;379 Alicante/Alacant;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;11.295 Alicante/Alacant;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;6.216 Alicante/Alacant;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;5.079 Alicante/Alacant;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.709 Alicante/Alacant;Group 1801 Pain in throat and chest 7841, 7865;Men;981 Alicante/Alacant;Group 1801 Pain in throat and chest 7841, 7865;Women;728 Alicante/Alacant;Group 1802 Abdominal pain 7890;Both sexes;1.242 Alicante/Alacant;Group 1802 Abdominal pain 7890;Men;470 Alicante/Alacant;Group 1802 Abdominal pain 7890;Women;772 Alicante/Alacant;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;379 Alicante/Alacant;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;196 Alicante/Alacant;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;183 Alicante/Alacant;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;7.965 Alicante/Alacant;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4.569 Alicante/Alacant;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3.396 Alicante/Alacant;Group 1900 Injuries and poisoning 800-999;Both sexes;17.213 Alicante/Alacant;Group 1900 Injuries and poisoning 800-999;Men;8.623 Alicante/Alacant;Group 1900 Injuries and poisoning 800-999;Women;8.590 Alicante/Alacant;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.025 Alicante/Alacant;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;624 Alicante/Alacant;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;401 Alicante/Alacant;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;429 Alicante/Alacant;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;292 Alicante/Alacant;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;137 Alicante/Alacant;Group 1903 Radius and ulna fracture 813;Both sexes;1.263 Alicante/Alacant;Group 1903 Radius and ulna fracture 813;Men;528 Alicante/Alacant;Group 1903 Radius and ulna fracture 813;Women;735 Alicante/Alacant;Group 1904 Femur fracture 820-821;Both sexes;2.668 Alicante/Alacant;Group 1904 Femur fracture 820-821;Men;809 Alicante/Alacant;Group 1904 Femur fracture 820-821;Women;1.859 Alicante/Alacant;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.388 Alicante/Alacant;Group 1905 Leg fracture, including the ankle 823-824;Men;644 Alicante/Alacant;Group 1905 Leg fracture, including the ankle 823-824;Women;744 Alicante/Alacant;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;5.197 Alicante/Alacant;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;3.062 Alicante/Alacant;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.135 Alicante/Alacant;Group 1907 Burns 940-949;Both sexes;122 Alicante/Alacant;Group 1907 Burns 940-949;Men;71 Alicante/Alacant;Group 1907 Burns 940-949;Women;51 Alicante/Alacant;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;563 Alicante/Alacant;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;230 Alicante/Alacant;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;333 Alicante/Alacant;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.819 Alicante/Alacant;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.994 Alicante/Alacant;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.825 Alicante/Alacant;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;79 Alicante/Alacant;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;43 Alicante/Alacant;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;36 Alicante/Alacant;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;660 Alicante/Alacant;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;326 Alicante/Alacant;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;334 Alicante/Alacant;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;3.300 Alicante/Alacant;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.657 Alicante/Alacant;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.643 Alicante/Alacant;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;315 Alicante/Alacant;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;167 Alicante/Alacant;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;148 Alicante/Alacant;Group 2102 Contraceptive management V25;Both sexes;29 Alicante/Alacant;Group 2102 Contraceptive management V25;Men;.. Alicante/Alacant;Group 2102 Contraceptive management V25;Women;29 Alicante/Alacant;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Alicante/Alacant;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Alicante/Alacant;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Alicante/Alacant;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;986 Alicante/Alacant;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;610 Alicante/Alacant;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;376 Alicante/Alacant;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.970 Alicante/Alacant;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;880 Alicante/Alacant;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.090 Castell¾n/Castell¾;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;49.557 Castell¾n/Castell¾;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;24.124 Castell¾n/Castell¾;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;25.433 Castell¾n/Castell¾;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.204 Castell¾n/Castell¾;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;661 Castell¾n/Castell¾;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;543 Castell¾n/Castell¾;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;171 Castell¾n/Castell¾;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;93 Castell¾n/Castell¾;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;78 Castell¾n/Castell¾;Group 0102 Imprecise intestinal infections 009;Both sexes;162 Castell¾n/Castell¾;Group 0102 Imprecise intestinal infections 009;Men;85 Castell¾n/Castell¾;Group 0102 Imprecise intestinal infections 009;Women;77 Castell¾n/Castell¾;Group 0103 Tuberculosis 010-018, 137;Both sexes;51 Castell¾n/Castell¾;Group 0103 Tuberculosis 010-018, 137;Men;34 Castell¾n/Castell¾;Group 0103 Tuberculosis 010-018, 137;Women;17 Castell¾n/Castell¾;Group 0104 Septicaemia 038;Both sexes;404 Castell¾n/Castell¾;Group 0104 Septicaemia 038;Men;224 Castell¾n/Castell¾;Group 0104 Septicaemia 038;Women;180 Castell¾n/Castell¾;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;9 Castell¾n/Castell¾;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;5 Castell¾n/Castell¾;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;4 Castell¾n/Castell¾;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;407 Castell¾n/Castell¾;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;220 Castell¾n/Castell¾;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;187 Castell¾n/Castell¾;Group 0200 Neoplasms 140-239;Both sexes;5.031 Castell¾n/Castell¾;Group 0200 Neoplasms 140-239;Men;2.701 Castell¾n/Castell¾;Group 0200 Neoplasms 140-239;Women;2.330 Castell¾n/Castell¾;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;614 Castell¾n/Castell¾;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;383 Castell¾n/Castell¾;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;231 Castell¾n/Castell¾;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;426 Castell¾n/Castell¾;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;342 Castell¾n/Castell¾;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;84 Castell¾n/Castell¾;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;58 Castell¾n/Castell¾;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;32 Castell¾n/Castell¾;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;26 Castell¾n/Castell¾;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;457 Castell¾n/Castell¾;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Castell¾n/Castell¾;Group 0204 Malignant neoplasm of breast 174-175;Women;456 Castell¾n/Castell¾;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;128 Castell¾n/Castell¾;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Castell¾n/Castell¾;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;128 Castell¾n/Castell¾;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;77 Castell¾n/Castell¾;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Castell¾n/Castell¾;Group 0206 Malignant neoplasm of ovary 1830;Women;77 Castell¾n/Castell¾;Group 0207 Malignant neoplasm of prostate 185;Both sexes;204 Castell¾n/Castell¾;Group 0207 Malignant neoplasm of prostate 185;Men;204 Castell¾n/Castell¾;Group 0207 Malignant neoplasm of prostate 185;Women;.. Castell¾n/Castell¾;Group 0208 Malignant neoplasm of bladder 188;Both sexes;538 Castell¾n/Castell¾;Group 0208 Malignant neoplasm of bladder 188;Men;453 Castell¾n/Castell¾;Group 0208 Malignant neoplasm of bladder 188;Women;85 Castell¾n/Castell¾;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.598 Castell¾n/Castell¾;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;995 Castell¾n/Castell¾;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;603 Castell¾n/Castell¾;Group 0210 Carcinoma in situ 230-234;Both sexes;69 Castell¾n/Castell¾;Group 0210 Carcinoma in situ 230-234;Men;28 Castell¾n/Castell¾;Group 0210 Carcinoma in situ 230-234;Women;41 Castell¾n/Castell¾;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;89 Castell¾n/Castell¾;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;60 Castell¾n/Castell¾;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;29 Castell¾n/Castell¾;Grupo 0212 Leiomyoma of uterus 218;Both sexes;204 Castell¾n/Castell¾;Grupo 0212 Leiomyoma of uterus 218;Men;.. Castell¾n/Castell¾;Grupo 0212 Leiomyoma of uterus 218;Women;204 Castell¾n/Castell¾;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;569 Castell¾n/Castell¾;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;203 Castell¾n/Castell¾;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;366 Castell¾n/Castell¾;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;327 Castell¾n/Castell¾;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;172 Castell¾n/Castell¾;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;155 Castell¾n/Castell¾;Group 0301 Anaemias 280-285;Both sexes;201 Castell¾n/Castell¾;Group 0301 Anaemias 280-285;Men;104 Castell¾n/Castell¾;Group 0301 Anaemias 280-285;Women;97 Castell¾n/Castell¾;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;126 Castell¾n/Castell¾;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;68 Castell¾n/Castell¾;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;58 Castell¾n/Castell¾;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.000 Castell¾n/Castell¾;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;443 Castell¾n/Castell¾;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;557 Castell¾n/Castell¾;Group 0401 Diabetes mellitus 249-250;Both sexes;401 Castell¾n/Castell¾;Group 0401 Diabetes mellitus 249-250;Men;236 Castell¾n/Castell¾;Group 0401 Diabetes mellitus 249-250;Women;165 Castell¾n/Castell¾;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;599 Castell¾n/Castell¾;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;207 Castell¾n/Castell¾;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;392 Castell¾n/Castell¾;Group 0500 Mental disorders 290-319;Both sexes;781 Castell¾n/Castell¾;Group 0500 Mental disorders 290-319;Men;441 Castell¾n/Castell¾;Group 0500 Mental disorders 290-319;Women;340 Castell¾n/Castell¾;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;25 Castell¾n/Castell¾;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;12 Castell¾n/Castell¾;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;13 Castell¾n/Castell¾;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;72 Castell¾n/Castell¾;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;52 Castell¾n/Castell¾;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;20 Castell¾n/Castell¾;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;80 Castell¾n/Castell¾;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;57 Castell¾n/Castell¾;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;23 Castell¾n/Castell¾;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;224 Castell¾n/Castell¾;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;140 Castell¾n/Castell¾;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;84 Castell¾n/Castell¾;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;190 Castell¾n/Castell¾;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;90 Castell¾n/Castell¾;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;100 Castell¾n/Castell¾;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;190 Castell¾n/Castell¾;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;90 Castell¾n/Castell¾;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;100 Castell¾n/Castell¾;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;879 Castell¾n/Castell¾;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;492 Castell¾n/Castell¾;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;387 Castell¾n/Castell¾;Group 0601 Alzheimer's disease 3310;Both sexes;11 Castell¾n/Castell¾;Group 0601 Alzheimer's disease 3310;Men;4 Castell¾n/Castell¾;Group 0601 Alzheimer's disease 3310;Women;7 Castell¾n/Castell¾;Group 0602 Multiple sclerosis 340;Both sexes;29 Castell¾n/Castell¾;Group 0602 Multiple sclerosis 340;Men;6 Castell¾n/Castell¾;Group 0602 Multiple sclerosis 340;Women;23 Castell¾n/Castell¾;Group 0603 Epilepsy 345;Both sexes;220 Castell¾n/Castell¾;Group 0603 Epilepsy 345;Men;128 Castell¾n/Castell¾;Group 0603 Epilepsy 345;Women;92 Castell¾n/Castell¾;Group 0604 Transient cerebral ischemia 435;Both sexes;159 Castell¾n/Castell¾;Group 0604 Transient cerebral ischemia 435;Men;97 Castell¾n/Castell¾;Group 0604 Transient cerebral ischemia 435;Women;62 Castell¾n/Castell¾;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;460 Castell¾n/Castell¾;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;257 Castell¾n/Castell¾;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;203 Castell¾n/Castell¾;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;219 Castell¾n/Castell¾;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;106 Castell¾n/Castell¾;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;113 Castell¾n/Castell¾;Grupo 0701 Cataract 366;Both sexes;46 Castell¾n/Castell¾;Grupo 0701 Cataract 366;Men;23 Castell¾n/Castell¾;Grupo 0701 Cataract 366;Women;23 Castell¾n/Castell¾;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;173 Castell¾n/Castell¾;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;83 Castell¾n/Castell¾;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;90 Castell¾n/Castell¾;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;180 Castell¾n/Castell¾;Group 0800 Diseases of the ear and the mastoid 380-389;Men;94 Castell¾n/Castell¾;Group 0800 Diseases of the ear and the mastoid 380-389;Women;86 Castell¾n/Castell¾;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6.567 Castell¾n/Castell¾;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3.780 Castell¾n/Castell¾;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.787 Castell¾n/Castell¾;Group 0901 Hypertensive disease 401-405;Both sexes;229 Castell¾n/Castell¾;Group 0901 Hypertensive disease 401-405;Men;122 Castell¾n/Castell¾;Group 0901 Hypertensive disease 401-405;Women;107 Castell¾n/Castell¾;Group 0902 Angina pectoris 4111, 413;Both sexes;409 Castell¾n/Castell¾;Group 0902 Angina pectoris 4111, 413;Men;269 Castell¾n/Castell¾;Group 0902 Angina pectoris 4111, 413;Women;140 Castell¾n/Castell¾;Group 0903 Acute myocardial infarction 410;Both sexes;562 Castell¾n/Castell¾;Group 0903 Acute myocardial infarction 410;Men;405 Castell¾n/Castell¾;Group 0903 Acute myocardial infarction 410;Women;157 Castell¾n/Castell¾;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;295 Castell¾n/Castell¾;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;216 Castell¾n/Castell¾;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;79 Castell¾n/Castell¾;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;146 Castell¾n/Castell¾;Group 0905 Diseases of the lungs circulation 415-417;Men;77 Castell¾n/Castell¾;Group 0905 Diseases of the lungs circulation 415-417;Women;69 Castell¾n/Castell¾;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;862 Castell¾n/Castell¾;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;472 Castell¾n/Castell¾;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;390 Castell¾n/Castell¾;Grupo 0907 Heart failure 428;Both sexes;1.539 Castell¾n/Castell¾;Grupo 0907 Heart failure 428;Men;736 Castell¾n/Castell¾;Grupo 0907 Heart failure 428;Women;803 Castell¾n/Castell¾;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.270 Castell¾n/Castell¾;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;706 Castell¾n/Castell¾;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;564 Castell¾n/Castell¾;Grupo 0909 Atherosclerosis 440;Both sexes;128 Castell¾n/Castell¾;Grupo 0909 Atherosclerosis 440;Men;103 Castell¾n/Castell¾;Grupo 0909 Atherosclerosis 440;Women;25 Castell¾n/Castell¾;Group 0910 Varicose veins of lower extremities 454;Both sexes;148 Castell¾n/Castell¾;Group 0910 Varicose veins of lower extremities 454;Men;52 Castell¾n/Castell¾;Group 0910 Varicose veins of lower extremities 454;Women;96 Castell¾n/Castell¾;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;979 Castell¾n/Castell¾;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;622 Castell¾n/Castell¾;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;357 Castell¾n/Castell¾;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6.191 Castell¾n/Castell¾;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.658 Castell¾n/Castell¾;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.533 Castell¾n/Castell¾;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;314 Castell¾n/Castell¾;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;173 Castell¾n/Castell¾;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;141 Castell¾n/Castell¾;Group 1002 Pneumonia 480-486;Both sexes;1.571 Castell¾n/Castell¾;Group 1002 Pneumonia 480-486;Men;945 Castell¾n/Castell¾;Group 1002 Pneumonia 480-486;Women;626 Castell¾n/Castell¾;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;841 Castell¾n/Castell¾;Group 1003 Acute bronchitis and bronchiolitis 466;Men;415 Castell¾n/Castell¾;Group 1003 Acute bronchitis and bronchiolitis 466;Women;426 Castell¾n/Castell¾;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;468 Castell¾n/Castell¾;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;249 Castell¾n/Castell¾;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;219 Castell¾n/Castell¾;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;196 Castell¾n/Castell¾;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;122 Castell¾n/Castell¾;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;74 Castell¾n/Castell¾;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.243 Castell¾n/Castell¾;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;984 Castell¾n/Castell¾;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;259 Castell¾n/Castell¾;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;201 Castell¾n/Castell¾;Group 1007 Asthma 4930-4931,4938-4939;Men;56 Castell¾n/Castell¾;Group 1007 Asthma 4930-4931,4938-4939;Women;145 Castell¾n/Castell¾;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.357 Castell¾n/Castell¾;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;714 Castell¾n/Castell¾;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;643 Castell¾n/Castell¾;Group 1100 Diseases of the digestive system 520-579;Both sexes;6.383 Castell¾n/Castell¾;Group 1100 Diseases of the digestive system 520-579;Men;3.575 Castell¾n/Castell¾;Group 1100 Diseases of the digestive system 520-579;Women;2.808 Castell¾n/Castell¾;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;38 Castell¾n/Castell¾;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;19 Castell¾n/Castell¾;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;19 Castell¾n/Castell¾;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;63 Castell¾n/Castell¾;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;40 Castell¾n/Castell¾;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;23 Castell¾n/Castell¾;Group 1103 Diseases of the esophagus 530;Both sexes;119 Castell¾n/Castell¾;Group 1103 Diseases of the esophagus 530;Men;72 Castell¾n/Castell¾;Group 1103 Diseases of the esophagus 530;Women;47 Castell¾n/Castell¾;Group 1104 Peptic ulcer 531-534;Both sexes;149 Castell¾n/Castell¾;Group 1104 Peptic ulcer 531-534;Men;104 Castell¾n/Castell¾;Group 1104 Peptic ulcer 531-534;Women;45 Castell¾n/Castell¾;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;166 Castell¾n/Castell¾;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;99 Castell¾n/Castell¾;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;67 Castell¾n/Castell¾;Group 1106 Appendicitis 540-543;Both sexes;571 Castell¾n/Castell¾;Group 1106 Appendicitis 540-543;Men;327 Castell¾n/Castell¾;Group 1106 Appendicitis 540-543;Women;244 Castell¾n/Castell¾;Group 1107 Inguinal hernia 550;Both sexes;602 Castell¾n/Castell¾;Group 1107 Inguinal hernia 550;Men;539 Castell¾n/Castell¾;Group 1107 Inguinal hernia 550;Women;63 Castell¾n/Castell¾;Group 1108 Other abdominal hernia 551-553;Both sexes;613 Castell¾n/Castell¾;Group 1108 Other abdominal hernia 551-553;Men;296 Castell¾n/Castell¾;Group 1108 Other abdominal hernia 551-553;Women;317 Castell¾n/Castell¾;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;113 Castell¾n/Castell¾;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;58 Castell¾n/Castell¾;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;55 Castell¾n/Castell¾;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;334 Castell¾n/Castell¾;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;159 Castell¾n/Castell¾;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;175 Castell¾n/Castell¾;Group 1111 Intestinal obstruction without hernia 560;Both sexes;283 Castell¾n/Castell¾;Group 1111 Intestinal obstruction without hernia 560;Men;166 Castell¾n/Castell¾;Group 1111 Intestinal obstruction without hernia 560;Women;117 Castell¾n/Castell¾;Group 1112 Intestinal diverticulosis 562;Both sexes;223 Castell¾n/Castell¾;Group 1112 Intestinal diverticulosis 562;Men;127 Castell¾n/Castell¾;Group 1112 Intestinal diverticulosis 562;Women;96 Castell¾n/Castell¾;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;407 Castell¾n/Castell¾;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;256 Castell¾n/Castell¾;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;151 Castell¾n/Castell¾;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;178 Castell¾n/Castell¾;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;95 Castell¾n/Castell¾;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;83 Castell¾n/Castell¾;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;111 Castell¾n/Castell¾;Group 1115 Alcoholic hepatitis 5710-5713;Men;88 Castell¾n/Castell¾;Group 1115 Alcoholic hepatitis 5710-5713;Women;23 Castell¾n/Castell¾;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;212 Castell¾n/Castell¾;Group 1116 Other diseases of the liver 570,5714-573;Men;115 Castell¾n/Castell¾;Group 1116 Other diseases of the liver 570,5714-573;Women;97 Castell¾n/Castell¾;Group 1117 Cholelithiasis 574;Both sexes;1.260 Castell¾n/Castell¾;Group 1117 Cholelithiasis 574;Men;524 Castell¾n/Castell¾;Group 1117 Cholelithiasis 574;Women;736 Castell¾n/Castell¾;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;314 Castell¾n/Castell¾;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;151 Castell¾n/Castell¾;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;163 Castell¾n/Castell¾;Group 1119 Pancreatic diseases 577;Both sexes;323 Castell¾n/Castell¾;Group 1119 Pancreatic diseases 577;Men;177 Castell¾n/Castell¾;Group 1119 Pancreatic diseases 577;Women;146 Castell¾n/Castell¾;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;304 Castell¾n/Castell¾;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;163 Castell¾n/Castell¾;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;141 Castell¾n/Castell¾;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;391 Castell¾n/Castell¾;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;209 Castell¾n/Castell¾;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;182 Castell¾n/Castell¾;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;261 Castell¾n/Castell¾;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;146 Castell¾n/Castell¾;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;115 Castell¾n/Castell¾;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;24 Castell¾n/Castell¾;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;9 Castell¾n/Castell¾;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;15 Castell¾n/Castell¾;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;106 Castell¾n/Castell¾;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;54 Castell¾n/Castell¾;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;52 Castell¾n/Castell¾;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.869 Castell¾n/Castell¾;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.481 Castell¾n/Castell¾;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.388 Castell¾n/Castell¾;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Castell¾n/Castell¾;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Castell¾n/Castell¾;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Castell¾n/Castell¾;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Castell¾n/Castell¾;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Castell¾n/Castell¾;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Castell¾n/Castell¾;Group 1303 Internal derangement of knee 717;Both sexes;464 Castell¾n/Castell¾;Group 1303 Internal derangement of knee 717;Men;352 Castell¾n/Castell¾;Group 1303 Internal derangement of knee 717;Women;112 Castell¾n/Castell¾;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.014 Castell¾n/Castell¾;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;450 Castell¾n/Castell¾;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;564 Castell¾n/Castell¾;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;52 Castell¾n/Castell¾;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;19 Castell¾n/Castell¾;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;33 Castell¾n/Castell¾;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;135 Castell¾n/Castell¾;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;72 Castell¾n/Castell¾;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;63 Castell¾n/Castell¾;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;225 Castell¾n/Castell¾;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;115 Castell¾n/Castell¾;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;110 Castell¾n/Castell¾;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;84 Castell¾n/Castell¾;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;66 Castell¾n/Castell¾;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;18 Castell¾n/Castell¾;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;381 Castell¾n/Castell¾;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;205 Castell¾n/Castell¾;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;176 Castell¾n/Castell¾;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;514 Castell¾n/Castell¾;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;202 Castell¾n/Castell¾;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;312 Castell¾n/Castell¾;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.496 Castell¾n/Castell¾;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.642 Castell¾n/Castell¾;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.854 Castell¾n/Castell¾;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;413 Castell¾n/Castell¾;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;153 Castell¾n/Castell¾;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;260 Castell¾n/Castell¾;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;237 Castell¾n/Castell¾;Group 1402 Renal failure 5836-5837, 584-586;Men;146 Castell¾n/Castell¾;Group 1402 Renal failure 5836-5837, 584-586;Women;91 Castell¾n/Castell¾;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;485 Castell¾n/Castell¾;Group 1403 Urolithiasis 592, 594, 7880;Men;307 Castell¾n/Castell¾;Group 1403 Urolithiasis 592, 594, 7880;Women;178 Castell¾n/Castell¾;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;915 Castell¾n/Castell¾;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;451 Castell¾n/Castell¾;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;464 Castell¾n/Castell¾;Group 1405 Prostatic hyperplasia 600;Both sexes;297 Castell¾n/Castell¾;Group 1405 Prostatic hyperplasia 600;Men;297 Castell¾n/Castell¾;Group 1405 Prostatic hyperplasia 600;Women;.. Castell¾n/Castell¾;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;263 Castell¾n/Castell¾;Group 1406 Other diseases of the male genital organs 601-608;Men;263 Castell¾n/Castell¾;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Castell¾n/Castell¾;Group 1407 Disorders of breast 610-612;Both sexes;171 Castell¾n/Castell¾;Group 1407 Disorders of breast 610-612;Men;16 Castell¾n/Castell¾;Group 1407 Disorders of breast 610-612;Women;155 Castell¾n/Castell¾;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;107 Castell¾n/Castell¾;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Castell¾n/Castell¾;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;107 Castell¾n/Castell¾;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;44 Castell¾n/Castell¾;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Castell¾n/Castell¾;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;44 Castell¾n/Castell¾;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;564 Castell¾n/Castell¾;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;9 Castell¾n/Castell¾;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;555 Castell¾n/Castell¾;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5.471 Castell¾n/Castell¾;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Castell¾n/Castell¾;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5.471 Castell¾n/Castell¾;Group 1501 Legally induced abortion 635;Both sexes;41 Castell¾n/Castell¾;Group 1501 Legally induced abortion 635;Men;.. Castell¾n/Castell¾;Group 1501 Legally induced abortion 635;Women;41 Castell¾n/Castell¾;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;212 Castell¾n/Castell¾;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Castell¾n/Castell¾;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;212 Castell¾n/Castell¾;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3.660 Castell¾n/Castell¾;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Castell¾n/Castell¾;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3.660 Castell¾n/Castell¾;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;794 Castell¾n/Castell¾;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Castell¾n/Castell¾;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;794 Castell¾n/Castell¾;Group 1505 Single spontaneous delivery 650;Both sexes;175 Castell¾n/Castell¾;Group 1505 Single spontaneous delivery 650;Men;.. Castell¾n/Castell¾;Group 1505 Single spontaneous delivery 650;Women;175 Castell¾n/Castell¾;Group 1506 Other deliveries 6695-6697;Both sexes;36 Castell¾n/Castell¾;Group 1506 Other deliveries 6695-6697;Men;.. Castell¾n/Castell¾;Group 1506 Other deliveries 6695-6697;Women;36 Castell¾n/Castell¾;Group 1507 Complications related to the puerperium 670-676;Both sexes;33 Castell¾n/Castell¾;Group 1507 Complications related to the puerperium 670-676;Men;.. Castell¾n/Castell¾;Group 1507 Complications related to the puerperium 670-676;Women;33 Castell¾n/Castell¾;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;520 Castell¾n/Castell¾;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Castell¾n/Castell¾;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;520 Castell¾n/Castell¾;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;953 Castell¾n/Castell¾;Group 1600 Some disorders originating in the perinatal period 760-779;Men;519 Castell¾n/Castell¾;Group 1600 Some disorders originating in the perinatal period 760-779;Women;434 Castell¾n/Castell¾;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;228 Castell¾n/Castell¾;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;107 Castell¾n/Castell¾;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;121 Castell¾n/Castell¾;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;725 Castell¾n/Castell¾;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;412 Castell¾n/Castell¾;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;313 Castell¾n/Castell¾;Grupo 1700 Congenital abnormalities 740-759;Both sexes;310 Castell¾n/Castell¾;Grupo 1700 Congenital abnormalities 740-759;Men;184 Castell¾n/Castell¾;Grupo 1700 Congenital abnormalities 740-759;Women;126 Castell¾n/Castell¾;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.821 Castell¾n/Castell¾;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.068 Castell¾n/Castell¾;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;753 Castell¾n/Castell¾;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;290 Castell¾n/Castell¾;Group 1801 Pain in throat and chest 7841, 7865;Men;165 Castell¾n/Castell¾;Group 1801 Pain in throat and chest 7841, 7865;Women;125 Castell¾n/Castell¾;Group 1802 Abdominal pain 7890;Both sexes;189 Castell¾n/Castell¾;Group 1802 Abdominal pain 7890;Men;81 Castell¾n/Castell¾;Group 1802 Abdominal pain 7890;Women;108 Castell¾n/Castell¾;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;45 Castell¾n/Castell¾;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;28 Castell¾n/Castell¾;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;17 Castell¾n/Castell¾;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.297 Castell¾n/Castell¾;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;794 Castell¾n/Castell¾;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;503 Castell¾n/Castell¾;Group 1900 Injuries and poisoning 800-999;Both sexes;4.436 Castell¾n/Castell¾;Group 1900 Injuries and poisoning 800-999;Men;2.303 Castell¾n/Castell¾;Group 1900 Injuries and poisoning 800-999;Women;2.133 Castell¾n/Castell¾;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;333 Castell¾n/Castell¾;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;193 Castell¾n/Castell¾;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;140 Castell¾n/Castell¾;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;120 Castell¾n/Castell¾;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;61 Castell¾n/Castell¾;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;59 Castell¾n/Castell¾;Group 1903 Radius and ulna fracture 813;Both sexes;329 Castell¾n/Castell¾;Group 1903 Radius and ulna fracture 813;Men;164 Castell¾n/Castell¾;Group 1903 Radius and ulna fracture 813;Women;165 Castell¾n/Castell¾;Group 1904 Femur fracture 820-821;Both sexes;786 Castell¾n/Castell¾;Group 1904 Femur fracture 820-821;Men;230 Castell¾n/Castell¾;Group 1904 Femur fracture 820-821;Women;556 Castell¾n/Castell¾;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;348 Castell¾n/Castell¾;Group 1905 Leg fracture, including the ankle 823-824;Men;176 Castell¾n/Castell¾;Group 1905 Leg fracture, including the ankle 823-824;Women;172 Castell¾n/Castell¾;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.200 Castell¾n/Castell¾;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;771 Castell¾n/Castell¾;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;429 Castell¾n/Castell¾;Group 1907 Burns 940-949;Both sexes;3 Castell¾n/Castell¾;Group 1907 Burns 940-949;Men;2 Castell¾n/Castell¾;Group 1907 Burns 940-949;Women;1 Castell¾n/Castell¾;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;107 Castell¾n/Castell¾;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;44 Castell¾n/Castell¾;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;63 Castell¾n/Castell¾;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.004 Castell¾n/Castell¾;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;542 Castell¾n/Castell¾;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;462 Castell¾n/Castell¾;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;9 Castell¾n/Castell¾;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;5 Castell¾n/Castell¾;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;4 Castell¾n/Castell¾;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;197 Castell¾n/Castell¾;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;115 Castell¾n/Castell¾;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;82 Castell¾n/Castell¾;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.048 Castell¾n/Castell¾;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;595 Castell¾n/Castell¾;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;453 Castell¾n/Castell¾;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;61 Castell¾n/Castell¾;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;32 Castell¾n/Castell¾;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;29 Castell¾n/Castell¾;Group 2102 Contraceptive management V25;Both sexes;38 Castell¾n/Castell¾;Group 2102 Contraceptive management V25;Men;.. Castell¾n/Castell¾;Group 2102 Contraceptive management V25;Women;38 Castell¾n/Castell¾;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Castell¾n/Castell¾;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Castell¾n/Castell¾;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Castell¾n/Castell¾;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;425 Castell¾n/Castell¾;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;293 Castell¾n/Castell¾;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;132 Castell¾n/Castell¾;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;524 Castell¾n/Castell¾;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;270 Castell¾n/Castell¾;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;254 Valencia/ValÞncia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;261.723 Valencia/ValÞncia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;124.749 Valencia/ValÞncia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;136.974 Valencia/ValÞncia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;5.473 Valencia/ValÞncia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;3.065 Valencia/ValÞncia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2.408 Valencia/ValÞncia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;907 Valencia/ValÞncia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;473 Valencia/ValÞncia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;434 Valencia/ValÞncia;Group 0102 Imprecise intestinal infections 009;Both sexes;334 Valencia/ValÞncia;Group 0102 Imprecise intestinal infections 009;Men;164 Valencia/ValÞncia;Group 0102 Imprecise intestinal infections 009;Women;170 Valencia/ValÞncia;Group 0103 Tuberculosis 010-018, 137;Both sexes;219 Valencia/ValÞncia;Group 0103 Tuberculosis 010-018, 137;Men;150 Valencia/ValÞncia;Group 0103 Tuberculosis 010-018, 137;Women;69 Valencia/ValÞncia;Group 0104 Septicaemia 038;Both sexes;1.645 Valencia/ValÞncia;Group 0104 Septicaemia 038;Men;922 Valencia/ValÞncia;Group 0104 Septicaemia 038;Women;723 Valencia/ValÞncia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;355 Valencia/ValÞncia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;241 Valencia/ValÞncia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;114 Valencia/ValÞncia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;2.013 Valencia/ValÞncia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;1.115 Valencia/ValÞncia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;898 Valencia/ValÞncia;Group 0200 Neoplasms 140-239;Both sexes;30.369 Valencia/ValÞncia;Group 0200 Neoplasms 140-239;Men;16.052 Valencia/ValÞncia;Group 0200 Neoplasms 140-239;Women;14.317 Valencia/ValÞncia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;2.997 Valencia/ValÞncia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1.754 Valencia/ValÞncia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;1.243 Valencia/ValÞncia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;2.592 Valencia/ValÞncia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;2.054 Valencia/ValÞncia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;538 Valencia/ValÞncia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;497 Valencia/ValÞncia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;312 Valencia/ValÞncia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;185 Valencia/ValÞncia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;2.839 Valencia/ValÞncia;Group 0204 Malignant neoplasm of breast 174-175;Men;12 Valencia/ValÞncia;Group 0204 Malignant neoplasm of breast 174-175;Women;2.827 Valencia/ValÞncia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;647 Valencia/ValÞncia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Valencia/ValÞncia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;647 Valencia/ValÞncia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;355 Valencia/ValÞncia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Valencia/ValÞncia;Group 0206 Malignant neoplasm of ovary 1830;Women;355 Valencia/ValÞncia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.348 Valencia/ValÞncia;Group 0207 Malignant neoplasm of prostate 185;Men;1.348 Valencia/ValÞncia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Valencia/ValÞncia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;3.496 Valencia/ValÞncia;Group 0208 Malignant neoplasm of bladder 188;Men;2.946 Valencia/ValÞncia;Group 0208 Malignant neoplasm of bladder 188;Women;550 Valencia/ValÞncia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;9.761 Valencia/ValÞncia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;5.651 Valencia/ValÞncia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;4.110 Valencia/ValÞncia;Group 0210 Carcinoma in situ 230-234;Both sexes;408 Valencia/ValÞncia;Group 0210 Carcinoma in situ 230-234;Men;138 Valencia/ValÞncia;Group 0210 Carcinoma in situ 230-234;Women;270 Valencia/ValÞncia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;218 Valencia/ValÞncia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;136 Valencia/ValÞncia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;82 Valencia/ValÞncia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1.384 Valencia/ValÞncia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Valencia/ValÞncia;Grupo 0212 Leiomyoma of uterus 218;Women;1.384 Valencia/ValÞncia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;3.827 Valencia/ValÞncia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.701 Valencia/ValÞncia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;2.126 Valencia/ValÞncia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2.102 Valencia/ValÞncia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1.049 Valencia/ValÞncia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1.053 Valencia/ValÞncia;Group 0301 Anaemias 280-285;Both sexes;1.164 Valencia/ValÞncia;Group 0301 Anaemias 280-285;Men;563 Valencia/ValÞncia;Group 0301 Anaemias 280-285;Women;601 Valencia/ValÞncia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;938 Valencia/ValÞncia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;486 Valencia/ValÞncia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;452 Valencia/ValÞncia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;5.318 Valencia/ValÞncia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;2.098 Valencia/ValÞncia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;3.220 Valencia/ValÞncia;Group 0401 Diabetes mellitus 249-250;Both sexes;1.621 Valencia/ValÞncia;Group 0401 Diabetes mellitus 249-250;Men;933 Valencia/ValÞncia;Group 0401 Diabetes mellitus 249-250;Women;688 Valencia/ValÞncia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;3.697 Valencia/ValÞncia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;1.165 Valencia/ValÞncia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;2.532 Valencia/ValÞncia;Group 0500 Mental disorders 290-319;Both sexes;5.256 Valencia/ValÞncia;Group 0500 Mental disorders 290-319;Men;2.782 Valencia/ValÞncia;Group 0500 Mental disorders 290-319;Women;2.474 Valencia/ValÞncia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;149 Valencia/ValÞncia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;69 Valencia/ValÞncia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;80 Valencia/ValÞncia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;347 Valencia/ValÞncia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;259 Valencia/ValÞncia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;88 Valencia/ValÞncia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;295 Valencia/ValÞncia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;207 Valencia/ValÞncia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;88 Valencia/ValÞncia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.623 Valencia/ValÞncia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;997 Valencia/ValÞncia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;626 Valencia/ValÞncia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1.183 Valencia/ValÞncia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;508 Valencia/ValÞncia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;675 Valencia/ValÞncia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.659 Valencia/ValÞncia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;742 Valencia/ValÞncia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;917 Valencia/ValÞncia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5.567 Valencia/ValÞncia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.767 Valencia/ValÞncia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.800 Valencia/ValÞncia;Group 0601 Alzheimer's disease 3310;Both sexes;86 Valencia/ValÞncia;Group 0601 Alzheimer's disease 3310;Men;31 Valencia/ValÞncia;Group 0601 Alzheimer's disease 3310;Women;55 Valencia/ValÞncia;Group 0602 Multiple sclerosis 340;Both sexes;127 Valencia/ValÞncia;Group 0602 Multiple sclerosis 340;Men;39 Valencia/ValÞncia;Group 0602 Multiple sclerosis 340;Women;88 Valencia/ValÞncia;Group 0603 Epilepsy 345;Both sexes;1.155 Valencia/ValÞncia;Group 0603 Epilepsy 345;Men;623 Valencia/ValÞncia;Group 0603 Epilepsy 345;Women;532 Valencia/ValÞncia;Group 0604 Transient cerebral ischemia 435;Both sexes;817 Valencia/ValÞncia;Group 0604 Transient cerebral ischemia 435;Men;434 Valencia/ValÞncia;Group 0604 Transient cerebral ischemia 435;Women;383 Valencia/ValÞncia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.382 Valencia/ValÞncia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.640 Valencia/ValÞncia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.742 Valencia/ValÞncia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.158 Valencia/ValÞncia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;629 Valencia/ValÞncia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;529 Valencia/ValÞncia;Grupo 0701 Cataract 366;Both sexes;118 Valencia/ValÞncia;Grupo 0701 Cataract 366;Men;63 Valencia/ValÞncia;Grupo 0701 Cataract 366;Women;55 Valencia/ValÞncia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1.040 Valencia/ValÞncia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;566 Valencia/ValÞncia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;474 Valencia/ValÞncia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1.436 Valencia/ValÞncia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;712 Valencia/ValÞncia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;724 Valencia/ValÞncia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;31.395 Valencia/ValÞncia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;17.900 Valencia/ValÞncia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;13.495 Valencia/ValÞncia;Group 0901 Hypertensive disease 401-405;Both sexes;631 Valencia/ValÞncia;Group 0901 Hypertensive disease 401-405;Men;305 Valencia/ValÞncia;Group 0901 Hypertensive disease 401-405;Women;326 Valencia/ValÞncia;Group 0902 Angina pectoris 4111, 413;Both sexes;1.759 Valencia/ValÞncia;Group 0902 Angina pectoris 4111, 413;Men;1.135 Valencia/ValÞncia;Group 0902 Angina pectoris 4111, 413;Women;624 Valencia/ValÞncia;Group 0903 Acute myocardial infarction 410;Both sexes;2.835 Valencia/ValÞncia;Group 0903 Acute myocardial infarction 410;Men;1.991 Valencia/ValÞncia;Group 0903 Acute myocardial infarction 410;Women;844 Valencia/ValÞncia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2.065 Valencia/ValÞncia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.610 Valencia/ValÞncia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;455 Valencia/ValÞncia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1.035 Valencia/ValÞncia;Group 0905 Diseases of the lungs circulation 415-417;Men;446 Valencia/ValÞncia;Group 0905 Diseases of the lungs circulation 415-417;Women;589 Valencia/ValÞncia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;3.753 Valencia/ValÞncia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.964 Valencia/ValÞncia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.789 Valencia/ValÞncia;Grupo 0907 Heart failure 428;Both sexes;6.296 Valencia/ValÞncia;Grupo 0907 Heart failure 428;Men;2.920 Valencia/ValÞncia;Grupo 0907 Heart failure 428;Women;3.376 Valencia/ValÞncia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;5.936 Valencia/ValÞncia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;3.264 Valencia/ValÞncia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2.672 Valencia/ValÞncia;Grupo 0909 Atherosclerosis 440;Both sexes;1.002 Valencia/ValÞncia;Grupo 0909 Atherosclerosis 440;Men;756 Valencia/ValÞncia;Grupo 0909 Atherosclerosis 440;Women;246 Valencia/ValÞncia;Group 0910 Varicose veins of lower extremities 454;Both sexes;537 Valencia/ValÞncia;Group 0910 Varicose veins of lower extremities 454;Men;175 Valencia/ValÞncia;Group 0910 Varicose veins of lower extremities 454;Women;362 Valencia/ValÞncia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;5.546 Valencia/ValÞncia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;3.334 Valencia/ValÞncia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2.212 Valencia/ValÞncia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;29.778 Valencia/ValÞncia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;16.937 Valencia/ValÞncia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;12.841 Valencia/ValÞncia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.654 Valencia/ValÞncia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;865 Valencia/ValÞncia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;789 Valencia/ValÞncia;Group 1002 Pneumonia 480-486;Both sexes;7.679 Valencia/ValÞncia;Group 1002 Pneumonia 480-486;Men;4.476 Valencia/ValÞncia;Group 1002 Pneumonia 480-486;Women;3.203 Valencia/ValÞncia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.460 Valencia/ValÞncia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.221 Valencia/ValÞncia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.239 Valencia/ValÞncia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1.932 Valencia/ValÞncia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.050 Valencia/ValÞncia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;882 Valencia/ValÞncia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;2.134 Valencia/ValÞncia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1.266 Valencia/ValÞncia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;868 Valencia/ValÞncia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;4.062 Valencia/ValÞncia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;3.069 Valencia/ValÞncia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;993 Valencia/ValÞncia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;856 Valencia/ValÞncia;Group 1007 Asthma 4930-4931,4938-4939;Men;245 Valencia/ValÞncia;Group 1007 Asthma 4930-4931,4938-4939;Women;611 Valencia/ValÞncia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;9.001 Valencia/ValÞncia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;4.745 Valencia/ValÞncia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;4.256 Valencia/ValÞncia;Group 1100 Diseases of the digestive system 520-579;Both sexes;31.288 Valencia/ValÞncia;Group 1100 Diseases of the digestive system 520-579;Men;17.158 Valencia/ValÞncia;Group 1100 Diseases of the digestive system 520-579;Women;14.130 Valencia/ValÞncia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;706 Valencia/ValÞncia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;331 Valencia/ValÞncia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;375 Valencia/ValÞncia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;530 Valencia/ValÞncia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;292 Valencia/ValÞncia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;238 Valencia/ValÞncia;Group 1103 Diseases of the esophagus 530;Both sexes;626 Valencia/ValÞncia;Group 1103 Diseases of the esophagus 530;Men;381 Valencia/ValÞncia;Group 1103 Diseases of the esophagus 530;Women;245 Valencia/ValÞncia;Group 1104 Peptic ulcer 531-534;Both sexes;584 Valencia/ValÞncia;Group 1104 Peptic ulcer 531-534;Men;420 Valencia/ValÞncia;Group 1104 Peptic ulcer 531-534;Women;164 Valencia/ValÞncia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;802 Valencia/ValÞncia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;387 Valencia/ValÞncia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;415 Valencia/ValÞncia;Group 1106 Appendicitis 540-543;Both sexes;2.885 Valencia/ValÞncia;Group 1106 Appendicitis 540-543;Men;1.633 Valencia/ValÞncia;Group 1106 Appendicitis 540-543;Women;1.252 Valencia/ValÞncia;Group 1107 Inguinal hernia 550;Both sexes;2.728 Valencia/ValÞncia;Group 1107 Inguinal hernia 550;Men;2.415 Valencia/ValÞncia;Group 1107 Inguinal hernia 550;Women;313 Valencia/ValÞncia;Group 1108 Other abdominal hernia 551-553;Both sexes;2.487 Valencia/ValÞncia;Group 1108 Other abdominal hernia 551-553;Men;1.066 Valencia/ValÞncia;Group 1108 Other abdominal hernia 551-553;Women;1.421 Valencia/ValÞncia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;692 Valencia/ValÞncia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;351 Valencia/ValÞncia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;341 Valencia/ValÞncia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.616 Valencia/ValÞncia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;749 Valencia/ValÞncia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;867 Valencia/ValÞncia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1.468 Valencia/ValÞncia;Group 1111 Intestinal obstruction without hernia 560;Men;748 Valencia/ValÞncia;Group 1111 Intestinal obstruction without hernia 560;Women;720 Valencia/ValÞncia;Group 1112 Intestinal diverticulosis 562;Both sexes;1.116 Valencia/ValÞncia;Group 1112 Intestinal diverticulosis 562;Men;584 Valencia/ValÞncia;Group 1112 Intestinal diverticulosis 562;Women;532 Valencia/ValÞncia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;2.071 Valencia/ValÞncia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1.325 Valencia/ValÞncia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;746 Valencia/ValÞncia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;941 Valencia/ValÞncia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;415 Valencia/ValÞncia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;526 Valencia/ValÞncia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;428 Valencia/ValÞncia;Group 1115 Alcoholic hepatitis 5710-5713;Men;368 Valencia/ValÞncia;Group 1115 Alcoholic hepatitis 5710-5713;Women;60 Valencia/ValÞncia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1.298 Valencia/ValÞncia;Group 1116 Other diseases of the liver 570,5714-573;Men;759 Valencia/ValÞncia;Group 1116 Other diseases of the liver 570,5714-573;Women;539 Valencia/ValÞncia;Group 1117 Cholelithiasis 574;Both sexes;5.003 Valencia/ValÞncia;Group 1117 Cholelithiasis 574;Men;2.028 Valencia/ValÞncia;Group 1117 Cholelithiasis 574;Women;2.975 Valencia/ValÞncia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.731 Valencia/ValÞncia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;947 Valencia/ValÞncia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;784 Valencia/ValÞncia;Group 1119 Pancreatic diseases 577;Both sexes;1.642 Valencia/ValÞncia;Group 1119 Pancreatic diseases 577;Men;904 Valencia/ValÞncia;Group 1119 Pancreatic diseases 577;Women;738 Valencia/ValÞncia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1.934 Valencia/ValÞncia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1.055 Valencia/ValÞncia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;879 Valencia/ValÞncia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2.388 Valencia/ValÞncia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1.314 Valencia/ValÞncia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1.074 Valencia/ValÞncia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.541 Valencia/ValÞncia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;912 Valencia/ValÞncia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;629 Valencia/ValÞncia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;77 Valencia/ValÞncia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;44 Valencia/ValÞncia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;33 Valencia/ValÞncia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;770 Valencia/ValÞncia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;358 Valencia/ValÞncia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;412 Valencia/ValÞncia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;19.826 Valencia/ValÞncia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;9.932 Valencia/ValÞncia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;9.894 Valencia/ValÞncia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Valencia/ValÞncia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Valencia/ValÞncia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Valencia/ValÞncia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Valencia/ValÞncia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Valencia/ValÞncia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Valencia/ValÞncia;Group 1303 Internal derangement of knee 717;Both sexes;3.243 Valencia/ValÞncia;Group 1303 Internal derangement of knee 717;Men;2.299 Valencia/ValÞncia;Group 1303 Internal derangement of knee 717;Women;944 Valencia/ValÞncia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;6.761 Valencia/ValÞncia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;2.910 Valencia/ValÞncia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;3.851 Valencia/ValÞncia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;369 Valencia/ValÞncia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;115 Valencia/ValÞncia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;254 Valencia/ValÞncia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;948 Valencia/ValÞncia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;488 Valencia/ValÞncia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;460 Valencia/ValÞncia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.808 Valencia/ValÞncia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;986 Valencia/ValÞncia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;822 Valencia/ValÞncia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;467 Valencia/ValÞncia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;214 Valencia/ValÞncia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;253 Valencia/ValÞncia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;3.140 Valencia/ValÞncia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.702 Valencia/ValÞncia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;1.438 Valencia/ValÞncia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;3.090 Valencia/ValÞncia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;1.218 Valencia/ValÞncia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.872 Valencia/ValÞncia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;18.656 Valencia/ValÞncia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;8.591 Valencia/ValÞncia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;10.065 Valencia/ValÞncia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.754 Valencia/ValÞncia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;684 Valencia/ValÞncia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;1.070 Valencia/ValÞncia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.738 Valencia/ValÞncia;Group 1402 Renal failure 5836-5837, 584-586;Men;1.016 Valencia/ValÞncia;Group 1402 Renal failure 5836-5837, 584-586;Women;722 Valencia/ValÞncia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;2.378 Valencia/ValÞncia;Group 1403 Urolithiasis 592, 594, 7880;Men;1.454 Valencia/ValÞncia;Group 1403 Urolithiasis 592, 594, 7880;Women;924 Valencia/ValÞncia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;5.655 Valencia/ValÞncia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2.812 Valencia/ValÞncia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2.843 Valencia/ValÞncia;Group 1405 Prostatic hyperplasia 600;Both sexes;1.519 Valencia/ValÞncia;Group 1405 Prostatic hyperplasia 600;Men;1.519 Valencia/ValÞncia;Group 1405 Prostatic hyperplasia 600;Women;.. Valencia/ValÞncia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;987 Valencia/ValÞncia;Group 1406 Other diseases of the male genital organs 601-608;Men;987 Valencia/ValÞncia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Valencia/ValÞncia;Group 1407 Disorders of breast 610-612;Both sexes;1.125 Valencia/ValÞncia;Group 1407 Disorders of breast 610-612;Men;94 Valencia/ValÞncia;Group 1407 Disorders of breast 610-612;Women;1.031 Valencia/ValÞncia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;491 Valencia/ValÞncia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Valencia/ValÞncia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;491 Valencia/ValÞncia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;224 Valencia/ValÞncia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Valencia/ValÞncia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;224 Valencia/ValÞncia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2.785 Valencia/ValÞncia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;25 Valencia/ValÞncia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2.760 Valencia/ValÞncia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;25.745 Valencia/ValÞncia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Valencia/ValÞncia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;25.745 Valencia/ValÞncia;Group 1501 Legally induced abortion 635;Both sexes;102 Valencia/ValÞncia;Group 1501 Legally induced abortion 635;Men;.. Valencia/ValÞncia;Group 1501 Legally induced abortion 635;Women;102 Valencia/ValÞncia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;915 Valencia/ValÞncia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Valencia/ValÞncia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;915 Valencia/ValÞncia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;15.682 Valencia/ValÞncia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Valencia/ValÞncia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;15.682 Valencia/ValÞncia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;4.157 Valencia/ValÞncia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Valencia/ValÞncia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;4.157 Valencia/ValÞncia;Group 1505 Single spontaneous delivery 650;Both sexes;2.044 Valencia/ValÞncia;Group 1505 Single spontaneous delivery 650;Men;.. Valencia/ValÞncia;Group 1505 Single spontaneous delivery 650;Women;2.044 Valencia/ValÞncia;Group 1506 Other deliveries 6695-6697;Both sexes;931 Valencia/ValÞncia;Group 1506 Other deliveries 6695-6697;Men;.. Valencia/ValÞncia;Group 1506 Other deliveries 6695-6697;Women;931 Valencia/ValÞncia;Group 1507 Complications related to the puerperium 670-676;Both sexes;180 Valencia/ValÞncia;Group 1507 Complications related to the puerperium 670-676;Men;.. Valencia/ValÞncia;Group 1507 Complications related to the puerperium 670-676;Women;180 Valencia/ValÞncia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.734 Valencia/ValÞncia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Valencia/ValÞncia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.734 Valencia/ValÞncia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;3.597 Valencia/ValÞncia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.967 Valencia/ValÞncia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.630 Valencia/ValÞncia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;1.026 Valencia/ValÞncia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;539 Valencia/ValÞncia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;487 Valencia/ValÞncia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2.571 Valencia/ValÞncia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.428 Valencia/ValÞncia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;1.143 Valencia/ValÞncia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;2.500 Valencia/ValÞncia;Grupo 1700 Congenital abnormalities 740-759;Men;1.331 Valencia/ValÞncia;Grupo 1700 Congenital abnormalities 740-759;Women;1.169 Valencia/ValÞncia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;11.149 Valencia/ValÞncia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;6.117 Valencia/ValÞncia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;5.032 Valencia/ValÞncia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.317 Valencia/ValÞncia;Group 1801 Pain in throat and chest 7841, 7865;Men;750 Valencia/ValÞncia;Group 1801 Pain in throat and chest 7841, 7865;Women;567 Valencia/ValÞncia;Group 1802 Abdominal pain 7890;Both sexes;998 Valencia/ValÞncia;Group 1802 Abdominal pain 7890;Men;357 Valencia/ValÞncia;Group 1802 Abdominal pain 7890;Women;641 Valencia/ValÞncia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;136 Valencia/ValÞncia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;84 Valencia/ValÞncia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;52 Valencia/ValÞncia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;8.698 Valencia/ValÞncia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4.926 Valencia/ValÞncia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3.772 Valencia/ValÞncia;Group 1900 Injuries and poisoning 800-999;Both sexes;23.387 Valencia/ValÞncia;Group 1900 Injuries and poisoning 800-999;Men;11.881 Valencia/ValÞncia;Group 1900 Injuries and poisoning 800-999;Women;11.506 Valencia/ValÞncia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.134 Valencia/ValÞncia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;621 Valencia/ValÞncia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;513 Valencia/ValÞncia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;511 Valencia/ValÞncia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;380 Valencia/ValÞncia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;131 Valencia/ValÞncia;Group 1903 Radius and ulna fracture 813;Both sexes;1.714 Valencia/ValÞncia;Group 1903 Radius and ulna fracture 813;Men;837 Valencia/ValÞncia;Group 1903 Radius and ulna fracture 813;Women;877 Valencia/ValÞncia;Group 1904 Femur fracture 820-821;Both sexes;3.783 Valencia/ValÞncia;Group 1904 Femur fracture 820-821;Men;1.118 Valencia/ValÞncia;Group 1904 Femur fracture 820-821;Women;2.665 Valencia/ValÞncia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.791 Valencia/ValÞncia;Group 1905 Leg fracture, including the ankle 823-824;Men;959 Valencia/ValÞncia;Group 1905 Leg fracture, including the ankle 823-824;Women;832 Valencia/ValÞncia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;7.326 Valencia/ValÞncia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;4.330 Valencia/ValÞncia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.996 Valencia/ValÞncia;Group 1907 Burns 940-949;Both sexes;164 Valencia/ValÞncia;Group 1907 Burns 940-949;Men;131 Valencia/ValÞncia;Group 1907 Burns 940-949;Women;33 Valencia/ValÞncia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;647 Valencia/ValÞncia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;250 Valencia/ValÞncia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;397 Valencia/ValÞncia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;5.282 Valencia/ValÞncia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2.708 Valencia/ValÞncia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;2.574 Valencia/ValÞncia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;123 Valencia/ValÞncia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;81 Valencia/ValÞncia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;42 Valencia/ValÞncia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;912 Valencia/ValÞncia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;466 Valencia/ValÞncia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;446 Valencia/ValÞncia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;5.335 Valencia/ValÞncia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;2.467 Valencia/ValÞncia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2.868 Valencia/ValÞncia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;216 Valencia/ValÞncia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;131 Valencia/ValÞncia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;85 Valencia/ValÞncia;Group 2102 Contraceptive management V25;Both sexes;59 Valencia/ValÞncia;Group 2102 Contraceptive management V25;Men;5 Valencia/ValÞncia;Group 2102 Contraceptive management V25;Women;54 Valencia/ValÞncia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Valencia/ValÞncia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Valencia/ValÞncia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Valencia/ValÞncia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.649 Valencia/ValÞncia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;938 Valencia/ValÞncia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;711 Valencia/ValÞncia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;3.411 Valencia/ValÞncia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.393 Valencia/ValÞncia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;2.018 EXTREMADURA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;113.053 EXTREMADURA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;54.226 EXTREMADURA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;58.827 EXTREMADURA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.000 EXTREMADURA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.098 EXTREMADURA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;902 EXTREMADURA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;398 EXTREMADURA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;204 EXTREMADURA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;194 EXTREMADURA;Group 0102 Imprecise intestinal infections 009;Both sexes;213 EXTREMADURA;Group 0102 Imprecise intestinal infections 009;Men;122 EXTREMADURA;Group 0102 Imprecise intestinal infections 009;Women;91 EXTREMADURA;Group 0103 Tuberculosis 010-018, 137;Both sexes;72 EXTREMADURA;Group 0103 Tuberculosis 010-018, 137;Men;48 EXTREMADURA;Group 0103 Tuberculosis 010-018, 137;Women;24 EXTREMADURA;Group 0104 Septicaemia 038;Both sexes;446 EXTREMADURA;Group 0104 Septicaemia 038;Men;211 EXTREMADURA;Group 0104 Septicaemia 038;Women;235 EXTREMADURA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;53 EXTREMADURA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;46 EXTREMADURA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;7 EXTREMADURA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;818 EXTREMADURA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;467 EXTREMADURA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;351 EXTREMADURA;Group 0200 Neoplasms 140-239;Both sexes;10.240 EXTREMADURA;Group 0200 Neoplasms 140-239;Men;5.467 EXTREMADURA;Group 0200 Neoplasms 140-239;Women;4.773 EXTREMADURA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;961 EXTREMADURA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;561 EXTREMADURA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;400 EXTREMADURA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;829 EXTREMADURA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;715 EXTREMADURA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;114 EXTREMADURA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;528 EXTREMADURA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;307 EXTREMADURA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;221 EXTREMADURA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;800 EXTREMADURA;Group 0204 Malignant neoplasm of breast 174-175;Men;7 EXTREMADURA;Group 0204 Malignant neoplasm of breast 174-175;Women;793 EXTREMADURA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;214 EXTREMADURA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. EXTREMADURA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;214 EXTREMADURA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;107 EXTREMADURA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. EXTREMADURA;Group 0206 Malignant neoplasm of ovary 1830;Women;107 EXTREMADURA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;273 EXTREMADURA;Group 0207 Malignant neoplasm of prostate 185;Men;273 EXTREMADURA;Group 0207 Malignant neoplasm of prostate 185;Women;.. EXTREMADURA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;749 EXTREMADURA;Group 0208 Malignant neoplasm of bladder 188;Men;651 EXTREMADURA;Group 0208 Malignant neoplasm of bladder 188;Women;98 EXTREMADURA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.832 EXTREMADURA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.771 EXTREMADURA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.061 EXTREMADURA;Group 0210 Carcinoma in situ 230-234;Both sexes;221 EXTREMADURA;Group 0210 Carcinoma in situ 230-234;Men;71 EXTREMADURA;Group 0210 Carcinoma in situ 230-234;Women;150 EXTREMADURA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;154 EXTREMADURA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;93 EXTREMADURA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;61 EXTREMADURA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;561 EXTREMADURA;Grupo 0212 Leiomyoma of uterus 218;Men;.. EXTREMADURA;Grupo 0212 Leiomyoma of uterus 218;Women;561 EXTREMADURA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2.011 EXTREMADURA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.018 EXTREMADURA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;993 EXTREMADURA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.045 EXTREMADURA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;535 EXTREMADURA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;510 EXTREMADURA;Group 0301 Anaemias 280-285;Both sexes;676 EXTREMADURA;Group 0301 Anaemias 280-285;Men;328 EXTREMADURA;Group 0301 Anaemias 280-285;Women;348 EXTREMADURA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;369 EXTREMADURA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;207 EXTREMADURA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;162 EXTREMADURA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.653 EXTREMADURA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;720 EXTREMADURA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;933 EXTREMADURA;Group 0401 Diabetes mellitus 249-250;Both sexes;572 EXTREMADURA;Group 0401 Diabetes mellitus 249-250;Men;315 EXTREMADURA;Group 0401 Diabetes mellitus 249-250;Women;257 EXTREMADURA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.081 EXTREMADURA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;405 EXTREMADURA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;676 EXTREMADURA;Group 0500 Mental disorders 290-319;Both sexes;3.180 EXTREMADURA;Group 0500 Mental disorders 290-319;Men;1.783 EXTREMADURA;Group 0500 Mental disorders 290-319;Women;1.397 EXTREMADURA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;60 EXTREMADURA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;26 EXTREMADURA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;34 EXTREMADURA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;274 EXTREMADURA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;226 EXTREMADURA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;48 EXTREMADURA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;106 EXTREMADURA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;77 EXTREMADURA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;29 EXTREMADURA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;745 EXTREMADURA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;472 EXTREMADURA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;273 EXTREMADURA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;670 EXTREMADURA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;290 EXTREMADURA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;380 EXTREMADURA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.325 EXTREMADURA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;692 EXTREMADURA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;633 EXTREMADURA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.509 EXTREMADURA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.263 EXTREMADURA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.246 EXTREMADURA;Group 0601 Alzheimer's disease 3310;Both sexes;49 EXTREMADURA;Group 0601 Alzheimer's disease 3310;Men;25 EXTREMADURA;Group 0601 Alzheimer's disease 3310;Women;24 EXTREMADURA;Group 0602 Multiple sclerosis 340;Both sexes;95 EXTREMADURA;Group 0602 Multiple sclerosis 340;Men;38 EXTREMADURA;Group 0602 Multiple sclerosis 340;Women;57 EXTREMADURA;Group 0603 Epilepsy 345;Both sexes;530 EXTREMADURA;Group 0603 Epilepsy 345;Men;284 EXTREMADURA;Group 0603 Epilepsy 345;Women;246 EXTREMADURA;Group 0604 Transient cerebral ischemia 435;Both sexes;550 EXTREMADURA;Group 0604 Transient cerebral ischemia 435;Men;282 EXTREMADURA;Group 0604 Transient cerebral ischemia 435;Women;268 EXTREMADURA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.285 EXTREMADURA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;634 EXTREMADURA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;651 EXTREMADURA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.646 EXTREMADURA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;868 EXTREMADURA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;778 EXTREMADURA;Grupo 0701 Cataract 366;Both sexes;500 EXTREMADURA;Grupo 0701 Cataract 366;Men;244 EXTREMADURA;Grupo 0701 Cataract 366;Women;256 EXTREMADURA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1.146 EXTREMADURA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;624 EXTREMADURA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;522 EXTREMADURA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;542 EXTREMADURA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;252 EXTREMADURA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;290 EXTREMADURA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;15.605 EXTREMADURA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;8.532 EXTREMADURA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;7.073 EXTREMADURA;Group 0901 Hypertensive disease 401-405;Both sexes;629 EXTREMADURA;Group 0901 Hypertensive disease 401-405;Men;242 EXTREMADURA;Group 0901 Hypertensive disease 401-405;Women;387 EXTREMADURA;Group 0902 Angina pectoris 4111, 413;Both sexes;892 EXTREMADURA;Group 0902 Angina pectoris 4111, 413;Men;524 EXTREMADURA;Group 0902 Angina pectoris 4111, 413;Women;368 EXTREMADURA;Group 0903 Acute myocardial infarction 410;Both sexes;1.225 EXTREMADURA;Group 0903 Acute myocardial infarction 410;Men;854 EXTREMADURA;Group 0903 Acute myocardial infarction 410;Women;371 EXTREMADURA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;969 EXTREMADURA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;728 EXTREMADURA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;241 EXTREMADURA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;632 EXTREMADURA;Group 0905 Diseases of the lungs circulation 415-417;Men;308 EXTREMADURA;Group 0905 Diseases of the lungs circulation 415-417;Women;324 EXTREMADURA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.167 EXTREMADURA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.106 EXTREMADURA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.061 EXTREMADURA;Grupo 0907 Heart failure 428;Both sexes;3.374 EXTREMADURA;Grupo 0907 Heart failure 428;Men;1.488 EXTREMADURA;Grupo 0907 Heart failure 428;Women;1.886 EXTREMADURA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.837 EXTREMADURA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.598 EXTREMADURA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.239 EXTREMADURA;Grupo 0909 Atherosclerosis 440;Both sexes;305 EXTREMADURA;Grupo 0909 Atherosclerosis 440;Men;241 EXTREMADURA;Grupo 0909 Atherosclerosis 440;Women;64 EXTREMADURA;Group 0910 Varicose veins of lower extremities 454;Both sexes;302 EXTREMADURA;Group 0910 Varicose veins of lower extremities 454;Men;113 EXTREMADURA;Group 0910 Varicose veins of lower extremities 454;Women;189 EXTREMADURA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.273 EXTREMADURA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.330 EXTREMADURA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;943 EXTREMADURA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;15.003 EXTREMADURA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8.844 EXTREMADURA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6.159 EXTREMADURA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;655 EXTREMADURA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;361 EXTREMADURA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;294 EXTREMADURA;Group 1002 Pneumonia 480-486;Both sexes;3.162 EXTREMADURA;Group 1002 Pneumonia 480-486;Men;1.901 EXTREMADURA;Group 1002 Pneumonia 480-486;Women;1.261 EXTREMADURA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;973 EXTREMADURA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;496 EXTREMADURA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;477 EXTREMADURA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;945 EXTREMADURA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;506 EXTREMADURA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;439 EXTREMADURA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.026 EXTREMADURA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;662 EXTREMADURA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;364 EXTREMADURA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.632 EXTREMADURA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.419 EXTREMADURA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;213 EXTREMADURA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;278 EXTREMADURA;Group 1007 Asthma 4930-4931,4938-4939;Men;92 EXTREMADURA;Group 1007 Asthma 4930-4931,4938-4939;Women;186 EXTREMADURA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;6.332 EXTREMADURA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3.407 EXTREMADURA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.925 EXTREMADURA;Group 1100 Diseases of the digestive system 520-579;Both sexes;13.733 EXTREMADURA;Group 1100 Diseases of the digestive system 520-579;Men;7.828 EXTREMADURA;Group 1100 Diseases of the digestive system 520-579;Women;5.905 EXTREMADURA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;208 EXTREMADURA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;75 EXTREMADURA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;133 EXTREMADURA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;189 EXTREMADURA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;106 EXTREMADURA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;83 EXTREMADURA;Group 1103 Diseases of the esophagus 530;Both sexes;296 EXTREMADURA;Group 1103 Diseases of the esophagus 530;Men;179 EXTREMADURA;Group 1103 Diseases of the esophagus 530;Women;117 EXTREMADURA;Group 1104 Peptic ulcer 531-534;Both sexes;209 EXTREMADURA;Group 1104 Peptic ulcer 531-534;Men;138 EXTREMADURA;Group 1104 Peptic ulcer 531-534;Women;71 EXTREMADURA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;314 EXTREMADURA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;165 EXTREMADURA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;149 EXTREMADURA;Group 1106 Appendicitis 540-543;Both sexes;1.026 EXTREMADURA;Group 1106 Appendicitis 540-543;Men;570 EXTREMADURA;Group 1106 Appendicitis 540-543;Women;456 EXTREMADURA;Group 1107 Inguinal hernia 550;Both sexes;1.321 EXTREMADURA;Group 1107 Inguinal hernia 550;Men;1.188 EXTREMADURA;Group 1107 Inguinal hernia 550;Women;133 EXTREMADURA;Group 1108 Other abdominal hernia 551-553;Both sexes;1.017 EXTREMADURA;Group 1108 Other abdominal hernia 551-553;Men;474 EXTREMADURA;Group 1108 Other abdominal hernia 551-553;Women;543 EXTREMADURA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;243 EXTREMADURA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;125 EXTREMADURA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;118 EXTREMADURA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.055 EXTREMADURA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;542 EXTREMADURA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;513 EXTREMADURA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;792 EXTREMADURA;Group 1111 Intestinal obstruction without hernia 560;Men;409 EXTREMADURA;Group 1111 Intestinal obstruction without hernia 560;Women;383 EXTREMADURA;Group 1112 Intestinal diverticulosis 562;Both sexes;433 EXTREMADURA;Group 1112 Intestinal diverticulosis 562;Men;210 EXTREMADURA;Group 1112 Intestinal diverticulosis 562;Women;223 EXTREMADURA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;978 EXTREMADURA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;650 EXTREMADURA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;328 EXTREMADURA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;445 EXTREMADURA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;219 EXTREMADURA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;226 EXTREMADURA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;236 EXTREMADURA;Group 1115 Alcoholic hepatitis 5710-5713;Men;206 EXTREMADURA;Group 1115 Alcoholic hepatitis 5710-5713;Women;30 EXTREMADURA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;445 EXTREMADURA;Group 1116 Other diseases of the liver 570,5714-573;Men;286 EXTREMADURA;Group 1116 Other diseases of the liver 570,5714-573;Women;159 EXTREMADURA;Group 1117 Cholelithiasis 574;Both sexes;2.072 EXTREMADURA;Group 1117 Cholelithiasis 574;Men;904 EXTREMADURA;Group 1117 Cholelithiasis 574;Women;1.168 EXTREMADURA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;920 EXTREMADURA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;507 EXTREMADURA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;413 EXTREMADURA;Group 1119 Pancreatic diseases 577;Both sexes;763 EXTREMADURA;Group 1119 Pancreatic diseases 577;Men;440 EXTREMADURA;Group 1119 Pancreatic diseases 577;Women;323 EXTREMADURA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;771 EXTREMADURA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;435 EXTREMADURA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;336 EXTREMADURA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.050 EXTREMADURA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;524 EXTREMADURA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;526 EXTREMADURA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;635 EXTREMADURA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;340 EXTREMADURA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;295 EXTREMADURA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;43 EXTREMADURA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;18 EXTREMADURA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;25 EXTREMADURA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;372 EXTREMADURA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;166 EXTREMADURA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;206 EXTREMADURA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6.419 EXTREMADURA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3.038 EXTREMADURA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.381 EXTREMADURA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. EXTREMADURA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. EXTREMADURA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. EXTREMADURA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. EXTREMADURA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. EXTREMADURA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. EXTREMADURA;Group 1303 Internal derangement of knee 717;Both sexes;956 EXTREMADURA;Group 1303 Internal derangement of knee 717;Men;678 EXTREMADURA;Group 1303 Internal derangement of knee 717;Women;278 EXTREMADURA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.179 EXTREMADURA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;880 EXTREMADURA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.299 EXTREMADURA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;115 EXTREMADURA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;53 EXTREMADURA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;62 EXTREMADURA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;374 EXTREMADURA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;178 EXTREMADURA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;196 EXTREMADURA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;637 EXTREMADURA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;331 EXTREMADURA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;306 EXTREMADURA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;144 EXTREMADURA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;67 EXTREMADURA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;77 EXTREMADURA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;773 EXTREMADURA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;446 EXTREMADURA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;327 EXTREMADURA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.241 EXTREMADURA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;405 EXTREMADURA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;836 EXTREMADURA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;7.926 EXTREMADURA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.357 EXTREMADURA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4.569 EXTREMADURA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;649 EXTREMADURA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;285 EXTREMADURA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;364 EXTREMADURA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;875 EXTREMADURA;Group 1402 Renal failure 5836-5837, 584-586;Men;453 EXTREMADURA;Group 1402 Renal failure 5836-5837, 584-586;Women;422 EXTREMADURA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;791 EXTREMADURA;Group 1403 Urolithiasis 592, 594, 7880;Men;450 EXTREMADURA;Group 1403 Urolithiasis 592, 594, 7880;Women;341 EXTREMADURA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.694 EXTREMADURA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;783 EXTREMADURA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;911 EXTREMADURA;Group 1405 Prostatic hyperplasia 600;Both sexes;537 EXTREMADURA;Group 1405 Prostatic hyperplasia 600;Men;537 EXTREMADURA;Group 1405 Prostatic hyperplasia 600;Women;.. EXTREMADURA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;800 EXTREMADURA;Group 1406 Other diseases of the male genital organs 601-608;Men;800 EXTREMADURA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. EXTREMADURA;Group 1407 Disorders of breast 610-612;Both sexes;344 EXTREMADURA;Group 1407 Disorders of breast 610-612;Men;31 EXTREMADURA;Group 1407 Disorders of breast 610-612;Women;313 EXTREMADURA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;298 EXTREMADURA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. EXTREMADURA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;298 EXTREMADURA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;291 EXTREMADURA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. EXTREMADURA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;291 EXTREMADURA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.647 EXTREMADURA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;18 EXTREMADURA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.629 EXTREMADURA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;11.338 EXTREMADURA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. EXTREMADURA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;11.338 EXTREMADURA;Group 1501 Legally induced abortion 635;Both sexes;3 EXTREMADURA;Group 1501 Legally induced abortion 635;Men;.. EXTREMADURA;Group 1501 Legally induced abortion 635;Women;3 EXTREMADURA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.155 EXTREMADURA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. EXTREMADURA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.155 EXTREMADURA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;5.939 EXTREMADURA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. EXTREMADURA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;5.939 EXTREMADURA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.549 EXTREMADURA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. EXTREMADURA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.549 EXTREMADURA;Group 1505 Single spontaneous delivery 650;Both sexes;610 EXTREMADURA;Group 1505 Single spontaneous delivery 650;Men;.. EXTREMADURA;Group 1505 Single spontaneous delivery 650;Women;610 EXTREMADURA;Group 1506 Other deliveries 6695-6697;Both sexes;501 EXTREMADURA;Group 1506 Other deliveries 6695-6697;Men;.. EXTREMADURA;Group 1506 Other deliveries 6695-6697;Women;501 EXTREMADURA;Group 1507 Complications related to the puerperium 670-676;Both sexes;66 EXTREMADURA;Group 1507 Complications related to the puerperium 670-676;Men;.. EXTREMADURA;Group 1507 Complications related to the puerperium 670-676;Women;66 EXTREMADURA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;515 EXTREMADURA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. EXTREMADURA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;515 EXTREMADURA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.546 EXTREMADURA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;855 EXTREMADURA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;691 EXTREMADURA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;373 EXTREMADURA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;207 EXTREMADURA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;166 EXTREMADURA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.173 EXTREMADURA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;648 EXTREMADURA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;525 EXTREMADURA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;743 EXTREMADURA;Grupo 1700 Congenital abnormalities 740-759;Men;480 EXTREMADURA;Grupo 1700 Congenital abnormalities 740-759;Women;263 EXTREMADURA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;6.784 EXTREMADURA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3.711 EXTREMADURA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.073 EXTREMADURA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;717 EXTREMADURA;Group 1801 Pain in throat and chest 7841, 7865;Men;404 EXTREMADURA;Group 1801 Pain in throat and chest 7841, 7865;Women;313 EXTREMADURA;Group 1802 Abdominal pain 7890;Both sexes;734 EXTREMADURA;Group 1802 Abdominal pain 7890;Men;297 EXTREMADURA;Group 1802 Abdominal pain 7890;Women;437 EXTREMADURA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;101 EXTREMADURA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;43 EXTREMADURA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;58 EXTREMADURA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.232 EXTREMADURA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.967 EXTREMADURA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.265 EXTREMADURA;Group 1900 Injuries and poisoning 800-999;Both sexes;8.234 EXTREMADURA;Group 1900 Injuries and poisoning 800-999;Men;4.082 EXTREMADURA;Group 1900 Injuries and poisoning 800-999;Women;4.152 EXTREMADURA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;365 EXTREMADURA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;195 EXTREMADURA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;170 EXTREMADURA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;235 EXTREMADURA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;167 EXTREMADURA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;68 EXTREMADURA;Group 1903 Radius and ulna fracture 813;Both sexes;462 EXTREMADURA;Group 1903 Radius and ulna fracture 813;Men;242 EXTREMADURA;Group 1903 Radius and ulna fracture 813;Women;220 EXTREMADURA;Group 1904 Femur fracture 820-821;Both sexes;1.645 EXTREMADURA;Group 1904 Femur fracture 820-821;Men;458 EXTREMADURA;Group 1904 Femur fracture 820-821;Women;1.187 EXTREMADURA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;602 EXTREMADURA;Group 1905 Leg fracture, including the ankle 823-824;Men;291 EXTREMADURA;Group 1905 Leg fracture, including the ankle 823-824;Women;311 EXTREMADURA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2.206 EXTREMADURA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.321 EXTREMADURA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;885 EXTREMADURA;Group 1907 Burns 940-949;Both sexes;83 EXTREMADURA;Group 1907 Burns 940-949;Men;45 EXTREMADURA;Group 1907 Burns 940-949;Women;38 EXTREMADURA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;260 EXTREMADURA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;128 EXTREMADURA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;132 EXTREMADURA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.059 EXTREMADURA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.068 EXTREMADURA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;991 EXTREMADURA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;25 EXTREMADURA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;14 EXTREMADURA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;11 EXTREMADURA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;292 EXTREMADURA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;153 EXTREMADURA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;139 EXTREMADURA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.857 EXTREMADURA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;989 EXTREMADURA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;868 EXTREMADURA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;268 EXTREMADURA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;172 EXTREMADURA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;96 EXTREMADURA;Group 2102 Contraceptive management V25;Both sexes;53 EXTREMADURA;Group 2102 Contraceptive management V25;Men;2 EXTREMADURA;Group 2102 Contraceptive management V25;Women;51 EXTREMADURA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. EXTREMADURA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. EXTREMADURA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. EXTREMADURA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;676 EXTREMADURA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;396 EXTREMADURA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;280 EXTREMADURA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;860 EXTREMADURA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;419 EXTREMADURA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;441 Badajoz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;73.113 Badajoz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;34.934 Badajoz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;38.179 Badajoz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.461 Badajoz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;793 Badajoz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;668 Badajoz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;231 Badajoz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;108 Badajoz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;123 Badajoz;Group 0102 Imprecise intestinal infections 009;Both sexes;177 Badajoz;Group 0102 Imprecise intestinal infections 009;Men;99 Badajoz;Group 0102 Imprecise intestinal infections 009;Women;78 Badajoz;Group 0103 Tuberculosis 010-018, 137;Both sexes;49 Badajoz;Group 0103 Tuberculosis 010-018, 137;Men;34 Badajoz;Group 0103 Tuberculosis 010-018, 137;Women;15 Badajoz;Group 0104 Septicaemia 038;Both sexes;365 Badajoz;Group 0104 Septicaemia 038;Men;168 Badajoz;Group 0104 Septicaemia 038;Women;197 Badajoz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;44 Badajoz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;37 Badajoz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;7 Badajoz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;595 Badajoz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;347 Badajoz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;248 Badajoz;Group 0200 Neoplasms 140-239;Both sexes;6.373 Badajoz;Group 0200 Neoplasms 140-239;Men;3.487 Badajoz;Group 0200 Neoplasms 140-239;Women;2.886 Badajoz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;632 Badajoz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;389 Badajoz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;243 Badajoz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;560 Badajoz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;478 Badajoz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;82 Badajoz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;60 Badajoz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;36 Badajoz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;24 Badajoz;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;477 Badajoz;Group 0204 Malignant neoplasm of breast 174-175;Men;6 Badajoz;Group 0204 Malignant neoplasm of breast 174-175;Women;471 Badajoz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;130 Badajoz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Badajoz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;130 Badajoz;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;66 Badajoz;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Badajoz;Group 0206 Malignant neoplasm of ovary 1830;Women;66 Badajoz;Group 0207 Malignant neoplasm of prostate 185;Both sexes;178 Badajoz;Group 0207 Malignant neoplasm of prostate 185;Men;178 Badajoz;Group 0207 Malignant neoplasm of prostate 185;Women;.. Badajoz;Group 0208 Malignant neoplasm of bladder 188;Both sexes;493 Badajoz;Group 0208 Malignant neoplasm of bladder 188;Men;431 Badajoz;Group 0208 Malignant neoplasm of bladder 188;Women;62 Badajoz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.927 Badajoz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.213 Badajoz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;714 Badajoz;Group 0210 Carcinoma in situ 230-234;Both sexes;151 Badajoz;Group 0210 Carcinoma in situ 230-234;Men;52 Badajoz;Group 0210 Carcinoma in situ 230-234;Women;99 Badajoz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;104 Badajoz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;60 Badajoz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;44 Badajoz;Grupo 0212 Leiomyoma of uterus 218;Both sexes;328 Badajoz;Grupo 0212 Leiomyoma of uterus 218;Men;.. Badajoz;Grupo 0212 Leiomyoma of uterus 218;Women;328 Badajoz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.267 Badajoz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;644 Badajoz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;623 Badajoz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;717 Badajoz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;361 Badajoz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;356 Badajoz;Group 0301 Anaemias 280-285;Both sexes;489 Badajoz;Group 0301 Anaemias 280-285;Men;230 Badajoz;Group 0301 Anaemias 280-285;Women;259 Badajoz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;228 Badajoz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;131 Badajoz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;97 Badajoz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.040 Badajoz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;470 Badajoz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;570 Badajoz;Group 0401 Diabetes mellitus 249-250;Both sexes;408 Badajoz;Group 0401 Diabetes mellitus 249-250;Men;229 Badajoz;Group 0401 Diabetes mellitus 249-250;Women;179 Badajoz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;632 Badajoz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;241 Badajoz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;391 Badajoz;Group 0500 Mental disorders 290-319;Both sexes;1.507 Badajoz;Group 0500 Mental disorders 290-319;Men;786 Badajoz;Group 0500 Mental disorders 290-319;Women;721 Badajoz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;47 Badajoz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;23 Badajoz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;24 Badajoz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;85 Badajoz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;70 Badajoz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;15 Badajoz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;62 Badajoz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;44 Badajoz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;18 Badajoz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;272 Badajoz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;171 Badajoz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;101 Badajoz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;325 Badajoz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;125 Badajoz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;200 Badajoz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;716 Badajoz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;353 Badajoz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;363 Badajoz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.882 Badajoz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;937 Badajoz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;945 Badajoz;Group 0601 Alzheimer's disease 3310;Both sexes;39 Badajoz;Group 0601 Alzheimer's disease 3310;Men;18 Badajoz;Group 0601 Alzheimer's disease 3310;Women;21 Badajoz;Group 0602 Multiple sclerosis 340;Both sexes;84 Badajoz;Group 0602 Multiple sclerosis 340;Men;35 Badajoz;Group 0602 Multiple sclerosis 340;Women;49 Badajoz;Group 0603 Epilepsy 345;Both sexes;382 Badajoz;Group 0603 Epilepsy 345;Men;211 Badajoz;Group 0603 Epilepsy 345;Women;171 Badajoz;Group 0604 Transient cerebral ischemia 435;Both sexes;435 Badajoz;Group 0604 Transient cerebral ischemia 435;Men;219 Badajoz;Group 0604 Transient cerebral ischemia 435;Women;216 Badajoz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;942 Badajoz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;454 Badajoz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;488 Badajoz;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;825 Badajoz;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;470 Badajoz;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;355 Badajoz;Grupo 0701 Cataract 366;Both sexes;107 Badajoz;Grupo 0701 Cataract 366;Men;55 Badajoz;Grupo 0701 Cataract 366;Women;52 Badajoz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;718 Badajoz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;415 Badajoz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;303 Badajoz;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;333 Badajoz;Group 0800 Diseases of the ear and the mastoid 380-389;Men;152 Badajoz;Group 0800 Diseases of the ear and the mastoid 380-389;Women;181 Badajoz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;10.109 Badajoz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5.541 Badajoz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.568 Badajoz;Group 0901 Hypertensive disease 401-405;Both sexes;468 Badajoz;Group 0901 Hypertensive disease 401-405;Men;196 Badajoz;Group 0901 Hypertensive disease 401-405;Women;272 Badajoz;Group 0902 Angina pectoris 4111, 413;Both sexes;618 Badajoz;Group 0902 Angina pectoris 4111, 413;Men;368 Badajoz;Group 0902 Angina pectoris 4111, 413;Women;250 Badajoz;Group 0903 Acute myocardial infarction 410;Both sexes;728 Badajoz;Group 0903 Acute myocardial infarction 410;Men;505 Badajoz;Group 0903 Acute myocardial infarction 410;Women;223 Badajoz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;570 Badajoz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;420 Badajoz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;150 Badajoz;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;406 Badajoz;Group 0905 Diseases of the lungs circulation 415-417;Men;198 Badajoz;Group 0905 Diseases of the lungs circulation 415-417;Women;208 Badajoz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.557 Badajoz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;797 Badajoz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;760 Badajoz;Grupo 0907 Heart failure 428;Both sexes;2.187 Badajoz;Grupo 0907 Heart failure 428;Men;987 Badajoz;Grupo 0907 Heart failure 428;Women;1.200 Badajoz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.799 Badajoz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.019 Badajoz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;780 Badajoz;Grupo 0909 Atherosclerosis 440;Both sexes;126 Badajoz;Grupo 0909 Atherosclerosis 440;Men;103 Badajoz;Grupo 0909 Atherosclerosis 440;Women;23 Badajoz;Group 0910 Varicose veins of lower extremities 454;Both sexes;152 Badajoz;Group 0910 Varicose veins of lower extremities 454;Men;71 Badajoz;Group 0910 Varicose veins of lower extremities 454;Women;81 Badajoz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.498 Badajoz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;877 Badajoz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;621 Badajoz;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;10.099 Badajoz;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5.926 Badajoz;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4.173 Badajoz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;378 Badajoz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;198 Badajoz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;180 Badajoz;Group 1002 Pneumonia 480-486;Both sexes;1.980 Badajoz;Group 1002 Pneumonia 480-486;Men;1.187 Badajoz;Group 1002 Pneumonia 480-486;Women;793 Badajoz;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;562 Badajoz;Group 1003 Acute bronchitis and bronchiolitis 466;Men;290 Badajoz;Group 1003 Acute bronchitis and bronchiolitis 466;Women;272 Badajoz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;624 Badajoz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;353 Badajoz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;271 Badajoz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;560 Badajoz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;363 Badajoz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;197 Badajoz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.035 Badajoz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;875 Badajoz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;160 Badajoz;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;180 Badajoz;Group 1007 Asthma 4930-4931,4938-4939;Men;61 Badajoz;Group 1007 Asthma 4930-4931,4938-4939;Women;119 Badajoz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4.780 Badajoz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.599 Badajoz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.181 Badajoz;Group 1100 Diseases of the digestive system 520-579;Both sexes;8.681 Badajoz;Group 1100 Diseases of the digestive system 520-579;Men;4.823 Badajoz;Group 1100 Diseases of the digestive system 520-579;Women;3.858 Badajoz;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;196 Badajoz;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;69 Badajoz;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;127 Badajoz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;139 Badajoz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;84 Badajoz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;55 Badajoz;Group 1103 Diseases of the esophagus 530;Both sexes;207 Badajoz;Group 1103 Diseases of the esophagus 530;Men;123 Badajoz;Group 1103 Diseases of the esophagus 530;Women;84 Badajoz;Group 1104 Peptic ulcer 531-534;Both sexes;128 Badajoz;Group 1104 Peptic ulcer 531-534;Men;87 Badajoz;Group 1104 Peptic ulcer 531-534;Women;41 Badajoz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;230 Badajoz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;115 Badajoz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;115 Badajoz;Group 1106 Appendicitis 540-543;Both sexes;751 Badajoz;Group 1106 Appendicitis 540-543;Men;411 Badajoz;Group 1106 Appendicitis 540-543;Women;340 Badajoz;Group 1107 Inguinal hernia 550;Both sexes;672 Badajoz;Group 1107 Inguinal hernia 550;Men;592 Badajoz;Group 1107 Inguinal hernia 550;Women;80 Badajoz;Group 1108 Other abdominal hernia 551-553;Both sexes;630 Badajoz;Group 1108 Other abdominal hernia 551-553;Men;270 Badajoz;Group 1108 Other abdominal hernia 551-553;Women;360 Badajoz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;176 Badajoz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;96 Badajoz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;80 Badajoz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;651 Badajoz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;322 Badajoz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;329 Badajoz;Group 1111 Intestinal obstruction without hernia 560;Both sexes;496 Badajoz;Group 1111 Intestinal obstruction without hernia 560;Men;260 Badajoz;Group 1111 Intestinal obstruction without hernia 560;Women;236 Badajoz;Group 1112 Intestinal diverticulosis 562;Both sexes;292 Badajoz;Group 1112 Intestinal diverticulosis 562;Men;140 Badajoz;Group 1112 Intestinal diverticulosis 562;Women;152 Badajoz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;573 Badajoz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;398 Badajoz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;175 Badajoz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;302 Badajoz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;142 Badajoz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;160 Badajoz;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;184 Badajoz;Group 1115 Alcoholic hepatitis 5710-5713;Men;162 Badajoz;Group 1115 Alcoholic hepatitis 5710-5713;Women;22 Badajoz;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;287 Badajoz;Group 1116 Other diseases of the liver 570,5714-573;Men;178 Badajoz;Group 1116 Other diseases of the liver 570,5714-573;Women;109 Badajoz;Group 1117 Cholelithiasis 574;Both sexes;1.256 Badajoz;Group 1117 Cholelithiasis 574;Men;547 Badajoz;Group 1117 Cholelithiasis 574;Women;709 Badajoz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;531 Badajoz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;286 Badajoz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;245 Badajoz;Group 1119 Pancreatic diseases 577;Both sexes;506 Badajoz;Group 1119 Pancreatic diseases 577;Men;290 Badajoz;Group 1119 Pancreatic diseases 577;Women;216 Badajoz;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;474 Badajoz;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;251 Badajoz;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;223 Badajoz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;626 Badajoz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;314 Badajoz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;312 Badajoz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;381 Badajoz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;205 Badajoz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;176 Badajoz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;27 Badajoz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;11 Badajoz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;16 Badajoz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;218 Badajoz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;98 Badajoz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;120 Badajoz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4.345 Badajoz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2.089 Badajoz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2.256 Badajoz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Badajoz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Badajoz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Badajoz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Badajoz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Badajoz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Badajoz;Group 1303 Internal derangement of knee 717;Both sexes;689 Badajoz;Group 1303 Internal derangement of knee 717;Men;489 Badajoz;Group 1303 Internal derangement of knee 717;Women;200 Badajoz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.444 Badajoz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;577 Badajoz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;867 Badajoz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;96 Badajoz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;45 Badajoz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;51 Badajoz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;261 Badajoz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;128 Badajoz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;133 Badajoz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;450 Badajoz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;238 Badajoz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;212 Badajoz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;77 Badajoz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;33 Badajoz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;44 Badajoz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;534 Badajoz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;309 Badajoz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;225 Badajoz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;794 Badajoz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;270 Badajoz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;524 Badajoz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5.001 Badajoz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.117 Badajoz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.884 Badajoz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;456 Badajoz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;199 Badajoz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;257 Badajoz;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;641 Badajoz;Group 1402 Renal failure 5836-5837, 584-586;Men;328 Badajoz;Group 1402 Renal failure 5836-5837, 584-586;Women;313 Badajoz;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;546 Badajoz;Group 1403 Urolithiasis 592, 594, 7880;Men;325 Badajoz;Group 1403 Urolithiasis 592, 594, 7880;Women;221 Badajoz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.028 Badajoz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;461 Badajoz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;567 Badajoz;Group 1405 Prostatic hyperplasia 600;Both sexes;277 Badajoz;Group 1405 Prostatic hyperplasia 600;Men;277 Badajoz;Group 1405 Prostatic hyperplasia 600;Women;.. Badajoz;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;494 Badajoz;Group 1406 Other diseases of the male genital organs 601-608;Men;494 Badajoz;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Badajoz;Group 1407 Disorders of breast 610-612;Both sexes;234 Badajoz;Group 1407 Disorders of breast 610-612;Men;18 Badajoz;Group 1407 Disorders of breast 610-612;Women;216 Badajoz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;191 Badajoz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Badajoz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;191 Badajoz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;147 Badajoz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Badajoz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;147 Badajoz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;987 Badajoz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;15 Badajoz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;972 Badajoz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;7.760 Badajoz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Badajoz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;7.760 Badajoz;Group 1501 Legally induced abortion 635;Both sexes;1 Badajoz;Group 1501 Legally induced abortion 635;Men;.. Badajoz;Group 1501 Legally induced abortion 635;Women;1 Badajoz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;764 Badajoz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Badajoz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;764 Badajoz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.144 Badajoz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Badajoz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.144 Badajoz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.711 Badajoz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Badajoz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.711 Badajoz;Group 1505 Single spontaneous delivery 650;Both sexes;314 Badajoz;Group 1505 Single spontaneous delivery 650;Men;.. Badajoz;Group 1505 Single spontaneous delivery 650;Women;314 Badajoz;Group 1506 Other deliveries 6695-6697;Both sexes;406 Badajoz;Group 1506 Other deliveries 6695-6697;Men;.. Badajoz;Group 1506 Other deliveries 6695-6697;Women;406 Badajoz;Group 1507 Complications related to the puerperium 670-676;Both sexes;57 Badajoz;Group 1507 Complications related to the puerperium 670-676;Men;.. Badajoz;Group 1507 Complications related to the puerperium 670-676;Women;57 Badajoz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;363 Badajoz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Badajoz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;363 Badajoz;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;857 Badajoz;Group 1600 Some disorders originating in the perinatal period 760-779;Men;495 Badajoz;Group 1600 Some disorders originating in the perinatal period 760-779;Women;362 Badajoz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;205 Badajoz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;119 Badajoz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;86 Badajoz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;652 Badajoz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;376 Badajoz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;276 Badajoz;Grupo 1700 Congenital abnormalities 740-759;Both sexes;561 Badajoz;Grupo 1700 Congenital abnormalities 740-759;Men;376 Badajoz;Grupo 1700 Congenital abnormalities 740-759;Women;185 Badajoz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;4.781 Badajoz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2.601 Badajoz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.180 Badajoz;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;459 Badajoz;Group 1801 Pain in throat and chest 7841, 7865;Men;248 Badajoz;Group 1801 Pain in throat and chest 7841, 7865;Women;211 Badajoz;Group 1802 Abdominal pain 7890;Both sexes;473 Badajoz;Group 1802 Abdominal pain 7890;Men;190 Badajoz;Group 1802 Abdominal pain 7890;Women;283 Badajoz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;97 Badajoz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;41 Badajoz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;56 Badajoz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;3.752 Badajoz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.122 Badajoz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.630 Badajoz;Group 1900 Injuries and poisoning 800-999;Both sexes;5.083 Badajoz;Group 1900 Injuries and poisoning 800-999;Men;2.582 Badajoz;Group 1900 Injuries and poisoning 800-999;Women;2.501 Badajoz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;250 Badajoz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;134 Badajoz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;116 Badajoz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;147 Badajoz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;109 Badajoz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;38 Badajoz;Group 1903 Radius and ulna fracture 813;Both sexes;255 Badajoz;Group 1903 Radius and ulna fracture 813;Men;143 Badajoz;Group 1903 Radius and ulna fracture 813;Women;112 Badajoz;Group 1904 Femur fracture 820-821;Both sexes;965 Badajoz;Group 1904 Femur fracture 820-821;Men;275 Badajoz;Group 1904 Femur fracture 820-821;Women;690 Badajoz;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;344 Badajoz;Group 1905 Leg fracture, including the ankle 823-824;Men;167 Badajoz;Group 1905 Leg fracture, including the ankle 823-824;Women;177 Badajoz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.298 Badajoz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;792 Badajoz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;506 Badajoz;Group 1907 Burns 940-949;Both sexes;13 Badajoz;Group 1907 Burns 940-949;Men;9 Badajoz;Group 1907 Burns 940-949;Women;4 Badajoz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;171 Badajoz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;86 Badajoz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;85 Badajoz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.442 Badajoz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;757 Badajoz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;685 Badajoz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;20 Badajoz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;12 Badajoz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;8 Badajoz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;178 Badajoz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;98 Badajoz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;80 Badajoz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.072 Badajoz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;614 Badajoz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;458 Badajoz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;263 Badajoz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;169 Badajoz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;94 Badajoz;Group 2102 Contraceptive management V25;Both sexes;24 Badajoz;Group 2102 Contraceptive management V25;Men;.. Badajoz;Group 2102 Contraceptive management V25;Women;24 Badajoz;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Badajoz;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Badajoz;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Badajoz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;318 Badajoz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;203 Badajoz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;115 Badajoz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;467 Badajoz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;242 Badajoz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;225 Cßceres;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;39.940 Cßceres;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;19.292 Cßceres;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;20.648 Cßceres;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;539 Cßceres;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;305 Cßceres;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;234 Cßceres;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;167 Cßceres;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;96 Cßceres;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;71 Cßceres;Group 0102 Imprecise intestinal infections 009;Both sexes;36 Cßceres;Group 0102 Imprecise intestinal infections 009;Men;23 Cßceres;Group 0102 Imprecise intestinal infections 009;Women;13 Cßceres;Group 0103 Tuberculosis 010-018, 137;Both sexes;23 Cßceres;Group 0103 Tuberculosis 010-018, 137;Men;14 Cßceres;Group 0103 Tuberculosis 010-018, 137;Women;9 Cßceres;Group 0104 Septicaemia 038;Both sexes;81 Cßceres;Group 0104 Septicaemia 038;Men;43 Cßceres;Group 0104 Septicaemia 038;Women;38 Cßceres;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;9 Cßceres;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;9 Cßceres;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;.. Cßceres;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;223 Cßceres;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;120 Cßceres;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;103 Cßceres;Group 0200 Neoplasms 140-239;Both sexes;3.867 Cßceres;Group 0200 Neoplasms 140-239;Men;1.980 Cßceres;Group 0200 Neoplasms 140-239;Women;1.887 Cßceres;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;329 Cßceres;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;172 Cßceres;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;157 Cßceres;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;269 Cßceres;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;237 Cßceres;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;32 Cßceres;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;468 Cßceres;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;271 Cßceres;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;197 Cßceres;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;323 Cßceres;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Cßceres;Group 0204 Malignant neoplasm of breast 174-175;Women;322 Cßceres;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;84 Cßceres;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Cßceres;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;84 Cßceres;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;41 Cßceres;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Cßceres;Group 0206 Malignant neoplasm of ovary 1830;Women;41 Cßceres;Group 0207 Malignant neoplasm of prostate 185;Both sexes;95 Cßceres;Group 0207 Malignant neoplasm of prostate 185;Men;95 Cßceres;Group 0207 Malignant neoplasm of prostate 185;Women;.. Cßceres;Group 0208 Malignant neoplasm of bladder 188;Both sexes;256 Cßceres;Group 0208 Malignant neoplasm of bladder 188;Men;220 Cßceres;Group 0208 Malignant neoplasm of bladder 188;Women;36 Cßceres;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;905 Cßceres;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;558 Cßceres;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;347 Cßceres;Group 0210 Carcinoma in situ 230-234;Both sexes;70 Cßceres;Group 0210 Carcinoma in situ 230-234;Men;19 Cßceres;Group 0210 Carcinoma in situ 230-234;Women;51 Cßceres;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;50 Cßceres;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;33 Cßceres;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;17 Cßceres;Grupo 0212 Leiomyoma of uterus 218;Both sexes;233 Cßceres;Grupo 0212 Leiomyoma of uterus 218;Men;.. Cßceres;Grupo 0212 Leiomyoma of uterus 218;Women;233 Cßceres;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;744 Cßceres;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;374 Cßceres;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;370 Cßceres;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;328 Cßceres;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;174 Cßceres;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;154 Cßceres;Group 0301 Anaemias 280-285;Both sexes;187 Cßceres;Group 0301 Anaemias 280-285;Men;98 Cßceres;Group 0301 Anaemias 280-285;Women;89 Cßceres;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;141 Cßceres;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;76 Cßceres;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;65 Cßceres;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;613 Cßceres;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;250 Cßceres;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;363 Cßceres;Group 0401 Diabetes mellitus 249-250;Both sexes;164 Cßceres;Group 0401 Diabetes mellitus 249-250;Men;86 Cßceres;Group 0401 Diabetes mellitus 249-250;Women;78 Cßceres;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;449 Cßceres;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;164 Cßceres;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;285 Cßceres;Group 0500 Mental disorders 290-319;Both sexes;1.673 Cßceres;Group 0500 Mental disorders 290-319;Men;997 Cßceres;Group 0500 Mental disorders 290-319;Women;676 Cßceres;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;13 Cßceres;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;3 Cßceres;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;10 Cßceres;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;189 Cßceres;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;156 Cßceres;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;33 Cßceres;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;44 Cßceres;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;33 Cßceres;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;11 Cßceres;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;473 Cßceres;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;301 Cßceres;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;172 Cßceres;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;345 Cßceres;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;165 Cßceres;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;180 Cßceres;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;609 Cßceres;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;339 Cßceres;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;270 Cßceres;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;627 Cßceres;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;326 Cßceres;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;301 Cßceres;Group 0601 Alzheimer's disease 3310;Both sexes;10 Cßceres;Group 0601 Alzheimer's disease 3310;Men;7 Cßceres;Group 0601 Alzheimer's disease 3310;Women;3 Cßceres;Group 0602 Multiple sclerosis 340;Both sexes;11 Cßceres;Group 0602 Multiple sclerosis 340;Men;3 Cßceres;Group 0602 Multiple sclerosis 340;Women;8 Cßceres;Group 0603 Epilepsy 345;Both sexes;148 Cßceres;Group 0603 Epilepsy 345;Men;73 Cßceres;Group 0603 Epilepsy 345;Women;75 Cßceres;Group 0604 Transient cerebral ischemia 435;Both sexes;115 Cßceres;Group 0604 Transient cerebral ischemia 435;Men;63 Cßceres;Group 0604 Transient cerebral ischemia 435;Women;52 Cßceres;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;343 Cßceres;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;180 Cßceres;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;163 Cßceres;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;821 Cßceres;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;398 Cßceres;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;423 Cßceres;Grupo 0701 Cataract 366;Both sexes;393 Cßceres;Grupo 0701 Cataract 366;Men;189 Cßceres;Grupo 0701 Cataract 366;Women;204 Cßceres;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;428 Cßceres;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;209 Cßceres;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;219 Cßceres;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;209 Cßceres;Group 0800 Diseases of the ear and the mastoid 380-389;Men;100 Cßceres;Group 0800 Diseases of the ear and the mastoid 380-389;Women;109 Cßceres;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5.496 Cßceres;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.991 Cßceres;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.505 Cßceres;Group 0901 Hypertensive disease 401-405;Both sexes;161 Cßceres;Group 0901 Hypertensive disease 401-405;Men;46 Cßceres;Group 0901 Hypertensive disease 401-405;Women;115 Cßceres;Group 0902 Angina pectoris 4111, 413;Both sexes;274 Cßceres;Group 0902 Angina pectoris 4111, 413;Men;156 Cßceres;Group 0902 Angina pectoris 4111, 413;Women;118 Cßceres;Group 0903 Acute myocardial infarction 410;Both sexes;497 Cßceres;Group 0903 Acute myocardial infarction 410;Men;349 Cßceres;Group 0903 Acute myocardial infarction 410;Women;148 Cßceres;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;399 Cßceres;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;308 Cßceres;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;91 Cßceres;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;226 Cßceres;Group 0905 Diseases of the lungs circulation 415-417;Men;110 Cßceres;Group 0905 Diseases of the lungs circulation 415-417;Women;116 Cßceres;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;610 Cßceres;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;309 Cßceres;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;301 Cßceres;Grupo 0907 Heart failure 428;Both sexes;1.187 Cßceres;Grupo 0907 Heart failure 428;Men;501 Cßceres;Grupo 0907 Heart failure 428;Women;686 Cßceres;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.038 Cßceres;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;579 Cßceres;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;459 Cßceres;Grupo 0909 Atherosclerosis 440;Both sexes;179 Cßceres;Grupo 0909 Atherosclerosis 440;Men;138 Cßceres;Grupo 0909 Atherosclerosis 440;Women;41 Cßceres;Group 0910 Varicose veins of lower extremities 454;Both sexes;150 Cßceres;Group 0910 Varicose veins of lower extremities 454;Men;42 Cßceres;Group 0910 Varicose veins of lower extremities 454;Women;108 Cßceres;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;775 Cßceres;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;453 Cßceres;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;322 Cßceres;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4.904 Cßceres;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.918 Cßceres;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.986 Cßceres;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;277 Cßceres;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;163 Cßceres;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;114 Cßceres;Group 1002 Pneumonia 480-486;Both sexes;1.182 Cßceres;Group 1002 Pneumonia 480-486;Men;714 Cßceres;Group 1002 Pneumonia 480-486;Women;468 Cßceres;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;411 Cßceres;Group 1003 Acute bronchitis and bronchiolitis 466;Men;206 Cßceres;Group 1003 Acute bronchitis and bronchiolitis 466;Women;205 Cßceres;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;321 Cßceres;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;153 Cßceres;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;168 Cßceres;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;466 Cßceres;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;299 Cßceres;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;167 Cßceres;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;597 Cßceres;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;544 Cßceres;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;53 Cßceres;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;98 Cßceres;Group 1007 Asthma 4930-4931,4938-4939;Men;31 Cßceres;Group 1007 Asthma 4930-4931,4938-4939;Women;67 Cßceres;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.552 Cßceres;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;808 Cßceres;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;744 Cßceres;Group 1100 Diseases of the digestive system 520-579;Both sexes;5.052 Cßceres;Group 1100 Diseases of the digestive system 520-579;Men;3.005 Cßceres;Group 1100 Diseases of the digestive system 520-579;Women;2.047 Cßceres;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;12 Cßceres;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;6 Cßceres;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;6 Cßceres;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;50 Cßceres;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;22 Cßceres;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;28 Cßceres;Group 1103 Diseases of the esophagus 530;Both sexes;89 Cßceres;Group 1103 Diseases of the esophagus 530;Men;56 Cßceres;Group 1103 Diseases of the esophagus 530;Women;33 Cßceres;Group 1104 Peptic ulcer 531-534;Both sexes;81 Cßceres;Group 1104 Peptic ulcer 531-534;Men;51 Cßceres;Group 1104 Peptic ulcer 531-534;Women;30 Cßceres;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;84 Cßceres;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;50 Cßceres;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;34 Cßceres;Group 1106 Appendicitis 540-543;Both sexes;275 Cßceres;Group 1106 Appendicitis 540-543;Men;159 Cßceres;Group 1106 Appendicitis 540-543;Women;116 Cßceres;Group 1107 Inguinal hernia 550;Both sexes;649 Cßceres;Group 1107 Inguinal hernia 550;Men;596 Cßceres;Group 1107 Inguinal hernia 550;Women;53 Cßceres;Group 1108 Other abdominal hernia 551-553;Both sexes;387 Cßceres;Group 1108 Other abdominal hernia 551-553;Men;204 Cßceres;Group 1108 Other abdominal hernia 551-553;Women;183 Cßceres;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;67 Cßceres;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;29 Cßceres;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;38 Cßceres;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;404 Cßceres;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;220 Cßceres;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;184 Cßceres;Group 1111 Intestinal obstruction without hernia 560;Both sexes;296 Cßceres;Group 1111 Intestinal obstruction without hernia 560;Men;149 Cßceres;Group 1111 Intestinal obstruction without hernia 560;Women;147 Cßceres;Group 1112 Intestinal diverticulosis 562;Both sexes;141 Cßceres;Group 1112 Intestinal diverticulosis 562;Men;70 Cßceres;Group 1112 Intestinal diverticulosis 562;Women;71 Cßceres;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;405 Cßceres;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;252 Cßceres;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;153 Cßceres;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;143 Cßceres;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;77 Cßceres;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;66 Cßceres;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;52 Cßceres;Group 1115 Alcoholic hepatitis 5710-5713;Men;44 Cßceres;Group 1115 Alcoholic hepatitis 5710-5713;Women;8 Cßceres;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;158 Cßceres;Group 1116 Other diseases of the liver 570,5714-573;Men;108 Cßceres;Group 1116 Other diseases of the liver 570,5714-573;Women;50 Cßceres;Group 1117 Cholelithiasis 574;Both sexes;816 Cßceres;Group 1117 Cholelithiasis 574;Men;357 Cßceres;Group 1117 Cholelithiasis 574;Women;459 Cßceres;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;389 Cßceres;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;221 Cßceres;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;168 Cßceres;Group 1119 Pancreatic diseases 577;Both sexes;257 Cßceres;Group 1119 Pancreatic diseases 577;Men;150 Cßceres;Group 1119 Pancreatic diseases 577;Women;107 Cßceres;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;297 Cßceres;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;184 Cßceres;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;113 Cßceres;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;424 Cßceres;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;210 Cßceres;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;214 Cßceres;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;254 Cßceres;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;135 Cßceres;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;119 Cßceres;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;16 Cßceres;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;7 Cßceres;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;9 Cßceres;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;154 Cßceres;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;68 Cßceres;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;86 Cßceres;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.074 Cßceres;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;949 Cßceres;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.125 Cßceres;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Cßceres;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Cßceres;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Cßceres;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Cßceres;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Cßceres;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Cßceres;Group 1303 Internal derangement of knee 717;Both sexes;267 Cßceres;Group 1303 Internal derangement of knee 717;Men;189 Cßceres;Group 1303 Internal derangement of knee 717;Women;78 Cßceres;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;735 Cßceres;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;303 Cßceres;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;432 Cßceres;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;19 Cßceres;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;8 Cßceres;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;11 Cßceres;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;113 Cßceres;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;50 Cßceres;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;63 Cßceres;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;187 Cßceres;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;93 Cßceres;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;94 Cßceres;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;67 Cßceres;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;34 Cßceres;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;33 Cßceres;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;239 Cßceres;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;137 Cßceres;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;102 Cßceres;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;447 Cßceres;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;135 Cßceres;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;312 Cßceres;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.925 Cßceres;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.240 Cßceres;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.685 Cßceres;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;193 Cßceres;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;86 Cßceres;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;107 Cßceres;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;234 Cßceres;Group 1402 Renal failure 5836-5837, 584-586;Men;125 Cßceres;Group 1402 Renal failure 5836-5837, 584-586;Women;109 Cßceres;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;245 Cßceres;Group 1403 Urolithiasis 592, 594, 7880;Men;125 Cßceres;Group 1403 Urolithiasis 592, 594, 7880;Women;120 Cßceres;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;666 Cßceres;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;322 Cßceres;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;344 Cßceres;Group 1405 Prostatic hyperplasia 600;Both sexes;260 Cßceres;Group 1405 Prostatic hyperplasia 600;Men;260 Cßceres;Group 1405 Prostatic hyperplasia 600;Women;.. Cßceres;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;306 Cßceres;Group 1406 Other diseases of the male genital organs 601-608;Men;306 Cßceres;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Cßceres;Group 1407 Disorders of breast 610-612;Both sexes;110 Cßceres;Group 1407 Disorders of breast 610-612;Men;13 Cßceres;Group 1407 Disorders of breast 610-612;Women;97 Cßceres;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;107 Cßceres;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Cßceres;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;107 Cßceres;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;144 Cßceres;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Cßceres;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;144 Cßceres;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;660 Cßceres;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;3 Cßceres;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;657 Cßceres;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3.578 Cßceres;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Cßceres;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3.578 Cßceres;Group 1501 Legally induced abortion 635;Both sexes;2 Cßceres;Group 1501 Legally induced abortion 635;Men;.. Cßceres;Group 1501 Legally induced abortion 635;Women;2 Cßceres;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;391 Cßceres;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Cßceres;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;391 Cßceres;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.795 Cßceres;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Cßceres;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.795 Cßceres;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;838 Cßceres;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Cßceres;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;838 Cßceres;Group 1505 Single spontaneous delivery 650;Both sexes;296 Cßceres;Group 1505 Single spontaneous delivery 650;Men;.. Cßceres;Group 1505 Single spontaneous delivery 650;Women;296 Cßceres;Group 1506 Other deliveries 6695-6697;Both sexes;95 Cßceres;Group 1506 Other deliveries 6695-6697;Men;.. Cßceres;Group 1506 Other deliveries 6695-6697;Women;95 Cßceres;Group 1507 Complications related to the puerperium 670-676;Both sexes;9 Cßceres;Group 1507 Complications related to the puerperium 670-676;Men;.. Cßceres;Group 1507 Complications related to the puerperium 670-676;Women;9 Cßceres;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;152 Cßceres;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Cßceres;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;152 Cßceres;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;689 Cßceres;Group 1600 Some disorders originating in the perinatal period 760-779;Men;360 Cßceres;Group 1600 Some disorders originating in the perinatal period 760-779;Women;329 Cßceres;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;168 Cßceres;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;88 Cßceres;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;80 Cßceres;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;521 Cßceres;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;272 Cßceres;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;249 Cßceres;Grupo 1700 Congenital abnormalities 740-759;Both sexes;182 Cßceres;Grupo 1700 Congenital abnormalities 740-759;Men;104 Cßceres;Grupo 1700 Congenital abnormalities 740-759;Women;78 Cßceres;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.003 Cßceres;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.110 Cßceres;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;893 Cßceres;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;258 Cßceres;Group 1801 Pain in throat and chest 7841, 7865;Men;156 Cßceres;Group 1801 Pain in throat and chest 7841, 7865;Women;102 Cßceres;Group 1802 Abdominal pain 7890;Both sexes;261 Cßceres;Group 1802 Abdominal pain 7890;Men;107 Cßceres;Group 1802 Abdominal pain 7890;Women;154 Cßceres;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;4 Cßceres;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;2 Cßceres;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;2 Cßceres;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.480 Cßceres;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;845 Cßceres;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;635 Cßceres;Group 1900 Injuries and poisoning 800-999;Both sexes;3.151 Cßceres;Group 1900 Injuries and poisoning 800-999;Men;1.500 Cßceres;Group 1900 Injuries and poisoning 800-999;Women;1.651 Cßceres;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;115 Cßceres;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;61 Cßceres;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;54 Cßceres;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;88 Cßceres;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;58 Cßceres;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;30 Cßceres;Group 1903 Radius and ulna fracture 813;Both sexes;207 Cßceres;Group 1903 Radius and ulna fracture 813;Men;99 Cßceres;Group 1903 Radius and ulna fracture 813;Women;108 Cßceres;Group 1904 Femur fracture 820-821;Both sexes;680 Cßceres;Group 1904 Femur fracture 820-821;Men;183 Cßceres;Group 1904 Femur fracture 820-821;Women;497 Cßceres;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;258 Cßceres;Group 1905 Leg fracture, including the ankle 823-824;Men;124 Cßceres;Group 1905 Leg fracture, including the ankle 823-824;Women;134 Cßceres;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;908 Cßceres;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;529 Cßceres;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;379 Cßceres;Group 1907 Burns 940-949;Both sexes;70 Cßceres;Group 1907 Burns 940-949;Men;36 Cßceres;Group 1907 Burns 940-949;Women;34 Cßceres;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;89 Cßceres;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;42 Cßceres;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;47 Cßceres;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;617 Cßceres;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;311 Cßceres;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;306 Cßceres;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;5 Cßceres;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Cßceres;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;3 Cßceres;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;114 Cßceres;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;55 Cßceres;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;59 Cßceres;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;785 Cßceres;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;375 Cßceres;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;410 Cßceres;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;5 Cßceres;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;3 Cßceres;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2 Cßceres;Group 2102 Contraceptive management V25;Both sexes;29 Cßceres;Group 2102 Contraceptive management V25;Men;2 Cßceres;Group 2102 Contraceptive management V25;Women;27 Cßceres;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Cßceres;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Cßceres;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Cßceres;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;358 Cßceres;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;193 Cßceres;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;165 Cßceres;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;393 Cßceres;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;177 Cßceres;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;216 GALICIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;293.807 GALICIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;142.684 GALICIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;151.123 GALICIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;6.045 GALICIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;3.363 GALICIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2.682 GALICIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1.075 GALICIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;567 GALICIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;508 GALICIA;Group 0102 Imprecise intestinal infections 009;Both sexes;199 GALICIA;Group 0102 Imprecise intestinal infections 009;Men;106 GALICIA;Group 0102 Imprecise intestinal infections 009;Women;93 GALICIA;Group 0103 Tuberculosis 010-018, 137;Both sexes;303 GALICIA;Group 0103 Tuberculosis 010-018, 137;Men;200 GALICIA;Group 0103 Tuberculosis 010-018, 137;Women;103 GALICIA;Group 0104 Septicaemia 038;Both sexes;2.115 GALICIA;Group 0104 Septicaemia 038;Men;1.115 GALICIA;Group 0104 Septicaemia 038;Women;1.000 GALICIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;190 GALICIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;143 GALICIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;47 GALICIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;2.163 GALICIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;1.232 GALICIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;931 GALICIA;Group 0200 Neoplasms 140-239;Both sexes;30.261 GALICIA;Group 0200 Neoplasms 140-239;Men;16.191 GALICIA;Group 0200 Neoplasms 140-239;Women;14.070 GALICIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;3.299 GALICIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1.944 GALICIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;1.355 GALICIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;2.060 GALICIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1.586 GALICIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;474 GALICIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;477 GALICIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;269 GALICIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;208 GALICIA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;2.116 GALICIA;Group 0204 Malignant neoplasm of breast 174-175;Men;16 GALICIA;Group 0204 Malignant neoplasm of breast 174-175;Women;2.100 GALICIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;659 GALICIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. GALICIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;659 GALICIA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;254 GALICIA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. GALICIA;Group 0206 Malignant neoplasm of ovary 1830;Women;254 GALICIA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.640 GALICIA;Group 0207 Malignant neoplasm of prostate 185;Men;1.640 GALICIA;Group 0207 Malignant neoplasm of prostate 185;Women;.. GALICIA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;2.390 GALICIA;Group 0208 Malignant neoplasm of bladder 188;Men;1.998 GALICIA;Group 0208 Malignant neoplasm of bladder 188;Women;392 GALICIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;11.543 GALICIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;6.806 GALICIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;4.737 GALICIA;Group 0210 Carcinoma in situ 230-234;Both sexes;726 GALICIA;Group 0210 Carcinoma in situ 230-234;Men;330 GALICIA;Group 0210 Carcinoma in situ 230-234;Women;396 GALICIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;381 GALICIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;247 GALICIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;134 GALICIA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1.205 GALICIA;Grupo 0212 Leiomyoma of uterus 218;Men;.. GALICIA;Grupo 0212 Leiomyoma of uterus 218;Women;1.205 GALICIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;3.511 GALICIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.355 GALICIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;2.156 GALICIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2.805 GALICIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1.401 GALICIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1.404 GALICIA;Group 0301 Anaemias 280-285;Both sexes;1.808 GALICIA;Group 0301 Anaemias 280-285;Men;897 GALICIA;Group 0301 Anaemias 280-285;Women;911 GALICIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;997 GALICIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;504 GALICIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;493 GALICIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;4.567 GALICIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.757 GALICIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2.810 GALICIA;Group 0401 Diabetes mellitus 249-250;Both sexes;1.563 GALICIA;Group 0401 Diabetes mellitus 249-250;Men;821 GALICIA;Group 0401 Diabetes mellitus 249-250;Women;742 GALICIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;3.004 GALICIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;936 GALICIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;2.068 GALICIA;Group 0500 Mental disorders 290-319;Both sexes;5.556 GALICIA;Group 0500 Mental disorders 290-319;Men;2.878 GALICIA;Group 0500 Mental disorders 290-319;Women;2.678 GALICIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;206 GALICIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;77 GALICIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;129 GALICIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;474 GALICIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;385 GALICIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;89 GALICIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;262 GALICIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;205 GALICIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;57 GALICIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.567 GALICIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;874 GALICIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;693 GALICIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1.221 GALICIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;477 GALICIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;744 GALICIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.826 GALICIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;860 GALICIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;966 GALICIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5.568 GALICIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.718 GALICIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.850 GALICIA;Group 0601 Alzheimer's disease 3310;Both sexes;112 GALICIA;Group 0601 Alzheimer's disease 3310;Men;46 GALICIA;Group 0601 Alzheimer's disease 3310;Women;66 GALICIA;Group 0602 Multiple sclerosis 340;Both sexes;284 GALICIA;Group 0602 Multiple sclerosis 340;Men;108 GALICIA;Group 0602 Multiple sclerosis 340;Women;176 GALICIA;Group 0603 Epilepsy 345;Both sexes;967 GALICIA;Group 0603 Epilepsy 345;Men;473 GALICIA;Group 0603 Epilepsy 345;Women;494 GALICIA;Group 0604 Transient cerebral ischemia 435;Both sexes;963 GALICIA;Group 0604 Transient cerebral ischemia 435;Men;485 GALICIA;Group 0604 Transient cerebral ischemia 435;Women;478 GALICIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.242 GALICIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.606 GALICIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.636 GALICIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1.394 GALICIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;705 GALICIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;689 GALICIA;Grupo 0701 Cataract 366;Both sexes;88 GALICIA;Grupo 0701 Cataract 366;Men;46 GALICIA;Grupo 0701 Cataract 366;Women;42 GALICIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1.306 GALICIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;659 GALICIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;647 GALICIA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1.187 GALICIA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;616 GALICIA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;571 GALICIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;39.501 GALICIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;22.116 GALICIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;17.385 GALICIA;Group 0901 Hypertensive disease 401-405;Both sexes;2.342 GALICIA;Group 0901 Hypertensive disease 401-405;Men;1.110 GALICIA;Group 0901 Hypertensive disease 401-405;Women;1.232 GALICIA;Group 0902 Angina pectoris 4111, 413;Both sexes;1.413 GALICIA;Group 0902 Angina pectoris 4111, 413;Men;880 GALICIA;Group 0902 Angina pectoris 4111, 413;Women;533 GALICIA;Group 0903 Acute myocardial infarction 410;Both sexes;3.251 GALICIA;Group 0903 Acute myocardial infarction 410;Men;2.334 GALICIA;Group 0903 Acute myocardial infarction 410;Women;917 GALICIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2.696 GALICIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;2.103 GALICIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;593 GALICIA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1.522 GALICIA;Group 0905 Diseases of the lungs circulation 415-417;Men;615 GALICIA;Group 0905 Diseases of the lungs circulation 415-417;Women;907 GALICIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4.548 GALICIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2.560 GALICIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.988 GALICIA;Grupo 0907 Heart failure 428;Both sexes;8.201 GALICIA;Grupo 0907 Heart failure 428;Men;4.060 GALICIA;Grupo 0907 Heart failure 428;Women;4.141 GALICIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;6.657 GALICIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;3.298 GALICIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;3.359 GALICIA;Grupo 0909 Atherosclerosis 440;Both sexes;1.503 GALICIA;Grupo 0909 Atherosclerosis 440;Men;1.095 GALICIA;Grupo 0909 Atherosclerosis 440;Women;408 GALICIA;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.031 GALICIA;Group 0910 Varicose veins of lower extremities 454;Men;310 GALICIA;Group 0910 Varicose veins of lower extremities 454;Women;721 GALICIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;6.337 GALICIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;3.751 GALICIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2.586 GALICIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;40.810 GALICIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;22.720 GALICIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;18.090 GALICIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.310 GALICIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;685 GALICIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;625 GALICIA;Group 1002 Pneumonia 480-486;Both sexes;9.112 GALICIA;Group 1002 Pneumonia 480-486;Men;5.261 GALICIA;Group 1002 Pneumonia 480-486;Women;3.851 GALICIA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.491 GALICIA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;821 GALICIA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;670 GALICIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1.811 GALICIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.002 GALICIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;809 GALICIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;2.715 GALICIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1.706 GALICIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;1.009 GALICIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;6.364 GALICIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;4.771 GALICIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1.593 GALICIA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.607 GALICIA;Group 1007 Asthma 4930-4931,4938-4939;Men;430 GALICIA;Group 1007 Asthma 4930-4931,4938-4939;Women;1.177 GALICIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;16.400 GALICIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;8.044 GALICIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;8.356 GALICIA;Group 1100 Diseases of the digestive system 520-579;Both sexes;34.723 GALICIA;Group 1100 Diseases of the digestive system 520-579;Men;19.545 GALICIA;Group 1100 Diseases of the digestive system 520-579;Women;15.178 GALICIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;446 GALICIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;214 GALICIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;232 GALICIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;466 GALICIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;272 GALICIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;194 GALICIA;Group 1103 Diseases of the esophagus 530;Both sexes;558 GALICIA;Group 1103 Diseases of the esophagus 530;Men;353 GALICIA;Group 1103 Diseases of the esophagus 530;Women;205 GALICIA;Group 1104 Peptic ulcer 531-534;Both sexes;550 GALICIA;Group 1104 Peptic ulcer 531-534;Men;364 GALICIA;Group 1104 Peptic ulcer 531-534;Women;186 GALICIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;743 GALICIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;400 GALICIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;343 GALICIA;Group 1106 Appendicitis 540-543;Both sexes;2.989 GALICIA;Group 1106 Appendicitis 540-543;Men;1.709 GALICIA;Group 1106 Appendicitis 540-543;Women;1.280 GALICIA;Group 1107 Inguinal hernia 550;Both sexes;3.519 GALICIA;Group 1107 Inguinal hernia 550;Men;3.128 GALICIA;Group 1107 Inguinal hernia 550;Women;391 GALICIA;Group 1108 Other abdominal hernia 551-553;Both sexes;2.475 GALICIA;Group 1108 Other abdominal hernia 551-553;Men;1.235 GALICIA;Group 1108 Other abdominal hernia 551-553;Women;1.240 GALICIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;674 GALICIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;332 GALICIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;342 GALICIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.673 GALICIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;781 GALICIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;892 GALICIA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1.809 GALICIA;Group 1111 Intestinal obstruction without hernia 560;Men;951 GALICIA;Group 1111 Intestinal obstruction without hernia 560;Women;858 GALICIA;Group 1112 Intestinal diverticulosis 562;Both sexes;1.653 GALICIA;Group 1112 Intestinal diverticulosis 562;Men;789 GALICIA;Group 1112 Intestinal diverticulosis 562;Women;864 GALICIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.971 GALICIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1.294 GALICIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;677 GALICIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;1.205 GALICIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;539 GALICIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;666 GALICIA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;811 GALICIA;Group 1115 Alcoholic hepatitis 5710-5713;Men;648 GALICIA;Group 1115 Alcoholic hepatitis 5710-5713;Women;163 GALICIA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1.457 GALICIA;Group 1116 Other diseases of the liver 570,5714-573;Men;902 GALICIA;Group 1116 Other diseases of the liver 570,5714-573;Women;555 GALICIA;Group 1117 Cholelithiasis 574;Both sexes;6.716 GALICIA;Group 1117 Cholelithiasis 574;Men;2.887 GALICIA;Group 1117 Cholelithiasis 574;Women;3.829 GALICIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.549 GALICIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;868 GALICIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;681 GALICIA;Group 1119 Pancreatic diseases 577;Both sexes;2.022 GALICIA;Group 1119 Pancreatic diseases 577;Men;1.091 GALICIA;Group 1119 Pancreatic diseases 577;Women;931 GALICIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1.437 GALICIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;788 GALICIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;649 GALICIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;3.548 GALICIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1.925 GALICIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1.623 GALICIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;2.389 GALICIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1.351 GALICIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1.038 GALICIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;220 GALICIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;119 GALICIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;101 GALICIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;939 GALICIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;455 GALICIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;484 GALICIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;21.798 GALICIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;9.946 GALICIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;11.852 GALICIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. GALICIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. GALICIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. GALICIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. GALICIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. GALICIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. GALICIA;Group 1303 Internal derangement of knee 717;Both sexes;2.750 GALICIA;Group 1303 Internal derangement of knee 717;Men;1.891 GALICIA;Group 1303 Internal derangement of knee 717;Women;859 GALICIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;8.798 GALICIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;3.514 GALICIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;5.284 GALICIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;484 GALICIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;178 GALICIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;306 GALICIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;734 GALICIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;372 GALICIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;362 GALICIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.550 GALICIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;876 GALICIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;674 GALICIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;321 GALICIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;152 GALICIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;169 GALICIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;3.497 GALICIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.801 GALICIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;1.696 GALICIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;3.664 GALICIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;1.162 GALICIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;2.502 GALICIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;17.689 GALICIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;8.492 GALICIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;9.197 GALICIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.488 GALICIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;579 GALICIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;909 GALICIA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.573 GALICIA;Group 1402 Renal failure 5836-5837, 584-586;Men;896 GALICIA;Group 1402 Renal failure 5836-5837, 584-586;Women;677 GALICIA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;2.009 GALICIA;Group 1403 Urolithiasis 592, 594, 7880;Men;1.224 GALICIA;Group 1403 Urolithiasis 592, 594, 7880;Women;785 GALICIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;5.510 GALICIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2.562 GALICIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2.948 GALICIA;Group 1405 Prostatic hyperplasia 600;Both sexes;1.770 GALICIA;Group 1405 Prostatic hyperplasia 600;Men;1.770 GALICIA;Group 1405 Prostatic hyperplasia 600;Women;.. GALICIA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;1.361 GALICIA;Group 1406 Other diseases of the male genital organs 601-608;Men;1.361 GALICIA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. GALICIA;Group 1407 Disorders of breast 610-612;Both sexes;735 GALICIA;Group 1407 Disorders of breast 610-612;Men;80 GALICIA;Group 1407 Disorders of breast 610-612;Women;655 GALICIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;490 GALICIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. GALICIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;490 GALICIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;250 GALICIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. GALICIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;250 GALICIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2.503 GALICIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;20 GALICIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2.483 GALICIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;25.055 GALICIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. GALICIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;25.055 GALICIA;Group 1501 Legally induced abortion 635;Both sexes;259 GALICIA;Group 1501 Legally induced abortion 635;Men;.. GALICIA;Group 1501 Legally induced abortion 635;Women;259 GALICIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;2.413 GALICIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. GALICIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;2.413 GALICIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;14.749 GALICIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. GALICIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;14.749 GALICIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;4.085 GALICIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. GALICIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;4.085 GALICIA;Group 1505 Single spontaneous delivery 650;Both sexes;1.161 GALICIA;Group 1505 Single spontaneous delivery 650;Men;.. GALICIA;Group 1505 Single spontaneous delivery 650;Women;1.161 GALICIA;Group 1506 Other deliveries 6695-6697;Both sexes;557 GALICIA;Group 1506 Other deliveries 6695-6697;Men;.. GALICIA;Group 1506 Other deliveries 6695-6697;Women;557 GALICIA;Group 1507 Complications related to the puerperium 670-676;Both sexes;212 GALICIA;Group 1507 Complications related to the puerperium 670-676;Men;.. GALICIA;Group 1507 Complications related to the puerperium 670-676;Women;212 GALICIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.619 GALICIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. GALICIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.619 GALICIA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;3.486 GALICIA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.927 GALICIA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1.559 GALICIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;776 GALICIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;414 GALICIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;362 GALICIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2.710 GALICIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1.513 GALICIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;1.197 GALICIA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;2.083 GALICIA;Grupo 1700 Congenital abnormalities 740-759;Men;1.285 GALICIA;Grupo 1700 Congenital abnormalities 740-759;Women;798 GALICIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;12.547 GALICIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;6.795 GALICIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;5.752 GALICIA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.251 GALICIA;Group 1801 Pain in throat and chest 7841, 7865;Men;689 GALICIA;Group 1801 Pain in throat and chest 7841, 7865;Women;562 GALICIA;Group 1802 Abdominal pain 7890;Both sexes;1.072 GALICIA;Group 1802 Abdominal pain 7890;Men;417 GALICIA;Group 1802 Abdominal pain 7890;Women;655 GALICIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.824 GALICIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;884 GALICIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;940 GALICIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;8.400 GALICIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4.805 GALICIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3.595 GALICIA;Group 1900 Injuries and poisoning 800-999;Both sexes;29.130 GALICIA;Group 1900 Injuries and poisoning 800-999;Men;15.040 GALICIA;Group 1900 Injuries and poisoning 800-999;Women;14.090 GALICIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.951 GALICIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1.137 GALICIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;814 GALICIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;938 GALICIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;677 GALICIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;261 GALICIA;Group 1903 Radius and ulna fracture 813;Both sexes;1.682 GALICIA;Group 1903 Radius and ulna fracture 813;Men;741 GALICIA;Group 1903 Radius and ulna fracture 813;Women;941 GALICIA;Group 1904 Femur fracture 820-821;Both sexes;4.265 GALICIA;Group 1904 Femur fracture 820-821;Men;1.068 GALICIA;Group 1904 Femur fracture 820-821;Women;3.197 GALICIA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;2.130 GALICIA;Group 1905 Leg fracture, including the ankle 823-824;Men;973 GALICIA;Group 1905 Leg fracture, including the ankle 823-824;Women;1.157 GALICIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;8.950 GALICIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;5.389 GALICIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;3.561 GALICIA;Group 1907 Burns 940-949;Both sexes;267 GALICIA;Group 1907 Burns 940-949;Men;170 GALICIA;Group 1907 Burns 940-949;Women;97 GALICIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;649 GALICIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;284 GALICIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;365 GALICIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;7.674 GALICIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;4.254 GALICIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;3.420 GALICIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;69 GALICIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;40 GALICIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;29 GALICIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;555 GALICIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;307 GALICIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;248 GALICIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;6.054 GALICIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;3.264 GALICIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2.790 GALICIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;258 GALICIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;137 GALICIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;121 GALICIA;Group 2102 Contraceptive management V25;Both sexes;80 GALICIA;Group 2102 Contraceptive management V25;Men;3 GALICIA;Group 2102 Contraceptive management V25;Women;77 GALICIA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. GALICIA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. GALICIA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. GALICIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;2.893 GALICIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1.782 GALICIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1.111 GALICIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2.823 GALICIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.342 GALICIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.481 Coru±a, A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;125.291 Coru±a, A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;61.033 Coru±a, A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;64.258 Coru±a, A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.503 Coru±a, A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.416 Coru±a, A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.087 Coru±a, A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;364 Coru±a, A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;188 Coru±a, A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;176 Coru±a, A;Group 0102 Imprecise intestinal infections 009;Both sexes;111 Coru±a, A;Group 0102 Imprecise intestinal infections 009;Men;56 Coru±a, A;Group 0102 Imprecise intestinal infections 009;Women;55 Coru±a, A;Group 0103 Tuberculosis 010-018, 137;Both sexes;145 Coru±a, A;Group 0103 Tuberculosis 010-018, 137;Men;104 Coru±a, A;Group 0103 Tuberculosis 010-018, 137;Women;41 Coru±a, A;Group 0104 Septicaemia 038;Both sexes;827 Coru±a, A;Group 0104 Septicaemia 038;Men;452 Coru±a, A;Group 0104 Septicaemia 038;Women;375 Coru±a, A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;90 Coru±a, A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;64 Coru±a, A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;26 Coru±a, A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;966 Coru±a, A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;552 Coru±a, A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;414 Coru±a, A;Group 0200 Neoplasms 140-239;Both sexes;14.456 Coru±a, A;Group 0200 Neoplasms 140-239;Men;7.724 Coru±a, A;Group 0200 Neoplasms 140-239;Women;6.732 Coru±a, A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.486 Coru±a, A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;884 Coru±a, A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;602 Coru±a, A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.119 Coru±a, A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;857 Coru±a, A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;262 Coru±a, A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;298 Coru±a, A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;156 Coru±a, A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;142 Coru±a, A;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.014 Coru±a, A;Group 0204 Malignant neoplasm of breast 174-175;Men;6 Coru±a, A;Group 0204 Malignant neoplasm of breast 174-175;Women;1.008 Coru±a, A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;350 Coru±a, A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Coru±a, A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;350 Coru±a, A;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;152 Coru±a, A;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Coru±a, A;Group 0206 Malignant neoplasm of ovary 1830;Women;152 Coru±a, A;Group 0207 Malignant neoplasm of prostate 185;Both sexes;703 Coru±a, A;Group 0207 Malignant neoplasm of prostate 185;Men;703 Coru±a, A;Group 0207 Malignant neoplasm of prostate 185;Women;.. Coru±a, A;Group 0208 Malignant neoplasm of bladder 188;Both sexes;923 Coru±a, A;Group 0208 Malignant neoplasm of bladder 188;Men;778 Coru±a, A;Group 0208 Malignant neoplasm of bladder 188;Women;145 Coru±a, A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5.442 Coru±a, A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3.244 Coru±a, A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2.198 Coru±a, A;Group 0210 Carcinoma in situ 230-234;Both sexes;434 Coru±a, A;Group 0210 Carcinoma in situ 230-234;Men;241 Coru±a, A;Group 0210 Carcinoma in situ 230-234;Women;193 Coru±a, A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;217 Coru±a, A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;153 Coru±a, A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;64 Coru±a, A;Grupo 0212 Leiomyoma of uterus 218;Both sexes;588 Coru±a, A;Grupo 0212 Leiomyoma of uterus 218;Men;.. Coru±a, A;Grupo 0212 Leiomyoma of uterus 218;Women;588 Coru±a, A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.730 Coru±a, A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;702 Coru±a, A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.028 Coru±a, A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.097 Coru±a, A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;526 Coru±a, A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;571 Coru±a, A;Group 0301 Anaemias 280-285;Both sexes;666 Coru±a, A;Group 0301 Anaemias 280-285;Men;321 Coru±a, A;Group 0301 Anaemias 280-285;Women;345 Coru±a, A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;431 Coru±a, A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;205 Coru±a, A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;226 Coru±a, A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.790 Coru±a, A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;672 Coru±a, A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.118 Coru±a, A;Group 0401 Diabetes mellitus 249-250;Both sexes;630 Coru±a, A;Group 0401 Diabetes mellitus 249-250;Men;352 Coru±a, A;Group 0401 Diabetes mellitus 249-250;Women;278 Coru±a, A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.160 Coru±a, A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;320 Coru±a, A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;840 Coru±a, A;Group 0500 Mental disorders 290-319;Both sexes;2.224 Coru±a, A;Group 0500 Mental disorders 290-319;Men;1.175 Coru±a, A;Group 0500 Mental disorders 290-319;Women;1.049 Coru±a, A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;81 Coru±a, A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;33 Coru±a, A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;48 Coru±a, A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;217 Coru±a, A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;176 Coru±a, A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;41 Coru±a, A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;141 Coru±a, A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;100 Coru±a, A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;41 Coru±a, A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;598 Coru±a, A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;346 Coru±a, A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;252 Coru±a, A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;472 Coru±a, A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;191 Coru±a, A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;281 Coru±a, A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;715 Coru±a, A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;329 Coru±a, A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;386 Coru±a, A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.294 Coru±a, A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.141 Coru±a, A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.153 Coru±a, A;Group 0601 Alzheimer's disease 3310;Both sexes;30 Coru±a, A;Group 0601 Alzheimer's disease 3310;Men;10 Coru±a, A;Group 0601 Alzheimer's disease 3310;Women;20 Coru±a, A;Group 0602 Multiple sclerosis 340;Both sexes;72 Coru±a, A;Group 0602 Multiple sclerosis 340;Men;35 Coru±a, A;Group 0602 Multiple sclerosis 340;Women;37 Coru±a, A;Group 0603 Epilepsy 345;Both sexes;367 Coru±a, A;Group 0603 Epilepsy 345;Men;176 Coru±a, A;Group 0603 Epilepsy 345;Women;191 Coru±a, A;Group 0604 Transient cerebral ischemia 435;Both sexes;387 Coru±a, A;Group 0604 Transient cerebral ischemia 435;Men;211 Coru±a, A;Group 0604 Transient cerebral ischemia 435;Women;176 Coru±a, A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.438 Coru±a, A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;709 Coru±a, A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;729 Coru±a, A;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;513 Coru±a, A;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;242 Coru±a, A;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;271 Coru±a, A;Grupo 0701 Cataract 366;Both sexes;19 Coru±a, A;Grupo 0701 Cataract 366;Men;12 Coru±a, A;Grupo 0701 Cataract 366;Women;7 Coru±a, A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;494 Coru±a, A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;230 Coru±a, A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;264 Coru±a, A;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;484 Coru±a, A;Group 0800 Diseases of the ear and the mastoid 380-389;Men;259 Coru±a, A;Group 0800 Diseases of the ear and the mastoid 380-389;Women;225 Coru±a, A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;17.608 Coru±a, A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10.123 Coru±a, A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;7.485 Coru±a, A;Group 0901 Hypertensive disease 401-405;Both sexes;1.032 Coru±a, A;Group 0901 Hypertensive disease 401-405;Men;520 Coru±a, A;Group 0901 Hypertensive disease 401-405;Women;512 Coru±a, A;Group 0902 Angina pectoris 4111, 413;Both sexes;576 Coru±a, A;Group 0902 Angina pectoris 4111, 413;Men;341 Coru±a, A;Group 0902 Angina pectoris 4111, 413;Women;235 Coru±a, A;Group 0903 Acute myocardial infarction 410;Both sexes;1.616 Coru±a, A;Group 0903 Acute myocardial infarction 410;Men;1.176 Coru±a, A;Group 0903 Acute myocardial infarction 410;Women;440 Coru±a, A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.501 Coru±a, A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.176 Coru±a, A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;325 Coru±a, A;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;580 Coru±a, A;Group 0905 Diseases of the lungs circulation 415-417;Men;233 Coru±a, A;Group 0905 Diseases of the lungs circulation 415-417;Women;347 Coru±a, A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.965 Coru±a, A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.108 Coru±a, A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;857 Coru±a, A;Grupo 0907 Heart failure 428;Both sexes;3.257 Coru±a, A;Grupo 0907 Heart failure 428;Men;1.675 Coru±a, A;Grupo 0907 Heart failure 428;Women;1.582 Coru±a, A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.738 Coru±a, A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.365 Coru±a, A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.373 Coru±a, A;Grupo 0909 Atherosclerosis 440;Both sexes;614 Coru±a, A;Grupo 0909 Atherosclerosis 440;Men;468 Coru±a, A;Grupo 0909 Atherosclerosis 440;Women;146 Coru±a, A;Group 0910 Varicose veins of lower extremities 454;Both sexes;546 Coru±a, A;Group 0910 Varicose veins of lower extremities 454;Men;148 Coru±a, A;Group 0910 Varicose veins of lower extremities 454;Women;398 Coru±a, A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3.183 Coru±a, A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.913 Coru±a, A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.270 Coru±a, A;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;15.763 Coru±a, A;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;9.028 Coru±a, A;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6.735 Coru±a, A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;564 Coru±a, A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;292 Coru±a, A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;272 Coru±a, A;Group 1002 Pneumonia 480-486;Both sexes;3.416 Coru±a, A;Group 1002 Pneumonia 480-486;Men;2.001 Coru±a, A;Group 1002 Pneumonia 480-486;Women;1.415 Coru±a, A;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;492 Coru±a, A;Group 1003 Acute bronchitis and bronchiolitis 466;Men;270 Coru±a, A;Group 1003 Acute bronchitis and bronchiolitis 466;Women;222 Coru±a, A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;716 Coru±a, A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;386 Coru±a, A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;330 Coru±a, A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.140 Coru±a, A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;721 Coru±a, A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;419 Coru±a, A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.758 Coru±a, A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.190 Coru±a, A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;568 Coru±a, A;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;726 Coru±a, A;Group 1007 Asthma 4930-4931,4938-4939;Men;161 Coru±a, A;Group 1007 Asthma 4930-4931,4938-4939;Women;565 Coru±a, A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.951 Coru±a, A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3.007 Coru±a, A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.944 Coru±a, A;Group 1100 Diseases of the digestive system 520-579;Both sexes;14.616 Coru±a, A;Group 1100 Diseases of the digestive system 520-579;Men;8.150 Coru±a, A;Group 1100 Diseases of the digestive system 520-579;Women;6.466 Coru±a, A;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;204 Coru±a, A;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;90 Coru±a, A;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;114 Coru±a, A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;203 Coru±a, A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;114 Coru±a, A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;89 Coru±a, A;Group 1103 Diseases of the esophagus 530;Both sexes;239 Coru±a, A;Group 1103 Diseases of the esophagus 530;Men;150 Coru±a, A;Group 1103 Diseases of the esophagus 530;Women;89 Coru±a, A;Group 1104 Peptic ulcer 531-534;Both sexes;243 Coru±a, A;Group 1104 Peptic ulcer 531-534;Men;162 Coru±a, A;Group 1104 Peptic ulcer 531-534;Women;81 Coru±a, A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;271 Coru±a, A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;142 Coru±a, A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;129 Coru±a, A;Group 1106 Appendicitis 540-543;Both sexes;1.276 Coru±a, A;Group 1106 Appendicitis 540-543;Men;722 Coru±a, A;Group 1106 Appendicitis 540-543;Women;554 Coru±a, A;Group 1107 Inguinal hernia 550;Both sexes;1.385 Coru±a, A;Group 1107 Inguinal hernia 550;Men;1.251 Coru±a, A;Group 1107 Inguinal hernia 550;Women;134 Coru±a, A;Group 1108 Other abdominal hernia 551-553;Both sexes;1.074 Coru±a, A;Group 1108 Other abdominal hernia 551-553;Men;536 Coru±a, A;Group 1108 Other abdominal hernia 551-553;Women;538 Coru±a, A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;322 Coru±a, A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;156 Coru±a, A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;166 Coru±a, A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;599 Coru±a, A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;291 Coru±a, A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;308 Coru±a, A;Group 1111 Intestinal obstruction without hernia 560;Both sexes;745 Coru±a, A;Group 1111 Intestinal obstruction without hernia 560;Men;390 Coru±a, A;Group 1111 Intestinal obstruction without hernia 560;Women;355 Coru±a, A;Group 1112 Intestinal diverticulosis 562;Both sexes;681 Coru±a, A;Group 1112 Intestinal diverticulosis 562;Men;311 Coru±a, A;Group 1112 Intestinal diverticulosis 562;Women;370 Coru±a, A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;888 Coru±a, A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;594 Coru±a, A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;294 Coru±a, A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;458 Coru±a, A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;217 Coru±a, A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;241 Coru±a, A;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;373 Coru±a, A;Group 1115 Alcoholic hepatitis 5710-5713;Men;305 Coru±a, A;Group 1115 Alcoholic hepatitis 5710-5713;Women;68 Coru±a, A;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;572 Coru±a, A;Group 1116 Other diseases of the liver 570,5714-573;Men;319 Coru±a, A;Group 1116 Other diseases of the liver 570,5714-573;Women;253 Coru±a, A;Group 1117 Cholelithiasis 574;Both sexes;3.105 Coru±a, A;Group 1117 Cholelithiasis 574;Men;1.316 Coru±a, A;Group 1117 Cholelithiasis 574;Women;1.789 Coru±a, A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;529 Coru±a, A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;297 Coru±a, A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;232 Coru±a, A;Group 1119 Pancreatic diseases 577;Both sexes;831 Coru±a, A;Group 1119 Pancreatic diseases 577;Men;438 Coru±a, A;Group 1119 Pancreatic diseases 577;Women;393 Coru±a, A;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;618 Coru±a, A;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;349 Coru±a, A;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;269 Coru±a, A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.408 Coru±a, A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;783 Coru±a, A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;625 Coru±a, A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;923 Coru±a, A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;539 Coru±a, A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;384 Coru±a, A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;91 Coru±a, A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;55 Coru±a, A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;36 Coru±a, A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;394 Coru±a, A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;189 Coru±a, A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;205 Coru±a, A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9.159 Coru±a, A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.026 Coru±a, A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5.133 Coru±a, A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Coru±a, A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Coru±a, A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Coru±a, A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Coru±a, A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Coru±a, A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Coru±a, A;Group 1303 Internal derangement of knee 717;Both sexes;882 Coru±a, A;Group 1303 Internal derangement of knee 717;Men;639 Coru±a, A;Group 1303 Internal derangement of knee 717;Women;243 Coru±a, A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.540 Coru±a, A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.383 Coru±a, A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.157 Coru±a, A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;254 Coru±a, A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;75 Coru±a, A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;179 Coru±a, A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;280 Coru±a, A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;142 Coru±a, A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;138 Coru±a, A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;713 Coru±a, A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;395 Coru±a, A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;318 Coru±a, A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;136 Coru±a, A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;69 Coru±a, A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;67 Coru±a, A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.536 Coru±a, A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;772 Coru±a, A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;764 Coru±a, A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.818 Coru±a, A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;551 Coru±a, A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.267 Coru±a, A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;7.166 Coru±a, A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3.470 Coru±a, A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3.696 Coru±a, A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;592 Coru±a, A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;250 Coru±a, A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;342 Coru±a, A;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;651 Coru±a, A;Group 1402 Renal failure 5836-5837, 584-586;Men;381 Coru±a, A;Group 1402 Renal failure 5836-5837, 584-586;Women;270 Coru±a, A;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;799 Coru±a, A;Group 1403 Urolithiasis 592, 594, 7880;Men;464 Coru±a, A;Group 1403 Urolithiasis 592, 594, 7880;Women;335 Coru±a, A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.088 Coru±a, A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.047 Coru±a, A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.041 Coru±a, A;Group 1405 Prostatic hyperplasia 600;Both sexes;778 Coru±a, A;Group 1405 Prostatic hyperplasia 600;Men;778 Coru±a, A;Group 1405 Prostatic hyperplasia 600;Women;.. Coru±a, A;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;506 Coru±a, A;Group 1406 Other diseases of the male genital organs 601-608;Men;506 Coru±a, A;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Coru±a, A;Group 1407 Disorders of breast 610-612;Both sexes;378 Coru±a, A;Group 1407 Disorders of breast 610-612;Men;39 Coru±a, A;Group 1407 Disorders of breast 610-612;Women;339 Coru±a, A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;170 Coru±a, A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Coru±a, A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;170 Coru±a, A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;98 Coru±a, A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Coru±a, A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;98 Coru±a, A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.106 Coru±a, A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;5 Coru±a, A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.101 Coru±a, A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;11.336 Coru±a, A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Coru±a, A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;11.336 Coru±a, A;Group 1501 Legally induced abortion 635;Both sexes;64 Coru±a, A;Group 1501 Legally induced abortion 635;Men;.. Coru±a, A;Group 1501 Legally induced abortion 635;Women;64 Coru±a, A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1.162 Coru±a, A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Coru±a, A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1.162 Coru±a, A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;7.195 Coru±a, A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Coru±a, A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;7.195 Coru±a, A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.250 Coru±a, A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Coru±a, A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.250 Coru±a, A;Group 1505 Single spontaneous delivery 650;Both sexes;575 Coru±a, A;Group 1505 Single spontaneous delivery 650;Men;.. Coru±a, A;Group 1505 Single spontaneous delivery 650;Women;575 Coru±a, A;Group 1506 Other deliveries 6695-6697;Both sexes;229 Coru±a, A;Group 1506 Other deliveries 6695-6697;Men;.. Coru±a, A;Group 1506 Other deliveries 6695-6697;Women;229 Coru±a, A;Group 1507 Complications related to the puerperium 670-676;Both sexes;78 Coru±a, A;Group 1507 Complications related to the puerperium 670-676;Men;.. Coru±a, A;Group 1507 Complications related to the puerperium 670-676;Women;78 Coru±a, A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;783 Coru±a, A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Coru±a, A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;783 Coru±a, A;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.844 Coru±a, A;Group 1600 Some disorders originating in the perinatal period 760-779;Men;999 Coru±a, A;Group 1600 Some disorders originating in the perinatal period 760-779;Women;845 Coru±a, A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;324 Coru±a, A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;162 Coru±a, A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;162 Coru±a, A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.520 Coru±a, A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;837 Coru±a, A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;683 Coru±a, A;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.251 Coru±a, A;Grupo 1700 Congenital abnormalities 740-759;Men;767 Coru±a, A;Grupo 1700 Congenital abnormalities 740-759;Women;484 Coru±a, A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;4.603 Coru±a, A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2.511 Coru±a, A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.092 Coru±a, A;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;624 Coru±a, A;Group 1801 Pain in throat and chest 7841, 7865;Men;339 Coru±a, A;Group 1801 Pain in throat and chest 7841, 7865;Women;285 Coru±a, A;Group 1802 Abdominal pain 7890;Both sexes;404 Coru±a, A;Group 1802 Abdominal pain 7890;Men;160 Coru±a, A;Group 1802 Abdominal pain 7890;Women;244 Coru±a, A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;307 Coru±a, A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;158 Coru±a, A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;149 Coru±a, A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;3.268 Coru±a, A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.854 Coru±a, A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.414 Coru±a, A;Group 1900 Injuries and poisoning 800-999;Both sexes;12.166 Coru±a, A;Group 1900 Injuries and poisoning 800-999;Men;6.402 Coru±a, A;Group 1900 Injuries and poisoning 800-999;Women;5.764 Coru±a, A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;602 Coru±a, A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;360 Coru±a, A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;242 Coru±a, A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;478 Coru±a, A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;352 Coru±a, A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;126 Coru±a, A;Group 1903 Radius and ulna fracture 813;Both sexes;750 Coru±a, A;Group 1903 Radius and ulna fracture 813;Men;334 Coru±a, A;Group 1903 Radius and ulna fracture 813;Women;416 Coru±a, A;Group 1904 Femur fracture 820-821;Both sexes;1.734 Coru±a, A;Group 1904 Femur fracture 820-821;Men;416 Coru±a, A;Group 1904 Femur fracture 820-821;Women;1.318 Coru±a, A;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;858 Coru±a, A;Group 1905 Leg fracture, including the ankle 823-824;Men;384 Coru±a, A;Group 1905 Leg fracture, including the ankle 823-824;Women;474 Coru±a, A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.396 Coru±a, A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.101 Coru±a, A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.295 Coru±a, A;Group 1907 Burns 940-949;Both sexes;142 Coru±a, A;Group 1907 Burns 940-949;Men;87 Coru±a, A;Group 1907 Burns 940-949;Women;55 Coru±a, A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;210 Coru±a, A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;100 Coru±a, A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;110 Coru±a, A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.718 Coru±a, A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2.116 Coru±a, A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.602 Coru±a, A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;56 Coru±a, A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;33 Coru±a, A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;23 Coru±a, A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;222 Coru±a, A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;119 Coru±a, A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;103 Coru±a, A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;3.010 Coru±a, A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.619 Coru±a, A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.391 Coru±a, A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;132 Coru±a, A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;71 Coru±a, A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;61 Coru±a, A;Group 2102 Contraceptive management V25;Both sexes;19 Coru±a, A;Group 2102 Contraceptive management V25;Men;1 Coru±a, A;Group 2102 Contraceptive management V25;Women;18 Coru±a, A;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Coru±a, A;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Coru±a, A;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Coru±a, A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.305 Coru±a, A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;800 Coru±a, A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;505 Coru±a, A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.554 Coru±a, A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;747 Coru±a, A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;807 Lugo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;35.113 Lugo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;17.306 Lugo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;17.807 Lugo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;764 Lugo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;451 Lugo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;313 Lugo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;199 Lugo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;115 Lugo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;84 Lugo;Group 0102 Imprecise intestinal infections 009;Both sexes;27 Lugo;Group 0102 Imprecise intestinal infections 009;Men;19 Lugo;Group 0102 Imprecise intestinal infections 009;Women;8 Lugo;Group 0103 Tuberculosis 010-018, 137;Both sexes;24 Lugo;Group 0103 Tuberculosis 010-018, 137;Men;18 Lugo;Group 0103 Tuberculosis 010-018, 137;Women;6 Lugo;Group 0104 Septicaemia 038;Both sexes;158 Lugo;Group 0104 Septicaemia 038;Men;88 Lugo;Group 0104 Septicaemia 038;Women;70 Lugo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;16 Lugo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;14 Lugo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;2 Lugo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;340 Lugo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;197 Lugo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;143 Lugo;Group 0200 Neoplasms 140-239;Both sexes;2.906 Lugo;Group 0200 Neoplasms 140-239;Men;1.501 Lugo;Group 0200 Neoplasms 140-239;Women;1.405 Lugo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;418 Lugo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;268 Lugo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;150 Lugo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;125 Lugo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;101 Lugo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;24 Lugo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;31 Lugo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;24 Lugo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;7 Lugo;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;229 Lugo;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Lugo;Group 0204 Malignant neoplasm of breast 174-175;Women;229 Lugo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;87 Lugo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Lugo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;87 Lugo;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;30 Lugo;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Lugo;Group 0206 Malignant neoplasm of ovary 1830;Women;30 Lugo;Group 0207 Malignant neoplasm of prostate 185;Both sexes;118 Lugo;Group 0207 Malignant neoplasm of prostate 185;Men;118 Lugo;Group 0207 Malignant neoplasm of prostate 185;Women;.. Lugo;Group 0208 Malignant neoplasm of bladder 188;Both sexes;273 Lugo;Group 0208 Malignant neoplasm of bladder 188;Men;217 Lugo;Group 0208 Malignant neoplasm of bladder 188;Women;56 Lugo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.038 Lugo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;632 Lugo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;406 Lugo;Group 0210 Carcinoma in situ 230-234;Both sexes;65 Lugo;Group 0210 Carcinoma in situ 230-234;Men;25 Lugo;Group 0210 Carcinoma in situ 230-234;Women;40 Lugo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;29 Lugo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;15 Lugo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;14 Lugo;Grupo 0212 Leiomyoma of uterus 218;Both sexes;133 Lugo;Grupo 0212 Leiomyoma of uterus 218;Men;.. Lugo;Grupo 0212 Leiomyoma of uterus 218;Women;133 Lugo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;330 Lugo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;101 Lugo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;229 Lugo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;442 Lugo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;223 Lugo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;219 Lugo;Group 0301 Anaemias 280-285;Both sexes;286 Lugo;Group 0301 Anaemias 280-285;Men;139 Lugo;Group 0301 Anaemias 280-285;Women;147 Lugo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;156 Lugo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;84 Lugo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;72 Lugo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;632 Lugo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;282 Lugo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;350 Lugo;Group 0401 Diabetes mellitus 249-250;Both sexes;220 Lugo;Group 0401 Diabetes mellitus 249-250;Men;129 Lugo;Group 0401 Diabetes mellitus 249-250;Women;91 Lugo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;412 Lugo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;153 Lugo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;259 Lugo;Group 0500 Mental disorders 290-319;Both sexes;684 Lugo;Group 0500 Mental disorders 290-319;Men;333 Lugo;Group 0500 Mental disorders 290-319;Women;351 Lugo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;49 Lugo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;20 Lugo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;29 Lugo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;63 Lugo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;53 Lugo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;10 Lugo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;31 Lugo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;27 Lugo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;4 Lugo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;185 Lugo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;84 Lugo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;101 Lugo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;139 Lugo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;56 Lugo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;83 Lugo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;217 Lugo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;93 Lugo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;124 Lugo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;753 Lugo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;385 Lugo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;368 Lugo;Group 0601 Alzheimer's disease 3310;Both sexes;24 Lugo;Group 0601 Alzheimer's disease 3310;Men;11 Lugo;Group 0601 Alzheimer's disease 3310;Women;13 Lugo;Group 0602 Multiple sclerosis 340;Both sexes;58 Lugo;Group 0602 Multiple sclerosis 340;Men;21 Lugo;Group 0602 Multiple sclerosis 340;Women;37 Lugo;Group 0603 Epilepsy 345;Both sexes;155 Lugo;Group 0603 Epilepsy 345;Men;75 Lugo;Group 0603 Epilepsy 345;Women;80 Lugo;Group 0604 Transient cerebral ischemia 435;Both sexes;82 Lugo;Group 0604 Transient cerebral ischemia 435;Men;41 Lugo;Group 0604 Transient cerebral ischemia 435;Women;41 Lugo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;434 Lugo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;237 Lugo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;197 Lugo;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;246 Lugo;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;140 Lugo;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;106 Lugo;Grupo 0701 Cataract 366;Both sexes;35 Lugo;Grupo 0701 Cataract 366;Men;19 Lugo;Grupo 0701 Cataract 366;Women;16 Lugo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;211 Lugo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;121 Lugo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;90 Lugo;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;118 Lugo;Group 0800 Diseases of the ear and the mastoid 380-389;Men;64 Lugo;Group 0800 Diseases of the ear and the mastoid 380-389;Women;54 Lugo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4.648 Lugo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.643 Lugo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.005 Lugo;Group 0901 Hypertensive disease 401-405;Both sexes;383 Lugo;Group 0901 Hypertensive disease 401-405;Men;170 Lugo;Group 0901 Hypertensive disease 401-405;Women;213 Lugo;Group 0902 Angina pectoris 4111, 413;Both sexes;261 Lugo;Group 0902 Angina pectoris 4111, 413;Men;170 Lugo;Group 0902 Angina pectoris 4111, 413;Women;91 Lugo;Group 0903 Acute myocardial infarction 410;Both sexes;325 Lugo;Group 0903 Acute myocardial infarction 410;Men;236 Lugo;Group 0903 Acute myocardial infarction 410;Women;89 Lugo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;249 Lugo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;181 Lugo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;68 Lugo;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;240 Lugo;Group 0905 Diseases of the lungs circulation 415-417;Men;93 Lugo;Group 0905 Diseases of the lungs circulation 415-417;Women;147 Lugo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;539 Lugo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;320 Lugo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;219 Lugo;Grupo 0907 Heart failure 428;Both sexes;816 Lugo;Grupo 0907 Heart failure 428;Men;451 Lugo;Grupo 0907 Heart failure 428;Women;365 Lugo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;898 Lugo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;466 Lugo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;432 Lugo;Grupo 0909 Atherosclerosis 440;Both sexes;224 Lugo;Grupo 0909 Atherosclerosis 440;Men;154 Lugo;Grupo 0909 Atherosclerosis 440;Women;70 Lugo;Group 0910 Varicose veins of lower extremities 454;Both sexes;26 Lugo;Group 0910 Varicose veins of lower extremities 454;Men;11 Lugo;Group 0910 Varicose veins of lower extremities 454;Women;15 Lugo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;687 Lugo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;391 Lugo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;296 Lugo;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4.449 Lugo;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.615 Lugo;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.834 Lugo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;198 Lugo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;100 Lugo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;98 Lugo;Group 1002 Pneumonia 480-486;Both sexes;1.123 Lugo;Group 1002 Pneumonia 480-486;Men;698 Lugo;Group 1002 Pneumonia 480-486;Women;425 Lugo;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;134 Lugo;Group 1003 Acute bronchitis and bronchiolitis 466;Men;86 Lugo;Group 1003 Acute bronchitis and bronchiolitis 466;Women;48 Lugo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;108 Lugo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;58 Lugo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;50 Lugo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;247 Lugo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;148 Lugo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;99 Lugo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;604 Lugo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;460 Lugo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;144 Lugo;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;155 Lugo;Group 1007 Asthma 4930-4931,4938-4939;Men;73 Lugo;Group 1007 Asthma 4930-4931,4938-4939;Women;82 Lugo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.880 Lugo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;992 Lugo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;888 Lugo;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.681 Lugo;Group 1100 Diseases of the digestive system 520-579;Men;2.681 Lugo;Group 1100 Diseases of the digestive system 520-579;Women;2.000 Lugo;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;45 Lugo;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;26 Lugo;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;19 Lugo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;39 Lugo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;21 Lugo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;18 Lugo;Group 1103 Diseases of the esophagus 530;Both sexes;71 Lugo;Group 1103 Diseases of the esophagus 530;Men;44 Lugo;Group 1103 Diseases of the esophagus 530;Women;27 Lugo;Group 1104 Peptic ulcer 531-534;Both sexes;56 Lugo;Group 1104 Peptic ulcer 531-534;Men;26 Lugo;Group 1104 Peptic ulcer 531-534;Women;30 Lugo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;107 Lugo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;60 Lugo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;47 Lugo;Group 1106 Appendicitis 540-543;Both sexes;389 Lugo;Group 1106 Appendicitis 540-543;Men;226 Lugo;Group 1106 Appendicitis 540-543;Women;163 Lugo;Group 1107 Inguinal hernia 550;Both sexes;457 Lugo;Group 1107 Inguinal hernia 550;Men;413 Lugo;Group 1107 Inguinal hernia 550;Women;44 Lugo;Group 1108 Other abdominal hernia 551-553;Both sexes;338 Lugo;Group 1108 Other abdominal hernia 551-553;Men;171 Lugo;Group 1108 Other abdominal hernia 551-553;Women;167 Lugo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;59 Lugo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;27 Lugo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;32 Lugo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;267 Lugo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;118 Lugo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;149 Lugo;Group 1111 Intestinal obstruction without hernia 560;Both sexes;291 Lugo;Group 1111 Intestinal obstruction without hernia 560;Men;148 Lugo;Group 1111 Intestinal obstruction without hernia 560;Women;143 Lugo;Group 1112 Intestinal diverticulosis 562;Both sexes;285 Lugo;Group 1112 Intestinal diverticulosis 562;Men;142 Lugo;Group 1112 Intestinal diverticulosis 562;Women;143 Lugo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;205 Lugo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;141 Lugo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;64 Lugo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;187 Lugo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;85 Lugo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;102 Lugo;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;113 Lugo;Group 1115 Alcoholic hepatitis 5710-5713;Men;88 Lugo;Group 1115 Alcoholic hepatitis 5710-5713;Women;25 Lugo;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;138 Lugo;Group 1116 Other diseases of the liver 570,5714-573;Men;89 Lugo;Group 1116 Other diseases of the liver 570,5714-573;Women;49 Lugo;Group 1117 Cholelithiasis 574;Both sexes;837 Lugo;Group 1117 Cholelithiasis 574;Men;417 Lugo;Group 1117 Cholelithiasis 574;Women;420 Lugo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;301 Lugo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;167 Lugo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;134 Lugo;Group 1119 Pancreatic diseases 577;Both sexes;293 Lugo;Group 1119 Pancreatic diseases 577;Men;167 Lugo;Group 1119 Pancreatic diseases 577;Women;126 Lugo;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;203 Lugo;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;105 Lugo;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;98 Lugo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;446 Lugo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;233 Lugo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;213 Lugo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;302 Lugo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;167 Lugo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;135 Lugo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;33 Lugo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;18 Lugo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;15 Lugo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;111 Lugo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;48 Lugo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;63 Lugo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.705 Lugo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.222 Lugo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.483 Lugo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Lugo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Lugo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Lugo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Lugo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Lugo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Lugo;Group 1303 Internal derangement of knee 717;Both sexes;336 Lugo;Group 1303 Internal derangement of knee 717;Men;215 Lugo;Group 1303 Internal derangement of knee 717;Women;121 Lugo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.145 Lugo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;468 Lugo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;677 Lugo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;58 Lugo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;23 Lugo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;35 Lugo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;102 Lugo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;45 Lugo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;57 Lugo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;140 Lugo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;84 Lugo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;56 Lugo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;37 Lugo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;20 Lugo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;17 Lugo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;440 Lugo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;226 Lugo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;214 Lugo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;447 Lugo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;141 Lugo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;306 Lugo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.185 Lugo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.085 Lugo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.100 Lugo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;182 Lugo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;79 Lugo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;103 Lugo;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;238 Lugo;Group 1402 Renal failure 5836-5837, 584-586;Men;131 Lugo;Group 1402 Renal failure 5836-5837, 584-586;Women;107 Lugo;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;195 Lugo;Group 1403 Urolithiasis 592, 594, 7880;Men;128 Lugo;Group 1403 Urolithiasis 592, 594, 7880;Women;67 Lugo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;636 Lugo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;319 Lugo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;317 Lugo;Group 1405 Prostatic hyperplasia 600;Both sexes;206 Lugo;Group 1405 Prostatic hyperplasia 600;Men;206 Lugo;Group 1405 Prostatic hyperplasia 600;Women;.. Lugo;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;208 Lugo;Group 1406 Other diseases of the male genital organs 601-608;Men;208 Lugo;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Lugo;Group 1407 Disorders of breast 610-612;Both sexes;58 Lugo;Group 1407 Disorders of breast 610-612;Men;13 Lugo;Group 1407 Disorders of breast 610-612;Women;45 Lugo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;58 Lugo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Lugo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;58 Lugo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;50 Lugo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Lugo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;50 Lugo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;354 Lugo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Lugo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;353 Lugo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2.846 Lugo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Lugo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2.846 Lugo;Group 1501 Legally induced abortion 635;Both sexes;26 Lugo;Group 1501 Legally induced abortion 635;Men;.. Lugo;Group 1501 Legally induced abortion 635;Women;26 Lugo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;288 Lugo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Lugo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;288 Lugo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.474 Lugo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Lugo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.474 Lugo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;720 Lugo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Lugo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;720 Lugo;Group 1505 Single spontaneous delivery 650;Both sexes;85 Lugo;Group 1505 Single spontaneous delivery 650;Men;.. Lugo;Group 1505 Single spontaneous delivery 650;Women;85 Lugo;Group 1506 Other deliveries 6695-6697;Both sexes;64 Lugo;Group 1506 Other deliveries 6695-6697;Men;.. Lugo;Group 1506 Other deliveries 6695-6697;Women;64 Lugo;Group 1507 Complications related to the puerperium 670-676;Both sexes;21 Lugo;Group 1507 Complications related to the puerperium 670-676;Men;.. Lugo;Group 1507 Complications related to the puerperium 670-676;Women;21 Lugo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;168 Lugo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Lugo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;168 Lugo;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;391 Lugo;Group 1600 Some disorders originating in the perinatal period 760-779;Men;197 Lugo;Group 1600 Some disorders originating in the perinatal period 760-779;Women;194 Lugo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;99 Lugo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;50 Lugo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;49 Lugo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;292 Lugo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;147 Lugo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;145 Lugo;Grupo 1700 Congenital abnormalities 740-759;Both sexes;113 Lugo;Grupo 1700 Congenital abnormalities 740-759;Men;69 Lugo;Grupo 1700 Congenital abnormalities 740-759;Women;44 Lugo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.846 Lugo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.046 Lugo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;800 Lugo;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;149 Lugo;Group 1801 Pain in throat and chest 7841, 7865;Men;87 Lugo;Group 1801 Pain in throat and chest 7841, 7865;Women;62 Lugo;Group 1802 Abdominal pain 7890;Both sexes;166 Lugo;Group 1802 Abdominal pain 7890;Men;66 Lugo;Group 1802 Abdominal pain 7890;Women;100 Lugo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;308 Lugo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;164 Lugo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;144 Lugo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.223 Lugo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;729 Lugo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;494 Lugo;Group 1900 Injuries and poisoning 800-999;Both sexes;3.617 Lugo;Group 1900 Injuries and poisoning 800-999;Men;1.815 Lugo;Group 1900 Injuries and poisoning 800-999;Women;1.802 Lugo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;301 Lugo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;178 Lugo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;123 Lugo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;91 Lugo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;75 Lugo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;16 Lugo;Group 1903 Radius and ulna fracture 813;Both sexes;143 Lugo;Group 1903 Radius and ulna fracture 813;Men;61 Lugo;Group 1903 Radius and ulna fracture 813;Women;82 Lugo;Group 1904 Femur fracture 820-821;Both sexes;682 Lugo;Group 1904 Femur fracture 820-821;Men;158 Lugo;Group 1904 Femur fracture 820-821;Women;524 Lugo;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;231 Lugo;Group 1905 Leg fracture, including the ankle 823-824;Men;95 Lugo;Group 1905 Leg fracture, including the ankle 823-824;Women;136 Lugo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.018 Lugo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;634 Lugo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;384 Lugo;Group 1907 Burns 940-949;Both sexes;33 Lugo;Group 1907 Burns 940-949;Men;20 Lugo;Group 1907 Burns 940-949;Women;13 Lugo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;90 Lugo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;36 Lugo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;54 Lugo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;931 Lugo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;501 Lugo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;430 Lugo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;3 Lugo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Lugo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Lugo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;94 Lugo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;55 Lugo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;39 Lugo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;641 Lugo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;321 Lugo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;320 Lugo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;41 Lugo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;18 Lugo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;23 Lugo;Group 2102 Contraceptive management V25;Both sexes;17 Lugo;Group 2102 Contraceptive management V25;Men;1 Lugo;Group 2102 Contraceptive management V25;Women;16 Lugo;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Lugo;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Lugo;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Lugo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;190 Lugo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;104 Lugo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;86 Lugo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;393 Lugo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;198 Lugo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;195 Ourense;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;38.393 Ourense;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;19.199 Ourense;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;19.194 Ourense;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;836 Ourense;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;459 Ourense;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;377 Ourense;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;217 Ourense;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;121 Ourense;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;96 Ourense;Group 0102 Imprecise intestinal infections 009;Both sexes;13 Ourense;Group 0102 Imprecise intestinal infections 009;Men;7 Ourense;Group 0102 Imprecise intestinal infections 009;Women;6 Ourense;Group 0103 Tuberculosis 010-018, 137;Both sexes;22 Ourense;Group 0103 Tuberculosis 010-018, 137;Men;14 Ourense;Group 0103 Tuberculosis 010-018, 137;Women;8 Ourense;Group 0104 Septicaemia 038;Both sexes;376 Ourense;Group 0104 Septicaemia 038;Men;203 Ourense;Group 0104 Septicaemia 038;Women;173 Ourense;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;2 Ourense;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;2 Ourense;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;.. Ourense;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;206 Ourense;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;112 Ourense;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;94 Ourense;Group 0200 Neoplasms 140-239;Both sexes;3.477 Ourense;Group 0200 Neoplasms 140-239;Men;1.958 Ourense;Group 0200 Neoplasms 140-239;Women;1.519 Ourense;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;483 Ourense;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;288 Ourense;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;195 Ourense;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;191 Ourense;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;148 Ourense;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;43 Ourense;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;32 Ourense;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;16 Ourense;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;16 Ourense;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;235 Ourense;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Ourense;Group 0204 Malignant neoplasm of breast 174-175;Women;232 Ourense;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;78 Ourense;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Ourense;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;78 Ourense;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;22 Ourense;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Ourense;Group 0206 Malignant neoplasm of ovary 1830;Women;22 Ourense;Group 0207 Malignant neoplasm of prostate 185;Both sexes;145 Ourense;Group 0207 Malignant neoplasm of prostate 185;Men;145 Ourense;Group 0207 Malignant neoplasm of prostate 185;Women;.. Ourense;Group 0208 Malignant neoplasm of bladder 188;Both sexes;390 Ourense;Group 0208 Malignant neoplasm of bladder 188;Men;325 Ourense;Group 0208 Malignant neoplasm of bladder 188;Women;65 Ourense;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.287 Ourense;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;792 Ourense;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;495 Ourense;Group 0210 Carcinoma in situ 230-234;Both sexes;42 Ourense;Group 0210 Carcinoma in situ 230-234;Men;6 Ourense;Group 0210 Carcinoma in situ 230-234;Women;36 Ourense;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;55 Ourense;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;33 Ourense;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;22 Ourense;Grupo 0212 Leiomyoma of uterus 218;Both sexes;93 Ourense;Grupo 0212 Leiomyoma of uterus 218;Men;.. Ourense;Grupo 0212 Leiomyoma of uterus 218;Women;93 Ourense;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;424 Ourense;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;202 Ourense;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;222 Ourense;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;326 Ourense;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;158 Ourense;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;168 Ourense;Group 0301 Anaemias 280-285;Both sexes;235 Ourense;Group 0301 Anaemias 280-285;Men;113 Ourense;Group 0301 Anaemias 280-285;Women;122 Ourense;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;91 Ourense;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;45 Ourense;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;46 Ourense;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;445 Ourense;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;189 Ourense;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;256 Ourense;Group 0401 Diabetes mellitus 249-250;Both sexes;197 Ourense;Group 0401 Diabetes mellitus 249-250;Men;98 Ourense;Group 0401 Diabetes mellitus 249-250;Women;99 Ourense;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;248 Ourense;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;91 Ourense;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;157 Ourense;Group 0500 Mental disorders 290-319;Both sexes;606 Ourense;Group 0500 Mental disorders 290-319;Men;323 Ourense;Group 0500 Mental disorders 290-319;Women;283 Ourense;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;21 Ourense;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;8 Ourense;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;13 Ourense;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;57 Ourense;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;49 Ourense;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;8 Ourense;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;20 Ourense;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;20 Ourense;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;.. Ourense;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;195 Ourense;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;107 Ourense;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;88 Ourense;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;111 Ourense;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;41 Ourense;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;70 Ourense;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;202 Ourense;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;98 Ourense;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;104 Ourense;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;745 Ourense;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;339 Ourense;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;406 Ourense;Group 0601 Alzheimer's disease 3310;Both sexes;14 Ourense;Group 0601 Alzheimer's disease 3310;Men;3 Ourense;Group 0601 Alzheimer's disease 3310;Women;11 Ourense;Group 0602 Multiple sclerosis 340;Both sexes;68 Ourense;Group 0602 Multiple sclerosis 340;Men;22 Ourense;Group 0602 Multiple sclerosis 340;Women;46 Ourense;Group 0603 Epilepsy 345;Both sexes;142 Ourense;Group 0603 Epilepsy 345;Men;69 Ourense;Group 0603 Epilepsy 345;Women;73 Ourense;Group 0604 Transient cerebral ischemia 435;Both sexes;182 Ourense;Group 0604 Transient cerebral ischemia 435;Men;84 Ourense;Group 0604 Transient cerebral ischemia 435;Women;98 Ourense;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;339 Ourense;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;161 Ourense;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;178 Ourense;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;123 Ourense;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;63 Ourense;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;60 Ourense;Grupo 0701 Cataract 366;Both sexes;5 Ourense;Grupo 0701 Cataract 366;Men;1 Ourense;Grupo 0701 Cataract 366;Women;4 Ourense;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;118 Ourense;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;62 Ourense;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;56 Ourense;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;146 Ourense;Group 0800 Diseases of the ear and the mastoid 380-389;Men;74 Ourense;Group 0800 Diseases of the ear and the mastoid 380-389;Women;72 Ourense;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4.867 Ourense;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.665 Ourense;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.202 Ourense;Group 0901 Hypertensive disease 401-405;Both sexes;189 Ourense;Group 0901 Hypertensive disease 401-405;Men;98 Ourense;Group 0901 Hypertensive disease 401-405;Women;91 Ourense;Group 0902 Angina pectoris 4111, 413;Both sexes;352 Ourense;Group 0902 Angina pectoris 4111, 413;Men;230 Ourense;Group 0902 Angina pectoris 4111, 413;Women;122 Ourense;Group 0903 Acute myocardial infarction 410;Both sexes;290 Ourense;Group 0903 Acute myocardial infarction 410;Men;202 Ourense;Group 0903 Acute myocardial infarction 410;Women;88 Ourense;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;127 Ourense;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;94 Ourense;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;33 Ourense;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;229 Ourense;Group 0905 Diseases of the lungs circulation 415-417;Men;92 Ourense;Group 0905 Diseases of the lungs circulation 415-417;Women;137 Ourense;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;638 Ourense;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;360 Ourense;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;278 Ourense;Grupo 0907 Heart failure 428;Both sexes;1.079 Ourense;Grupo 0907 Heart failure 428;Men;530 Ourense;Grupo 0907 Heart failure 428;Women;549 Ourense;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.042 Ourense;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;521 Ourense;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;521 Ourense;Grupo 0909 Atherosclerosis 440;Both sexes;169 Ourense;Grupo 0909 Atherosclerosis 440;Men;115 Ourense;Grupo 0909 Atherosclerosis 440;Women;54 Ourense;Group 0910 Varicose veins of lower extremities 454;Both sexes;48 Ourense;Group 0910 Varicose veins of lower extremities 454;Men;18 Ourense;Group 0910 Varicose veins of lower extremities 454;Women;30 Ourense;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;704 Ourense;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;405 Ourense;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;299 Ourense;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6.264 Ourense;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3.405 Ourense;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2.859 Ourense;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;209 Ourense;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;117 Ourense;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;92 Ourense;Group 1002 Pneumonia 480-486;Both sexes;1.543 Ourense;Group 1002 Pneumonia 480-486;Men;898 Ourense;Group 1002 Pneumonia 480-486;Women;645 Ourense;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;230 Ourense;Group 1003 Acute bronchitis and bronchiolitis 466;Men;128 Ourense;Group 1003 Acute bronchitis and bronchiolitis 466;Women;102 Ourense;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;200 Ourense;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;98 Ourense;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;102 Ourense;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;318 Ourense;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;192 Ourense;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;126 Ourense;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;800 Ourense;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;586 Ourense;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;214 Ourense;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;214 Ourense;Group 1007 Asthma 4930-4931,4938-4939;Men;42 Ourense;Group 1007 Asthma 4930-4931,4938-4939;Women;172 Ourense;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.750 Ourense;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.344 Ourense;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.406 Ourense;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.832 Ourense;Group 1100 Diseases of the digestive system 520-579;Men;2.827 Ourense;Group 1100 Diseases of the digestive system 520-579;Women;2.005 Ourense;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;5 Ourense;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;3 Ourense;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;2 Ourense;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;29 Ourense;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;14 Ourense;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;15 Ourense;Group 1103 Diseases of the esophagus 530;Both sexes;67 Ourense;Group 1103 Diseases of the esophagus 530;Men;42 Ourense;Group 1103 Diseases of the esophagus 530;Women;25 Ourense;Group 1104 Peptic ulcer 531-534;Both sexes;79 Ourense;Group 1104 Peptic ulcer 531-534;Men;53 Ourense;Group 1104 Peptic ulcer 531-534;Women;26 Ourense;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;114 Ourense;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;61 Ourense;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;53 Ourense;Group 1106 Appendicitis 540-543;Both sexes;345 Ourense;Group 1106 Appendicitis 540-543;Men;199 Ourense;Group 1106 Appendicitis 540-543;Women;146 Ourense;Group 1107 Inguinal hernia 550;Both sexes;534 Ourense;Group 1107 Inguinal hernia 550;Men;485 Ourense;Group 1107 Inguinal hernia 550;Women;49 Ourense;Group 1108 Other abdominal hernia 551-553;Both sexes;294 Ourense;Group 1108 Other abdominal hernia 551-553;Men;150 Ourense;Group 1108 Other abdominal hernia 551-553;Women;144 Ourense;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;64 Ourense;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;36 Ourense;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;28 Ourense;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;310 Ourense;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;143 Ourense;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;167 Ourense;Group 1111 Intestinal obstruction without hernia 560;Both sexes;290 Ourense;Group 1111 Intestinal obstruction without hernia 560;Men;164 Ourense;Group 1111 Intestinal obstruction without hernia 560;Women;126 Ourense;Group 1112 Intestinal diverticulosis 562;Both sexes;211 Ourense;Group 1112 Intestinal diverticulosis 562;Men;101 Ourense;Group 1112 Intestinal diverticulosis 562;Women;110 Ourense;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;247 Ourense;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;158 Ourense;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;89 Ourense;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;182 Ourense;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;81 Ourense;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;101 Ourense;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;112 Ourense;Group 1115 Alcoholic hepatitis 5710-5713;Men;96 Ourense;Group 1115 Alcoholic hepatitis 5710-5713;Women;16 Ourense;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;245 Ourense;Group 1116 Other diseases of the liver 570,5714-573;Men;176 Ourense;Group 1116 Other diseases of the liver 570,5714-573;Women;69 Ourense;Group 1117 Cholelithiasis 574;Both sexes;913 Ourense;Group 1117 Cholelithiasis 574;Men;422 Ourense;Group 1117 Cholelithiasis 574;Women;491 Ourense;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;242 Ourense;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;154 Ourense;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;88 Ourense;Group 1119 Pancreatic diseases 577;Both sexes;292 Ourense;Group 1119 Pancreatic diseases 577;Men;142 Ourense;Group 1119 Pancreatic diseases 577;Women;150 Ourense;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;257 Ourense;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;147 Ourense;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;110 Ourense;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;479 Ourense;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;264 Ourense;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;215 Ourense;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;336 Ourense;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;185 Ourense;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;151 Ourense;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;22 Ourense;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;11 Ourense;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;11 Ourense;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;121 Ourense;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;68 Ourense;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;53 Ourense;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.715 Ourense;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.218 Ourense;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.497 Ourense;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Ourense;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Ourense;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Ourense;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Ourense;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Ourense;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Ourense;Group 1303 Internal derangement of knee 717;Both sexes;345 Ourense;Group 1303 Internal derangement of knee 717;Men;222 Ourense;Group 1303 Internal derangement of knee 717;Women;123 Ourense;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.322 Ourense;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;528 Ourense;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;794 Ourense;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;46 Ourense;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;24 Ourense;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;22 Ourense;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;89 Ourense;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;47 Ourense;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;42 Ourense;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;133 Ourense;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;83 Ourense;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;50 Ourense;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;44 Ourense;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;21 Ourense;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;23 Ourense;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;404 Ourense;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;200 Ourense;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;204 Ourense;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;332 Ourense;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;93 Ourense;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;239 Ourense;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.234 Ourense;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.047 Ourense;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.187 Ourense;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;166 Ourense;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;72 Ourense;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;94 Ourense;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;183 Ourense;Group 1402 Renal failure 5836-5837, 584-586;Men;102 Ourense;Group 1402 Renal failure 5836-5837, 584-586;Women;81 Ourense;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;283 Ourense;Group 1403 Urolithiasis 592, 594, 7880;Men;173 Ourense;Group 1403 Urolithiasis 592, 594, 7880;Women;110 Ourense;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;881 Ourense;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;383 Ourense;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;498 Ourense;Group 1405 Prostatic hyperplasia 600;Both sexes;157 Ourense;Group 1405 Prostatic hyperplasia 600;Men;157 Ourense;Group 1405 Prostatic hyperplasia 600;Women;.. Ourense;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;153 Ourense;Group 1406 Other diseases of the male genital organs 601-608;Men;153 Ourense;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Ourense;Group 1407 Disorders of breast 610-612;Both sexes;56 Ourense;Group 1407 Disorders of breast 610-612;Men;5 Ourense;Group 1407 Disorders of breast 610-612;Women;51 Ourense;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;45 Ourense;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Ourense;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;45 Ourense;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;32 Ourense;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Ourense;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;32 Ourense;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;278 Ourense;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 Ourense;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;276 Ourense;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2.071 Ourense;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Ourense;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2.071 Ourense;Group 1501 Legally induced abortion 635;Both sexes;3 Ourense;Group 1501 Legally induced abortion 635;Men;.. Ourense;Group 1501 Legally induced abortion 635;Women;3 Ourense;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;57 Ourense;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Ourense;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;57 Ourense;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.234 Ourense;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Ourense;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.234 Ourense;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;532 Ourense;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Ourense;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;532 Ourense;Group 1505 Single spontaneous delivery 650;Both sexes;88 Ourense;Group 1505 Single spontaneous delivery 650;Men;.. Ourense;Group 1505 Single spontaneous delivery 650;Women;88 Ourense;Group 1506 Other deliveries 6695-6697;Both sexes;32 Ourense;Group 1506 Other deliveries 6695-6697;Men;.. Ourense;Group 1506 Other deliveries 6695-6697;Women;32 Ourense;Group 1507 Complications related to the puerperium 670-676;Both sexes;8 Ourense;Group 1507 Complications related to the puerperium 670-676;Men;.. Ourense;Group 1507 Complications related to the puerperium 670-676;Women;8 Ourense;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;117 Ourense;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Ourense;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;117 Ourense;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;355 Ourense;Group 1600 Some disorders originating in the perinatal period 760-779;Men;206 Ourense;Group 1600 Some disorders originating in the perinatal period 760-779;Women;149 Ourense;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;84 Ourense;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;43 Ourense;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;41 Ourense;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;271 Ourense;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;163 Ourense;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;108 Ourense;Grupo 1700 Congenital abnormalities 740-759;Both sexes;115 Ourense;Grupo 1700 Congenital abnormalities 740-759;Men;57 Ourense;Grupo 1700 Congenital abnormalities 740-759;Women;58 Ourense;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3.437 Ourense;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.826 Ourense;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.611 Ourense;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;228 Ourense;Group 1801 Pain in throat and chest 7841, 7865;Men;129 Ourense;Group 1801 Pain in throat and chest 7841, 7865;Women;99 Ourense;Group 1802 Abdominal pain 7890;Both sexes;208 Ourense;Group 1802 Abdominal pain 7890;Men;82 Ourense;Group 1802 Abdominal pain 7890;Women;126 Ourense;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.153 Ourense;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;555 Ourense;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;598 Ourense;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.848 Ourense;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.060 Ourense;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;788 Ourense;Group 1900 Injuries and poisoning 800-999;Both sexes;3.723 Ourense;Group 1900 Injuries and poisoning 800-999;Men;1.746 Ourense;Group 1900 Injuries and poisoning 800-999;Women;1.977 Ourense;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;302 Ourense;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;167 Ourense;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;135 Ourense;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;55 Ourense;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;36 Ourense;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;19 Ourense;Group 1903 Radius and ulna fracture 813;Both sexes;229 Ourense;Group 1903 Radius and ulna fracture 813;Men;95 Ourense;Group 1903 Radius and ulna fracture 813;Women;134 Ourense;Group 1904 Femur fracture 820-821;Both sexes;691 Ourense;Group 1904 Femur fracture 820-821;Men;177 Ourense;Group 1904 Femur fracture 820-821;Women;514 Ourense;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;274 Ourense;Group 1905 Leg fracture, including the ankle 823-824;Men;134 Ourense;Group 1905 Leg fracture, including the ankle 823-824;Women;140 Ourense;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.319 Ourense;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;727 Ourense;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;592 Ourense;Group 1907 Burns 940-949;Both sexes;9 Ourense;Group 1907 Burns 940-949;Men;8 Ourense;Group 1907 Burns 940-949;Women;1 Ourense;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;108 Ourense;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;42 Ourense;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;66 Ourense;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;671 Ourense;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;326 Ourense;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;345 Ourense;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Ourense;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Ourense;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Ourense;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;63 Ourense;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;32 Ourense;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;31 Ourense;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;597 Ourense;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;375 Ourense;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;222 Ourense;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;34 Ourense;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;23 Ourense;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;11 Ourense;Group 2102 Contraceptive management V25;Both sexes;8 Ourense;Group 2102 Contraceptive management V25;Men;.. Ourense;Group 2102 Contraceptive management V25;Women;8 Ourense;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Ourense;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Ourense;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Ourense;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;304 Ourense;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;215 Ourense;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;89 Ourense;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;251 Ourense;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;137 Ourense;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;114 Pontevedra;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;95.010 Pontevedra;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;45.146 Pontevedra;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;49.864 Pontevedra;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.942 Pontevedra;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.037 Pontevedra;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;905 Pontevedra;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;295 Pontevedra;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;143 Pontevedra;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;152 Pontevedra;Group 0102 Imprecise intestinal infections 009;Both sexes;48 Pontevedra;Group 0102 Imprecise intestinal infections 009;Men;24 Pontevedra;Group 0102 Imprecise intestinal infections 009;Women;24 Pontevedra;Group 0103 Tuberculosis 010-018, 137;Both sexes;112 Pontevedra;Group 0103 Tuberculosis 010-018, 137;Men;64 Pontevedra;Group 0103 Tuberculosis 010-018, 137;Women;48 Pontevedra;Group 0104 Septicaemia 038;Both sexes;754 Pontevedra;Group 0104 Septicaemia 038;Men;372 Pontevedra;Group 0104 Septicaemia 038;Women;382 Pontevedra;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;82 Pontevedra;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;63 Pontevedra;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;19 Pontevedra;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;651 Pontevedra;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;371 Pontevedra;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;280 Pontevedra;Group 0200 Neoplasms 140-239;Both sexes;9.422 Pontevedra;Group 0200 Neoplasms 140-239;Men;5.008 Pontevedra;Group 0200 Neoplasms 140-239;Women;4.414 Pontevedra;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;912 Pontevedra;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;504 Pontevedra;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;408 Pontevedra;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;625 Pontevedra;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;480 Pontevedra;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;145 Pontevedra;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;116 Pontevedra;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;73 Pontevedra;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;43 Pontevedra;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;638 Pontevedra;Group 0204 Malignant neoplasm of breast 174-175;Men;7 Pontevedra;Group 0204 Malignant neoplasm of breast 174-175;Women;631 Pontevedra;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;144 Pontevedra;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Pontevedra;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;144 Pontevedra;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;50 Pontevedra;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Pontevedra;Group 0206 Malignant neoplasm of ovary 1830;Women;50 Pontevedra;Group 0207 Malignant neoplasm of prostate 185;Both sexes;674 Pontevedra;Group 0207 Malignant neoplasm of prostate 185;Men;674 Pontevedra;Group 0207 Malignant neoplasm of prostate 185;Women;.. Pontevedra;Group 0208 Malignant neoplasm of bladder 188;Both sexes;804 Pontevedra;Group 0208 Malignant neoplasm of bladder 188;Men;678 Pontevedra;Group 0208 Malignant neoplasm of bladder 188;Women;126 Pontevedra;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3.776 Pontevedra;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.138 Pontevedra;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.638 Pontevedra;Group 0210 Carcinoma in situ 230-234;Both sexes;185 Pontevedra;Group 0210 Carcinoma in situ 230-234;Men;58 Pontevedra;Group 0210 Carcinoma in situ 230-234;Women;127 Pontevedra;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;80 Pontevedra;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;46 Pontevedra;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;34 Pontevedra;Grupo 0212 Leiomyoma of uterus 218;Both sexes;391 Pontevedra;Grupo 0212 Leiomyoma of uterus 218;Men;.. Pontevedra;Grupo 0212 Leiomyoma of uterus 218;Women;391 Pontevedra;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.027 Pontevedra;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;350 Pontevedra;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;677 Pontevedra;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;940 Pontevedra;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;494 Pontevedra;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;446 Pontevedra;Group 0301 Anaemias 280-285;Both sexes;621 Pontevedra;Group 0301 Anaemias 280-285;Men;324 Pontevedra;Group 0301 Anaemias 280-285;Women;297 Pontevedra;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;319 Pontevedra;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;170 Pontevedra;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;149 Pontevedra;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.700 Pontevedra;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;614 Pontevedra;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.086 Pontevedra;Group 0401 Diabetes mellitus 249-250;Both sexes;516 Pontevedra;Group 0401 Diabetes mellitus 249-250;Men;242 Pontevedra;Group 0401 Diabetes mellitus 249-250;Women;274 Pontevedra;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.184 Pontevedra;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;372 Pontevedra;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;812 Pontevedra;Group 0500 Mental disorders 290-319;Both sexes;2.042 Pontevedra;Group 0500 Mental disorders 290-319;Men;1.047 Pontevedra;Group 0500 Mental disorders 290-319;Women;995 Pontevedra;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;55 Pontevedra;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;16 Pontevedra;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;39 Pontevedra;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;137 Pontevedra;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;107 Pontevedra;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;30 Pontevedra;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;70 Pontevedra;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;58 Pontevedra;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;12 Pontevedra;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;589 Pontevedra;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;337 Pontevedra;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;252 Pontevedra;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;499 Pontevedra;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;189 Pontevedra;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;310 Pontevedra;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;692 Pontevedra;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;340 Pontevedra;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;352 Pontevedra;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.776 Pontevedra;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;853 Pontevedra;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;923 Pontevedra;Group 0601 Alzheimer's disease 3310;Both sexes;44 Pontevedra;Group 0601 Alzheimer's disease 3310;Men;22 Pontevedra;Group 0601 Alzheimer's disease 3310;Women;22 Pontevedra;Group 0602 Multiple sclerosis 340;Both sexes;86 Pontevedra;Group 0602 Multiple sclerosis 340;Men;30 Pontevedra;Group 0602 Multiple sclerosis 340;Women;56 Pontevedra;Group 0603 Epilepsy 345;Both sexes;303 Pontevedra;Group 0603 Epilepsy 345;Men;153 Pontevedra;Group 0603 Epilepsy 345;Women;150 Pontevedra;Group 0604 Transient cerebral ischemia 435;Both sexes;312 Pontevedra;Group 0604 Transient cerebral ischemia 435;Men;149 Pontevedra;Group 0604 Transient cerebral ischemia 435;Women;163 Pontevedra;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.031 Pontevedra;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;499 Pontevedra;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;532 Pontevedra;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;512 Pontevedra;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;260 Pontevedra;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;252 Pontevedra;Grupo 0701 Cataract 366;Both sexes;29 Pontevedra;Grupo 0701 Cataract 366;Men;14 Pontevedra;Grupo 0701 Cataract 366;Women;15 Pontevedra;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;483 Pontevedra;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;246 Pontevedra;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;237 Pontevedra;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;439 Pontevedra;Group 0800 Diseases of the ear and the mastoid 380-389;Men;219 Pontevedra;Group 0800 Diseases of the ear and the mastoid 380-389;Women;220 Pontevedra;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;12.378 Pontevedra;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6.685 Pontevedra;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;5.693 Pontevedra;Group 0901 Hypertensive disease 401-405;Both sexes;738 Pontevedra;Group 0901 Hypertensive disease 401-405;Men;322 Pontevedra;Group 0901 Hypertensive disease 401-405;Women;416 Pontevedra;Group 0902 Angina pectoris 4111, 413;Both sexes;224 Pontevedra;Group 0902 Angina pectoris 4111, 413;Men;139 Pontevedra;Group 0902 Angina pectoris 4111, 413;Women;85 Pontevedra;Group 0903 Acute myocardial infarction 410;Both sexes;1.020 Pontevedra;Group 0903 Acute myocardial infarction 410;Men;720 Pontevedra;Group 0903 Acute myocardial infarction 410;Women;300 Pontevedra;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;819 Pontevedra;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;652 Pontevedra;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;167 Pontevedra;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;473 Pontevedra;Group 0905 Diseases of the lungs circulation 415-417;Men;197 Pontevedra;Group 0905 Diseases of the lungs circulation 415-417;Women;276 Pontevedra;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.406 Pontevedra;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;772 Pontevedra;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;634 Pontevedra;Grupo 0907 Heart failure 428;Both sexes;3.049 Pontevedra;Grupo 0907 Heart failure 428;Men;1.404 Pontevedra;Grupo 0907 Heart failure 428;Women;1.645 Pontevedra;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.979 Pontevedra;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;946 Pontevedra;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.033 Pontevedra;Grupo 0909 Atherosclerosis 440;Both sexes;496 Pontevedra;Grupo 0909 Atherosclerosis 440;Men;358 Pontevedra;Grupo 0909 Atherosclerosis 440;Women;138 Pontevedra;Group 0910 Varicose veins of lower extremities 454;Both sexes;411 Pontevedra;Group 0910 Varicose veins of lower extremities 454;Men;133 Pontevedra;Group 0910 Varicose veins of lower extremities 454;Women;278 Pontevedra;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.763 Pontevedra;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.042 Pontevedra;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;721 Pontevedra;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;14.334 Pontevedra;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;7.672 Pontevedra;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6.662 Pontevedra;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;339 Pontevedra;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;176 Pontevedra;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;163 Pontevedra;Group 1002 Pneumonia 480-486;Both sexes;3.030 Pontevedra;Group 1002 Pneumonia 480-486;Men;1.664 Pontevedra;Group 1002 Pneumonia 480-486;Women;1.366 Pontevedra;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;635 Pontevedra;Group 1003 Acute bronchitis and bronchiolitis 466;Men;337 Pontevedra;Group 1003 Acute bronchitis and bronchiolitis 466;Women;298 Pontevedra;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;787 Pontevedra;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;460 Pontevedra;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;327 Pontevedra;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.010 Pontevedra;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;645 Pontevedra;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;365 Pontevedra;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.202 Pontevedra;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.535 Pontevedra;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;667 Pontevedra;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;512 Pontevedra;Group 1007 Asthma 4930-4931,4938-4939;Men;154 Pontevedra;Group 1007 Asthma 4930-4931,4938-4939;Women;358 Pontevedra;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.819 Pontevedra;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.701 Pontevedra;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;3.118 Pontevedra;Group 1100 Diseases of the digestive system 520-579;Both sexes;10.594 Pontevedra;Group 1100 Diseases of the digestive system 520-579;Men;5.887 Pontevedra;Group 1100 Diseases of the digestive system 520-579;Women;4.707 Pontevedra;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;192 Pontevedra;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;95 Pontevedra;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;97 Pontevedra;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;195 Pontevedra;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;123 Pontevedra;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;72 Pontevedra;Group 1103 Diseases of the esophagus 530;Both sexes;181 Pontevedra;Group 1103 Diseases of the esophagus 530;Men;117 Pontevedra;Group 1103 Diseases of the esophagus 530;Women;64 Pontevedra;Group 1104 Peptic ulcer 531-534;Both sexes;172 Pontevedra;Group 1104 Peptic ulcer 531-534;Men;123 Pontevedra;Group 1104 Peptic ulcer 531-534;Women;49 Pontevedra;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;251 Pontevedra;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;137 Pontevedra;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;114 Pontevedra;Group 1106 Appendicitis 540-543;Both sexes;979 Pontevedra;Group 1106 Appendicitis 540-543;Men;562 Pontevedra;Group 1106 Appendicitis 540-543;Women;417 Pontevedra;Group 1107 Inguinal hernia 550;Both sexes;1.143 Pontevedra;Group 1107 Inguinal hernia 550;Men;979 Pontevedra;Group 1107 Inguinal hernia 550;Women;164 Pontevedra;Group 1108 Other abdominal hernia 551-553;Both sexes;769 Pontevedra;Group 1108 Other abdominal hernia 551-553;Men;378 Pontevedra;Group 1108 Other abdominal hernia 551-553;Women;391 Pontevedra;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;229 Pontevedra;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;113 Pontevedra;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;116 Pontevedra;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;497 Pontevedra;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;229 Pontevedra;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;268 Pontevedra;Group 1111 Intestinal obstruction without hernia 560;Both sexes;483 Pontevedra;Group 1111 Intestinal obstruction without hernia 560;Men;249 Pontevedra;Group 1111 Intestinal obstruction without hernia 560;Women;234 Pontevedra;Group 1112 Intestinal diverticulosis 562;Both sexes;476 Pontevedra;Group 1112 Intestinal diverticulosis 562;Men;235 Pontevedra;Group 1112 Intestinal diverticulosis 562;Women;241 Pontevedra;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;631 Pontevedra;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;401 Pontevedra;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;230 Pontevedra;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;378 Pontevedra;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;156 Pontevedra;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;222 Pontevedra;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;213 Pontevedra;Group 1115 Alcoholic hepatitis 5710-5713;Men;159 Pontevedra;Group 1115 Alcoholic hepatitis 5710-5713;Women;54 Pontevedra;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;502 Pontevedra;Group 1116 Other diseases of the liver 570,5714-573;Men;318 Pontevedra;Group 1116 Other diseases of the liver 570,5714-573;Women;184 Pontevedra;Group 1117 Cholelithiasis 574;Both sexes;1.861 Pontevedra;Group 1117 Cholelithiasis 574;Men;732 Pontevedra;Group 1117 Cholelithiasis 574;Women;1.129 Pontevedra;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;477 Pontevedra;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;250 Pontevedra;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;227 Pontevedra;Group 1119 Pancreatic diseases 577;Both sexes;606 Pontevedra;Group 1119 Pancreatic diseases 577;Men;344 Pontevedra;Group 1119 Pancreatic diseases 577;Women;262 Pontevedra;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;359 Pontevedra;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;187 Pontevedra;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;172 Pontevedra;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.215 Pontevedra;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;645 Pontevedra;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;570 Pontevedra;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;828 Pontevedra;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;460 Pontevedra;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;368 Pontevedra;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;74 Pontevedra;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;35 Pontevedra;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;39 Pontevedra;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;313 Pontevedra;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;150 Pontevedra;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;163 Pontevedra;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;7.219 Pontevedra;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3.480 Pontevedra;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.739 Pontevedra;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Pontevedra;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Pontevedra;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Pontevedra;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Pontevedra;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Pontevedra;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Pontevedra;Group 1303 Internal derangement of knee 717;Both sexes;1.187 Pontevedra;Group 1303 Internal derangement of knee 717;Men;815 Pontevedra;Group 1303 Internal derangement of knee 717;Women;372 Pontevedra;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.791 Pontevedra;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.135 Pontevedra;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.656 Pontevedra;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;126 Pontevedra;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;56 Pontevedra;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;70 Pontevedra;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;263 Pontevedra;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;138 Pontevedra;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;125 Pontevedra;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;564 Pontevedra;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;314 Pontevedra;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;250 Pontevedra;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;104 Pontevedra;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;42 Pontevedra;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;62 Pontevedra;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.117 Pontevedra;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;603 Pontevedra;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;514 Pontevedra;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.067 Pontevedra;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;377 Pontevedra;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;690 Pontevedra;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;6.104 Pontevedra;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.890 Pontevedra;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3.214 Pontevedra;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;548 Pontevedra;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;178 Pontevedra;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;370 Pontevedra;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;501 Pontevedra;Group 1402 Renal failure 5836-5837, 584-586;Men;282 Pontevedra;Group 1402 Renal failure 5836-5837, 584-586;Women;219 Pontevedra;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;732 Pontevedra;Group 1403 Urolithiasis 592, 594, 7880;Men;459 Pontevedra;Group 1403 Urolithiasis 592, 594, 7880;Women;273 Pontevedra;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.905 Pontevedra;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;813 Pontevedra;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.092 Pontevedra;Group 1405 Prostatic hyperplasia 600;Both sexes;629 Pontevedra;Group 1405 Prostatic hyperplasia 600;Men;629 Pontevedra;Group 1405 Prostatic hyperplasia 600;Women;.. Pontevedra;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;494 Pontevedra;Group 1406 Other diseases of the male genital organs 601-608;Men;494 Pontevedra;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Pontevedra;Group 1407 Disorders of breast 610-612;Both sexes;243 Pontevedra;Group 1407 Disorders of breast 610-612;Men;23 Pontevedra;Group 1407 Disorders of breast 610-612;Women;220 Pontevedra;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;217 Pontevedra;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Pontevedra;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;217 Pontevedra;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;70 Pontevedra;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Pontevedra;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;70 Pontevedra;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;765 Pontevedra;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;12 Pontevedra;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;753 Pontevedra;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;8.802 Pontevedra;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Pontevedra;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;8.802 Pontevedra;Group 1501 Legally induced abortion 635;Both sexes;166 Pontevedra;Group 1501 Legally induced abortion 635;Men;.. Pontevedra;Group 1501 Legally induced abortion 635;Women;166 Pontevedra;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;906 Pontevedra;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Pontevedra;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;906 Pontevedra;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.846 Pontevedra;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Pontevedra;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.846 Pontevedra;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.583 Pontevedra;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Pontevedra;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.583 Pontevedra;Group 1505 Single spontaneous delivery 650;Both sexes;413 Pontevedra;Group 1505 Single spontaneous delivery 650;Men;.. Pontevedra;Group 1505 Single spontaneous delivery 650;Women;413 Pontevedra;Group 1506 Other deliveries 6695-6697;Both sexes;232 Pontevedra;Group 1506 Other deliveries 6695-6697;Men;.. Pontevedra;Group 1506 Other deliveries 6695-6697;Women;232 Pontevedra;Group 1507 Complications related to the puerperium 670-676;Both sexes;105 Pontevedra;Group 1507 Complications related to the puerperium 670-676;Men;.. Pontevedra;Group 1507 Complications related to the puerperium 670-676;Women;105 Pontevedra;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;551 Pontevedra;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Pontevedra;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;551 Pontevedra;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;896 Pontevedra;Group 1600 Some disorders originating in the perinatal period 760-779;Men;525 Pontevedra;Group 1600 Some disorders originating in the perinatal period 760-779;Women;371 Pontevedra;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;269 Pontevedra;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;159 Pontevedra;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;110 Pontevedra;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;627 Pontevedra;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;366 Pontevedra;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;261 Pontevedra;Grupo 1700 Congenital abnormalities 740-759;Both sexes;604 Pontevedra;Grupo 1700 Congenital abnormalities 740-759;Men;392 Pontevedra;Grupo 1700 Congenital abnormalities 740-759;Women;212 Pontevedra;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.661 Pontevedra;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.412 Pontevedra;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.249 Pontevedra;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;250 Pontevedra;Group 1801 Pain in throat and chest 7841, 7865;Men;134 Pontevedra;Group 1801 Pain in throat and chest 7841, 7865;Women;116 Pontevedra;Group 1802 Abdominal pain 7890;Both sexes;294 Pontevedra;Group 1802 Abdominal pain 7890;Men;109 Pontevedra;Group 1802 Abdominal pain 7890;Women;185 Pontevedra;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;56 Pontevedra;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;7 Pontevedra;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;49 Pontevedra;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2.061 Pontevedra;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.162 Pontevedra;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;899 Pontevedra;Group 1900 Injuries and poisoning 800-999;Both sexes;9.624 Pontevedra;Group 1900 Injuries and poisoning 800-999;Men;5.077 Pontevedra;Group 1900 Injuries and poisoning 800-999;Women;4.547 Pontevedra;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;746 Pontevedra;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;432 Pontevedra;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;314 Pontevedra;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;314 Pontevedra;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;214 Pontevedra;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;100 Pontevedra;Group 1903 Radius and ulna fracture 813;Both sexes;560 Pontevedra;Group 1903 Radius and ulna fracture 813;Men;251 Pontevedra;Group 1903 Radius and ulna fracture 813;Women;309 Pontevedra;Group 1904 Femur fracture 820-821;Both sexes;1.158 Pontevedra;Group 1904 Femur fracture 820-821;Men;317 Pontevedra;Group 1904 Femur fracture 820-821;Women;841 Pontevedra;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;767 Pontevedra;Group 1905 Leg fracture, including the ankle 823-824;Men;360 Pontevedra;Group 1905 Leg fracture, including the ankle 823-824;Women;407 Pontevedra;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.217 Pontevedra;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.927 Pontevedra;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.290 Pontevedra;Group 1907 Burns 940-949;Both sexes;83 Pontevedra;Group 1907 Burns 940-949;Men;55 Pontevedra;Group 1907 Burns 940-949;Women;28 Pontevedra;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;241 Pontevedra;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;106 Pontevedra;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;135 Pontevedra;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.354 Pontevedra;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.311 Pontevedra;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.043 Pontevedra;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;8 Pontevedra;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 Pontevedra;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 Pontevedra;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;176 Pontevedra;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;101 Pontevedra;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;75 Pontevedra;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.806 Pontevedra;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;949 Pontevedra;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;857 Pontevedra;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;51 Pontevedra;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;25 Pontevedra;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;26 Pontevedra;Group 2102 Contraceptive management V25;Both sexes;36 Pontevedra;Group 2102 Contraceptive management V25;Men;1 Pontevedra;Group 2102 Contraceptive management V25;Women;35 Pontevedra;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Pontevedra;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Pontevedra;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Pontevedra;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.094 Pontevedra;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;663 Pontevedra;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;431 Pontevedra;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;625 Pontevedra;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;260 Pontevedra;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;365 MADRID, COMUNIDAD DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;704.396 MADRID, COMUNIDAD DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;322.316 MADRID, COMUNIDAD DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;382.080 MADRID, COMUNIDAD DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;18.822 MADRID, COMUNIDAD DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;10.312 MADRID, COMUNIDAD DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;8.510 MADRID, COMUNIDAD DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;3.082 MADRID, COMUNIDAD DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;1.510 MADRID, COMUNIDAD DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;1.572 MADRID, COMUNIDAD DE;Group 0102 Imprecise intestinal infections 009;Both sexes;952 MADRID, COMUNIDAD DE;Group 0102 Imprecise intestinal infections 009;Men;466 MADRID, COMUNIDAD DE;Group 0102 Imprecise intestinal infections 009;Women;486 MADRID, COMUNIDAD DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;547 MADRID, COMUNIDAD DE;Group 0103 Tuberculosis 010-018, 137;Men;331 MADRID, COMUNIDAD DE;Group 0103 Tuberculosis 010-018, 137;Women;216 MADRID, COMUNIDAD DE;Group 0104 Septicaemia 038;Both sexes;8.440 MADRID, COMUNIDAD DE;Group 0104 Septicaemia 038;Men;4.478 MADRID, COMUNIDAD DE;Group 0104 Septicaemia 038;Women;3.963 MADRID, COMUNIDAD DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;323 MADRID, COMUNIDAD DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;273 MADRID, COMUNIDAD DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;50 MADRID, COMUNIDAD DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;5.478 MADRID, COMUNIDAD DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;3.255 MADRID, COMUNIDAD DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;2.223 MADRID, COMUNIDAD DE;Group 0200 Neoplasms 140-239;Both sexes;70.224 MADRID, COMUNIDAD DE;Group 0200 Neoplasms 140-239;Men;35.155 MADRID, COMUNIDAD DE;Group 0200 Neoplasms 140-239;Women;35.069 MADRID, COMUNIDAD DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;6.179 MADRID, COMUNIDAD DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;3.594 MADRID, COMUNIDAD DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2.585 MADRID, COMUNIDAD DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;4.730 MADRID, COMUNIDAD DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;3.490 MADRID, COMUNIDAD DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;1.239 MADRID, COMUNIDAD DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;1.081 MADRID, COMUNIDAD DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;625 MADRID, COMUNIDAD DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;456 MADRID, COMUNIDAD DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;5.162 MADRID, COMUNIDAD DE;Group 0204 Malignant neoplasm of breast 174-175;Men;31 MADRID, COMUNIDAD DE;Group 0204 Malignant neoplasm of breast 174-175;Women;5.131 MADRID, COMUNIDAD DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1.247 MADRID, COMUNIDAD DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. MADRID, COMUNIDAD DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1.247 MADRID, COMUNIDAD DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;737 MADRID, COMUNIDAD DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. MADRID, COMUNIDAD DE;Group 0206 Malignant neoplasm of ovary 1830;Women;737 MADRID, COMUNIDAD DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;2.771 MADRID, COMUNIDAD DE;Group 0207 Malignant neoplasm of prostate 185;Men;2.771 MADRID, COMUNIDAD DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. MADRID, COMUNIDAD DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;6.382 MADRID, COMUNIDAD DE;Group 0208 Malignant neoplasm of bladder 188;Men;5.239 MADRID, COMUNIDAD DE;Group 0208 Malignant neoplasm of bladder 188;Women;1.142 MADRID, COMUNIDAD DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;26.417 MADRID, COMUNIDAD DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;14.430 MADRID, COMUNIDAD DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;11.987 MADRID, COMUNIDAD DE;Group 0210 Carcinoma in situ 230-234;Both sexes;1.088 MADRID, COMUNIDAD DE;Group 0210 Carcinoma in situ 230-234;Men;366 MADRID, COMUNIDAD DE;Group 0210 Carcinoma in situ 230-234;Women;722 MADRID, COMUNIDAD DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;1.101 MADRID, COMUNIDAD DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;622 MADRID, COMUNIDAD DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;479 MADRID, COMUNIDAD DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;3.504 MADRID, COMUNIDAD DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. MADRID, COMUNIDAD DE;Grupo 0212 Leiomyoma of uterus 218;Women;3.504 MADRID, COMUNIDAD DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;9.825 MADRID, COMUNIDAD DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;3.986 MADRID, COMUNIDAD DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;5.839 MADRID, COMUNIDAD DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;6.063 MADRID, COMUNIDAD DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;2.842 MADRID, COMUNIDAD DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;3.220 MADRID, COMUNIDAD DE;Group 0301 Anaemias 280-285;Both sexes;3.474 MADRID, COMUNIDAD DE;Group 0301 Anaemias 280-285;Men;1.574 MADRID, COMUNIDAD DE;Group 0301 Anaemias 280-285;Women;1.900 MADRID, COMUNIDAD DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;2.589 MADRID, COMUNIDAD DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1.268 MADRID, COMUNIDAD DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1.320 MADRID, COMUNIDAD DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;13.348 MADRID, COMUNIDAD DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;4.856 MADRID, COMUNIDAD DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;8.493 MADRID, COMUNIDAD DE;Group 0401 Diabetes mellitus 249-250;Both sexes;2.739 MADRID, COMUNIDAD DE;Group 0401 Diabetes mellitus 249-250;Men;1.582 MADRID, COMUNIDAD DE;Group 0401 Diabetes mellitus 249-250;Women;1.157 MADRID, COMUNIDAD DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;10.609 MADRID, COMUNIDAD DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;3.274 MADRID, COMUNIDAD DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;7.335 MADRID, COMUNIDAD DE;Group 0500 Mental disorders 290-319;Both sexes;17.530 MADRID, COMUNIDAD DE;Group 0500 Mental disorders 290-319;Men;8.495 MADRID, COMUNIDAD DE;Group 0500 Mental disorders 290-319;Women;9.035 MADRID, COMUNIDAD DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;327 MADRID, COMUNIDAD DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;135 MADRID, COMUNIDAD DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;191 MADRID, COMUNIDAD DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;1.558 MADRID, COMUNIDAD DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;1.111 MADRID, COMUNIDAD DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;447 MADRID, COMUNIDAD DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;1.175 MADRID, COMUNIDAD DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;831 MADRID, COMUNIDAD DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;344 MADRID, COMUNIDAD DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;4.456 MADRID, COMUNIDAD DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;2.582 MADRID, COMUNIDAD DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;1.875 MADRID, COMUNIDAD DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;4.136 MADRID, COMUNIDAD DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;1.532 MADRID, COMUNIDAD DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;2.604 MADRID, COMUNIDAD DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;5.878 MADRID, COMUNIDAD DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;2.304 MADRID, COMUNIDAD DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;3.574 MADRID, COMUNIDAD DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;17.559 MADRID, COMUNIDAD DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;9.047 MADRID, COMUNIDAD DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;8.512 MADRID, COMUNIDAD DE;Group 0601 Alzheimer's disease 3310;Both sexes;297 MADRID, COMUNIDAD DE;Group 0601 Alzheimer's disease 3310;Men;116 MADRID, COMUNIDAD DE;Group 0601 Alzheimer's disease 3310;Women;181 MADRID, COMUNIDAD DE;Group 0602 Multiple sclerosis 340;Both sexes;211 MADRID, COMUNIDAD DE;Group 0602 Multiple sclerosis 340;Men;79 MADRID, COMUNIDAD DE;Group 0602 Multiple sclerosis 340;Women;132 MADRID, COMUNIDAD DE;Group 0603 Epilepsy 345;Both sexes;3.383 MADRID, COMUNIDAD DE;Group 0603 Epilepsy 345;Men;1.712 MADRID, COMUNIDAD DE;Group 0603 Epilepsy 345;Women;1.671 MADRID, COMUNIDAD DE;Group 0604 Transient cerebral ischemia 435;Both sexes;2.018 MADRID, COMUNIDAD DE;Group 0604 Transient cerebral ischemia 435;Men;987 MADRID, COMUNIDAD DE;Group 0604 Transient cerebral ischemia 435;Women;1.031 MADRID, COMUNIDAD DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;11.649 MADRID, COMUNIDAD DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;6.153 MADRID, COMUNIDAD DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;5.496 MADRID, COMUNIDAD DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;4.093 MADRID, COMUNIDAD DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;2.066 MADRID, COMUNIDAD DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;2.027 MADRID, COMUNIDAD DE;Grupo 0701 Cataract 366;Both sexes;473 MADRID, COMUNIDAD DE;Grupo 0701 Cataract 366;Men;215 MADRID, COMUNIDAD DE;Grupo 0701 Cataract 366;Women;258 MADRID, COMUNIDAD DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;3.620 MADRID, COMUNIDAD DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;1.851 MADRID, COMUNIDAD DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1.770 MADRID, COMUNIDAD DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;3.604 MADRID, COMUNIDAD DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1.725 MADRID, COMUNIDAD DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1.879 MADRID, COMUNIDAD DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;79.809 MADRID, COMUNIDAD DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;43.097 MADRID, COMUNIDAD DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;36.711 MADRID, COMUNIDAD DE;Group 0901 Hypertensive disease 401-405;Both sexes;4.371 MADRID, COMUNIDAD DE;Group 0901 Hypertensive disease 401-405;Men;1.742 MADRID, COMUNIDAD DE;Group 0901 Hypertensive disease 401-405;Women;2.629 MADRID, COMUNIDAD DE;Group 0902 Angina pectoris 4111, 413;Both sexes;1.985 MADRID, COMUNIDAD DE;Group 0902 Angina pectoris 4111, 413;Men;1.215 MADRID, COMUNIDAD DE;Group 0902 Angina pectoris 4111, 413;Women;770 MADRID, COMUNIDAD DE;Group 0903 Acute myocardial infarction 410;Both sexes;5.580 MADRID, COMUNIDAD DE;Group 0903 Acute myocardial infarction 410;Men;3.969 MADRID, COMUNIDAD DE;Group 0903 Acute myocardial infarction 410;Women;1.611 MADRID, COMUNIDAD DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;5.815 MADRID, COMUNIDAD DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;4.531 MADRID, COMUNIDAD DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1.284 MADRID, COMUNIDAD DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;3.147 MADRID, COMUNIDAD DE;Group 0905 Diseases of the lungs circulation 415-417;Men;1.407 MADRID, COMUNIDAD DE;Group 0905 Diseases of the lungs circulation 415-417;Women;1.740 MADRID, COMUNIDAD DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;10.662 MADRID, COMUNIDAD DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;5.678 MADRID, COMUNIDAD DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;4.984 MADRID, COMUNIDAD DE;Grupo 0907 Heart failure 428;Both sexes;17.690 MADRID, COMUNIDAD DE;Grupo 0907 Heart failure 428;Men;7.767 MADRID, COMUNIDAD DE;Grupo 0907 Heart failure 428;Women;9.923 MADRID, COMUNIDAD DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;12.032 MADRID, COMUNIDAD DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;6.169 MADRID, COMUNIDAD DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;5.863 MADRID, COMUNIDAD DE;Grupo 0909 Atherosclerosis 440;Both sexes;2.477 MADRID, COMUNIDAD DE;Grupo 0909 Atherosclerosis 440;Men;1.863 MADRID, COMUNIDAD DE;Grupo 0909 Atherosclerosis 440;Women;614 MADRID, COMUNIDAD DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;1.719 MADRID, COMUNIDAD DE;Group 0910 Varicose veins of lower extremities 454;Men;656 MADRID, COMUNIDAD DE;Group 0910 Varicose veins of lower extremities 454;Women;1.062 MADRID, COMUNIDAD DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;14.331 MADRID, COMUNIDAD DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;8.100 MADRID, COMUNIDAD DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;6.231 MADRID, COMUNIDAD DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;86.986 MADRID, COMUNIDAD DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;46.796 MADRID, COMUNIDAD DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;40.190 MADRID, COMUNIDAD DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;3.869 MADRID, COMUNIDAD DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1.960 MADRID, COMUNIDAD DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1.910 MADRID, COMUNIDAD DE;Group 1002 Pneumonia 480-486;Both sexes;20.102 MADRID, COMUNIDAD DE;Group 1002 Pneumonia 480-486;Men;11.205 MADRID, COMUNIDAD DE;Group 1002 Pneumonia 480-486;Women;8.897 MADRID, COMUNIDAD DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;7.265 MADRID, COMUNIDAD DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;3.506 MADRID, COMUNIDAD DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;3.759 MADRID, COMUNIDAD DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;3.680 MADRID, COMUNIDAD DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1.949 MADRID, COMUNIDAD DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1.731 MADRID, COMUNIDAD DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;6.432 MADRID, COMUNIDAD DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;3.761 MADRID, COMUNIDAD DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2.672 MADRID, COMUNIDAD DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;14.176 MADRID, COMUNIDAD DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;10.146 MADRID, COMUNIDAD DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;4.030 MADRID, COMUNIDAD DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;4.024 MADRID, COMUNIDAD DE;Group 1007 Asthma 4930-4931,4938-4939;Men;1.324 MADRID, COMUNIDAD DE;Group 1007 Asthma 4930-4931,4938-4939;Women;2.700 MADRID, COMUNIDAD DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;27.436 MADRID, COMUNIDAD DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;12.945 MADRID, COMUNIDAD DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;14.491 MADRID, COMUNIDAD DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;82.160 MADRID, COMUNIDAD DE;Group 1100 Diseases of the digestive system 520-579;Men;44.442 MADRID, COMUNIDAD DE;Group 1100 Diseases of the digestive system 520-579;Women;37.718 MADRID, COMUNIDAD DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;2.402 MADRID, COMUNIDAD DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;1.033 MADRID, COMUNIDAD DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;1.369 MADRID, COMUNIDAD DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1.462 MADRID, COMUNIDAD DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;821 MADRID, COMUNIDAD DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;641 MADRID, COMUNIDAD DE;Group 1103 Diseases of the esophagus 530;Both sexes;1.866 MADRID, COMUNIDAD DE;Group 1103 Diseases of the esophagus 530;Men;1.093 MADRID, COMUNIDAD DE;Group 1103 Diseases of the esophagus 530;Women;773 MADRID, COMUNIDAD DE;Group 1104 Peptic ulcer 531-534;Both sexes;1.234 MADRID, COMUNIDAD DE;Group 1104 Peptic ulcer 531-534;Men;848 MADRID, COMUNIDAD DE;Group 1104 Peptic ulcer 531-534;Women;387 MADRID, COMUNIDAD DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;1.695 MADRID, COMUNIDAD DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;774 MADRID, COMUNIDAD DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;922 MADRID, COMUNIDAD DE;Group 1106 Appendicitis 540-543;Both sexes;7.092 MADRID, COMUNIDAD DE;Group 1106 Appendicitis 540-543;Men;3.897 MADRID, COMUNIDAD DE;Group 1106 Appendicitis 540-543;Women;3.194 MADRID, COMUNIDAD DE;Group 1107 Inguinal hernia 550;Both sexes;8.486 MADRID, COMUNIDAD DE;Group 1107 Inguinal hernia 550;Men;7.457 MADRID, COMUNIDAD DE;Group 1107 Inguinal hernia 550;Women;1.028 MADRID, COMUNIDAD DE;Group 1108 Other abdominal hernia 551-553;Both sexes;7.031 MADRID, COMUNIDAD DE;Group 1108 Other abdominal hernia 551-553;Men;3.319 MADRID, COMUNIDAD DE;Group 1108 Other abdominal hernia 551-553;Women;3.712 MADRID, COMUNIDAD DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1.262 MADRID, COMUNIDAD DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;648 MADRID, COMUNIDAD DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;614 MADRID, COMUNIDAD DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;4.464 MADRID, COMUNIDAD DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;2.057 MADRID, COMUNIDAD DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2.407 MADRID, COMUNIDAD DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;3.306 MADRID, COMUNIDAD DE;Group 1111 Intestinal obstruction without hernia 560;Men;1.558 MADRID, COMUNIDAD DE;Group 1111 Intestinal obstruction without hernia 560;Women;1.748 MADRID, COMUNIDAD DE;Group 1112 Intestinal diverticulosis 562;Both sexes;3.661 MADRID, COMUNIDAD DE;Group 1112 Intestinal diverticulosis 562;Men;1.786 MADRID, COMUNIDAD DE;Group 1112 Intestinal diverticulosis 562;Women;1.875 MADRID, COMUNIDAD DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;4.969 MADRID, COMUNIDAD DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;3.190 MADRID, COMUNIDAD DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1.780 MADRID, COMUNIDAD DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2.659 MADRID, COMUNIDAD DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1.152 MADRID, COMUNIDAD DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1.507 MADRID, COMUNIDAD DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1.161 MADRID, COMUNIDAD DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;984 MADRID, COMUNIDAD DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;177 MADRID, COMUNIDAD DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;2.754 MADRID, COMUNIDAD DE;Group 1116 Other diseases of the liver 570,5714-573;Men;1.654 MADRID, COMUNIDAD DE;Group 1116 Other diseases of the liver 570,5714-573;Women;1.100 MADRID, COMUNIDAD DE;Group 1117 Cholelithiasis 574;Both sexes;15.383 MADRID, COMUNIDAD DE;Group 1117 Cholelithiasis 574;Men;6.204 MADRID, COMUNIDAD DE;Group 1117 Cholelithiasis 574;Women;9.179 MADRID, COMUNIDAD DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;3.894 MADRID, COMUNIDAD DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;2.018 MADRID, COMUNIDAD DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;1.876 MADRID, COMUNIDAD DE;Group 1119 Pancreatic diseases 577;Both sexes;4.422 MADRID, COMUNIDAD DE;Group 1119 Pancreatic diseases 577;Men;2.403 MADRID, COMUNIDAD DE;Group 1119 Pancreatic diseases 577;Women;2.019 MADRID, COMUNIDAD DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;2.957 MADRID, COMUNIDAD DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1.546 MADRID, COMUNIDAD DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1.411 MADRID, COMUNIDAD DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;6.522 MADRID, COMUNIDAD DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;3.281 MADRID, COMUNIDAD DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;3.241 MADRID, COMUNIDAD DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;3.528 MADRID, COMUNIDAD DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1.921 MADRID, COMUNIDAD DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1.607 MADRID, COMUNIDAD DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;345 MADRID, COMUNIDAD DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;157 MADRID, COMUNIDAD DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;187 MADRID, COMUNIDAD DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;2.650 MADRID, COMUNIDAD DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;1.203 MADRID, COMUNIDAD DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1.447 MADRID, COMUNIDAD DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;60.345 MADRID, COMUNIDAD DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;28.393 MADRID, COMUNIDAD DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;31.952 MADRID, COMUNIDAD DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. MADRID, COMUNIDAD DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. MADRID, COMUNIDAD DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. MADRID, COMUNIDAD DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. MADRID, COMUNIDAD DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. MADRID, COMUNIDAD DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. MADRID, COMUNIDAD DE;Group 1303 Internal derangement of knee 717;Both sexes;9.828 MADRID, COMUNIDAD DE;Group 1303 Internal derangement of knee 717;Men;6.599 MADRID, COMUNIDAD DE;Group 1303 Internal derangement of knee 717;Women;3.229 MADRID, COMUNIDAD DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;19.206 MADRID, COMUNIDAD DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;8.013 MADRID, COMUNIDAD DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;11.193 MADRID, COMUNIDAD DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;986 MADRID, COMUNIDAD DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;300 MADRID, COMUNIDAD DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;686 MADRID, COMUNIDAD DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;3.773 MADRID, COMUNIDAD DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1.690 MADRID, COMUNIDAD DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;2.083 MADRID, COMUNIDAD DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;6.829 MADRID, COMUNIDAD DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;3.558 MADRID, COMUNIDAD DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;3.272 MADRID, COMUNIDAD DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;808 MADRID, COMUNIDAD DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;341 MADRID, COMUNIDAD DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;467 MADRID, COMUNIDAD DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;8.745 MADRID, COMUNIDAD DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;4.320 MADRID, COMUNIDAD DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;4.425 MADRID, COMUNIDAD DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;10.171 MADRID, COMUNIDAD DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;3.573 MADRID, COMUNIDAD DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;6.598 MADRID, COMUNIDAD DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;47.424 MADRID, COMUNIDAD DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;22.840 MADRID, COMUNIDAD DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;24.584 MADRID, COMUNIDAD DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;4.842 MADRID, COMUNIDAD DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1.688 MADRID, COMUNIDAD DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;3.154 MADRID, COMUNIDAD DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;4.215 MADRID, COMUNIDAD DE;Group 1402 Renal failure 5836-5837, 584-586;Men;2.402 MADRID, COMUNIDAD DE;Group 1402 Renal failure 5836-5837, 584-586;Women;1.814 MADRID, COMUNIDAD DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;5.987 MADRID, COMUNIDAD DE;Group 1403 Urolithiasis 592, 594, 7880;Men;3.620 MADRID, COMUNIDAD DE;Group 1403 Urolithiasis 592, 594, 7880;Women;2.367 MADRID, COMUNIDAD DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;14.461 MADRID, COMUNIDAD DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;7.245 MADRID, COMUNIDAD DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;7.216 MADRID, COMUNIDAD DE;Group 1405 Prostatic hyperplasia 600;Both sexes;4.748 MADRID, COMUNIDAD DE;Group 1405 Prostatic hyperplasia 600;Men;4.748 MADRID, COMUNIDAD DE;Group 1405 Prostatic hyperplasia 600;Women;.. MADRID, COMUNIDAD DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;2.748 MADRID, COMUNIDAD DE;Group 1406 Other diseases of the male genital organs 601-608;Men;2.748 MADRID, COMUNIDAD DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. MADRID, COMUNIDAD DE;Group 1407 Disorders of breast 610-612;Both sexes;2.837 MADRID, COMUNIDAD DE;Group 1407 Disorders of breast 610-612;Men;246 MADRID, COMUNIDAD DE;Group 1407 Disorders of breast 610-612;Women;2.592 MADRID, COMUNIDAD DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;1.111 MADRID, COMUNIDAD DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. MADRID, COMUNIDAD DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;1.111 MADRID, COMUNIDAD DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;343 MADRID, COMUNIDAD DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. MADRID, COMUNIDAD DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;343 MADRID, COMUNIDAD DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;6.132 MADRID, COMUNIDAD DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;144 MADRID, COMUNIDAD DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;5.987 MADRID, COMUNIDAD DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;74.063 MADRID, COMUNIDAD DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. MADRID, COMUNIDAD DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;74.063 MADRID, COMUNIDAD DE;Group 1501 Legally induced abortion 635;Both sexes;121 MADRID, COMUNIDAD DE;Group 1501 Legally induced abortion 635;Men;.. MADRID, COMUNIDAD DE;Group 1501 Legally induced abortion 635;Women;121 MADRID, COMUNIDAD DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;2.583 MADRID, COMUNIDAD DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. MADRID, COMUNIDAD DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;2.583 MADRID, COMUNIDAD DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;48.703 MADRID, COMUNIDAD DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. MADRID, COMUNIDAD DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;48.703 MADRID, COMUNIDAD DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;11.313 MADRID, COMUNIDAD DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. MADRID, COMUNIDAD DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;11.313 MADRID, COMUNIDAD DE;Group 1505 Single spontaneous delivery 650;Both sexes;3.404 MADRID, COMUNIDAD DE;Group 1505 Single spontaneous delivery 650;Men;.. MADRID, COMUNIDAD DE;Group 1505 Single spontaneous delivery 650;Women;3.404 MADRID, COMUNIDAD DE;Group 1506 Other deliveries 6695-6697;Both sexes;1.910 MADRID, COMUNIDAD DE;Group 1506 Other deliveries 6695-6697;Men;.. MADRID, COMUNIDAD DE;Group 1506 Other deliveries 6695-6697;Women;1.910 MADRID, COMUNIDAD DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;580 MADRID, COMUNIDAD DE;Group 1507 Complications related to the puerperium 670-676;Men;.. MADRID, COMUNIDAD DE;Group 1507 Complications related to the puerperium 670-676;Women;580 MADRID, COMUNIDAD DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;5.448 MADRID, COMUNIDAD DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. MADRID, COMUNIDAD DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;5.448 MADRID, COMUNIDAD DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;10.634 MADRID, COMUNIDAD DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;5.947 MADRID, COMUNIDAD DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;4.687 MADRID, COMUNIDAD DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;2.484 MADRID, COMUNIDAD DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1.340 MADRID, COMUNIDAD DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1.144 MADRID, COMUNIDAD DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;8.150 MADRID, COMUNIDAD DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;4.607 MADRID, COMUNIDAD DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;3.543 MADRID, COMUNIDAD DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;7.219 MADRID, COMUNIDAD DE;Grupo 1700 Congenital abnormalities 740-759;Men;3.768 MADRID, COMUNIDAD DE;Grupo 1700 Congenital abnormalities 740-759;Women;3.451 MADRID, COMUNIDAD DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;23.930 MADRID, COMUNIDAD DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;12.660 MADRID, COMUNIDAD DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;11.270 MADRID, COMUNIDAD DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;2.456 MADRID, COMUNIDAD DE;Group 1801 Pain in throat and chest 7841, 7865;Men;1.348 MADRID, COMUNIDAD DE;Group 1801 Pain in throat and chest 7841, 7865;Women;1.108 MADRID, COMUNIDAD DE;Group 1802 Abdominal pain 7890;Both sexes;2.635 MADRID, COMUNIDAD DE;Group 1802 Abdominal pain 7890;Men;1.018 MADRID, COMUNIDAD DE;Group 1802 Abdominal pain 7890;Women;1.617 MADRID, COMUNIDAD DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.150 MADRID, COMUNIDAD DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;655 MADRID, COMUNIDAD DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;495 MADRID, COMUNIDAD DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;17.689 MADRID, COMUNIDAD DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;9.638 MADRID, COMUNIDAD DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;8.051 MADRID, COMUNIDAD DE;Group 1900 Injuries and poisoning 800-999;Both sexes;55.232 MADRID, COMUNIDAD DE;Group 1900 Injuries and poisoning 800-999;Men;28.430 MADRID, COMUNIDAD DE;Group 1900 Injuries and poisoning 800-999;Women;26.802 MADRID, COMUNIDAD DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;2.448 MADRID, COMUNIDAD DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1.344 MADRID, COMUNIDAD DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;1.104 MADRID, COMUNIDAD DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1.457 MADRID, COMUNIDAD DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;1.023 MADRID, COMUNIDAD DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;434 MADRID, COMUNIDAD DE;Group 1903 Radius and ulna fracture 813;Both sexes;3.152 MADRID, COMUNIDAD DE;Group 1903 Radius and ulna fracture 813;Men;1.600 MADRID, COMUNIDAD DE;Group 1903 Radius and ulna fracture 813;Women;1.552 MADRID, COMUNIDAD DE;Group 1904 Femur fracture 820-821;Both sexes;7.488 MADRID, COMUNIDAD DE;Group 1904 Femur fracture 820-821;Men;1.996 MADRID, COMUNIDAD DE;Group 1904 Femur fracture 820-821;Women;5.492 MADRID, COMUNIDAD DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;3.724 MADRID, COMUNIDAD DE;Group 1905 Leg fracture, including the ankle 823-824;Men;1.908 MADRID, COMUNIDAD DE;Group 1905 Leg fracture, including the ankle 823-824;Women;1.816 MADRID, COMUNIDAD DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;14.449 MADRID, COMUNIDAD DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;8.756 MADRID, COMUNIDAD DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;5.694 MADRID, COMUNIDAD DE;Group 1907 Burns 940-949;Both sexes;503 MADRID, COMUNIDAD DE;Group 1907 Burns 940-949;Men;305 MADRID, COMUNIDAD DE;Group 1907 Burns 940-949;Women;198 MADRID, COMUNIDAD DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;1.505 MADRID, COMUNIDAD DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;658 MADRID, COMUNIDAD DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;847 MADRID, COMUNIDAD DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;18.344 MADRID, COMUNIDAD DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;9.760 MADRID, COMUNIDAD DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;8.584 MADRID, COMUNIDAD DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;94 MADRID, COMUNIDAD DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;52 MADRID, COMUNIDAD DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;42 MADRID, COMUNIDAD DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;2.069 MADRID, COMUNIDAD DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;1.029 MADRID, COMUNIDAD DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;1.040 MADRID, COMUNIDAD DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;18.830 MADRID, COMUNIDAD DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;8.166 MADRID, COMUNIDAD DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;10.664 MADRID, COMUNIDAD DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;445 MADRID, COMUNIDAD DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;228 MADRID, COMUNIDAD DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;216 MADRID, COMUNIDAD DE;Group 2102 Contraceptive management V25;Both sexes;134 MADRID, COMUNIDAD DE;Group 2102 Contraceptive management V25;Men;11 MADRID, COMUNIDAD DE;Group 2102 Contraceptive management V25;Women;123 MADRID, COMUNIDAD DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. MADRID, COMUNIDAD DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. MADRID, COMUNIDAD DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. MADRID, COMUNIDAD DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;5.864 MADRID, COMUNIDAD DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;3.229 MADRID, COMUNIDAD DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;2.634 MADRID, COMUNIDAD DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;12.387 MADRID, COMUNIDAD DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;4.697 MADRID, COMUNIDAD DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;7.690 MURCIA, REGIËN DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;149.343 MURCIA, REGIËN DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;69.584 MURCIA, REGIËN DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;79.759 MURCIA, REGIËN DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3.495 MURCIA, REGIËN DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.936 MURCIA, REGIËN DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.559 MURCIA, REGIËN DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;555 MURCIA, REGIËN DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;293 MURCIA, REGIËN DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;262 MURCIA, REGIËN DE;Group 0102 Imprecise intestinal infections 009;Both sexes;107 MURCIA, REGIËN DE;Group 0102 Imprecise intestinal infections 009;Men;56 MURCIA, REGIËN DE;Group 0102 Imprecise intestinal infections 009;Women;51 MURCIA, REGIËN DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;141 MURCIA, REGIËN DE;Group 0103 Tuberculosis 010-018, 137;Men;84 MURCIA, REGIËN DE;Group 0103 Tuberculosis 010-018, 137;Women;57 MURCIA, REGIËN DE;Group 0104 Septicaemia 038;Both sexes;1.553 MURCIA, REGIËN DE;Group 0104 Septicaemia 038;Men;830 MURCIA, REGIËN DE;Group 0104 Septicaemia 038;Women;723 MURCIA, REGIËN DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;96 MURCIA, REGIËN DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;78 MURCIA, REGIËN DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;18 MURCIA, REGIËN DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.043 MURCIA, REGIËN DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;595 MURCIA, REGIËN DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;448 MURCIA, REGIËN DE;Group 0200 Neoplasms 140-239;Both sexes;11.929 MURCIA, REGIËN DE;Group 0200 Neoplasms 140-239;Men;6.275 MURCIA, REGIËN DE;Group 0200 Neoplasms 140-239;Women;5.654 MURCIA, REGIËN DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.012 MURCIA, REGIËN DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;629 MURCIA, REGIËN DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;383 MURCIA, REGIËN DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;880 MURCIA, REGIËN DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;713 MURCIA, REGIËN DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;167 MURCIA, REGIËN DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;145 MURCIA, REGIËN DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;82 MURCIA, REGIËN DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;63 MURCIA, REGIËN DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;975 MURCIA, REGIËN DE;Group 0204 Malignant neoplasm of breast 174-175;Men;10 MURCIA, REGIËN DE;Group 0204 Malignant neoplasm of breast 174-175;Women;965 MURCIA, REGIËN DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;251 MURCIA, REGIËN DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. MURCIA, REGIËN DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;251 MURCIA, REGIËN DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;118 MURCIA, REGIËN DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. MURCIA, REGIËN DE;Group 0206 Malignant neoplasm of ovary 1830;Women;118 MURCIA, REGIËN DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;400 MURCIA, REGIËN DE;Group 0207 Malignant neoplasm of prostate 185;Men;400 MURCIA, REGIËN DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. MURCIA, REGIËN DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.161 MURCIA, REGIËN DE;Group 0208 Malignant neoplasm of bladder 188;Men;986 MURCIA, REGIËN DE;Group 0208 Malignant neoplasm of bladder 188;Women;175 MURCIA, REGIËN DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4.216 MURCIA, REGIËN DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.483 MURCIA, REGIËN DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.733 MURCIA, REGIËN DE;Group 0210 Carcinoma in situ 230-234;Both sexes;219 MURCIA, REGIËN DE;Group 0210 Carcinoma in situ 230-234;Men;100 MURCIA, REGIËN DE;Group 0210 Carcinoma in situ 230-234;Women;119 MURCIA, REGIËN DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;125 MURCIA, REGIËN DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;72 MURCIA, REGIËN DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;53 MURCIA, REGIËN DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;617 MURCIA, REGIËN DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. MURCIA, REGIËN DE;Grupo 0212 Leiomyoma of uterus 218;Women;617 MURCIA, REGIËN DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.809 MURCIA, REGIËN DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;799 MURCIA, REGIËN DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.010 MURCIA, REGIËN DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.377 MURCIA, REGIËN DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;674 MURCIA, REGIËN DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;703 MURCIA, REGIËN DE;Group 0301 Anaemias 280-285;Both sexes;740 MURCIA, REGIËN DE;Group 0301 Anaemias 280-285;Men;358 MURCIA, REGIËN DE;Group 0301 Anaemias 280-285;Women;382 MURCIA, REGIËN DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;637 MURCIA, REGIËN DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;316 MURCIA, REGIËN DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;321 MURCIA, REGIËN DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3.075 MURCIA, REGIËN DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.309 MURCIA, REGIËN DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.765 MURCIA, REGIËN DE;Group 0401 Diabetes mellitus 249-250;Both sexes;1.033 MURCIA, REGIËN DE;Group 0401 Diabetes mellitus 249-250;Men;647 MURCIA, REGIËN DE;Group 0401 Diabetes mellitus 249-250;Women;386 MURCIA, REGIËN DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2.042 MURCIA, REGIËN DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;662 MURCIA, REGIËN DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.379 MURCIA, REGIËN DE;Group 0500 Mental disorders 290-319;Both sexes;3.577 MURCIA, REGIËN DE;Group 0500 Mental disorders 290-319;Men;2.014 MURCIA, REGIËN DE;Group 0500 Mental disorders 290-319;Women;1.563 MURCIA, REGIËN DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;98 MURCIA, REGIËN DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;41 MURCIA, REGIËN DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;56 MURCIA, REGIËN DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;212 MURCIA, REGIËN DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;161 MURCIA, REGIËN DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;50 MURCIA, REGIËN DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;272 MURCIA, REGIËN DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;211 MURCIA, REGIËN DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;61 MURCIA, REGIËN DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.092 MURCIA, REGIËN DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;689 MURCIA, REGIËN DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;403 MURCIA, REGIËN DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;668 MURCIA, REGIËN DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;332 MURCIA, REGIËN DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;336 MURCIA, REGIËN DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.236 MURCIA, REGIËN DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;579 MURCIA, REGIËN DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;657 MURCIA, REGIËN DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3.614 MURCIA, REGIËN DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.867 MURCIA, REGIËN DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.748 MURCIA, REGIËN DE;Group 0601 Alzheimer's disease 3310;Both sexes;108 MURCIA, REGIËN DE;Group 0601 Alzheimer's disease 3310;Men;33 MURCIA, REGIËN DE;Group 0601 Alzheimer's disease 3310;Women;75 MURCIA, REGIËN DE;Group 0602 Multiple sclerosis 340;Both sexes;79 MURCIA, REGIËN DE;Group 0602 Multiple sclerosis 340;Men;26 MURCIA, REGIËN DE;Group 0602 Multiple sclerosis 340;Women;53 MURCIA, REGIËN DE;Group 0603 Epilepsy 345;Both sexes;720 MURCIA, REGIËN DE;Group 0603 Epilepsy 345;Men;405 MURCIA, REGIËN DE;Group 0603 Epilepsy 345;Women;315 MURCIA, REGIËN DE;Group 0604 Transient cerebral ischemia 435;Both sexes;619 MURCIA, REGIËN DE;Group 0604 Transient cerebral ischemia 435;Men;340 MURCIA, REGIËN DE;Group 0604 Transient cerebral ischemia 435;Women;279 MURCIA, REGIËN DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2.088 MURCIA, REGIËN DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.062 MURCIA, REGIËN DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.025 MURCIA, REGIËN DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;497 MURCIA, REGIËN DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;252 MURCIA, REGIËN DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;245 MURCIA, REGIËN DE;Grupo 0701 Cataract 366;Both sexes;63 MURCIA, REGIËN DE;Grupo 0701 Cataract 366;Men;31 MURCIA, REGIËN DE;Grupo 0701 Cataract 366;Women;32 MURCIA, REGIËN DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;434 MURCIA, REGIËN DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;221 MURCIA, REGIËN DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;213 MURCIA, REGIËN DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;664 MURCIA, REGIËN DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;340 MURCIA, REGIËN DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;324 MURCIA, REGIËN DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;18.528 MURCIA, REGIËN DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10.473 MURCIA, REGIËN DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;8.055 MURCIA, REGIËN DE;Group 0901 Hypertensive disease 401-405;Both sexes;823 MURCIA, REGIËN DE;Group 0901 Hypertensive disease 401-405;Men;355 MURCIA, REGIËN DE;Group 0901 Hypertensive disease 401-405;Women;468 MURCIA, REGIËN DE;Group 0902 Angina pectoris 4111, 413;Both sexes;997 MURCIA, REGIËN DE;Group 0902 Angina pectoris 4111, 413;Men;597 MURCIA, REGIËN DE;Group 0902 Angina pectoris 4111, 413;Women;400 MURCIA, REGIËN DE;Group 0903 Acute myocardial infarction 410;Both sexes;1.839 MURCIA, REGIËN DE;Group 0903 Acute myocardial infarction 410;Men;1.347 MURCIA, REGIËN DE;Group 0903 Acute myocardial infarction 410;Women;492 MURCIA, REGIËN DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.447 MURCIA, REGIËN DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.102 MURCIA, REGIËN DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;345 MURCIA, REGIËN DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;445 MURCIA, REGIËN DE;Group 0905 Diseases of the lungs circulation 415-417;Men;194 MURCIA, REGIËN DE;Group 0905 Diseases of the lungs circulation 415-417;Women;251 MURCIA, REGIËN DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.454 MURCIA, REGIËN DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.276 MURCIA, REGIËN DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.178 MURCIA, REGIËN DE;Grupo 0907 Heart failure 428;Both sexes;3.276 MURCIA, REGIËN DE;Grupo 0907 Heart failure 428;Men;1.495 MURCIA, REGIËN DE;Grupo 0907 Heart failure 428;Women;1.781 MURCIA, REGIËN DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3.333 MURCIA, REGIËN DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.863 MURCIA, REGIËN DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.470 MURCIA, REGIËN DE;Grupo 0909 Atherosclerosis 440;Both sexes;262 MURCIA, REGIËN DE;Grupo 0909 Atherosclerosis 440;Men;203 MURCIA, REGIËN DE;Grupo 0909 Atherosclerosis 440;Women;59 MURCIA, REGIËN DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;645 MURCIA, REGIËN DE;Group 0910 Varicose veins of lower extremities 454;Men;223 MURCIA, REGIËN DE;Group 0910 Varicose veins of lower extremities 454;Women;422 MURCIA, REGIËN DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3.007 MURCIA, REGIËN DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.816 MURCIA, REGIËN DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.190 MURCIA, REGIËN DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;17.584 MURCIA, REGIËN DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;9.972 MURCIA, REGIËN DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;7.611 MURCIA, REGIËN DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;932 MURCIA, REGIËN DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;481 MURCIA, REGIËN DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;451 MURCIA, REGIËN DE;Group 1002 Pneumonia 480-486;Both sexes;4.092 MURCIA, REGIËN DE;Group 1002 Pneumonia 480-486;Men;2.347 MURCIA, REGIËN DE;Group 1002 Pneumonia 480-486;Women;1.746 MURCIA, REGIËN DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1.660 MURCIA, REGIËN DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;823 MURCIA, REGIËN DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;837 MURCIA, REGIËN DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;764 MURCIA, REGIËN DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;404 MURCIA, REGIËN DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;360 MURCIA, REGIËN DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.199 MURCIA, REGIËN DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;721 MURCIA, REGIËN DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;478 MURCIA, REGIËN DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.332 MURCIA, REGIËN DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.922 MURCIA, REGIËN DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;410 MURCIA, REGIËN DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;798 MURCIA, REGIËN DE;Group 1007 Asthma 4930-4931,4938-4939;Men;251 MURCIA, REGIËN DE;Group 1007 Asthma 4930-4931,4938-4939;Women;547 MURCIA, REGIËN DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5.806 MURCIA, REGIËN DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3.023 MURCIA, REGIËN DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2.782 MURCIA, REGIËN DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;18.102 MURCIA, REGIËN DE;Group 1100 Diseases of the digestive system 520-579;Men;9.981 MURCIA, REGIËN DE;Group 1100 Diseases of the digestive system 520-579;Women;8.122 MURCIA, REGIËN DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;304 MURCIA, REGIËN DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;151 MURCIA, REGIËN DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;153 MURCIA, REGIËN DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;293 MURCIA, REGIËN DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;161 MURCIA, REGIËN DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;132 MURCIA, REGIËN DE;Group 1103 Diseases of the esophagus 530;Both sexes;319 MURCIA, REGIËN DE;Group 1103 Diseases of the esophagus 530;Men;192 MURCIA, REGIËN DE;Group 1103 Diseases of the esophagus 530;Women;127 MURCIA, REGIËN DE;Group 1104 Peptic ulcer 531-534;Both sexes;301 MURCIA, REGIËN DE;Group 1104 Peptic ulcer 531-534;Men;194 MURCIA, REGIËN DE;Group 1104 Peptic ulcer 531-534;Women;107 MURCIA, REGIËN DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;479 MURCIA, REGIËN DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;235 MURCIA, REGIËN DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;244 MURCIA, REGIËN DE;Group 1106 Appendicitis 540-543;Both sexes;1.619 MURCIA, REGIËN DE;Group 1106 Appendicitis 540-543;Men;947 MURCIA, REGIËN DE;Group 1106 Appendicitis 540-543;Women;672 MURCIA, REGIËN DE;Group 1107 Inguinal hernia 550;Both sexes;1.577 MURCIA, REGIËN DE;Group 1107 Inguinal hernia 550;Men;1.407 MURCIA, REGIËN DE;Group 1107 Inguinal hernia 550;Women;169 MURCIA, REGIËN DE;Group 1108 Other abdominal hernia 551-553;Both sexes;1.626 MURCIA, REGIËN DE;Group 1108 Other abdominal hernia 551-553;Men;797 MURCIA, REGIËN DE;Group 1108 Other abdominal hernia 551-553;Women;828 MURCIA, REGIËN DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;393 MURCIA, REGIËN DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;204 MURCIA, REGIËN DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;189 MURCIA, REGIËN DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.126 MURCIA, REGIËN DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;534 MURCIA, REGIËN DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;592 MURCIA, REGIËN DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;761 MURCIA, REGIËN DE;Group 1111 Intestinal obstruction without hernia 560;Men;373 MURCIA, REGIËN DE;Group 1111 Intestinal obstruction without hernia 560;Women;388 MURCIA, REGIËN DE;Group 1112 Intestinal diverticulosis 562;Both sexes;760 MURCIA, REGIËN DE;Group 1112 Intestinal diverticulosis 562;Men;427 MURCIA, REGIËN DE;Group 1112 Intestinal diverticulosis 562;Women;333 MURCIA, REGIËN DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.130 MURCIA, REGIËN DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;765 MURCIA, REGIËN DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;364 MURCIA, REGIËN DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;585 MURCIA, REGIËN DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;277 MURCIA, REGIËN DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;308 MURCIA, REGIËN DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;214 MURCIA, REGIËN DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;186 MURCIA, REGIËN DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;28 MURCIA, REGIËN DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;662 MURCIA, REGIËN DE;Group 1116 Other diseases of the liver 570,5714-573;Men;411 MURCIA, REGIËN DE;Group 1116 Other diseases of the liver 570,5714-573;Women;251 MURCIA, REGIËN DE;Group 1117 Cholelithiasis 574;Both sexes;3.399 MURCIA, REGIËN DE;Group 1117 Cholelithiasis 574;Men;1.306 MURCIA, REGIËN DE;Group 1117 Cholelithiasis 574;Women;2.092 MURCIA, REGIËN DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;839 MURCIA, REGIËN DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;450 MURCIA, REGIËN DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;389 MURCIA, REGIËN DE;Group 1119 Pancreatic diseases 577;Both sexes;937 MURCIA, REGIËN DE;Group 1119 Pancreatic diseases 577;Men;540 MURCIA, REGIËN DE;Group 1119 Pancreatic diseases 577;Women;397 MURCIA, REGIËN DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;779 MURCIA, REGIËN DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;422 MURCIA, REGIËN DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;357 MURCIA, REGIËN DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.553 MURCIA, REGIËN DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;840 MURCIA, REGIËN DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;713 MURCIA, REGIËN DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.017 MURCIA, REGIËN DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;599 MURCIA, REGIËN DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;418 MURCIA, REGIËN DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;74 MURCIA, REGIËN DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;31 MURCIA, REGIËN DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;43 MURCIA, REGIËN DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;462 MURCIA, REGIËN DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;210 MURCIA, REGIËN DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;252 MURCIA, REGIËN DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;10.321 MURCIA, REGIËN DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;5.003 MURCIA, REGIËN DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5.318 MURCIA, REGIËN DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. MURCIA, REGIËN DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. MURCIA, REGIËN DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. MURCIA, REGIËN DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. MURCIA, REGIËN DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. MURCIA, REGIËN DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. MURCIA, REGIËN DE;Group 1303 Internal derangement of knee 717;Both sexes;1.382 MURCIA, REGIËN DE;Group 1303 Internal derangement of knee 717;Men;997 MURCIA, REGIËN DE;Group 1303 Internal derangement of knee 717;Women;384 MURCIA, REGIËN DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.761 MURCIA, REGIËN DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.589 MURCIA, REGIËN DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.172 MURCIA, REGIËN DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;196 MURCIA, REGIËN DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;85 MURCIA, REGIËN DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;111 MURCIA, REGIËN DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;354 MURCIA, REGIËN DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;164 MURCIA, REGIËN DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;190 MURCIA, REGIËN DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.248 MURCIA, REGIËN DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;676 MURCIA, REGIËN DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;572 MURCIA, REGIËN DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;308 MURCIA, REGIËN DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;137 MURCIA, REGIËN DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;171 MURCIA, REGIËN DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.411 MURCIA, REGIËN DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;726 MURCIA, REGIËN DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;684 MURCIA, REGIËN DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.661 MURCIA, REGIËN DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;628 MURCIA, REGIËN DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.033 MURCIA, REGIËN DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;10.686 MURCIA, REGIËN DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.949 MURCIA, REGIËN DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5.738 MURCIA, REGIËN DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.200 MURCIA, REGIËN DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;431 MURCIA, REGIËN DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;769 MURCIA, REGIËN DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;987 MURCIA, REGIËN DE;Group 1402 Renal failure 5836-5837, 584-586;Men;557 MURCIA, REGIËN DE;Group 1402 Renal failure 5836-5837, 584-586;Women;430 MURCIA, REGIËN DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.629 MURCIA, REGIËN DE;Group 1403 Urolithiasis 592, 594, 7880;Men;1.014 MURCIA, REGIËN DE;Group 1403 Urolithiasis 592, 594, 7880;Women;615 MURCIA, REGIËN DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;3.150 MURCIA, REGIËN DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.499 MURCIA, REGIËN DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.651 MURCIA, REGIËN DE;Group 1405 Prostatic hyperplasia 600;Both sexes;723 MURCIA, REGIËN DE;Group 1405 Prostatic hyperplasia 600;Men;723 MURCIA, REGIËN DE;Group 1405 Prostatic hyperplasia 600;Women;.. MURCIA, REGIËN DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;668 MURCIA, REGIËN DE;Group 1406 Other diseases of the male genital organs 601-608;Men;668 MURCIA, REGIËN DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. MURCIA, REGIËN DE;Group 1407 Disorders of breast 610-612;Both sexes;738 MURCIA, REGIËN DE;Group 1407 Disorders of breast 610-612;Men;46 MURCIA, REGIËN DE;Group 1407 Disorders of breast 610-612;Women;692 MURCIA, REGIËN DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;268 MURCIA, REGIËN DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. MURCIA, REGIËN DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;268 MURCIA, REGIËN DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;109 MURCIA, REGIËN DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. MURCIA, REGIËN DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;109 MURCIA, REGIËN DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.214 MURCIA, REGIËN DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;10 MURCIA, REGIËN DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.204 MURCIA, REGIËN DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;18.595 MURCIA, REGIËN DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. MURCIA, REGIËN DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;18.595 MURCIA, REGIËN DE;Group 1501 Legally induced abortion 635;Both sexes;4 MURCIA, REGIËN DE;Group 1501 Legally induced abortion 635;Men;.. MURCIA, REGIËN DE;Group 1501 Legally induced abortion 635;Women;4 MURCIA, REGIËN DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;964 MURCIA, REGIËN DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. MURCIA, REGIËN DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;964 MURCIA, REGIËN DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;12.536 MURCIA, REGIËN DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. MURCIA, REGIËN DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;12.536 MURCIA, REGIËN DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.214 MURCIA, REGIËN DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. MURCIA, REGIËN DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.214 MURCIA, REGIËN DE;Group 1505 Single spontaneous delivery 650;Both sexes;583 MURCIA, REGIËN DE;Group 1505 Single spontaneous delivery 650;Men;.. MURCIA, REGIËN DE;Group 1505 Single spontaneous delivery 650;Women;583 MURCIA, REGIËN DE;Group 1506 Other deliveries 6695-6697;Both sexes;792 MURCIA, REGIËN DE;Group 1506 Other deliveries 6695-6697;Men;.. MURCIA, REGIËN DE;Group 1506 Other deliveries 6695-6697;Women;792 MURCIA, REGIËN DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;135 MURCIA, REGIËN DE;Group 1507 Complications related to the puerperium 670-676;Men;.. MURCIA, REGIËN DE;Group 1507 Complications related to the puerperium 670-676;Women;135 MURCIA, REGIËN DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.367 MURCIA, REGIËN DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. MURCIA, REGIËN DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.367 MURCIA, REGIËN DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1.692 MURCIA, REGIËN DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;955 MURCIA, REGIËN DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;737 MURCIA, REGIËN DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;599 MURCIA, REGIËN DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;342 MURCIA, REGIËN DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;257 MURCIA, REGIËN DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.093 MURCIA, REGIËN DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;613 MURCIA, REGIËN DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;480 MURCIA, REGIËN DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.086 MURCIA, REGIËN DE;Grupo 1700 Congenital abnormalities 740-759;Men;576 MURCIA, REGIËN DE;Grupo 1700 Congenital abnormalities 740-759;Women;510 MURCIA, REGIËN DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;7.768 MURCIA, REGIËN DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4.341 MURCIA, REGIËN DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3.427 MURCIA, REGIËN DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.069 MURCIA, REGIËN DE;Group 1801 Pain in throat and chest 7841, 7865;Men;626 MURCIA, REGIËN DE;Group 1801 Pain in throat and chest 7841, 7865;Women;443 MURCIA, REGIËN DE;Group 1802 Abdominal pain 7890;Both sexes;705 MURCIA, REGIËN DE;Group 1802 Abdominal pain 7890;Men;286 MURCIA, REGIËN DE;Group 1802 Abdominal pain 7890;Women;419 MURCIA, REGIËN DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;614 MURCIA, REGIËN DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;346 MURCIA, REGIËN DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;268 MURCIA, REGIËN DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5.380 MURCIA, REGIËN DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;3.083 MURCIA, REGIËN DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2.296 MURCIA, REGIËN DE;Group 1900 Injuries and poisoning 800-999;Both sexes;12.241 MURCIA, REGIËN DE;Group 1900 Injuries and poisoning 800-999;Men;6.612 MURCIA, REGIËN DE;Group 1900 Injuries and poisoning 800-999;Women;5.629 MURCIA, REGIËN DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;739 MURCIA, REGIËN DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;445 MURCIA, REGIËN DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;294 MURCIA, REGIËN DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;311 MURCIA, REGIËN DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;219 MURCIA, REGIËN DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;92 MURCIA, REGIËN DE;Group 1903 Radius and ulna fracture 813;Both sexes;762 MURCIA, REGIËN DE;Group 1903 Radius and ulna fracture 813;Men;376 MURCIA, REGIËN DE;Group 1903 Radius and ulna fracture 813;Women;386 MURCIA, REGIËN DE;Group 1904 Femur fracture 820-821;Both sexes;1.739 MURCIA, REGIËN DE;Group 1904 Femur fracture 820-821;Men;595 MURCIA, REGIËN DE;Group 1904 Femur fracture 820-821;Women;1.144 MURCIA, REGIËN DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;844 MURCIA, REGIËN DE;Group 1905 Leg fracture, including the ankle 823-824;Men;453 MURCIA, REGIËN DE;Group 1905 Leg fracture, including the ankle 823-824;Women;391 MURCIA, REGIËN DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.676 MURCIA, REGIËN DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.327 MURCIA, REGIËN DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.349 MURCIA, REGIËN DE;Group 1907 Burns 940-949;Both sexes;82 MURCIA, REGIËN DE;Group 1907 Burns 940-949;Men;47 MURCIA, REGIËN DE;Group 1907 Burns 940-949;Women;35 MURCIA, REGIËN DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;362 MURCIA, REGIËN DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;174 MURCIA, REGIËN DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;188 MURCIA, REGIËN DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3.249 MURCIA, REGIËN DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.715 MURCIA, REGIËN DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.534 MURCIA, REGIËN DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;12 MURCIA, REGIËN DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;6 MURCIA, REGIËN DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;6 MURCIA, REGIËN DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;464 MURCIA, REGIËN DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;254 MURCIA, REGIËN DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;210 MURCIA, REGIËN DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.958 MURCIA, REGIËN DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.216 MURCIA, REGIËN DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.742 MURCIA, REGIËN DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;53 MURCIA, REGIËN DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;27 MURCIA, REGIËN DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;26 MURCIA, REGIËN DE;Group 2102 Contraceptive management V25;Both sexes;76 MURCIA, REGIËN DE;Group 2102 Contraceptive management V25;Men;9 MURCIA, REGIËN DE;Group 2102 Contraceptive management V25;Women;67 MURCIA, REGIËN DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. MURCIA, REGIËN DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. MURCIA, REGIËN DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. MURCIA, REGIËN DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;885 MURCIA, REGIËN DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;596 MURCIA, REGIËN DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;289 MURCIA, REGIËN DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.944 MURCIA, REGIËN DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;584 MURCIA, REGIËN DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.360 NAVARRA, COMUNIDAD FORAL DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;68.553 NAVARRA, COMUNIDAD FORAL DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;33.380 NAVARRA, COMUNIDAD FORAL DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;35.173 NAVARRA, COMUNIDAD FORAL DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.265 NAVARRA, COMUNIDAD FORAL DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;733 NAVARRA, COMUNIDAD FORAL DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;532 NAVARRA, COMUNIDAD FORAL DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;203 NAVARRA, COMUNIDAD FORAL DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;117 NAVARRA, COMUNIDAD FORAL DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;86 NAVARRA, COMUNIDAD FORAL DE;Group 0102 Imprecise intestinal infections 009;Both sexes;86 NAVARRA, COMUNIDAD FORAL DE;Group 0102 Imprecise intestinal infections 009;Men;44 NAVARRA, COMUNIDAD FORAL DE;Group 0102 Imprecise intestinal infections 009;Women;42 NAVARRA, COMUNIDAD FORAL DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;42 NAVARRA, COMUNIDAD FORAL DE;Group 0103 Tuberculosis 010-018, 137;Men;24 NAVARRA, COMUNIDAD FORAL DE;Group 0103 Tuberculosis 010-018, 137;Women;18 NAVARRA, COMUNIDAD FORAL DE;Group 0104 Septicaemia 038;Both sexes;496 NAVARRA, COMUNIDAD FORAL DE;Group 0104 Septicaemia 038;Men;285 NAVARRA, COMUNIDAD FORAL DE;Group 0104 Septicaemia 038;Women;211 NAVARRA, COMUNIDAD FORAL DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;31 NAVARRA, COMUNIDAD FORAL DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;20 NAVARRA, COMUNIDAD FORAL DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;11 NAVARRA, COMUNIDAD FORAL DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;407 NAVARRA, COMUNIDAD FORAL DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;243 NAVARRA, COMUNIDAD FORAL DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;164 NAVARRA, COMUNIDAD FORAL DE;Group 0200 Neoplasms 140-239;Both sexes;7.833 NAVARRA, COMUNIDAD FORAL DE;Group 0200 Neoplasms 140-239;Men;4.148 NAVARRA, COMUNIDAD FORAL DE;Group 0200 Neoplasms 140-239;Women;3.685 NAVARRA, COMUNIDAD FORAL DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;809 NAVARRA, COMUNIDAD FORAL DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;544 NAVARRA, COMUNIDAD FORAL DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;265 NAVARRA, COMUNIDAD FORAL DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;615 NAVARRA, COMUNIDAD FORAL DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;472 NAVARRA, COMUNIDAD FORAL DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;143 NAVARRA, COMUNIDAD FORAL DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;132 NAVARRA, COMUNIDAD FORAL DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;73 NAVARRA, COMUNIDAD FORAL DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;59 NAVARRA, COMUNIDAD FORAL DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;605 NAVARRA, COMUNIDAD FORAL DE;Group 0204 Malignant neoplasm of breast 174-175;Men;10 NAVARRA, COMUNIDAD FORAL DE;Group 0204 Malignant neoplasm of breast 174-175;Women;595 NAVARRA, COMUNIDAD FORAL DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;177 NAVARRA, COMUNIDAD FORAL DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;177 NAVARRA, COMUNIDAD FORAL DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;98 NAVARRA, COMUNIDAD FORAL DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 0206 Malignant neoplasm of ovary 1830;Women;98 NAVARRA, COMUNIDAD FORAL DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;310 NAVARRA, COMUNIDAD FORAL DE;Group 0207 Malignant neoplasm of prostate 185;Men;310 NAVARRA, COMUNIDAD FORAL DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;509 NAVARRA, COMUNIDAD FORAL DE;Group 0208 Malignant neoplasm of bladder 188;Men;400 NAVARRA, COMUNIDAD FORAL DE;Group 0208 Malignant neoplasm of bladder 188;Women;109 NAVARRA, COMUNIDAD FORAL DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3.041 NAVARRA, COMUNIDAD FORAL DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.803 NAVARRA, COMUNIDAD FORAL DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.238 NAVARRA, COMUNIDAD FORAL DE;Group 0210 Carcinoma in situ 230-234;Both sexes;120 NAVARRA, COMUNIDAD FORAL DE;Group 0210 Carcinoma in situ 230-234;Men;39 NAVARRA, COMUNIDAD FORAL DE;Group 0210 Carcinoma in situ 230-234;Women;81 NAVARRA, COMUNIDAD FORAL DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;109 NAVARRA, COMUNIDAD FORAL DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;62 NAVARRA, COMUNIDAD FORAL DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;47 NAVARRA, COMUNIDAD FORAL DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;312 NAVARRA, COMUNIDAD FORAL DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. NAVARRA, COMUNIDAD FORAL DE;Grupo 0212 Leiomyoma of uterus 218;Women;312 NAVARRA, COMUNIDAD FORAL DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;996 NAVARRA, COMUNIDAD FORAL DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;435 NAVARRA, COMUNIDAD FORAL DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;561 NAVARRA, COMUNIDAD FORAL DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;691 NAVARRA, COMUNIDAD FORAL DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;375 NAVARRA, COMUNIDAD FORAL DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;316 NAVARRA, COMUNIDAD FORAL DE;Group 0301 Anaemias 280-285;Both sexes;436 NAVARRA, COMUNIDAD FORAL DE;Group 0301 Anaemias 280-285;Men;253 NAVARRA, COMUNIDAD FORAL DE;Group 0301 Anaemias 280-285;Women;183 NAVARRA, COMUNIDAD FORAL DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;255 NAVARRA, COMUNIDAD FORAL DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;122 NAVARRA, COMUNIDAD FORAL DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;133 NAVARRA, COMUNIDAD FORAL DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.242 NAVARRA, COMUNIDAD FORAL DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;538 NAVARRA, COMUNIDAD FORAL DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;704 NAVARRA, COMUNIDAD FORAL DE;Group 0401 Diabetes mellitus 249-250;Both sexes;390 NAVARRA, COMUNIDAD FORAL DE;Group 0401 Diabetes mellitus 249-250;Men;246 NAVARRA, COMUNIDAD FORAL DE;Group 0401 Diabetes mellitus 249-250;Women;144 NAVARRA, COMUNIDAD FORAL DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;852 NAVARRA, COMUNIDAD FORAL DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;292 NAVARRA, COMUNIDAD FORAL DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;560 NAVARRA, COMUNIDAD FORAL DE;Group 0500 Mental disorders 290-319;Both sexes;1.769 NAVARRA, COMUNIDAD FORAL DE;Group 0500 Mental disorders 290-319;Men;909 NAVARRA, COMUNIDAD FORAL DE;Group 0500 Mental disorders 290-319;Women;860 NAVARRA, COMUNIDAD FORAL DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;77 NAVARRA, COMUNIDAD FORAL DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;45 NAVARRA, COMUNIDAD FORAL DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;32 NAVARRA, COMUNIDAD FORAL DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;118 NAVARRA, COMUNIDAD FORAL DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;91 NAVARRA, COMUNIDAD FORAL DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;27 NAVARRA, COMUNIDAD FORAL DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;108 NAVARRA, COMUNIDAD FORAL DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;64 NAVARRA, COMUNIDAD FORAL DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;44 NAVARRA, COMUNIDAD FORAL DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;506 NAVARRA, COMUNIDAD FORAL DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;306 NAVARRA, COMUNIDAD FORAL DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;200 NAVARRA, COMUNIDAD FORAL DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;453 NAVARRA, COMUNIDAD FORAL DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;190 NAVARRA, COMUNIDAD FORAL DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;263 NAVARRA, COMUNIDAD FORAL DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;507 NAVARRA, COMUNIDAD FORAL DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;213 NAVARRA, COMUNIDAD FORAL DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;294 NAVARRA, COMUNIDAD FORAL DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.958 NAVARRA, COMUNIDAD FORAL DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.036 NAVARRA, COMUNIDAD FORAL DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;922 NAVARRA, COMUNIDAD FORAL DE;Group 0601 Alzheimer's disease 3310;Both sexes;203 NAVARRA, COMUNIDAD FORAL DE;Group 0601 Alzheimer's disease 3310;Men;83 NAVARRA, COMUNIDAD FORAL DE;Group 0601 Alzheimer's disease 3310;Women;120 NAVARRA, COMUNIDAD FORAL DE;Group 0602 Multiple sclerosis 340;Both sexes;11 NAVARRA, COMUNIDAD FORAL DE;Group 0602 Multiple sclerosis 340;Men;3 NAVARRA, COMUNIDAD FORAL DE;Group 0602 Multiple sclerosis 340;Women;8 NAVARRA, COMUNIDAD FORAL DE;Group 0603 Epilepsy 345;Both sexes;183 NAVARRA, COMUNIDAD FORAL DE;Group 0603 Epilepsy 345;Men;90 NAVARRA, COMUNIDAD FORAL DE;Group 0603 Epilepsy 345;Women;93 NAVARRA, COMUNIDAD FORAL DE;Group 0604 Transient cerebral ischemia 435;Both sexes;165 NAVARRA, COMUNIDAD FORAL DE;Group 0604 Transient cerebral ischemia 435;Men;81 NAVARRA, COMUNIDAD FORAL DE;Group 0604 Transient cerebral ischemia 435;Women;84 NAVARRA, COMUNIDAD FORAL DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.396 NAVARRA, COMUNIDAD FORAL DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;779 NAVARRA, COMUNIDAD FORAL DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;617 NAVARRA, COMUNIDAD FORAL DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;377 NAVARRA, COMUNIDAD FORAL DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;174 NAVARRA, COMUNIDAD FORAL DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;203 NAVARRA, COMUNIDAD FORAL DE;Grupo 0701 Cataract 366;Both sexes;43 NAVARRA, COMUNIDAD FORAL DE;Grupo 0701 Cataract 366;Men;19 NAVARRA, COMUNIDAD FORAL DE;Grupo 0701 Cataract 366;Women;24 NAVARRA, COMUNIDAD FORAL DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;334 NAVARRA, COMUNIDAD FORAL DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;155 NAVARRA, COMUNIDAD FORAL DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;179 NAVARRA, COMUNIDAD FORAL DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;426 NAVARRA, COMUNIDAD FORAL DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;222 NAVARRA, COMUNIDAD FORAL DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;204 NAVARRA, COMUNIDAD FORAL DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;8.320 NAVARRA, COMUNIDAD FORAL DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;4.821 NAVARRA, COMUNIDAD FORAL DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3.499 NAVARRA, COMUNIDAD FORAL DE;Group 0901 Hypertensive disease 401-405;Both sexes;718 NAVARRA, COMUNIDAD FORAL DE;Group 0901 Hypertensive disease 401-405;Men;327 NAVARRA, COMUNIDAD FORAL DE;Group 0901 Hypertensive disease 401-405;Women;391 NAVARRA, COMUNIDAD FORAL DE;Group 0902 Angina pectoris 4111, 413;Both sexes;209 NAVARRA, COMUNIDAD FORAL DE;Group 0902 Angina pectoris 4111, 413;Men;122 NAVARRA, COMUNIDAD FORAL DE;Group 0902 Angina pectoris 4111, 413;Women;87 NAVARRA, COMUNIDAD FORAL DE;Group 0903 Acute myocardial infarction 410;Both sexes;622 NAVARRA, COMUNIDAD FORAL DE;Group 0903 Acute myocardial infarction 410;Men;455 NAVARRA, COMUNIDAD FORAL DE;Group 0903 Acute myocardial infarction 410;Women;167 NAVARRA, COMUNIDAD FORAL DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;649 NAVARRA, COMUNIDAD FORAL DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;514 NAVARRA, COMUNIDAD FORAL DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;135 NAVARRA, COMUNIDAD FORAL DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;405 NAVARRA, COMUNIDAD FORAL DE;Group 0905 Diseases of the lungs circulation 415-417;Men;185 NAVARRA, COMUNIDAD FORAL DE;Group 0905 Diseases of the lungs circulation 415-417;Women;220 NAVARRA, COMUNIDAD FORAL DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.120 NAVARRA, COMUNIDAD FORAL DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;639 NAVARRA, COMUNIDAD FORAL DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;481 NAVARRA, COMUNIDAD FORAL DE;Grupo 0907 Heart failure 428;Both sexes;1.265 NAVARRA, COMUNIDAD FORAL DE;Grupo 0907 Heart failure 428;Men;648 NAVARRA, COMUNIDAD FORAL DE;Grupo 0907 Heart failure 428;Women;617 NAVARRA, COMUNIDAD FORAL DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.411 NAVARRA, COMUNIDAD FORAL DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;738 NAVARRA, COMUNIDAD FORAL DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;673 NAVARRA, COMUNIDAD FORAL DE;Grupo 0909 Atherosclerosis 440;Both sexes;353 NAVARRA, COMUNIDAD FORAL DE;Grupo 0909 Atherosclerosis 440;Men;283 NAVARRA, COMUNIDAD FORAL DE;Grupo 0909 Atherosclerosis 440;Women;70 NAVARRA, COMUNIDAD FORAL DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;96 NAVARRA, COMUNIDAD FORAL DE;Group 0910 Varicose veins of lower extremities 454;Men;41 NAVARRA, COMUNIDAD FORAL DE;Group 0910 Varicose veins of lower extremities 454;Women;55 NAVARRA, COMUNIDAD FORAL DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.472 NAVARRA, COMUNIDAD FORAL DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;869 NAVARRA, COMUNIDAD FORAL DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;603 NAVARRA, COMUNIDAD FORAL DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;8.082 NAVARRA, COMUNIDAD FORAL DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4.638 NAVARRA, COMUNIDAD FORAL DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3.444 NAVARRA, COMUNIDAD FORAL DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;345 NAVARRA, COMUNIDAD FORAL DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;184 NAVARRA, COMUNIDAD FORAL DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;161 NAVARRA, COMUNIDAD FORAL DE;Group 1002 Pneumonia 480-486;Both sexes;1.748 NAVARRA, COMUNIDAD FORAL DE;Group 1002 Pneumonia 480-486;Men;979 NAVARRA, COMUNIDAD FORAL DE;Group 1002 Pneumonia 480-486;Women;769 NAVARRA, COMUNIDAD FORAL DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;486 NAVARRA, COMUNIDAD FORAL DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;265 NAVARRA, COMUNIDAD FORAL DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;221 NAVARRA, COMUNIDAD FORAL DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;713 NAVARRA, COMUNIDAD FORAL DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;402 NAVARRA, COMUNIDAD FORAL DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;311 NAVARRA, COMUNIDAD FORAL DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;835 NAVARRA, COMUNIDAD FORAL DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;529 NAVARRA, COMUNIDAD FORAL DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;306 NAVARRA, COMUNIDAD FORAL DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.173 NAVARRA, COMUNIDAD FORAL DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;863 NAVARRA, COMUNIDAD FORAL DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;310 NAVARRA, COMUNIDAD FORAL DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;250 NAVARRA, COMUNIDAD FORAL DE;Group 1007 Asthma 4930-4931,4938-4939;Men;94 NAVARRA, COMUNIDAD FORAL DE;Group 1007 Asthma 4930-4931,4938-4939;Women;156 NAVARRA, COMUNIDAD FORAL DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2.532 NAVARRA, COMUNIDAD FORAL DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.322 NAVARRA, COMUNIDAD FORAL DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.210 NAVARRA, COMUNIDAD FORAL DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;8.440 NAVARRA, COMUNIDAD FORAL DE;Group 1100 Diseases of the digestive system 520-579;Men;4.830 NAVARRA, COMUNIDAD FORAL DE;Group 1100 Diseases of the digestive system 520-579;Women;3.610 NAVARRA, COMUNIDAD FORAL DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;158 NAVARRA, COMUNIDAD FORAL DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;83 NAVARRA, COMUNIDAD FORAL DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;75 NAVARRA, COMUNIDAD FORAL DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;159 NAVARRA, COMUNIDAD FORAL DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;97 NAVARRA, COMUNIDAD FORAL DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;62 NAVARRA, COMUNIDAD FORAL DE;Group 1103 Diseases of the esophagus 530;Both sexes;166 NAVARRA, COMUNIDAD FORAL DE;Group 1103 Diseases of the esophagus 530;Men;95 NAVARRA, COMUNIDAD FORAL DE;Group 1103 Diseases of the esophagus 530;Women;71 NAVARRA, COMUNIDAD FORAL DE;Group 1104 Peptic ulcer 531-534;Both sexes;130 NAVARRA, COMUNIDAD FORAL DE;Group 1104 Peptic ulcer 531-534;Men;92 NAVARRA, COMUNIDAD FORAL DE;Group 1104 Peptic ulcer 531-534;Women;38 NAVARRA, COMUNIDAD FORAL DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;222 NAVARRA, COMUNIDAD FORAL DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;101 NAVARRA, COMUNIDAD FORAL DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;121 NAVARRA, COMUNIDAD FORAL DE;Group 1106 Appendicitis 540-543;Both sexes;744 NAVARRA, COMUNIDAD FORAL DE;Group 1106 Appendicitis 540-543;Men;430 NAVARRA, COMUNIDAD FORAL DE;Group 1106 Appendicitis 540-543;Women;314 NAVARRA, COMUNIDAD FORAL DE;Group 1107 Inguinal hernia 550;Both sexes;702 NAVARRA, COMUNIDAD FORAL DE;Group 1107 Inguinal hernia 550;Men;616 NAVARRA, COMUNIDAD FORAL DE;Group 1107 Inguinal hernia 550;Women;86 NAVARRA, COMUNIDAD FORAL DE;Group 1108 Other abdominal hernia 551-553;Both sexes;628 NAVARRA, COMUNIDAD FORAL DE;Group 1108 Other abdominal hernia 551-553;Men;317 NAVARRA, COMUNIDAD FORAL DE;Group 1108 Other abdominal hernia 551-553;Women;311 NAVARRA, COMUNIDAD FORAL DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;187 NAVARRA, COMUNIDAD FORAL DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;107 NAVARRA, COMUNIDAD FORAL DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;80 NAVARRA, COMUNIDAD FORAL DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;430 NAVARRA, COMUNIDAD FORAL DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;205 NAVARRA, COMUNIDAD FORAL DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;225 NAVARRA, COMUNIDAD FORAL DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;405 NAVARRA, COMUNIDAD FORAL DE;Group 1111 Intestinal obstruction without hernia 560;Men;211 NAVARRA, COMUNIDAD FORAL DE;Group 1111 Intestinal obstruction without hernia 560;Women;194 NAVARRA, COMUNIDAD FORAL DE;Group 1112 Intestinal diverticulosis 562;Both sexes;352 NAVARRA, COMUNIDAD FORAL DE;Group 1112 Intestinal diverticulosis 562;Men;154 NAVARRA, COMUNIDAD FORAL DE;Group 1112 Intestinal diverticulosis 562;Women;198 NAVARRA, COMUNIDAD FORAL DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;551 NAVARRA, COMUNIDAD FORAL DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;379 NAVARRA, COMUNIDAD FORAL DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;172 NAVARRA, COMUNIDAD FORAL DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;375 NAVARRA, COMUNIDAD FORAL DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;177 NAVARRA, COMUNIDAD FORAL DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;198 NAVARRA, COMUNIDAD FORAL DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;209 NAVARRA, COMUNIDAD FORAL DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;182 NAVARRA, COMUNIDAD FORAL DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;27 NAVARRA, COMUNIDAD FORAL DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;282 NAVARRA, COMUNIDAD FORAL DE;Group 1116 Other diseases of the liver 570,5714-573;Men;162 NAVARRA, COMUNIDAD FORAL DE;Group 1116 Other diseases of the liver 570,5714-573;Women;120 NAVARRA, COMUNIDAD FORAL DE;Group 1117 Cholelithiasis 574;Both sexes;1.502 NAVARRA, COMUNIDAD FORAL DE;Group 1117 Cholelithiasis 574;Men;676 NAVARRA, COMUNIDAD FORAL DE;Group 1117 Cholelithiasis 574;Women;826 NAVARRA, COMUNIDAD FORAL DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;412 NAVARRA, COMUNIDAD FORAL DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;240 NAVARRA, COMUNIDAD FORAL DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;172 NAVARRA, COMUNIDAD FORAL DE;Group 1119 Pancreatic diseases 577;Both sexes;383 NAVARRA, COMUNIDAD FORAL DE;Group 1119 Pancreatic diseases 577;Men;241 NAVARRA, COMUNIDAD FORAL DE;Group 1119 Pancreatic diseases 577;Women;142 NAVARRA, COMUNIDAD FORAL DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;443 NAVARRA, COMUNIDAD FORAL DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;265 NAVARRA, COMUNIDAD FORAL DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;178 NAVARRA, COMUNIDAD FORAL DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;665 NAVARRA, COMUNIDAD FORAL DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;378 NAVARRA, COMUNIDAD FORAL DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;287 NAVARRA, COMUNIDAD FORAL DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;371 NAVARRA, COMUNIDAD FORAL DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;229 NAVARRA, COMUNIDAD FORAL DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;142 NAVARRA, COMUNIDAD FORAL DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;33 NAVARRA, COMUNIDAD FORAL DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;20 NAVARRA, COMUNIDAD FORAL DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;13 NAVARRA, COMUNIDAD FORAL DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;261 NAVARRA, COMUNIDAD FORAL DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;129 NAVARRA, COMUNIDAD FORAL DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;132 NAVARRA, COMUNIDAD FORAL DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6.415 NAVARRA, COMUNIDAD FORAL DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3.239 NAVARRA, COMUNIDAD FORAL DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.176 NAVARRA, COMUNIDAD FORAL DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. NAVARRA, COMUNIDAD FORAL DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. NAVARRA, COMUNIDAD FORAL DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1303 Internal derangement of knee 717;Both sexes;868 NAVARRA, COMUNIDAD FORAL DE;Group 1303 Internal derangement of knee 717;Men;608 NAVARRA, COMUNIDAD FORAL DE;Group 1303 Internal derangement of knee 717;Women;260 NAVARRA, COMUNIDAD FORAL DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.009 NAVARRA, COMUNIDAD FORAL DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.029 NAVARRA, COMUNIDAD FORAL DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;980 NAVARRA, COMUNIDAD FORAL DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;186 NAVARRA, COMUNIDAD FORAL DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;53 NAVARRA, COMUNIDAD FORAL DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;133 NAVARRA, COMUNIDAD FORAL DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;290 NAVARRA, COMUNIDAD FORAL DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;159 NAVARRA, COMUNIDAD FORAL DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;131 NAVARRA, COMUNIDAD FORAL DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;492 NAVARRA, COMUNIDAD FORAL DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;293 NAVARRA, COMUNIDAD FORAL DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;199 NAVARRA, COMUNIDAD FORAL DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;233 NAVARRA, COMUNIDAD FORAL DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;95 NAVARRA, COMUNIDAD FORAL DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;138 NAVARRA, COMUNIDAD FORAL DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.176 NAVARRA, COMUNIDAD FORAL DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;586 NAVARRA, COMUNIDAD FORAL DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;590 NAVARRA, COMUNIDAD FORAL DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.161 NAVARRA, COMUNIDAD FORAL DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;416 NAVARRA, COMUNIDAD FORAL DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;745 NAVARRA, COMUNIDAD FORAL DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3.316 NAVARRA, COMUNIDAD FORAL DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.520 NAVARRA, COMUNIDAD FORAL DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.796 NAVARRA, COMUNIDAD FORAL DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;296 NAVARRA, COMUNIDAD FORAL DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;117 NAVARRA, COMUNIDAD FORAL DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;179 NAVARRA, COMUNIDAD FORAL DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;365 NAVARRA, COMUNIDAD FORAL DE;Group 1402 Renal failure 5836-5837, 584-586;Men;226 NAVARRA, COMUNIDAD FORAL DE;Group 1402 Renal failure 5836-5837, 584-586;Women;139 NAVARRA, COMUNIDAD FORAL DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;260 NAVARRA, COMUNIDAD FORAL DE;Group 1403 Urolithiasis 592, 594, 7880;Men;160 NAVARRA, COMUNIDAD FORAL DE;Group 1403 Urolithiasis 592, 594, 7880;Women;100 NAVARRA, COMUNIDAD FORAL DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;985 NAVARRA, COMUNIDAD FORAL DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;486 NAVARRA, COMUNIDAD FORAL DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;499 NAVARRA, COMUNIDAD FORAL DE;Group 1405 Prostatic hyperplasia 600;Both sexes;343 NAVARRA, COMUNIDAD FORAL DE;Group 1405 Prostatic hyperplasia 600;Men;343 NAVARRA, COMUNIDAD FORAL DE;Group 1405 Prostatic hyperplasia 600;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;160 NAVARRA, COMUNIDAD FORAL DE;Group 1406 Other diseases of the male genital organs 601-608;Men;160 NAVARRA, COMUNIDAD FORAL DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1407 Disorders of breast 610-612;Both sexes;227 NAVARRA, COMUNIDAD FORAL DE;Group 1407 Disorders of breast 610-612;Men;26 NAVARRA, COMUNIDAD FORAL DE;Group 1407 Disorders of breast 610-612;Women;201 NAVARRA, COMUNIDAD FORAL DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;77 NAVARRA, COMUNIDAD FORAL DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;77 NAVARRA, COMUNIDAD FORAL DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;39 NAVARRA, COMUNIDAD FORAL DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;39 NAVARRA, COMUNIDAD FORAL DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;564 NAVARRA, COMUNIDAD FORAL DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 NAVARRA, COMUNIDAD FORAL DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;562 NAVARRA, COMUNIDAD FORAL DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;6.794 NAVARRA, COMUNIDAD FORAL DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;6.794 NAVARRA, COMUNIDAD FORAL DE;Group 1501 Legally induced abortion 635;Both sexes;1 NAVARRA, COMUNIDAD FORAL DE;Group 1501 Legally induced abortion 635;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1501 Legally induced abortion 635;Women;1 NAVARRA, COMUNIDAD FORAL DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;420 NAVARRA, COMUNIDAD FORAL DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;420 NAVARRA, COMUNIDAD FORAL DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.252 NAVARRA, COMUNIDAD FORAL DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.252 NAVARRA, COMUNIDAD FORAL DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.303 NAVARRA, COMUNIDAD FORAL DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.303 NAVARRA, COMUNIDAD FORAL DE;Group 1505 Single spontaneous delivery 650;Both sexes;98 NAVARRA, COMUNIDAD FORAL DE;Group 1505 Single spontaneous delivery 650;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1505 Single spontaneous delivery 650;Women;98 NAVARRA, COMUNIDAD FORAL DE;Group 1506 Other deliveries 6695-6697;Both sexes;229 NAVARRA, COMUNIDAD FORAL DE;Group 1506 Other deliveries 6695-6697;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1506 Other deliveries 6695-6697;Women;229 NAVARRA, COMUNIDAD FORAL DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;37 NAVARRA, COMUNIDAD FORAL DE;Group 1507 Complications related to the puerperium 670-676;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1507 Complications related to the puerperium 670-676;Women;37 NAVARRA, COMUNIDAD FORAL DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;454 NAVARRA, COMUNIDAD FORAL DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;454 NAVARRA, COMUNIDAD FORAL DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;659 NAVARRA, COMUNIDAD FORAL DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;373 NAVARRA, COMUNIDAD FORAL DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;286 NAVARRA, COMUNIDAD FORAL DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;160 NAVARRA, COMUNIDAD FORAL DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;84 NAVARRA, COMUNIDAD FORAL DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;76 NAVARRA, COMUNIDAD FORAL DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;499 NAVARRA, COMUNIDAD FORAL DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;289 NAVARRA, COMUNIDAD FORAL DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;210 NAVARRA, COMUNIDAD FORAL DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;535 NAVARRA, COMUNIDAD FORAL DE;Grupo 1700 Congenital abnormalities 740-759;Men;294 NAVARRA, COMUNIDAD FORAL DE;Grupo 1700 Congenital abnormalities 740-759;Women;241 NAVARRA, COMUNIDAD FORAL DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.586 NAVARRA, COMUNIDAD FORAL DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.373 NAVARRA, COMUNIDAD FORAL DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1.213 NAVARRA, COMUNIDAD FORAL DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;146 NAVARRA, COMUNIDAD FORAL DE;Group 1801 Pain in throat and chest 7841, 7865;Men;88 NAVARRA, COMUNIDAD FORAL DE;Group 1801 Pain in throat and chest 7841, 7865;Women;58 NAVARRA, COMUNIDAD FORAL DE;Group 1802 Abdominal pain 7890;Both sexes;337 NAVARRA, COMUNIDAD FORAL DE;Group 1802 Abdominal pain 7890;Men;119 NAVARRA, COMUNIDAD FORAL DE;Group 1802 Abdominal pain 7890;Women;218 NAVARRA, COMUNIDAD FORAL DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;315 NAVARRA, COMUNIDAD FORAL DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;182 NAVARRA, COMUNIDAD FORAL DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;133 NAVARRA, COMUNIDAD FORAL DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.788 NAVARRA, COMUNIDAD FORAL DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;984 NAVARRA, COMUNIDAD FORAL DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;804 NAVARRA, COMUNIDAD FORAL DE;Group 1900 Injuries and poisoning 800-999;Both sexes;5.715 NAVARRA, COMUNIDAD FORAL DE;Group 1900 Injuries and poisoning 800-999;Men;2.994 NAVARRA, COMUNIDAD FORAL DE;Group 1900 Injuries and poisoning 800-999;Women;2.721 NAVARRA, COMUNIDAD FORAL DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;385 NAVARRA, COMUNIDAD FORAL DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;216 NAVARRA, COMUNIDAD FORAL DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;169 NAVARRA, COMUNIDAD FORAL DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;169 NAVARRA, COMUNIDAD FORAL DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;118 NAVARRA, COMUNIDAD FORAL DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;51 NAVARRA, COMUNIDAD FORAL DE;Group 1903 Radius and ulna fracture 813;Both sexes;362 NAVARRA, COMUNIDAD FORAL DE;Group 1903 Radius and ulna fracture 813;Men;176 NAVARRA, COMUNIDAD FORAL DE;Group 1903 Radius and ulna fracture 813;Women;186 NAVARRA, COMUNIDAD FORAL DE;Group 1904 Femur fracture 820-821;Both sexes;827 NAVARRA, COMUNIDAD FORAL DE;Group 1904 Femur fracture 820-821;Men;217 NAVARRA, COMUNIDAD FORAL DE;Group 1904 Femur fracture 820-821;Women;610 NAVARRA, COMUNIDAD FORAL DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;386 NAVARRA, COMUNIDAD FORAL DE;Group 1905 Leg fracture, including the ankle 823-824;Men;194 NAVARRA, COMUNIDAD FORAL DE;Group 1905 Leg fracture, including the ankle 823-824;Women;192 NAVARRA, COMUNIDAD FORAL DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.706 NAVARRA, COMUNIDAD FORAL DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.039 NAVARRA, COMUNIDAD FORAL DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;667 NAVARRA, COMUNIDAD FORAL DE;Group 1907 Burns 940-949;Both sexes;41 NAVARRA, COMUNIDAD FORAL DE;Group 1907 Burns 940-949;Men;26 NAVARRA, COMUNIDAD FORAL DE;Group 1907 Burns 940-949;Women;15 NAVARRA, COMUNIDAD FORAL DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;94 NAVARRA, COMUNIDAD FORAL DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;34 NAVARRA, COMUNIDAD FORAL DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;60 NAVARRA, COMUNIDAD FORAL DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.532 NAVARRA, COMUNIDAD FORAL DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;872 NAVARRA, COMUNIDAD FORAL DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;660 NAVARRA, COMUNIDAD FORAL DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;15 NAVARRA, COMUNIDAD FORAL DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;9 NAVARRA, COMUNIDAD FORAL DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;6 NAVARRA, COMUNIDAD FORAL DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;198 NAVARRA, COMUNIDAD FORAL DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;93 NAVARRA, COMUNIDAD FORAL DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;105 NAVARRA, COMUNIDAD FORAL DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1.465 NAVARRA, COMUNIDAD FORAL DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;785 NAVARRA, COMUNIDAD FORAL DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;680 NAVARRA, COMUNIDAD FORAL DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;43 NAVARRA, COMUNIDAD FORAL DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;20 NAVARRA, COMUNIDAD FORAL DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;23 NAVARRA, COMUNIDAD FORAL DE;Group 2102 Contraceptive management V25;Both sexes;8 NAVARRA, COMUNIDAD FORAL DE;Group 2102 Contraceptive management V25;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 2102 Contraceptive management V25;Women;8 NAVARRA, COMUNIDAD FORAL DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. NAVARRA, COMUNIDAD FORAL DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;800 NAVARRA, COMUNIDAD FORAL DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;475 NAVARRA, COMUNIDAD FORAL DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;325 NAVARRA, COMUNIDAD FORAL DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;614 NAVARRA, COMUNIDAD FORAL DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;290 NAVARRA, COMUNIDAD FORAL DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;324 PA═S VASCO;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;246.170 PA═S VASCO;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;122.390 PA═S VASCO;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;123.780 PA═S VASCO;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;4.937 PA═S VASCO;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2.766 PA═S VASCO;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2.171 PA═S VASCO;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;591 PA═S VASCO;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;306 PA═S VASCO;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;286 PA═S VASCO;Group 0102 Imprecise intestinal infections 009;Both sexes;270 PA═S VASCO;Group 0102 Imprecise intestinal infections 009;Men;127 PA═S VASCO;Group 0102 Imprecise intestinal infections 009;Women;142 PA═S VASCO;Group 0103 Tuberculosis 010-018, 137;Both sexes;174 PA═S VASCO;Group 0103 Tuberculosis 010-018, 137;Men;99 PA═S VASCO;Group 0103 Tuberculosis 010-018, 137;Women;75 PA═S VASCO;Group 0104 Septicaemia 038;Both sexes;2.359 PA═S VASCO;Group 0104 Septicaemia 038;Men;1.320 PA═S VASCO;Group 0104 Septicaemia 038;Women;1.039 PA═S VASCO;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;233 PA═S VASCO;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;169 PA═S VASCO;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;64 PA═S VASCO;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1.310 PA═S VASCO;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;745 PA═S VASCO;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;565 PA═S VASCO;Group 0200 Neoplasms 140-239;Both sexes;23.712 PA═S VASCO;Group 0200 Neoplasms 140-239;Men;12.798 PA═S VASCO;Group 0200 Neoplasms 140-239;Women;10.913 PA═S VASCO;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;2.399 PA═S VASCO;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1.483 PA═S VASCO;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;915 PA═S VASCO;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1.646 PA═S VASCO;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1.224 PA═S VASCO;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;422 PA═S VASCO;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;404 PA═S VASCO;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;217 PA═S VASCO;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;188 PA═S VASCO;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1.759 PA═S VASCO;Group 0204 Malignant neoplasm of breast 174-175;Men;16 PA═S VASCO;Group 0204 Malignant neoplasm of breast 174-175;Women;1.743 PA═S VASCO;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;466 PA═S VASCO;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. PA═S VASCO;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;466 PA═S VASCO;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;232 PA═S VASCO;Group 0206 Malignant neoplasm of ovary 1830;Men;.. PA═S VASCO;Group 0206 Malignant neoplasm of ovary 1830;Women;232 PA═S VASCO;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1.226 PA═S VASCO;Group 0207 Malignant neoplasm of prostate 185;Men;1.226 PA═S VASCO;Group 0207 Malignant neoplasm of prostate 185;Women;.. PA═S VASCO;Group 0208 Malignant neoplasm of bladder 188;Both sexes;2.197 PA═S VASCO;Group 0208 Malignant neoplasm of bladder 188;Men;1.783 PA═S VASCO;Group 0208 Malignant neoplasm of bladder 188;Women;414 PA═S VASCO;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;8.753 PA═S VASCO;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;5.216 PA═S VASCO;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;3.537 PA═S VASCO;Group 0210 Carcinoma in situ 230-234;Both sexes;301 PA═S VASCO;Group 0210 Carcinoma in situ 230-234;Men;108 PA═S VASCO;Group 0210 Carcinoma in situ 230-234;Women;193 PA═S VASCO;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;355 PA═S VASCO;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;214 PA═S VASCO;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;140 PA═S VASCO;Grupo 0212 Leiomyoma of uterus 218;Both sexes;936 PA═S VASCO;Grupo 0212 Leiomyoma of uterus 218;Men;.. PA═S VASCO;Grupo 0212 Leiomyoma of uterus 218;Women;936 PA═S VASCO;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;3.038 PA═S VASCO;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1.311 PA═S VASCO;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1.727 PA═S VASCO;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2.799 PA═S VASCO;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1.364 PA═S VASCO;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1.435 PA═S VASCO;Group 0301 Anaemias 280-285;Both sexes;1.890 PA═S VASCO;Group 0301 Anaemias 280-285;Men;910 PA═S VASCO;Group 0301 Anaemias 280-285;Women;980 PA═S VASCO;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;909 PA═S VASCO;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;454 PA═S VASCO;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;454 PA═S VASCO;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3.984 PA═S VASCO;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1.716 PA═S VASCO;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2.268 PA═S VASCO;Group 0401 Diabetes mellitus 249-250;Both sexes;1.394 PA═S VASCO;Group 0401 Diabetes mellitus 249-250;Men;855 PA═S VASCO;Group 0401 Diabetes mellitus 249-250;Women;539 PA═S VASCO;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2.590 PA═S VASCO;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;861 PA═S VASCO;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1.729 PA═S VASCO;Group 0500 Mental disorders 290-319;Both sexes;7.417 PA═S VASCO;Group 0500 Mental disorders 290-319;Men;3.928 PA═S VASCO;Group 0500 Mental disorders 290-319;Women;3.488 PA═S VASCO;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;169 PA═S VASCO;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;83 PA═S VASCO;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;86 PA═S VASCO;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;618 PA═S VASCO;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;428 PA═S VASCO;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;190 PA═S VASCO;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;547 PA═S VASCO;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;399 PA═S VASCO;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;147 PA═S VASCO;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;2.474 PA═S VASCO;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;1.516 PA═S VASCO;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;958 PA═S VASCO;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1.748 PA═S VASCO;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;671 PA═S VASCO;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;1.076 PA═S VASCO;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1.861 PA═S VASCO;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;831 PA═S VASCO;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1.030 PA═S VASCO;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5.297 PA═S VASCO;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2.818 PA═S VASCO;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2.479 PA═S VASCO;Group 0601 Alzheimer's disease 3310;Both sexes;110 PA═S VASCO;Group 0601 Alzheimer's disease 3310;Men;49 PA═S VASCO;Group 0601 Alzheimer's disease 3310;Women;61 PA═S VASCO;Group 0602 Multiple sclerosis 340;Both sexes;76 PA═S VASCO;Group 0602 Multiple sclerosis 340;Men;19 PA═S VASCO;Group 0602 Multiple sclerosis 340;Women;57 PA═S VASCO;Group 0603 Epilepsy 345;Both sexes;851 PA═S VASCO;Group 0603 Epilepsy 345;Men;481 PA═S VASCO;Group 0603 Epilepsy 345;Women;370 PA═S VASCO;Group 0604 Transient cerebral ischemia 435;Both sexes;741 PA═S VASCO;Group 0604 Transient cerebral ischemia 435;Men;368 PA═S VASCO;Group 0604 Transient cerebral ischemia 435;Women;373 PA═S VASCO;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3.518 PA═S VASCO;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.901 PA═S VASCO;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1.618 PA═S VASCO;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;792 PA═S VASCO;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;364 PA═S VASCO;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;428 PA═S VASCO;Grupo 0701 Cataract 366;Both sexes;45 PA═S VASCO;Grupo 0701 Cataract 366;Men;19 PA═S VASCO;Grupo 0701 Cataract 366;Women;26 PA═S VASCO;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;747 PA═S VASCO;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;345 PA═S VASCO;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;402 PA═S VASCO;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1.221 PA═S VASCO;Group 0800 Diseases of the ear and the mastoid 380-389;Men;611 PA═S VASCO;Group 0800 Diseases of the ear and the mastoid 380-389;Women;609 PA═S VASCO;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;32.516 PA═S VASCO;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;18.703 PA═S VASCO;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;13.813 PA═S VASCO;Group 0901 Hypertensive disease 401-405;Both sexes;1.687 PA═S VASCO;Group 0901 Hypertensive disease 401-405;Men;757 PA═S VASCO;Group 0901 Hypertensive disease 401-405;Women;930 PA═S VASCO;Group 0902 Angina pectoris 4111, 413;Both sexes;757 PA═S VASCO;Group 0902 Angina pectoris 4111, 413;Men;467 PA═S VASCO;Group 0902 Angina pectoris 4111, 413;Women;290 PA═S VASCO;Group 0903 Acute myocardial infarction 410;Both sexes;2.131 PA═S VASCO;Group 0903 Acute myocardial infarction 410;Men;1.495 PA═S VASCO;Group 0903 Acute myocardial infarction 410;Women;637 PA═S VASCO;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2.305 PA═S VASCO;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.816 PA═S VASCO;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;489 PA═S VASCO;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1.154 PA═S VASCO;Group 0905 Diseases of the lungs circulation 415-417;Men;528 PA═S VASCO;Group 0905 Diseases of the lungs circulation 415-417;Women;626 PA═S VASCO;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4.884 PA═S VASCO;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2.814 PA═S VASCO;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;2.070 PA═S VASCO;Grupo 0907 Heart failure 428;Both sexes;6.863 PA═S VASCO;Grupo 0907 Heart failure 428;Men;3.520 PA═S VASCO;Grupo 0907 Heart failure 428;Women;3.343 PA═S VASCO;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;5.333 PA═S VASCO;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2.808 PA═S VASCO;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2.525 PA═S VASCO;Grupo 0909 Atherosclerosis 440;Both sexes;1.562 PA═S VASCO;Grupo 0909 Atherosclerosis 440;Men;1.176 PA═S VASCO;Grupo 0909 Atherosclerosis 440;Women;386 PA═S VASCO;Group 0910 Varicose veins of lower extremities 454;Both sexes;811 PA═S VASCO;Group 0910 Varicose veins of lower extremities 454;Men;334 PA═S VASCO;Group 0910 Varicose veins of lower extremities 454;Women;478 PA═S VASCO;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;5.028 PA═S VASCO;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;2.988 PA═S VASCO;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2.041 PA═S VASCO;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;30.723 PA═S VASCO;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;17.326 PA═S VASCO;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;13.397 PA═S VASCO;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1.296 PA═S VASCO;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;674 PA═S VASCO;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;622 PA═S VASCO;Group 1002 Pneumonia 480-486;Both sexes;6.336 PA═S VASCO;Group 1002 Pneumonia 480-486;Men;3.748 PA═S VASCO;Group 1002 Pneumonia 480-486;Women;2.588 PA═S VASCO;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;3.163 PA═S VASCO;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1.390 PA═S VASCO;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.773 PA═S VASCO;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1.418 PA═S VASCO;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;779 PA═S VASCO;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;639 PA═S VASCO;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;2.482 PA═S VASCO;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1.561 PA═S VASCO;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;921 PA═S VASCO;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;5.335 PA═S VASCO;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;3.923 PA═S VASCO;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1.412 PA═S VASCO;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.887 PA═S VASCO;Group 1007 Asthma 4930-4931,4938-4939;Men;600 PA═S VASCO;Group 1007 Asthma 4930-4931,4938-4939;Women;1.287 PA═S VASCO;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;8.807 PA═S VASCO;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;4.652 PA═S VASCO;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;4.155 PA═S VASCO;Group 1100 Diseases of the digestive system 520-579;Both sexes;29.582 PA═S VASCO;Group 1100 Diseases of the digestive system 520-579;Men;16.985 PA═S VASCO;Group 1100 Diseases of the digestive system 520-579;Women;12.597 PA═S VASCO;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;351 PA═S VASCO;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;176 PA═S VASCO;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;175 PA═S VASCO;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;410 PA═S VASCO;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;237 PA═S VASCO;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;173 PA═S VASCO;Group 1103 Diseases of the esophagus 530;Both sexes;579 PA═S VASCO;Group 1103 Diseases of the esophagus 530;Men;352 PA═S VASCO;Group 1103 Diseases of the esophagus 530;Women;227 PA═S VASCO;Group 1104 Peptic ulcer 531-534;Both sexes;595 PA═S VASCO;Group 1104 Peptic ulcer 531-534;Men;421 PA═S VASCO;Group 1104 Peptic ulcer 531-534;Women;174 PA═S VASCO;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;575 PA═S VASCO;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;312 PA═S VASCO;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;263 PA═S VASCO;Group 1106 Appendicitis 540-543;Both sexes;2.648 PA═S VASCO;Group 1106 Appendicitis 540-543;Men;1.468 PA═S VASCO;Group 1106 Appendicitis 540-543;Women;1.179 PA═S VASCO;Group 1107 Inguinal hernia 550;Both sexes;3.416 PA═S VASCO;Group 1107 Inguinal hernia 550;Men;3.008 PA═S VASCO;Group 1107 Inguinal hernia 550;Women;408 PA═S VASCO;Group 1108 Other abdominal hernia 551-553;Both sexes;2.447 PA═S VASCO;Group 1108 Other abdominal hernia 551-553;Men;1.196 PA═S VASCO;Group 1108 Other abdominal hernia 551-553;Women;1.252 PA═S VASCO;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;634 PA═S VASCO;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;331 PA═S VASCO;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;303 PA═S VASCO;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1.198 PA═S VASCO;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;557 PA═S VASCO;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;640 PA═S VASCO;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1.685 PA═S VASCO;Group 1111 Intestinal obstruction without hernia 560;Men;904 PA═S VASCO;Group 1111 Intestinal obstruction without hernia 560;Women;781 PA═S VASCO;Group 1112 Intestinal diverticulosis 562;Both sexes;1.436 PA═S VASCO;Group 1112 Intestinal diverticulosis 562;Men;655 PA═S VASCO;Group 1112 Intestinal diverticulosis 562;Women;781 PA═S VASCO;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.985 PA═S VASCO;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1.301 PA═S VASCO;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;684 PA═S VASCO;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;1.110 PA═S VASCO;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;518 PA═S VASCO;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;593 PA═S VASCO;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;574 PA═S VASCO;Group 1115 Alcoholic hepatitis 5710-5713;Men;453 PA═S VASCO;Group 1115 Alcoholic hepatitis 5710-5713;Women;120 PA═S VASCO;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1.040 PA═S VASCO;Group 1116 Other diseases of the liver 570,5714-573;Men;627 PA═S VASCO;Group 1116 Other diseases of the liver 570,5714-573;Women;413 PA═S VASCO;Group 1117 Cholelithiasis 574;Both sexes;4.778 PA═S VASCO;Group 1117 Cholelithiasis 574;Men;2.097 PA═S VASCO;Group 1117 Cholelithiasis 574;Women;2.681 PA═S VASCO;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1.403 PA═S VASCO;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;802 PA═S VASCO;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;601 PA═S VASCO;Group 1119 Pancreatic diseases 577;Both sexes;1.346 PA═S VASCO;Group 1119 Pancreatic diseases 577;Men;793 PA═S VASCO;Group 1119 Pancreatic diseases 577;Women;553 PA═S VASCO;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1.374 PA═S VASCO;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;779 PA═S VASCO;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;595 PA═S VASCO;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2.550 PA═S VASCO;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1.425 PA═S VASCO;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1.125 PA═S VASCO;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1.775 PA═S VASCO;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1.088 PA═S VASCO;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;688 PA═S VASCO;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;112 PA═S VASCO;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;56 PA═S VASCO;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;56 PA═S VASCO;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;662 PA═S VASCO;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;282 PA═S VASCO;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;381 PA═S VASCO;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;19.469 PA═S VASCO;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;9.887 PA═S VASCO;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;9.582 PA═S VASCO;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. PA═S VASCO;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. PA═S VASCO;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. PA═S VASCO;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. PA═S VASCO;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. PA═S VASCO;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. PA═S VASCO;Group 1303 Internal derangement of knee 717;Both sexes;2.535 PA═S VASCO;Group 1303 Internal derangement of knee 717;Men;1.674 PA═S VASCO;Group 1303 Internal derangement of knee 717;Women;862 PA═S VASCO;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;7.594 PA═S VASCO;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;3.676 PA═S VASCO;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;3.918 PA═S VASCO;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;289 PA═S VASCO;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;120 PA═S VASCO;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;169 PA═S VASCO;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;1.121 PA═S VASCO;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;583 PA═S VASCO;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;538 PA═S VASCO;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1.330 PA═S VASCO;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;733 PA═S VASCO;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;597 PA═S VASCO;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;626 PA═S VASCO;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;295 PA═S VASCO;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;331 PA═S VASCO;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;3.031 PA═S VASCO;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1.730 PA═S VASCO;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;1.301 PA═S VASCO;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;2.943 PA═S VASCO;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;1.076 PA═S VASCO;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1.867 PA═S VASCO;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;16.110 PA═S VASCO;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;7.943 PA═S VASCO;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;8.167 PA═S VASCO;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1.430 PA═S VASCO;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;545 PA═S VASCO;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;886 PA═S VASCO;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1.394 PA═S VASCO;Group 1402 Renal failure 5836-5837, 584-586;Men;809 PA═S VASCO;Group 1402 Renal failure 5836-5837, 584-586;Women;585 PA═S VASCO;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;2.433 PA═S VASCO;Group 1403 Urolithiasis 592, 594, 7880;Men;1.529 PA═S VASCO;Group 1403 Urolithiasis 592, 594, 7880;Women;904 PA═S VASCO;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;4.787 PA═S VASCO;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2.419 PA═S VASCO;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2.368 PA═S VASCO;Group 1405 Prostatic hyperplasia 600;Both sexes;1.577 PA═S VASCO;Group 1405 Prostatic hyperplasia 600;Men;1.577 PA═S VASCO;Group 1405 Prostatic hyperplasia 600;Women;.. PA═S VASCO;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;922 PA═S VASCO;Group 1406 Other diseases of the male genital organs 601-608;Men;922 PA═S VASCO;Group 1406 Other diseases of the male genital organs 601-608;Women;.. PA═S VASCO;Group 1407 Disorders of breast 610-612;Both sexes;1.136 PA═S VASCO;Group 1407 Disorders of breast 610-612;Men;85 PA═S VASCO;Group 1407 Disorders of breast 610-612;Women;1.051 PA═S VASCO;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;378 PA═S VASCO;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. PA═S VASCO;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;378 PA═S VASCO;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;98 PA═S VASCO;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. PA═S VASCO;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;98 PA═S VASCO;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.955 PA═S VASCO;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;57 PA═S VASCO;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.898 PA═S VASCO;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;20.675 PA═S VASCO;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. PA═S VASCO;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;20.675 PA═S VASCO;Group 1501 Legally induced abortion 635;Both sexes;166 PA═S VASCO;Group 1501 Legally induced abortion 635;Men;.. PA═S VASCO;Group 1501 Legally induced abortion 635;Women;166 PA═S VASCO;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;499 PA═S VASCO;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. PA═S VASCO;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;499 PA═S VASCO;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;12.657 PA═S VASCO;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. PA═S VASCO;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;12.657 PA═S VASCO;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3.851 PA═S VASCO;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. PA═S VASCO;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3.851 PA═S VASCO;Group 1505 Single spontaneous delivery 650;Both sexes;1.572 PA═S VASCO;Group 1505 Single spontaneous delivery 650;Men;.. PA═S VASCO;Group 1505 Single spontaneous delivery 650;Women;1.572 PA═S VASCO;Group 1506 Other deliveries 6695-6697;Both sexes;314 PA═S VASCO;Group 1506 Other deliveries 6695-6697;Men;.. PA═S VASCO;Group 1506 Other deliveries 6695-6697;Women;314 PA═S VASCO;Group 1507 Complications related to the puerperium 670-676;Both sexes;163 PA═S VASCO;Group 1507 Complications related to the puerperium 670-676;Men;.. PA═S VASCO;Group 1507 Complications related to the puerperium 670-676;Women;163 PA═S VASCO;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1.452 PA═S VASCO;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. PA═S VASCO;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1.452 PA═S VASCO;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2.178 PA═S VASCO;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1.200 PA═S VASCO;Group 1600 Some disorders originating in the perinatal period 760-779;Women;978 PA═S VASCO;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;617 PA═S VASCO;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;303 PA═S VASCO;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;314 PA═S VASCO;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1.562 PA═S VASCO;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;897 PA═S VASCO;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;665 PA═S VASCO;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1.212 PA═S VASCO;Grupo 1700 Congenital abnormalities 740-759;Men;681 PA═S VASCO;Grupo 1700 Congenital abnormalities 740-759;Women;531 PA═S VASCO;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;13.569 PA═S VASCO;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;7.468 PA═S VASCO;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;6.101 PA═S VASCO;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;2.267 PA═S VASCO;Group 1801 Pain in throat and chest 7841, 7865;Men;1.311 PA═S VASCO;Group 1801 Pain in throat and chest 7841, 7865;Women;956 PA═S VASCO;Group 1802 Abdominal pain 7890;Both sexes;1.378 PA═S VASCO;Group 1802 Abdominal pain 7890;Men;560 PA═S VASCO;Group 1802 Abdominal pain 7890;Women;818 PA═S VASCO;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.590 PA═S VASCO;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;883 PA═S VASCO;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;707 PA═S VASCO;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;8.333 PA═S VASCO;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4.713 PA═S VASCO;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3.620 PA═S VASCO;Group 1900 Injuries and poisoning 800-999;Both sexes;21.215 PA═S VASCO;Group 1900 Injuries and poisoning 800-999;Men;11.347 PA═S VASCO;Group 1900 Injuries and poisoning 800-999;Women;9.868 PA═S VASCO;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1.274 PA═S VASCO;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;719 PA═S VASCO;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;555 PA═S VASCO;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;534 PA═S VASCO;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;369 PA═S VASCO;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;165 PA═S VASCO;Group 1903 Radius and ulna fracture 813;Both sexes;1.400 PA═S VASCO;Group 1903 Radius and ulna fracture 813;Men;586 PA═S VASCO;Group 1903 Radius and ulna fracture 813;Women;814 PA═S VASCO;Group 1904 Femur fracture 820-821;Both sexes;2.986 PA═S VASCO;Group 1904 Femur fracture 820-821;Men;843 PA═S VASCO;Group 1904 Femur fracture 820-821;Women;2.143 PA═S VASCO;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1.478 PA═S VASCO;Group 1905 Leg fracture, including the ankle 823-824;Men;713 PA═S VASCO;Group 1905 Leg fracture, including the ankle 823-824;Women;766 PA═S VASCO;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;6.514 PA═S VASCO;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;4.119 PA═S VASCO;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2.396 PA═S VASCO;Group 1907 Burns 940-949;Both sexes;123 PA═S VASCO;Group 1907 Burns 940-949;Men;86 PA═S VASCO;Group 1907 Burns 940-949;Women;37 PA═S VASCO;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;554 PA═S VASCO;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;242 PA═S VASCO;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;313 PA═S VASCO;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;5.553 PA═S VASCO;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;3.250 PA═S VASCO;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;2.302 PA═S VASCO;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;61 PA═S VASCO;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;42 PA═S VASCO;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;19 PA═S VASCO;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;736 PA═S VASCO;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;379 PA═S VASCO;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;358 PA═S VASCO;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;6.212 PA═S VASCO;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;3.058 PA═S VASCO;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;3.154 PA═S VASCO;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;247 PA═S VASCO;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;120 PA═S VASCO;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;126 PA═S VASCO;Group 2102 Contraceptive management V25;Both sexes;95 PA═S VASCO;Group 2102 Contraceptive management V25;Men;9 PA═S VASCO;Group 2102 Contraceptive management V25;Women;86 PA═S VASCO;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. PA═S VASCO;Group 2103 Living newborns by type of delivery V30-V39;Men;.. PA═S VASCO;Group 2103 Living newborns by type of delivery V30-V39;Women;.. PA═S VASCO;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1.645 PA═S VASCO;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;999 PA═S VASCO;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;647 PA═S VASCO;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;4.225 PA═S VASCO;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1.930 PA═S VASCO;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;2.295 Araba/┴lava;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;36.721 Araba/┴lava;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18.648 Araba/┴lava;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;18.073 Araba/┴lava;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;611 Araba/┴lava;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;342 Araba/┴lava;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;269 Araba/┴lava;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;79 Araba/┴lava;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;41 Araba/┴lava;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;38 Araba/┴lava;Group 0102 Imprecise intestinal infections 009;Both sexes;15 Araba/┴lava;Group 0102 Imprecise intestinal infections 009;Men;10 Araba/┴lava;Group 0102 Imprecise intestinal infections 009;Women;5 Araba/┴lava;Group 0103 Tuberculosis 010-018, 137;Both sexes;28 Araba/┴lava;Group 0103 Tuberculosis 010-018, 137;Men;16 Araba/┴lava;Group 0103 Tuberculosis 010-018, 137;Women;12 Araba/┴lava;Group 0104 Septicaemia 038;Both sexes;269 Araba/┴lava;Group 0104 Septicaemia 038;Men;143 Araba/┴lava;Group 0104 Septicaemia 038;Women;126 Araba/┴lava;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;12 Araba/┴lava;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;7 Araba/┴lava;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;5 Araba/┴lava;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;208 Araba/┴lava;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;125 Araba/┴lava;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;83 Araba/┴lava;Group 0200 Neoplasms 140-239;Both sexes;3.183 Araba/┴lava;Group 0200 Neoplasms 140-239;Men;1.798 Araba/┴lava;Group 0200 Neoplasms 140-239;Women;1.385 Araba/┴lava;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;297 Araba/┴lava;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;179 Araba/┴lava;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;118 Araba/┴lava;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;164 Araba/┴lava;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;126 Araba/┴lava;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;38 Araba/┴lava;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;13 Araba/┴lava;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;9 Araba/┴lava;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;4 Araba/┴lava;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;241 Araba/┴lava;Group 0204 Malignant neoplasm of breast 174-175;Men;4 Araba/┴lava;Group 0204 Malignant neoplasm of breast 174-175;Women;237 Araba/┴lava;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;59 Araba/┴lava;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Araba/┴lava;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;59 Araba/┴lava;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;36 Araba/┴lava;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Araba/┴lava;Group 0206 Malignant neoplasm of ovary 1830;Women;36 Araba/┴lava;Group 0207 Malignant neoplasm of prostate 185;Both sexes;233 Araba/┴lava;Group 0207 Malignant neoplasm of prostate 185;Men;233 Araba/┴lava;Group 0207 Malignant neoplasm of prostate 185;Women;.. Araba/┴lava;Group 0208 Malignant neoplasm of bladder 188;Both sexes;400 Araba/┴lava;Group 0208 Malignant neoplasm of bladder 188;Men;330 Araba/┴lava;Group 0208 Malignant neoplasm of bladder 188;Women;70 Araba/┴lava;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.184 Araba/┴lava;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;703 Araba/┴lava;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;481 Araba/┴lava;Group 0210 Carcinoma in situ 230-234;Both sexes;39 Araba/┴lava;Group 0210 Carcinoma in situ 230-234;Men;21 Araba/┴lava;Group 0210 Carcinoma in situ 230-234;Women;18 Araba/┴lava;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;61 Araba/┴lava;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;30 Araba/┴lava;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;31 Araba/┴lava;Grupo 0212 Leiomyoma of uterus 218;Both sexes;82 Araba/┴lava;Grupo 0212 Leiomyoma of uterus 218;Men;.. Araba/┴lava;Grupo 0212 Leiomyoma of uterus 218;Women;82 Araba/┴lava;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;374 Araba/┴lava;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;163 Araba/┴lava;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;211 Araba/┴lava;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;466 Araba/┴lava;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;196 Araba/┴lava;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;270 Araba/┴lava;Group 0301 Anaemias 280-285;Both sexes;271 Araba/┴lava;Group 0301 Anaemias 280-285;Men;116 Araba/┴lava;Group 0301 Anaemias 280-285;Women;155 Araba/┴lava;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;195 Araba/┴lava;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;80 Araba/┴lava;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;115 Araba/┴lava;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;624 Araba/┴lava;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;281 Araba/┴lava;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;343 Araba/┴lava;Group 0401 Diabetes mellitus 249-250;Both sexes;254 Araba/┴lava;Group 0401 Diabetes mellitus 249-250;Men;149 Araba/┴lava;Group 0401 Diabetes mellitus 249-250;Women;105 Araba/┴lava;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;370 Araba/┴lava;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;132 Araba/┴lava;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;238 Araba/┴lava;Group 0500 Mental disorders 290-319;Both sexes;1.007 Araba/┴lava;Group 0500 Mental disorders 290-319;Men;528 Araba/┴lava;Group 0500 Mental disorders 290-319;Women;479 Araba/┴lava;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;24 Araba/┴lava;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;10 Araba/┴lava;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;14 Araba/┴lava;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;112 Araba/┴lava;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;72 Araba/┴lava;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;40 Araba/┴lava;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;36 Araba/┴lava;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;23 Araba/┴lava;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;13 Araba/┴lava;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;318 Araba/┴lava;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;197 Araba/┴lava;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;121 Araba/┴lava;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;203 Araba/┴lava;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;86 Araba/┴lava;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;117 Araba/┴lava;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;314 Araba/┴lava;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;140 Araba/┴lava;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;174 Araba/┴lava;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;819 Araba/┴lava;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;446 Araba/┴lava;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;373 Araba/┴lava;Group 0601 Alzheimer's disease 3310;Both sexes;9 Araba/┴lava;Group 0601 Alzheimer's disease 3310;Men;3 Araba/┴lava;Group 0601 Alzheimer's disease 3310;Women;6 Araba/┴lava;Group 0602 Multiple sclerosis 340;Both sexes;15 Araba/┴lava;Group 0602 Multiple sclerosis 340;Men;3 Araba/┴lava;Group 0602 Multiple sclerosis 340;Women;12 Araba/┴lava;Group 0603 Epilepsy 345;Both sexes;177 Araba/┴lava;Group 0603 Epilepsy 345;Men;114 Araba/┴lava;Group 0603 Epilepsy 345;Women;63 Araba/┴lava;Group 0604 Transient cerebral ischemia 435;Both sexes;130 Araba/┴lava;Group 0604 Transient cerebral ischemia 435;Men;68 Araba/┴lava;Group 0604 Transient cerebral ischemia 435;Women;62 Araba/┴lava;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;488 Araba/┴lava;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;258 Araba/┴lava;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;230 Araba/┴lava;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;125 Araba/┴lava;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;63 Araba/┴lava;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;62 Araba/┴lava;Grupo 0701 Cataract 366;Both sexes;7 Araba/┴lava;Grupo 0701 Cataract 366;Men;4 Araba/┴lava;Grupo 0701 Cataract 366;Women;3 Araba/┴lava;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;118 Araba/┴lava;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;59 Araba/┴lava;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;59 Araba/┴lava;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;175 Araba/┴lava;Group 0800 Diseases of the ear and the mastoid 380-389;Men;80 Araba/┴lava;Group 0800 Diseases of the ear and the mastoid 380-389;Women;95 Araba/┴lava;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4.628 Araba/┴lava;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.680 Araba/┴lava;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1.948 Araba/┴lava;Group 0901 Hypertensive disease 401-405;Both sexes;282 Araba/┴lava;Group 0901 Hypertensive disease 401-405;Men;114 Araba/┴lava;Group 0901 Hypertensive disease 401-405;Women;168 Araba/┴lava;Group 0902 Angina pectoris 4111, 413;Both sexes;106 Araba/┴lava;Group 0902 Angina pectoris 4111, 413;Men;69 Araba/┴lava;Group 0902 Angina pectoris 4111, 413;Women;37 Araba/┴lava;Group 0903 Acute myocardial infarction 410;Both sexes;460 Araba/┴lava;Group 0903 Acute myocardial infarction 410;Men;318 Araba/┴lava;Group 0903 Acute myocardial infarction 410;Women;142 Araba/┴lava;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;187 Araba/┴lava;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;152 Araba/┴lava;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;35 Araba/┴lava;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;198 Araba/┴lava;Group 0905 Diseases of the lungs circulation 415-417;Men;105 Araba/┴lava;Group 0905 Diseases of the lungs circulation 415-417;Women;93 Araba/┴lava;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;557 Araba/┴lava;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;340 Araba/┴lava;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;217 Araba/┴lava;Grupo 0907 Heart failure 428;Both sexes;903 Araba/┴lava;Grupo 0907 Heart failure 428;Men;481 Araba/┴lava;Grupo 0907 Heart failure 428;Women;422 Araba/┴lava;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;734 Araba/┴lava;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;415 Araba/┴lava;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;319 Araba/┴lava;Grupo 0909 Atherosclerosis 440;Both sexes;240 Araba/┴lava;Grupo 0909 Atherosclerosis 440;Men;183 Araba/┴lava;Grupo 0909 Atherosclerosis 440;Women;57 Araba/┴lava;Group 0910 Varicose veins of lower extremities 454;Both sexes;270 Araba/┴lava;Group 0910 Varicose veins of lower extremities 454;Men;92 Araba/┴lava;Group 0910 Varicose veins of lower extremities 454;Women;178 Araba/┴lava;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;691 Araba/┴lava;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;411 Araba/┴lava;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;280 Araba/┴lava;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4.620 Araba/┴lava;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.666 Araba/┴lava;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.954 Araba/┴lava;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;217 Araba/┴lava;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;108 Araba/┴lava;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;109 Araba/┴lava;Group 1002 Pneumonia 480-486;Both sexes;1.057 Araba/┴lava;Group 1002 Pneumonia 480-486;Men;667 Araba/┴lava;Group 1002 Pneumonia 480-486;Women;390 Araba/┴lava;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;589 Araba/┴lava;Group 1003 Acute bronchitis and bronchiolitis 466;Men;279 Araba/┴lava;Group 1003 Acute bronchitis and bronchiolitis 466;Women;310 Araba/┴lava;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;169 Araba/┴lava;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;88 Araba/┴lava;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;81 Araba/┴lava;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;299 Araba/┴lava;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;192 Araba/┴lava;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;107 Araba/┴lava;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;799 Araba/┴lava;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;619 Araba/┴lava;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;180 Araba/┴lava;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;277 Araba/┴lava;Group 1007 Asthma 4930-4931,4938-4939;Men;82 Araba/┴lava;Group 1007 Asthma 4930-4931,4938-4939;Women;195 Araba/┴lava;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.213 Araba/┴lava;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;631 Araba/┴lava;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;582 Araba/┴lava;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.415 Araba/┴lava;Group 1100 Diseases of the digestive system 520-579;Men;2.557 Araba/┴lava;Group 1100 Diseases of the digestive system 520-579;Women;1.858 Araba/┴lava;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;57 Araba/┴lava;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;25 Araba/┴lava;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;32 Araba/┴lava;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;65 Araba/┴lava;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;41 Araba/┴lava;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;24 Araba/┴lava;Group 1103 Diseases of the esophagus 530;Both sexes;128 Araba/┴lava;Group 1103 Diseases of the esophagus 530;Men;74 Araba/┴lava;Group 1103 Diseases of the esophagus 530;Women;54 Araba/┴lava;Group 1104 Peptic ulcer 531-534;Both sexes;90 Araba/┴lava;Group 1104 Peptic ulcer 531-534;Men;69 Araba/┴lava;Group 1104 Peptic ulcer 531-534;Women;21 Araba/┴lava;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;106 Araba/┴lava;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;64 Araba/┴lava;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;42 Araba/┴lava;Group 1106 Appendicitis 540-543;Both sexes;344 Araba/┴lava;Group 1106 Appendicitis 540-543;Men;197 Araba/┴lava;Group 1106 Appendicitis 540-543;Women;147 Araba/┴lava;Group 1107 Inguinal hernia 550;Both sexes;452 Araba/┴lava;Group 1107 Inguinal hernia 550;Men;399 Araba/┴lava;Group 1107 Inguinal hernia 550;Women;53 Araba/┴lava;Group 1108 Other abdominal hernia 551-553;Both sexes;327 Araba/┴lava;Group 1108 Other abdominal hernia 551-553;Men;145 Araba/┴lava;Group 1108 Other abdominal hernia 551-553;Women;182 Araba/┴lava;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;132 Araba/┴lava;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;68 Araba/┴lava;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;64 Araba/┴lava;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;241 Araba/┴lava;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;120 Araba/┴lava;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;121 Araba/┴lava;Group 1111 Intestinal obstruction without hernia 560;Both sexes;293 Araba/┴lava;Group 1111 Intestinal obstruction without hernia 560;Men;163 Araba/┴lava;Group 1111 Intestinal obstruction without hernia 560;Women;130 Araba/┴lava;Group 1112 Intestinal diverticulosis 562;Both sexes;190 Araba/┴lava;Group 1112 Intestinal diverticulosis 562;Men;106 Araba/┴lava;Group 1112 Intestinal diverticulosis 562;Women;84 Araba/┴lava;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;231 Araba/┴lava;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;140 Araba/┴lava;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;91 Araba/┴lava;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;149 Araba/┴lava;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;84 Araba/┴lava;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;65 Araba/┴lava;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;86 Araba/┴lava;Group 1115 Alcoholic hepatitis 5710-5713;Men;67 Araba/┴lava;Group 1115 Alcoholic hepatitis 5710-5713;Women;19 Araba/┴lava;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;165 Araba/┴lava;Group 1116 Other diseases of the liver 570,5714-573;Men;89 Araba/┴lava;Group 1116 Other diseases of the liver 570,5714-573;Women;76 Araba/┴lava;Group 1117 Cholelithiasis 574;Both sexes;674 Araba/┴lava;Group 1117 Cholelithiasis 574;Men;322 Araba/┴lava;Group 1117 Cholelithiasis 574;Women;352 Araba/┴lava;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;237 Araba/┴lava;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;133 Araba/┴lava;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;104 Araba/┴lava;Group 1119 Pancreatic diseases 577;Both sexes;200 Araba/┴lava;Group 1119 Pancreatic diseases 577;Men;124 Araba/┴lava;Group 1119 Pancreatic diseases 577;Women;76 Araba/┴lava;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;248 Araba/┴lava;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;127 Araba/┴lava;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;121 Araba/┴lava;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;336 Araba/┴lava;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;189 Araba/┴lava;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;147 Araba/┴lava;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;233 Araba/┴lava;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;136 Araba/┴lava;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;97 Araba/┴lava;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;17 Araba/┴lava;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;10 Araba/┴lava;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;7 Araba/┴lava;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;86 Araba/┴lava;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;43 Araba/┴lava;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;43 Araba/┴lava;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3.604 Araba/┴lava;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.889 Araba/┴lava;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.715 Araba/┴lava;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Araba/┴lava;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Araba/┴lava;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Araba/┴lava;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Araba/┴lava;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Araba/┴lava;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Araba/┴lava;Group 1303 Internal derangement of knee 717;Both sexes;614 Araba/┴lava;Group 1303 Internal derangement of knee 717;Men;436 Araba/┴lava;Group 1303 Internal derangement of knee 717;Women;178 Araba/┴lava;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1.330 Araba/┴lava;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;704 Araba/┴lava;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;626 Araba/┴lava;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;29 Araba/┴lava;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;13 Araba/┴lava;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;16 Araba/┴lava;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;182 Araba/┴lava;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;92 Araba/┴lava;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;90 Araba/┴lava;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;209 Araba/┴lava;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;117 Araba/┴lava;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;92 Araba/┴lava;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;158 Araba/┴lava;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;72 Araba/┴lava;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;86 Araba/┴lava;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;504 Araba/┴lava;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;257 Araba/┴lava;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;247 Araba/┴lava;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;578 Araba/┴lava;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;198 Araba/┴lava;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;380 Araba/┴lava;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.523 Araba/┴lava;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.437 Araba/┴lava;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.086 Araba/┴lava;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;231 Araba/┴lava;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;103 Araba/┴lava;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;128 Araba/┴lava;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;221 Araba/┴lava;Group 1402 Renal failure 5836-5837, 584-586;Men;133 Araba/┴lava;Group 1402 Renal failure 5836-5837, 584-586;Women;88 Araba/┴lava;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;477 Araba/┴lava;Group 1403 Urolithiasis 592, 594, 7880;Men;306 Araba/┴lava;Group 1403 Urolithiasis 592, 594, 7880;Women;171 Araba/┴lava;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;826 Araba/┴lava;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;447 Araba/┴lava;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;379 Araba/┴lava;Group 1405 Prostatic hyperplasia 600;Both sexes;271 Araba/┴lava;Group 1405 Prostatic hyperplasia 600;Men;271 Araba/┴lava;Group 1405 Prostatic hyperplasia 600;Women;.. Araba/┴lava;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;168 Araba/┴lava;Group 1406 Other diseases of the male genital organs 601-608;Men;168 Araba/┴lava;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Araba/┴lava;Group 1407 Disorders of breast 610-612;Both sexes;90 Araba/┴lava;Group 1407 Disorders of breast 610-612;Men;4 Araba/┴lava;Group 1407 Disorders of breast 610-612;Women;86 Araba/┴lava;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;47 Araba/┴lava;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Araba/┴lava;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;47 Araba/┴lava;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;13 Araba/┴lava;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Araba/┴lava;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;13 Araba/┴lava;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;179 Araba/┴lava;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;5 Araba/┴lava;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;174 Araba/┴lava;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2.996 Araba/┴lava;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Araba/┴lava;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2.996 Araba/┴lava;Group 1501 Legally induced abortion 635;Both sexes;20 Araba/┴lava;Group 1501 Legally induced abortion 635;Men;.. Araba/┴lava;Group 1501 Legally induced abortion 635;Women;20 Araba/┴lava;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;64 Araba/┴lava;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Araba/┴lava;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;64 Araba/┴lava;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;2.074 Araba/┴lava;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Araba/┴lava;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;2.074 Araba/┴lava;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;561 Araba/┴lava;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Araba/┴lava;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;561 Araba/┴lava;Group 1505 Single spontaneous delivery 650;Both sexes;100 Araba/┴lava;Group 1505 Single spontaneous delivery 650;Men;.. Araba/┴lava;Group 1505 Single spontaneous delivery 650;Women;100 Araba/┴lava;Group 1506 Other deliveries 6695-6697;Both sexes;2 Araba/┴lava;Group 1506 Other deliveries 6695-6697;Men;.. Araba/┴lava;Group 1506 Other deliveries 6695-6697;Women;2 Araba/┴lava;Group 1507 Complications related to the puerperium 670-676;Both sexes;14 Araba/┴lava;Group 1507 Complications related to the puerperium 670-676;Men;.. Araba/┴lava;Group 1507 Complications related to the puerperium 670-676;Women;14 Araba/┴lava;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;161 Araba/┴lava;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Araba/┴lava;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;161 Araba/┴lava;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;341 Araba/┴lava;Group 1600 Some disorders originating in the perinatal period 760-779;Men;181 Araba/┴lava;Group 1600 Some disorders originating in the perinatal period 760-779;Women;160 Araba/┴lava;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;86 Araba/┴lava;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;33 Araba/┴lava;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;53 Araba/┴lava;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;255 Araba/┴lava;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;148 Araba/┴lava;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;107 Araba/┴lava;Grupo 1700 Congenital abnormalities 740-759;Both sexes;144 Araba/┴lava;Grupo 1700 Congenital abnormalities 740-759;Men;86 Araba/┴lava;Grupo 1700 Congenital abnormalities 740-759;Women;58 Araba/┴lava;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2.136 Araba/┴lava;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1.182 Araba/┴lava;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;954 Araba/┴lava;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;244 Araba/┴lava;Group 1801 Pain in throat and chest 7841, 7865;Men;133 Araba/┴lava;Group 1801 Pain in throat and chest 7841, 7865;Women;111 Araba/┴lava;Group 1802 Abdominal pain 7890;Both sexes;274 Araba/┴lava;Group 1802 Abdominal pain 7890;Men;109 Araba/┴lava;Group 1802 Abdominal pain 7890;Women;165 Araba/┴lava;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;3 Araba/┴lava;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;2 Araba/┴lava;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1 Araba/┴lava;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.615 Araba/┴lava;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;938 Araba/┴lava;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;677 Araba/┴lava;Group 1900 Injuries and poisoning 800-999;Both sexes;3.282 Araba/┴lava;Group 1900 Injuries and poisoning 800-999;Men;1.650 Araba/┴lava;Group 1900 Injuries and poisoning 800-999;Women;1.632 Araba/┴lava;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;422 Araba/┴lava;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;233 Araba/┴lava;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;189 Araba/┴lava;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;81 Araba/┴lava;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;57 Araba/┴lava;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;24 Araba/┴lava;Group 1903 Radius and ulna fracture 813;Both sexes;191 Araba/┴lava;Group 1903 Radius and ulna fracture 813;Men;70 Araba/┴lava;Group 1903 Radius and ulna fracture 813;Women;121 Araba/┴lava;Group 1904 Femur fracture 820-821;Both sexes;352 Araba/┴lava;Group 1904 Femur fracture 820-821;Men;93 Araba/┴lava;Group 1904 Femur fracture 820-821;Women;259 Araba/┴lava;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;205 Araba/┴lava;Group 1905 Leg fracture, including the ankle 823-824;Men;97 Araba/┴lava;Group 1905 Leg fracture, including the ankle 823-824;Women;108 Araba/┴lava;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;844 Araba/┴lava;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;481 Araba/┴lava;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;363 Araba/┴lava;Group 1907 Burns 940-949;Both sexes;4 Araba/┴lava;Group 1907 Burns 940-949;Men;2 Araba/┴lava;Group 1907 Burns 940-949;Women;2 Araba/┴lava;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;166 Araba/┴lava;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;60 Araba/┴lava;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;106 Araba/┴lava;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;907 Araba/┴lava;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;494 Araba/┴lava;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;413 Araba/┴lava;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;5 Araba/┴lava;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;4 Araba/┴lava;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Araba/┴lava;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;105 Araba/┴lava;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;59 Araba/┴lava;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;46 Araba/┴lava;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;686 Araba/┴lava;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;397 Araba/┴lava;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;289 Araba/┴lava;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;11 Araba/┴lava;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;8 Araba/┴lava;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;3 Araba/┴lava;Group 2102 Contraceptive management V25;Both sexes;9 Araba/┴lava;Group 2102 Contraceptive management V25;Men;1 Araba/┴lava;Group 2102 Contraceptive management V25;Women;8 Araba/┴lava;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Araba/┴lava;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Araba/┴lava;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Araba/┴lava;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;199 Araba/┴lava;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;119 Araba/┴lava;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;80 Araba/┴lava;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;467 Araba/┴lava;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;269 Araba/┴lava;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;198 Bizkaia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;126.486 Bizkaia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;62.695 Bizkaia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;63.791 Bizkaia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2.604 Bizkaia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1.440 Bizkaia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1.164 Bizkaia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;255 Bizkaia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;129 Bizkaia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;127 Bizkaia;Group 0102 Imprecise intestinal infections 009;Both sexes;166 Bizkaia;Group 0102 Imprecise intestinal infections 009;Men;73 Bizkaia;Group 0102 Imprecise intestinal infections 009;Women;92 Bizkaia;Group 0103 Tuberculosis 010-018, 137;Both sexes;84 Bizkaia;Group 0103 Tuberculosis 010-018, 137;Men;52 Bizkaia;Group 0103 Tuberculosis 010-018, 137;Women;32 Bizkaia;Group 0104 Septicaemia 038;Both sexes;1.258 Bizkaia;Group 0104 Septicaemia 038;Men;679 Bizkaia;Group 0104 Septicaemia 038;Women;579 Bizkaia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;164 Bizkaia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;115 Bizkaia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;49 Bizkaia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;677 Bizkaia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;392 Bizkaia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;285 Bizkaia;Group 0200 Neoplasms 140-239;Both sexes;12.800 Bizkaia;Group 0200 Neoplasms 140-239;Men;6.888 Bizkaia;Group 0200 Neoplasms 140-239;Women;5.911 Bizkaia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1.340 Bizkaia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;847 Bizkaia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;492 Bizkaia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;863 Bizkaia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;637 Bizkaia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;226 Bizkaia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;240 Bizkaia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;124 Bizkaia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;117 Bizkaia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;897 Bizkaia;Group 0204 Malignant neoplasm of breast 174-175;Men;9 Bizkaia;Group 0204 Malignant neoplasm of breast 174-175;Women;888 Bizkaia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;239 Bizkaia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Bizkaia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;239 Bizkaia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;103 Bizkaia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Bizkaia;Group 0206 Malignant neoplasm of ovary 1830;Women;103 Bizkaia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;584 Bizkaia;Group 0207 Malignant neoplasm of prostate 185;Men;584 Bizkaia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Bizkaia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1.203 Bizkaia;Group 0208 Malignant neoplasm of bladder 188;Men;988 Bizkaia;Group 0208 Malignant neoplasm of bladder 188;Women;215 Bizkaia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4.826 Bizkaia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2.848 Bizkaia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.978 Bizkaia;Group 0210 Carcinoma in situ 230-234;Both sexes;163 Bizkaia;Group 0210 Carcinoma in situ 230-234;Men;54 Bizkaia;Group 0210 Carcinoma in situ 230-234;Women;109 Bizkaia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;123 Bizkaia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;78 Bizkaia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;44 Bizkaia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;520 Bizkaia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Bizkaia;Grupo 0212 Leiomyoma of uterus 218;Women;520 Bizkaia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1.699 Bizkaia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;719 Bizkaia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;980 Bizkaia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1.449 Bizkaia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;736 Bizkaia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;713 Bizkaia;Group 0301 Anaemias 280-285;Both sexes;951 Bizkaia;Group 0301 Anaemias 280-285;Men;480 Bizkaia;Group 0301 Anaemias 280-285;Women;471 Bizkaia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;498 Bizkaia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;256 Bizkaia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;241 Bizkaia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2.013 Bizkaia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;819 Bizkaia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1.194 Bizkaia;Group 0401 Diabetes mellitus 249-250;Both sexes;638 Bizkaia;Group 0401 Diabetes mellitus 249-250;Men;378 Bizkaia;Group 0401 Diabetes mellitus 249-250;Women;260 Bizkaia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1.375 Bizkaia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;441 Bizkaia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;934 Bizkaia;Group 0500 Mental disorders 290-319;Both sexes;4.404 Bizkaia;Group 0500 Mental disorders 290-319;Men;2.303 Bizkaia;Group 0500 Mental disorders 290-319;Women;2.100 Bizkaia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;51 Bizkaia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;24 Bizkaia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;27 Bizkaia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;319 Bizkaia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;229 Bizkaia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;90 Bizkaia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;398 Bizkaia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;291 Bizkaia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;106 Bizkaia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1.519 Bizkaia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;893 Bizkaia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;626 Bizkaia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1.126 Bizkaia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;424 Bizkaia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;701 Bizkaia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;991 Bizkaia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;442 Bizkaia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;549 Bizkaia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2.843 Bizkaia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1.487 Bizkaia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1.356 Bizkaia;Group 0601 Alzheimer's disease 3310;Both sexes;49 Bizkaia;Group 0601 Alzheimer's disease 3310;Men;22 Bizkaia;Group 0601 Alzheimer's disease 3310;Women;27 Bizkaia;Group 0602 Multiple sclerosis 340;Both sexes;37 Bizkaia;Group 0602 Multiple sclerosis 340;Men;13 Bizkaia;Group 0602 Multiple sclerosis 340;Women;24 Bizkaia;Group 0603 Epilepsy 345;Both sexes;401 Bizkaia;Group 0603 Epilepsy 345;Men;209 Bizkaia;Group 0603 Epilepsy 345;Women;192 Bizkaia;Group 0604 Transient cerebral ischemia 435;Both sexes;356 Bizkaia;Group 0604 Transient cerebral ischemia 435;Men;179 Bizkaia;Group 0604 Transient cerebral ischemia 435;Women;177 Bizkaia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.999 Bizkaia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1.064 Bizkaia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;936 Bizkaia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;434 Bizkaia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;193 Bizkaia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;241 Bizkaia;Grupo 0701 Cataract 366;Both sexes;27 Bizkaia;Grupo 0701 Cataract 366;Men;9 Bizkaia;Grupo 0701 Cataract 366;Women;18 Bizkaia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;407 Bizkaia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;184 Bizkaia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;223 Bizkaia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;484 Bizkaia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;260 Bizkaia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;223 Bizkaia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;17.408 Bizkaia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;9.922 Bizkaia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;7.486 Bizkaia;Group 0901 Hypertensive disease 401-405;Both sexes;948 Bizkaia;Group 0901 Hypertensive disease 401-405;Men;436 Bizkaia;Group 0901 Hypertensive disease 401-405;Women;512 Bizkaia;Group 0902 Angina pectoris 4111, 413;Both sexes;364 Bizkaia;Group 0902 Angina pectoris 4111, 413;Men;202 Bizkaia;Group 0902 Angina pectoris 4111, 413;Women;162 Bizkaia;Group 0903 Acute myocardial infarction 410;Both sexes;1.028 Bizkaia;Group 0903 Acute myocardial infarction 410;Men;704 Bizkaia;Group 0903 Acute myocardial infarction 410;Women;325 Bizkaia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1.407 Bizkaia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1.089 Bizkaia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;318 Bizkaia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;659 Bizkaia;Group 0905 Diseases of the lungs circulation 415-417;Men;288 Bizkaia;Group 0905 Diseases of the lungs circulation 415-417;Women;371 Bizkaia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2.666 Bizkaia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1.536 Bizkaia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1.130 Bizkaia;Grupo 0907 Heart failure 428;Both sexes;3.804 Bizkaia;Grupo 0907 Heart failure 428;Men;1.904 Bizkaia;Grupo 0907 Heart failure 428;Women;1.900 Bizkaia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2.760 Bizkaia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1.432 Bizkaia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1.328 Bizkaia;Grupo 0909 Atherosclerosis 440;Both sexes;788 Bizkaia;Grupo 0909 Atherosclerosis 440;Men;591 Bizkaia;Grupo 0909 Atherosclerosis 440;Women;197 Bizkaia;Group 0910 Varicose veins of lower extremities 454;Both sexes;236 Bizkaia;Group 0910 Varicose veins of lower extremities 454;Men;111 Bizkaia;Group 0910 Varicose veins of lower extremities 454;Women;126 Bizkaia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2.747 Bizkaia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1.629 Bizkaia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1.119 Bizkaia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;15.542 Bizkaia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8.653 Bizkaia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6.889 Bizkaia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;569 Bizkaia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;314 Bizkaia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;255 Bizkaia;Group 1002 Pneumonia 480-486;Both sexes;2.716 Bizkaia;Group 1002 Pneumonia 480-486;Men;1.533 Bizkaia;Group 1002 Pneumonia 480-486;Women;1.183 Bizkaia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2.036 Bizkaia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;830 Bizkaia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1.206 Bizkaia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;685 Bizkaia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;371 Bizkaia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;314 Bizkaia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1.297 Bizkaia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;782 Bizkaia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;515 Bizkaia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2.920 Bizkaia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2.145 Bizkaia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;775 Bizkaia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1.120 Bizkaia;Group 1007 Asthma 4930-4931,4938-4939;Men;327 Bizkaia;Group 1007 Asthma 4930-4931,4938-4939;Women;793 Bizkaia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4.200 Bizkaia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2.352 Bizkaia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.848 Bizkaia;Group 1100 Diseases of the digestive system 520-579;Both sexes;15.900 Bizkaia;Group 1100 Diseases of the digestive system 520-579;Men;9.099 Bizkaia;Group 1100 Diseases of the digestive system 520-579;Women;6.801 Bizkaia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;183 Bizkaia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;102 Bizkaia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;81 Bizkaia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;197 Bizkaia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;107 Bizkaia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;90 Bizkaia;Group 1103 Diseases of the esophagus 530;Both sexes;297 Bizkaia;Group 1103 Diseases of the esophagus 530;Men;174 Bizkaia;Group 1103 Diseases of the esophagus 530;Women;123 Bizkaia;Group 1104 Peptic ulcer 531-534;Both sexes;330 Bizkaia;Group 1104 Peptic ulcer 531-534;Men;228 Bizkaia;Group 1104 Peptic ulcer 531-534;Women;102 Bizkaia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;292 Bizkaia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;150 Bizkaia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;142 Bizkaia;Group 1106 Appendicitis 540-543;Both sexes;1.402 Bizkaia;Group 1106 Appendicitis 540-543;Men;770 Bizkaia;Group 1106 Appendicitis 540-543;Women;631 Bizkaia;Group 1107 Inguinal hernia 550;Both sexes;2.063 Bizkaia;Group 1107 Inguinal hernia 550;Men;1.833 Bizkaia;Group 1107 Inguinal hernia 550;Women;230 Bizkaia;Group 1108 Other abdominal hernia 551-553;Both sexes;1.386 Bizkaia;Group 1108 Other abdominal hernia 551-553;Men;686 Bizkaia;Group 1108 Other abdominal hernia 551-553;Women;701 Bizkaia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;302 Bizkaia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;153 Bizkaia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;149 Bizkaia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;520 Bizkaia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;238 Bizkaia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;281 Bizkaia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;749 Bizkaia;Group 1111 Intestinal obstruction without hernia 560;Men;392 Bizkaia;Group 1111 Intestinal obstruction without hernia 560;Women;357 Bizkaia;Group 1112 Intestinal diverticulosis 562;Both sexes;779 Bizkaia;Group 1112 Intestinal diverticulosis 562;Men;353 Bizkaia;Group 1112 Intestinal diverticulosis 562;Women;426 Bizkaia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1.067 Bizkaia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;688 Bizkaia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;379 Bizkaia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;667 Bizkaia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;295 Bizkaia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;373 Bizkaia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;335 Bizkaia;Group 1115 Alcoholic hepatitis 5710-5713;Men;270 Bizkaia;Group 1115 Alcoholic hepatitis 5710-5713;Women;64 Bizkaia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;615 Bizkaia;Group 1116 Other diseases of the liver 570,5714-573;Men;379 Bizkaia;Group 1116 Other diseases of the liver 570,5714-573;Women;236 Bizkaia;Group 1117 Cholelithiasis 574;Both sexes;2.659 Bizkaia;Group 1117 Cholelithiasis 574;Men;1.139 Bizkaia;Group 1117 Cholelithiasis 574;Women;1.520 Bizkaia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;774 Bizkaia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;416 Bizkaia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;358 Bizkaia;Group 1119 Pancreatic diseases 577;Both sexes;695 Bizkaia;Group 1119 Pancreatic diseases 577;Men;405 Bizkaia;Group 1119 Pancreatic diseases 577;Women;290 Bizkaia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;590 Bizkaia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;323 Bizkaia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;267 Bizkaia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.183 Bizkaia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;665 Bizkaia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;518 Bizkaia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;813 Bizkaia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;511 Bizkaia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;303 Bizkaia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;63 Bizkaia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;30 Bizkaia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;33 Bizkaia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;306 Bizkaia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;125 Bizkaia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;182 Bizkaia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9.083 Bizkaia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4.505 Bizkaia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4.578 Bizkaia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Bizkaia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Bizkaia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Bizkaia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Bizkaia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Bizkaia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Bizkaia;Group 1303 Internal derangement of knee 717;Both sexes;903 Bizkaia;Group 1303 Internal derangement of knee 717;Men;589 Bizkaia;Group 1303 Internal derangement of knee 717;Women;315 Bizkaia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3.781 Bizkaia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.708 Bizkaia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2.073 Bizkaia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;189 Bizkaia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;77 Bizkaia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;112 Bizkaia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;444 Bizkaia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;227 Bizkaia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;217 Bizkaia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;542 Bizkaia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;314 Bizkaia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;228 Bizkaia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;230 Bizkaia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;116 Bizkaia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;114 Bizkaia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.522 Bizkaia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;936 Bizkaia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;586 Bizkaia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1.472 Bizkaia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;538 Bizkaia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;934 Bizkaia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;8.469 Bizkaia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4.029 Bizkaia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4.440 Bizkaia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;812 Bizkaia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;293 Bizkaia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;520 Bizkaia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;812 Bizkaia;Group 1402 Renal failure 5836-5837, 584-586;Men;474 Bizkaia;Group 1402 Renal failure 5836-5837, 584-586;Women;338 Bizkaia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1.105 Bizkaia;Group 1403 Urolithiasis 592, 594, 7880;Men;688 Bizkaia;Group 1403 Urolithiasis 592, 594, 7880;Women;417 Bizkaia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2.321 Bizkaia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1.169 Bizkaia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1.152 Bizkaia;Group 1405 Prostatic hyperplasia 600;Both sexes;768 Bizkaia;Group 1405 Prostatic hyperplasia 600;Men;768 Bizkaia;Group 1405 Prostatic hyperplasia 600;Women;.. Bizkaia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;546 Bizkaia;Group 1406 Other diseases of the male genital organs 601-608;Men;546 Bizkaia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Bizkaia;Group 1407 Disorders of breast 610-612;Both sexes;720 Bizkaia;Group 1407 Disorders of breast 610-612;Men;49 Bizkaia;Group 1407 Disorders of breast 610-612;Women;671 Bizkaia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;200 Bizkaia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Bizkaia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;200 Bizkaia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;41 Bizkaia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Bizkaia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;41 Bizkaia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1.144 Bizkaia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;42 Bizkaia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1.102 Bizkaia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;10.217 Bizkaia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Bizkaia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;10.217 Bizkaia;Group 1501 Legally induced abortion 635;Both sexes;74 Bizkaia;Group 1501 Legally induced abortion 635;Men;.. Bizkaia;Group 1501 Legally induced abortion 635;Women;74 Bizkaia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;223 Bizkaia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Bizkaia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;223 Bizkaia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;5.736 Bizkaia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Bizkaia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;5.736 Bizkaia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2.100 Bizkaia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Bizkaia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2.100 Bizkaia;Group 1505 Single spontaneous delivery 650;Both sexes;809 Bizkaia;Group 1505 Single spontaneous delivery 650;Men;.. Bizkaia;Group 1505 Single spontaneous delivery 650;Women;809 Bizkaia;Group 1506 Other deliveries 6695-6697;Both sexes;174 Bizkaia;Group 1506 Other deliveries 6695-6697;Men;.. Bizkaia;Group 1506 Other deliveries 6695-6697;Women;174 Bizkaia;Group 1507 Complications related to the puerperium 670-676;Both sexes;107 Bizkaia;Group 1507 Complications related to the puerperium 670-676;Men;.. Bizkaia;Group 1507 Complications related to the puerperium 670-676;Women;107 Bizkaia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;993 Bizkaia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Bizkaia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;993 Bizkaia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;969 Bizkaia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;529 Bizkaia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;440 Bizkaia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;287 Bizkaia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;134 Bizkaia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;153 Bizkaia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;683 Bizkaia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;395 Bizkaia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;288 Bizkaia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;797 Bizkaia;Grupo 1700 Congenital abnormalities 740-759;Men;456 Bizkaia;Grupo 1700 Congenital abnormalities 740-759;Women;341 Bizkaia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;5.908 Bizkaia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3.189 Bizkaia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.719 Bizkaia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1.151 Bizkaia;Group 1801 Pain in throat and chest 7841, 7865;Men;643 Bizkaia;Group 1801 Pain in throat and chest 7841, 7865;Women;508 Bizkaia;Group 1802 Abdominal pain 7890;Both sexes;582 Bizkaia;Group 1802 Abdominal pain 7890;Men;240 Bizkaia;Group 1802 Abdominal pain 7890;Women;342 Bizkaia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;36 Bizkaia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;16 Bizkaia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;20 Bizkaia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;4.138 Bizkaia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2.289 Bizkaia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.849 Bizkaia;Group 1900 Injuries and poisoning 800-999;Both sexes;11.255 Bizkaia;Group 1900 Injuries and poisoning 800-999;Men;6.183 Bizkaia;Group 1900 Injuries and poisoning 800-999;Women;5.072 Bizkaia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;393 Bizkaia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;228 Bizkaia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;165 Bizkaia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;198 Bizkaia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;133 Bizkaia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;65 Bizkaia;Group 1903 Radius and ulna fracture 813;Both sexes;773 Bizkaia;Group 1903 Radius and ulna fracture 813;Men;349 Bizkaia;Group 1903 Radius and ulna fracture 813;Women;424 Bizkaia;Group 1904 Femur fracture 820-821;Both sexes;1.694 Bizkaia;Group 1904 Femur fracture 820-821;Men;500 Bizkaia;Group 1904 Femur fracture 820-821;Women;1.194 Bizkaia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;804 Bizkaia;Group 1905 Leg fracture, including the ankle 823-824;Men;394 Bizkaia;Group 1905 Leg fracture, including the ankle 823-824;Women;411 Bizkaia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3.713 Bizkaia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2.435 Bizkaia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1.279 Bizkaia;Group 1907 Burns 940-949;Both sexes;73 Bizkaia;Group 1907 Burns 940-949;Men;49 Bizkaia;Group 1907 Burns 940-949;Women;24 Bizkaia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;233 Bizkaia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;107 Bizkaia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;127 Bizkaia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2.998 Bizkaia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1.799 Bizkaia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1.198 Bizkaia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;36 Bizkaia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;23 Bizkaia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;13 Bizkaia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;338 Bizkaia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;167 Bizkaia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;172 Bizkaia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.724 Bizkaia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.337 Bizkaia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.387 Bizkaia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;169 Bizkaia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;80 Bizkaia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;88 Bizkaia;Group 2102 Contraceptive management V25;Both sexes;60 Bizkaia;Group 2102 Contraceptive management V25;Men;4 Bizkaia;Group 2102 Contraceptive management V25;Women;56 Bizkaia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Bizkaia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Bizkaia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Bizkaia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;816 Bizkaia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;516 Bizkaia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;301 Bizkaia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1.679 Bizkaia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;737 Bizkaia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;942 Gipuzkoa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;82.963 Gipuzkoa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;41.047 Gipuzkoa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;41.916 Gipuzkoa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1.722 Gipuzkoa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;984 Gipuzkoa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;738 Gipuzkoa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;257 Gipuzkoa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;136 Gipuzkoa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;121 Gipuzkoa;Group 0102 Imprecise intestinal infections 009;Both sexes;89 Gipuzkoa;Group 0102 Imprecise intestinal infections 009;Men;44 Gipuzkoa;Group 0102 Imprecise intestinal infections 009;Women;45 Gipuzkoa;Group 0103 Tuberculosis 010-018, 137;Both sexes;62 Gipuzkoa;Group 0103 Tuberculosis 010-018, 137;Men;31 Gipuzkoa;Group 0103 Tuberculosis 010-018, 137;Women;31 Gipuzkoa;Group 0104 Septicaemia 038;Both sexes;832 Gipuzkoa;Group 0104 Septicaemia 038;Men;498 Gipuzkoa;Group 0104 Septicaemia 038;Women;334 Gipuzkoa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;57 Gipuzkoa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;47 Gipuzkoa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;10 Gipuzkoa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;425 Gipuzkoa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;228 Gipuzkoa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;197 Gipuzkoa;Group 0200 Neoplasms 140-239;Both sexes;7.729 Gipuzkoa;Group 0200 Neoplasms 140-239;Men;4.112 Gipuzkoa;Group 0200 Neoplasms 140-239;Women;3.617 Gipuzkoa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;762 Gipuzkoa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;457 Gipuzkoa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;305 Gipuzkoa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;619 Gipuzkoa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;461 Gipuzkoa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;158 Gipuzkoa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;151 Gipuzkoa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;84 Gipuzkoa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;67 Gipuzkoa;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;621 Gipuzkoa;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Gipuzkoa;Group 0204 Malignant neoplasm of breast 174-175;Women;618 Gipuzkoa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;168 Gipuzkoa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Gipuzkoa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;168 Gipuzkoa;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;93 Gipuzkoa;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Gipuzkoa;Group 0206 Malignant neoplasm of ovary 1830;Women;93 Gipuzkoa;Group 0207 Malignant neoplasm of prostate 185;Both sexes;409 Gipuzkoa;Group 0207 Malignant neoplasm of prostate 185;Men;409 Gipuzkoa;Group 0207 Malignant neoplasm of prostate 185;Women;.. Gipuzkoa;Group 0208 Malignant neoplasm of bladder 188;Both sexes;594 Gipuzkoa;Group 0208 Malignant neoplasm of bladder 188;Men;465 Gipuzkoa;Group 0208 Malignant neoplasm of bladder 188;Women;129 Gipuzkoa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2.743 Gipuzkoa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1.665 Gipuzkoa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1.078 Gipuzkoa;Group 0210 Carcinoma in situ 230-234;Both sexes;99 Gipuzkoa;Group 0210 Carcinoma in situ 230-234;Men;33 Gipuzkoa;Group 0210 Carcinoma in situ 230-234;Women;66 Gipuzkoa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;171 Gipuzkoa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;106 Gipuzkoa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;65 Gipuzkoa;Grupo 0212 Leiomyoma of uterus 218;Both sexes;334 Gipuzkoa;Grupo 0212 Leiomyoma of uterus 218;Men;.. Gipuzkoa;Grupo 0212 Leiomyoma of uterus 218;Women;334 Gipuzkoa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;965 Gipuzkoa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;429 Gipuzkoa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;536 Gipuzkoa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;884 Gipuzkoa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;432 Gipuzkoa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;452 Gipuzkoa;Group 0301 Anaemias 280-285;Both sexes;668 Gipuzkoa;Group 0301 Anaemias 280-285;Men;314 Gipuzkoa;Group 0301 Anaemias 280-285;Women;354 Gipuzkoa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;216 Gipuzkoa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;118 Gipuzkoa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;98 Gipuzkoa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1.347 Gipuzkoa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;616 Gipuzkoa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;731 Gipuzkoa;Group 0401 Diabetes mellitus 249-250;Both sexes;502 Gipuzkoa;Group 0401 Diabetes mellitus 249-250;Men;328 Gipuzkoa;Group 0401 Diabetes mellitus 249-250;Women;174 Gipuzkoa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;845 Gipuzkoa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;288 Gipuzkoa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;557 Gipuzkoa;Group 0500 Mental disorders 290-319;Both sexes;2.006 Gipuzkoa;Group 0500 Mental disorders 290-319;Men;1.097 Gipuzkoa;Group 0500 Mental disorders 290-319;Women;909 Gipuzkoa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;94 Gipuzkoa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;49 Gipuzkoa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;45 Gipuzkoa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;187 Gipuzkoa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;127 Gipuzkoa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;60 Gipuzkoa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;113 Gipuzkoa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;85 Gipuzkoa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;28 Gipuzkoa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;637 Gipuzkoa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;426 Gipuzkoa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;211 Gipuzkoa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;419 Gipuzkoa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;161 Gipuzkoa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;258 Gipuzkoa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;556 Gipuzkoa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;249 Gipuzkoa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;307 Gipuzkoa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1.635 Gipuzkoa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;885 Gipuzkoa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;750 Gipuzkoa;Group 0601 Alzheimer's disease 3310;Both sexes;52 Gipuzkoa;Group 0601 Alzheimer's disease 3310;Men;24 Gipuzkoa;Group 0601 Alzheimer's disease 3310;Women;28 Gipuzkoa;Group 0602 Multiple sclerosis 340;Both sexes;24 Gipuzkoa;Group 0602 Multiple sclerosis 340;Men;3 Gipuzkoa;Group 0602 Multiple sclerosis 340;Women;21 Gipuzkoa;Group 0603 Epilepsy 345;Both sexes;273 Gipuzkoa;Group 0603 Epilepsy 345;Men;158 Gipuzkoa;Group 0603 Epilepsy 345;Women;115 Gipuzkoa;Group 0604 Transient cerebral ischemia 435;Both sexes;255 Gipuzkoa;Group 0604 Transient cerebral ischemia 435;Men;121 Gipuzkoa;Group 0604 Transient cerebral ischemia 435;Women;134 Gipuzkoa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1.031 Gipuzkoa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;579 Gipuzkoa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;452 Gipuzkoa;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;233 Gipuzkoa;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;108 Gipuzkoa;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;125 Gipuzkoa;Grupo 0701 Cataract 366;Both sexes;11 Gipuzkoa;Grupo 0701 Cataract 366;Men;6 Gipuzkoa;Grupo 0701 Cataract 366;Women;5 Gipuzkoa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;222 Gipuzkoa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;102 Gipuzkoa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;120 Gipuzkoa;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;562 Gipuzkoa;Group 0800 Diseases of the ear and the mastoid 380-389;Men;271 Gipuzkoa;Group 0800 Diseases of the ear and the mastoid 380-389;Women;291 Gipuzkoa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;10.480 Gipuzkoa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6.101 Gipuzkoa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4.379 Gipuzkoa;Group 0901 Hypertensive disease 401-405;Both sexes;457 Gipuzkoa;Group 0901 Hypertensive disease 401-405;Men;207 Gipuzkoa;Group 0901 Hypertensive disease 401-405;Women;250 Gipuzkoa;Group 0902 Angina pectoris 4111, 413;Both sexes;287 Gipuzkoa;Group 0902 Angina pectoris 4111, 413;Men;196 Gipuzkoa;Group 0902 Angina pectoris 4111, 413;Women;91 Gipuzkoa;Group 0903 Acute myocardial infarction 410;Both sexes;643 Gipuzkoa;Group 0903 Acute myocardial infarction 410;Men;473 Gipuzkoa;Group 0903 Acute myocardial infarction 410;Women;170 Gipuzkoa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;711 Gipuzkoa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;575 Gipuzkoa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;136 Gipuzkoa;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;297 Gipuzkoa;Group 0905 Diseases of the lungs circulation 415-417;Men;135 Gipuzkoa;Group 0905 Diseases of the lungs circulation 415-417;Women;162 Gipuzkoa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1.661 Gipuzkoa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;938 Gipuzkoa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;723 Gipuzkoa;Grupo 0907 Heart failure 428;Both sexes;2.156 Gipuzkoa;Grupo 0907 Heart failure 428;Men;1.135 Gipuzkoa;Grupo 0907 Heart failure 428;Women;1.021 Gipuzkoa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1.839 Gipuzkoa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;961 Gipuzkoa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;878 Gipuzkoa;Grupo 0909 Atherosclerosis 440;Both sexes;534 Gipuzkoa;Grupo 0909 Atherosclerosis 440;Men;402 Gipuzkoa;Grupo 0909 Atherosclerosis 440;Women;132 Gipuzkoa;Group 0910 Varicose veins of lower extremities 454;Both sexes;305 Gipuzkoa;Group 0910 Varicose veins of lower extremities 454;Men;131 Gipuzkoa;Group 0910 Varicose veins of lower extremities 454;Women;174 Gipuzkoa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1.590 Gipuzkoa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;948 Gipuzkoa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;642 Gipuzkoa;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;10.561 Gipuzkoa;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;6.007 Gipuzkoa;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4.554 Gipuzkoa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;510 Gipuzkoa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;252 Gipuzkoa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;258 Gipuzkoa;Group 1002 Pneumonia 480-486;Both sexes;2.563 Gipuzkoa;Group 1002 Pneumonia 480-486;Men;1.548 Gipuzkoa;Group 1002 Pneumonia 480-486;Women;1.015 Gipuzkoa;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;538 Gipuzkoa;Group 1003 Acute bronchitis and bronchiolitis 466;Men;281 Gipuzkoa;Group 1003 Acute bronchitis and bronchiolitis 466;Women;257 Gipuzkoa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;564 Gipuzkoa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;320 Gipuzkoa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;244 Gipuzkoa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;886 Gipuzkoa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;587 Gipuzkoa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;299 Gipuzkoa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1.616 Gipuzkoa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1.159 Gipuzkoa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;457 Gipuzkoa;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;490 Gipuzkoa;Group 1007 Asthma 4930-4931,4938-4939;Men;191 Gipuzkoa;Group 1007 Asthma 4930-4931,4938-4939;Women;299 Gipuzkoa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3.394 Gipuzkoa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1.669 Gipuzkoa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1.725 Gipuzkoa;Group 1100 Diseases of the digestive system 520-579;Both sexes;9.267 Gipuzkoa;Group 1100 Diseases of the digestive system 520-579;Men;5.329 Gipuzkoa;Group 1100 Diseases of the digestive system 520-579;Women;3.938 Gipuzkoa;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;111 Gipuzkoa;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;49 Gipuzkoa;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;62 Gipuzkoa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;148 Gipuzkoa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;89 Gipuzkoa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;59 Gipuzkoa;Group 1103 Diseases of the esophagus 530;Both sexes;154 Gipuzkoa;Group 1103 Diseases of the esophagus 530;Men;104 Gipuzkoa;Group 1103 Diseases of the esophagus 530;Women;50 Gipuzkoa;Group 1104 Peptic ulcer 531-534;Both sexes;175 Gipuzkoa;Group 1104 Peptic ulcer 531-534;Men;124 Gipuzkoa;Group 1104 Peptic ulcer 531-534;Women;51 Gipuzkoa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;177 Gipuzkoa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;98 Gipuzkoa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;79 Gipuzkoa;Group 1106 Appendicitis 540-543;Both sexes;902 Gipuzkoa;Group 1106 Appendicitis 540-543;Men;501 Gipuzkoa;Group 1106 Appendicitis 540-543;Women;401 Gipuzkoa;Group 1107 Inguinal hernia 550;Both sexes;901 Gipuzkoa;Group 1107 Inguinal hernia 550;Men;776 Gipuzkoa;Group 1107 Inguinal hernia 550;Women;125 Gipuzkoa;Group 1108 Other abdominal hernia 551-553;Both sexes;734 Gipuzkoa;Group 1108 Other abdominal hernia 551-553;Men;365 Gipuzkoa;Group 1108 Other abdominal hernia 551-553;Women;369 Gipuzkoa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;200 Gipuzkoa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;110 Gipuzkoa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;90 Gipuzkoa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;437 Gipuzkoa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;199 Gipuzkoa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;238 Gipuzkoa;Group 1111 Intestinal obstruction without hernia 560;Both sexes;643 Gipuzkoa;Group 1111 Intestinal obstruction without hernia 560;Men;349 Gipuzkoa;Group 1111 Intestinal obstruction without hernia 560;Women;294 Gipuzkoa;Group 1112 Intestinal diverticulosis 562;Both sexes;467 Gipuzkoa;Group 1112 Intestinal diverticulosis 562;Men;196 Gipuzkoa;Group 1112 Intestinal diverticulosis 562;Women;271 Gipuzkoa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;687 Gipuzkoa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;473 Gipuzkoa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;214 Gipuzkoa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;294 Gipuzkoa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;139 Gipuzkoa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;155 Gipuzkoa;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;153 Gipuzkoa;Group 1115 Alcoholic hepatitis 5710-5713;Men;116 Gipuzkoa;Group 1115 Alcoholic hepatitis 5710-5713;Women;37 Gipuzkoa;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;260 Gipuzkoa;Group 1116 Other diseases of the liver 570,5714-573;Men;159 Gipuzkoa;Group 1116 Other diseases of the liver 570,5714-573;Women;101 Gipuzkoa;Group 1117 Cholelithiasis 574;Both sexes;1.445 Gipuzkoa;Group 1117 Cholelithiasis 574;Men;636 Gipuzkoa;Group 1117 Cholelithiasis 574;Women;809 Gipuzkoa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;392 Gipuzkoa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;253 Gipuzkoa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;139 Gipuzkoa;Group 1119 Pancreatic diseases 577;Both sexes;451 Gipuzkoa;Group 1119 Pancreatic diseases 577;Men;264 Gipuzkoa;Group 1119 Pancreatic diseases 577;Women;187 Gipuzkoa;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;536 Gipuzkoa;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;329 Gipuzkoa;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;207 Gipuzkoa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1.031 Gipuzkoa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;571 Gipuzkoa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;460 Gipuzkoa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;729 Gipuzkoa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;441 Gipuzkoa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;288 Gipuzkoa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;32 Gipuzkoa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;16 Gipuzkoa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;16 Gipuzkoa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;270 Gipuzkoa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;114 Gipuzkoa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;156 Gipuzkoa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6.782 Gipuzkoa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3.493 Gipuzkoa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3.289 Gipuzkoa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Gipuzkoa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Gipuzkoa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Gipuzkoa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Gipuzkoa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Gipuzkoa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Gipuzkoa;Group 1303 Internal derangement of knee 717;Both sexes;1.018 Gipuzkoa;Group 1303 Internal derangement of knee 717;Men;649 Gipuzkoa;Group 1303 Internal derangement of knee 717;Women;369 Gipuzkoa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2.483 Gipuzkoa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1.264 Gipuzkoa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1.219 Gipuzkoa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;71 Gipuzkoa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;30 Gipuzkoa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;41 Gipuzkoa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;495 Gipuzkoa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;264 Gipuzkoa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;231 Gipuzkoa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;579 Gipuzkoa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;302 Gipuzkoa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;277 Gipuzkoa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;238 Gipuzkoa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;107 Gipuzkoa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;131 Gipuzkoa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1.005 Gipuzkoa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;537 Gipuzkoa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;468 Gipuzkoa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;893 Gipuzkoa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;340 Gipuzkoa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;553 Gipuzkoa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5.118 Gipuzkoa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2.477 Gipuzkoa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2.641 Gipuzkoa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;387 Gipuzkoa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;149 Gipuzkoa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;238 Gipuzkoa;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;361 Gipuzkoa;Group 1402 Renal failure 5836-5837, 584-586;Men;202 Gipuzkoa;Group 1402 Renal failure 5836-5837, 584-586;Women;159 Gipuzkoa;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;851 Gipuzkoa;Group 1403 Urolithiasis 592, 594, 7880;Men;535 Gipuzkoa;Group 1403 Urolithiasis 592, 594, 7880;Women;316 Gipuzkoa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1.640 Gipuzkoa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;803 Gipuzkoa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;837 Gipuzkoa;Group 1405 Prostatic hyperplasia 600;Both sexes;538 Gipuzkoa;Group 1405 Prostatic hyperplasia 600;Men;538 Gipuzkoa;Group 1405 Prostatic hyperplasia 600;Women;.. Gipuzkoa;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;208 Gipuzkoa;Group 1406 Other diseases of the male genital organs 601-608;Men;208 Gipuzkoa;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Gipuzkoa;Group 1407 Disorders of breast 610-612;Both sexes;326 Gipuzkoa;Group 1407 Disorders of breast 610-612;Men;32 Gipuzkoa;Group 1407 Disorders of breast 610-612;Women;294 Gipuzkoa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;131 Gipuzkoa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Gipuzkoa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;131 Gipuzkoa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;44 Gipuzkoa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Gipuzkoa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;44 Gipuzkoa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;632 Gipuzkoa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;10 Gipuzkoa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;622 Gipuzkoa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;7.462 Gipuzkoa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Gipuzkoa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;7.462 Gipuzkoa;Group 1501 Legally induced abortion 635;Both sexes;72 Gipuzkoa;Group 1501 Legally induced abortion 635;Men;.. Gipuzkoa;Group 1501 Legally induced abortion 635;Women;72 Gipuzkoa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;212 Gipuzkoa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Gipuzkoa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;212 Gipuzkoa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4.847 Gipuzkoa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Gipuzkoa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4.847 Gipuzkoa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.190 Gipuzkoa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Gipuzkoa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.190 Gipuzkoa;Group 1505 Single spontaneous delivery 650;Both sexes;663 Gipuzkoa;Group 1505 Single spontaneous delivery 650;Men;.. Gipuzkoa;Group 1505 Single spontaneous delivery 650;Women;663 Gipuzkoa;Group 1506 Other deliveries 6695-6697;Both sexes;138 Gipuzkoa;Group 1506 Other deliveries 6695-6697;Men;.. Gipuzkoa;Group 1506 Other deliveries 6695-6697;Women;138 Gipuzkoa;Group 1507 Complications related to the puerperium 670-676;Both sexes;42 Gipuzkoa;Group 1507 Complications related to the puerperium 670-676;Men;.. Gipuzkoa;Group 1507 Complications related to the puerperium 670-676;Women;42 Gipuzkoa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;298 Gipuzkoa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Gipuzkoa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;298 Gipuzkoa;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;868 Gipuzkoa;Group 1600 Some disorders originating in the perinatal period 760-779;Men;490 Gipuzkoa;Group 1600 Some disorders originating in the perinatal period 760-779;Women;378 Gipuzkoa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;244 Gipuzkoa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;136 Gipuzkoa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;108 Gipuzkoa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;624 Gipuzkoa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;354 Gipuzkoa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;270 Gipuzkoa;Grupo 1700 Congenital abnormalities 740-759;Both sexes;271 Gipuzkoa;Grupo 1700 Congenital abnormalities 740-759;Men;139 Gipuzkoa;Grupo 1700 Congenital abnormalities 740-759;Women;132 Gipuzkoa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;5.525 Gipuzkoa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3.097 Gipuzkoa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2.428 Gipuzkoa;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;872 Gipuzkoa;Group 1801 Pain in throat and chest 7841, 7865;Men;535 Gipuzkoa;Group 1801 Pain in throat and chest 7841, 7865;Women;337 Gipuzkoa;Group 1802 Abdominal pain 7890;Both sexes;522 Gipuzkoa;Group 1802 Abdominal pain 7890;Men;211 Gipuzkoa;Group 1802 Abdominal pain 7890;Women;311 Gipuzkoa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1.551 Gipuzkoa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;865 Gipuzkoa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;686 Gipuzkoa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2.580 Gipuzkoa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1.486 Gipuzkoa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1.094 Gipuzkoa;Group 1900 Injuries and poisoning 800-999;Both sexes;6.678 Gipuzkoa;Group 1900 Injuries and poisoning 800-999;Men;3.514 Gipuzkoa;Group 1900 Injuries and poisoning 800-999;Women;3.164 Gipuzkoa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;459 Gipuzkoa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;258 Gipuzkoa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;201 Gipuzkoa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;255 Gipuzkoa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;179 Gipuzkoa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;76 Gipuzkoa;Group 1903 Radius and ulna fracture 813;Both sexes;436 Gipuzkoa;Group 1903 Radius and ulna fracture 813;Men;167 Gipuzkoa;Group 1903 Radius and ulna fracture 813;Women;269 Gipuzkoa;Group 1904 Femur fracture 820-821;Both sexes;940 Gipuzkoa;Group 1904 Femur fracture 820-821;Men;250 Gipuzkoa;Group 1904 Femur fracture 820-821;Women;690 Gipuzkoa;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;469 Gipuzkoa;Group 1905 Leg fracture, including the ankle 823-824;Men;222 Gipuzkoa;Group 1905 Leg fracture, including the ankle 823-824;Women;247 Gipuzkoa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1.957 Gipuzkoa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1.203 Gipuzkoa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;754 Gipuzkoa;Group 1907 Burns 940-949;Both sexes;46 Gipuzkoa;Group 1907 Burns 940-949;Men;35 Gipuzkoa;Group 1907 Burns 940-949;Women;11 Gipuzkoa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;155 Gipuzkoa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;75 Gipuzkoa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;80 Gipuzkoa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1.648 Gipuzkoa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;957 Gipuzkoa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;691 Gipuzkoa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;20 Gipuzkoa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;15 Gipuzkoa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 Gipuzkoa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;293 Gipuzkoa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;153 Gipuzkoa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;140 Gipuzkoa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2.802 Gipuzkoa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1.324 Gipuzkoa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1.478 Gipuzkoa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;67 Gipuzkoa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;32 Gipuzkoa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;35 Gipuzkoa;Group 2102 Contraceptive management V25;Both sexes;26 Gipuzkoa;Group 2102 Contraceptive management V25;Men;4 Gipuzkoa;Group 2102 Contraceptive management V25;Women;22 Gipuzkoa;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Gipuzkoa;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Gipuzkoa;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Gipuzkoa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;630 Gipuzkoa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;364 Gipuzkoa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;266 Gipuzkoa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2.079 Gipuzkoa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;924 Gipuzkoa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1.155 RIOJA, LA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;34.988 RIOJA, LA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;17.097 RIOJA, LA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;17.891 RIOJA, LA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;767 RIOJA, LA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;418 RIOJA, LA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;349 RIOJA, LA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;142 RIOJA, LA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;74 RIOJA, LA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;68 RIOJA, LA;Group 0102 Imprecise intestinal infections 009;Both sexes;25 RIOJA, LA;Group 0102 Imprecise intestinal infections 009;Men;15 RIOJA, LA;Group 0102 Imprecise intestinal infections 009;Women;10 RIOJA, LA;Group 0103 Tuberculosis 010-018, 137;Both sexes;22 RIOJA, LA;Group 0103 Tuberculosis 010-018, 137;Men;11 RIOJA, LA;Group 0103 Tuberculosis 010-018, 137;Women;11 RIOJA, LA;Group 0104 Septicaemia 038;Both sexes;318 RIOJA, LA;Group 0104 Septicaemia 038;Men;164 RIOJA, LA;Group 0104 Septicaemia 038;Women;154 RIOJA, LA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;10 RIOJA, LA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;7 RIOJA, LA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 RIOJA, LA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;250 RIOJA, LA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;147 RIOJA, LA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;103 RIOJA, LA;Group 0200 Neoplasms 140-239;Both sexes;2.929 RIOJA, LA;Group 0200 Neoplasms 140-239;Men;1.534 RIOJA, LA;Group 0200 Neoplasms 140-239;Women;1.395 RIOJA, LA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;248 RIOJA, LA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;160 RIOJA, LA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;88 RIOJA, LA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;212 RIOJA, LA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;171 RIOJA, LA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;41 RIOJA, LA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;101 RIOJA, LA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;60 RIOJA, LA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;41 RIOJA, LA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;268 RIOJA, LA;Group 0204 Malignant neoplasm of breast 174-175;Men;2 RIOJA, LA;Group 0204 Malignant neoplasm of breast 174-175;Women;266 RIOJA, LA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;62 RIOJA, LA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. RIOJA, LA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;62 RIOJA, LA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;26 RIOJA, LA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. RIOJA, LA;Group 0206 Malignant neoplasm of ovary 1830;Women;26 RIOJA, LA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;77 RIOJA, LA;Group 0207 Malignant neoplasm of prostate 185;Men;77 RIOJA, LA;Group 0207 Malignant neoplasm of prostate 185;Women;.. RIOJA, LA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;253 RIOJA, LA;Group 0208 Malignant neoplasm of bladder 188;Men;201 RIOJA, LA;Group 0208 Malignant neoplasm of bladder 188;Women;52 RIOJA, LA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1.039 RIOJA, LA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;626 RIOJA, LA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;413 RIOJA, LA;Group 0210 Carcinoma in situ 230-234;Both sexes;44 RIOJA, LA;Group 0210 Carcinoma in situ 230-234;Men;7 RIOJA, LA;Group 0210 Carcinoma in situ 230-234;Women;37 RIOJA, LA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;38 RIOJA, LA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;23 RIOJA, LA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;15 RIOJA, LA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;151 RIOJA, LA;Grupo 0212 Leiomyoma of uterus 218;Men;.. RIOJA, LA;Grupo 0212 Leiomyoma of uterus 218;Women;151 RIOJA, LA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;410 RIOJA, LA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;207 RIOJA, LA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;203 RIOJA, LA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;524 RIOJA, LA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;265 RIOJA, LA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;259 RIOJA, LA;Group 0301 Anaemias 280-285;Both sexes;387 RIOJA, LA;Group 0301 Anaemias 280-285;Men;193 RIOJA, LA;Group 0301 Anaemias 280-285;Women;194 RIOJA, LA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;137 RIOJA, LA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;72 RIOJA, LA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;65 RIOJA, LA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;645 RIOJA, LA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;310 RIOJA, LA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;335 RIOJA, LA;Group 0401 Diabetes mellitus 249-250;Both sexes;316 RIOJA, LA;Group 0401 Diabetes mellitus 249-250;Men;184 RIOJA, LA;Group 0401 Diabetes mellitus 249-250;Women;132 RIOJA, LA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;329 RIOJA, LA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;126 RIOJA, LA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;203 RIOJA, LA;Group 0500 Mental disorders 290-319;Both sexes;730 RIOJA, LA;Group 0500 Mental disorders 290-319;Men;418 RIOJA, LA;Group 0500 Mental disorders 290-319;Women;312 RIOJA, LA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;28 RIOJA, LA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;13 RIOJA, LA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;15 RIOJA, LA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;41 RIOJA, LA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;23 RIOJA, LA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;18 RIOJA, LA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;45 RIOJA, LA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;34 RIOJA, LA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;11 RIOJA, LA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;211 RIOJA, LA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;131 RIOJA, LA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;80 RIOJA, LA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;122 RIOJA, LA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;46 RIOJA, LA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;76 RIOJA, LA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;283 RIOJA, LA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;171 RIOJA, LA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;112 RIOJA, LA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;596 RIOJA, LA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;304 RIOJA, LA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;292 RIOJA, LA;Group 0601 Alzheimer's disease 3310;Both sexes;20 RIOJA, LA;Group 0601 Alzheimer's disease 3310;Men;1 RIOJA, LA;Group 0601 Alzheimer's disease 3310;Women;19 RIOJA, LA;Group 0602 Multiple sclerosis 340;Both sexes;9 RIOJA, LA;Group 0602 Multiple sclerosis 340;Men;1 RIOJA, LA;Group 0602 Multiple sclerosis 340;Women;8 RIOJA, LA;Group 0603 Epilepsy 345;Both sexes;102 RIOJA, LA;Group 0603 Epilepsy 345;Men;57 RIOJA, LA;Group 0603 Epilepsy 345;Women;45 RIOJA, LA;Group 0604 Transient cerebral ischemia 435;Both sexes;118 RIOJA, LA;Group 0604 Transient cerebral ischemia 435;Men;59 RIOJA, LA;Group 0604 Transient cerebral ischemia 435;Women;59 RIOJA, LA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;347 RIOJA, LA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;186 RIOJA, LA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;161 RIOJA, LA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;261 RIOJA, LA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;140 RIOJA, LA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;121 RIOJA, LA;Grupo 0701 Cataract 366;Both sexes;18 RIOJA, LA;Grupo 0701 Cataract 366;Men;9 RIOJA, LA;Grupo 0701 Cataract 366;Women;9 RIOJA, LA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;243 RIOJA, LA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;131 RIOJA, LA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;112 RIOJA, LA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;147 RIOJA, LA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;72 RIOJA, LA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;75 RIOJA, LA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4.954 RIOJA, LA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2.783 RIOJA, LA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2.171 RIOJA, LA;Group 0901 Hypertensive disease 401-405;Both sexes;333 RIOJA, LA;Group 0901 Hypertensive disease 401-405;Men;154 RIOJA, LA;Group 0901 Hypertensive disease 401-405;Women;179 RIOJA, LA;Group 0902 Angina pectoris 4111, 413;Both sexes;116 RIOJA, LA;Group 0902 Angina pectoris 4111, 413;Men;80 RIOJA, LA;Group 0902 Angina pectoris 4111, 413;Women;36 RIOJA, LA;Group 0903 Acute myocardial infarction 410;Both sexes;404 RIOJA, LA;Group 0903 Acute myocardial infarction 410;Men;290 RIOJA, LA;Group 0903 Acute myocardial infarction 410;Women;114 RIOJA, LA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;216 RIOJA, LA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;176 RIOJA, LA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;40 RIOJA, LA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;194 RIOJA, LA;Group 0905 Diseases of the lungs circulation 415-417;Men;94 RIOJA, LA;Group 0905 Diseases of the lungs circulation 415-417;Women;100 RIOJA, LA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;601 RIOJA, LA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;327 RIOJA, LA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;274 RIOJA, LA;Grupo 0907 Heart failure 428;Both sexes;1.103 RIOJA, LA;Grupo 0907 Heart failure 428;Men;553 RIOJA, LA;Grupo 0907 Heart failure 428;Women;550 RIOJA, LA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;799 RIOJA, LA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;419 RIOJA, LA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;380 RIOJA, LA;Grupo 0909 Atherosclerosis 440;Both sexes;137 RIOJA, LA;Grupo 0909 Atherosclerosis 440;Men;103 RIOJA, LA;Grupo 0909 Atherosclerosis 440;Women;34 RIOJA, LA;Group 0910 Varicose veins of lower extremities 454;Both sexes;266 RIOJA, LA;Group 0910 Varicose veins of lower extremities 454;Men;87 RIOJA, LA;Group 0910 Varicose veins of lower extremities 454;Women;179 RIOJA, LA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;785 RIOJA, LA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;500 RIOJA, LA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;285 RIOJA, LA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4.529 RIOJA, LA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2.533 RIOJA, LA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1.996 RIOJA, LA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;150 RIOJA, LA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;93 RIOJA, LA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;57 RIOJA, LA;Group 1002 Pneumonia 480-486;Both sexes;884 RIOJA, LA;Group 1002 Pneumonia 480-486;Men;509 RIOJA, LA;Group 1002 Pneumonia 480-486;Women;375 RIOJA, LA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;229 RIOJA, LA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;120 RIOJA, LA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;109 RIOJA, LA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;216 RIOJA, LA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;102 RIOJA, LA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;114 RIOJA, LA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;216 RIOJA, LA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;136 RIOJA, LA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;80 RIOJA, LA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;857 RIOJA, LA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;657 RIOJA, LA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;200 RIOJA, LA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;208 RIOJA, LA;Group 1007 Asthma 4930-4931,4938-4939;Men;53 RIOJA, LA;Group 1007 Asthma 4930-4931,4938-4939;Women;155 RIOJA, LA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1.769 RIOJA, LA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;863 RIOJA, LA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;906 RIOJA, LA;Group 1100 Diseases of the digestive system 520-579;Both sexes;4.751 RIOJA, LA;Group 1100 Diseases of the digestive system 520-579;Men;2.737 RIOJA, LA;Group 1100 Diseases of the digestive system 520-579;Women;2.014 RIOJA, LA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;33 RIOJA, LA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;18 RIOJA, LA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;15 RIOJA, LA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;65 RIOJA, LA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;32 RIOJA, LA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;33 RIOJA, LA;Group 1103 Diseases of the esophagus 530;Both sexes;77 RIOJA, LA;Group 1103 Diseases of the esophagus 530;Men;54 RIOJA, LA;Group 1103 Diseases of the esophagus 530;Women;23 RIOJA, LA;Group 1104 Peptic ulcer 531-534;Both sexes;106 RIOJA, LA;Group 1104 Peptic ulcer 531-534;Men;72 RIOJA, LA;Group 1104 Peptic ulcer 531-534;Women;34 RIOJA, LA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;106 RIOJA, LA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;54 RIOJA, LA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;52 RIOJA, LA;Group 1106 Appendicitis 540-543;Both sexes;329 RIOJA, LA;Group 1106 Appendicitis 540-543;Men;191 RIOJA, LA;Group 1106 Appendicitis 540-543;Women;138 RIOJA, LA;Group 1107 Inguinal hernia 550;Both sexes;512 RIOJA, LA;Group 1107 Inguinal hernia 550;Men;455 RIOJA, LA;Group 1107 Inguinal hernia 550;Women;57 RIOJA, LA;Group 1108 Other abdominal hernia 551-553;Both sexes;329 RIOJA, LA;Group 1108 Other abdominal hernia 551-553;Men;147 RIOJA, LA;Group 1108 Other abdominal hernia 551-553;Women;182 RIOJA, LA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;64 RIOJA, LA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;25 RIOJA, LA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;39 RIOJA, LA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;417 RIOJA, LA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;207 RIOJA, LA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;210 RIOJA, LA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;289 RIOJA, LA;Group 1111 Intestinal obstruction without hernia 560;Men;174 RIOJA, LA;Group 1111 Intestinal obstruction without hernia 560;Women;115 RIOJA, LA;Group 1112 Intestinal diverticulosis 562;Both sexes;312 RIOJA, LA;Group 1112 Intestinal diverticulosis 562;Men;144 RIOJA, LA;Group 1112 Intestinal diverticulosis 562;Women;168 RIOJA, LA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;211 RIOJA, LA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;130 RIOJA, LA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;81 RIOJA, LA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;184 RIOJA, LA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;83 RIOJA, LA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;101 RIOJA, LA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;73 RIOJA, LA;Group 1115 Alcoholic hepatitis 5710-5713;Men;65 RIOJA, LA;Group 1115 Alcoholic hepatitis 5710-5713;Women;8 RIOJA, LA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;135 RIOJA, LA;Group 1116 Other diseases of the liver 570,5714-573;Men;75 RIOJA, LA;Group 1116 Other diseases of the liver 570,5714-573;Women;60 RIOJA, LA;Group 1117 Cholelithiasis 574;Both sexes;683 RIOJA, LA;Group 1117 Cholelithiasis 574;Men;325 RIOJA, LA;Group 1117 Cholelithiasis 574;Women;358 RIOJA, LA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;281 RIOJA, LA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;166 RIOJA, LA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;115 RIOJA, LA;Group 1119 Pancreatic diseases 577;Both sexes;322 RIOJA, LA;Group 1119 Pancreatic diseases 577;Men;189 RIOJA, LA;Group 1119 Pancreatic diseases 577;Women;133 RIOJA, LA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;223 RIOJA, LA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;131 RIOJA, LA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;92 RIOJA, LA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;345 RIOJA, LA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;179 RIOJA, LA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;166 RIOJA, LA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;200 RIOJA, LA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;108 RIOJA, LA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;92 RIOJA, LA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;18 RIOJA, LA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;7 RIOJA, LA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;11 RIOJA, LA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;127 RIOJA, LA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;64 RIOJA, LA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;63 RIOJA, LA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2.652 RIOJA, LA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1.346 RIOJA, LA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1.306 RIOJA, LA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. RIOJA, LA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. RIOJA, LA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. RIOJA, LA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. RIOJA, LA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. RIOJA, LA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. RIOJA, LA;Group 1303 Internal derangement of knee 717;Both sexes;390 RIOJA, LA;Group 1303 Internal derangement of knee 717;Men;262 RIOJA, LA;Group 1303 Internal derangement of knee 717;Women;128 RIOJA, LA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;970 RIOJA, LA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;471 RIOJA, LA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;499 RIOJA, LA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;40 RIOJA, LA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;19 RIOJA, LA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;21 RIOJA, LA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;55 RIOJA, LA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;35 RIOJA, LA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;20 RIOJA, LA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;339 RIOJA, LA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;195 RIOJA, LA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;144 RIOJA, LA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;65 RIOJA, LA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;35 RIOJA, LA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;30 RIOJA, LA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;392 RIOJA, LA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;195 RIOJA, LA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;197 RIOJA, LA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;401 RIOJA, LA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;134 RIOJA, LA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;267 RIOJA, LA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2.127 RIOJA, LA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1.005 RIOJA, LA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1.122 RIOJA, LA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;199 RIOJA, LA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;59 RIOJA, LA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;140 RIOJA, LA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;127 RIOJA, LA;Group 1402 Renal failure 5836-5837, 584-586;Men;88 RIOJA, LA;Group 1402 Renal failure 5836-5837, 584-586;Women;39 RIOJA, LA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;277 RIOJA, LA;Group 1403 Urolithiasis 592, 594, 7880;Men;154 RIOJA, LA;Group 1403 Urolithiasis 592, 594, 7880;Women;123 RIOJA, LA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;726 RIOJA, LA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;307 RIOJA, LA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;419 RIOJA, LA;Group 1405 Prostatic hyperplasia 600;Both sexes;188 RIOJA, LA;Group 1405 Prostatic hyperplasia 600;Men;188 RIOJA, LA;Group 1405 Prostatic hyperplasia 600;Women;.. RIOJA, LA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;184 RIOJA, LA;Group 1406 Other diseases of the male genital organs 601-608;Men;184 RIOJA, LA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. RIOJA, LA;Group 1407 Disorders of breast 610-612;Both sexes;76 RIOJA, LA;Group 1407 Disorders of breast 610-612;Men;7 RIOJA, LA;Group 1407 Disorders of breast 610-612;Women;69 RIOJA, LA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;75 RIOJA, LA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. RIOJA, LA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;75 RIOJA, LA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;14 RIOJA, LA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. RIOJA, LA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;14 RIOJA, LA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;261 RIOJA, LA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;18 RIOJA, LA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;243 RIOJA, LA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3.151 RIOJA, LA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. RIOJA, LA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3.151 RIOJA, LA;Group 1501 Legally induced abortion 635;Both sexes;26 RIOJA, LA;Group 1501 Legally induced abortion 635;Men;.. RIOJA, LA;Group 1501 Legally induced abortion 635;Women;26 RIOJA, LA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;141 RIOJA, LA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. RIOJA, LA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;141 RIOJA, LA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.935 RIOJA, LA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. RIOJA, LA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.935 RIOJA, LA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;771 RIOJA, LA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. RIOJA, LA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;771 RIOJA, LA;Group 1505 Single spontaneous delivery 650;Both sexes;71 RIOJA, LA;Group 1505 Single spontaneous delivery 650;Men;.. RIOJA, LA;Group 1505 Single spontaneous delivery 650;Women;71 RIOJA, LA;Group 1506 Other deliveries 6695-6697;Both sexes;6 RIOJA, LA;Group 1506 Other deliveries 6695-6697;Men;.. RIOJA, LA;Group 1506 Other deliveries 6695-6697;Women;6 RIOJA, LA;Group 1507 Complications related to the puerperium 670-676;Both sexes;13 RIOJA, LA;Group 1507 Complications related to the puerperium 670-676;Men;.. RIOJA, LA;Group 1507 Complications related to the puerperium 670-676;Women;13 RIOJA, LA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;188 RIOJA, LA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. RIOJA, LA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;188 RIOJA, LA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;229 RIOJA, LA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;133 RIOJA, LA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;96 RIOJA, LA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;97 RIOJA, LA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;56 RIOJA, LA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;41 RIOJA, LA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;132 RIOJA, LA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;77 RIOJA, LA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;55 RIOJA, LA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;130 RIOJA, LA;Grupo 1700 Congenital abnormalities 740-759;Men;88 RIOJA, LA;Grupo 1700 Congenital abnormalities 740-759;Women;42 RIOJA, LA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1.667 RIOJA, LA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;933 RIOJA, LA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;734 RIOJA, LA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;162 RIOJA, LA;Group 1801 Pain in throat and chest 7841, 7865;Men;106 RIOJA, LA;Group 1801 Pain in throat and chest 7841, 7865;Women;56 RIOJA, LA;Group 1802 Abdominal pain 7890;Both sexes;253 RIOJA, LA;Group 1802 Abdominal pain 7890;Men;106 RIOJA, LA;Group 1802 Abdominal pain 7890;Women;147 RIOJA, LA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;6 RIOJA, LA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;2 RIOJA, LA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;4 RIOJA, LA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1.246 RIOJA, LA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;719 RIOJA, LA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;527 RIOJA, LA;Group 1900 Injuries and poisoning 800-999;Both sexes;2.916 RIOJA, LA;Group 1900 Injuries and poisoning 800-999;Men;1.447 RIOJA, LA;Group 1900 Injuries and poisoning 800-999;Women;1.469 RIOJA, LA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;436 RIOJA, LA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;217 RIOJA, LA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;219 RIOJA, LA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;100 RIOJA, LA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;60 RIOJA, LA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;40 RIOJA, LA;Group 1903 Radius and ulna fracture 813;Both sexes;109 RIOJA, LA;Group 1903 Radius and ulna fracture 813;Men;55 RIOJA, LA;Group 1903 Radius and ulna fracture 813;Women;54 RIOJA, LA;Group 1904 Femur fracture 820-821;Both sexes;513 RIOJA, LA;Group 1904 Femur fracture 820-821;Men;135 RIOJA, LA;Group 1904 Femur fracture 820-821;Women;378 RIOJA, LA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;161 RIOJA, LA;Group 1905 Leg fracture, including the ankle 823-824;Men;81 RIOJA, LA;Group 1905 Leg fracture, including the ankle 823-824;Women;80 RIOJA, LA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;667 RIOJA, LA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;377 RIOJA, LA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;290 RIOJA, LA;Group 1907 Burns 940-949;Both sexes;20 RIOJA, LA;Group 1907 Burns 940-949;Men;8 RIOJA, LA;Group 1907 Burns 940-949;Women;12 RIOJA, LA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;72 RIOJA, LA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;31 RIOJA, LA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;41 RIOJA, LA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;718 RIOJA, LA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;418 RIOJA, LA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;300 RIOJA, LA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 RIOJA, LA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. RIOJA, LA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 RIOJA, LA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;118 RIOJA, LA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;65 RIOJA, LA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;53 RIOJA, LA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;938 RIOJA, LA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;452 RIOJA, LA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;486 RIOJA, LA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;21 RIOJA, LA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;9 RIOJA, LA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;12 RIOJA, LA;Group 2102 Contraceptive management V25;Both sexes;5 RIOJA, LA;Group 2102 Contraceptive management V25;Men;2 RIOJA, LA;Group 2102 Contraceptive management V25;Women;3 RIOJA, LA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. RIOJA, LA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. RIOJA, LA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. RIOJA, LA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;212 RIOJA, LA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;120 RIOJA, LA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;92 RIOJA, LA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;700 RIOJA, LA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;321 RIOJA, LA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;379 Ceuta;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;6.701 Ceuta;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;2.496 Ceuta;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;4.205 Ceuta;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;199 Ceuta;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;123 Ceuta;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;76 Ceuta;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;83 Ceuta;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;50 Ceuta;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;33 Ceuta;Group 0102 Imprecise intestinal infections 009;Both sexes;8 Ceuta;Group 0102 Imprecise intestinal infections 009;Men;4 Ceuta;Group 0102 Imprecise intestinal infections 009;Women;4 Ceuta;Group 0103 Tuberculosis 010-018, 137;Both sexes;37 Ceuta;Group 0103 Tuberculosis 010-018, 137;Men;32 Ceuta;Group 0103 Tuberculosis 010-018, 137;Women;5 Ceuta;Group 0104 Septicaemia 038;Both sexes;42 Ceuta;Group 0104 Septicaemia 038;Men;21 Ceuta;Group 0104 Septicaemia 038;Women;21 Ceuta;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;1 Ceuta;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;.. Ceuta;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Ceuta;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;28 Ceuta;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;16 Ceuta;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;12 Ceuta;Group 0200 Neoplasms 140-239;Both sexes;294 Ceuta;Group 0200 Neoplasms 140-239;Men;150 Ceuta;Group 0200 Neoplasms 140-239;Women;144 Ceuta;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;43 Ceuta;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;20 Ceuta;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;23 Ceuta;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;27 Ceuta;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;20 Ceuta;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;7 Ceuta;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;3 Ceuta;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;1 Ceuta;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;2 Ceuta;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;12 Ceuta;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Ceuta;Group 0204 Malignant neoplasm of breast 174-175;Women;12 Ceuta;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;7 Ceuta;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Ceuta;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;7 Ceuta;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;5 Ceuta;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Ceuta;Group 0206 Malignant neoplasm of ovary 1830;Women;5 Ceuta;Group 0207 Malignant neoplasm of prostate 185;Both sexes;8 Ceuta;Group 0207 Malignant neoplasm of prostate 185;Men;8 Ceuta;Group 0207 Malignant neoplasm of prostate 185;Women;.. Ceuta;Group 0208 Malignant neoplasm of bladder 188;Both sexes;17 Ceuta;Group 0208 Malignant neoplasm of bladder 188;Men;13 Ceuta;Group 0208 Malignant neoplasm of bladder 188;Women;4 Ceuta;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;69 Ceuta;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;40 Ceuta;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;29 Ceuta;Group 0210 Carcinoma in situ 230-234;Both sexes;4 Ceuta;Group 0210 Carcinoma in situ 230-234;Men;1 Ceuta;Group 0210 Carcinoma in situ 230-234;Women;3 Ceuta;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;4 Ceuta;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;4 Ceuta;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;.. Ceuta;Grupo 0212 Leiomyoma of uterus 218;Both sexes;14 Ceuta;Grupo 0212 Leiomyoma of uterus 218;Men;.. Ceuta;Grupo 0212 Leiomyoma of uterus 218;Women;14 Ceuta;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;81 Ceuta;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;43 Ceuta;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;38 Ceuta;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;69 Ceuta;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;36 Ceuta;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;33 Ceuta;Group 0301 Anaemias 280-285;Both sexes;38 Ceuta;Group 0301 Anaemias 280-285;Men;17 Ceuta;Group 0301 Anaemias 280-285;Women;21 Ceuta;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;31 Ceuta;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;19 Ceuta;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;12 Ceuta;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;149 Ceuta;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;66 Ceuta;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;83 Ceuta;Group 0401 Diabetes mellitus 249-250;Both sexes;82 Ceuta;Group 0401 Diabetes mellitus 249-250;Men;50 Ceuta;Group 0401 Diabetes mellitus 249-250;Women;32 Ceuta;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;67 Ceuta;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;16 Ceuta;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;51 Ceuta;Group 0500 Mental disorders 290-319;Both sexes;171 Ceuta;Group 0500 Mental disorders 290-319;Men;90 Ceuta;Group 0500 Mental disorders 290-319;Women;81 Ceuta;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;4 Ceuta;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;2 Ceuta;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2 Ceuta;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;7 Ceuta;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;5 Ceuta;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;2 Ceuta;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;7 Ceuta;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;6 Ceuta;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;1 Ceuta;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;46 Ceuta;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;39 Ceuta;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;7 Ceuta;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;39 Ceuta;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;13 Ceuta;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;26 Ceuta;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;68 Ceuta;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;25 Ceuta;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;43 Ceuta;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;171 Ceuta;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;72 Ceuta;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;99 Ceuta;Group 0601 Alzheimer's disease 3310;Both sexes;2 Ceuta;Group 0601 Alzheimer's disease 3310;Men;.. Ceuta;Group 0601 Alzheimer's disease 3310;Women;2 Ceuta;Group 0602 Multiple sclerosis 340;Both sexes;13 Ceuta;Group 0602 Multiple sclerosis 340;Men;1 Ceuta;Group 0602 Multiple sclerosis 340;Women;12 Ceuta;Group 0603 Epilepsy 345;Both sexes;49 Ceuta;Group 0603 Epilepsy 345;Men;31 Ceuta;Group 0603 Epilepsy 345;Women;18 Ceuta;Group 0604 Transient cerebral ischemia 435;Both sexes;18 Ceuta;Group 0604 Transient cerebral ischemia 435;Men;4 Ceuta;Group 0604 Transient cerebral ischemia 435;Women;14 Ceuta;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;89 Ceuta;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;36 Ceuta;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;53 Ceuta;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;64 Ceuta;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;37 Ceuta;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;27 Ceuta;Grupo 0701 Cataract 366;Both sexes;9 Ceuta;Grupo 0701 Cataract 366;Men;6 Ceuta;Grupo 0701 Cataract 366;Women;3 Ceuta;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;55 Ceuta;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;31 Ceuta;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;24 Ceuta;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;18 Ceuta;Group 0800 Diseases of the ear and the mastoid 380-389;Men;8 Ceuta;Group 0800 Diseases of the ear and the mastoid 380-389;Women;10 Ceuta;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;653 Ceuta;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;341 Ceuta;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;312 Ceuta;Group 0901 Hypertensive disease 401-405;Both sexes;55 Ceuta;Group 0901 Hypertensive disease 401-405;Men;16 Ceuta;Group 0901 Hypertensive disease 401-405;Women;39 Ceuta;Group 0902 Angina pectoris 4111, 413;Both sexes;101 Ceuta;Group 0902 Angina pectoris 4111, 413;Men;59 Ceuta;Group 0902 Angina pectoris 4111, 413;Women;42 Ceuta;Group 0903 Acute myocardial infarction 410;Both sexes;67 Ceuta;Group 0903 Acute myocardial infarction 410;Men;53 Ceuta;Group 0903 Acute myocardial infarction 410;Women;14 Ceuta;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;8 Ceuta;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;7 Ceuta;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1 Ceuta;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;7 Ceuta;Group 0905 Diseases of the lungs circulation 415-417;Men;3 Ceuta;Group 0905 Diseases of the lungs circulation 415-417;Women;4 Ceuta;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;74 Ceuta;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;40 Ceuta;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;34 Ceuta;Grupo 0907 Heart failure 428;Both sexes;142 Ceuta;Grupo 0907 Heart failure 428;Men;59 Ceuta;Grupo 0907 Heart failure 428;Women;83 Ceuta;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;117 Ceuta;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;66 Ceuta;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;51 Ceuta;Grupo 0909 Atherosclerosis 440;Both sexes;6 Ceuta;Grupo 0909 Atherosclerosis 440;Men;3 Ceuta;Grupo 0909 Atherosclerosis 440;Women;3 Ceuta;Group 0910 Varicose veins of lower extremities 454;Both sexes;8 Ceuta;Group 0910 Varicose veins of lower extremities 454;Men;3 Ceuta;Group 0910 Varicose veins of lower extremities 454;Women;5 Ceuta;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;68 Ceuta;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;32 Ceuta;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;36 Ceuta;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;580 Ceuta;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;323 Ceuta;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;257 Ceuta;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;33 Ceuta;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;16 Ceuta;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;17 Ceuta;Group 1002 Pneumonia 480-486;Both sexes;176 Ceuta;Group 1002 Pneumonia 480-486;Men;99 Ceuta;Group 1002 Pneumonia 480-486;Women;77 Ceuta;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;83 Ceuta;Group 1003 Acute bronchitis and bronchiolitis 466;Men;38 Ceuta;Group 1003 Acute bronchitis and bronchiolitis 466;Women;45 Ceuta;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;7 Ceuta;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;4 Ceuta;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;3 Ceuta;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;27 Ceuta;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;21 Ceuta;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;6 Ceuta;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;55 Ceuta;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;49 Ceuta;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;6 Ceuta;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;9 Ceuta;Group 1007 Asthma 4930-4931,4938-4939;Men;3 Ceuta;Group 1007 Asthma 4930-4931,4938-4939;Women;6 Ceuta;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;190 Ceuta;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;93 Ceuta;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;97 Ceuta;Group 1100 Diseases of the digestive system 520-579;Both sexes;668 Ceuta;Group 1100 Diseases of the digestive system 520-579;Men;336 Ceuta;Group 1100 Diseases of the digestive system 520-579;Women;332 Ceuta;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;8 Ceuta;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;3 Ceuta;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;5 Ceuta;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;4 Ceuta;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;3 Ceuta;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;1 Ceuta;Group 1103 Diseases of the esophagus 530;Both sexes;7 Ceuta;Group 1103 Diseases of the esophagus 530;Men;7 Ceuta;Group 1103 Diseases of the esophagus 530;Women;.. Ceuta;Group 1104 Peptic ulcer 531-534;Both sexes;6 Ceuta;Group 1104 Peptic ulcer 531-534;Men;6 Ceuta;Group 1104 Peptic ulcer 531-534;Women;.. Ceuta;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;13 Ceuta;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;9 Ceuta;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;4 Ceuta;Group 1106 Appendicitis 540-543;Both sexes;80 Ceuta;Group 1106 Appendicitis 540-543;Men;52 Ceuta;Group 1106 Appendicitis 540-543;Women;28 Ceuta;Group 1107 Inguinal hernia 550;Both sexes;18 Ceuta;Group 1107 Inguinal hernia 550;Men;18 Ceuta;Group 1107 Inguinal hernia 550;Women;.. Ceuta;Group 1108 Other abdominal hernia 551-553;Both sexes;43 Ceuta;Group 1108 Other abdominal hernia 551-553;Men;16 Ceuta;Group 1108 Other abdominal hernia 551-553;Women;27 Ceuta;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;11 Ceuta;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;8 Ceuta;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;3 Ceuta;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;109 Ceuta;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;53 Ceuta;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;56 Ceuta;Group 1111 Intestinal obstruction without hernia 560;Both sexes;16 Ceuta;Group 1111 Intestinal obstruction without hernia 560;Men;5 Ceuta;Group 1111 Intestinal obstruction without hernia 560;Women;11 Ceuta;Group 1112 Intestinal diverticulosis 562;Both sexes;18 Ceuta;Group 1112 Intestinal diverticulosis 562;Men;11 Ceuta;Group 1112 Intestinal diverticulosis 562;Women;7 Ceuta;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;22 Ceuta;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;17 Ceuta;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;5 Ceuta;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;28 Ceuta;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;12 Ceuta;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;16 Ceuta;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;9 Ceuta;Group 1115 Alcoholic hepatitis 5710-5713;Men;8 Ceuta;Group 1115 Alcoholic hepatitis 5710-5713;Women;1 Ceuta;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;20 Ceuta;Group 1116 Other diseases of the liver 570,5714-573;Men;10 Ceuta;Group 1116 Other diseases of the liver 570,5714-573;Women;10 Ceuta;Group 1117 Cholelithiasis 574;Both sexes;128 Ceuta;Group 1117 Cholelithiasis 574;Men;40 Ceuta;Group 1117 Cholelithiasis 574;Women;88 Ceuta;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;53 Ceuta;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;23 Ceuta;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;30 Ceuta;Group 1119 Pancreatic diseases 577;Both sexes;49 Ceuta;Group 1119 Pancreatic diseases 577;Men;23 Ceuta;Group 1119 Pancreatic diseases 577;Women;26 Ceuta;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;26 Ceuta;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;12 Ceuta;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;14 Ceuta;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;73 Ceuta;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;29 Ceuta;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;44 Ceuta;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;57 Ceuta;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;23 Ceuta;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;34 Ceuta;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;.. Ceuta;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;.. Ceuta;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;.. Ceuta;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;16 Ceuta;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;6 Ceuta;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;10 Ceuta;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;162 Ceuta;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;59 Ceuta;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;103 Ceuta;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Ceuta;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Ceuta;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Ceuta;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Ceuta;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Ceuta;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Ceuta;Group 1303 Internal derangement of knee 717;Both sexes;11 Ceuta;Group 1303 Internal derangement of knee 717;Men;7 Ceuta;Group 1303 Internal derangement of knee 717;Women;4 Ceuta;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;38 Ceuta;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;14 Ceuta;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;24 Ceuta;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;8 Ceuta;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;1 Ceuta;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;7 Ceuta;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;9 Ceuta;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;2 Ceuta;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;7 Ceuta;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;12 Ceuta;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;3 Ceuta;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;9 Ceuta;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;9 Ceuta;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;6 Ceuta;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;3 Ceuta;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;35 Ceuta;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;14 Ceuta;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;21 Ceuta;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;40 Ceuta;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;12 Ceuta;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;28 Ceuta;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;305 Ceuta;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;134 Ceuta;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;171 Ceuta;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;30 Ceuta;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;15 Ceuta;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;15 Ceuta;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;38 Ceuta;Group 1402 Renal failure 5836-5837, 584-586;Men;21 Ceuta;Group 1402 Renal failure 5836-5837, 584-586;Women;17 Ceuta;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;42 Ceuta;Group 1403 Urolithiasis 592, 594, 7880;Men;26 Ceuta;Group 1403 Urolithiasis 592, 594, 7880;Women;16 Ceuta;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;77 Ceuta;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;32 Ceuta;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;45 Ceuta;Group 1405 Prostatic hyperplasia 600;Both sexes;22 Ceuta;Group 1405 Prostatic hyperplasia 600;Men;22 Ceuta;Group 1405 Prostatic hyperplasia 600;Women;.. Ceuta;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;17 Ceuta;Group 1406 Other diseases of the male genital organs 601-608;Men;17 Ceuta;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Ceuta;Group 1407 Disorders of breast 610-612;Both sexes;11 Ceuta;Group 1407 Disorders of breast 610-612;Men;1 Ceuta;Group 1407 Disorders of breast 610-612;Women;10 Ceuta;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;10 Ceuta;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Ceuta;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;10 Ceuta;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;18 Ceuta;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Ceuta;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;18 Ceuta;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;40 Ceuta;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Ceuta;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;40 Ceuta;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1.909 Ceuta;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Ceuta;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1.909 Ceuta;Group 1501 Legally induced abortion 635;Both sexes;1 Ceuta;Group 1501 Legally induced abortion 635;Men;.. Ceuta;Group 1501 Legally induced abortion 635;Women;1 Ceuta;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;181 Ceuta;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Ceuta;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;181 Ceuta;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.236 Ceuta;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Ceuta;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.236 Ceuta;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;284 Ceuta;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Ceuta;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;284 Ceuta;Group 1505 Single spontaneous delivery 650;Both sexes;85 Ceuta;Group 1505 Single spontaneous delivery 650;Men;.. Ceuta;Group 1505 Single spontaneous delivery 650;Women;85 Ceuta;Group 1506 Other deliveries 6695-6697;Both sexes;19 Ceuta;Group 1506 Other deliveries 6695-6697;Men;.. Ceuta;Group 1506 Other deliveries 6695-6697;Women;19 Ceuta;Group 1507 Complications related to the puerperium 670-676;Both sexes;2 Ceuta;Group 1507 Complications related to the puerperium 670-676;Men;.. Ceuta;Group 1507 Complications related to the puerperium 670-676;Women;2 Ceuta;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;101 Ceuta;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Ceuta;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;101 Ceuta;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;131 Ceuta;Group 1600 Some disorders originating in the perinatal period 760-779;Men;84 Ceuta;Group 1600 Some disorders originating in the perinatal period 760-779;Women;47 Ceuta;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;29 Ceuta;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;20 Ceuta;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;9 Ceuta;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;102 Ceuta;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;64 Ceuta;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;38 Ceuta;Grupo 1700 Congenital abnormalities 740-759;Both sexes;38 Ceuta;Grupo 1700 Congenital abnormalities 740-759;Men;24 Ceuta;Grupo 1700 Congenital abnormalities 740-759;Women;14 Ceuta;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;375 Ceuta;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;198 Ceuta;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;177 Ceuta;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;18 Ceuta;Group 1801 Pain in throat and chest 7841, 7865;Men;11 Ceuta;Group 1801 Pain in throat and chest 7841, 7865;Women;7 Ceuta;Group 1802 Abdominal pain 7890;Both sexes;49 Ceuta;Group 1802 Abdominal pain 7890;Men;15 Ceuta;Group 1802 Abdominal pain 7890;Women;34 Ceuta;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;2 Ceuta;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1 Ceuta;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1 Ceuta;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;306 Ceuta;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;171 Ceuta;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;135 Ceuta;Group 1900 Injuries and poisoning 800-999;Both sexes;523 Ceuta;Group 1900 Injuries and poisoning 800-999;Men;297 Ceuta;Group 1900 Injuries and poisoning 800-999;Women;226 Ceuta;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;43 Ceuta;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;28 Ceuta;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;15 Ceuta;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;20 Ceuta;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;15 Ceuta;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;5 Ceuta;Group 1903 Radius and ulna fracture 813;Both sexes;61 Ceuta;Group 1903 Radius and ulna fracture 813;Men;47 Ceuta;Group 1903 Radius and ulna fracture 813;Women;14 Ceuta;Group 1904 Femur fracture 820-821;Both sexes;91 Ceuta;Group 1904 Femur fracture 820-821;Men;30 Ceuta;Group 1904 Femur fracture 820-821;Women;61 Ceuta;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;62 Ceuta;Group 1905 Leg fracture, including the ankle 823-824;Men;35 Ceuta;Group 1905 Leg fracture, including the ankle 823-824;Women;27 Ceuta;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;138 Ceuta;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;89 Ceuta;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;49 Ceuta;Group 1907 Burns 940-949;Both sexes;5 Ceuta;Group 1907 Burns 940-949;Men;2 Ceuta;Group 1907 Burns 940-949;Women;3 Ceuta;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;11 Ceuta;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;6 Ceuta;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;5 Ceuta;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;78 Ceuta;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;37 Ceuta;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;41 Ceuta;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1 Ceuta;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Ceuta;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Ceuta;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;13 Ceuta;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;8 Ceuta;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;5 Ceuta;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;149 Ceuta;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;89 Ceuta;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;60 Ceuta;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;1 Ceuta;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;.. Ceuta;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;1 Ceuta;Group 2102 Contraceptive management V25;Both sexes;1 Ceuta;Group 2102 Contraceptive management V25;Men;.. Ceuta;Group 2102 Contraceptive management V25;Women;1 Ceuta;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Ceuta;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Ceuta;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Ceuta;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;100 Ceuta;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;59 Ceuta;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;41 Ceuta;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;47 Ceuta;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;30 Ceuta;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;17 Melilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;7.353 Melilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;2.037 Melilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;5.316 Melilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;154 Melilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;90 Melilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;64 Melilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;47 Melilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;30 Melilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;17 Melilla;Group 0102 Imprecise intestinal infections 009;Both sexes;2 Melilla;Group 0102 Imprecise intestinal infections 009;Men;1 Melilla;Group 0102 Imprecise intestinal infections 009;Women;1 Melilla;Group 0103 Tuberculosis 010-018, 137;Both sexes;16 Melilla;Group 0103 Tuberculosis 010-018, 137;Men;10 Melilla;Group 0103 Tuberculosis 010-018, 137;Women;6 Melilla;Group 0104 Septicaemia 038;Both sexes;29 Melilla;Group 0104 Septicaemia 038;Men;11 Melilla;Group 0104 Septicaemia 038;Women;18 Melilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;8 Melilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;7 Melilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Melilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;52 Melilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;31 Melilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;21 Melilla;Group 0200 Neoplasms 140-239;Both sexes;286 Melilla;Group 0200 Neoplasms 140-239;Men;135 Melilla;Group 0200 Neoplasms 140-239;Women;151 Melilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;30 Melilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;16 Melilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;14 Melilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;26 Melilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;19 Melilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;7 Melilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;1 Melilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;.. Melilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;1 Melilla;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;25 Melilla;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Melilla;Group 0204 Malignant neoplasm of breast 174-175;Women;25 Melilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;3 Melilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Melilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;3 Melilla;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;.. Melilla;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Melilla;Group 0206 Malignant neoplasm of ovary 1830;Women;.. Melilla;Group 0207 Malignant neoplasm of prostate 185;Both sexes;4 Melilla;Group 0207 Malignant neoplasm of prostate 185;Men;4 Melilla;Group 0207 Malignant neoplasm of prostate 185;Women;.. Melilla;Group 0208 Malignant neoplasm of bladder 188;Both sexes;32 Melilla;Group 0208 Malignant neoplasm of bladder 188;Men;32 Melilla;Group 0208 Malignant neoplasm of bladder 188;Women;.. Melilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;92 Melilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;41 Melilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;51 Melilla;Group 0210 Carcinoma in situ 230-234;Both sexes;4 Melilla;Group 0210 Carcinoma in situ 230-234;Men;1 Melilla;Group 0210 Carcinoma in situ 230-234;Women;3 Melilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;4 Melilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;3 Melilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;1 Melilla;Grupo 0212 Leiomyoma of uterus 218;Both sexes;21 Melilla;Grupo 0212 Leiomyoma of uterus 218;Men;.. Melilla;Grupo 0212 Leiomyoma of uterus 218;Women;21 Melilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;44 Melilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;19 Melilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;25 Melilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;58 Melilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;34 Melilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;24 Melilla;Group 0301 Anaemias 280-285;Both sexes;23 Melilla;Group 0301 Anaemias 280-285;Men;13 Melilla;Group 0301 Anaemias 280-285;Women;10 Melilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;35 Melilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;21 Melilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;14 Melilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;168 Melilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;84 Melilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;84 Melilla;Group 0401 Diabetes mellitus 249-250;Both sexes;88 Melilla;Group 0401 Diabetes mellitus 249-250;Men;55 Melilla;Group 0401 Diabetes mellitus 249-250;Women;33 Melilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;80 Melilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;29 Melilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;51 Melilla;Group 0500 Mental disorders 290-319;Both sexes;125 Melilla;Group 0500 Mental disorders 290-319;Men;81 Melilla;Group 0500 Mental disorders 290-319;Women;44 Melilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;1 Melilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;.. Melilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;1 Melilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;5 Melilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;5 Melilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;.. Melilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;24 Melilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;21 Melilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;3 Melilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;32 Melilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;22 Melilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;10 Melilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;21 Melilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;8 Melilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;13 Melilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;42 Melilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;25 Melilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;17 Melilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;63 Melilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;31 Melilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;32 Melilla;Group 0601 Alzheimer's disease 3310;Both sexes;.. Melilla;Group 0601 Alzheimer's disease 3310;Men;.. Melilla;Group 0601 Alzheimer's disease 3310;Women;.. Melilla;Group 0602 Multiple sclerosis 340;Both sexes;3 Melilla;Group 0602 Multiple sclerosis 340;Men;.. Melilla;Group 0602 Multiple sclerosis 340;Women;3 Melilla;Group 0603 Epilepsy 345;Both sexes;27 Melilla;Group 0603 Epilepsy 345;Men;18 Melilla;Group 0603 Epilepsy 345;Women;9 Melilla;Group 0604 Transient cerebral ischemia 435;Both sexes;7 Melilla;Group 0604 Transient cerebral ischemia 435;Men;2 Melilla;Group 0604 Transient cerebral ischemia 435;Women;5 Melilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;26 Melilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;11 Melilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;15 Melilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;31 Melilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;15 Melilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;16 Melilla;Grupo 0701 Cataract 366;Both sexes;5 Melilla;Grupo 0701 Cataract 366;Men;3 Melilla;Grupo 0701 Cataract 366;Women;2 Melilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;26 Melilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;12 Melilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;14 Melilla;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;16 Melilla;Group 0800 Diseases of the ear and the mastoid 380-389;Men;8 Melilla;Group 0800 Diseases of the ear and the mastoid 380-389;Women;8 Melilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;510 Melilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;262 Melilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;248 Melilla;Group 0901 Hypertensive disease 401-405;Both sexes;8 Melilla;Group 0901 Hypertensive disease 401-405;Men;5 Melilla;Group 0901 Hypertensive disease 401-405;Women;3 Melilla;Group 0902 Angina pectoris 4111, 413;Both sexes;59 Melilla;Group 0902 Angina pectoris 4111, 413;Men;29 Melilla;Group 0902 Angina pectoris 4111, 413;Women;30 Melilla;Group 0903 Acute myocardial infarction 410;Both sexes;68 Melilla;Group 0903 Acute myocardial infarction 410;Men;42 Melilla;Group 0903 Acute myocardial infarction 410;Women;26 Melilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;10 Melilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;6 Melilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;4 Melilla;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;4 Melilla;Group 0905 Diseases of the lungs circulation 415-417;Men;1 Melilla;Group 0905 Diseases of the lungs circulation 415-417;Women;3 Melilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;58 Melilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;31 Melilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;27 Melilla;Grupo 0907 Heart failure 428;Both sexes;129 Melilla;Grupo 0907 Heart failure 428;Men;64 Melilla;Grupo 0907 Heart failure 428;Women;65 Melilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;109 Melilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;49 Melilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;60 Melilla;Grupo 0909 Atherosclerosis 440;Both sexes;2 Melilla;Grupo 0909 Atherosclerosis 440;Men;.. Melilla;Grupo 0909 Atherosclerosis 440;Women;2 Melilla;Group 0910 Varicose veins of lower extremities 454;Both sexes;8 Melilla;Group 0910 Varicose veins of lower extremities 454;Men;2 Melilla;Group 0910 Varicose veins of lower extremities 454;Women;6 Melilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;55 Melilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;33 Melilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;22 Melilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;500 Melilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;299 Melilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;201 Melilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;12 Melilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;6 Melilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;6 Melilla;Group 1002 Pneumonia 480-486;Both sexes;166 Melilla;Group 1002 Pneumonia 480-486;Men;97 Melilla;Group 1002 Pneumonia 480-486;Women;69 Melilla;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;77 Melilla;Group 1003 Acute bronchitis and bronchiolitis 466;Men;49 Melilla;Group 1003 Acute bronchitis and bronchiolitis 466;Women;28 Melilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;.. Melilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;.. Melilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;.. Melilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;9 Melilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;4 Melilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;5 Melilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;44 Melilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;37 Melilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;7 Melilla;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;24 Melilla;Group 1007 Asthma 4930-4931,4938-4939;Men;10 Melilla;Group 1007 Asthma 4930-4931,4938-4939;Women;14 Melilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;168 Melilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;96 Melilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;72 Melilla;Group 1100 Diseases of the digestive system 520-579;Both sexes;698 Melilla;Group 1100 Diseases of the digestive system 520-579;Men;388 Melilla;Group 1100 Diseases of the digestive system 520-579;Women;310 Melilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;8 Melilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;4 Melilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;4 Melilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1 Melilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;.. Melilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;1 Melilla;Group 1103 Diseases of the esophagus 530;Both sexes;7 Melilla;Group 1103 Diseases of the esophagus 530;Men;4 Melilla;Group 1103 Diseases of the esophagus 530;Women;3 Melilla;Group 1104 Peptic ulcer 531-534;Both sexes;28 Melilla;Group 1104 Peptic ulcer 531-534;Men;21 Melilla;Group 1104 Peptic ulcer 531-534;Women;7 Melilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;12 Melilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;9 Melilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;3 Melilla;Group 1106 Appendicitis 540-543;Both sexes;80 Melilla;Group 1106 Appendicitis 540-543;Men;46 Melilla;Group 1106 Appendicitis 540-543;Women;34 Melilla;Group 1107 Inguinal hernia 550;Both sexes;75 Melilla;Group 1107 Inguinal hernia 550;Men;73 Melilla;Group 1107 Inguinal hernia 550;Women;2 Melilla;Group 1108 Other abdominal hernia 551-553;Both sexes;52 Melilla;Group 1108 Other abdominal hernia 551-553;Men;18 Melilla;Group 1108 Other abdominal hernia 551-553;Women;34 Melilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;9 Melilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;6 Melilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;3 Melilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;39 Melilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;18 Melilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;21 Melilla;Group 1111 Intestinal obstruction without hernia 560;Both sexes;29 Melilla;Group 1111 Intestinal obstruction without hernia 560;Men;16 Melilla;Group 1111 Intestinal obstruction without hernia 560;Women;13 Melilla;Group 1112 Intestinal diverticulosis 562;Both sexes;11 Melilla;Group 1112 Intestinal diverticulosis 562;Men;7 Melilla;Group 1112 Intestinal diverticulosis 562;Women;4 Melilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;34 Melilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;19 Melilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;15 Melilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;15 Melilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;8 Melilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;7 Melilla;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;13 Melilla;Group 1115 Alcoholic hepatitis 5710-5713;Men;11 Melilla;Group 1115 Alcoholic hepatitis 5710-5713;Women;2 Melilla;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;41 Melilla;Group 1116 Other diseases of the liver 570,5714-573;Men;23 Melilla;Group 1116 Other diseases of the liver 570,5714-573;Women;18 Melilla;Group 1117 Cholelithiasis 574;Both sexes;134 Melilla;Group 1117 Cholelithiasis 574;Men;50 Melilla;Group 1117 Cholelithiasis 574;Women;84 Melilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;35 Melilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;19 Melilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;16 Melilla;Group 1119 Pancreatic diseases 577;Both sexes;49 Melilla;Group 1119 Pancreatic diseases 577;Men;21 Melilla;Group 1119 Pancreatic diseases 577;Women;28 Melilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;26 Melilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;15 Melilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;11 Melilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;33 Melilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;18 Melilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;15 Melilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;21 Melilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;13 Melilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;8 Melilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;.. Melilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;.. Melilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;.. Melilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;12 Melilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;5 Melilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;7 Melilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;100 Melilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;50 Melilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;50 Melilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Melilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Melilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Melilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Melilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Melilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Melilla;Group 1303 Internal derangement of knee 717;Both sexes;7 Melilla;Group 1303 Internal derangement of knee 717;Men;6 Melilla;Group 1303 Internal derangement of knee 717;Women;1 Melilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;34 Melilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;10 Melilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;24 Melilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;6 Melilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;3 Melilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;3 Melilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;7 Melilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;4 Melilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;3 Melilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;19 Melilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;11 Melilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;8 Melilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;2 Melilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;.. Melilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;2 Melilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;15 Melilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;11 Melilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;4 Melilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;10 Melilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;5 Melilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;5 Melilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;299 Melilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;106 Melilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;193 Melilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;15 Melilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;7 Melilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;8 Melilla;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;45 Melilla;Group 1402 Renal failure 5836-5837, 584-586;Men;22 Melilla;Group 1402 Renal failure 5836-5837, 584-586;Women;23 Melilla;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;28 Melilla;Group 1403 Urolithiasis 592, 594, 7880;Men;13 Melilla;Group 1403 Urolithiasis 592, 594, 7880;Women;15 Melilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;58 Melilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;32 Melilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;26 Melilla;Group 1405 Prostatic hyperplasia 600;Both sexes;11 Melilla;Group 1405 Prostatic hyperplasia 600;Men;11 Melilla;Group 1405 Prostatic hyperplasia 600;Women;.. Melilla;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;16 Melilla;Group 1406 Other diseases of the male genital organs 601-608;Men;16 Melilla;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Melilla;Group 1407 Disorders of breast 610-612;Both sexes;7 Melilla;Group 1407 Disorders of breast 610-612;Men;4 Melilla;Group 1407 Disorders of breast 610-612;Women;3 Melilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;21 Melilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Melilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;21 Melilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;34 Melilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Melilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;34 Melilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;64 Melilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Melilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;63 Melilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3.516 Melilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Melilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3.516 Melilla;Group 1501 Legally induced abortion 635;Both sexes;.. Melilla;Group 1501 Legally induced abortion 635;Men;.. Melilla;Group 1501 Legally induced abortion 635;Women;.. Melilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;261 Melilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Melilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;261 Melilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1.550 Melilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Melilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1.550 Melilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1.031 Melilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Melilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1.031 Melilla;Group 1505 Single spontaneous delivery 650;Both sexes;220 Melilla;Group 1505 Single spontaneous delivery 650;Men;.. Melilla;Group 1505 Single spontaneous delivery 650;Women;220 Melilla;Group 1506 Other deliveries 6695-6697;Both sexes;32 Melilla;Group 1506 Other deliveries 6695-6697;Men;.. Melilla;Group 1506 Other deliveries 6695-6697;Women;32 Melilla;Group 1507 Complications related to the puerperium 670-676;Both sexes;15 Melilla;Group 1507 Complications related to the puerperium 670-676;Men;.. Melilla;Group 1507 Complications related to the puerperium 670-676;Women;15 Melilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;407 Melilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Melilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;407 Melilla;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;200 Melilla;Group 1600 Some disorders originating in the perinatal period 760-779;Men;98 Melilla;Group 1600 Some disorders originating in the perinatal period 760-779;Women;102 Melilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;48 Melilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;22 Melilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;26 Melilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;152 Melilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;76 Melilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;76 Melilla;Grupo 1700 Congenital abnormalities 740-759;Both sexes;55 Melilla;Grupo 1700 Congenital abnormalities 740-759;Men;35 Melilla;Grupo 1700 Congenital abnormalities 740-759;Women;20 Melilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;135 Melilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;63 Melilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;72 Melilla;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1 Melilla;Group 1801 Pain in throat and chest 7841, 7865;Men;1 Melilla;Group 1801 Pain in throat and chest 7841, 7865;Women;.. Melilla;Group 1802 Abdominal pain 7890;Both sexes;21 Melilla;Group 1802 Abdominal pain 7890;Men;7 Melilla;Group 1802 Abdominal pain 7890;Women;14 Melilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;9 Melilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;2 Melilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;7 Melilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;104 Melilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;53 Melilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;51 Melilla;Group 1900 Injuries and poisoning 800-999;Both sexes;379 Melilla;Group 1900 Injuries and poisoning 800-999;Men;229 Melilla;Group 1900 Injuries and poisoning 800-999;Women;150 Melilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;17 Melilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;14 Melilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;3 Melilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;19 Melilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;16 Melilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;3 Melilla;Group 1903 Radius and ulna fracture 813;Both sexes;30 Melilla;Group 1903 Radius and ulna fracture 813;Men;21 Melilla;Group 1903 Radius and ulna fracture 813;Women;9 Melilla;Group 1904 Femur fracture 820-821;Both sexes;72 Melilla;Group 1904 Femur fracture 820-821;Men;24 Melilla;Group 1904 Femur fracture 820-821;Women;48 Melilla;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;49 Melilla;Group 1905 Leg fracture, including the ankle 823-824;Men;36 Melilla;Group 1905 Leg fracture, including the ankle 823-824;Women;13 Melilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;106 Melilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;72 Melilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;34 Melilla;Group 1907 Burns 940-949;Both sexes;14 Melilla;Group 1907 Burns 940-949;Men;7 Melilla;Group 1907 Burns 940-949;Women;7 Melilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;12 Melilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;6 Melilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;6 Melilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;53 Melilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;30 Melilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;23 Melilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Melilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 Melilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Melilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;5 Melilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;2 Melilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;3 Melilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;27 Melilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;11 Melilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;16 Melilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;.. Melilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;.. Melilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;.. Melilla;Group 2102 Contraceptive management V25;Both sexes;9 Melilla;Group 2102 Contraceptive management V25;Men;.. Melilla;Group 2102 Contraceptive management V25;Women;9 Melilla;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Melilla;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Melilla;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Melilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1 Melilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1 Melilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;.. Melilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;17 Melilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;10 Melilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;7